Sentence Id: DrugDDI.d505.s0
No/DT formal/JJ drug/NN /drug/NN interaction/NN studies/NNS with/IN Plenaxis/NN @/NN were/VBD performed/VBN ./.

(ROOT (S1 (S (S (NP (NP (DT No) (JJ formal) (NN drug) (NN /drug) (NN interaction) (NNS studies)) (PP (IN with) (NP (NN Plenaxis) (NN @)))) (VP (VBD were) (VP (VBN performed)))) (. .))))

Sentence Id: DrugDDI.d505.s1
Cytochrome/NN P-450/NN is/VBZ not/RB known/VBN to/TO be/VB involved/VBN in/IN the/DT metabolism/NN of/IN Plenaxis/NN @./NNS

(ROOT (S1 (S (NP (NP (NN Cytochrome) (NN P-450)) (VP (VBZ is) (RB not) (VP (VBN known) (S (VP (TO to) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN Plenaxis) (NNS @.)))))))))))))))

Sentence Id: DrugDDI.d505.s2
Plenaxis/NN @/NN is/VBZ highly/RB bound/VBN to/TO plasma/NN proteins/NNS (/-LRB- 96/CD to/TO 99/CD %)./NN

(ROOT (S1 (S (NP (NP (NP (NN Plenaxis) (NN @)) (VP (VBZ is) (ADVP (RB highly)) (VP (VBN bound) (PP (TO to) (NP (NN plasma) (NNS proteins)))))) (-LRB- -LRB-) (NP (QP (CD 96) (TO to) (CD 99)) (NN %-RRB-.))))))

Sentence Id: DrugDDI.d505.s3
Laboratory/NN Tests/NNS Response/NN to/TO Plenaxis/NN @/NN should/MD be/VB monitored/VBN by/IN measuring/VBG serum/NN total/JJ testosterone/NN concentrations/NNS just/RB prior/RB to/TO administration/NN on/IN Day/NN 29/CD and/CC every/DT 8/CD weeks/NNS thereafter/RB ./.

(ROOT (S1 (S (S (NP (NP (NN Laboratory) (NNS Tests)) (VP (NN Response) (PP (TO to) (NP (NN Plenaxis) (NN @))))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (PP (IN by) (S (VP (VBG measuring) (NP (NP (NN serum) (JJ total) (NN testosterone) (NNS concentrations)) (ADVP (ADVP (RB just) (RB prior)) (PP (TO to) (NP (NN administration))))) (PP (IN on) (NP (NP (NN Day) (CD 29)) (CC and) (NP (NP (DT every) (CD 8) (NNS weeks)) (ADVP (RB thereafter)))))))))))) (. .))))

Sentence Id: DrugDDI.d505.s4
Serum/NN transaminase/NN levels/NNS should/MD be/VB obtained/VBN before/IN starting/VBG treatment/NN with/IN Plenaxis/NN @/NN and/CC periodically/RB during/IN treatment/NN ./.

(ROOT (S1 (S (S (NP (NN Serum) (NN transaminase) (NNS levels)) (VP (MD should) (VP (VB be) (VP (VBN obtained) (PP (PP (IN before) (S (VP (VBG starting) (NP (NP (NN treatment)) (PP (IN with) (NP (NN Plenaxis) (NN @))))))) (CC and) (ADVP (RB periodically)) (PP (IN during) (NP (NN treatment)))))))) (. .))))

Sentence Id: DrugDDI.d103.s0
Certain/JJ drugs/NNS tend/VBP to/TO produce/VB hyperglycemia/NN and/CC may/MD lead/VB to/TO loss/NN of/IN blood/NN glucose/NN control/NN ./.

(ROOT (S1 (S (S (NP (JJ Certain) (NNS drugs)) (VP (VP (VBP tend) (S (VP (TO to) (VP (VB produce) (NP (NN hyperglycemia)))))) (CC and) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (NN loss)) (PP (IN of) (NP (NN blood) (NN glucose) (NN control))))))))) (. .))))

Sentence Id: DrugDDI.d103.s1
These/DT drugs/NNS include/VBP the/DT thiazides/NNS and/CC other/JJ diuretics/NNS ,/, corticosteroids/NNS ,/, phenothiazines/NNS ,/, thyroid/NN products/NNS ,/, estrogens/NNS ,/, oral/JJ contraceptives/NNS ,/, phenytoin/NN ,/, nicotinic/JJ acid/NN ,/, sympathomimetics/NNS ,/, calcium/NN channel-blocking/JJ drugs/NNS ,/, and/CC isoniazid/NN ./.

(ROOT (S1 (S (S (NP (DT These) (NNS drugs)) (VP (VBP include) (NP (NP (DT the) (NNS thiazides)) (CC and) (NP (NP (JJ other) (NNS diuretics)) (, ,) (NP (NNS corticosteroids)) (, ,) (NP (NNS phenothiazines)) (, ,) (NP (NN thyroid) (NNS products)) (, ,) (NP (NNS estrogens)) (, ,) (NP (JJ oral) (NNS contraceptives)) (, ,) (NP (NN phenytoin)) (, ,) (NP (JJ nicotinic) (NN acid)) (, ,) (NP (NNS sympathomimetics)) (, ,) (NP (NN calcium) (JJ channel-blocking) (NNS drugs)) (, ,) (CC and) (NP (NN isoniazid)))))) (. .))))

Sentence Id: DrugDDI.d103.s2
When/WRB such/JJ drugs/NNS are/VBP administered/VBN to/TO a/DT patient/NN receiving/VBG Acarbose/NN ,/, the/DT patient/NN should/MD be/VB closely/RB observed/VBN for/IN loss/NN of/IN blood/NN glucose/NN control/NN ./.

(ROOT (S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (JJ such) (NNS drugs)) (VP (VBP are) (VP (VBN administered) (PP (TO to) (NP (NP (DT a) (NN patient)) (VP (VBG receiving) (NP (NN Acarbose))))))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN observed) (PP (IN for) (NP (NP (NN loss)) (PP (IN of) (NP (NN blood) (NN glucose) (NN control))))))))) (. .))))

Sentence Id: DrugDDI.d103.s3
When/WRB such/JJ drugs/NNS are/VBP withdrawn/VBN from/IN patients/NNS receiving/VBG Acarbose/NN in/IN combination/NN with/IN sulfonylureas/NN or/CC insulin/NN ,/, patients/NNS should/MD be/VB observed/VBN closely/RB for/IN any/DT evidence/NN of/IN hypoglycemia/NN ./.

(ROOT (S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (JJ such) (NNS drugs)) (VP (VBP are) (VP (VBN withdrawn) (PP (IN from) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN Acarbose)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NN sulfonylureas)) (CC or) (NP (NN insulin))))))))))))) (, ,) (NP (NNS patients)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (PP (IN for) (NP (NP (DT any) (NN evidence)) (PP (IN of) (NP (NN hypoglycemia))))))))) (. .))))

Sentence Id: DrugDDI.d103.s4
Intestinal/JJ adsorbents/NNS (/-LRB- e./FW g./FW ,/, charcoal/NN )/-RRB- and/CC digestive/JJ enzyme/NN preparations/NNS containing/VBG carbohydrate-splitting/JJ enzymes/NNS (/-LRB- e./FW g./FW ,/, amylase/NN ,/, pancreatin/NN )/-RRB- may/MD reduce/VB the/DT effect/NN of/IN Acarbose/NN and/CC should/MD not/RB be/VB taken/VBN concomitantly/RB ./.

(ROOT (S1 (S (NP (NP (NP (JJ Intestinal) (NNS adsorbents)) (PRN (-LRB- -LRB-) (NP (NP (FW e.) (FW g.)) (, ,) (NP (NN charcoal))) (-RRB- -RRB-))) (CC and) (NP (NP (NP (JJ digestive) (NN enzyme) (NNS preparations)) (VP (VBG containing) (NP (JJ carbohydrate-splitting) (NNS enzymes)))) (PRN (-LRB- -LRB-) (NP (NP (FW e.) (FW g.)) (, ,) (NP (NN amylase)) (, ,) (NP (NN pancreatin))) (-RRB- -RRB-)))) (VP (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN Acarbose)))))) (CC and) (VP (MD should) (RB not) (VP (VB be) (VP (VBN taken) (ADVP (RB concomitantly)))))) (. .))))

Sentence Id: DrugDDI.d103.s5
Acarbose/NN has/VBZ been/VBN shown/VBN to/TO change/VB the/DT bioavailabillty/NN digoxin/NN when/WRB they/PRP are/VBP co-administered/VBN ,/, which/WDT may/MD require/VB digoxin/NN dose/NN adjustment/NN ./.

(ROOT (S1 (S (S (NP (NN Acarbose)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB change) (NP (DT the) (NN bioavailabillty) (NN digoxin)) (SBAR (WHADVP (WRB when)) (S (NP (PRP they)) (VP (VBP are) (VP (VBN co-administered) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB require) (NP (NN digoxin) (NN dose) (NN adjustment))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d103.s6
Studies/NNS in/IN healthy/JJ volunteers/NNS have/VBP shown/VBN that/IN Acarbose/NN has/VBZ no/DT effect/NN on/IN either/CC the/DT pharmacokinetics/NNS or/CC pharmacodynamics/NNS of/IN digoxin/NN ,/, nifedipine/NN ,/, propranolol/NN ,/, or/CC ranitidine/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Studies)) (PP (IN in) (NP (JJ healthy) (NNS volunteers)))) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN Acarbose)) (VP (VBZ has) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (CC either) (DT the) (NP (NNS pharmacokinetics)) (CC or) (NP (NNS pharmacodynamics))) (PP (IN of) (NP (NP (NN digoxin)) (, ,) (NP (NN nifedipine)) (, ,) (NP (NN propranolol)) (, ,) (CC or) (NP (NN ranitidine)))))))))))) (. .))))

Sentence Id: DrugDDI.d103.s7
Acarbose/NN did/VBD not/RB interfere/VB with/IN the/DT absorption/NN or/CC disposition/NN of/IN the/DT sulfonylurea/NN glyburide/NN in/IN diabetic/JJ patients/NNS ./.

(ROOT (S1 (S (S (NP (NN Acarbose)) (VP (VBD did) (RB not) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NP (NN absorption)) (CC or) (NP (NN disposition))) (PP (IN of) (NP (DT the) (NN sulfonylurea) (NN glyburide))) (PP (IN in) (NP (JJ diabetic) (NNS patients)))))))) (. .))))

Sentence Id: DrugDDI.d103.s8
Acarbose/NN may/MD affect/VB digoxin/NN bioavailabillty/NN and/CC may/MD require/VB dose/NN adjustment/NN of/IN digoxin/NN by/IN 16/CD %/NN (/-LRB- 90/CD %/NN confidence/NN interval/NN :/: 8-23/CD %/NN )/-RRB- ,/, decrease/VB mean/NN C/NN max/NN digoxin/NN by/IN 26/CD %/NN (/-LRB- 90/CD %/NN confidence/NN interval/NN :/: 16-34/CD %/NN )/-RRB- and/CC decrease/VB mean/JJ trough/NN concentrations/NNS of/IN digoxin/NN by/IN 9/CD %/NN (/-LRB- 90/CD %/NN confidence/NN limit/NN :/: 19/CD %/NN decrease/NN to/TO 2/CD %/NN increase/NN )./NN

(ROOT (S1 (S (S (NP (NN Acarbose)) (VP (VP (MD may) (VP (VB affect) (NP (NN digoxin) (NN bioavailabillty)))) (CC and) (VP (MD may) (VP (VP (VB require) (NP (NP (NN dose) (NN adjustment)) (PP (IN of) (NP (NN digoxin)))) (PP (IN by) (NP (NP (CD 16) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 90) (NN %) (NN confidence) (NN interval) (: :) (CD 8-23) (NN %)) (-RRB- -RRB-))))) (, ,) (VP (VB decrease) (NP (NN mean) (NN C) (NN max) (NN digoxin)) (PP (IN by) (NP (NP (CD 26) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 90) (NN %) (NN confidence) (NN interval) (: :) (CD 16-34) (NN %)) (-RRB- -RRB-))))) (CC and) (VP (VB decrease) (NP (NP (JJ mean) (NN trough) (NNS concentrations)) (PP (IN of) (NP (NN digoxin)))) (PP (IN by) (NP (NP (CD 9) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 90) (NN %) (NN confidence) (NN limit)))))))))) (: :) (NP (NP (ADJP (CD 19) (NN %)) (NN decrease)) (PP (TO to) (NP (NP (ADJP (CD 2) (NN %)) (NN increase)) (NN -RRB-.)))))))

Sentence Id: DrugDDI.d103.s9
The/DT amount/NN of/IN metformin/NN absorbed/VBD while/IN taking/VBG Acarbose/NN was/VBD bioequivalent/JJ to/TO the/DT amount/NN absorbed/VBN when/WRB taking/VBG placebo/NN ,/, as/IN indicated/VBN by/IN the/DT plasma/NN AUC/NN values/NNS ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN amount)) (PP (IN of) (NP (NN metformin)))) (VP (VBD absorbed) (SBAR (IN while) (S (PP (VBG taking) (NP (NN Acarbose))) (VP (VBD was) (ADJP (JJ bioequivalent) (PP (TO to) (NP (NP (DT the) (NN amount)) (VP (VBN absorbed) (SBAR (WHADVP (WRB when)) (S (VP (VBG taking) (NP (NN placebo))))))))) (, ,) (SBAR (IN as) (S (VP (VBN indicated) (PP (IN by) (NP (DT the) (NN plasma) (NN AUC) (NNS values))))))))))) (. .))))

Sentence Id: DrugDDI.d103.s10
However/RB ,/, the/DT peak/JJ plasma/NN level/NN of/IN metformin/NN was/VBD reduced/VBN by/IN approximately/RB 20/CD %/NN when/WRB taking/VBG Acarbose/NN due/IN to/TO a/DT slight/JJ delay/NN in/IN the/DT absorption/NN of/IN metformin/NN ./.

(ROOT (S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ peak) (NN plasma) (NN level)) (PP (IN of) (NP (NN metformin)))) (VP (VBD was) (VP (VBN reduced) (PP (IN by) (NP (QP (RB approximately) (CD 20)) (NN %))) (SBAR (WHADVP (WRB when)) (S (VP (VBG taking) (NP (NN Acarbose)) (PP (IN due) (TO to) (NP (NP (DT a) (JJ slight) (NN delay)) (PP (IN in) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NN metformin))))))))))))) (. .))))

Sentence Id: DrugDDI.d103.s11
There/EX is/VBZ little/JJ if/IN any/DT clinically/RB significant/JJ interaction/NN between/IN Acarbose/NN and/CC metformin/NN ./.

(ROOT (S1 (S (S (NP (EX There)) (VP (VBZ is) (ADJP (JJ little) (PP (IN if) (NP (NP (DT any) (ADJP (RB clinically) (JJ significant)) (NN interaction)) (PP (IN between) (NP (NP (NN Acarbose)) (CC and) (NP (NN metformin))))))))) (. .))))

Sentence Id: DrugDDI.d518.s0
Catecholamine-depleting/JJ drugs/NNS ,/, such/JJ as/IN reserpine/NN ,/, may/MD have/VB an/DT additive/JJ effect/NN when/WRB given/VBN with/IN beta-blocking/JJ agent/NN s/NNS ./.

(ROOT (S1 (S (S (NP (NP (JJ Catecholamine-depleting) (NNS drugs)) (, ,) (PP (JJ such) (IN as) (NP (NN reserpine))) (, ,)) (VP (MD may) (VP (VB have) (NP (DT an) (JJ additive) (NN effect)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN with) (NP (JJ beta-blocking) (NN agent) (NNS s))))))))) (. .))))

Sentence Id: DrugDDI.d518.s1
Patients/NNS treated/VBN with/IN acebutolol/NN plus/CC catecholamine/NN depletors/NNS should/MD ,/, therefore/RB ,/, be/VB observed/VBN closely/RB for/IN evidence/NN of/IN marked/JJ bradycardia/NN or/CC hypotension/NN which/WDT may/MD present/VBP as/IN vertigo/NN ,/, syncope/presyncope/NN ,/, or/CC orthostatic/JJ changes/NNS in/IN blood/NN pressure/NN without/IN compensatory/JJ tachycardia/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NN acebutolol)) (CC plus) (NP (NN catecholamine) (NNS depletors)))))) (VP (MD should) (, ,) (ADVP (RB therefore)) (, ,) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (PP (IN for) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (NP (JJ marked) (NN bradycardia)) (CC or) (NP (NN hypotension))) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VBP present) (PP (IN as) (NP (NP (NN vertigo)) (, ,) (NP (NN syncope/presyncope)) (, ,) (CC or) (NP (NP (JJ orthostatic) (NNS changes)) (PP (IN in) (NP (NN blood) (NN pressure))) (PP (IN without) (NP (JJ compensatory) (NN tachycardia)))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d518.s2
Exaggerated/JJ hypertensive/JJ responses/NNS have/VBP been/VBN reported/VBN from/IN the/DT combined/JJ use/NN of/IN beta-adrenergic/JJ antagonist/NN s/NN and/CC alpha-adrenergic/JJ stimulants/NNS ,/, including/VBG those/DT contained/VBN in/IN proprietary/JJ cold/JJ remedies/NNS and/CC vasoconstrictive/JJ nasal/JJ drops/NN ./.

(ROOT (S1 (S (S (NP (JJ Exaggerated) (JJ hypertensive) (NNS responses)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN from) (NP (NP (DT the) (JJ combined) (NN use)) (PP (IN of) (NP (NP (JJ beta-adrenergic) (NN antagonist) (NN s)) (CC and) (NP (JJ alpha-adrenergic) (NNS stimulants)))))) (, ,) (PP (VBG including) (NP (NP (DT those)) (VP (VBN contained) (PP (IN in) (NP (NP (JJ proprietary) (JJ cold) (NNS remedies)) (CC and) (NP (JJ vasoconstrictive) (JJ nasal) (NN drops))))))))))) (. .))))

Sentence Id: DrugDDI.d518.s3
Patients/NNS receiving/VBG beta-blockers/NN should/MD be/VB warned/VBN of/IN this/DT potential/JJ hazard/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NN beta-blockers)))) (VP (MD should) (VP (VB be) (VP (VBN warned) (PP (IN of) (NP (DT this) (JJ potential) (NN hazard))))))) (. .))))

Sentence Id: DrugDDI.d518.s4
Blunting/NN of/IN the/DT antihypertensive/JJ effect/NN of/IN beta-adrenoceptor/NN blocking/NN agent/NN s/NNS by/IN nonsteroidal/JJ anti-inflammatory/JJ drugs/NNS has/VBZ been/VBN reported/VBN ./.

(ROOT (S1 (S (S (NP (NP (NN Blunting)) (PP (IN of) (NP (NP (DT the) (JJ antihypertensive) (NN effect)) (PP (IN of) (NP (NN beta-adrenoceptor) (NN blocking) (NN agent) (NNS s))))) (PP (IN by) (NP (JJ nonsteroidal) (JJ anti-inflammatory) (NNS drugs)))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported))))) (. .))))

Sentence Id: DrugDDI.d518.s5
No/DT significant/JJ interactions/NNS with/IN digoxin/NN ,/, hydrochlorothiazide/NN ,/, hydralazine/NN ,/, sulfinpyrazone/NN ,/, oral/JJ contraceptives/NNS ,/, tolbutamide/NN ,/, or/CC warfarin/NN have/VBP been/VBN observed/VBN ./.

(ROOT (S1 (S (S (NP (NP (DT No) (JJ significant) (NNS interactions)) (PP (IN with) (NP (NP (NN digoxin)) (, ,) (NP (NN hydrochlorothiazide)) (, ,) (NP (NN hydralazine)) (, ,) (NP (NN sulfinpyrazone)) (, ,) (NP (JJ oral) (NNS contraceptives)) (, ,) (NP (NN tolbutamide)) (, ,) (CC or) (NP (NN warfarin))))) (VP (VBP have) (VP (VBN been) (VP (VBN observed))))) (. .))))

Sentence Id: DrugDDI.d452.s0
DIAMOX/NN modifies/VBZ phenytoin/NN metabolism/NN with/IN increased/VBN serum/NN levels/NNS of/IN phenytoin/NN ./.

(ROOT (S1 (S (S (NP (NN DIAMOX)) (VP (VBZ modifies) (NP (NN phenytoin) (NN metabolism)) (PP (IN with) (NP (NP (VBN increased) (NN serum) (NNS levels)) (PP (IN of) (NP (NN phenytoin))))))) (. .))))

Sentence Id: DrugDDI.d452.s1
This/DT may/MD increase/VB or/CC enhance/VB the/DT occurrence/NN of/IN osteomalacia/NN in/IN some/DT patients/NNS receiving/VBG chronic/JJ phenytoin/NN therapy/NN ./.

(ROOT (S1 (S (S (NP (DT This)) (VP (MD may) (VP (VP (VB increase)) (CC or) (VP (VB enhance) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NN osteomalacia))) (PP (IN in) (NP (NP (DT some) (NNS patients)) (VP (VBG receiving) (NP (JJ chronic) (NN phenytoin) (NN therapy)))))))))) (. .))))

Sentence Id: DrugDDI.d452.s3
By/IN decreasing/VBG the/DT gastrointestinal/JJ absorption/NN of/IN primidone/NN ,/, DIAMOX/NN may/MD decrease/VB serum/NN concentrations/NNS of/IN primidone/NN and/CC its/PRP$ metabolites/NNS ,/, with/IN a/DT consequent/JJ possible/JJ decrease/NN in/IN anticonvulsant/JJ effect/NN ./.

(ROOT (S1 (S (S (PP (IN By) (S (VP (VBG decreasing) (NP (NP (DT the) (JJ gastrointestinal) (NN absorption)) (PP (IN of) (NP (NN primidone))))))) (, ,) (NP (NN DIAMOX)) (VP (MD may) (VP (VB decrease) (NP (NP (NN serum) (NNS concentrations)) (PP (IN of) (NP (NP (NN primidone)) (CC and) (NP (PRP$ its) (NNS metabolites))))) (, ,) (PP (IN with) (NP (NP (DT a) (JJ consequent) (JJ possible) (NN decrease)) (PP (IN in) (NP (JJ anticonvulsant) (NN effect)))))))) (. .))))

Sentence Id: DrugDDI.d452.s4
Caution/NN is/VBZ advised/JJ when/WRB beginning/VBG ,/, discontinuing/VBG ,/, or/CC changing/VBG the/DT dose/NN of/IN DIAMOX/NN in/IN patients/NNS receiving/VBG primidone/NN ./.

(ROOT (S1 (S (S (NP (NN Caution)) (VP (VBZ is) (ADJP (JJ advised)) (SBAR (WHADVP (WRB when)) (S (VP (VP (VBG beginning)) (, ,) (VP (VBG discontinuing)) (, ,) (CC or) (VP (VBG changing) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN DIAMOX))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN primidone)))))))))))) (. .))))

Sentence Id: DrugDDI.d452.s5
Because/IN of/IN possible/JJ additive/JJ effects/NNS with/IN other/JJ carbonic/JJ anhydrase/NN inhibitors/NNS ,/, concomitant/JJ use/NN is/VBZ not/RB advisable/JJ ./.

(ROOT (S1 (S (S (PP (IN Because) (PP (IN of) (NP (NP (JJ possible) (JJ additive) (NNS effects)) (PP (IN with) (NP (JJ other) (NP (JJ carbonic) (NN anhydrase)) (NNS inhibitors)))))) (, ,) (NP (JJ concomitant) (NN use)) (VP (VBZ is) (RB not) (ADJP (JJ advisable)))) (. .))))

Sentence Id: DrugDDI.d452.s6
Acetazolamide/NN may/MD increase/VB the/DT effects/NNS of/IN other/JJ folic/JJ acid/NN antagonists/NNS ./.

(ROOT (S1 (S (S (NP (NN Acetazolamide)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ other) (JJ folic) (NN acid) (NNS antagonists))))))) (. .))))

Sentence Id: DrugDDI.d452.s7
Acetazolamide/NN may/MD increase/VB or/CC decrease/VB blood/NN glucose/NN levels/NNS ./.

(ROOT (S1 (S (S (NP (NN Acetazolamide)) (VP (MD may) (VP (VP (VB increase)) (CC or) (VP (VB decrease) (NP (NN blood) (NN glucose) (NNS levels)))))) (. .))))

Sentence Id: DrugDDI.d452.s8
Consideration/NN should/MD be/VB taken/VBN in/IN patients/NNS being/VBG treated/VBN with/IN antidiabetic/JJ agents/NNS ./.

(ROOT (S1 (S (S (NP (NN Consideration)) (VP (MD should) (VP (VB be) (VP (VBN taken) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ antidiabetic) (NNS agents))))))))))) (. .))))

Sentence Id: DrugDDI.d452.s9
Acetazolamide/NN decreases/VBZ urinary/JJ excretion/NN of/IN amphetamine/NN and/CC may/MD enhance/VB the/DT magnitude/NN and/CC duration/NN of/IN their/PRP$ effect/NN ./.

(ROOT (S1 (S (S (NP (NN Acetazolamide)) (VP (VP (VBZ decreases) (NP (NP (JJ urinary) (NN excretion)) (PP (IN of) (NP (NN amphetamine))))) (CC and) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NP (NP (NN magnitude)) (CC and) (NP (NN duration)))) (PP (IN of) (NP (PRP$ their) (NN effect)))))))) (. .))))

Sentence Id: DrugDDI.d452.s10
Acetazolamide/NN reduces/VBZ urinary/JJ excretion/NN of/IN quinidine/NN and/CC may/MD enhance/VB its/PRP$ effect/NN ./.

(ROOT (S1 (S (S (NP (NN Acetazolamide)) (VP (VP (VBZ reduces) (NP (NP (JJ urinary) (NN excretion)) (PP (IN of) (NP (NN quinidine))))) (CC and) (VP (MD may) (VP (VB enhance) (NP (PRP$ its) (NN effect)))))) (. .))))

Sentence Id: DrugDDI.d452.s11
Acetazolamide/NN may/MD prevent/VB the/DT urinary/JJ antiseptic/JJ effect/NN of/IN methenamine/NN ./.

(ROOT (S1 (S (S (NP (NN Acetazolamide)) (VP (MD may) (VP (VB prevent) (NP (NP (DT the) (JJ urinary) (JJ antiseptic) (NN effect)) (PP (IN of) (NP (NN methenamine))))))) (. .))))

Sentence Id: DrugDDI.d452.s12
Acetazolamide/NN increases/VBZ lithium/NN excretion/NN and/CC the/DT lithium/NN may/MD be/VB decreased/VBN ./.

(ROOT (S1 (S (S (S (NP (NN Acetazolamide)) (VP (VBZ increases) (NP (NN lithium) (NN excretion)))) (CC and) (S (NP (DT the) (NN lithium)) (VP (MD may) (VP (VB be) (VP (VBN decreased)))))) (. .))))

Sentence Id: DrugDDI.d452.s13
Acetazolamide/NN and/CC sodium/NN bicarbonate/NN used/VBN concurrently/RB increases/VBZ the/DT risk/NN of/IN renal/JJ calculus/NNS formation/NN ./.

(ROOT (S1 (S (S (NP (NP (NP (NN Acetazolamide)) (CC and) (NP (NN sodium) (NN bicarbonate))) (VP (VBN used) (ADVP (RB concurrently)))) (VP (VBZ increases) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ renal) (NNS calculus) (NN formation)))))) (. .))))

Sentence Id: DrugDDI.d452.s14
Acetazolamide/NN may/MD elevate/VBP cyclosporine/NN levels/NNS ./.

(ROOT (S1 (S (S (NP (NN Acetazolamide)) (VP (MD may) (VP (VBP elevate) (NP (NN cyclosporine) (NNS levels))))) (. .))))

Sentence Id: DrugDDI.d60.s0
As/IN DIFFERIN/NN Gel/NN has/VBZ the/DT potential/NN to/TO produce/VB local/JJ irritation/NN in/IN some/DT patients/NNS ,/, concomitant/JJ use/NN of/IN other/JJ potentially/RB irritating/JJ topical/JJ products/NNS (/-LRB- medicated/JJ or/CC abrasive/JJ soaps/NNS and/CC cleansers/NNS ,/, soaps/NNS and/CC cosmetics/NNS that/WDT have/VBP a/DT strong/JJ drying/NN effect/NN ,/, and/CC products/NNS with/IN high/JJ concentrations/NNS of/IN alcohol/NN ,/, astringents/NNS ,/, spices/NNS or/CC lime/NN )/-RRB- should/MD be/VB approached/VBN with/IN caution/NN ./.

(ROOT (S1 (S (SBAR (IN As) (S (NP (NN DIFFERIN) (NN Gel)) (VP (VBZ has) (NP (NP (DT the) (NN potential)) (VP (TO to) (VP (VB produce) (NP (JJ local) (NN irritation)) (PP (IN in) (NP (DT some) (NNS patients))))))))) (, ,) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (JJ other) (ADJP (RB potentially) (JJ irritating)) (JJ topical) (NNS products)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (ADJP (ADJP (JJ medicated)) (CC or) (ADJP (JJ abrasive))) (NP (NP (NNS soaps)) (CC and) (NP (NNS cleansers)))) (, ,) (NP (NP (NP (NNS soaps)) (CC and) (NP (NNS cosmetics))) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (NP (DT a) (JJ strong) (NN drying) (NN effect)))))) (, ,) (CC and) (NP (NNS products))) (PP (IN with) (NP (NP (JJ high) (NNS concentrations)) (PP (IN of) (NP (NN alcohol)))))) (, ,) (NP (NNS astringents)) (, ,) (NP (NNS spices)) (CC or) (NP (NN lime))) (-RRB- -RRB-))))) (VP (MD should) (VP (VB be) (VP (VBN approached) (PP (IN with) (NP (NN caution)))))) (. .))))

Sentence Id: DrugDDI.d60.s1
Particular/JJ caution/NN should/MD be/VB exercised/VBN in/IN using/VBG preparations/NNS containing/VBG sulfur/NN ,/, resorcinol/JJ ,/, or/CC salicylic/JJ acid/NN in/IN combination/NN with/IN DIFFERIN/NN Gel/NN ./.

(ROOT (S1 (S (S (NP (JJ Particular) (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (PP (IN in) (S (VP (VBG using) (NP (NP (NNS preparations)) (VP (VBG containing) (NP (NP (NN sulfur)) (, ,) (NP (ADJP (JJ resorcinol))) (, ,) (CC or) (NP (JJ salicylic) (NN acid))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN DIFFERIN) (NN Gel)))))))))))))) (. .))))

Sentence Id: DrugDDI.d60.s2
If/IN these/DT preparations/NNS have/VBP been/VBN used/VBN it/PRP is/VBZ advisable/JJ not/RB to/TO start/NN therapy/NN with/IN DIFFERIN/NN Gel/NN until/IN the/DT effects/NNS of/IN such/JJ preparations/NNS in/IN the/DT skin/NN have/VBP subsided/VBN ./.

(ROOT (S1 (S (S (SBAR (IN If) (S (NP (DT these) (NNS preparations)) (VP (VBP have) (VP (VBN been) (VP (VBN used)))))) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ advisable) (PP (RB not) (TO to) (NP (NP (NN start) (NN therapy)) (PP (IN with) (NP (NN DIFFERIN) (NN Gel)))))) (SBAR (IN until) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ such) (NNS preparations))) (PP (IN in) (NP (DT the) (NN skin)))) (VP (VBP have) (VP (VBN subsided))))))) (. .))))

Sentence Id: DrugDDI.d409.s0
Before/IN using/VBG this/DT medication/NN ,/, tell/NN your/NN doctor/NN or/CC pharmacist/NN of/IN all/DT prescription/NN and/CC nonprescription/NN products/NNS you/VBZ may/MD use/VB ,/, especially/RB of/IN :/: aminoglycosides/NN (/-LRB- e.g./FW ,/, gentamicin/NN ,/, amikacin/NN )/-RRB- ,/, amphotericin/NN B/NN ,/, cyclosporine/NN ,/, non-steroidal/JJ anti-inflammatory/JJ drugs/NNS (/-LRB- e.g./FW ,/, ibuprofen/NN )/-RRB- ,/, tacrolimus/NN ,/, vancomycin/NN ./.

(ROOT (S1 (S (PP (IN Before) (S (VP (VBG using) (NP (DT this) (NN medication))))) (, ,) (NP (NP (NP (NN tell) (NN your) (NN doctor)) (CC or) (NP (NN pharmacist))) (PP (IN of) (NP (DT all) (NN prescription) (CC and) (NN nonprescription) (NNS products)))) (VP (VBZ you) (S (VP (MD may) (VP (VB use) (, ,) (ADVP (RB especially)) (PP (IN of) (: :) (NP (NP (NP (NN aminoglycosides)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN gentamicin))) (, ,) (NP (NN amikacin)) (-RRB- -RRB-))) (, ,) (NP (NN amphotericin) (NN B)) (, ,) (NP (NN cyclosporine)) (, ,) (NP (NP (JJ non-steroidal) (JJ anti-inflammatory) (NNS drugs)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN ibuprofen)) (-RRB- -RRB-))) (, ,) (NP (NN tacrolimus)) (, ,) (NP (NN vancomycin)))))))) (. .))))

Sentence Id: DrugDDI.d409.s1
Do/VBP not/RB start/VBP or/CC stop/NN any/DT medicine/NN without/IN doctor/NN or/CC pharmacist/NN approval/NN ./.

(ROOT (S1 (S (S (VP (VP (VBP Do) (RB not) (VP (VBP start))) (CC or) (VP (NN stop) (NP (DT any) (NN medicine)) (PP (IN without) (NP (NP (NN doctor)) (CC or) (NP (NN pharmacist)) (NP (NN approval))))))) (. .))))

Sentence Id: DrugDDI.d167.s0
Drug/NN /Laboratory/NN Interactions/NNS :/: No/DT formal/JJ drug/NN interaction/NN studies/NNS have/VBP been/VBN performed/VBN with/IN Campath/NN ./.

(ROOT (S1 (S (NP (NP (NN Drug) (NN /Laboratory) (NNS Interactions)) (: :) (S (NP (DT No) (JJ formal) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN performed) (PP (IN with) (NP (NN Campath))))))) (. .)))))

Sentence Id: DrugDDI.d167.s1
An/DT immune/JJ response/NN to/TO Campath/NN may/MD interfere/VB with/IN subsequent/JJ diagnostic/JJ serum/NN tests/NNS that/WDT utilize/VBP antibodies/NNS ./.

(ROOT (S1 (S (S (NP (NP (DT An) (JJ immune) (NN response)) (PP (TO to) (NP (NN Campath)))) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (JJ subsequent) (JJ diagnostic) (NN serum) (NNS tests)) (SBAR (WHNP (WDT that)) (S (VP (VBP utilize) (NP (NNS antibodies)))))))))) (. .))))

Sentence Id: DrugDDI.d450.s0
Because/IN alosetron/NN is/VBZ metabolized/VBN by/IN a/DT variety/NN of/IN hepatic/JJ CYP/JJ drug-metabolizing/JJ enzymes/NNS ,/, inducers/NNS or/CC inhibitors/NNS of/IN these/DT enzymes/NNS may/MD change/VB the/DT clearance/NN of/IN alosetron/NN ./.

(ROOT (S1 (S (S (SBAR (IN Because) (S (NP (NN alosetron)) (VP (VBZ is) (VP (VBN metabolized) (PP (IN by) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (JJ hepatic) (JJ CYP) (JJ drug-metabolizing) (NNS enzymes))))))))) (, ,) (NP (NP (NP (NNS inducers)) (CC or) (NP (NNS inhibitors))) (PP (IN of) (NP (DT these) (NNS enzymes)))) (VP (MD may) (VP (VB change) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN alosetron))))))) (. .))))

Sentence Id: DrugDDI.d450.s1
Fluvoxamine/NN is/VBZ a/DT known/JJ strong/JJ inhibitor/NN of/IN CYP1A2/NN and/CC also/RB inhibits/VBZ CYP3A4/NN ,/, CYP2C9/NN ,/, and/CC CYP2C19/NN ./.

(ROOT (S1 (S (S (S (NP (NN Fluvoxamine)) (VP (VBZ is) (NP (NP (DT a) (JJ known) (JJ strong) (NN inhibitor)) (PP (IN of) (NP (NN CYP1A2)))))) (CC and) (S (ADVP (RB also)) (VP (VBZ inhibits) (NP (NP (NN CYP3A4)) (, ,) (NP (NN CYP2C9)) (, ,) (CC and) (NP (NN CYP2C19)))))) (. .))))

Sentence Id: DrugDDI.d450.s2
In/IN a/DT pharmacokinetic/JJ study/NN ,/, 40/CD healthy/JJ female/NN subjects/NNS received/VBD fluvoxamine/NN in/IN escalating/JJ doses/NNS from/IN 50/CD to/TO 200/CD mg/NN per/IN day/NN for/IN 16/CD days/NNS ,/, with/IN coadministration/NN of/IN alosetron/NN 1/CD mg/NN on/IN the/DT last/JJ day/NN ./.

(ROOT (S1 (S (PP (IN In) (NP (DT a) (JJ pharmacokinetic) (NN study))) (, ,) (NP (CD 40) (JJ healthy) (NN female) (NNS subjects)) (VP (VBD received) (NP (NP (NN fluvoxamine)) (PP (IN in) (NP (NP (JJ escalating) (NNS doses)) (PP (IN from) (NP (NP (QP (CD 50) (TO to) (CD 200)) (NN mg)) (PP (IN per) (NP (NN day))) (PP (IN for) (NP (CD 16) (NNS days)))))))) (, ,) (PP (IN with) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NN alosetron) (CD 1) (NN mg)) (PP (IN on) (NP (DT the) (JJ last) (NN day)))))))) (. .))))

Sentence Id: DrugDDI.d450.s3
Fluvoxamine/NN increased/VBD mean/JJ alosetron/NN plasma/NN concentrations/NNS (/-LRB- AUC/NN )/-RRB- approximately/RB 6-fold/RB and/CC prolonged/VBD the/DT half-life/NN by/IN approximately/RB 3-fold/RB ./.

(ROOT (S1 (S (S (NP (NN Fluvoxamine)) (VP (VP (VBD increased) (NP (NP (JJ mean) (NN alosetron) (NN plasma) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (NN AUC)) (-RRB- -RRB-))) (ADVP (RB approximately) (RB 6-fold))) (CC and) (VP (VBD prolonged) (NP (DT the) (NN half-life)) (PP (IN by) (NP (RB approximately) (RB 3-fold)))))) (. .))))

Sentence Id: DrugDDI.d450.s4
Concomitant/JJ administration/NN of/IN alosetron/NN and/CC fluvoxamine/NN is/VBZ contraindicated/VBN ./.

(ROOT (S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN alosetron)) (CC and) (NP (NN fluvoxamine))))) (VP (VBZ is) (VP (VBN contraindicated)))) (. .))))

Sentence Id: DrugDDI.d450.s5
Concomitant/JJ administration/NN of/IN alosetron/NN and/CC moderate/JJ CYP1A2/NN inhibitors/NNS ,/, including/VBG quinolone/NN antibiotic/JJ s/NN and/CC cimetidine/NN ,/, has/VBZ not/RB been/VBN evaluated/VBN ,/, but/CC should/MD be/VB avoided/VBN unless/IN clinically/RB necessary/JJ because/IN of/IN similar/JJ potential/JJ drug/NN interactions/NNS ./.

(ROOT (S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN alosetron)) (CC and) (NP (NP (JJ moderate) (NN CYP1A2) (NNS inhibitors)) (, ,) (PP (VBG including) (NP (NP (NN quinolone) (JJ antibiotic) (NN s)) (CC and) (NP (NN cimetidine)))) (, ,))))) (VP (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN evaluated)))) (, ,) (CC but) (VP (MD should) (VP (VB be) (VP (VBN avoided) (PP (IN unless) (ADJP (RB clinically) (JJ necessary))) (PP (IN because) (IN of) (NP (JJ similar) (JJ potential) (NN drug) (NNS interactions)))))))) (. .))))

Sentence Id: DrugDDI.d450.s6
Ketoconazole/NN is/VBZ a/DT known/JJ strong/JJ inhibitor/NN of/IN CYP3A4/NN ./.

(ROOT (S1 (S (S (NP (NN Ketoconazole)) (VP (VBZ is) (NP (NP (DT a) (JJ known) (JJ strong) (NN inhibitor)) (PP (IN of) (NP (NN CYP3A4)))))) (. .))))

Sentence Id: DrugDDI.d450.s7
In/IN a/DT pharmacokinetic/JJ study/NN ,/, 38/CD healthy/JJ female/JJ subjects/NNS received/VBD ketoconazole/NN 200/CD mg/NN twice/RB daily/JJ for/IN 7/CD days/NNS ,/, with/IN coadministration/NN of/IN alosetron/NN 1/CD mg/NN on/IN the/DT last/JJ day/NN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (DT a) (JJ pharmacokinetic) (NN study))) (, ,) (NP (CD 38) (JJ healthy) (JJ female) (NNS subjects)) (VP (VBD received) (NP (NP (NN ketoconazole) (CD 200) (NN mg)) (ADJP (RB twice) (JJ daily) (PP (IN for) (NP (CD 7) (NNS days))))) (, ,) (PP (IN with) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NN alosetron) (CD 1) (NN mg)) (PP (IN on) (NP (DT the) (JJ last) (NN day))))))))) (. .))))

Sentence Id: DrugDDI.d450.s8
Ketoconazole/NN increased/VBD mean/JJ alosetron/NN plasma/NN concentrations/NNS (/-LRB- AUC/NN )/-RRB- by/IN 29/CD %./NN

(ROOT (S1 (S (NP (NN Ketoconazole)) (VP (VBD increased) (NP (NP (JJ mean) (NN alosetron) (NN plasma) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (NN AUC)) (-RRB- -RRB-))) (PP (IN by) (NP (CD 29) (NN %.)))))))

Sentence Id: DrugDDI.d450.s9
Caution/NN should/MD be/VB used/VBN when/WRB alosetron/NN and/CC ketoconazole/NN are/VBP administered/VBN concomitantly/RB ./.

(ROOT (S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN used))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN alosetron)) (CC and) (NP (NN ketoconazole))) (VP (VBP are) (VP (VBN administered) (ADVP (RB concomitantly)))))))) (. .))))

Sentence Id: DrugDDI.d450.s10
Coadministration/NN of/IN alosetron/JJ and/CC strong/JJ CYP3A4/JJ inhibitors/NNS ,/, such/JJ as/IN clarithromycin/NN ,/, telithromycin/NN ,/, protease/NN inhibitors/NNS ,/, voriconazole/NN ,/, and/CC itraconazole/NN has/VBZ not/RB been/VBN evaluated/VBN but/CC should/MD be/VB undertaken/VBN with/IN caution/NN because/IN of/IN similar/JJ potential/JJ drug/NN interactions/NNS ./.

(ROOT (S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ alosetron)) (CC and) (ADJP (JJ strong))) (JJ CYP3A4) (NNS inhibitors)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN clarithromycin)) (, ,) (NP (NN telithromycin)) (, ,) (NP (NN protease) (NNS inhibitors)) (, ,) (NP (NN voriconazole)) (, ,) (CC and) (NP (NN itraconazole))))))) (VP (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN evaluated)))) (CC but) (VP (MD should) (VP (VB be) (VP (VBN undertaken) (PP (IN with) (NP (NN caution))) (PP (IN because) (IN of) (NP (JJ similar) (JJ potential) (NN drug) (NNS interactions)))))))) (. .))))

Sentence Id: DrugDDI.d450.s11
The/DT effect/NN of/IN induction/NN or/CC inhibition/NN of/IN other/JJ pathways/NNS on/IN exposure/NN to/TO alosetron/NN and/CC its/PRP$ metabolites/NNS is/VBZ not/RB known/VBN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (NP (NN induction)) (CC or) (NP (NN inhibition))) (PP (IN of) (NP (JJ other) (NNS pathways))))) (PP (IN on) (NP (NP (NN exposure)) (PP (TO to) (NP (NP (NN alosetron)) (CC and) (NP (PRP$ its) (NNS metabolites))))))) (VP (VBZ is) (RB not) (VP (VBN known)))) (. .))))

Sentence Id: DrugDDI.d450.s12
In/FW vitro/FW human/JJ liver/NN microsome/NN studies/NNS and/CC an/DT in/FW vivo/FW metabolic/JJ probe/NN study/NN demonstrated/VBD that/IN alosetron/NN did/VBD not/RB inhibit/VB CYP/NN enzyme/NN s/NN 2D6/NN ,/, 3A4/NN ,/, 2C9/NN ,/, or/CC 2C19/NN ./.

(ROOT (S1 (S (S (NP (NP (ADJP (FW In) (FW vitro)) (JJ human) (NN liver) (NN microsome) (NNS studies)) (CC and) (NP (DT an) (ADJP (FW in) (FW vivo)) (JJ metabolic) (NN probe) (NN study))) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NN alosetron)) (VP (VBD did) (RB not) (VP (VB inhibit) (NP (NP (NN CYP) (NN enzyme) (NN s) (NN 2D6)) (, ,) (NP (NN 3A4)) (, ,) (NP (NN 2C9)) (, ,) (CC or) (NP (NN 2C19))))))))) (. .))))

Sentence Id: DrugDDI.d450.s13
In/FW vitro/FW ,/, at/IN total/JJ drug/NN concentrations/NNS 27-fold/RB higher/JJR than/IN peak/NN plasma/NN concentrations/NNS observed/VBN with/IN the/DT 1-mg/JJ dosage/NN ,/, alosetron/NN inhibited/VBD CYP/NN enzyme/NN s/NN 1A2/NN (/-LRB- 60/CD %/NN )/-RRB- and/CC 2E1/NN (/-LRB- 50%)./NN

(ROOT (S1 (S (ADVP (FW In) (FW vitro)) (, ,) (PP (IN at) (NP (NP (JJ total) (NN drug) (NNS concentrations)) (ADJP (RB 27-fold) (JJR higher) (PP (IN than) (NP (NP (NN peak) (NN plasma) (NNS concentrations)) (VP (VBN observed) (PP (IN with) (NP (DT the) (JJ 1-mg) (NN dosage))))))))) (, ,) (NP (NN alosetron)) (VP (VBD inhibited) (NP (NP (NP (NN CYP) (NN enzyme) (NN s) (NN 1A2)) (PRN (-LRB- -LRB-) (NP (CD 60) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NN 2E1)))) (PRN (-LRB- -LRB-) (NP (NN 50%-RRB-.))))))

Sentence Id: DrugDDI.d450.s14
In/IN an/DT in/FW vivo/FW metabolic/JJ probe/NN study/NN ,/, alosetron/NN did/VBD not/RB inhibit/VB CYP2E1/NN but/CC did/VBD produce/VB 30/CD %/NN inhibition/NN of/IN both/CC CYP1A2/NN and/CC N-acetyltransferase/NN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (DT an) (ADJP (FW in) (FW vivo)) (JJ metabolic) (NN probe) (NN study))) (, ,) (NP (NN alosetron)) (VP (VP (VBD did) (RB not) (VP (VB inhibit) (NP (NN CYP2E1)))) (CC but) (VP (VBD did) (VP (VB produce) (NP (NP (ADJP (CD 30) (NN %)) (NN inhibition)) (PP (IN of) (NP (CC both) (NP (NN CYP1A2)) (CC and) (NP (NN N-acetyltransferase))))))))) (. .))))

Sentence Id: DrugDDI.d450.s15
Although/IN not/RB studied/VBN with/IN alosetron/NN ,/, inhibition/NN of/IN N-/NN acetyltransferase/NN may/MD have/VB clinically/RB relevant/JJ consequences/NNS for/IN drugs/NNS such/JJ as/IN isoniazid/NN ,/, procainamide/NN ,/, and/CC hydralazine/NN ./.

(ROOT (S1 (S (S (SBAR (IN Although) (S (VP (RB not) (VBN studied) (PP (IN with) (NP (NN alosetron)))))) (, ,) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN N-) (NN acetyltransferase)))) (VP (MD may) (VP (VB have) (NP (ADJP (RB clinically) (JJ relevant)) (NNS consequences)) (PP (IN for) (NP (NP (NNS drugs)) (PP (JJ such) (IN as) (NP (NP (NN isoniazid)) (, ,) (NP (NN procainamide)) (, ,) (CC and) (NP (NN hydralazine))))))))) (. .))))

Sentence Id: DrugDDI.d450.s16
The/DT effect/NN on/IN CYP1A2/NN was/VBD explored/VBN further/RB in/IN a/DT clinical/JJ interaction/NN study/NN with/IN theophylline/NN and/CC no/DT effect/NN on/IN metabolism/NN was/VBD observed/VBN ./.

(ROOT (S1 (S (S (S (NP (NP (DT The) (NN effect)) (PP (IN on) (NP (NN CYP1A2)))) (VP (VBD was) (VP (VBN explored) (ADVP (RB further)) (PP (IN in) (NP (NP (DT a) (JJ clinical) (NN interaction) (NN study)) (PP (IN with) (NP (NN theophylline)))))))) (CC and) (S (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NN metabolism)))) (VP (VBD was) (VP (VBN observed))))) (. .))))

Sentence Id: DrugDDI.d450.s17
Another/DT study/NN showed/VBD that/IN alosetron/NN had/VBD no/DT clinically/RB significant/JJ effect/NN on/IN plasma/NN concentrations/NNS of/IN the/DT oral/JJ contraceptive/JJ agent/NN s/NN ethinyl/NN estradiol/NN and/CC levonorgestrel/NN (/-LRB- CYP3A4/NN substrates/NNS )./CD

(ROOT (S1 (S (NP (DT Another) (NN study)) (VP (VBD showed) (SBAR (IN that) (S (NP (NN alosetron)) (VP (VBD had) (NP (DT no) (ADJP (RB clinically) (JJ significant)) (NN effect)) (PP (IN on) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (DT the) (JJ oral) (JJ contraceptive) (NN agent) (NN s) (NN ethinyl) (NN estradiol)) (CC and) (NP (NN levonorgestrel)))))) (PRN (-LRB- -LRB-) (NP (NN CYP3A4) (NNS substrates) (CD -RRB-.))))))))))

Sentence Id: DrugDDI.d450.s18
A/DT clinical/JJ interaction/NN study/NN was/VBD also/RB conducted/VBN with/IN alosetron/NN and/CC the/DT CYP3A4/NN substrate/NN cisapride/NN ./.

(ROOT (S1 (S (S (NP (DT A) (JJ clinical) (NN interaction) (NN study)) (VP (VBD was) (ADVP (RB also)) (VP (VBN conducted) (PP (IN with) (NP (NP (NN alosetron)) (CC and) (NP (DT the) (NN CYP3A4) (NN substrate) (NN cisapride))))))) (. .))))

Sentence Id: DrugDDI.d450.s19
No/DT significant/JJ effects/NNS on/IN cisapride/NN metabolism/NN or/CC QT/NN interval/NN were/VBD noted/VBN ./.

(ROOT (S1 (S (S (NP (NP (DT No) (JJ significant) (NNS effects)) (PP (IN on) (NP (NP (NN cisapride) (NN metabolism)) (CC or) (NP (NN QT) (NN interval))))) (VP (VBD were) (VP (VBN noted)))) (. .))))

Sentence Id: DrugDDI.d450.s20
The/DT effect/NN of/IN alosetron/NN on/IN monoamine/NN oxidases/NNS and/CC on/IN intestinal/JJ first/JJ pass/NN secondary/JJ to/TO high/JJ intraluminal/JJ concentrations/NNS have/VBP not/RB been/VBN examined/VBN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN alosetron))) (PP (PP (IN on) (NP (NN monoamine) (NNS oxidases))) (CC and) (PP (IN on) (NP (NP (JJ intestinal) (JJ first) (NN pass)) (ADJP (JJ secondary) (PP (TO to) (NP (JJ high) (JJ intraluminal) (NNS concentrations)))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN examined))))) (. .))))

Sentence Id: DrugDDI.d450.s21
Based/VBN on/IN the/DT above/JJ data/NNS from/IN in/FW vitro/FW and/CC in/FW vivo/FW studies/NNS ,/, it/PRP is/VBZ unlikely/JJ that/IN alosetron/NN will/MD inhibit/VB the/DT hepatic/JJ metabolic/JJ clearance/NN of/IN drugs/NNS metabolized/VBN by/IN the/DT major/JJ CYP/NN enzyme/NN 3A4/NN ,/, as/RB well/RB as/IN the/DT CYP/NN enzyme/NN s/NN 2D6/NN ,/, 2C9/NN ,/, 2C19/NN ,/, 2E1/NN ,/, or/CC 1A2/NN ./.

(ROOT (S1 (S (S (PP (VBN Based) (PP (IN on) (NP (NP (DT the) (JJ above) (NNS data)) (PP (IN from) (NP (ADJP (ADJP (FW in) (FW vitro)) (CC and) (ADJP (FW in) (FW vivo))) (NNS studies)))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ unlikely) (SBAR (IN that) (S (NP (NN alosetron)) (VP (MD will) (VP (VB inhibit) (NP (NP (DT the) (JJ hepatic) (JJ metabolic) (NN clearance)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (NP (DT the) (JJ major) (NN CYP) (NN enzyme) (NN 3A4)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (DT the) (NN CYP) (NN enzyme) (NN s) (NN 2D6)) (, ,) (NP (NN 2C9)) (, ,) (NP (NN 2C19)) (, ,) (NP (NN 2E1)) (, ,) (CC or) (NP (NN 1A2))))))))))))))) (. .))))

Sentence Id: DrugDDI.d450.s22
Alosetron/NN does/VBZ not/RB appear/VB to/TO induce/VB the/DT major/JJ cytochrome/NN P450/NN (/-LRB- CYP/NN )/-RRB- drug/NN metabolizing/NN enzyme/NN 3A/NN ./.

(ROOT (S1 (S (S (NP (NN Alosetron)) (VP (VBZ does) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB induce) (NP (NP (NP (DT the) (JJ major) (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN CYP)) (-RRB- -RRB-))) (NP (NN drug) (NN metabolizing) (NN enzyme) (NN 3A))))))))) (. .))))

Sentence Id: DrugDDI.d450.s23
Alosetron/NN also/RB does/VBZ not/RB appear/VB to/TO induce/VB CYP/NN enzyme/NN s/NNS 2E1/NN or/CC 2C19/NN ./.

(ROOT (S1 (S (S (NP (NN Alosetron)) (ADVP (RB also)) (VP (VBZ does) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB induce) (NP (NN CYP) (NN enzyme) (NNS s) (NP (NP (NN 2E1)) (CC or) (NP (NN 2C19)))))))))) (. .))))

Sentence Id: DrugDDI.d450.s24
It/PRP is/VBZ not/RB known/VBN whether/IN alosetron/NN might/MD induce/VBP other/JJ enzymes/NNS ./.

(ROOT (S1 (S (S (NP (PRP It)) (VP (VBZ is) (RB not) (VP (VBN known) (SBAR (IN whether) (S (NP (NN alosetron)) (VP (MD might) (VP (VBP induce) (NP (JJ other) (NNS enzymes))))))))) (. .))))

Sentence Id: DrugDDI.d503.s0
The/DT interaction/NN of/IN Activase/NN with/IN other/JJ cardioactive/JJ or/CC cerebroactive/JJ drugs/NNS has/VBZ not/RB been/VBN studied/VBN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN interaction)) (PP (IN of) (NP (NN Activase))) (PP (IN with) (NP (JJ other) (ADJP (ADJP (JJ cardioactive)) (CC or) (ADJP (JJ cerebroactive))) (NNS drugs)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .))))

Sentence Id: DrugDDI.d503.s1
In/IN addition/NN to/TO bleeding/JJ associated/VBN with/IN heparin/NN and/CC vitamin/NN K/NN antagonists/NNS ,/, drugs/NNS that/WDT alter/VBP platelet/NN function/NN (/-LRB- such/JJ as/IN acetylsalicylic/JJ acid/NN ,/, dipyridamole/NN and/CC Abciximab/NN )/-RRB- may/MD increase/VB the/DT risk/NN of/IN bleeding/JJ if/IN administered/VBN prior/RB to/TO ,/, during/IN ,/, or/CC after/IN Activase/NN therapy/NN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (NP (JJ bleeding)) (VP (VBN associated) (PP (IN with) (NP (NP (NN heparin)) (CC and) (NP (NN vitamin) (NN K) (NNS antagonists))))))))) (, ,) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP alter) (NP (NN platelet) (NN function)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NP (JJ acetylsalicylic) (NN acid)) (, ,) (NP (NN dipyridamole)) (CC and) (NP (NN Abciximab))))) (-RRB- -RRB-)))))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (JJ bleeding)) (SBAR (IN if) (S (VP (VBN administered) (ADVP (ADVP (RB prior)) (PP (TO to))))))))) (, ,) (PP (PP (IN during)) (, ,) (CC or) (PP (IN after) (NP (NN Activase) (NN therapy))))))) (. .))))

Sentence Id: DrugDDI.d503.s2
Use/NN of/IN Antithrombotics/NN Aspirin/NN and/CC heparin/NN have/VBP been/VBN administered/VBN concomitantly/RB with/IN and/CC following/VBG infusions/NNS of/IN Activase/NN in/IN the/DT management/NN of/IN acute/JJ myocardial/JJ infarction/NN or/CC pulmonary/JJ embolism/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Use)) (PP (IN of) (NP (NP (NN Antithrombotics) (NN Aspirin)) (CC and) (NP (NN heparin))))) (VP (VBP have) (VP (VBN been) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (CC and) (VBG following) (NNS infusions)) (PP (IN of) (NP (NN Activase))))) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NP (JJ acute) (JJ myocardial) (NN infarction)) (CC or) (NP (JJ pulmonary) (NN embolism)))))))))) (. .))))

Sentence Id: DrugDDI.d503.s3
Because/IN heparin/NN ,/, aspirin/NN ,/, or/CC Activase/NN may/MD cause/VB bleeding/JJ complications/NNS ,/, careful/JJ monitoring/NN for/IN bleeding/JJ is/VBZ advised/JJ ,/, especially/RB at/IN arterial/JJ puncture/NN sites/NNS ./.

(ROOT (S1 (S (S (SBAR (IN Because) (S (NP (NP (NN heparin)) (, ,) (NP (NN aspirin)) (, ,) (CC or) (NP (NN Activase))) (VP (MD may) (VP (VB cause) (NP (JJ bleeding) (NNS complications)))))) (, ,) (NP (NP (JJ careful) (NN monitoring)) (PP (IN for) (NP (JJ bleeding)))) (VP (VBZ is) (ADJP (JJ advised)) (, ,) (PP (ADVP (RB especially)) (IN at) (NP (JJ arterial) (NN puncture) (NNS sites))))) (. .))))

Sentence Id: DrugDDI.d503.s4
The/DT concomitant/JJ use/NN of/IN heparin/NN or/CC aspirin/NN during/IN the/DT first/JJ 24/CD hours/NNS following/VBG symptom/NN onset/NN were/VBD prohibit/VB ed/NN in/IN The/DT NINDS/NN t-PA/NN Stroke/JJ Trial/NN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN heparin)) (CC or) (NP (NN aspirin)))) (PP (IN during) (NP (NP (DT the) (JJ first) (CD 24) (NNS hours)) (PP (VBG following) (NP (NN symptom) (NN onset)))))) (VP (VBD were) (VP (VB prohibit) (NP (NN ed)) (PP (IN in) (NP (DT The) (NN NINDS) (NN t-PA) (JJ Stroke) (NN Trial)))))) (. .))))

Sentence Id: DrugDDI.d503.s5
The/DT safety/NN of/IN such/JJ concomitant/JJ use/NN with/IN Activase/NN for/IN the/DT management/NN of/IN acute/JJ ischemic/JJ stroke/NN is/VBZ unknown/JJ ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN safety)) (PP (IN of) (NP (NP (JJ such) (JJ concomitant) (NN use)) (PP (IN with) (NP (NN Activase))))) (PP (IN for) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (JJ acute) (JJ ischemic) (NN stroke)))))) (VP (VBZ is) (ADJP (JJ unknown)))) (. .))))

Sentence Id: DrugDDI.d0.s0
Special/JJ consideration/NN should/MD be/VB given/VBN to/TO the/DT administration/NN of/IN ETHYOL/NN @/NN in/IN patients/NNS receiving/VBG antihypertensive/JJ medications/NNS or/CC other/JJ drugs/NNS that/WDT could/MD cause/VB or/CC potentiate/VB hypotension/NN ./.

(ROOT (S1 (S (S (NP (JJ Special) (NN consideration)) (VP (MD should) (VP (VB be) (VP (VBN given) (PP (TO to) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (NN ETHYOL) (NN @)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NP (JJ antihypertensive) (NNS medications)) (CC or) (NP (JJ other) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (VP (VB cause)) (CC or) (VP (VB potentiate) (NP (NN hypotension))))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d153.s0
Renal/JJ clearance/NN measurements/NNS of/IN PAH/NN cannot/MD be/VB made/VBN with/IN any/DT significant/JJ accuracy/NN in/IN patients/NNS receiving/VBG sulfonamides/NNS ,/, procaine/NN ,/, or/CC thiazolesulfone/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Renal) (NN clearance) (NNS measurements)) (PP (IN of) (NP (NN PAH)))) (VP (MD cannot) (VP (VB be) (VP (VBN made) (PP (IN with) (NP (NP (DT any) (JJ significant) (NN accuracy)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NNS sulfonamides)) (, ,) (NP (NN procaine)) (, ,) (CC or) (NP (NN thiazolesulfone)))))))))))) (. .))))

Sentence Id: DrugDDI.d153.s2
Probenecid/NN depresses/VBZ tubular/JJ secretion/NN of/IN certain/JJ weak/JJ acids/NNS such/JJ as/IN PAH/NN ./.

(ROOT (S1 (S (S (NP (NN Probenecid)) (VP (VBZ depresses) (NP (NP (JJ tubular) (NN secretion)) (PP (IN of) (NP (NP (JJ certain) (JJ weak) (NNS acids)) (PP (JJ such) (IN as) (NP (NN PAH)))))))) (. .))))

Sentence Id: DrugDDI.d153.s3
Therefore/RB ,/, patients/NNS receiving/VBG probenecid/NN will/MD have/VB erroneously/RB low/JJ ERPF/NN and/CC Tm/NN PAH/NN values/NNS ./.

(ROOT (S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN probenecid)))) (VP (MD will) (VP (VB have) (NP (NP (ADJP (RB erroneously) (JJ low)) (NN ERPF)) (CC and) (NP (NN Tm) (NN PAH) (NNS values))))) (. .))))

Sentence Id: DrugDDI.d342.s0
Aminosalicylic/JJ acid/NN may/MD decrease/VB the/DT amount/NN of/IN digoxin/NN (/-LRB- Lanoxin/NNP ,/, Lanoxicaps/NNP )/-RRB- that/WDT gets/VBZ absorbed/VBN into/IN your/JJ body/NN ./.

(ROOT (S1 (S (S (NP (JJ Aminosalicylic) (NN acid)) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NP (NP (NN digoxin)) (PRN (-LRB- -LRB-) (NP (NNP Lanoxin) (, ,) (NNP Lanoxicaps)) (-RRB- -RRB-))) (SBAR (WHNP (WDT that)) (S (VP (VBZ gets) (VP (VBN absorbed) (PP (IN into) (NP (JJ your) (NN body))))))))))))) (. .))))

Sentence Id: DrugDDI.d342.s1
In/IN the/DT case/NN that/WDT you/RB are/VBP taking/VBG digoxin/NN while/IN taking/VBG aminosalicylic/JJ acid/NN ,/, higher/JJR doses/NNS of/IN digoxin/NN may/MD be/VB needed/VBN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (NP (DT the) (NN case)) (SBAR (WHNP (WDT that)) (S (ADVP (RB you)) (VP (VBP are) (VP (VBG taking) (NP (NN digoxin)) (PP (IN while) (S (VP (VBG taking) (NP (JJ aminosalicylic) (NN acid))))))))))) (, ,) (NP (NP (JJR higher) (NNS doses)) (PP (IN of) (NP (NN digoxin)))) (VP (MD may) (VP (VB be) (VP (VBN needed))))) (. .))))

Sentence Id: DrugDDI.d342.s2
Aminosalicylic/JJ acid/NN may/MD also/RB decrease/VB the/DT absorption/NN of/IN vitamin/NN B12/NN ,/, which/WDT can/MD lead/VB to/TO a/NN deficiency/NN ./.

(ROOT (S1 (S (S (NP (JJ Aminosalicylic) (NN acid)) (VP (MD may) (ADVP (RB also)) (VP (VB decrease) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NN vitamin) (NN B12))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD can) (VP (VB lead) (PP (TO to) (NP (NN a) (NN deficiency))))))))))) (. .))))

Sentence Id: DrugDDI.d342.s3
Therefore/RB you/NN may/MD need/VBP to/TO take/VB a/DT vitamin/NN B12/NN supplement/NN while/IN taking/VBG aminosalicylic/JJ acid/NN ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (NP (NN you)) (VP (MD may) (VP (VBP need) (S (VP (TO to) (VP (VB take) (NP (DT a) (NN vitamin) (NN B12) (NN supplement)) (SBAR (IN while) (S (VP (VBG taking) (NP (JJ aminosalicylic) (NN acid))))))))))) (. .))))

Sentence Id: DrugDDI.d63.s0
Amiodarone/NN is/VBZ metabolized/VBN to/TO desethylamiodarone/NN by/IN the/DT cytochrome/NN P450/NN (/-LRB- CYP450/NN )/-RRB- enzyme/NN group/NN ,/, specifically/RB cytochromes/NN P450/NN 3A4/NN (/-LRB- CYP3A4/NN )/-RRB- and/CC CYP2C8/NN ./.

(ROOT (S1 (S (S (NP (NN Amiodarone)) (VP (VBZ is) (VP (VBN metabolized) (PP (TO to) (NP (NN desethylamiodarone))) (PP (IN by) (NP (NP (NP (DT the) (NP (NP (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN CYP450)) (-RRB- -RRB-))) (NN enzyme) (NN group)) (, ,) (NP (ADVP (RB specifically)) (NP (NP (NN cytochromes) (NN P450) (NN 3A4)) (PRN (-LRB- -LRB-) (NP (NN CYP3A4)) (-RRB- -RRB-))))) (CC and) (NP (NN CYP2C8))))))) (. .))))

Sentence Id: DrugDDI.d63.s1
The/DT CYP3A4/NN isoenzyme/NN is/VBZ present/JJ in/IN both/CC the/DT liver/NN and/CC intestines/NNS ./.

(ROOT (S1 (S (S (NP (DT The) (NN CYP3A4) (NN isoenzyme)) (VP (VBZ is) (ADJP (JJ present) (PP (IN in) (NP (CC both) (DT the) (NP (NN liver)) (CC and) (NP (NNS intestines))))))) (. .))))

Sentence Id: DrugDDI.d63.s2
Amiodarone/NN is/VBZ also/RB known/VBN to/TO be/VB an/DT inhibitor/NN of/IN CYP3A4/NN ./.

(ROOT (S1 (S (S (NP (NN Amiodarone)) (VP (VBZ is) (ADVP (RB also)) (VP (VBN known) (S (VP (TO to) (VP (VB be) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN CYP3A4)))))))))) (. .))))

Sentence Id: DrugDDI.d63.s3
Therefore/RB ,/, amiodarone/NN has/VBZ the/DT potential/NN for/IN interactions/NNS with/IN drugs/NNS or/CC substances/NNS that/WDT may/MD be/VB substrates/NNS ,/, inhibitors/NNS or/CC inducers/NNS of/IN CYP3A4/NN ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN amiodarone)) (VP (VBZ has) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NP (NNS interactions)) (PP (IN with) (NP (NP (NP (NNS drugs)) (CC or) (NP (NNS substances))) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB be) (NP (NP (NP (NNS substrates)) (, ,) (NP (NNS inhibitors)) (CC or) (NP (NNS inducers))) (PP (IN of) (NP (NN CYP3A4))))))))))))))) (. .))))

Sentence Id: DrugDDI.d63.s4
While/IN only/RB a/DT limited/JJ number/NN of/IN in/FW vivo/FW drug-drug/JJ interactions/NNS with/IN amiodarone/NN have/VBP been/VBN reported/VBN ,/, chiefly/RB with/IN the/DT oral/JJ formulation/NN ,/, the/DT potential/NN for/IN other/JJ interactions/NNS should/MD be/VB anticipated/VBN ./.

(ROOT (S1 (S (S (SBAR (IN While) (S (NP (NP (RB only) (DT a) (JJ limited) (NN number)) (PP (IN of) (NP (NP (ADJP (FW in) (FW vivo)) (JJ drug-drug) (NNS interactions)) (PP (IN with) (NP (NN amiodarone)))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (, ,) (ADVP (RB chiefly)) (PP (IN with) (NP (DT the) (JJ oral) (NN formulation)))))))) (, ,) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (JJ other) (NNS interactions)))) (VP (MD should) (VP (VB be) (VP (VBN anticipated))))) (. .))))

Sentence Id: DrugDDI.d63.s5
This/DT is/VBZ especially/RB important/JJ for/IN drugs/NNS associated/VBN with/IN serious/JJ toxicity/NN ,/, such/JJ as/IN other/JJ antiarrhythmics/NNS ./.

(ROOT (S1 (S (S (NP (DT This)) (VP (VBZ is) (ADJP (RB especially) (JJ important) (PP (IN for) (NP (NP (NNS drugs)) (VP (VBN associated) (PP (IN with) (NP (JJ serious) (NN toxicity)))) (, ,) (PP (JJ such) (IN as) (NP (JJ other) (NNS antiarrhythmics)))))))) (. .))))

Sentence Id: DrugDDI.d63.s6
If/IN such/JJ drugs/NNS are/VBP needed/VBN ,/, their/PRP$ dose/NN should/MD be/VB reassessed/VBN and/CC ,/, where/WRB appropriate/JJ ,/, plasma/NN concentration/NN measured/VBN ./.

(ROOT (S1 (S (S (SBAR (IN If) (S (NP (JJ such) (NNS drugs)) (VP (VBP are) (VP (VBN needed))))) (, ,) (NP (PRP$ their) (NN dose)) (VP (VP (MD should) (VP (VB be) (VP (VBN reassessed)))) (CC and) (, ,) (SBAR (WHADVP (WRB where)) (FRAG (JJ appropriate))) (, ,) (NP (NP (NN plasma) (NN concentration)) (VP (VBN measured))))) (. .))))

Sentence Id: DrugDDI.d63.s7
In/IN view/NN of/IN the/DT long/JJ and/CC variable/JJ half-life/NN of/IN amiodarone/NN ,/, potential/NN for/IN drug/NN interactions/NNS exists/VBZ not/RB only/RB with/IN concomitant/JJ medication/NN but/CC also/RB with/IN drugs/NNS administered/VBN after/IN discontinuation/NN of/IN amiodarone/NN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (NP (NN view)) (PP (IN of) (NP (NP (DT the) (ADJP (ADJP (JJ long)) (CC and) (ADJP (JJ variable))) (NN half-life)) (PP (IN of) (NP (NN amiodarone))))))) (, ,) (NP (NP (NN potential)) (PP (IN for) (NP (NN drug) (NNS interactions)))) (VP (VBZ exists) (PP (CONJP (RB not) (RB only)) (PP (IN with) (NP (JJ concomitant) (NN medication))) (CONJP (CC but) (RB also)) (PP (IN with) (NP (NP (NNS drugs)) (VP (VBN administered) (PP (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NN amiodarone))))))))))) (. .))))

Sentence Id: DrugDDI.d63.s8
Since/IN amiodarone/NN is/VBZ a/DT substrate/NN for/IN CYP3A4/NN and/CC CYP2C8/NN ,/, drugs/NNS /substances/NNS that/WDT inhibit/VBP these/DT isoenzymes/NNS may/MD decrease/VB the/DT metabolism/NN and/CC increase/VB serum/NN concentration/NN of/IN amiodarone/NN ./.

(ROOT (S1 (S (S (SBAR (IN Since) (S (NP (NN amiodarone)) (VP (VBZ is) (NP (NP (DT a) (NN substrate)) (PP (IN for) (NP (NP (NN CYP3A4)) (CC and) (NP (NN CYP2C8)))))))) (, ,) (NP (NP (NNS drugs) (NNS /substances)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (DT these) (NNS isoenzymes)))))) (VP (MD may) (VP (VP (VB decrease) (NP (DT the) (NN metabolism))) (CC and) (VP (VB increase) (NP (NP (NN serum) (NN concentration)) (PP (IN of) (NP (NN amiodarone)))))))) (. .))))

Sentence Id: DrugDDI.d63.s9
Reported/VBN examples/NNS include/VBP the/DT following/NN :/: Protease/NN Inhibitors/NNS :/: Protease/NN inhibitors/NNS are/VBP known/VBN to/TO inhibit/VB CYP3A4/NN to/TO varying/VBG degrees/NNS ./.

(ROOT (S1 (S (S (NP (VBN Reported) (NNS examples)) (VP (VBP include) (NP (NP (DT the) (NN following)) (: :) (NP (NN Protease) (NNS Inhibitors)) (: :) (S (NP (NN Protease) (NNS inhibitors)) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB inhibit) (NP (NP (NN CYP3A4)) (PP (TO to) (NP (VBG varying) (NNS degrees))))))))))))) (. .))))

Sentence Id: DrugDDI.d63.s10
A/DT case/NN report/NN of/IN one/CD patient/NN taking/VBG amiodarone/NN 200/CD mg/NN and/CC indinavir/NN 800/CD mg/NN three/CD times/NNS a/DT day/NN resulted/VBD in/IN increases/NNS in/IN amiodarone/NN concentrations/NNS from/IN 0.9/CD mg/L/NN to/TO 1.3/CD mg/L/NN ./.

(ROOT (S1 (S (S (NP (NP (DT A) (NN case) (NN report)) (PP (IN of) (NP (NP (CD one) (NN patient)) (VP (VBG taking) (NP (NP (NN amiodarone) (CD 200) (NN mg)) (CC and) (NP (NN indinavir) (CD 800) (NN mg)) (NP (NP (CD three) (NNS times)) (NP (DT a) (NN day)))))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (NN amiodarone) (NNS concentrations)) (PP (IN from) (NP (QP (CD 0.9) (NN mg/L) (TO to) (CD 1.3)) (NN mg/L))))))))) (. .))))

Sentence Id: DrugDDI.d63.s13
Monitoring/NN for/IN amiodarone/NN toxicity/NN and/CC serial/JJ measurement/NN of/IN amiodarone/NN serum/NN concentration/NN during/IN concomitant/JJ protease/NN inhibitor/NN therapy/NN should/MD be/VB considered/VBN ./.

(ROOT (S1 (S (S (NP (NP (NP (NP (NN Monitoring)) (PP (IN for) (NP (NN amiodarone) (NN toxicity)))) (CC and) (NP (NP (JJ serial) (NN measurement)) (PP (IN of) (NP (NN amiodarone) (NN serum) (NN concentration))))) (PP (IN during) (NP (JJ concomitant) (NN protease) (NN inhibitor) (NN therapy)))) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (. .))))

Sentence Id: DrugDDI.d63.s14
Histamine/NN H2/NN antagonists/NNS :/: Cimetidine/NN inhibits/VBZ CYP3A4/NN and/CC can/MD increase/VB serum/NN amiodarone/NN levels/NNS ./.

(ROOT (S1 (S (NP (NP (NN Histamine) (NN H2) (NNS antagonists)) (: :) (S (NP (NN Cimetidine)) (VP (VP (VBZ inhibits) (NP (NN CYP3A4))) (CC and) (VP (MD can) (VP (VB increase) (NP (NN serum) (NN amiodarone) (NNS levels)))))) (. .)))))

Sentence Id: DrugDDI.d63.s15
Other/JJ substances/NNS :/: Grapefruit/NN juice/NN given/VBN to/TO healthy/JJ volunteers/NNS increased/VBD amiodarone/NN AUC/NN by/IN 50/CD %/NN and/CC Cmax/NN by/IN 84/CD %/NN ,/, resulting/VBG in/IN increased/VBN plasma/NN levels/NNS of/IN amiodarone/NN ./.

(ROOT (S1 (S (NP (NP (JJ Other) (NNS substances)) (: :) (S (NP (NP (NN Grapefruit) (NN juice)) (VP (VBN given) (PP (TO to) (NP (JJ healthy) (NNS volunteers))))) (VP (VBD increased) (NP (NN amiodarone) (NN AUC)) (PP (IN by) (NP (NP (CD 50) (NN %)) (CC and) (NP (NN Cmax)))) (PP (IN by) (NP (CD 84) (NN %))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (VBN increased) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN amiodarone))))))))) (. .)))))

Sentence Id: DrugDDI.d63.s16
Grapefruit/NN juice/NN should/MD not/RB be/VB taken/VBN during/IN treatment/NN with/IN oral/JJ amiodarone/NN ./.

(ROOT (S1 (S (S (NP (NN Grapefruit) (NN juice)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN taken) (PP (IN during) (NP (NP (NN treatment)) (PP (IN with) (NP (JJ oral) (NN amiodarone))))))))) (. .))))

Sentence Id: DrugDDI.d63.s17
This/DT information/NN should/MD be/VB considered/VBN when/WRB changing/VBG from/IN intravenous/JJ amiodarone/NN to/TO oral/JJ amiodarone/NN ./.

(ROOT (S1 (S (S (NP (DT This) (NN information)) (VP (MD should) (VP (VB be) (VP (VBN considered) (SBAR (WHADVP (WRB when)) (S (VP (VBG changing) (PP (IN from) (NP (NP (JJ intravenous) (NN amiodarone)) (PP (TO to) (NP (JJ oral) (NN amiodarone)))))))))))) (. .))))

Sentence Id: DrugDDI.d63.s18
Amiodarone/NN may/MD suppress/VBP certain/JJ CYP450/NN enzymes/NNS ,/, including/VBG CYP1A2/NN ,/, CYP2C9/NN ,/, CYP2D6/NN ,/, and/CC CYP3A4/NN ./.

(ROOT (S1 (S (S (NP (NN Amiodarone)) (VP (MD may) (VP (VBP suppress) (NP (NP (JJ certain) (NN CYP450) (NNS enzymes)) (, ,) (PP (VBG including) (NP (NP (NN CYP1A2)) (, ,) (NP (NN CYP2C9)) (, ,) (NP (NN CYP2D6)) (, ,) (CC and) (NP (NN CYP3A4)))))))) (. .))))

Sentence Id: DrugDDI.d63.s19
This/DT inhibition/NN can/MD result/VB in/IN unexpectedly/RB high/JJ plasma/NN levels/NNS of/IN other/JJ drugs/NNS which/WDT are/VBP metabolized/VBN by/IN those/DT CYP450/CD enzymes/NNS ./.

(ROOT (S1 (S (S (NP (DT This) (NN inhibition)) (VP (MD can) (VP (VB result) (PP (IN in) (NP (NP (ADJP (RB unexpectedly) (JJ high)) (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (VP (VBN metabolized) (PP (IN by) (NP (DT those) (CD CYP450) (NNS enzymes)))))))))))))) (. .))))

Sentence Id: DrugDDI.d63.s20
Reported/VBN examples/NNS of/IN this/DT interaction/NN include/VBP the/DT following/NN :/: Immunosuppressive/JJ s/NN :/: Cyclosporine/NN (/-LRB- CYP3A4/NN substrate/NN )/-RRB- administered/VBN in/IN combination/NN with/IN oral/JJ amiodarone/NN has/VBZ been/VBN reported/VBN to/TO produce/VB persistently/RB elevated/JJ plasma/NN concentrations/NNS of/IN cyclosporine/NN resulting/VBG in/IN elevated/JJ creatinine/NN ,/, despite/IN reduction/NN in/IN dose/NN of/IN cyclosporine/NN ./.

(ROOT (S1 (S (S (NP (NP (VBN Reported) (NNS examples)) (PP (IN of) (NP (DT this) (NN interaction)))) (VP (VBP include) (NP (NP (DT the) (NN following)) (: :) (S (NP (NP (NP (JJ Immunosuppressive) (NN s) (: :) (NN Cyclosporine)) (PRN (-LRB- -LRB-) (NP (NN CYP3A4) (NN substrate)) (-RRB- -RRB-))) (VP (VBN administered) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ oral) (NN amiodarone))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB produce) (NP (NP (ADJP (RB persistently) (JJ elevated)) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NN cyclosporine)) (VP (VBG resulting) (PP (IN in) (NP (JJ elevated) (NN creatinine))))))) (, ,) (PP (IN despite) (NP (NP (NN reduction)) (PP (IN in) (NP (NP (NN dose)) (PP (IN of) (NP (NN cyclosporine))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d63.s21
HMG-CoA/NN Reductase/NN Inhibitors/NNS :/: Simvastatin/NN (/-LRB- CYP3A4/NN substrate/NN )/-RRB- in/IN combination/NN with/IN amiodarone/NN has/VBZ been/VBN associated/VBN with/IN reports/NNS of/IN myopathy/rhabdomyolysis/NN ./.

(ROOT (S1 (S (NP (NP (NN HMG-CoA) (NN Reductase) (NNS Inhibitors)) (: :) (S (NP (NP (NP (NN Simvastatin)) (PRN (-LRB- -LRB-) (NP (NN CYP3A4) (NN substrate)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN amiodarone)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (NNS reports)) (PP (IN of) (NP (NN myopathy/rhabdomyolysis))))))))) (. .)))))

Sentence Id: DrugDDI.d63.s22
Cardiovasculars/NN :/: Cardiac/JJ glycosides/NNS :/: In/IN patients/NNS receiving/VBG digoxin/NN therapy/NN ,/, administration/NN of/IN oral/JJ amiodarone/NN regularly/RB results/VBZ in/IN an/DT increase/NN in/IN serum/NN digoxin/NN concentration/NN that/WDT may/MD reach/VB toxic/JJ levels/NNS with/IN resultant/JJ clinical/JJ toxicity/NN ./.

(ROOT (S1 (S (NP (NP (NN Cardiovasculars) (: :) (JJ Cardiac) (NNS glycosides)) (: :) (S (PP (IN In) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN digoxin) (NN therapy))))) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (JJ oral) (NN amiodarone)))) (ADVP (RB regularly)) (VP (VBZ results) (PP (IN in) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NN serum) (NN digoxin) (NN concentration)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB reach) (NP (JJ toxic) (NNS levels)) (PP (IN with) (NP (JJ resultant) (JJ clinical) (NN toxicity))))))))))))) (. .)))))

Sentence Id: DrugDDI.d63.s23
Amiodarone/NN taken/VBN concomitantly/RB with/IN digoxin/NN increases/VBZ the/DT serum/NN digoxin/NN concentration/NN by/IN 70/CD %/NN after/IN one/CD day/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Amiodarone)) (VP (VBN taken) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN digoxin))))) (VP (VBZ increases) (NP (DT the) (NN serum) (NN digoxin) (NN concentration)) (PP (IN by) (NP (CD 70) (NN %))) (PP (IN after) (NP (CD one) (NN day))))) (. .))))

Sentence Id: DrugDDI.d63.s24
On/IN administration/NN of/IN oral/JJ amiodarone/NN ,/, the/DT need/NN for/IN digitalis/NN therapy/NN should/MD be/VB reviewed/VBN and/CC the/DT dose/NN reduced/VBD by/IN approximately/RB 50/CD %/NN or/CC discontinued/VBD ./.

(ROOT (S1 (S (S (S (PP (IN On) (NP (NP (NN administration)) (PP (IN of) (NP (JJ oral) (NN amiodarone))))) (, ,) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NN digitalis) (NN therapy)))) (VP (MD should) (VP (VB be) (VP (VBN reviewed))))) (CC and) (S (NP (DT the) (NN dose)) (VP (VP (VBD reduced) (PP (IN by) (NP (QP (RB approximately) (CD 50)) (NN %)))) (CC or) (VP (VBD discontinued))))) (. .))))

Sentence Id: DrugDDI.d63.s25
If/IN digitalis/NN treatment/NN is/VBZ continued/VBN ,/, serum/NN levels/NNS should/MD be/VB closely/RB monitored/VBN and/CC patients/NNS observed/VBN for/IN clinical/JJ evidence/NN of/IN toxicity/NN ./.

(ROOT (S1 (S (S (SBAR (IN If) (S (NP (NN digitalis) (NN treatment)) (VP (VBZ is) (VP (VBN continued))))) (, ,) (S (NP (NN serum) (NNS levels)) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored))))) (CC and) (S (NP (NNS patients)) (VP (VBN observed) (PP (IN for) (NP (NP (JJ clinical) (NN evidence)) (PP (IN of) (NP (NN toxicity)))))))) (. .))))

Sentence Id: DrugDDI.d63.s26
These/DT precautions/NNS probably/RB should/MD apply/VB to/TO digitoxin/NN administration/NN as/IN well/NN ./.

(ROOT (S1 (S (S (NP (DT These) (NNS precautions)) (VP (ADVP (RB probably)) (MD should) (VP (VB apply) (PP (TO to) (NP (NN digitoxin) (NN administration))) (PP (IN as) (NP (NN well)))))) (. .))))

Sentence Id: DrugDDI.d63.s27
Antiarrhythmics/NNS :/: Other/JJ antiarrhythmic/JJ drugs/NNS ,/, such/JJ as/IN quinidine/NN ,/, procainamide/NN ,/, disopyramide/NN ,/, and/CC phenytoin/NN ,/, have/VBP been/VBN used/VBN concurrently/RB with/IN amiodarone/NN ./.

(ROOT (S1 (S (NP (NP (NNS Antiarrhythmics)) (: :) (S (NP (NP (JJ Other) (JJ antiarrhythmic) (NNS drugs)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN quinidine)) (, ,) (NP (NN procainamide)) (, ,) (NP (NN disopyramide)) (, ,) (CC and) (NP (NN phenytoin)))) (, ,)) (VP (VBP have) (VP (VBN been) (VP (VBN used) (ADVP (RB concurrently)) (PP (IN with) (NP (NN amiodarone))))))) (. .)))))

Sentence Id: DrugDDI.d63.s28
There/EX have/VBP been/VBN case/NN reports/NNS of/IN increased/VBN steady-state/JJ levels/NNS of/IN quinidine/NN ,/, procainamide/NN ,/, and/CC phenytoin/NN during/IN concomitant/JJ therapy/NN with/IN amiodarone/NN ./.

(ROOT (S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (NN case) (NNS reports)) (PP (IN of) (NP (NP (VBN increased) (JJ steady-state) (NNS levels)) (PP (IN of) (NP (NP (NN quinidine)) (, ,) (NP (NN procainamide)) (, ,) (CC and) (NP (NN phenytoin))))))) (PP (IN during) (NP (NP (JJ concomitant) (NN therapy)) (PP (IN with) (NP (NN amiodarone)))))))) (. .))))

Sentence Id: DrugDDI.d63.s29
Phenytoin/NN decreases/VBZ serum/NN amiodarone/NN levels/NNS ./.

(ROOT (S1 (S (S (NP (NN Phenytoin)) (VP (VBZ decreases) (NP (NN serum) (NN amiodarone) (NNS levels)))) (. .))))

Sentence Id: DrugDDI.d63.s30
Amiodarone/NN taken/VBN concomitantly/RB with/IN quinidine/NN increases/VBZ quinidine/NN serum/NN concentration/NN by/IN 33/CD %/NN after/IN two/CD days/NNS ./.

(ROOT (S1 (S (S (NP (NP (NN Amiodarone)) (VP (VBN taken) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN quinidine))))) (VP (VBZ increases) (NP (NN quinidine) (NN serum) (NN concentration)) (PP (IN by) (NP (CD 33) (NN %))) (PP (IN after) (NP (CD two) (NNS days))))) (. .))))

Sentence Id: DrugDDI.d63.s31
Amiodarone/NN taken/VBN concomitantly/RB with/IN procainamide/NN for/IN less/JJR than/IN seven/CD days/NNS increases/VBZ plasma/NN concentrations/NNS of/IN procainamide/NN and/CC n-acetyl/JJ procainamide/NN by/IN 55/CD %/NN and/CC 33/CD %/NN ,/, respectively/RB ./.

(ROOT (S1 (S (S (NP (NP (NN Amiodarone)) (VP (VBN taken) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN procainamide))) (PP (IN for) (NP (QP (JJR less) (IN than) (CD seven)) (NNS days))))) (VP (VBZ increases) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NN procainamide)) (CC and) (NP (JJ n-acetyl) (NN procainamide))))) (PP (IN by) (NP (NP (CD 55) (NN %)) (CC and) (NP (CD 33) (NN %)) (, ,) (ADVP (RB respectively)))))) (. .))))

Sentence Id: DrugDDI.d63.s32
Quinidine/NN and/CC procainamide/NN doses/NNS should/MD be/VB reduced/VBN by/IN one-third/CD when/WRB either/DT is/VBZ administered/VBN with/IN amiodarone/NN ./.

(ROOT (S1 (S (S (NP (NP (NP (NN Quinidine)) (CC and) (NP (NN procainamide))) (NNS doses)) (VP (MD should) (VP (VB be) (VP (VBN reduced) (PP (IN by) (NP (CD one-third))) (SBAR (WHADVP (WRB when)) (S (NP (DT either)) (VP (VBZ is) (VP (VBN administered) (PP (IN with) (NP (NN amiodarone))))))))))) (. .))))

Sentence Id: DrugDDI.d63.s33
Plasma/NN levels/NNS of/IN flecainide/NN have/VBP been/VBN reported/VBN to/TO increase/VB in/IN the/DT presence/NN of/IN oral/JJ amiodarone/NN ;/: ./.

(ROOT (S1 (S (S (NP (NP (NN Plasma) (NNS levels)) (PP (IN of) (NP (NN flecainide)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB increase) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ oral) (NN amiodarone))))))))))) (: ;)) (. .))))

Sentence Id: DrugDDI.d63.s34
because/IN of/IN this/DT ,/, the/DT dosage/NN of/IN flecainide/NN should/MD be/VB adjusted/VBN when/WRB these/DT drugs/NNS are/VBP administered/VBN concomitantly/RB ./.

(ROOT (S1 (S (S (PP (IN because) (IN of) (NP (DT this))) (, ,) (NP (NP (DT the) (NN dosage)) (PP (IN of) (NP (NN flecainide)))) (VP (MD should) (VP (VB be) (VP (VBN adjusted) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (NNS drugs)) (VP (VBP are) (VP (VBN administered) (ADVP (RB concomitantly)))))))))) (. .))))

Sentence Id: DrugDDI.d63.s35
In/IN general/JJ ,/, any/DT added/VBN antiarrhythmic/JJ drug/NN should/MD be/VB initiated/VBN at/IN a/DT lower/JJR than/IN usual/JJ dose/NN with/IN careful/JJ monitoring/NN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (JJ general))) (, ,) (NP (DT any) (VBN added) (JJ antiarrhythmic) (NN drug)) (VP (MD should) (VP (VB be) (VP (VBN initiated) (PP (IN at) (NP (NP (DT a) (JJR lower) (IN than) (JJ usual) (NN dose)) (PP (IN with) (NP (JJ careful) (NN monitoring))))))))) (. .))))

Sentence Id: DrugDDI.d63.s36
Combination/NN of/IN amiodarone/NN with/IN other/JJ antiarrhythmic/JJ therapy/NN should/MD be/VB reserved/VBN for/IN patients/NNS with/IN life-threatening/JJ ventricular/JJ arrhythmias/NNS who/WP are/VBP incompletely/RB responsive/JJ to/TO a/DT single/JJ agent/NN or/CC incompletely/RB responsive/JJ to/TO amiodarone/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Combination)) (PP (IN of) (NP (NN amiodarone))) (PP (IN with) (NP (JJ other) (JJ antiarrhythmic) (NN therapy)))) (VP (MD should) (VP (VB be) (VP (VBN reserved) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ life-threatening) (JJ ventricular) (NNS arrhythmias))) (SBAR (WHNP (WP who)) (S (VP (VBP are) (ADVP (RB incompletely)) (ADJP (ADJP (JJ responsive) (PP (TO to) (NP (DT a) (JJ single) (NN agent)))) (CC or) (ADJP (RB incompletely) (JJ responsive) (PP (TO to) (NP (NN amiodarone)))))))))))))) (. .))))

Sentence Id: DrugDDI.d63.s37
During/IN transfer/NN to/TO oral/JJ amiodarone/NN ,/, the/DT dose/NN levels/NNS of/IN previously/RB administered/VBN agents/NNS should/MD be/VB reduced/VBN by/IN 30/CD to/TO 50/CD %/NN several/JJ days/NNS after/IN the/DT addition/NN of/IN oral/JJ amiodarone/NN ./.

(ROOT (S1 (S (S (PP (IN During) (NP (NP (NN transfer)) (PP (TO to) (NP (JJ oral) (NN amiodarone))))) (, ,) (NP (NP (DT the) (NN dose) (NNS levels)) (PP (IN of) (NP (ADJP (RB previously) (VBN administered)) (NNS agents)))) (VP (MD should) (VP (VB be) (VP (VBN reduced) (PP (IN by) (NP (QP (CD 30) (TO to) (CD 50)) (NN %))) (PP (NP (JJ several) (NNS days)) (IN after) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (JJ oral) (NN amiodarone))))))))) (. .))))

Sentence Id: DrugDDI.d63.s38
The/DT continued/JJ need/NN for/IN the/DT other/JJ antiarrhythmic/JJ agent/NN should/MD be/VB reviewed/VBN after/IN the/DT effects/NNS of/IN amiodarone/NN have/VBP been/VBN established/VBN ,/, and/CC discontinuation/NN ordinarily/RB should/MD be/VB attempted/VBN ./.

(ROOT (S1 (S (S (S (NP (NP (DT The) (JJ continued) (NN need)) (PP (IN for) (NP (DT the) (JJ other) (JJ antiarrhythmic) (NN agent)))) (VP (MD should) (VP (VB be) (VP (VBN reviewed) (SBAR (IN after) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN amiodarone)))) (VP (VBP have) (VP (VBN been) (VP (VBN established)))))))))) (, ,) (CC and) (S (NP (NN discontinuation)) (ADVP (RB ordinarily)) (VP (MD should) (VP (VB be) (VP (VBN attempted)))))) (. .))))

Sentence Id: DrugDDI.d63.s39
If/IN the/DT treatment/NN is/VBZ continued/VBN ,/, these/DT patients/NNS should/MD be/VB particularly/RB carefully/RB monitored/VBN for/IN adverse/JJ effects/NNS ,/, especially/RB conduction/NN disturbances/NNS and/CC exacerbation/NN of/IN tachyarrhythmias/NN ,/, as/IN amiodarone/NN is/VBZ continued/VBN ./.

(ROOT (S1 (S (SBAR (IN If) (S (NP (DT the) (NN treatment)) (VP (VBZ is) (VP (VBN continued))))) (, ,) (NP (DT these) (NNS patients)) (VP (MD should) (VP (VB be) (ADVP (RB particularly)) (VP (ADVP (RB carefully)) (VBN monitored) (PP (IN for) (NP (NP (JJ adverse) (NNS effects)) (, ,) (ADVP (RB especially)) (NP (NN conduction) (NNS disturbances)) (CC and) (NP (NP (NN exacerbation)) (PP (IN of) (NP (NN tachyarrhythmias)))))) (, ,) (SBAR (IN as) (S (NP (NN amiodarone)) (VP (VBZ is) (VP (VBN continued)))))))) (. .))))

Sentence Id: DrugDDI.d63.s40
In/IN amiodarone/NN -treated/JJ patients/NNS who/WP require/VBP additional/JJ antiarrhythmic/NN therapy/NN ,/, the/DT initial/JJ dose/NN of/IN such/JJ agents/NNS should/MD be/VB approximately/RB half/NN of/IN the/DT usual/JJ recommended/VBN dose/NN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (NP (NN amiodarone) (JJ -treated) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP require) (NP (JJ additional) (NN antiarrhythmic) (NN therapy))))))) (, ,) (NP (NP (DT the) (JJ initial) (NN dose)) (PP (IN of) (NP (JJ such) (NNS agents)))) (VP (MD should) (VP (VB be) (NP (NP (RB approximately) (NN half)) (PP (IN of) (NP (DT the) (JJ usual) (VBN recommended) (NN dose))))))) (. .))))

Sentence Id: DrugDDI.d63.s41
Antihypertensives/NNS :/: Amiodarone/NN should/MD be/VB used/VBN with/IN caution/NN in/IN patients/NNS receiving/VBG @/NN -/CC receptor/NN blocking/NN agents/NNS (/-LRB- e.g./FW ,/, propranolol/NN ,/, a/DT CYP3A4/NN inhibitor/NN )/-RRB- or/CC calcium/NN channel/NN antagonists/NNS (/-LRB- e.g./FW ,/, verapamil/NN ,/, a/DT CYP3A4/NN substrate/NN ,/, and/CC diltiazem/NN ,/, a/DT CYP3A4/NN inhibitor/NN )/-RRB- because/IN of/IN the/DT possible/JJ potentiation/NN of/IN bradycardia/NN ,/, sinus/NN arrest/NN ,/, and/CC AV/NN block/NN ;/: ./.

(ROOT (S1 (S (NP (NP (NNS Antihypertensives)) (: :) (S (NP (NN Amiodarone)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NP (NN caution)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NP (NN @) (CC -) (NN receptor) (NN blocking) (NNS agents)) (PRN (-LRB- -LRB-) (NP (FW e.g.) (, ,) (NP (NN propranolol)) (, ,) (NP (DT a) (NN CYP3A4) (NN inhibitor))) (-RRB- -RRB-))) (CC or) (NP (NP (NN calcium) (NN channel) (NNS antagonists)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN verapamil)) (, ,) (NP (DT a) (NN CYP3A4) (NN substrate)) (, ,) (CC and) (NP (NN diltiazem)))) (, ,) (NP (DT a) (NN CYP3A4) (NN inhibitor)) (-RRB- -RRB-))))))))) (PP (IN because) (IN of) (NP (NP (DT the) (JJ possible) (NN potentiation)) (PP (IN of) (NP (NP (NN bradycardia)) (, ,) (NP (NN sinus) (NN arrest)) (, ,) (CC and) (NP (NN AV) (NN block))))))))) (: ;)) (. .)))))

Sentence Id: DrugDDI.d63.s42
if/IN necessary/JJ ,/, amiodarone/NN can/MD continue/VBP to/TO be/VB used/VBN after/IN insertion/NN of/IN a/DT pacemaker/NN in/IN patients/NNS with/IN severe/JJ bradycardia/NN or/CC sinus/NN arrest/NN ./.

(ROOT (S1 (S (S (SBAR (IN if) (FRAG (JJ necessary))) (, ,) (NP (NN amiodarone)) (VP (MD can) (VP (VBP continue) (S (VP (TO to) (VP (VB be) (VP (VBN used) (PP (IN after) (NP (NP (NN insertion)) (PP (IN of) (NP (DT a) (NN pacemaker))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ severe) (NN bradycardia)) (CC or) (NP (NN sinus) (NN arrest))))))))))))))) (. .))))

Sentence Id: DrugDDI.d63.s43
Anticoagulants/NNS :/: Potentiation/NN of/IN warfarin/NN -type/JJ (/-LRB- CYP2C9/NN and/CC CYP3A4/NN substrate/NN )/-RRB- anticoagulant/NN response/NN is/VBZ almost/RB always/RB seen/VBN in/IN patients/NNS receiving/VBG amiodarone/NN and/CC can/MD result/VB in/IN serious/JJ or/CC fatal/JJ bleeding/JJ ./.

(ROOT (S1 (S (NP (NP (NNS Anticoagulants)) (: :) (S (NP (NP (NN Potentiation)) (PP (IN of) (NP (ADJP (ADJP (NN warfarin) (JJ -type)) (PRN (-LRB- -LRB-) (NP (NP (NN CYP2C9)) (CC and) (NP (NN CYP3A4)) (NP (NN substrate))) (-RRB- -RRB-))) (NN anticoagulant) (NN response)))) (VP (VP (VBZ is) (ADVP (RB almost) (RB always)) (VP (VBN seen) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN amiodarone))))))) (CC and) (VP (MD can) (VP (VB result) (PP (IN in) (NP (NP (ADJP (JJ serious))) (CC or) (NP (JJ fatal) (JJ bleeding)))))))) (. .)))))

Sentence Id: DrugDDI.d63.s44
Since/IN the/DT concomitant/JJ administration/NN of/IN warfarin/NN with/IN amiodarone/NN increases/VBZ the/DT prothrombin/NN time/NN by/IN 100/CD %/NN after/IN 3/CD to/TO 4/CD days/NNS ,/, the/DT dose/NN of/IN the/DT anticoagulant/NN should/MD be/VB reduced/VBN by/IN one-third/CD to/TO one-half/NN ,/, and/CC prothrombin/NN times/NNS should/MD be/VB monitored/VBN closely/RB ./.

(ROOT (S1 (S (SBAR (IN Since) (S (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN warfarin))) (PP (IN with) (NP (NN amiodarone)))) (VP (VBZ increases) (NP (DT the) (NN prothrombin) (NN time)) (PP (IN by) (NP (CD 100) (NN %))) (PP (IN after) (NP (QP (CD 3) (TO to) (CD 4)) (NNS days)))))) (, ,) (S (S (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (DT the) (NN anticoagulant)))) (VP (MD should) (VP (VB be) (VP (VBN reduced) (PP (IN by) (NP (NP (CD one-third)) (PP (TO to) (NP (NN one-half))))))))) (, ,) (CC and) (S (NP (NN prothrombin) (NNS times)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB closely))))))) (. .))))

Sentence Id: DrugDDI.d63.s45
Some/DT drugs/NNS /substances/RB are/VBP known/VBN to/TO accelerate/VB the/DT metabolism/NN of/IN amiodarone/NN by/IN stimulating/VBG the/DT synthesis/NN of/IN CYP3A4/NN (/-LRB- enzyme/NN induction/NN )./NN

(ROOT (S1 (S (NP (DT Some) (NNS drugs)) (ADVP (RB /substances)) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB accelerate) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN amiodarone)))) (PP (IN by) (S (VP (VBG stimulating) (NP (NP (NP (DT the) (NN synthesis)) (PP (IN of) (NP (NN CYP3A4)))) (-LRB- -LRB-) (NP (NN enzyme) (NN induction) (NN -RRB-.))))))))))))))

Sentence Id: DrugDDI.d63.s46
This/DT may/MD lead/VB to/TO low/JJ amiodarone/NN serum/NN levels/NNS and/CC potential/JJ decrease/NN in/IN efficacy/NN ./.

(ROOT (S1 (S (S (NP (DT This)) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (JJ low) (NN amiodarone) (NN serum) (NNS levels)) (CC and) (NP (NP (JJ potential) (NN decrease)) (PP (IN in) (NP (NN efficacy))))))))) (. .))))

Sentence Id: DrugDDI.d63.s47
Reported/VBN examples/NNS of/IN this/DT interaction/NN include/VBP the/DT following/NN :/: Antibiotics/NNS :/: Rifampin/NN is/VBZ a/DT potent/JJ inducer/NN of/IN CYP3A4/NN ./.

(ROOT (S1 (S (S (NP (NP (VBN Reported) (NNS examples)) (PP (IN of) (NP (DT this) (NN interaction)))) (VP (VBP include) (NP (NP (DT the) (NN following)) (: :) (NP (NNS Antibiotics)) (: :) (NP (NP (NN Rifampin)) (VP (VBZ is) (NP (NP (DT a) (JJ potent) (NN inducer)) (PP (IN of) (NP (NN CYP3A4))))))))) (. .))))

Sentence Id: DrugDDI.d63.s48
Administration/NN of/IN rifampin/NN concomitantly/RB with/IN oral/JJ amiodarone/NN has/VBZ been/VBN shown/VBN to/TO result/VB in/IN decreases/NNS in/IN serum/NN concentrations/NNS of/IN amiodarone/NN and/CC desethylamiodarone/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN rifampin))) (PP (ADVP (RB concomitantly)) (IN with) (NP (JJ oral) (NN amiodarone)))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB result) (PP (IN in) (NP (NP (NNS decreases)) (PP (IN in) (NP (NP (NN serum) (NNS concentrations)) (PP (IN of) (NP (NP (NN amiodarone)) (CC and) (NP (NN desethylamiodarone))))))))))))))) (. .))))

Sentence Id: DrugDDI.d63.s49
Other/JJ substances/NNS ,/, including/VBG herbal/NN preparations/NNS :/: St./NN John/NN @/NN s/NN Wort/NN (/-LRB- Hypericum/NN perforatum/NN )/-RRB- induces/VBZ CYP3A4/NN ./.

(ROOT (S1 (S (NP (NP (NP (JJ Other) (NNS substances)) (, ,) (PP (VBG including) (NP (NN herbal) (NNS preparations)))) (: :) (S (NP (NP (NN St.) (NN John) (NN @) (NN s) (NN Wort)) (PRN (-LRB- -LRB-) (NP (NN Hypericum) (NN perforatum)) (-RRB- -RRB-))) (VP (VBZ induces) (NP (NN CYP3A4)))) (. .)))))

Sentence Id: DrugDDI.d63.s50
Since/IN amiodarone/NN is/VBZ a/DT substrate/NN for/IN CYP3A4/NN ,/, there/EX is/VBZ the/DT potential/NN that/IN the/DT use/NN of/IN St./NN John/NN @/NN s/NN Wort/NN in/IN patients/NNS receiving/VBG amiodarone/NN could/MD result/VB in/IN reduced/VBN amiodarone/NN levels/NNS ./.

(ROOT (S1 (S (S (SBAR (IN Since) (S (NP (NN amiodarone)) (VP (VBZ is) (NP (NP (DT a) (NN substrate)) (PP (IN for) (NP (NN CYP3A4))))))) (, ,) (NP (EX there)) (VP (VBZ is) (NP (DT the) (NN potential) (SBAR (IN that) (S (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN St.) (NN John) (NN @) (NN s) (NN Wort))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN amiodarone)))))) (VP (MD could) (VP (VB result) (PP (IN in) (NP (VBN reduced) (NN amiodarone) (NNS levels)))))))))) (. .))))

Sentence Id: DrugDDI.d63.s51
Other/JJ reported/VBN interactions/NNS with/IN amiodarone/NN :/: Fentanyl/NN (/-LRB- CYP3A4/NN substrate/NN )/-RRB- in/IN combination/NN with/IN amiodarone/NN may/MD cause/VB hypotension/NN ,/, bradycardia/NN ,/, and/CC decreased/VBN cardiac/JJ output/NN ./.

(ROOT (S1 (S (S (NP (NP (NP (JJ Other) (VBN reported) (NNS interactions)) (PP (IN with) (NP (NN amiodarone)))) (: :) (NP (NP (NP (NN Fentanyl)) (PRN (-LRB- -LRB-) (NP (NN CYP3A4) (NN substrate)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN amiodarone))))))) (VP (MD may) (VP (VB cause) (NP (NP (NN hypotension)) (, ,) (NP (NN bradycardia)) (, ,) (CC and) (NP (VBN decreased) (JJ cardiac) (NN output)))))) (. .))))

Sentence Id: DrugDDI.d63.s52
Sinus/NN bradycardia/NN has/VBZ been/VBN reported/VBN with/IN oral/JJ amiodarone/NN in/IN combination/NN with/IN lidocaine/NN (/-LRB- CYP3A4/NN substrate/NN )/-RRB- given/VBN for/IN local/JJ anesthesia/NN ./.

(ROOT (S1 (S (S (NP (NN Sinus) (NN bradycardia)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NP (JJ oral) (NN amiodarone)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NP (NN lidocaine)) (PRN (-LRB- -LRB-) (NP (NN CYP3A4) (NN substrate)) (-RRB- -RRB-))) (VP (VBN given) (PP (IN for) (NP (JJ local) (NN anesthesia)))))))))))))) (. .))))

Sentence Id: DrugDDI.d63.s53
Seizure/NN ,/, associated/VBN with/IN increased/VBN lidocaine/NN concentrations/NNS ,/, has/VBZ been/VBN reported/VBN with/IN concomitant/JJ administration/NN of/IN intravenous/JJ amiodarone/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Seizure)) (, ,) (VP (VBN associated) (PP (IN with) (NP (VBN increased) (NN lidocaine) (NNS concentrations)))) (, ,)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (JJ intravenous) (NN amiodarone))))))))) (. .))))

Sentence Id: DrugDDI.d63.s54
Dextromethorphan/NN is/VBZ a/DT substrate/NN for/IN both/CC CYP2D6/NN and/CC CYP3A4/NN ./.

(ROOT (S1 (S (S (NP (NN Dextromethorphan)) (VP (VBZ is) (NP (NP (DT a) (NN substrate)) (PP (IN for) (NP (CC both) (NP (NN CYP2D6)) (CC and) (NP (NN CYP3A4))))))) (. .))))

Sentence Id: DrugDDI.d63.s55
Amiodarone/NN inhibits/VBZ CYP2D6/NN ./.

(ROOT (S1 (S (S (NP (NN Amiodarone)) (VP (VBZ inhibits) (NP (NN CYP2D6)))) (. .))))

Sentence Id: DrugDDI.d63.s56
Cholestyramine/NN increases/VBZ enterohepatic/JJ elimination/NN of/IN amiodarone/NN and/CC may/MD reduce/VB its/PRP$ serum/NN levels/NNS and/CC t1/NN /2/CD ./.

(ROOT (S1 (S (S (NP (NN Cholestyramine)) (VP (VP (VBZ increases) (NP (NP (JJ enterohepatic) (NN elimination)) (PP (IN of) (NP (NN amiodarone))))) (CC and) (VP (MD may) (VP (VB reduce) (NP (NP (PRP$ its) (NN serum) (NNS levels)) (CC and) (NP (NN t1) (CD /2))))))) (. .))))

Sentence Id: DrugDDI.d63.s57
Disopyramide/NN increases/VBZ QT/NN prolongation/NN which/WDT could/MD cause/VB arrhythmia/NN ./.

(ROOT (S1 (S (S (NP (NN Disopyramide)) (VP (VBZ increases) (NP (NP (NN QT) (NN prolongation)) (SBAR (WHNP (WDT which)) (S (VP (MD could) (VP (VB cause) (NP (NN arrhythmia))))))))) (. .))))

Sentence Id: DrugDDI.d63.s58
Fluoroquinolones/NNS ,/, macrolide/NN antibiotics/NNS ,/, and/CC azoles/NNS are/VBP known/VBN to/TO cause/VB QTc/NN prolongation/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Fluoroquinolones)) (, ,) (NP (NN macrolide) (NNS antibiotics)) (, ,) (CC and) (NP (NNS azoles))) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB cause) (NP (NN QTc) (NN prolongation)))))))) (. .))))

Sentence Id: DrugDDI.d63.s59
There/EX have/VBP been/VBN reports/NNS of/IN QTc/NN prolongation/NN ,/, with/IN or/CC without/IN TdP/NN ,/, in/IN patients/NNS taking/VBG amiodarone/NN when/WRB fluoroquinolones/NNS ,/, macrolide/NN antibiotics/NNS ,/, or/CC azoles/NNS were/VBD administered/VBN concomitantly/RB ./.

(ROOT (S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (NNS reports)) (PP (IN of) (NP (NN QTc) (NN prolongation)))) (, ,) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (NN TdP)))) (, ,) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN amiodarone)))))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NNS fluoroquinolones)) (, ,) (NP (NN macrolide) (NNS antibiotics)) (, ,) (CC or) (NP (NNS azoles))) (VP (VBD were) (VP (VBN administered) (ADVP (RB concomitantly)))))))) (. .))))

Sentence Id: DrugDDI.d63.s60
Hemodynamic/JJ and/CC electrophysiologic/JJ interactions/NNS have/VBP also/RB been/VBN observed/VBN after/IN concomitant/JJ administration/NN with/IN propranolol/NN ,/, diltiazem/NN ,/, and/CC verapamil/NN ./.

(ROOT (S1 (S (S (NP (ADJP (ADJP (JJ Hemodynamic)) (CC and) (ADJP (JJ electrophysiologic))) (NNS interactions)) (VP (VBP have) (ADVP (RB also)) (VP (VBN been) (VP (VBN observed) (PP (IN after) (NP (NP (JJ concomitant) (NN administration)) (PP (IN with) (NP (NP (NN propranolol)) (, ,) (NP (NN diltiazem)) (, ,) (CC and) (NP (NN verapamil)))))))))) (. .))))

Sentence Id: DrugDDI.d63.s61
Volatile/JJ Anesthetic/JJ Agents/NNS :/: ./.

(ROOT (S1 (S (NP (NP (NP (JJ Volatile) (JJ Anesthetic) (NNS Agents)) (: :)) (. .)))))

Sentence Id: DrugDDI.d63.s62
In/IN addition/NN to/TO the/DT interactions/NNS noted/VBN above/RB ,/, chronic/JJ (/-LRB- 2/CD weeks/NNS )/-RRB- oral/JJ Cordarone/NN administration/NN impairs/VBZ metabolism/NN of/IN phenytoin/NN ,/, dextromethorphan/NN ,/, and/CC methotrexate/NN ./.

(ROOT (S1 (S (S (PP (IN In) (NN addition) (TO to) (NP (NP (DT the) (NNS interactions)) (VP (VBN noted) (ADVP (RB above))))) (, ,) (NP (JJ chronic) (PRN (-LRB- -LRB-) (NP (CD 2) (NNS weeks)) (-RRB- -RRB-)) (JJ oral) (NN Cordarone) (NN administration)) (VP (VBZ impairs) (NP (NP (NN metabolism)) (PP (IN of) (NP (NP (NN phenytoin)) (, ,) (NP (NN dextromethorphan)) (, ,) (CC and) (NP (NN methotrexate))))))) (. .))))

Sentence Id: DrugDDI.d63.s63
Electrolyte/NN Disturbances/NNS Patients/NNS with/IN hypokalemia/NN or/CC hypomagnesemia/NN should/MD have/VB the/DT condition/NN corrected/VBN whenever/NN possible/JJ before/IN being/VBG treated/VBN with/IN Cordarone/NN I.V./NN ,/, as/IN these/DT disorders/NNS can/MD exaggerate/VB the/DT degree/NN of/IN QTc/NN prolongation/NN and/CC increase/VB the/DT potential/NN for/IN TdP/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Electrolyte) (NNS Disturbances)) (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (NN hypokalemia)) (CC or) (NP (NN hypomagnesemia)))))) (VP (MD should) (VP (VB have) (NP (NP (DT the) (NN condition)) (VP (VBN corrected) (S (ADJP (NN whenever) (JJ possible) (PP (IN before) (S (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (NN Cordarone) (NN I.V.))))))))))) (, ,) (SBAR (IN as) (S (NP (DT these) (NNS disorders)) (VP (MD can) (VP (VP (VB exaggerate) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NN QTc) (NN prolongation))))) (CC and) (VP (VB increase) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NN TdP)))))))))))) (. .))))

Sentence Id: DrugDDI.d63.s64
Special/JJ attention/NN should/MD be/VB given/VBN to/TO electrolyte/NN and/CC acid-base/NN balance/NN in/IN patients/NNS experiencing/VBG severe/JJ or/CC prolonged/JJ diarrhea/NN or/CC in/IN patients/NNS receiving/VBG concomitant/JJ diuretics/NNS ./.

(ROOT (S1 (S (S (NP (JJ Special) (NN attention)) (VP (MD should) (VP (VB be) (VP (VBN given) (PP (TO to) (NP (NP (NP (NN electrolyte)) (CC and) (NP (NN acid-base) (NN balance))) (PP (PP (IN in) (NP (NP (NNS patients)) (VP (VBG experiencing) (NP (ADJP (ADJP (JJ severe)) (CC or) (ADJP (JJ prolonged))) (NN diarrhea))))) (CC or) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ concomitant) (NNS diuretics)))))))))))) (. .))))

Sentence Id: DrugDDI.d539.s0
In/FW vitro/FW data/NNS indicate/VBP that/IN NORVASC/NN has/VBZ no/DT effect/NN on/IN the/DT human/JJ plasma/NN protein/NN binding/NN of/IN digoxin/NN ,/, phenytoin/NN ,/, warfarin/NN ,/, and/CC indomethacin/NN ./.

(ROOT (S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN NORVASC)) (VP (VBZ has) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ human) (NN plasma) (NN protein) (NN binding)) (PP (IN of) (NP (NP (NN digoxin)) (, ,) (NP (NN phenytoin)) (, ,) (NP (NN warfarin)) (, ,) (CC and) (NP (NN indomethacin))))))))))) (. .))))

Sentence Id: DrugDDI.d539.s1
Effect/NN of/IN other/JJ agents/NNS on/IN NORVASC/NN ./.

(ROOT (S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (JJ other) (NNS agents))) (PP (IN on) (NP (NN NORVASC))) (. .)))))

Sentence Id: DrugDDI.d539.s2
CIMETIDINE/NN :/: Co-administration/NN of/IN NORVASC/NN with/IN cimetidine/NN did/VBD not/RB alter/VB the/DT pharmacokinetics/NNS of/IN NORVASC/NN ./.

(ROOT (S1 (S (S (NP (NP (NN CIMETIDINE) (: :) (NN Co-administration)) (PP (IN of) (NP (NN NORVASC))) (PP (IN with) (NP (NN cimetidine)))) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN NORVASC))))))) (. .))))

Sentence Id: DrugDDI.d539.s3
GRAPEFRUIT/NN JUICE/NN :/: Co-administration/NN of/IN 240/CD mL/NN of/IN grapefruit/NN juice/NN with/IN a/DT single/JJ oral/JJ dose/NN of/IN amlodipine/NN 10/CD mg/NN in/IN 20/CD healthy/JJ volunteers/NNS had/VBD no/DT significant/JJ effect/NN on/IN the/DT pharmacokinetics/NNS of/IN amlodipine/NN ./.

(ROOT (S1 (S (NP (NP (NN GRAPEFRUIT) (NN JUICE)) (: :) (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NP (CD 240) (NN mL)) (PP (IN of) (NP (NN grapefruit) (NN juice))))) (PP (IN with) (NP (NP (DT a) (JJ single) (JJ oral) (NN dose)) (PP (IN of) (NP (NP (NN amlodipine) (CD 10) (NN mg)) (PP (IN in) (NP (CD 20) (JJ healthy) (NNS volunteers)))))))) (VP (VBD had) (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN amlodipine))))))) (. .)))))

Sentence Id: DrugDDI.d539.s4
MAALOX/NN (/-LRB- antacid/JJ )/-RRB- :/: Co-administration/NN of/IN the/DT antacid/JJ Maalox/NN with/IN a/DT single/JJ dose/NN of/IN NORVASC/NN had/VBD no/DT significant/JJ effect/NN on/IN the/DT pharmacokinetics/NNS of/IN NORVASC/NN ./.

(ROOT (S1 (S (NP (NP (NP (NN MAALOX)) (PRN (-LRB- -LRB-) (NP (JJ antacid)) (-RRB- -RRB-))) (: :) (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (DT the) (JJ antacid) (NN Maalox))) (PP (IN with) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NN NORVASC)))))) (VP (VBD had) (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN NORVASC))))))) (. .)))))

Sentence Id: DrugDDI.d539.s5
SILDENAFIL/NN :/: A/DT single/JJ 100/CD mg/NN dose/NN of/IN sildenafil/NN (/-LRB- Viagra/NN @/NN )/-RRB- in/IN subjects/NNS with/IN essential/JJ hypertension/NN had/VBD no/DT effect/NN on/IN the/DT pharmacokinetic/JJ parameters/NNS of/IN NORVASC/NN ./.

(ROOT (S1 (S (NP (NP (NN SILDENAFIL)) (: :) (S (NP (NP (NP (NP (DT A) (JJ single) (ADJP (CD 100) (NN mg)) (NN dose)) (PP (IN of) (NP (NN sildenafil)))) (PRN (-LRB- -LRB-) (NP (NN Viagra) (NN @)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NNS subjects)) (PP (IN with) (NP (JJ essential) (NN hypertension)))))) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ pharmacokinetic) (NNS parameters)) (PP (IN of) (NP (NN NORVASC))))))) (. .)))))

Sentence Id: DrugDDI.d539.s6
When/WRB NORVASC/NN and/CC sildenafil/NN were/VBD used/VBN in/IN combination/NN ,/, each/DT agent/NN independently/RB exerted/VBD its/PRP$ own/JJ blood/NN pressure/NN lowering/JJ effect/NN ./.

(ROOT (S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NN NORVASC)) (CC and) (NP (NN sildenafil))) (VP (VBD were) (VP (VBN used) (PP (IN in) (NP (NN combination))))))) (, ,) (NP (DT each) (NN agent)) (ADVP (RB independently)) (VP (VBD exerted) (NP (PRP$ its) (JJ own) (NN blood) (NN pressure) (JJ lowering) (NN effect)))) (. .))))

Sentence Id: DrugDDI.d539.s7
Effect/NN of/IN NORVASC/NN on/IN other/JJ agents/NNS ./.

(ROOT (S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (NN NORVASC))) (PP (IN on) (NP (JJ other) (NNS agents))) (. .)))))

Sentence Id: DrugDDI.d539.s8
ATORVASTATIN/NN :/: Co-administration/NN of/IN multiple/JJ 10/CD mg/NN doses/NNS of/IN NORVASC/NN with/IN 80/CD mg/NN of/IN atorvastatin/NN resulted/VBD in/IN no/DT significant/JJ change/NN in/IN the/DT steady/JJ state/NN pharmacokinetic/JJ parameters/NNS of/IN atorvastatin/NN ./.

(ROOT (S1 (S (NP (NP (NN ATORVASTATIN)) (: :) (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NP (JJ multiple) (CD 10) (NN mg) (NNS doses)) (PP (IN of) (NP (NN NORVASC))))) (PP (IN with) (NP (NP (CD 80) (NN mg)) (PP (IN of) (NP (NN atorvastatin)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT no) (JJ significant) (NN change)) (PP (IN in) (NP (NP (DT the) (JJ steady) (NN state) (JJ pharmacokinetic) (NNS parameters)) (PP (IN of) (NP (NN atorvastatin))))))))) (. .)))))

Sentence Id: DrugDDI.d539.s9
DIGOXIN/NN :/: Co-administration/NN of/IN NORVASC/NN with/IN digoxin/NN did/VBD not/RB change/VB serum/NN digoxin/NN levels/NNS or/CC digoxin/NN renal/JJ clearance/NN in/IN normal/JJ volunteers/NNS ./.

(ROOT (S1 (S (S (NP (NP (NN DIGOXIN) (: :) (NN Co-administration)) (PP (IN of) (NP (NN NORVASC))) (PP (IN with) (NP (NN digoxin)))) (VP (VBD did) (RB not) (VP (VB change) (NP (NP (NP (NN serum) (NN digoxin) (NNS levels)) (CC or) (NP (NN digoxin) (JJ renal) (NN clearance))) (PP (IN in) (NP (JJ normal) (NNS volunteers))))))) (. .))))

Sentence Id: DrugDDI.d539.s10
ETHANOL/NN (/-LRB- alcohol/NN )/-RRB- :/: Single/JJ and/CC multiple/JJ 10/CD mg/NN doses/NNS of/IN NORVASC/NN had/VBD no/DT significant/JJ effect/NN on/IN the/DT pharmacokinetics/NNS of/IN ethanol/NN ./.

(ROOT (S1 (S (S (NP (NP (ADJP (ADJP (NN ETHANOL) (-LRB- -LRB-) (NN alcohol) (-RRB- -RRB-) (: :) (ADJP (JJ Single)) (CC and) (ADJP (JJ multiple))) (ADJP (CD 10) (NN mg))) (NNS doses)) (PP (IN of) (NP (NN NORVASC)))) (VP (VBD had) (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN ethanol))))))) (. .))))

Sentence Id: DrugDDI.d539.s11
WARFARIN/NN :/: Co-administration/NN of/IN NORVASC/NN with/IN warfarin/NN did/VBD not/RB change/VB the/DT warfarin/NN prothrombin/NN response/NN time/NN ./.

(ROOT (S1 (S (S (NP (NN WARFARIN)) (: :) (NP (NP (NN Co-administration)) (PP (IN of) (NP (NN NORVASC))) (PP (IN with) (NP (NN warfarin)))) (VP (VBD did) (RB not) (VP (VB change) (NP (DT the) (NN warfarin) (NN prothrombin) (NN response) (NN time))))) (. .))))

Sentence Id: DrugDDI.d539.s12
In/IN clinical/JJ trials/NNS ,/, NORVASC/NN has/VBZ been/VBN safely/RB administered/VBN with/IN thiazide/NN diuretics/NNS ,/, beta-blockers/NNS ,/, angiotensin-converting/JJ enzyme/NN inhibitors/NNS ,/, long-acting/JJ nitrates/NNS ,/, sublingual/JJ nitroglycerin/NN ,/, digoxin/NN ,/, warfarin/NN ,/, non-steroidal/JJ anti-inflammatory/JJ drugs/NNS ,/, antibiotics/NNS ,/, and/CC oral/JJ hypoglycemic/JJ drugs/NNS ./.

(ROOT (S1 (S (PP (IN In) (NP (JJ clinical) (NNS trials))) (, ,) (NP (NN NORVASC)) (VP (VBZ has) (VP (VBN been) (ADVP (RB safely)) (VP (VBN administered) (PP (IN with) (NP (NP (NN thiazide) (NNS diuretics)) (, ,) (NP (NNS beta-blockers)) (, ,) (NP (JJ angiotensin-converting) (NN enzyme) (NNS inhibitors)) (, ,) (NP (JJ long-acting) (NNS nitrates)) (, ,) (NP (JJ sublingual) (NN nitroglycerin)) (, ,) (NP (NN digoxin)) (, ,) (NP (NN warfarin)) (, ,) (NP (JJ non-steroidal) (JJ anti-inflammatory) (NNS drugs)) (, ,) (NP (NNS antibiotics)) (, ,) (CC and) (NP (JJ oral) (JJ hypoglycemic) (NNS drugs))))))) (. .))))

Sentence Id: DrugDDI.d539.s13
Drug/NN /Laboratory/NN Test/NN Interactions/NNS :/: None/NN known/VBN ./.

(ROOT (S1 (S (NP (NP (NN Drug) (NN /Laboratory) (NN Test) (NNS Interactions)) (: :) (S (NP (NN None)) (VP (VBN known))) (. .)))))

Sentence Id: DrugDDI.d117.s0
Probenecid/NN decreases/VBZ the/DT renal/JJ tubular/JJ secretion/NN of/IN amoxicillin/NN ./.

(ROOT (S1 (S (S (NP (NN Probenecid)) (VP (VBZ decreases) (NP (NP (DT the) (JJ renal) (JJ tubular) (NN secretion)) (PP (IN of) (NP (NN amoxicillin)))))) (. .))))

Sentence Id: DrugDDI.d117.s1
Concurrent/JJ use/NN of/IN amoxicillin/NN and/CC probenecid/NN may/MD result/VB in/IN increased/VBN and/CC prolonged/JJ blood/NN levels/NNS of/IN amoxicillin/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (NP (NN amoxicillin)) (CC and) (NP (NN probenecid))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (ADJP (ADJP (VBN increased)) (CC and) (ADJP (JJ prolonged))) (NN blood) (NNS levels)) (PP (IN of) (NP (NN amoxicillin)))))))) (. .))))

Sentence Id: DrugDDI.d117.s2
Chloramphenicol/NN ,/, macrolides/NN ,/, sulfonamides/NNS ,/, and/CC tetracy-clines/NNS may/MD interfere/VB with/IN the/DT bactericidal/JJ effects/NNS of/IN penicillin/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Chloramphenicol)) (, ,) (NP (NN macrolides)) (, ,) (NP (NNS sulfonamides)) (, ,) (CC and) (NP (NNS tetracy-clines))) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (JJ bactericidal) (NNS effects)) (PP (IN of) (NP (NN penicillin)))))))) (. .))))

Sentence Id: DrugDDI.d117.s5
Drug/NN /Laboratory/NN Test/NN Interactions/NNS :/: High/JJ urine/NN concentrations/NNS of/IN ampicillin/NN may/MD result/VB in/IN false-positive/JJ reactions/NNS when/WRB testing/VBG for/IN the/DT presence/NN of/IN glucose/NN in/IN urine/NN using/VBG CLINITEST/NN @/NN ,/, Benedict/NN @/NN s/NN Solution/NN ,/, or/CC Fehling/NN @/NN s/NN Solution/NN ./.

(ROOT (S1 (S (NP (NP (NN Drug) (NN /Laboratory) (NN Test) (NNS Interactions)) (: :) (S (NP (NP (JJ High) (NN urine) (NNS concentrations)) (PP (IN of) (NP (NN ampicillin)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (JJ false-positive) (NNS reactions))) (SBAR (WHADVP (WRB when)) (S (VP (VBG testing) (PP (IN for) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN glucose))))) (PP (IN in) (NP (NP (NN urine)) (VP (VBG using) (NP (NP (NN CLINITEST) (NN @)) (, ,) (NP (NN Benedict) (NN @) (NN s) (NN Solution)) (, ,) (CC or) (NP (NN Fehling) (NN @) (NN s) (NN Solution)))))))))))) (. .)))))

Sentence Id: DrugDDI.d117.s6
Since/IN this/DT effect/NN may/MD also/RB occur/VB with/IN amoxicillin/NN ,/, it/PRP is/VBZ recommended/VBN that/IN glucose/NN tests/NNS based/VBN on/IN enzymatic/JJ glucose/NN oxi-dase/NN reactions/NNS (/-LRB- such/JJ as/IN CLINISTIX/NN @/NN )/-RRB- be/VB used/VBN ./.

(ROOT (S1 (S (S (SBAR (IN Since) (S (NP (DT this) (NN effect)) (VP (MD may) (ADVP (RB also)) (VP (VB occur) (PP (IN with) (NP (NN amoxicillin))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NP (NN glucose) (NNS tests)) (VP (VBN based) (PP (IN on) (NP (NP (JJ enzymatic) (NN glucose) (NN oxi-dase) (NNS reactions)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NN CLINISTIX) (NN @)))) (-RRB- -RRB-)))))) (VP (VB be) (VP (VBN used)))))))) (. .))))

Sentence Id: DrugDDI.d117.s7
Following/VBG administration/NN of/IN ampicillin/NN to/TO pregnant/JJ women/NNS ,/, a/DT transient/JJ decrease/NN in/IN plasma/NN concentration/NN of/IN total/JJ conjugated/VBN estriol/NN ,/, estriol-glucuronide/NN ,/, conjugated/VBN estrone/NN ,/, and/CC estradiol/NN has/VBZ been/VBN noted/VBN ./.

(ROOT (S1 (S (S (PP (VBG Following) (NP (NP (NN administration)) (PP (IN of) (NP (NN ampicillin))) (PP (TO to) (NP (JJ pregnant) (NNS women))))) (, ,) (NP (NP (DT a) (JJ transient) (NN decrease)) (PP (IN in) (NP (NP (NN plasma) (NN concentration)) (PP (IN of) (NP (NP (JJ total) (VBN conjugated) (NN estriol)) (, ,) (NP (NN estriol-glucuronide)) (, ,) (NP (VBN conjugated) (NN estrone)) (, ,) (CC and) (NP (NN estradiol))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN noted))))) (. .))))

Sentence Id: DrugDDI.d117.s8
This/DT effect/NN may/MD also/RB occur/VB with/IN amoxicillin/NN ./.

(ROOT (S1 (S (S (NP (DT This) (NN effect)) (VP (MD may) (ADVP (RB also)) (VP (VB occur) (PP (IN with) (NP (NN amoxicillin)))))) (. .))))

Sentence Id: DrugDDI.d117.s10
Studies/NNS to/TO detect/VB mutagenic/JJ potential/NN of/IN amoxicillin/NN alone/RB have/VBP not/RB been/VBN conducted/VBN ;/: ./.

(ROOT (S1 (S (S (NP (NP (NNS Studies)) (VP (TO to) (VP (VB detect) (NP (NP (JJ mutagenic) (NN potential)) (PP (IN of) (NP (NP (NN amoxicillin)) (ADVP (RB alone)))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN conducted)))) (: ;)) (. .))))

Sentence Id: DrugDDI.d117.s11
however/RB ,/, the/DT following/VBG information/NN is/VBZ available/JJ from/IN tests/NNS on/IN a/DT 4:1/JJ mixture/NN of/IN amoxicillin/NN and/CC potassium/NN clavulanate/NN (/-LRB- AUGMENTIN/NN )/-RRB- ./.

(ROOT (S1 (S (S (ADVP (RB however)) (, ,) (NP (DT the) (VBG following) (NN information)) (VP (VBZ is) (ADJP (JJ available) (PP (IN from) (NP (NP (NNS tests)) (PP (IN on) (NP (NP (NP (DT a) (JJ 4:1) (NN mixture)) (PP (IN of) (NP (NN amoxicillin)))) (CC and) (NP (NP (NN potassium) (NN clavulanate)) (PRN (-LRB- -LRB-) (NP (NN AUGMENTIN)) (-RRB- -RRB-)))))))))) (. .))))

Sentence Id: DrugDDI.d117.s12
AUGMENTIN/NN was/VBD non-mutagenic/JJ in/IN the/DT Ame/NN s/NN bacterial/JJ mutation/NN assay/NN ,/, and/CC the/DT yeast/NN gene/NN conversion/NN assay/NN ./.

(ROOT (S1 (S (S (NP (NN AUGMENTIN)) (VP (VBD was) (ADJP (JJ non-mutagenic)) (PP (IN in) (NP (NP (DT the) (NN Ame) (NN s) (JJ bacterial) (NN mutation) (NN assay)) (, ,) (CC and) (NP (DT the) (NN yeast) (NN gene) (NN conversion) (NN assay)))))) (. .))))

Sentence Id: DrugDDI.d117.s13
AUGMENTIN/NN was/VBD weakly/RB positive/JJ in/IN the/DT mouse/NN lymphoma/NN assay/NN ,/, but/CC the/DT trend/NN toward/IN increased/VBN mutation/NN frequencies/NNS in/IN this/DT assay/NN occurred/VBD at/IN doses/NNS that/WDT were/VBD also/RB associated/VBN with/IN decreased/VBN cell/NN survival/NN ./.

(ROOT (S1 (S (S (S (NP (NN AUGMENTIN)) (VP (VBD was) (ADJP (RB weakly) (JJ positive)) (PP (IN in) (NP (DT the) (NN mouse) (NN lymphoma) (NN assay))))) (, ,) (CC but) (S (NP (NP (DT the) (NN trend)) (PP (IN toward) (NP (NP (VBN increased) (NN mutation) (NNS frequencies)) (PP (IN in) (NP (DT this) (NN assay)))))) (VP (VBD occurred) (PP (IN at) (NP (NP (NNS doses)) (SBAR (WHNP (WDT that)) (S (VP (VBD were) (ADVP (RB also)) (VP (VBN associated) (PP (IN with) (NP (VBN decreased) (NN cell) (NN survival)))))))))))) (. .))))

Sentence Id: DrugDDI.d117.s14
AUGMENTIN/NN was/VBD negative/JJ in/IN the/DT mouse/NN micronucleus/NN test/NN ,/, and/CC in/IN the/DT dominant/JJ lethal/JJ assay/NN in/IN mice/NNS ./.

(ROOT (S1 (S (S (NP (NN AUGMENTIN)) (VP (VBD was) (ADJP (JJ negative)) (PP (PP (IN in) (NP (DT the) (NN mouse) (NN micronucleus) (NN test))) (, ,) (CC and) (PP (IN in) (NP (NP (DT the) (JJ dominant) (JJ lethal) (NN assay)) (PP (IN in) (NP (NNS mice)))))))) (. .))))

Sentence Id: DrugDDI.d117.s15
Potassium/NN clavulanate/NN alone/RB was/VBD tested/VBN in/IN the/DT Ame/NN s/NN bacterial/JJ mutation/NN assay/NN and/CC in/IN the/DT mouse/NN micronucleus/NN test/NN ,/, and/CC was/VBD negative/JJ in/IN each/DT of/IN these/DT assays/NNS ./.

(ROOT (S1 (S (S (NP (NP (NN Potassium) (NN clavulanate)) (ADVP (RB alone))) (VP (VP (VBD was) (VP (VBN tested) (PP (PP (IN in) (NP (DT the) (NN Ame) (NN s) (JJ bacterial) (NN mutation) (NN assay))) (CC and) (PP (IN in) (NP (DT the) (NN mouse) (NN micronucleus) (NN test)))))) (, ,) (CC and) (VP (VBD was) (ADJP (JJ negative)) (PP (IN in) (NP (NP (DT each)) (PP (IN of) (NP (DT these) (NNS assays)))))))) (. .))))

Sentence Id: DrugDDI.d117.s18
Reproduction/NN studies/NNS have/VBP been/VBN performed/VBN in/IN mice/NNS and/CC rats/NNS at/IN doses/NNS up/RB to/TO 10/CD times/NNS the/DT human/JJ dose/NN and/CC have/VBP revealed/VBN no/DT evidence/NN of/IN impaired/JJ fertility/NN or/CC harm/NN to/TO the/DT fetus/NN due/JJ to/TO amoxicillin/NN ./.

(ROOT (S1 (S (S (NP (NN Reproduction) (NNS studies)) (VP (VP (VBP have) (VP (VBN been) (VP (VBN performed) (PP (IN in) (NP (NP (NNS mice)) (CC and) (NP (NNS rats)))) (PP (IN at) (NP (NP (NNS doses)) (NP (QP (RB up) (TO to) (CD 10) (NNS times)) (NP (DT the) (JJ human) (NN dose)))))))) (CC and) (VP (VBP have) (VP (VBN revealed) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (JJ impaired) (NN fertility)) (CC or) (NP (NP (NN harm)) (PP (TO to) (NP (NP (DT the) (NN fetus)) (ADJP (JJ due) (PP (TO to) (NP (NN amoxicillin)))))))))))))) (. .))))

Sentence Id: DrugDDI.d117.s20
Because/IN animal/NN reproduction/NN studies/NNS are/VBP not/RB always/RB predictive/JJ of/IN human/JJ response/NN ,/, this/DT drug/NN should/MD be/VB used/VBN during/IN pregnancy/NN only/RB if/IN clearly/RB needed/VBN ./.

(ROOT (S1 (S (S (SBAR (IN Because) (S (NP (NN animal) (NN reproduction) (NNS studies)) (VP (VBP are) (RB not) (ADVP (RB always)) (ADJP (JJ predictive) (PP (IN of) (NP (JJ human) (NN response))))))) (, ,) (NP (DT this) (NN drug)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN during) (NP (NN pregnancy))) (SBAR (RB only) (IN if) (S (ADVP (RB clearly)) (VP (VBN needed)))))))) (. .))))

Sentence Id: DrugDDI.d117.s21
Labor/NN and/CC Delivery/NN :/: Oral/JJ ampicillin/NN -class/NN antibiotics/NNS are/VBP poorly/RB absorbed/VBN during/IN labor/NN ./.

(ROOT (S1 (S (NP (NP (NP (NN Labor)) (CC and) (NP (NN Delivery))) (: :) (S (NP (JJ Oral) (NN ampicillin) (NN -class) (NNS antibiotics)) (VP (VBP are) (ADVP (RB poorly)) (VP (VBN absorbed) (PP (IN during) (NP (NN labor)))))) (. .)))))

Sentence Id: DrugDDI.d117.s22
Studies/NNS in/IN guinea/NN pigs/NNS showed/VBD that/IN intravenous/JJ administration/NN of/IN ampicillin/NN slightly/RB decreased/VBD the/DT uterine/NN tone/NN and/CC frequency/NN of/IN contractions/NNS but/CC moderately/RB increased/VBD the/DT height/NN and/CC duration/NN of/IN contractions/NNS ./.

(ROOT (S1 (S (S (NP (NP (NNS Studies)) (PP (IN in) (NP (NN guinea) (NNS pigs)))) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (JJ intravenous) (NN administration)) (PP (IN of) (NP (NN ampicillin)))) (ADVP (RB slightly)) (VP (VP (VBD decreased) (NP (NP (DT the) (NP (NN uterine) (NN tone)) (CC and) (NP (NN frequency))) (PP (IN of) (NP (NNS contractions))))) (CC but) (VP (ADVP (RB moderately)) (VBD increased) (NP (NP (DT the) (NP (NN height)) (CC and) (NP (NN duration))) (PP (IN of) (NP (NNS contractions)))))))))) (. .))))

Sentence Id: DrugDDI.d117.s23
However/RB ,/, it/PRP is/VBZ not/RB known/VBN whether/IN use/NN of/IN amoxicillin/NN in/IN humans/NNS during/IN labor/NN or/CC delivery/NN has/VBZ immediate/JJ or/CC delayed/VBN adverse/JJ effects/NNS on/IN the/DT fetus/NN ,/, prolongs/VBZ the/DT duration/NN of/IN labor/NN ,/, or/CC increases/VBZ the/DT likelihood/NN that/IN forceps/NN delivery/NN or/CC other/JJ obstetrical/JJ intervention/NN or/CC resuscitation/NN of/IN the/DT newborn/JJ will/MD be/VB necessary/JJ ./.

(ROOT (S1 (S (ADVP (RB However)) (, ,) (NP (PRP it)) (VP (VBZ is) (RB not) (VP (VBN known) (SBAR (IN whether) (S (NP (NP (NN use)) (PP (IN of) (NP (NN amoxicillin))) (PP (IN in) (NP (NP (NNS humans)) (PP (IN during) (NP (NP (NN labor)) (CC or) (NP (NN delivery))))))) (VP (VP (VBZ has) (NP (NP (ADJP (ADJP (JJ immediate)) (CC or) (ADJP (VBN delayed))) (JJ adverse) (NNS effects)) (PP (IN on) (NP (DT the) (NN fetus))))) (, ,) (VP (VBZ prolongs) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NN labor))))) (, ,) (CC or) (VP (VBZ increases) (NP (DT the) (NN likelihood) (SBAR (IN that) (S (NP (NP (NN forceps) (NN delivery)) (CC or) (NP (NP (NP (JJ other) (JJ obstetrical) (NN intervention)) (CC or) (NP (NN resuscitation))) (PP (IN of) (NP (DT the) (JJ newborn))))) (VP (MD will) (VP (VB be) (ADJP (JJ necessary))))))))))))) (. .))))

Sentence Id: DrugDDI.d117.s24
Nursing/VBG Mothers/NNS :/: Penicillins/NNS have/VBP been/VBN shown/VBN to/TO be/VB excreted/VBN in/IN human/JJ milk/NN ./.

(ROOT (S1 (S (S (S (VP (VBG Nursing) (NP (NNS Mothers)))) (: :) (S (NP (NNS Penicillins)) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (VP (VBN excreted) (PP (IN in) (NP (JJ human) (NN milk)))))))))))) (. .))))

Sentence Id: DrugDDI.d117.s25
Amoxicillin/JJ use/NN by/IN nursing/JJ mothers/NNS may/MD lead/VB to/TO sensitization/NN of/IN infants/NNS ./.

(ROOT (S1 (S (S (NP (NP (JJ Amoxicillin) (NN use)) (PP (IN by) (NP (JJ nursing) (NNS mothers)))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (NN sensitization)) (PP (IN of) (NP (NNS infants)))))))) (. .))))

Sentence Id: DrugDDI.d117.s26
Caution/NN should/MD be/VB exercised/VBN when/WRB amoxicillin/NN is/VBZ administered/VBN to/TO a/DT nursing/JJ woman/NN ./.

(ROOT (S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (NP (NN amoxicillin)) (VP (VBZ is) (VP (VBN administered) (PP (TO to) (NP (DT a) (JJ nursing) (NN woman))))))))))) (. .))))

Sentence Id: DrugDDI.d117.s27
Pediatric/JJ Use/NN :/: Because/IN of/IN incompletely/RB developed/VBN renal/JJ function/NN in/IN neonates/NNS and/CC young/JJ infants/NNS ,/, the/DT elimination/NN of/IN amoxicillin/NN may/MD be/VB delayed/VBN ./.

(ROOT (S1 (S (S (NP (JJ Pediatric) (NN Use)) (: :) (PP (IN Because) (PP (IN of) (NP (NP (ADJP (RB incompletely) (VBN developed)) (JJ renal) (NN function)) (PP (IN in) (NP (NP (NNS neonates)) (CC and) (NP (JJ young) (NNS infants))))))) (, ,) (NP (NP (DT the) (NN elimination)) (PP (IN of) (NP (NN amoxicillin)))) (VP (MD may) (VP (VB be) (VP (VBN delayed))))) (. .))))

Sentence Id: DrugDDI.d117.s28
Dosing/NN of/IN AMOXIL/NN should/MD be/VB modified/VBN in/IN pediatric/JJ patients/NNS 12/CD weeks/NNS or/CC younger/JJR (/-LRB- @/NN 3/CD months/NNS )./NN

(ROOT (S1 (S (S (NP (NP (NN Dosing)) (PP (IN of) (NP (NN AMOXIL)))) (VP (MD should) (VP (VB be) (VP (VBN modified) (PP (IN in) (NP (JJ pediatric) (NNS patients))))))) (NP (ADJP (NP (NP (CD 12) (NNS weeks)) (CC or) (NP (JJR younger))) (-LRB- -LRB-) (NN @) (CD 3) (NNS months)) (NN -RRB-.)))))

Sentence Id: DrugDDI.d28.s1
Toxicologic/JJ and/CC toxicokinetic/JJ studies/NNS in/IN rats/NNS did/VBD not/RB demonstrate/VB any/DT alterations/NNS in/IN the/DT clearance/NN or/CC toxicologic/JJ profile/NN of/IN either/CC methotrexate/NN or/CC Kineret/NN @/NN when/WRB the/DT two/CD agents/NNS were/VBD administered/VBN together/RB ./.

(ROOT (S1 (S (S (NP (NP (ADJP (ADJP (JJ Toxicologic)) (CC and) (ADJP (JJ toxicokinetic))) (NNS studies)) (PP (IN in) (NP (NNS rats)))) (VP (VBD did) (RB not) (VP (VB demonstrate) (NP (NP (DT any) (NNS alterations)) (PP (IN in) (NP (NP (DT the) (NP (NN clearance)) (CC or) (NP (JJ toxicologic) (NN profile))) (PP (IN of) (NP (CC either) (NP (NN methotrexate)) (CC or) (NP (NN Kineret) (NN @)))))))) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (CD two) (NNS agents)) (VP (VBD were) (VP (VBN administered) (ADVP (RB together)))))))) (. .))))

Sentence Id: DrugDDI.d28.s2
In/IN a/DT study/NN in/IN which/WDT patients/NNS with/IN active/JJ RA/NN were/VBD treated/VBN for/IN up/RB to/TO 24/CD weeks/NNS with/IN concurrent/JJ Kineret/NN @/NN and/CC etanercept/NN therapy/NN ,/, a/DT 7/CD %/NN rate/NN of/IN serious/JJ infections/NNS was/VBD observed/VBN ,/, which/WDT was/VBD higher/JJR than/IN that/DT observed/VBN with/IN etanercept/NN alone/RB (/-LRB- 0%)./NN

(ROOT (S1 (S (PP (IN In) (NP (NP (DT a) (NN study)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (NNS patients)) (PP (IN with) (NP (JJ active) (NN RA)))) (VP (VBD were) (VP (VBN treated) (PP (IN for) (NP (QP (RB up) (TO to) (CD 24)) (NNS weeks))) (PP (IN with) (NP (NP (JJ concurrent) (NN Kineret) (NN @)) (CC and) (NP (NN etanercept) (NN therapy)))))))))) (, ,) (NP (NP (DT a) (ADJP (CD 7) (NN %)) (NN rate)) (PP (IN of) (NP (JJ serious) (NNS infections)))) (VP (VBD was) (VP (VBN observed) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (NP (DT that)) (VP (VBN observed) (PP (IN with) (NP (NP (NN etanercept)) (ADVP (RB alone)))))))) (PRN (-LRB- -LRB-) (NP (NN 0%-RRB-.)))))))))))

Sentence Id: DrugDDI.d28.s3
Two/CD percent/NN of/IN patients/NNS treated/VBN concurrently/RB with/IN Kineret/NN @/NN and/CC etanercept/NN developed/VBD neutropenia/NN (/-LRB- ANC/NN 1/CD x/NN 109/L/NN )/-RRB- ./.

(ROOT (S1 (S (S (NP (NP (CD Two) (NN percent)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN treated) (ADVP (RB concurrently)) (PP (IN with) (NP (NP (NN Kineret) (NN @)) (CC and) (NP (NN etanercept)))))))) (VP (VBD developed) (NP (NP (NN neutropenia)) (PRN (-LRB- -LRB-) (NP (NN ANC) (CD 1) (NN x) (NN 109/L)) (-RRB- -RRB-))))) (. .))))

Sentence Id: DrugDDI.d552.s0
No/DT clinically/RB relevant/JJ drug-drug/JJ interactions/NNS have/VBP been/VBN observed/VBN with/IN drugs/NNS likely/RB to/TO be/VB co-administered/VBN with/IN anidulafungin/NN ./.

(ROOT (S1 (S (S (NP (DT No) (ADJP (RB clinically) (JJ relevant)) (JJ drug-drug) (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (SBAR (IN with) (S (NP (NNS drugs)) (ADVP (RB likely)) (VP (TO to) (VP (VB be) (VP (VBN co-administered) (PP (IN with) (NP (NN anidulafungin)))))))))))) (. .))))

Sentence Id: DrugDDI.d290.s0
Caution/NN should/MD be/VB observed/VBN when/WRB anileridine/NN is/VBZ coadministered/VBN with/IN other/JJ opioids/NNS ,/, sedatives/NNS ,/, phenothiazines/NNS ,/, or/CC anesthetics/NNS ,/, as/IN these/DT agents/NNS may/MD increase/VB respiratory/JJ and/CC circulatory/JJ depression/NN ./.

(ROOT (S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (NN anileridine)) (VP (VBZ is) (VP (VBN coadministered) (PP (IN with) (NP (NP (JJ other) (NNS opioids)) (, ,) (NP (NNS sedatives)) (, ,) (NP (NNS phenothiazines)) (, ,) (CC or) (NP (NNS anesthetics))))) (, ,) (SBAR (IN as) (S (NP (DT these) (NNS agents)) (VP (MD may) (VP (VB increase) (NP (ADJP (ADJP (JJ respiratory)) (CC and) (ADJP (JJ circulatory))) (NN depression))))))))))))) (. .))))

Sentence Id: DrugDDI.d224.s0
Ketoconazole/NN //: Itraconazole/NN ,/, Macrolides/NN ,/, Including/VBG Erythromycin/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Ketoconazole)) (: /) (NP (NN Itraconazole)) (, ,) (NP (NN Macrolides)) (, ,)) (VP (VBG Including) (NP (NN Erythromycin)))) (. .))))

Sentence Id: DrugDDI.d582.s0
Atovaquone/NN is/VBZ highly/RB bound/VBN to/TO plasma/NN protein/NN (/-LRB- 99.9%)./NN

(ROOT (S1 (S (NP (NN Atovaquone)) (VP (VBZ is) (ADVP (RB highly)) (VP (VBN bound) (PP (TO to) (NP (NN plasma) (NN protein) (-LRB- -LRB-) (NN 99.9%-RRB-.))))))))

Sentence Id: DrugDDI.d582.s1
Therefore/RB ,/, caution/NN should/MD be/VB used/VBN when/WRB administering/VBG MEPRON/NN concurrently/RB with/IN other/JJ highly/RB plasma/NN protein-/NN bound/VBN drugs/NNS with/IN narrow/JJ therapeutic/JJ indices/NNS ,/, as/IN competition/NN for/IN binding/NN sites/NNS may/MD occur/VB ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NP (NN MEPRON)) (PP (ADVP (RB concurrently)) (IN with) (NP (JJ other) (ADJP (RB highly) (NP (NN plasma) (NN protein-)) (VBN bound)) (NNS drugs)))) (PP (IN with) (NP (JJ narrow) (JJ therapeutic) (NNS indices)))))))) (, ,) (SBAR (IN as) (S (NP (NP (NN competition)) (PP (IN for) (NP (NN binding) (NNS sites)))) (VP (MD may) (VP (VB occur))))))) (. .))))

Sentence Id: DrugDDI.d582.s2
The/DT extent/NN of/IN plasma/NN protein/NN binding/NN of/IN atovaquone/NN in/IN human/JJ plasma/NN is/VBZ not/RB affected/VBN by/IN the/DT presence/NN of/IN therapeutic/JJ concentrations/NNS of/IN phenytoin/NN (/-LRB- 15/CD mcg//NN mL/NN )/-RRB- ,/, nor/CC is/VBZ the/DT binding/NN of/IN phenytoin/NN affected/VBN by/IN the/DT presence/NN of/IN atovaquone/NN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN extent)) (PP (IN of) (NP (NP (NN plasma) (NN protein) (NN binding)) (PP (IN of) (NP (NN atovaquone))) (PP (IN in) (NP (JJ human) (NN plasma)))))) (VP (VP (VBZ is) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ therapeutic) (NNS concentrations)) (PP (IN of) (NP (NP (NN phenytoin)) (PRN (-LRB- -LRB-) (NP (CD 15) (NN mcg/) (NN mL)) (-RRB- -RRB-)))))))))) (, ,) (CC nor) (VP (VBZ is) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (NP (NN phenytoin)) (VP (VBN affected) (PP (IN by) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN atovaquone)))))))))))) (. .))))

Sentence Id: DrugDDI.d582.s3
Rifampin/NN :/: Coadministration/NN of/IN rifampin/NN and/CC MEPRON/NN Suspension/NN results/VBZ in/IN a/DT significant/JJ decrease/NN in/IN average/JJ steady-/JJ state/NN plasma/NN atovaquone/NN concentrations/NNS ./.

(ROOT (S1 (S (NP (NP (NN Rifampin)) (: :) (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NN rifampin)) (CC and) (NP (NN MEPRON)) (NP (NN Suspension))))) (VP (VBZ results) (PP (IN in) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (JJ average) (JJ steady-) (NN state) (NN plasma) (NN atovaquone) (NNS concentrations))))))) (. .)))))

Sentence Id: DrugDDI.d582.s4
Alternatives/NNS to/TO rifampin/NN should/MD be/VB considered/VBN during/IN the/DT course/NN of/IN PCP/NN treatment/NN with/IN MEPRON/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Alternatives)) (PP (TO to) (NP (NN rifampin)))) (VP (MD should) (VP (VB be) (VP (VBN considered) (PP (IN during) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (NP (NN PCP) (NN treatment)) (PP (IN with) (NP (NN MEPRON))))))))))) (. .))))

Sentence Id: DrugDDI.d582.s5
Rifabutin/NN ,/, another/DT rifamycin/NN ,/, is/VBZ structurally/RB similar/JJ to/TO rifampin/NN and/CC may/MD possibly/RB have/VB some/DT of/IN the/DT same/JJ drug/NN interactions/NNS as/IN rifampin/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Rifabutin)) (, ,) (NP (DT another) (NN rifamycin)) (, ,)) (VP (VP (VBZ is) (ADJP (RB structurally) (JJ similar) (PP (TO to) (NP (NN rifampin))))) (CC and) (VP (MD may) (ADVP (RB possibly)) (VP (VB have) (NP (NP (DT some)) (PP (IN of) (NP (NP (DT the) (JJ same) (NN drug) (NNS interactions)) (PP (IN as) (NP (NN rifampin)))))))))) (. .))))

Sentence Id: DrugDDI.d582.s6
No/NN interaction/NN trials/NNS have/VBP been/VBN conducted/VBN with/IN MEPRON/NN and/CC rifabutin/NN ./.

(ROOT (S1 (S (S (NP (NN No) (NN interaction) (NNS trials)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted) (PP (IN with) (NP (NP (NN MEPRON)) (CC and) (NP (NN rifabutin)))))))) (. .))))

Sentence Id: DrugDDI.d582.s7
Drug/NN //: Laboratory/NN Test/NN Interactions/NNS :/: It/PRP is/VBZ not/RB known/VBN if/IN MEPRON/NN interferes/VBZ with/IN clinical/JJ laboratory/JJ test/NN or/NN assay/NN results/NNS ./.

(ROOT (S1 (S (NP (NP (NN Drug) (: /) (NN Laboratory) (NN Test) (NNS Interactions)) (: :) (S (NP (PRP It)) (VP (VBZ is) (RB not) (VP (VBN known) (SBAR (IN if) (S (NP (NN MEPRON)) (VP (VBZ interferes) (PP (IN with) (NP (JJ clinical) (JJ laboratory) (NN test) (NN or) (NN assay) (NNS results))))))))) (. .)))))

Sentence Id: DrugDDI.d39.s0
When/WRB atropine/NN and/CC pralidoxime/NN are/VBP used/VBN together/RB ,/, the/DT signs/NNS of/IN atropinization/NN (/-LRB- flushing/NN ,/, mydriasis/NN ,/, tachycardia/NN ,/, dryness/NN of/IN the/DT mouth/NN and/CC nose/NN )/-RRB- may/MD occur/VB earlier/RBR than/IN might/MD be/VB expected/VBN than/IN when/WRB atropine/NN is/VBZ used/VBN alone/RB because/IN pralidoxime/NN may/MD potentiate/VB the/DT effect/NN of/IN atropine/NN ./.

(ROOT (S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NN atropine)) (CC and) (NP (NN pralidoxime))) (VP (VBP are) (VP (VBN used) (ADVP (RB together)))))) (, ,) (NP (NP (DT the) (NNS signs)) (PP (IN of) (NP (NP (NN atropinization)) (PRN (-LRB- -LRB-) (NP (NP (NN flushing)) (, ,) (NP (NN mydriasis)) (, ,) (NP (NN tachycardia)) (, ,) (NP (NP (NN dryness)) (PP (IN of) (NP (DT the) (NN mouth)))) (CC and) (NP (NN nose))) (-RRB- -RRB-))))) (VP (MD may) (VP (VB occur) (ADVP (RBR earlier)) (PP (IN than) (S (VP (MD might) (VP (VB be) (VP (VBN expected) (PP (IN than) (SBAR (WHADVP (WRB when)) (S (NP (NN atropine)) (VP (VBZ is) (VP (VBN used) (ADVP (RB alone)) (SBAR (IN because) (S (NP (NN pralidoxime)) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN atropine))))))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d39.s1
The/DT following/JJ precautions/NNS should/MD be/VB kept/VBN in/IN mind/NN in/IN the/DT treatment/NN of/IN anticholinesterase/NN poisoning/NN although/IN they/PRP do/VBP not/RB bear/VB directly/RB on/IN the/DT use/NN of/IN atropine/NN and/CC pralidoxime/NN ./.

(ROOT (S1 (S (S (NP (DT The) (JJ following) (NNS precautions)) (VP (MD should) (VP (VB be) (VP (VBN kept) (PP (IN in) (NP (NN mind))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN anticholinesterase) (NN poisoning))))) (SBAR (IN although) (S (NP (PRP they)) (VP (VBP do) (RB not) (VP (VB bear) (ADVP (RB directly)) (PP (IN on) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NN atropine)) (CC and) (NP (NN pralidoxime)))))))))))))) (. .))))

Sentence Id: DrugDDI.d39.s2
Since/IN barbiturates/NNS are/VBP potentiated/VBN by/IN the/DT anticholinesterases/NNS ,/, they/PRP should/MD be/VB used/VBN cautiously/RB in/IN the/DT treatment/NN of/IN convulsions/NNS ./.

(ROOT (S1 (S (S (SBAR (IN Since) (S (NP (NNS barbiturates)) (VP (VBP are) (VP (VBN potentiated) (PP (IN by) (NP (DT the) (NNS anticholinesterases))))))) (, ,) (NP (PRP they)) (VP (MD should) (VP (VB be) (VP (VBN used) (ADVP (RB cautiously)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNS convulsions))))))))) (. .))))

Sentence Id: DrugDDI.d554.s0
Co-administration/NN of/IN nelfinavir/NN at/IN steady-state/NN with/IN a/DT single/JJ dose/NN of/IN azithromycin/NN (/-LRB- 2/CD span/NN class=/NN c94/NN @/NN ?/.

(ROOT (S1 (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NN nelfinavir))) (PP (IN at) (NP (NN steady-state))) (PP (IN with) (NP (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NN azithromycin)))) (PRN (-LRB- -LRB-) (NP (CD 2) (NN span) (NN class=) (NN c94) (NN @))))) (. ?)))))

Sentence Id: DrugDDI.d554.s1
600/CD mg/NN tablets/NNS )/-RRB- results/VBZ in/IN increased/VBN azithromycin/NN serum/NN concentrations/NNS ./.

(ROOT (S1 (S (S (NP (ADJP (CD 600) (NN mg)) (NNS tablets) (-RRB- -RRB-)) (VP (VBZ results) (PP (IN in) (NP (VBN increased) (NN azithromycin) (NN serum) (NNS concentrations))))) (. .))))

Sentence Id: DrugDDI.d554.s2
Although/IN a/DT dose/NN adjustment/NN of/IN azithromycin/NN is/VBZ not/RB recommended/VBN when/WRB administered/VBN in/IN combination/NN with/IN nelfinavir/NN ,/, close/JJ monitoring/NN for/IN known/JJ side/JJ effects/NNS of/IN azithromycin/NN ,/, such/JJ as/IN liver/NN enzyme/NN abnormalities/NNS and/CC hearing/NN impairment/NN ,/, is/VBZ warranted/VBN ./.

(ROOT (S1 (S (S (SBAR (IN Although) (S (NP (NP (DT a) (NN dose) (NN adjustment)) (PP (IN of) (NP (NN azithromycin)))) (VP (VBZ is) (RB not) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN nelfinavir)))))))))))) (, ,) (NP (NP (JJ close) (NN monitoring)) (PP (IN for) (NP (NP (JJ known) (JJ side) (NNS effects)) (PP (IN of) (NP (NN azithromycin))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN liver) (NN enzyme) (NNS abnormalities)) (CC and) (NP (NN hearing) (NN impairment)))) (, ,)))) (VP (VBZ is) (VP (VBN warranted)))) (. .))))

Sentence Id: DrugDDI.d554.s3
Azithromycin/NN did/VBD not/RB affect/VB the/DT prothrombin/NN time/NN response/NN to/TO a/DT single/JJ dose/NN of/IN warfarin/NN ./.

(ROOT (S1 (S (S (NP (NN Azithromycin)) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (DT the) (NN prothrombin) (NN time) (NN response)) (PP (TO to) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NN warfarin))))))))) (. .))))

Sentence Id: DrugDDI.d554.s4
However/RB ,/, prudent/JJ medical/JJ practice/NN dictates/VBZ careful/JJ monitoring/NN of/IN prothrombin/NN time/NN in/IN all/DT patients/NNS treated/VBN with/IN azithromycin/NN and/CC warfarin/NN concomitantly/RB ./.

(ROOT (S1 (S (S (ADVP (RB However)) (, ,) (NP (JJ prudent) (JJ medical) (NN practice)) (VP (VBZ dictates) (NP (NP (JJ careful) (NN monitoring)) (PP (IN of) (NP (NN prothrombin) (NN time))) (PP (IN in) (NP (NP (DT all) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NN azithromycin)) (CC and) (NP (NN warfarin)))) (ADVP (RB concomitantly)))))))) (. .))))

Sentence Id: DrugDDI.d554.s5
Concurrent/JJ use/NN of/IN macrolides/NN and/CC warfarin/NN in/IN clinical/JJ practice/NN has/VBZ been/VBN associated/VBN with/IN increased/VBN anticoagulant/JJ effects/NNS ./.

(ROOT (S1 (S (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (NP (NN macrolides)) (CC and) (NP (NN warfarin)))) (PP (IN in) (NP (JJ clinical) (NN practice)))) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (VBN increased) (JJ anticoagulant) (NNS effects))))))) (. .))))

Sentence Id: DrugDDI.d554.s6
Drug/NN interaction/NN studies/NNS were/VBD performed/VBN with/IN azithromycin/NN and/CC other/JJ drugs/NNS likely/RB to/TO be/VB co-administered/VBN ./.

(ROOT (S1 (S (S (NP (NN Drug) (NN interaction) (NNS studies)) (VP (VBD were) (VP (VBN performed) (PP (IN with) (NP (NP (NN azithromycin)) (CC and) (NP (JJ other) (NNS drugs)))) (S (ADVP (RB likely)) (VP (TO to) (VP (VB be) (VP (VBN co-administered)))))))) (. .))))

Sentence Id: DrugDDI.d554.s7
When/WRB used/VBN in/IN therapeutic/JJ doses/NNS ,/, azithromycin/NN had/VBD a/DT modest/JJ effect/NN on/IN the/DT pharmacokinetics/NNS of/IN atorvastatin/NN ,/, carbamazepine/NN ,/, cetirizine/NN ,/, didanosine/NN ,/, efavirenz/NN ,/, fluconazole/NN ,/, indinavir/NN ,/, midazolam/NN ,/, rifabutin/NN ,/, sildenafil/NN ,/, theophylline/NN (/-LRB- intravenous/JJ and/CC oral/JJ )/-RRB- ,/, triazolam/NN ,/, trimethoprim/NN //: sulfamethoxazole/NN or/CC zidovudine/NN ./.

(ROOT (S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN used) (PP (IN in) (NP (JJ therapeutic) (NNS doses)))))) (, ,) (NP (NN azithromycin)) (VP (VBD had) (NP (DT a) (JJ modest) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN atorvastatin)) (, ,) (NP (NN carbamazepine)) (, ,) (NP (NN cetirizine)) (, ,) (NP (NN didanosine)) (, ,) (NP (NN efavirenz)) (, ,) (NP (NN fluconazole)) (, ,) (NP (NN indinavir)) (, ,) (NP (NN midazolam)) (, ,) (NP (NN rifabutin)) (, ,) (NP (NN sildenafil)) (, ,) (NP (NP (NP (NN theophylline)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ intravenous)) (CC and) (ADJP (JJ oral))) (-RRB- -RRB-))) (, ,) (NP (NN triazolam)) (, ,) (NP (NN trimethoprim)) (: /) (NP (NN sulfamethoxazole))) (CC or) (NP (NN zidovudine))))))) (. .))))

Sentence Id: DrugDDI.d554.s8
Co-administration/NN with/IN efavirenz/NN or/CC fluconazole/NN had/VBD a/DT modest/JJ effect/NN on/IN the/DT pharmacokinetics/NNS of/IN azithromycin/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Co-administration)) (PP (IN with) (NP (NP (NN efavirenz)) (CC or) (NP (NN fluconazole))))) (VP (VBD had) (NP (DT a) (JJ modest) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN azithromycin))))))) (. .))))

Sentence Id: DrugDDI.d554.s9
No/DT dosage/JJ adjustment/NN of/IN either/DT drug/NN is/VBZ recommended/VBN when/WRB azithromycin/NN is/VBZ co/RB administered/VBN with/IN any/DT of/IN the/DT above/JJ agents/NNS ./.

(ROOT (S1 (S (S (NP (NP (DT No) (JJ dosage) (NN adjustment)) (PP (IN of) (NP (DT either) (NN drug)))) (VP (VBZ is) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (NP (NN azithromycin)) (VP (VBZ is) (ADVP (RB co)) (VP (VBN administered) (PP (IN with) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (JJ above) (NNS agents)))))))))))) (. .))))

Sentence Id: DrugDDI.d554.s10
Interactions/NNS with/IN the/DT drugs/NNS listed/VBN below/IN have/VBP not/RB been/VBN reported/VBN in/IN clinical/JJ trials/NNS with/IN azithromycin/NN ;/: ./.

(ROOT (S1 (S (S (NP (NP (NNS Interactions)) (PP (IN with) (NP (NP (DT the) (NNS drugs)) (VP (VBN listed) (PP (IN below)))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (JJ clinical) (NNS trials)) (PP (IN with) (NP (NN azithromycin))) (: ;))))))) (. .))))

Sentence Id: DrugDDI.d554.s12
Nonetheless/RB ,/, they/PRP have/VBP been/VBN observed/VBN with/IN macrolide/NN products/NNS ./.

(ROOT (S1 (S (S (ADVP (RB Nonetheless)) (, ,) (NP (PRP they)) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (PP (IN with) (NP (NN macrolide) (NNS products))))))) (. .))))

Sentence Id: DrugDDI.d554.s13
Until/IN further/JJ data/NNS are/VBP developed/VBN regarding/VBG drug/NN interactions/NNS when/WRB azithromycin/NN and/CC these/DT drugs/NNS are/VBP used/VBN concomitantly/RB ,/, careful/JJ monitoring/NN of/IN patients/NNS is/VBZ advised/VBN :/: Digoxin/NN @/NN elevated/JJ digoxin/NN concentrations/NNS ./.

(ROOT (S1 (S (S (SBAR (IN Until) (S (NP (JJ further) (NNS data)) (VP (VBP are) (VP (VBN developed) (S (VP (VBG regarding) (NP (NP (NN drug) (NNS interactions)) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN azithromycin)) (CC and) (NP (DT these) (NNS drugs))) (VP (VBP are) (VP (VBN used) (ADVP (RB concomitantly))))))))))))) (, ,) (NP (NP (JJ careful) (NN monitoring)) (PP (IN of) (NP (NNS patients)))) (VP (VBZ is) (VP (VBN advised) (: :) (NP (NN Digoxin) (NN @) (JJ elevated) (NN digoxin) (NNS concentrations))))) (. .))))

Sentence Id: DrugDDI.d554.s14
Ergotamine/NN or/CC dihydro/NN ergot/NN amine/NN @/NN acute/JJ ergot/NN toxicity/NN characterized/VBN by/IN severe/JJ peripheral/JJ vasospasm/NN and/CC dysesthesia/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Ergotamine)) (CC or) (NP (NN dihydro) (NN ergot) (NN amine) (NN @) (JJ acute) (NN ergot) (NN toxicity))) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ severe) (JJ peripheral) (NN vasospasm)) (CC and) (NP (NN dysesthesia)))))) (. .))))

Sentence Id: DrugDDI.d554.s15
Cyclosporine/NN ,/, hexobarbital/NN and/CC phenytoin/NN concentrations/NNS ./.

(ROOT (S1 (S (S (NP (NP (NN Cyclosporine)) (, ,) (NP (NN hexobarbital)) (CC and) (NP (NN phenytoin))) (VP (NNS concentrations))) (. .))))

Sentence Id: DrugDDI.d554.s17
Repeat/NN Treatment/NN Studies/NNS evaluating/VBG the/DT use/NN of/IN repeated/JJ courses/NNS of/IN Zmax/NN have/VBP not/RB been/VBN conducted/VBN ./.

(ROOT (S1 (S (S (NP (NP (NN Repeat) (NN Treatment) (NNS Studies)) (VP (VBG evaluating) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (JJ repeated) (NNS courses)) (PP (IN of) (NP (NN Zmax)))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN conducted))))) (. .))))

Sentence Id: DrugDDI.d535.s0
Azlocillin/NN should/MD not/RB be/VB administered/VBN concomitantly/RB with/IN amikacin/NN ,/, ciprofloxacin/NN ,/, gentamicin/NN ,/, netilmicin/NN ,/, or/CC tobramycin/NN ./.

(ROOT (S1 (S (S (NP (NN Azlocillin)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NN amikacin)) (, ,) (NP (NN ciprofloxacin)) (, ,) (NP (NN gentamicin)) (, ,) (NP (NN netilmicin)) (, ,) (CC or) (NP (NN tobramycin)))))))) (. .))))

Sentence Id: DrugDDI.d517.s0
Injection/NN :/: There/EX is/VBZ inadequate/JJ systematic/JJ experience/VBP with/IN the/DT use/NN of/IN baclofen/NN injection/NN in/IN combination/NN with/IN other/JJ medications/NNS to/TO predict/VB specific/JJ drug-drug/JJ interactions/NNS ./.

(ROOT (S1 (S (NP (NP (NN Injection)) (: :) (S (NP (EX There)) (VP (VBZ is) (NP (NP (JJ inadequate) (JJ systematic) (VBP experience)) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN baclofen) (NN injection))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ other) (NNS medications))) (S (VP (TO to) (VP (VB predict) (NP (JJ specific) (JJ drug-drug) (NNS interactions)))))))))))) (. .)))))

Sentence Id: DrugDDI.d517.s1
Interactions/NNS attributed/VBN to/TO the/DT combined/JJ use/NN of/IN baclofen/JJ injection/NN and/CC epidural/JJ morphine/NN include/VBP hypotension/NN and/CC dyspnea/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Interactions)) (VP (VBN attributed) (PP (TO to) (NP (NP (DT the) (JJ combined) (NN use)) (PP (IN of) (NP (NP (JJ baclofen) (NN injection)) (CC and) (NP (JJ epidural) (NN morphine)))))))) (VP (VBP include) (NP (NP (NN hypotension)) (CC and) (NP (NN dyspnea))))) (. .))))

Sentence Id: DrugDDI.d517.s2
SIDE/JJ EFFECTS/NNS (/-LRB- KEMSTRO/NN )/-RRB- :/: The/DT most/RBS common/JJ adverse/JJ reaction/NN during/IN treatment/NN with/IN baclofen/NN is/VBZ transient/JJ drowsiness/NN (/-LRB- 10-63%)./CD

(ROOT (S1 (S (NP (NP (NP (JJ SIDE) (NNS EFFECTS)) (PRN (-LRB- -LRB-) (NP (NN KEMSTRO)) (-RRB- -RRB-))) (: :) (S (NP (NP (DT The) (ADJP (RBS most) (JJ common)) (JJ adverse) (NN reaction)) (PP (IN during) (NP (NN treatment))) (PP (IN with) (NP (NN baclofen)))) (VP (VBZ is) (NP (JJ transient) (NN drowsiness)))) (-LRB- -LRB-) (CD 10-63%-RRB-.)))))

Sentence Id: DrugDDI.d517.s3
In/IN one/CD controlled/JJ study/NN of/IN 175/CD patients/NNS ,/, transient/JJ drowsiness/NN was/VBD observed/VBN in/IN 63/CD %/NN of/IN those/DT receiving/VBG baclofen/NN tablets/NNS compared/VBN to/TO 36/CD %/NN of/IN those/DT in/IN the/DT placebo/NN group/NN ./.

(ROOT (S1 (S (PP (IN In) (NP (NP (CD one) (JJ controlled) (NN study)) (PP (IN of) (NP (CD 175) (NNS patients))))) (, ,) (NP (JJ transient) (NN drowsiness)) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP (NP (CD 63) (NN %)) (PP (IN of) (NP (DT those) (VBG receiving) (NN baclofen) (NNS tablets))))) (PP (VBN compared) (PP (TO to) (NP (NP (CD 36) (NN %)) (PP (IN of) (NP (NP (DT those)) (PP (IN in) (NP (DT the) (NN placebo) (NN group)))))))))) (. .))))

Sentence Id: DrugDDI.d517.s15
The/DT following/JJ laboratory/NN tests/NNS have/VBP been/VBN found/VBN to/TO be/VB abnormal/JJ in/IN a/DT few/JJ patients/NNS receiving/VBG baclofen/NN :/: increased/VBN SGOT/NN ,/, elevated/JJ alkaline/NN phosphatase/NN ,/, and/CC elevation/NN of/IN blood/NN sugar/NN ./.

(ROOT (S1 (S (S (NP (DT The) (JJ following) (NN laboratory) (NNS tests)) (VP (VBP have) (VP (VBN been) (VP (VBN found) (S (VP (TO to) (VP (VB be) (ADJP (JJ abnormal) (PP (IN in) (NP (NP (NP (DT a) (JJ few) (NNS patients)) (VP (VBG receiving) (NP (NN baclofen)))) (: :) (NP (NP (VBN increased) (NN SGOT)) (, ,) (NP (JJ elevated) (NN alkaline) (NN phosphatase)) (, ,) (CC and) (NP (NP (NN elevation)) (PP (IN of) (NP (NN blood) (NN sugar))))))))))))))) (. .))))

Sentence Id: DrugDDI.d517.s16
The/DT adverse/JJ experience/VBP profile/NN seen/VBN with/IN KEMSTROTM/NN was/VBD similar/JJ to/TO that/DT seen/VBN with/IN baclofen/JJ tablets/NNS ./.

(ROOT (S1 (S (S (NP (NP (DT The) (JJ adverse) (VBP experience) (NN profile)) (VP (VBN seen) (PP (IN with) (NP (NN KEMSTROTM))))) (VP (VBD was) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (VP (VBN seen) (PP (IN with) (NP (JJ baclofen) (NNS tablets))))))))) (. .))))

Sentence Id: DrugDDI.d500.s0
Bentiromide/NN may/MD interact/VB with/IN acetaminophen/NN (/-LRB- e.g./FW ,/, Tylenol/NN )/-RRB- ,/, chloramphenicol/NN (/-LRB- e.g./FW ,/, Chloromycetin/NN )/-RRB- ,/, local/JJ anesthetics/NNS (/-LRB- e.g./FW ,/, benzocaine/NN and/CC lidocaine/NN )/-RRB- ,/, para-aminobenzoic/JJ acid/NN (/-LRB- PABA/NN )/-RRB- -containing/JJ preparations/NNS (/-LRB- e.g./FW ,/, sunscreens/NNS and/CC some/DT multivitamins/NNS )/-RRB- ,/, procainamide/NN (/-LRB- e.g./FW ,/, Pronestyl/NN )/-RRB- ,/, sulfonamides/NNS (/-LRB- sulfa/NN medicines/NNS )/-RRB- ,/, thiazide/NN diuretics/NNS (/-LRB- use/NN of/IN these/DT medicines/NNS during/IN the/DT test/NN period/NN will/MD affect/VB the/DT test/NN results/NNS )/-RRB- ,/, and/CC pancreatic/JJ supplements/NNS (/-LRB- use/NN of/IN pancreatic/JJ supplements/NNS may/MD give/VB false/JJ test/NN results/NNS )./RB

(ROOT (S1 (S (NP (NN Bentiromide)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NP (NP (NN acetaminophen)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN Tylenol)) (-RRB- -RRB-))) (, ,) (NP (NP (NN chloramphenicol)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN Chloromycetin)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ local) (NNS anesthetics)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN benzocaine)) (CC and) (NP (NN lidocaine)))) (-RRB- -RRB-))) (, ,) (NP (NP (JJ para-aminobenzoic) (ADJP (NN acid) (-LRB- -LRB-) (NN PABA) (-RRB- -RRB-) (JJ -containing)) (NNS preparations)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NNS sunscreens)) (CC and) (NP (DT some) (NNS multivitamins))) (-RRB- -RRB-))) (, ,) (NP (NP (NN procainamide)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN Pronestyl))) (-RRB- -RRB-))) (, ,) (NP (NP (NNS sulfonamides)) (PRN (-LRB- -LRB-) (NP (NN sulfa) (NNS medicines)) (-RRB- -RRB-))) (, ,) (NP (NP (NN thiazide) (NNS diuretics)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN use)) (PP (IN of) (NP (DT these) (NNS medicines))) (PP (IN during) (NP (DT the) (NN test) (NN period)))) (VP (MD will) (VP (VB affect) (NP (DT the) (NN test) (NNS results))))) (-RRB- -RRB-))) (, ,) (CC and) (NP (JJ pancreatic) (NNS supplements)))) (-LRB- -LRB-) (NP (NP (NN use)) (PP (IN of) (NP (JJ pancreatic) (NNS supplements)))))) (VP (MD may) (VP (VB give) (NP (JJ false) (NN test) (NNS results)) (ADVP (RB -RRB-.)))))))

Sentence Id: DrugDDI.d194.s0
Hypertensive/JJ crises/NNS have/VBP resulted/VBD when/WRB sympathomimetic/JJ amines/NNS have/VBP been/VBN used/VBN concomitantly/RB within14/CD days/NNS following/VBG use/NN of/IN monoamine/NN oxidase/NN inhibitors/NNS ./.

(ROOT (S1 (S (S (NP (JJ Hypertensive) (NNS crises)) (VP (VBP have) (S (VP (VBD resulted) (SBAR (WHADVP (WRB when)) (S (NP (JJ sympathomimetic) (NNS amines)) (VP (VBP have) (VP (VBN been) (VP (VBN used) (ADVP (RB concomitantly)) (PP (NP (CD within14) (NNS days)) (VBG following) (NP (NP (NN use)) (PP (IN of) (NP (NN monoamine) (NN oxidase) (NNS inhibitors)))))))))))))) (. .))))

Sentence Id: DrugDDI.d194.s1
DIDREX/NN should/MD not/RB be/VB used/VBN concomitantly/RB with/IN other/JJ CNS/NN stimulants/NNS ./.

(ROOT (S1 (S (S (NP (NN DIDREX)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (JJ other) (NN CNS) (NNS stimulants))))))) (. .))))

Sentence Id: DrugDDI.d194.s2
Amphetamines/NN may/MD decrease/VB the/DT hypotensive/JJ effect/NN of/IN antihypertensives/NNS ./.

(ROOT (S1 (S (S (NP (NN Amphetamines)) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (JJ hypotensive) (NN effect)) (PP (IN of) (NP (NNS antihypertensives))))))) (. .))))

Sentence Id: DrugDDI.d194.s3
Amphetamines/NN may/MD enhance/VB the/DT effects/NNS of/IN tricyclic/JJ antidepressants/NNS ./.

(ROOT (S1 (S (S (NP (NN Amphetamines)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ tricyclic) (NNS antidepressants))))))) (. .))))

Sentence Id: DrugDDI.d194.s4
Urinary/JJ alkalinizing/NN agents/NNS increase/VBP blood/NN levels/NNS and/CC decrease/VBP excretion/NN of/IN amphetamines/NN ./.

(ROOT (S1 (S (S (NP (JJ Urinary) (NN alkalinizing) (NNS agents)) (VP (VP (VBP increase) (NP (NN blood) (NNS levels))) (CC and) (VP (VBP decrease) (NP (NP (NN excretion)) (PP (IN of) (NP (NN amphetamines))))))) (. .))))

Sentence Id: DrugDDI.d194.s5
Urinary/JJ acidifying/JJ agents/NNS decrease/VB blood/NN levels/NNS and/CC increase/VB excretion/NN of/IN amphetamines/NN ./.

(ROOT (S1 (S (S (NP (JJ Urinary) (JJ acidifying) (NNS agents)) (VP (VP (VB decrease) (NP (NN blood) (NNS levels))) (CC and) (VP (VB increase) (NP (NP (NN excretion)) (PP (IN of) (NP (NN amphetamines))))))) (. .))))

Sentence Id: DrugDDI.d236.s0
Benzthiazide/NN may/MD interact/VB with/IN alcohol/NN ,/, blood/NN thinner/NN s/NNS ,/, decongestant/JJ drugs/NNS (/-LRB- allergy/NN ,/, cold/NN ,/, and/CC sinus/NN medicines/NNS )/-RRB- ,/, diabetic/JJ drugs/NNS ,/, lithium/NN ,/, norepinephrine/NN ,/, NSAIDs/NNS like/IN Aleve/NN or/CC Ibuprofen/NN ,/, and/CC high/JJ blood/NN pressure/NN medications/NNS ./.

(ROOT (S1 (S (S (NP (NN Benzthiazide)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NP (NN alcohol)) (, ,) (NP (NN blood) (NN thinner) (NNS s)) (, ,) (NP (NP (JJ decongestant) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NP (NN allergy)) (, ,) (NP (NN cold)) (, ,) (CC and) (NP (NN sinus) (NNS medicines))) (-RRB- -RRB-))) (, ,) (NP (NP (JJ diabetic) (NNS drugs)) (, ,) (NP (NP (NN lithium)) (, ,) (NP (NN norepinephrine)) (, ,) (NP (NP (NNS NSAIDs)) (PP (IN like) (NP (NN Aleve)))) (CC or) (NP (NN Ibuprofen))) (, ,)) (CC and) (NP (JJ high) (NN blood) (NN pressure)) (NP (NNS medications))))))) (. .))))

Sentence Id: DrugDDI.d285.s0
No/DT formal/JJ drug/NN interaction/NN studies/NNS with/IN anti-neoplastic/JJ agents/NNS have/VBP been/VBN conducted/VBN ./.

(ROOT (S1 (S (S (NP (NP (DT No) (JJ formal) (NN drug) (NN interaction) (NNS studies)) (PP (IN with) (NP (JJ anti-neoplastic) (NNS agents)))) (VP (VBP have) (VP (VBN been) (VP (VBN conducted))))) (. .))))

Sentence Id: DrugDDI.d285.s1
In/IN Study/NN 1/CD ,/, patients/NNS with/IN colorectal/JJ cancer/NN were/VBD given/VBN irinotecan/NN /5-FU/leucovorin/NN (/-LRB- bolus-IFL/NN )/-RRB- with/IN or/CC without/IN AVASTIN/NN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (NN Study) (CD 1))) (, ,) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ colorectal) (NN cancer)))) (VP (VBD were) (VP (VBN given) (NP (NP (NN irinotecan) (NN /5-FU/leucovorin)) (PRN (-LRB- -LRB-) (NP (NN bolus-IFL)) (-RRB- -RRB-))) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (NN AVASTIN))))))) (. .))))

Sentence Id: DrugDDI.d285.s2
Irinotecan/NN concentrations/NNS were/VBD similar/JJ in/IN patients/NNS receiving/VBG bolus-IFL/NN alone/RB and/CC in/IN combination/NN with/IN AVASTIN/NN ./.

(ROOT (S1 (S (S (NP (NN Irinotecan) (NNS concentrations)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN bolus-IFL)))))) (UCP (ADVP (RB alone)) (CC and) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN AVASTIN)))))))) (. .))))

Sentence Id: DrugDDI.d285.s3
The/DT concentrations/NNS of/IN SN38/NN ,/, the/DT active/JJ metabolite/NN of/IN irinotecan/NN ,/, were/VBD on/IN average/NN 33/CD %/NN higher/JJR in/IN patients/NNS receiving/VBG bolus-IFL/NN in/IN combination/NN with/IN AVASTIN/NN when/WRB compared/VBN with/IN bolus-IFL/NN alone/RB ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NNS concentrations)) (PP (IN of) (NP (NP (NN SN38)) (, ,) (NP (NP (DT the) (JJ active) (NN metabolite)) (PP (IN of) (NP (NN irinotecan)))) (, ,)))) (VP (VBD were) (PP (IN on) (NP (NN average))) (ADJP (NP (CD 33) (NN %)) (JJR higher) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN bolus-IFL)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN AVASTIN))))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (NP (NN bolus-IFL)) (ADVP (RB alone))))))))) (. .))))

Sentence Id: DrugDDI.d285.s4
In/IN Study/NN 1/CD ,/, patients/NNS receiving/VBG bolus-IFL/NN plus/CC AVASTIN/NN had/VBD a/DT higher/JJR incidence/NN of/IN Grade/NN 3-4/JJ diarrhea/NN and/CC neutropenia/NN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (NN Study) (CD 1))) (, ,) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN bolus-IFL)) (CC plus) (NP (NN AVASTIN))))) (VP (VBD had) (NP (NP (DT a) (JJR higher) (NN incidence)) (PP (IN of) (NP (NP (NN Grade) (JJ 3-4) (NN diarrhea)) (CC and) (NP (NN neutropenia))))))) (. .))))

Sentence Id: DrugDDI.d285.s5
Due/JJ to/TO high/JJ inter-patient/JJ variability/NN and/CC limited/JJ sampling/NN ,/, the/DT extent/NN of/IN the/DT increase/NN in/IN SN38/NN levels/NNS in/IN patients/NNS receiving/VBG concurrent/JJ irinotecan/NN and/CC AVASTIN/NN is/VBZ uncertain/JJ ./.

(ROOT (S1 (S (S (PP (JJ Due) (TO to) (NP (NP (JJ high) (JJ inter-patient) (NN variability)) (CC and) (NP (JJ limited) (NN sampling)))) (, ,) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NN SN38) (NNS levels))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ concurrent) (NN irinotecan)))))) (CC and) (NP (NN AVASTIN))))) (VP (VBZ is) (ADJP (JJ uncertain)))) (. .))))

Sentence Id: DrugDDI.d498.s0
In/FW vitro/FW studies/NNS have/VBP shown/VBN CASODEX/NN can/MD displace/VB coumarin/NN anticoagulant/NN s/NNS ,/, such/JJ as/IN warfarin/NN ,/, from/IN their/PRP$ protein/NN -binding/JJ sites/NNS ./.

(ROOT (S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP have) (VP (VBN shown) (S (NP (NN CASODEX)) (VP (MD can) (VP (VB displace) (NP (NP (NN coumarin) (NN anticoagulant) (NNS s)) (, ,) (ADJP (JJ such) (PP (IN as) (NP (NN warfarin)))) (, ,)) (PP (IN from) (NP (PRP$ their) (ADJP (NN protein) (JJ -binding)) (NNS sites))))))))) (. .))))

Sentence Id: DrugDDI.d498.s1
It/PRP is/VBZ recommended/VBN that/IN if/IN CASODEX/NN is/VBZ started/VBN in/IN patients/NNS already/RB receiving/VBG coumarin/NN anticoagulant/NN s/NNS ,/, prothrombin/NN times/NNS should/MD be/VB closely/RB monitored/VBN and/CC adjustment/NN of/IN the/DT anticoagulant/JJ dose/NN may/MD be/VB necessary/JJ ./.

(ROOT (S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (SBAR (IN if) (S (NP (NN CASODEX)) (VP (VBZ is) (VP (VBN started) (PP (IN in) (NP (NP (NNS patients)) (VP (ADVP (RB already)) (VBG receiving) (NP (NN coumarin) (NN anticoagulant) (NNS s))))))))) (, ,) (S (S (NP (NN prothrombin) (NNS times)) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored))))) (CC and) (S (NP (NP (NN adjustment)) (PP (IN of) (NP (DT the) (JJ anticoagulant) (NN dose)))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary))))))))))) (. .))))

Sentence Id: DrugDDI.d222.s0
No/DT formal/JJ drug/NN interaction/NN studies/NNS have/VBP been/VBN conducted/VBN with/IN VELCADE/NN ./.

(ROOT (S1 (S (S (NP (DT No) (JJ formal) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted) (PP (IN with) (NP (NN VELCADE))))))) (. .))))

Sentence Id: DrugDDI.d222.s1
In/FW vitro/FW studies/NNS with/IN human/JJ liver/NN microsomes/NNS indicate/VBP that/IN bortezomib/NN is/VBZ primarily/RB a/DT substrate/NN for/IN cytochrome/NN P450/NN 3A4/NN ,/, 2C19/NN ,/, and/CC 1A2/NN ./.

(ROOT (S1 (S (S (NP (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (PP (IN with) (NP (JJ human) (NN liver) (NNS microsomes)))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN bortezomib)) (VP (VBZ is) (ADVP (RB primarily)) (NP (NP (DT a) (NN substrate)) (PP (IN for) (NP (NP (NN cytochrome) (NN P450) (NN 3A4)) (, ,) (NP (NN 2C19)) (, ,) (CC and) (NP (NN 1A2)))))))))) (. .))))

Sentence Id: DrugDDI.d222.s2
Patients/NNS who/WP are/VBP concomitantly/RB receiving/VBG VELCADE/NN and/CC drugs/NNS that/WDT are/VBP inhibitors/NNS or/CC inducers/NNS of/IN cytochrome/NN P450/NN 3A4/NN should/MD be/VB closely/RB monitored/VBN for/IN either/CC toxicities/NNS or/CC reduced/VBN efficacy/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (ADVP (RB concomitantly)) (VP (VBG receiving) (NP (NP (NP (NN VELCADE)) (CC and) (NP (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NP (NNS inhibitors)) (CC or) (NP (NNS inducers))) (PP (IN of) (NP (NN cytochrome) (NN P450) (NN 3A4))))))))))))) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored) (PP (IN for) (NP (CC either) (NP (NNS toxicities)) (CC or) (NP (VBN reduced) (NN efficacy)))))))) (. .))))

Sentence Id: DrugDDI.d222.s3
During/IN clinical/JJ trials/NNS ,/, hypoglycemia/NN and/CC hyperglycemia/NN were/VBD reported/VBN in/IN diabetic/JJ patients/NNS receiving/VBG oral/JJ hypoglycemics/NNS ./.

(ROOT (S1 (S (S (PP (IN During) (NP (JJ clinical) (NNS trials))) (, ,) (NP (NP (NN hypoglycemia)) (CC and) (NP (NN hyperglycemia))) (VP (VBD were) (VP (VBN reported) (PP (IN in) (NP (NP (JJ diabetic) (NNS patients)) (VP (VBG receiving) (NP (JJ oral) (NNS hypoglycemics)))))))) (. .))))

Sentence Id: DrugDDI.d222.s4
Patients/NNS on/IN oral/JJ antidiabetic/JJ agents/NNS receiving/VBG VELCADE/NN treatment/NN may/MD require/VB close/JJ monitoring/NN of/IN their/PRP$ blood/NN glucose/NN levels/NNS and/CC adjustment/NN of/IN the/DT dose/NN of/IN their/PRP$ antidiabetic/JJ medication/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Patients)) (PP (IN on) (NP (NP (JJ oral) (JJ antidiabetic) (NNS agents)) (VP (VBG receiving) (NP (NN VELCADE) (NN treatment)))))) (VP (MD may) (VP (VB require) (NP (NP (NP (JJ close) (NN monitoring)) (PP (IN of) (NP (PRP$ their) (NN blood) (NN glucose) (NNS levels)))) (CC and) (NP (NP (NN adjustment)) (PP (IN of) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (PRP$ their) (JJ antidiabetic) (NN medication)))))))))) (. .))))

Sentence Id: DrugDDI.d134.s0
Co-administration/NN of/IN BOTOX/NN @/NN and/CC aminoglycosides/NNS or/CC other/JJ agents/NNS interfering/VBG with/IN neuromuscular/JJ transmission/NN (/-LRB- e.g./FW ,/, curare/NN -like/JJ compounds/NNS )/-RRB- should/MD only/RB be/VB performed/VBN with/IN caution/NN as/IN the/DT effect/NN of/IN the/DT toxin/NN may/MD be/VB potentiated/VBN ./.

(ROOT (S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NP (NN BOTOX) (NN @)) (CC and) (NP (NP (NP (NNS aminoglycosides)) (CC or) (NP (NP (JJ other) (NNS agents)) (VP (VBG interfering) (PP (IN with) (NP (JJ neuromuscular) (NN transmission)))))) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN curare) (JJ -like) (NNS compounds)) (-RRB- -RRB-)))))) (VP (MD should) (ADVP (RB only)) (VP (VB be) (VP (VBN performed) (PP (IN with) (NP (NN caution))) (SBAR (IN as) (S (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (DT the) (NN toxin)))) (VP (MD may) (VP (VB be) (VP (VBN potentiated)))))))))) (. .))))

Sentence Id: DrugDDI.d134.s1
The/DT effect/NN of/IN administering/VBG different/JJ botulinum/NN neurotoxin/NN serotypes/NNS at/IN the/DT same/JJ time/NN or/CC within/IN several/JJ months/NNS of/IN each/DT other/JJ is/VBZ unknown/JJ ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (S (VP (VBG administering) (NP (JJ different) (NN botulinum) (NN neurotoxin) (NNS serotypes)) (PP (PP (IN at) (NP (DT the) (JJ same) (NN time))) (CC or) (PP (IN within) (NP (NP (JJ several) (NNS months)) (PP (IN of) (NP (DT each) (JJ other)))))))))) (VP (VBZ is) (ADJP (JJ unknown)))) (. .))))

Sentence Id: DrugDDI.d134.s2
Excessive/JJ neuromuscular/NN weakness/NN may/MD be/VB exacerbated/JJ by/IN administration/NN of/IN another/DT botulinum/NN toxin/NN prior/JJ to/TO the/DT resolution/NN of/IN the/DT effects/NNS of/IN a/DT previously/RB administered/VBN botulinum/NN toxin/NN ./.

(ROOT (S1 (S (S (NP (JJ Excessive) (NN neuromuscular) (NN weakness)) (VP (MD may) (VP (VB be) (ADJP (JJ exacerbated) (PP (IN by) (NP (NP (NN administration)) (PP (IN of) (NP (NP (DT another) (NN botulinum) (NN toxin)) (ADJP (JJ prior) (PP (TO to) (NP (NP (DT the) (NN resolution)) (PP (IN of) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (DT a) (ADJP (RB previously) (VBN administered)) (NN botulinum) (NN toxin)))))))))))))))) (. .))))

Sentence Id: DrugDDI.d398.s0
Digitalis/NN toxicity/NN may/MD be/VB aggravated/VBN by/IN the/DT initial/JJ release/NN of/IN norepinephrine/NN caused/VBN by/IN Bretylium/NN Tosylate/NN Injection/NN ./.

(ROOT (S1 (S (S (NP (NN Digitalis) (NN toxicity)) (VP (MD may) (VP (VB be) (VP (VBN aggravated) (PP (IN by) (NP (NP (DT the) (JJ initial) (NN release)) (PP (IN of) (NP (NP (NN norepinephrine)) (VP (VBN caused) (PP (IN by) (NP (NP (NN Bretylium) (NN Tosylate)) (NN Injection)))))))))))) (. .))))

Sentence Id: DrugDDI.d398.s1
The/DT pressor/NN effects/NNS of/IN catecholamines/NNS such/JJ as/IN dopamine/NN or/CC norepinephrine/NN are/VBP enhanced/VBN by/IN Bretylium/NN Tosylate/NN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN pressor) (NNS effects)) (PP (IN of) (NP (NNS catecholamines))) (PP (JJ such) (IN as) (NP (NP (NN dopamine)) (CC or) (NP (NN norepinephrine))))) (VP (VBP are) (VP (VBN enhanced) (PP (IN by) (NP (NN Bretylium) (NN Tosylate)))))) (. .))))

Sentence Id: DrugDDI.d398.s3
Although/IN there/EX is/VBZ little/JJ published/VBN information/NN on/IN concomitant/JJ administration/NN of/IN lidocaine/NN and/CC Bretylium/NN Tosylate/NN ,/, these/DT drugs/NNS are/VBP often/RB administered/VBN concurrently/RB without/IN any/DT evidence/NN of/IN interactions/NNS resulting/VBG in/IN adverse/JJ effects/NNS or/CC diminished/VBN efficacy/NN ./.

(ROOT (S1 (S (S (SBAR (IN Although) (S (NP (EX there)) (VP (VBZ is) (NP (NP (JJ little) (VBN published) (NN information)) (PP (IN on) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN lidocaine)) (CC and) (NP (NN Bretylium) (NN Tosylate)))))))))) (, ,) (NP (DT these) (NNS drugs)) (VP (VBP are) (ADVP (RB often)) (VP (VBN administered) (ADVP (RB concurrently)) (PP (IN without) (NP (NP (DT any) (NN evidence)) (PP (IN of) (NP (NP (NNS interactions)) (VP (VBG resulting) (PP (IN in) (NP (NP (JJ adverse) (NNS effects)) (CC or) (NP (VBN diminished) (NN efficacy)))))))))))) (. .))))

Sentence Id: DrugDDI.d316.s0
Concomitant/JJ oral/JJ administration/NN of/IN ketoconazole/NN (/-LRB- a/DT known/JJ inhibitor/NN of/IN CYP3A4/NN activity/NN in/IN the/DT liver/NN and/CC in/IN the/DT intestinal/JJ mucosa/NN )/-RRB- caused/VBD an/DT eight-fold/JJ increase/NN of/IN the/DT systemic/JJ exposure/NN to/TO oral/JJ budesonide/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Concomitant) (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NN ketoconazole)) (PRN (-LRB- -LRB-) (NP (NP (DT a) (JJ known) (NN inhibitor)) (PP (IN of) (NP (NP (NN CYP3A4) (NN activity)) (PP (PP (IN in) (NP (DT the) (NN liver))) (CC and) (PP (IN in) (NP (DT the) (JJ intestinal) (NN mucosa))))))) (-RRB- -RRB-))))) (VP (VBD caused) (NP (NP (DT an) (JJ eight-fold) (NN increase)) (PP (IN of) (NP (NP (DT the) (JJ systemic) (NN exposure)) (PP (TO to) (NP (JJ oral) (NN budesonide)))))))) (. .))))

Sentence Id: DrugDDI.d316.s1
If/IN treatment/NN with/IN inhibitors/NNS of/IN CYP3A4/NN activity/NN (/-LRB- such/JJ as/IN ketoconazole/NN ,/, intraconazole/NN ,/, ritonavir/NN ,/, indinavir/NN ,/, saquinavir/NN ,/, erythromycin/NN ,/, etc./NN )/-RRB- is/VBZ indicated/VBN ,/, reduction/NN of/IN the/DT budesonide/NN dose/NN should/MD be/VB considered/VBN ./.

(ROOT (S1 (S (S (SBAR (IN If) (S (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (NP (NN CYP3A4) (NN activity)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (JJ such) (PP (IN as) (NP (NN ketoconazole))))) (, ,) (NP (NN intraconazole)) (, ,) (NP (NP (NN ritonavir)) (, ,) (NP (NN indinavir)) (, ,) (NP (NN saquinavir)) (, ,) (NP (NN erythromycin))) (, ,) (NP (NN etc.))) (-RRB- -RRB-))))))) (VP (VBZ is) (VP (VBN indicated))))) (, ,) (NP (NP (NN reduction)) (PP (IN of) (NP (DT the) (NN budesonide) (NN dose)))) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (. .))))

Sentence Id: DrugDDI.d316.s2
After/IN extensive/JJ intake/NN of/IN grapefruit/NN juice/NN (/-LRB- which/WDT inhibits/VBZ CYP3A4/NN activity/NN predominantly/RB in/IN the/DT intestinal/JJ mucosa/NN )/-RRB- ,/, the/DT systemic/JJ exposure/NN for/IN oral/JJ budesonide/NN increased/VBD about/RB two/CD times/NNS ./.

(ROOT (S1 (S (S (PP (IN After) (NP (NP (JJ extensive) (NN intake)) (PP (IN of) (NP (NP (NN grapefruit) (NN juice)) (-LRB- -LRB-) (SBAR (WHNP (WDT which)) (S (VP (VBZ inhibits) (NP (NN CYP3A4) (NN activity)) (ADVP (RB predominantly)) (PP (IN in) (NP (DT the) (JJ intestinal) (NN mucosa)))))) (-RRB- -RRB-))))) (, ,) (NP (NP (DT the) (JJ systemic) (NN exposure)) (PP (IN for) (NP (JJ oral) (NN budesonide)))) (VP (VBD increased) (NP (QP (RB about) (CD two)) (NNS times)))) (. .))))

Sentence Id: DrugDDI.d316.s3
As/IN with/IN other/JJ drugs/NNS primarily/RB being/VBG metabolized/VBN through/IN CYP3A4/NN ,/, ingestion/NN of/IN grapefruit/NN or/CC grapefruit/NN juice/NN should/MD be/VB avoided/VBN in/IN connection/NN with/IN budesonide/NN administration/NN ./.

(ROOT (S1 (S (S (PP (IN As) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (VP (ADVP (RB primarily)) (VBG being) (VP (VBN metabolized) (PP (IN through) (NP (NN CYP3A4)))))))) (, ,) (NP (NP (NN ingestion)) (PP (IN of) (NP (NP (NN grapefruit)) (CC or) (NP (NN grapefruit)) (NP (NN juice))))) (VP (MD should) (VP (VB be) (VP (VBN avoided) (PP (IN in) (NP (NP (NN connection)) (PP (IN with) (NP (NN budesonide) (NN administration))))))))) (. .))))

Sentence Id: DrugDDI.d570.s0
The/DT administration/NN of/IN local/JJ anesthetic/JJ solutions/NNS containing/VBG epinephrine/NN or/CC norepinephrine/NN to/TO patients/NNS receiving/VBG monoamine/NN oxidase/NN inhibitors/NNS or/CC tricyclic/JJ antidepressants/NNS may/MD produce/VB severe/JJ ,/, prolonged/JJ hypertension/NN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NP (JJ local) (JJ anesthetic) (NNS solutions)) (VP (VBG containing) (NP (NP (NN epinephrine)) (CC or) (NP (NN norepinephrine))) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN monoamine) (NN oxidase) (NNS inhibitors)) (CC or) (NP (JJ tricyclic) (NNS antidepressants)))))))))) (VP (MD may) (VP (VB produce) (NP (ADJP (ADJP (JJ severe)) (, ,) (ADJP (JJ prolonged))) (NN hypertension))))) (. .))))

Sentence Id: DrugDDI.d570.s3
Concurrent/JJ administration/NN of/IN vasopressor/JJ drugs/NNS and/CC of/IN ergot-type/JJ oxytocic/JJ drugs/NNS may/MD cause/VB severe/JJ ,/, persistent/JJ hypertension/NN or/CC cerebrovascular/JJ accidents/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Concurrent) (NN administration)) (PP (PP (IN of) (NP (JJ vasopressor) (NNS drugs))) (CC and) (PP (IN of) (NP (JJ ergot-type) (JJ oxytocic) (NNS drugs))))) (VP (MD may) (VP (VB cause) (NP (JJ severe) (, ,) (NP (NP (JJ persistent) (NN hypertension)) (CC or) (NP (JJ cerebrovascular) (NN accidents))))))) (. .))))

Sentence Id: DrugDDI.d570.s4
Phenothiazines/NNS and/CC butyrophenones/NNS may/MD reduce/VB or/CC reverse/VB the/DT pressor/JJ effect/NN of/IN epinephrine/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Phenothiazines)) (CC and) (NP (NNS butyrophenones))) (VP (MD may) (VP (VP (VB reduce)) (CC or) (VP (VB reverse) (NP (NP (DT the) (JJ pressor) (NN effect)) (PP (IN of) (NP (NN epinephrine)))))))) (. .))))

Sentence Id: DrugDDI.d223.s0
The/DT CNS/NN effects/NNS of/IN butalbital/NN may/MD be/VB enhanced/VBN by/IN monoamine/NN oxidase/NN (/-LRB- MAO/NN )/-RRB- inhibitors/NNS ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN CNS) (NNS effects)) (PP (IN of) (NP (NN butalbital)))) (VP (MD may) (VP (VB be) (VP (VBN enhanced) (PP (IN by) (NP (NP (NP (NN monoamine) (NN oxidase)) (PRN (-LRB- -LRB-) (NP (NN MAO)) (-RRB- -RRB-))) (NNS inhibitors))))))) (. .))))

Sentence Id: DrugDDI.d223.s1
Butalbital/NN ,/, acetaminophen/NN and/CC caffeine/NN may/MD enhance/VB the/DT effects/NNS of/IN :/: other/JJ narcotic/JJ analgesic/JJ s/NNS ,/, alcohol/NN ,/, general/JJ anesthetics/NNS ,/, tranquilizers/NNS such/JJ as/IN chlordiazepoxide/NN ,/, sedative-hypnotics/NN ,/, or/CC other/JJ CNS/NN depressants/NNS ,/, causing/VBG increased/VBN CNS/NN depression/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Butalbital)) (, ,) (NP (NN acetaminophen)) (CC and) (NP (NN caffeine))) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NNS effects)) (PP (IN of) (: :) (NP (NP (JJ other) (JJ narcotic) (JJ analgesic) (NNS s)) (, ,) (NP (NN alcohol)) (, ,) (NP (JJ general) (NNS anesthetics)) (, ,) (NP (NP (NNS tranquilizers)) (PP (JJ such) (IN as) (NP (NN chlordiazepoxide)))) (, ,) (NP (NN sedative-hypnotics)) (, ,) (CC or) (NP (JJ other) (NN CNS) (NNS depressants))))) (, ,) (S (VP (VBG causing) (NP (VBN increased) (NN CNS) (NN depression))))))) (. .))))

Sentence Id: DrugDDI.d223.s2
Drug/NN /Laboratory/NN Test/NN Interactions/NNS Acetaminophen/NN may/MD produce/VB false-positive/JJ test/NN results/NNS for/IN urinary/JJ 5-hydroxyindoleacetic/JJ acid/NN ./.

(ROOT (S1 (S (S (NP (NN Drug) (NN /Laboratory) (NN Test) (NNS Interactions) (NP (NN Acetaminophen))) (VP (MD may) (VP (VB produce) (NP (NP (JJ false-positive) (NN test) (NNS results)) (PP (IN for) (NP (JJ urinary) (JJ 5-hydroxyindoleacetic) (NN acid))))))) (. .))))

Sentence Id: DrugDDI.d38.s0
Interactions/NNS may/MD occur/VB with/IN the/DT following/NN :/: adrenocorticoids/NNS (/-LRB- cortisone/NN -like/JJ medicine/NN )/-RRB- ,/, anticoagulants/NNS (/-LRB- blood/NN thinner/NN s/NNS )/-RRB- ,/, carbamazepine/NN ,/, corticotropin/NN (/-LRB- barbiturates/NNS may/MD decrease/VB the/DT effects/NNS of/IN these/DT medicines/NNS )/-RRB- ,/, central/JJ nervous/JJ system/NN (/-LRB- CNS/NN )/-RRB- depressants/NNS (/-LRB- using/VBG these/DT medicines/NNS with/IN barbiturates/NNS may/MD result/VB in/IN increased/VBN CNS/NN depressant/NN effects/NNS )/-RRB- ,/, divalproex/NN sodium/NN ,/, valproic/JJ acid/NN (/-LRB- using/VBG these/DT medicines/NNS with/IN barbiturates/NNS may/MD change/VB the/DT amount/NN of/IN either/DT medicine/NN that/WDT you/RB need/VBP to/TO take/VB )/-RRB- ,/, and/CC oral/JJ contraceptives/NNS containing/VBG estrogens/NNS (/-LRB- barbiturates/NNS may/MD decrease/VB the/DT effectiveness/NN of/IN these/DT oral/JJ contraceptives/NNS ,/, and/CC you/RB may/MD need/VBP to/TO change/NN to/TO a/DT different/JJ type/NN of/IN birth/NN control/NN )/-RRB- ./.

(ROOT (S1 (S (S (NP (NNS Interactions)) (VP (MD may) (VP (VB occur) (PP (IN with) (NP (DT the) (NN following)))))) (: :) (S (NP (NP (NP (NP (NP (NNS adrenocorticoids)) (PRN (-LRB- -LRB-) (NP (NN cortisone) (JJ -like) (NN medicine)) (-RRB- -RRB-))) (, ,) (NP (NP (NNS anticoagulants)) (PRN (-LRB- -LRB-) (NP (NN blood) (NN thinner) (NNS s)) (-RRB- -RRB-))) (, ,) (NP (NN carbamazepine)) (, ,) (NP (NN corticotropin)) (-LRB- -LRB-) (NP (NNS barbiturates)) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (DT these) (NNS medicines)))))) (-RRB- -RRB-)) (, ,) (NP (NP (NP (NP (JJ central) (JJ nervous) (NN system)) (PRN (-LRB- -LRB-) (NP (NN CNS)) (-RRB- -RRB-))) (NNS depressants)) (PRN (-LRB- -LRB-) (VP (VBG using) (NP (DT these) (NNS medicines)) (PP (IN with) (NP (NP (NNS barbiturates)) (VP (MD may) (VP (VB result) (PP (IN in) (NP (VBN increased) (NN CNS) (NN depressant) (NNS effects)))))))) (-RRB- -RRB-))) (, ,) (NP (NN divalproex) (NN sodium)) (, ,) (NP (NP (JJ valproic) (NN acid)) (PRN (-LRB- -LRB-) (VP (VBG using) (NP (NP (DT these) (NNS medicines)) (PP (IN with) (NP (NP (NNS barbiturates)) (VP (MD may) (VP (VB change) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NP (DT either) (NN medicine)) (SBAR (WHNP (WDT that)) (S (ADVP (RB you)) (VP (VBP need) (S (VP (TO to) (VP (VB take)))))))))))))))) (-RRB- -RRB-))) (, ,) (CC and) (NP (JJ oral) (NNS contraceptives))) (VP (VBG containing) (NP (NNS estrogens)))) (-LRB- -LRB-) (NP (NNS barbiturates)) (VP (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (DT these) (JJ oral) (NNS contraceptives)))))) (, ,) (CC and) (ADVP (RB you)) (VP (MD may) (VP (VBP need) (PP (TO to) (NP (NN change))) (PP (TO to) (NP (NP (DT a) (JJ different) (NN type)) (PP (IN of) (NP (NN birth) (NN control)))))))) (-RRB- -RRB-)) (. .))))

Sentence Id: DrugDDI.d218.s0
DOSTINEX/NN should/MD not/RB be/VB administered/VBN concurrently/RB with/IN D2-antagonists/NNS ,/, such/JJ as/IN phenothiazines/NNS ,/, butyrophenones/NNS ,/, thioxanthines/NNS ,/, or/CC metoclopramide/NN ./.

(ROOT (S1 (S (S (NP (NN DOSTINEX)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (ADVP (RB concurrently)) (PP (IN with) (NP (NP (NNS D2-antagonists)) (, ,) (PP (JJ such) (IN as) (NP (NP (NNS phenothiazines)) (, ,) (NP (NNS butyrophenones)) (, ,) (NP (NNS thioxanthines)) (, ,) (CC or) (NP (NN metoclopramide)))))))))) (. .))))

Sentence Id: DrugDDI.d349.s0
No/DT significant/JJ drug/NN interactions/NNS have/VBP been/VBN reported/VBN in/IN studies/NNS of/IN candesartan/NN cilexetil/NN given/VBN with/IN other/JJ drugs/NNS such/JJ as/IN glyburide/NN ,/, nifedipine/NN ,/, digoxin/NN ,/, warfarin/NN ,/, hydrochlorothiazide/NN ,/, and/CC oral/JJ contraceptives/NNS in/IN healthy/JJ volunteers/NNS ,/, or/CC given/VBN with/IN enalapril/NN to/TO patients/NNS with/IN heart/NN failure/NN (/-LRB- NYHA/NN class/NN II/CD and/CC III/CD )./NN

(ROOT (S1 (S (NP (DT No) (JJ significant) (NN drug) (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NP (NNS studies)) (PP (IN of) (NP (NP (NN candesartan) (NN cilexetil)) (VP (VP (VBN given) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (PP (JJ such) (IN as) (NP (NP (NN glyburide)) (, ,) (NP (NN nifedipine)) (, ,) (NP (NN digoxin)) (, ,) (NP (NN warfarin)) (, ,) (NP (NN hydrochlorothiazide)) (, ,) (CC and) (NP (JJ oral) (NNS contraceptives)))))) (PP (IN in) (NP (JJ healthy) (NNS volunteers)))) (, ,) (CC or) (VP (VBN given) (PP (IN with) (NP (NN enalapril))) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (NN heart) (NN failure)))))))))) (-LRB- -LRB-) (NP (NP (NN NYHA) (NN class) (CD II)) (CC and) (NP (CD III) (NN -RRB-.)))))))))))

Sentence Id: DrugDDI.d349.s1
Because/IN candesartan/NN is/VBZ not/RB significantly/RB metabolized/VBN by/IN the/DT cytochrome/NN P450/NN system/NN and/CC at/IN therapeutic/JJ concentrations/NNS has/VBZ no/DT effects/NNS on/IN P450/NN enzymes/NNS ,/, interactions/NNS with/IN drugs/NNS that/WDT inhibit/VBP or/CC are/VBP metabolized/VBN by/IN those/DT enzymes/NNS would/MD not/RB be/VB expected/VBN ./.

(ROOT (S1 (S (S (SBAR (IN Because) (S (NP (NN candesartan)) (VP (VP (VBZ is) (RB not) (ADVP (RB significantly)) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (NN cytochrome) (NN P450) (NN system))))) (CC and) (PP (IN at) (NP (JJ therapeutic) (NNS concentrations))) (VP (VBZ has) (NP (NP (DT no) (NNS effects)) (PP (IN on) (NP (NN P450) (NNS enzymes)))))))) (, ,) (NP (NP (NNS interactions)) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBP inhibit)) (CC or) (VP (VBP are) (VP (VBN metabolized) (PP (IN by) (NP (DT those) (NNS enzymes))))))))))) (VP (MD would) (RB not) (VP (VB be) (VP (VBN expected))))) (. .))))

Sentence Id: DrugDDI.d349.s2
Lithium/NN @/NN Reversible/JJ increases/NNS in/IN serum/NN lithium/NN concentrations/NNS and/CC toxicity/NN have/VBP been/VBN reported/VBN during/IN concomitant/JJ administration/NN of/IN lithium/NN with/IN ACE/NN inhibitors/NNS ,/, and/CC with/IN some/DT angiotensin/NN II/CD receptor/NN antagonists/NNS ./.

(ROOT (S1 (S (S (NP (NP (NN Lithium) (NN @) (JJ Reversible) (NNS increases)) (PP (IN in) (NP (NP (NN serum) (NN lithium) (NNS concentrations)) (CC and) (NP (NN toxicity))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN during) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN lithium))) (PP (PP (IN with) (NP (NN ACE) (NNS inhibitors))) (, ,) (CC and) (PP (IN with) (NP (DT some) (NN angiotensin) (CD II) (NN receptor) (NNS antagonists)))))))))) (. .))))

Sentence Id: DrugDDI.d349.s3
An/DT increase/NN in/IN serum/NN lithium/NN concentration/NN has/VBZ been/VBN reported/VBN during/IN concomitant/JJ administration/NN of/IN lithium/NN with/IN ATACAND/NN ,/, so/IN careful/JJ monitoring/NN of/IN serum/NN lithium/NN levels/NNS is/VBZ recommended/VBN during/IN concomitant/JJ use/NN ./.

(ROOT (S1 (S (S (NP (NP (DT An) (NN increase)) (PP (IN in) (NP (NN serum) (NN lithium) (NN concentration)))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN during) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN lithium))) (PP (IN with) (NP (NN ATACAND))))))) (, ,) (SBAR (IN so) (S (NP (NP (JJ careful) (NN monitoring)) (PP (IN of) (NP (NN serum) (NN lithium) (NNS levels)))) (VP (VBZ is) (VP (VBN recommended) (PP (IN during) (NP (JJ concomitant) (NN use))))))))) (. .))))

Sentence Id: DrugDDI.d303.s0
Geocillin/NN (/-LRB- carbenicillin/NN indanyl/NN sodium/NN )/-RRB- blood/NN levels/NNS may/MD be/VB increased/VBN and/CC prolonged/VBD by/IN concurrent/JJ administration/NN of/IN probenecid/NN ./.

(ROOT (S1 (S (S (NP (NP (NP (NN Geocillin)) (PRN (-LRB- -LRB-) (NP (NN carbenicillin) (NN indanyl) (NN sodium)) (-RRB- -RRB-))) (NN blood) (NNS levels)) (VP (VP (MD may) (VP (VB be) (VP (VBN increased)))) (CC and) (VP (VBD prolonged) (PP (IN by) (NP (NP (JJ concurrent) (NN administration)) (PP (IN of) (NP (NN probenecid)))))))) (. .))))

Sentence Id: DrugDDI.d156.s0
Iodine/NN or/CC iodine/NN excess/NN may/MD decrease/VB the/DT effect/NN of/IN Carbimazole/NN ,/, and/CC an/DT iodine/NN deficiency/NN can/MD increase/VB the/DT effect/NN of/IN Carbimazole/NN ./.

(ROOT (S1 (S (S (S (NP (NP (NN Iodine)) (CC or) (NP (NN iodine) (NN excess))) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN Carbimazole))))))) (, ,) (CC and) (S (NP (DT an) (NN iodine) (NN deficiency)) (VP (MD can) (VP (VB increase) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN Carbimazole)))))))) (. .))))

Sentence Id: DrugDDI.d156.s1
Serum/NN concentration/NN of/IN digoxin/NN and/CC digitoxin/NN may/MD increase/VB when/WRB patients/NNS take/VBP antithyroid/JJ agents/NNS ./.

(ROOT (S1 (S (S (NP (NP (NN Serum) (NN concentration)) (PP (IN of) (NP (NP (NN digoxin)) (CC and) (NP (NN digitoxin))))) (VP (MD may) (VP (VB increase) (SBAR (WHADVP (WRB when)) (S (NP (NNS patients)) (VP (VBP take) (NP (JJ antithyroid) (NNS agents)))))))) (. .))))

Sentence Id: DrugDDI.d156.s3
Antithyroid/JJ agents/NNS may/MD decrease/VB thyroid/NN al/FW uptake/NN of/IN sodium/NN iodide/NN I131/CD ,/, a/DT rebound/NN in/IN uptake/NN may/MD occur/VB up/RB to/TO 5/CD days/NNS after/IN sudden/CD withdrawal/NN of/IN Carbimazole/NN ./.

(ROOT (S1 (S (S (NP (JJ Antithyroid) (NNS agents)) (VP (MD may) (VP (VB decrease) (NP (NP (NN thyroid) (FW al) (NN uptake)) (PP (IN of) (NP (NN sodium) (NN iodide) (CD I131))))))) (, ,) (S (NP (NP (DT a) (NN rebound)) (PP (IN in) (NP (NN uptake)))) (VP (MD may) (VP (VB occur) (NP (QP (RB up) (TO to) (CD 5)) (NNS days)) (PP (IN after) (NP (NP (CD sudden) (NN withdrawal)) (PP (IN of) (NP (NN Carbimazole)))))))) (. .))))

Sentence Id: DrugDDI.d156.s4
Patients/NNS response/NN to/TO oral/JJ anticoagulants/NNS may/MD be/VB affected/VBN by/IN his/her/JJ thyroid/NN and/CC metabolic/JJ status/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Patients) (NN response)) (PP (TO to) (NP (JJ oral) (NNS anticoagulants)))) (VP (MD may) (VP (VB be) (VP (VBN affected) (PP (IN by) (NP (NP (JJ his/her) (NN thyroid)) (CC and) (NP (JJ metabolic) (NN status)))))))) (. .))))

Sentence Id: DrugDDI.d156.s5
An/DT evaluation/NN of/IN prothrombin/NN time/NN and/CC an/DT adjustment/NN of/IN anticoagulant/JJ dosage/NN are/VBP recommended/VBN ./.

(ROOT (S1 (S (S (NP (NP (NP (DT An) (NN evaluation)) (PP (IN of) (NP (NN prothrombin) (NN time)))) (CC and) (NP (NP (DT an) (NN adjustment)) (PP (IN of) (NP (JJ anticoagulant) (NN dosage))))) (VP (VBP are) (VP (VBN recommended)))) (. .))))

Sentence Id: DrugDDI.d506.s0
The/DT renal/JJ effects/NNS of/IN nephrotoxic/JJ compounds/NNS may/MD be/VB potentiated/VBN by/IN Carboplatin/NN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (JJ renal) (NNS effects)) (PP (IN of) (NP (JJ nephrotoxic) (NNS compounds)))) (VP (MD may) (VP (VB be) (VP (VBN potentiated) (PP (IN by) (NP (NN Carboplatin))))))) (. .))))

Sentence Id: DrugDDI.d348.s0
Inhibitors/NNS of/IN CYP2D6/NN ;/: ./.

(ROOT (S1 (S (NP (NP (NP (NNS Inhibitors)) (PP (IN of) (NP (NN CYP2D6))) (: ;)) (. .)))))

Sentence Id: DrugDDI.d348.s1
poor/JJ metabolizers/NNS of/IN debrisoquin/NN :/: Interactions/NNS of/IN carvedilol/NN with/IN strong/JJ inhibitors/NNS of/IN CYP2D6/NN (/-LRB- such/JJ as/IN quinidine/NN ,/, fluoxetine/NN ,/, paroxetine/NN ,/, and/CC propafenone/NN )/-RRB- have/VBP not/RB been/VBN studied/VBN ,/, but/CC these/DT drugs/NNS would/MD be/VB expected/VBN to/TO increase/VB blood/NN levels/NNS of/IN the/DT R/NN (/-LRB- +/CC )/-RRB- enantiomer/NN of/IN carvedilol/NN ./.

(ROOT (S1 (S (NP (NP (NP (JJ poor) (NNS metabolizers)) (PP (IN of) (NP (NN debrisoquin)))) (: :) (S (S (NP (NP (NNS Interactions)) (PP (IN of) (NP (NN carvedilol))) (PP (IN with) (NP (NP (NP (JJ strong) (NNS inhibitors)) (PP (IN of) (NP (NN CYP2D6)))) (PRN (-LRB- -LRB-) (CONJP (JJ such) (IN as)) (NP (NP (NN quinidine)) (, ,) (NP (NN fluoxetine)) (, ,) (NP (NN paroxetine)) (, ,) (CC and) (NP (NN propafenone))) (-RRB- -RRB-))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN studied))))) (, ,) (CC but) (S (NP (DT these) (NNS drugs)) (VP (MD would) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB increase) (NP (NP (NN blood) (NNS levels)) (PP (IN of) (NP (NP (DT the) (NP (NP (NN R)) (-LRB- -LRB-) (CC +) (-RRB- -RRB-)) (NN enantiomer)) (PP (IN of) (NP (NN carvedilol)))))))))))))) (. .)))))

Sentence Id: DrugDDI.d348.s2
Retrospective/JJ analysis/NN of/IN side/JJ effects/NNS in/IN clinical/JJ trials/NNS showed/VBD that/IN poor/JJ 2D6/NN metabolizers/NNS had/VBD a/DT higher/JJR rate/NN of/IN dizziness/NN during/IN up-titration/NN ,/, presumably/RB resulting/VBG from/IN vasodilating/JJ effects/NNS of/IN the/DT higher/JJR concentrations/NNS of/IN the/DT a-blocking/JJ R/NN (/-LRB- +/CC )/-RRB- enantiomer/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Retrospective) (NN analysis)) (PP (IN of) (NP (NP (JJ side) (NNS effects)) (PP (IN in) (NP (JJ clinical) (NNS trials)))))) (VP (VBD showed) (SBAR (IN that) (S (NP (JJ poor) (NN 2D6) (NNS metabolizers)) (VP (VBD had) (NP (NP (DT a) (JJR higher) (NN rate)) (PP (IN of) (NP (NN dizziness)))) (PP (IN during) (NP (NN up-titration))) (, ,) (S (ADVP (RB presumably)) (VP (VBG resulting) (PP (IN from) (NP (NP (JJ vasodilating) (NNS effects)) (PP (IN of) (NP (NP (DT the) (JJR higher) (NNS concentrations)) (PP (IN of) (NP (DT the) (JJ a-blocking) (NP (NP (NN R)) (-LRB- -LRB-) (CC +) (-RRB- -RRB-)) (NN enantiomer)))))))))))))) (. .))))

Sentence Id: DrugDDI.d348.s3
Catecholamine-depleting/JJ Agents/NNS :/: Patients/NNS taking/VBG both/DT agents/NNS with/IN b-blocking/JJ properties/NNS and/CC a/DT drug/NN that/WDT can/MD deplete/VB catecholamines/NNS (/-LRB- e.g./FW ,/, reserpine/NN and/CC monoamine/NN oxidase/NN inhibitors/NNS )/-RRB- should/MD be/VB observed/VBN closely/RB for/IN signs/NNS of/IN hypotension/NN and/or/CC severe/JJ bradycardia/NN ./.

(ROOT (S1 (S (NP (NP (JJ Catecholamine-depleting) (NNS Agents)) (: :) (S (NP (NP (NNS Patients)) (VP (VBG taking) (NP (DT both) (NNS agents)) (PP (IN with) (NP (NP (JJ b-blocking) (NNS properties)) (CC and) (NP (NP (DT a) (NN drug)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB deplete) (NP (NP (NNS catecholamines)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN reserpine)) (CC and) (NP (NN monoamine) (NN oxidase) (NNS inhibitors)))) (-RRB- -RRB-)))))))))))) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (PP (IN for) (NP (NP (NNS signs)) (PP (IN of) (NP (NP (NN hypotension)) (CC and/or) (NP (JJ severe) (NN bradycardia)))))))))) (. .)))))

Sentence Id: DrugDDI.d348.s4
Clonidine/NN :/: Concomitant/JJ administration/NN of/IN clonidine/NN with/IN agents/NNS with/IN b-blocking/JJ properties/NNS may/MD potentiate/VB blood-pressure-/JJ and/CC heart-rate-lowering/JJ effects/NNS ./.

(ROOT (S1 (S (NP (NP (NN Clonidine)) (: :) (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NN clonidine))) (PP (IN with) (NP (NP (NNS agents)) (PP (IN with) (NP (JJ b-blocking) (NNS properties)))))) (VP (MD may) (VP (VB potentiate) (NP (ADJP (ADJP (JJ blood-pressure-)) (CC and) (ADJP (JJ heart-rate-lowering))) (NNS effects))))) (. .)))))

Sentence Id: DrugDDI.d348.s5
When/WRB concomitant/JJ treatment/NN with/IN agents/NNS with/IN b-blocking/JJ properties/NNS and/CC clonidine/NN is/VBZ to/TO be/VB terminated/VBN ,/, the/DT b-blocking/JJ agent/NN should/MD be/VB discontinued/VBN first/RB ./.

(ROOT (S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NP (JJ concomitant) (NN treatment)) (PP (IN with) (NP (NNS agents))) (PP (IN with) (NP (NP (JJ b-blocking) (NNS properties)) (CC and) (NP (NN clonidine))))) (VP (VBZ is) (S (VP (TO to) (VP (VB be) (VP (VBN terminated)))))))) (, ,) (NP (DT the) (JJ b-blocking) (NN agent)) (VP (MD should) (VP (VB be) (VP (VBN discontinued) (ADVP (RB first)))))) (. .))))

Sentence Id: DrugDDI.d348.s6
Clonidine/NN therapy/NN can/MD then/RB be/VB discontinued/VBN several/JJ days/NNS later/RB by/IN gradually/RB decreasing/VBG the/DT dosage/NN ./.

(ROOT (S1 (S (S (NP (NN Clonidine) (NN therapy)) (VP (MD can) (ADVP (RB then)) (VP (VB be) (VP (VBN discontinued) (ADVP (NP (JJ several) (NNS days)) (RB later)) (PP (IN by) (S (VP (ADVP (RB gradually)) (VBG decreasing) (NP (DT the) (NN dosage))))))))) (. .))))

Sentence Id: DrugDDI.d348.s7
Cyclosporine/NN :/: Modest/JJ increases/NNS in/IN mean/JJ trough/NN cyclosporine/NN concentrations/NNS were/VBD observed/VBN following/VBG initiation/NN of/IN carvedilol/NN treatment/NN in/IN 21/CD renal/JJ transplant/NN patients/NNS suffering/VBG from/IN chronic/JJ vascular/JJ rejection/NN ./.

(ROOT (S1 (S (NP (NP (NN Cyclosporine)) (: :) (S (NP (NP (JJ Modest) (NNS increases)) (PP (IN in) (NP (JJ mean) (NN trough) (NN cyclosporine) (NNS concentrations)))) (VP (VBD were) (VP (VBN observed) (PP (VBG following) (NP (NP (NN initiation)) (PP (IN of) (NP (NN carvedilol) (NN treatment))) (PP (IN in) (NP (NP (CD 21) (JJ renal) (NN transplant) (NNS patients)) (VP (VBG suffering) (PP (IN from) (NP (JJ chronic) (JJ vascular) (NN rejection))))))))))) (. .)))))

Sentence Id: DrugDDI.d348.s8
In/IN about/RB 30/CD %/NN of/IN patients/NNS ,/, the/DT dose/NN of/IN cyclosporine/NN had/VBD to/TO be/VB reduced/VBN in/IN order/NN to/TO maintain/VB cyclosporine/NN concentrations/NNS within/IN the/DT therapeutic/JJ range/NN ,/, while/IN in/IN the/DT remainder/NN no/DT adjustment/NN was/VBD needed/VBN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (NP (QP (RB about) (CD 30)) (NN %)) (PP (IN of) (NP (NNS patients))))) (, ,) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN cyclosporine)))) (VP (VBD had) (S (VP (TO to) (VP (VB be) (VP (VBN reduced) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB maintain) (NP (NN cyclosporine) (NNS concentrations)) (PP (IN within) (NP (DT the) (JJ therapeutic) (NN range))))))))))) (, ,) (SBAR (IN while) (S (PP (IN in) (NP (DT the) (NN remainder))) (NP (DT no) (NN adjustment)) (VP (VBD was) (VP (VBN needed))))))) (. .))))

Sentence Id: DrugDDI.d348.s9
On/IN the/DT average/NN for/IN the/DT group/NN ,/, the/DT dose/NN of/IN cyclosporine/NN was/VBD reduced/VBN about/RB 20/CD %/NN in/IN these/DT patients/NNS ./.

(ROOT (S1 (S (S (PP (IN On) (NP (NP (DT the) (NN average)) (PP (IN for) (NP (DT the) (NN group))))) (, ,) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN cyclosporine)))) (VP (VBD was) (VP (VBN reduced) (NP (QP (RB about) (CD 20)) (NN %)) (PP (IN in) (NP (DT these) (NNS patients)))))) (. .))))

Sentence Id: DrugDDI.d348.s10
Due/JJ to/TO wide/JJ interindividual/JJ variability/NN in/IN the/DT dose/NN adjustment/NN required/VBN ,/, it/PRP is/VBZ recommended/VBN that/IN cyclosporine/NN concentrations/NNS be/VB monitored/VBN closely/RB after/IN initiation/NN of/IN carvedilol/NN therapy/NN and/CC that/IN the/DT dose/NN of/IN cyclosporine/NN be/VB adjusted/VBN as/IN appropriate/JJ ./.

(ROOT (S1 (S (S (PP (JJ Due) (TO to) (NP (NP (JJ wide) (JJ interindividual) (NN variability)) (PP (IN in) (NP (NP (DT the) (NN dose) (NN adjustment)) (VP (VBN required)))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN recommended) (SBAR (SBAR (IN that) (S (NP (NN cyclosporine) (NNS concentrations)) (VP (VB be) (VP (VBN monitored) (ADVP (RB closely)) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (NN carvedilol) (NN therapy))))))))) (CC and) (SBAR (IN that) (S (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN cyclosporine)))) (VP (VB be) (VP (VBN adjusted) (PP (IN as) (NP (JJ appropriate))))))))))) (. .))))

Sentence Id: DrugDDI.d348.s11
Digoxin/NN :/: Digoxin/NN concentrations/NNS are/VBP increased/VBN by/IN about/RB 15/CD %/NN when/WRB digoxin/NN and/CC carvedilol/NN are/VBP administered/VBN concomitantly/RB ./.

(ROOT (S1 (S (S (NP (NN Digoxin) (: :) (NN Digoxin) (NNS concentrations)) (VP (VBP are) (VP (VBN increased) (PP (IN by) (NP (QP (RB about) (CD 15)) (NN %))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN digoxin)) (CC and) (NP (NN carvedilol))) (VP (VBP are) (VP (VBN administered) (ADVP (RB concomitantly))))))))) (. .))))

Sentence Id: DrugDDI.d348.s12
Both/CC digoxin/NN and/CC COREG/NN slow/JJ AV/NN conduction/NN ./.

(ROOT (S1 (S (S (NP (CC Both) (NP (NN digoxin)) (CC and) (NP (NN COREG))) (VP (JJ slow) (NP (NN AV) (NN conduction)))) (. .))))

Sentence Id: DrugDDI.d348.s13
Therefore/RB ,/, increased/VBN monitoring/NN of/IN digoxin/NN is/VBZ recommended/VBN when/WRB initiating/VBG ,/, adjusting/VBG ,/, or/CC discontinuing/VBG COREG/NN ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (VBN increased) (NN monitoring)) (PP (IN of) (NP (NN digoxin)))) (VP (VBZ is) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (VP (VP (VBG initiating)) (, ,) (VP (VBG adjusting)) (, ,) (CC or) (VP (VBG discontinuing) (NP (NN COREG))))))))) (. .))))

Sentence Id: DrugDDI.d348.s14
Inducers/NNS and/CC Inhibitors/NNS of/IN Hepatic/JJ Metabolism/NN :/: Rifampin/NN reduced/VBD plasma/NN concentrations/NNS of/IN carvedilol/NN by/IN about/RB 70/CD %./NN

(ROOT (S1 (S (NP (NP (NP (NP (NNS Inducers)) (CC and) (NP (NNS Inhibitors))) (PP (IN of) (NP (JJ Hepatic) (NN Metabolism)))) (: :) (NP (NP (NN Rifampin)) (VP (VBD reduced) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN carvedilol)))) (PP (IN by) (NP (QP (RB about) (CD 70)) (NN %.)))))))))

Sentence Id: DrugDDI.d348.s15
Cimetidine/NN increased/VBD AUC/NN by/IN about/RB 30/CD %/NN but/CC caused/VBD no/DT change/NN in/IN Cmax/NN ./.

(ROOT (S1 (S (S (NP (NN Cimetidine)) (VP (VP (VBD increased) (NP (NN AUC)) (PP (IN by) (NP (QP (RB about) (CD 30)) (NN %)))) (CC but) (VP (VBD caused) (NP (DT no) (NN change)) (PP (IN in) (NP (NN Cmax)))))) (. .))))

Sentence Id: DrugDDI.d348.s16
Calcium/NN Channel/NN Blockers/NNS :/: Isolated/VBN cases/NNS of/IN conduction/NN disturbance/NN (/-LRB- rarely/RB with/IN hemodynamic/JJ compromise/VB )/-RRB- have/VBP been/VBN observed/VBN when/WRB COREG/NN is/VBZ co-administered/VBN with/IN diltiazem/NN ./.

(ROOT (S1 (S (NP (NP (NN Calcium) (NN Channel) (NNS Blockers)) (: :) (S (NP (NP (VBN Isolated) (NNS cases)) (PP (IN of) (NP (NP (NN conduction) (NN disturbance)) (PRN (-LRB- -LRB-) (ADVP (RB rarely)) (PP (IN with) (NP (JJ hemodynamic) (VB compromise))) (-RRB- -RRB-))))) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (NN COREG)) (VP (VBZ is) (VP (VBN co-administered) (PP (IN with) (NP (NN diltiazem))))))))))) (. .)))))

Sentence Id: DrugDDI.d348.s17
As/IN with/IN other/JJ agents/NNS with/IN b-blocking/JJ properties/NNS ,/, if/IN COREG/NN is/VBZ to/TO be/VB administered/VBN orally/RB with/IN calcium/NN channel/NN blockers/NNS of/IN the/DT verapamil/NN or/CC diltiazem/NN type/NN ,/, it/PRP is/VBZ recommended/VBN that/IN ECG/NN and/CC blood/NN pressure/NN be/VB monitored/VBN ./.

(ROOT (S1 (S (S (PP (IN As) (PP (IN with) (NP (NP (JJ other) (NNS agents)) (PP (IN with) (NP (JJ b-blocking) (NNS properties)))))) (, ,) (SBAR (IN if) (S (NP (NN COREG)) (VP (VBZ is) (S (VP (TO to) (VP (VB be) (VP (VBN administered) (ADVP (RB orally)) (PP (IN with) (NP (NP (NN calcium) (NN channel) (NNS blockers)) (PP (IN of) (NP (DT the) (NP (NN verapamil)) (CC or) (NP (NN diltiazem)) (NP (NN type))))))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NP (NN ECG)) (CC and) (NP (NN blood) (NN pressure))) (VP (VB be) (VP (VBN monitored)))))))) (. .))))

Sentence Id: DrugDDI.d348.s18
Insulin/NN or/CC Oral/JJ Hypoglycemics/NN :/: Agents/NNS with/IN b-blocking/JJ properties/NNS may/MD enhance/VB the/DT blood-sugar-reducing/JJ effect/NN of/IN insulin/NN and/CC oral/JJ hypoglycemics/NN ./.

(ROOT (S1 (S (NP (NP (NP (NN Insulin)) (CC or) (NP (JJ Oral) (NN Hypoglycemics))) (: :) (S (NP (NP (NNS Agents)) (PP (IN with) (NP (JJ b-blocking) (NNS properties)))) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (JJ blood-sugar-reducing) (NN effect)) (PP (IN of) (NP (NP (NN insulin)) (CC and) (NP (JJ oral) (NN hypoglycemics)))))))) (. .)))))

Sentence Id: DrugDDI.d348.s19
Therefore/RB ,/, in/IN patients/NNS taking/VBG insulin/NN or/CC oral/JJ hypoglycemics/NN ,/, regular/JJ monitoring/NN of/IN blood/NN glucose/NN is/VBZ recommended/VBN ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (NN insulin)) (CC or) (NP (JJ oral) (NN hypoglycemics)))))) (, ,) (NP (NP (JJ regular) (NN monitoring)) (PP (IN of) (NP (NN blood) (NN glucose)))) (VP (VBZ is) (VP (VBN recommended)))) (. .))))

Sentence Id: DrugDDI.d59.s0
Studies/NNS in/FW vitro/FW show/VBP that/IN caspofungin/NN acetate/NN is/VBZ not/RB an/DT inhibitor/NN of/IN any/DT enzyme/NN in/IN the/DT cytochrome/NN P450/NN (/-LRB- CYP/NN )/-RRB- system/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Studies)) (ADVP (FW in) (FW vitro))) (VP (VBP show) (SBAR (IN that) (S (NP (NN caspofungin) (NN acetate)) (VP (VBZ is) (RB not) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (DT any) (NN enzyme))) (PP (IN in) (NP (DT the) (NP (NP (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN CYP)) (-RRB- -RRB-))) (NN system))))))))) (. .))))

Sentence Id: DrugDDI.d59.s1
In/IN clinical/JJ studies/NNS ,/, caspofungin/NN did/VBD not/RB induce/VB the/DT CYP3A4/NN metabolism/NN of/IN other/JJ drugs/NNS ./.

(ROOT (S1 (S (S (PP (IN In) (NP (JJ clinical) (NNS studies))) (, ,) (NP (NN caspofungin)) (VP (VBD did) (RB not) (VP (VB induce) (NP (NP (DT the) (NN CYP3A4) (NN metabolism)) (PP (IN of) (NP (JJ other) (NNS drugs))))))) (. .))))

Sentence Id: DrugDDI.d59.s2
Caspofungin/NN is/VBZ not/RB a/DT substrate/NN for/IN P-/NN glycoprotein/NN and/CC is/VBZ a/DT poor/JJ substrate/NN for/IN cytochrome/NN P450/NN enzymes/NNS ./.

(ROOT (S1 (S (S (NP (NN Caspofungin)) (VP (VP (VBZ is) (RB not) (NP (NP (DT a) (NN substrate)) (PP (IN for) (NP (NN P-) (NN glycoprotein))))) (CC and) (VP (VBZ is) (NP (NP (DT a) (JJ poor) (NN substrate)) (PP (IN for) (NP (NN cytochrome) (NN P450) (NNS enzymes))))))) (. .))))

Sentence Id: DrugDDI.d59.s3
Clinical/JJ studies/NNS in/IN healthy/JJ volunteers/NNS show/VBP that/IN the/DT pharmacokinetics/NNS of/IN CANCIDAS/NNS are/VBP not/RB altered/VBN by/IN itraconazole/NN ,/, amphotericin/NN B/NN ,/, mycophenolate/NN ,/, nelfinavir/NN ,/, or/CC tacrolimus/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Clinical) (NNS studies)) (PP (IN in) (NP (JJ healthy) (NNS volunteers)))) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NNS CANCIDAS)))) (VP (VBP are) (RB not) (VP (VBN altered) (PP (IN by) (NP (NP (NN itraconazole)) (, ,) (NP (NN amphotericin) (NN B)) (, ,) (NP (NN mycophenolate)) (, ,) (NP (NN nelfinavir)) (, ,) (CC or) (NP (NN tacrolimus)))))))))) (. .))))

Sentence Id: DrugDDI.d59.s4
CANCIDAS/NN has/VBZ no/DT effect/NN on/IN the/DT pharmacokinetics/NNS of/IN itraconazole/NN ,/, amphotericin/NN B/NN ,/, or/CC the/DT active/JJ metabolite/NN of/IN mycophenolate/NN ./.

(ROOT (S1 (S (S (NP (NN CANCIDAS)) (VP (VBZ has) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN itraconazole)) (, ,) (NP (NN amphotericin) (NN B)) (, ,) (CC or) (NP (NP (DT the) (JJ active) (NN metabolite)) (PP (IN of) (NP (NN mycophenolate)))))))))) (. .))))

Sentence Id: DrugDDI.d59.s5
CANCIDAS/NN reduced/VBD the/DT blood/NN AUC0-12/CD of/IN tacrolimus/NN (/-LRB- FK-506/NN ,/, Prograf/NN span/NN class=/NN c4/NN @/NN 3/CD )/-RRB- by/IN approximately/RB 20/CD %/NN ,/, peak/JJ blood/NN concentration/NN (/-LRB- Cmax/NN )/-RRB- by/IN 16/CD %/NN ,/, and/CC 12-hour/JJ blood/NN concentration/NN (/-LRB- C12hr/NN )/-RRB- by/IN 26/CD %/NN in/IN healthy/JJ subjects/NNS when/WRB tacrolimus/NN (/-LRB- 2/CD doses/NNS of/IN 0.1/CD mg/kg/NN 12/CD hours/NNS apart/RB )/-RRB- was/VBD administered/VBN on/IN the/DT 10th/JJ day/NN of/IN CANCIDAS/NN 70/CD mg/NN daily/RB ,/, as/IN compared/VBN to/TO results/NNS from/IN a/DT control/NN period/NN in/IN which/WDT tacrolimus/NN was/VBD administered/VBN alone/RB ./.

(ROOT (S1 (S (NP (NN CANCIDAS)) (VP (VBD reduced) (NP (NP (DT the) (NN blood) (CD AUC0-12)) (PP (IN of) (NP (NP (NP (NP (NN tacrolimus)) (PRN (-LRB- -LRB-) (NP (NN FK-506)) (, ,) (NP (NN Prograf) (NN span) (NN class=) (NN c4) (NN @) (CD 3)) (-RRB- -RRB-))) (PP (IN by) (NP (QP (RB approximately) (CD 20)) (NN %)))) (, ,) (NP (NP (NP (JJ peak) (NN blood) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NN Cmax)) (-RRB- -RRB-))) (PP (IN by) (NP (CD 16) (NN %)))) (, ,) (CC and) (NP (NP (JJ 12-hour) (NN blood) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NN C12hr)) (-RRB- -RRB-)))))) (PP (IN by) (NP (NP (CD 26) (NN %)) (PP (IN in) (NP (JJ healthy) (NNS subjects))))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN tacrolimus)) (PRN (-LRB- -LRB-) (NP (NP (CD 2) (NNS doses)) (PP (IN of) (NP (QP (CD 0.1) (NN mg/kg) (CD 12)) (NNS hours))) (ADVP (RB apart))) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN administered) (PP (IN on) (NP (NP (DT the) (JJ 10th) (NN day)) (PP (IN of) (NP (NP (NN CANCIDAS) (CD 70) (NN mg)) (ADVP (RB daily)))))))))) (, ,) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (NP (NNS results)) (PP (IN from) (NP (NP (DT a) (NN control) (NN period)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NN tacrolimus)) (VP (VBD was) (VP (VBN administered) (ADVP (RB alone)))))))))))))) (. .))))

Sentence Id: DrugDDI.d59.s6
For/IN patients/NNS receiving/VBG both/DT therapies/NNS ,/, standard/JJ monitoring/NN of/IN tacrolimus/NN blood/NN concentrations/NNS and/CC appropriate/JJ tacrolimus/NN dosage/NN adjustments/NNS are/VBP recommended/VBN ./.

(ROOT (S1 (S (S (PP (IN For) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (DT both) (NNS therapies))))) (, ,) (NP (NP (JJ standard) (NN monitoring)) (PP (IN of) (NP (NP (NN tacrolimus) (NN blood) (NNS concentrations)) (CC and) (NP (JJ appropriate) (NN tacrolimus) (NN dosage) (NNS adjustments))))) (VP (VBP are) (VP (VBN recommended)))) (. .))))

Sentence Id: DrugDDI.d59.s7
In/IN two/CD clinical/JJ studies/NNS ,/, cyclosporine/NN (/-LRB- one/CD 4/CD mg/kg/NN dose/NN or/CC two/CD 3/CD mg/kg/NN doses/NNS )/-RRB- increased/VBD the/DT AUC/NN of/IN caspofungin/NN by/IN approximately/RB 35/CD %./NN

(ROOT (S1 (S (PP (IN In) (NP (CD two) (JJ clinical) (NNS studies))) (, ,) (NP (NP (NN cyclosporine)) (PRN (-LRB- -LRB-) (NP (NP (CD one) (ADJP (CD 4) (NN mg/kg)) (NN dose)) (CC or) (NP (CD two) (CD 3) (NN mg/kg) (NNS doses))) (-RRB- -RRB-))) (VP (VBD increased) (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NN caspofungin)))) (PP (IN by) (NP (QP (RB approximately) (CD 35)) (NN %.)))))))

Sentence Id: DrugDDI.d59.s8
CANCIDAS/NN did/VBD not/RB increase/VB the/DT plasma/NN levels/NNS of/IN cyclosporine/NN ./.

(ROOT (S1 (S (S (NP (NN CANCIDAS)) (VP (VBD did) (RB not) (VP (VB increase) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN cyclosporine))))))) (. .))))

Sentence Id: DrugDDI.d59.s9
There/EX were/VBD transient/JJ increases/NNS in/IN liver/NN ALT/NN and/CC AST/NN when/WRB CANCIDAS/NN and/CC cyclosporine/NN were/VBD co-administered/VBN ./.

(ROOT (S1 (S (S (NP (EX There)) (VP (VBD were) (NP (NP (JJ transient) (NNS increases)) (PP (IN in) (NP (NP (NN liver) (NN ALT)) (CC and) (NP (NN AST))))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN CANCIDAS)) (CC and) (NP (NN cyclosporine))) (VP (VBD were) (VP (VBN co-administered))))))) (. .))))

Sentence Id: DrugDDI.d59.s10
A/DT drug-drug/JJ interaction/NN study/NN with/IN rifampin/NN in/IN healthy/JJ volunteers/NNS has/VBZ shown/VBN a/DT 30/CD %/NN decrease/NN in/IN caspofungin/NN trough/NN concentrations/NNS ./.

(ROOT (S1 (S (S (NP (NP (DT A) (JJ drug-drug) (NN interaction) (NN study)) (PP (IN with) (NP (NN rifampin))) (PP (IN in) (NP (JJ healthy) (NNS volunteers)))) (VP (VBZ has) (VP (VBN shown) (NP (NP (DT a) (ADJP (CD 30) (NN %)) (NN decrease)) (PP (IN in) (NP (NN caspofungin) (NN trough) (NNS concentrations))))))) (. .))))

Sentence Id: DrugDDI.d59.s11
Patients/NNS on/IN rifampin/NN should/MD receive/VBP 70/CD mg/NN of/IN CANCIDAS/NNS daily/RB ./.

(ROOT (S1 (S (S (NP (NP (NNS Patients)) (PP (IN on) (NP (NN rifampin)))) (VP (MD should) (VP (VBP receive) (NP (NP (CD 70) (NN mg)) (PP (IN of) (NP (NNS CANCIDAS)))) (ADVP (RB daily))))) (. .))))

Sentence Id: DrugDDI.d59.s12
In/IN addition/NN ,/, results/NNS from/IN regression/NN analyses/NNS of/IN patient/NN pharmacokinetic/JJ data/NNS suggest/VBP that/IN co-administration/NN of/IN other/JJ inducers/NNS of/IN drug/NN clearance/NN (/-LRB- efavirenz/NN ,/, nevirapine/NN ,/, phenytoin/NN ,/, dexamethasone/NN ,/, or/CC carbamazepine/NN )/-RRB- with/IN CANCIDAS/NN may/MD result/VB in/IN clinically/RB meaningful/JJ reductions/NNS in/IN caspofungin/NN concentrations/NNS ./.

(ROOT (S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NNS results)) (PP (IN from) (NP (NP (NN regression) (NNS analyses)) (PP (IN of) (NP (NN patient) (JJ pharmacokinetic) (NNS data)))))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN co-administration)) (PP (IN of) (NP (NP (JJ other) (NNS inducers)) (PP (IN of) (NP (NP (NN drug) (NN clearance)) (PRN (-LRB- -LRB-) (NP (NP (NN efavirenz)) (, ,) (NP (NN nevirapine)) (, ,) (NP (NN phenytoin)) (, ,) (NP (NN dexamethasone)) (, ,) (CC or) (NP (NN carbamazepine))) (-RRB- -RRB-)))))) (PP (IN with) (NP (NN CANCIDAS)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (ADJP (RB clinically) (JJ meaningful)) (NNS reductions)) (PP (IN in) (NP (NN caspofungin) (NNS concentrations)))))))))) (. .))))

Sentence Id: DrugDDI.d59.s13
It/PRP is/VBZ not/RB known/VBN which/WDT drug/NN clearance/NN mechanism/NN involved/VBN in/IN caspofungin/NN disposition/NN may/MD be/VB inducible/JJ ./.

(ROOT (S1 (S (S (NP (PRP It)) (VP (VBZ is) (RB not) (VP (VBN known) (SBAR (WHNP (WDT which)) (S (NP (NP (NN drug) (NN clearance) (NN mechanism)) (VP (VBN involved) (PP (IN in) (NP (NN caspofungin) (NN disposition))))) (VP (MD may) (VP (VB be) (ADJP (JJ inducible))))))))) (. .))))

Sentence Id: DrugDDI.d59.s14
When/WRB CANCIDAS/NN is/VBZ co-administered/VBN with/IN inducers/NNS of/IN drug/NN clearance/NN ,/, such/JJ as/IN efavirenz/NN ,/, nevirapine/NN ,/, phenytoin/NN ,/, dexamethasone/NN ,/, or/CC carbamazepine/NN ,/, use/NN of/IN a/DT daily/JJ dose/NN of/IN 70/CD mg/NN of/IN CANCIDAS/NN should/MD be/VB considered/VBN ./.

(ROOT (S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NN CANCIDAS)) (VP (VBZ is) (VP (VBN co-administered) (PP (IN with) (NP (NP (NNS inducers)) (PP (IN of) (NP (NN drug) (NN clearance))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN efavirenz)) (, ,) (NP (NN nevirapine)) (, ,) (NP (NN phenytoin)) (, ,) (NP (NN dexamethasone)) (, ,) (CC or) (NP (NN carbamazepine)))))))))) (, ,) (NP (NP (NN use)) (PP (IN of) (NP (NP (DT a) (JJ daily) (NN dose)) (PP (IN of) (NP (NP (CD 70) (NN mg)) (PP (IN of) (NP (NN CANCIDAS)))))))) (VP (MD should) (VP (VB be) (VP (VBN considered)))) (. .))))

Sentence Id: DrugDDI.d67.s0
Probenecid/NN may/MD decrease/VB renal/JJ tubular/JJ secretion/NN of/IN cephalosporins/NNS when/WRB used/VBN concurrently/RB ,/, resulting/VBG in/IN increased/VBN and/CC more/RBR prolonged/JJ cephalosporin/NN blood/NN levels/NNS ./.

(ROOT (S1 (S (S (NP (NN Probenecid)) (VP (MD may) (VP (VB decrease) (NP (NP (JJ renal) (JJ tubular) (NN secretion)) (PP (IN of) (NP (NNS cephalosporins)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (ADVP (RB concurrently))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (ADJP (ADJP (VBN increased)) (CC and) (ADJP (RBR more) (JJ prolonged))) (NN cephalosporin) (NN blood) (NNS levels)))))))) (. .))))

Sentence Id: DrugDDI.d67.s1
Drug/NN /Laboratory/NN Test/NN Interactions/NNS :/: A/DT false/JJ positive/JJ reaction/NN for/IN glucose/NN in/IN the/DT urine/NN may/MD occur/VB with/IN Benedicts/NN solution/NN ,/, Fehlings/NN solution/NN or/CC with/IN CLINITEST/NN @/NN tablets/NNS ,/, but/CC not/RB with/IN enzyme-based/JJ tests/NNS such/JJ as/IN CLINISTIX/JJ @./NNS

(ROOT (S1 (S (NP (NP (NN Drug) (NN /Laboratory) (NN Test) (NNS Interactions)) (: :) (S (NP (NP (DT A) (ADJP (ADJP (JJ false)) (ADJP (JJ positive))) (NN reaction)) (PP (IN for) (NP (NN glucose))) (PP (IN in) (NP (DT the) (NN urine)))) (VP (MD may) (VP (VB occur) (PP (IN with) (NP (NP (NN Benedicts) (NN solution)) (, ,) (NP (NN Fehlings) (NN solution)))) (PP (CC or) (PP (IN with) (NP (NN CLINITEST) (NN @) (NNS tablets))) (, ,) (CC but) (PP (RB not) (IN with) (NP (NP (JJ enzyme-based) (NNS tests)) (PP (JJ such) (IN as) (NP (JJ CLINISTIX) (NNS @.)))))))))))))

Sentence Id: DrugDDI.d67.s2
Positive/JJ direct/JJ and/CC indirect/JJ antiglobulin/NN (/-LRB- Coombs/NN )/-RRB- tests/NNS have/VBP occurred/VBN ;/: ./.

(ROOT (S1 (S (S (NP (JJ Positive) (ADJP (ADJP (JJ direct)) (CC and) (ADJP (JJ indirect))) (NN antiglobulin) (-LRB- -LRB-) (NN Coombs) (-RRB- -RRB-) (NNS tests)) (VP (VBP have) (VP (VBN occurred))) (: ;)) (. .))))

Sentence Id: DrugDDI.d67.s3
these/DT may/MD also/RB occur/VB in/IN neonates/NNS whose/WP$ mothers/NNS received/VBD cephalosporins/NN before/IN delivery/NN ./.

(ROOT (S1 (S (S (NP (DT these)) (VP (MD may) (ADVP (RB also)) (VP (VB occur) (PP (IN in) (NP (NP (NNS neonates)) (SBAR (WHNP (WP$ whose) (NNS mothers)) (S (VP (VBD received) (NP (NN cephalosporins)) (PP (IN before) (NP (NN delivery))))))))))) (. .))))

Sentence Id: DrugDDI.d152.s0
Oral/JJ Contraceptives/NN Multiple/JJ doses/NNS of/IN cefditoren/CD pivoxil/NN had/VBD no/DT effect/NN on/IN the/DT pharmacokinetics/NNS of/IN ethinyl/NN estradiol/NN ,/, the/DT estrogenic/JJ component/NN in/IN most/JJS oral/JJ contraceptives/NNS ./.

(ROOT (S1 (S (S (NP (NP (JJ Oral) (NN Contraceptives) (JJ Multiple) (NNS doses)) (PP (IN of) (NP (CD cefditoren) (NN pivoxil)))) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN ethinyl) (NN estradiol)) (, ,) (NP (NP (DT the) (JJ estrogenic) (NN component)) (PP (IN in) (NP (JJS most) (JJ oral) (NNS contraceptives)))))))))) (. .))))

Sentence Id: DrugDDI.d152.s1
Antacids/NNS Co-administration/NN of/IN a/DT single/JJ dose/NN of/IN an/DT antacid/JJ which/WDT contained/VBD both/CC magnesium/NN (/-LRB- 800/CD mg/NN )/-RRB- and/CC aluminum/NN (/-LRB- 900/CD mg/NN )/-RRB- hydroxides/NNS reduced/VBD the/DT oral/JJ absorption/NN of/IN a/DT single/JJ 400/CD mg/NN dose/NN of/IN cefditoren/CD pivoxil/NN administered/VBN following/VBG a/DT meal/NN ,/, as/IN evidenced/VBN by/IN a/DT 14/CD %/NN decrease/NN in/IN mean/JJ Cmax/NN and/CC an/DT 11/CD %/NN decrease/NN in/IN mean/JJ AUC/NN ./.

(ROOT (S1 (S (NP (NP (NNS Antacids) (NN Co-administration)) (PP (IN of) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NP (DT an) (JJ antacid)) (SBAR (WHNP (WDT which)) (S (VP (VBD contained) (NP (NP (NP (CC both) (NP (NP (NN magnesium)) (PRN (-LRB- -LRB-) (NP (CD 800) (NN mg)) (-RRB- -RRB-))) (CC and) (NP (NN aluminum))) (PRN (-LRB- -LRB-) (NP (CD 900) (NN mg)) (-RRB- -RRB-))) (NNS hydroxides)))))))))) (VP (VBD reduced) (NP (NP (DT the) (JJ oral) (NN absorption)) (PP (IN of) (NP (NP (NP (DT a) (JJ single) (ADJP (CD 400) (NN mg)) (NN dose)) (PP (IN of) (NP (CD cefditoren) (NN pivoxil)))) (VP (VBN administered) (PP (VBG following) (NP (DT a) (NN meal))))))) (, ,) (SBAR (IN as) (S (VP (VBN evidenced) (PP (IN by) (NP (NP (NP (DT a) (ADJP (CD 14) (NN %)) (NN decrease)) (PP (IN in) (NP (JJ mean) (NN Cmax)))) (CC and) (NP (NP (DT an) (ADJP (CD 11) (NN %)) (NN decrease)) (PP (IN in) (NP (JJ mean) (NN AUC)))))))))) (. .))))

Sentence Id: DrugDDI.d152.s2
Although/IN the/DT clinical/JJ significance/NN is/VBZ not/RB known/VBN ,/, it/PRP is/VBZ not/RB recommended/VBN that/IN cefditoren/CD pivoxil/NN be/VB taken/VBN concomitantly/RB with/IN antacids/NNS ./.

(ROOT (S1 (S (S (SBAR (IN Although) (S (NP (DT the) (JJ clinical) (NN significance)) (VP (VBZ is) (RB not) (VP (VBN known))))) (, ,) (NP (PRP it)) (VP (VBZ is) (RB not) (VP (VBN recommended) (SBAR (IN that) (S (NP (CD cefditoren) (NN pivoxil)) (VP (VB be) (VP (VBN taken) (ADVP (RB concomitantly)) (PP (IN with) (NP (NNS antacids)))))))))) (. .))))

Sentence Id: DrugDDI.d152.s3
H2-Receptor/JJ Antagonists/NNS Co-administration/NN of/IN a/DT single/JJ dose/NN of/IN intravenously/RB administered/VBN famotidine/NN (/-LRB- 20/CD mg/NN )/-RRB- reduced/VBD the/DT oral/JJ absorption/NN of/IN a/DT single/JJ 400/CD mg/NN dose/NN of/IN cefditoren/CD pivoxil/NN administered/VBN following/VBG a/DT meal/NN ,/, as/IN evidenced/VBN by/IN a/DT 27/CD %/NN decrease/NN in/IN mean/JJ Cmax/NN and/CC a/DT 22/CD %/NN decrease/NN in/IN mean/JJ AUC/NN ./.

(ROOT (S1 (S (NP (NP (JJ H2-Receptor) (NNS Antagonists) (NN Co-administration)) (PP (IN of) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NP (ADJP (RB intravenously) (VBN administered)) (NN famotidine)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN mg)) (-RRB- -RRB-))))))) (VP (VBD reduced) (NP (NP (DT the) (JJ oral) (NN absorption)) (PP (IN of) (NP (NP (NP (DT a) (JJ single) (ADJP (CD 400) (NN mg)) (NN dose)) (PP (IN of) (NP (CD cefditoren) (NN pivoxil)))) (VP (VBN administered) (PP (VBG following) (NP (DT a) (NN meal))))))) (, ,) (SBAR (IN as) (S (VP (VBN evidenced) (PP (IN by) (NP (NP (NP (DT a) (ADJP (CD 27) (NN %)) (NN decrease)) (PP (IN in) (NP (JJ mean) (NN Cmax)))) (CC and) (NP (NP (DT a) (ADJP (CD 22) (NN %)) (NN decrease)) (PP (IN in) (NP (JJ mean) (NN AUC)))))))))) (. .))))

Sentence Id: DrugDDI.d152.s4
Although/IN the/DT clinical/JJ significance/NN is/VBZ not/RB known/VBN ,/, it/PRP is/VBZ not/RB recommended/VBN that/IN cefditoren/CD pivoxil/NN be/VB taken/VBN concomitantly/RB with/IN H2/NN receptor/NN antagonists/NNS ./.

(ROOT (S1 (S (S (SBAR (IN Although) (S (NP (DT the) (JJ clinical) (NN significance)) (VP (VBZ is) (RB not) (VP (VBN known))))) (, ,) (NP (PRP it)) (VP (VBZ is) (RB not) (VP (VBN recommended) (SBAR (IN that) (S (NP (CD cefditoren) (NN pivoxil)) (VP (VB be) (VP (VBN taken) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN H2) (NN receptor) (NNS antagonists)))))))))) (. .))))

Sentence Id: DrugDDI.d152.s5
Probenecid/NN :/: As/IN with/IN other/JJ b-lactam/NN antibiotics/NNS ,/, co-administration/NN of/IN probenecid/NN with/IN cefditoren/CD pivoxil/NN resulted/VBD in/IN an/DT increase/NN in/IN the/DT plasma/NN exposure/NN of/IN cefditoren/NN ,/, with/IN a/DT 49/CD %/NN increase/NN in/IN mean/NN Cmax/NN ,/, a/DT 122/CD %/NN increase/NN in/IN mean/JJ AUC/NN ,/, and/CC a/DT 53/CD %/NN increase/NN in/IN half-life/NN ./.

(ROOT (S1 (S (NP (NP (NN Probenecid)) (: :) (S (PP (IN As) (PP (IN with) (NP (JJ other) (NN b-lactam) (NNS antibiotics)))) (, ,) (NP (NP (NN co-administration)) (PP (IN of) (NP (NN probenecid))) (PP (IN with) (NP (CD cefditoren) (NN pivoxil)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN plasma) (NN exposure)) (PP (IN of) (NP (NN cefditoren))))))) (, ,) (PP (IN with) (NP (NP (NP (DT a) (ADJP (CD 49) (NN %)) (NN increase)) (PP (IN in) (NP (NN mean) (NN Cmax)))) (, ,) (NP (NP (DT a) (CD 122) (NN %) (NN increase)) (PP (IN in) (NP (JJ mean) (NN AUC)))) (, ,) (CC and) (NP (NP (DT a) (CD 53) (NN %) (NN increase)) (PP (IN in) (NP (NN half-life)))))))) (. .)))))

Sentence Id: DrugDDI.d152.s6
Drug/NN /Laboratory/JJ Test/NN Interactions/NNS Cephalosporins/NNS are/VBP known/VBN to/TO occasionally/RB induce/VB a/DT positive/JJ direct/JJ Coombs/NN test/NN ./.

(ROOT (S1 (S (S (NP (NN Drug) (JJ /Laboratory) (NN Test) (NNS Interactions) (NNS Cephalosporins)) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (ADVP (RB occasionally)) (VP (VB induce) (NP (DT a) (JJ positive) (JJ direct) (NN Coombs) (NN test)))))))) (. .))))

Sentence Id: DrugDDI.d152.s7
A/DT false-positive/JJ reaction/NN for/IN glucose/NN in/IN the/DT urine/NN may/MD occur/VB with/IN copper/NN reduction/NN tests/NNS (/-LRB- Benedicts/NNP or/CC Fehlings/NNP solution/NN or/CC with/IN CLINITEST/JJ tablets/NNS )/-RRB- ,/, but/CC not/RB with/IN enzyme-based/JJ tests/NNS for/IN glycosuria/NN (/-LRB- e.g./FW ,/, CLINISTIX/NN ,/, TES-TAPE/JJ )./NN

(ROOT (S1 (S (NP (NP (DT A) (JJ false-positive) (NN reaction)) (PP (IN for) (NP (NN glucose))) (PP (IN in) (NP (DT the) (NN urine)))) (VP (MD may) (VP (VB occur) (PP (PP (IN with) (NP (NP (NN copper) (NN reduction) (NNS tests)) (PRN (-LRB- -LRB-) (NP (NP (NP (NNP Benedicts)) (CC or) (NP (NNP Fehlings))) (NP (NN solution))) (CC or) (PP (IN with) (NP (JJ CLINITEST) (NNS tablets))) (-RRB- -RRB-)))) (, ,) (CC but) (PP (RB not) (IN with) (NP (NP (JJ enzyme-based) (NNS tests)) (PP (IN for) (NP (NN glycosuria)))))))) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN CLINISTIX)) (, ,) (NP (JJ TES-TAPE) (NN -RRB-.)))))))

Sentence Id: DrugDDI.d152.s8
As/IN a/DT false-negative/JJ result/NN may/MD occur/VB in/IN the/DT ferricyanide/NN test/NN ,/, it/PRP is/VBZ recommended/VBN that/IN either/CC the/DT glucose/NN oxidase/NN or/CC hexokinase/NN method/NN be/VB used/VBN to/TO determine/VB blood/plasma/NN glucose/NN levels/NNS in/IN patients/NNS receiving/VBG cefditoren/NN pivoxil/NN ./.

(ROOT (S1 (S (SBAR (IN As) (S (NP (DT a) (JJ false-negative) (NN result)) (VP (MD may) (VP (VB occur) (PP (IN in) (NP (DT the) (NN ferricyanide) (NN test))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (CC either) (NP (DT the) (NN glucose) (NN oxidase)) (CC or) (NP (NN hexokinase) (NN method))) (VP (VB be) (VP (VBN used) (S (VP (TO to) (VP (VB determine) (NP (NP (NN blood/plasma) (NN glucose) (NNS levels)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN cefditoren) (NN pivoxil))))))))))))))) (. .))))

Sentence Id: DrugDDI.d373.s0
Increased/VBN nephrotoxicity/NN has/VBZ been/VBN reported/VBN following/VBG concomitant/JJ administration/NN of/IN cephalosporins/NNS and/CC aminoglycoside/NN antibiotics/NNS ./.

(ROOT (S1 (S (S (NP (VBN Increased) (NN nephrotoxicity)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (VBG following) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NNS cephalosporins)) (CC and) (NP (NN aminoglycoside) (NNS antibiotics)))))))))) (. .))))

Sentence Id: DrugDDI.d373.s1
Drug/NN /Laboratory/NN Test/NN Interactions/NNS :/: As/IN with/IN cephalothin/NN ,/, high/JJ concentrations/NNS of/IN cefoxitin/NN (/-LRB- 100/CD micrograms/mL/NNS )/-RRB- may/MD interfere/VB with/IN measurement/NN of/IN serum/NN and/CC urine/NN creatinine/NN levels/NNS by/IN the/DT Jaff/NN @/NN reaction/NN ,/, and/CC produce/VBP false/JJ increases/NNS of/IN modest/JJ degree/NN in/IN the/DT levels/NNS of/IN creatinine/NN reported/VBD ./.

(ROOT (S1 (S (NP (NP (NN Drug) (NN /Laboratory) (NN Test) (NNS Interactions)) (: :) (S (PP (IN As) (PP (IN with) (NP (NN cephalothin)))) (, ,) (NP (NP (JJ high) (NNS concentrations)) (PP (IN of) (NP (NP (NN cefoxitin)) (PRN (-LRB- -LRB-) (NP (CD 100) (NNS micrograms/mL)) (-RRB- -RRB-))))) (VP (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (NN measurement)) (PP (IN of) (NP (NP (NN serum)) (CC and) (NP (NN urine)) (NP (NN creatinine) (NNS levels)))))) (PP (IN by) (NP (DT the) (NN Jaff) (NN @) (NN reaction))))) (, ,) (CC and) (VP (VBP produce) (NP (NP (JJ false) (NNS increases)) (PP (IN of) (NP (JJ modest) (NN degree))) (PP (IN in) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NP (NN creatinine)) (VP (VBD reported)))))))))) (. .)))))

Sentence Id: DrugDDI.d373.s2
Serum/NN samples/NNS from/IN patients/NNS treated/VBN with/IN cefoxitin/NN should/MD not/RB be/VB analyzed/VBN for/IN creatinine/NN if/IN withdrawn/VBN within/IN 2/CD hours/NNS of/IN drug/NN administration/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Serum) (NNS samples)) (PP (IN from) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NN cefoxitin))))))) (VP (MD should) (RB not) (VP (VB be) (VP (VBN analyzed) (PP (IN for) (NP (NN creatinine))) (SBAR (IN if) (S (VP (VBN withdrawn) (PP (IN within) (NP (NP (CD 2) (NNS hours)) (PP (IN of) (NP (NN drug) (NN administration)))))))))))) (. .))))

Sentence Id: DrugDDI.d373.s3
High/JJ concentrations/NNS of/IN cefoxitin/NN in/IN the/DT urine/NN may/MD interfere/VB with/IN measurement/NN of/IN urinary/JJ 17-hydroxy-/JJ corticosteroids/NNS by/IN the/DT Porter-Silber/NN reaction/NN ,/, and/CC produce/VB false/JJ increases/NNS of/IN modest/JJ degree/NN in/IN the/DT levels/NNS reported/VBN ./.

(ROOT (S1 (S (S (NP (NP (JJ High) (NNS concentrations)) (PP (IN of) (NP (NN cefoxitin))) (PP (IN in) (NP (DT the) (NN urine)))) (VP (MD may) (VP (VP (VB interfere) (PP (IN with) (NP (NP (NN measurement)) (PP (IN of) (NP (JJ urinary) (JJ 17-hydroxy-) (NNS corticosteroids))))) (PP (IN by) (NP (DT the) (NN Porter-Silber) (NN reaction)))) (, ,) (CC and) (VP (VB produce) (NP (NP (JJ false) (NNS increases)) (PP (IN of) (NP (JJ modest) (NN degree))) (PP (IN in) (NP (NP (DT the) (NNS levels)) (VP (VBN reported))))))))) (. .))))

Sentence Id: DrugDDI.d373.s4
A/DT false-positive/JJ reaction/NN for/IN glucose/NN in/IN the/DT urine/NN may/MD occur/VB ./.

(ROOT (S1 (S (S (NP (NP (DT A) (JJ false-positive) (NN reaction)) (PP (IN for) (NP (NN glucose))) (PP (IN in) (NP (DT the) (NN urine)))) (VP (MD may) (VP (VB occur)))) (. .))))

Sentence Id: DrugDDI.d373.s7
@/NN Registered/JJ trademark/NN of/IN Ame/NN s/NN Company/NN ,/, Division/NN of/IN Miles/NN Laboratories/NNS ,/, Inc./NNP ./.

(ROOT (S1 (S (S (NP (NP (NP (NN @) (JJ Registered) (NN trademark)) (PP (IN of) (NP (NN Ame) (NN s) (NN Company)))) (, ,) (NP (NP (NN Division)) (PP (IN of) (NP (NN Miles) (NNS Laboratories)))) (, ,)) (NP (NNP Inc.))) (. .))))

Sentence Id: DrugDDI.d169.s0
Immunosuppressive/JJ Drugs/NNS ,/, Fibric/JJ Acid/NN Derivatives/NNS ,/, Niacin/NN (/-LRB- Nicotinic/JJ Acid/NN ,/, Erythromycin/NN ,/, Azole/JJ Antifungals/NNS :/: Skeletal/JJ Muscle/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Immunosuppressive) (NNS Drugs)) (, ,) (NP (JJ Fibric) (NN Acid) (NNS Derivatives)) (, ,) (NP (NP (NN Niacin)) (-LRB- -LRB-) (NP (JJ Nicotinic) (NN Acid)) (, ,) (NP (NN Erythromycin)) (, ,) (NP (JJ Azole) (NNS Antifungals)))) (: :) (NP (JJ Skeletal) (NN Muscle))) (. .))))

Sentence Id: DrugDDI.d169.s1
ANTACID/JJ (/-LRB- Magnesium-Aluminum/NN Hydroxide/NN )/-RRB- :/: Cerivastatin/NN plasma/NN concentrations/NNS were/VBD not/RB affected/VBN by/IN co-administration/NN of/IN antacid/JJ ./.

(ROOT (S1 (S (S (NP (ADJP (ADJP (JJ ANTACID)) (-LRB- -LRB-) (NP (NN Magnesium-Aluminum) (NN Hydroxide)) (-RRB- -RRB-) (: :)) (NN Cerivastatin) (NN plasma) (NNS concentrations)) (VP (VBD were) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (NN co-administration)) (PP (IN of) (NP (JJ antacid)))))))) (. .))))

Sentence Id: DrugDDI.d169.s2
CIMETlDINE/NN :/: Cerivastatin/NN plasma/NN concentrations/NNS were/VBD not/RB affected/VBN by/IN co-administration/NN of/IN cimetidine/NN ./.

(ROOT (S1 (S (S (NP (NN CIMETlDINE) (: :) (NN Cerivastatin) (NN plasma) (NNS concentrations)) (VP (VBD were) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (NN co-administration)) (PP (IN of) (NP (NN cimetidine)))))))) (. .))))

Sentence Id: DrugDDI.d169.s3
CHOLESTYRAMINE/NN :/: The/DT influence/NN of/IN the/DT bile-acidsequestering/JJ agent/NN cholestyramine/NN on/IN the/DT pharmacokinetits/NNS of/IN cerivastatin/NN sodium/NN was/VBD evaluated/VBN in/IN 12/CD healthy/JJ males/NNS in/IN 2/CD separate/JJ randomized/JJ crossover/NN studies/NNS ./.

(ROOT (S1 (S (NP (NP (NN CHOLESTYRAMINE)) (: :) (S (NP (NP (DT The) (NN influence)) (PP (IN of) (NP (DT the) (JJ bile-acidsequestering) (NN agent) (NN cholestyramine))) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetits)) (PP (IN of) (NP (NN cerivastatin) (NN sodium)))))) (VP (VBD was) (VP (VBN evaluated) (PP (IN in) (NP (NP (CD 12) (JJ healthy) (NNS males)) (PP (IN in) (NP (CD 2) (JJ separate) (JJ randomized) (NN crossover) (NNS studies)))))))) (. .)))))

Sentence Id: DrugDDI.d169.s4
In/IN the/DT first/JJ study/NN ,/, concomitant/JJ administration/NN of/IN 0.2/CD mg/NN cerivastatin/NN sodium/NN and/CC 12/CD g/NN cholestyramine/NN resulted/VBD in/IN decreases/NNS of/IN more/JJR than/IN 22/CD %/NN for/IN AUC/NN and/CC 40/CD %/NN for/IN Cmax/NN when/WRB compared/VBN to/TO dosing/NN cerivastatin/NN sodium/NN alone/RB ./.

(ROOT (S1 (S (PP (IN In) (NP (DT the) (JJ first) (NN study))) (, ,) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (ADJP (CD 0.2) (NN mg)) (NN cerivastatin) (NN sodium)) (CC and) (NP (CD 12) (NN g) (NN cholestyramine))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NNS decreases)) (PP (IN of) (NP (NP (NP (QP (JJR more) (IN than) (CD 22)) (NN %)) (PP (IN for) (NP (NN AUC)))) (CC and) (NP (NP (CD 40) (NN %)) (PP (IN for) (NP (NN Cmax)))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NN dosing) (NN cerivastatin) (NN sodium))) (ADVP (RB alone)))))) (. .))))

Sentence Id: DrugDDI.d169.s5
However/RB ,/, in/IN the/DT second/JJ study/NN ,/, administration/NN of/IN 12/CD g/NN cholestyramine/NN 1/CD hour/NN before/IN the/DT evening/NN meal/NN and/CC 0.3/CD mg/NN cerivastatin/NN sodium/NN approximately/RB 4/CD hours/NNS after/IN the/DT same/JJ evening/NN meal/NN resulted/VBD in/IN a/DT decrease/NN in/IN the/DT cerivastatin/NN AUC/NN of/IN less/JJR than/IN 8/CD %/NN ,/, and/CC a/DT decrease/NN in/IN Cmax/NN of/IN about/RB 30/CD %/NN when/WRB compared/VBN to/TO dosing/NN cerivastatin/NN sodium/NN alone/RB ./.

(ROOT (S1 (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (DT the) (JJ second) (NN study))) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (CD 12) (NN g) (NN cholestyramine) (CD 1) (NN hour))) (PP (IN before) (NP (NP (DT the) (NN evening) (NN meal)) (CC and) (NP (ADJP (CD 0.3) (NN mg)) (NN cerivastatin) (NN sodium)) (NP (NP (QP (RB approximately) (CD 4)) (NNS hours)) (PP (IN after) (NP (DT the) (JJ same) (NN evening) (NN meal))))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN cerivastatin) (NN AUC)) (PP (IN of) (NP (QP (JJR less) (IN than) (CD 8)) (NN %)))))) (, ,) (CC and) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (NN Cmax)) (PP (IN of) (NP (QP (RB about) (CD 30)) (NN %)))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NN dosing) (NN cerivastatin) (NN sodium))) (ADVP (RB alone)))))) (. .))))

Sentence Id: DrugDDI.d169.s6
Therefore/RB ,/, it/PRP would/MD be/VB expected/VBN that/IN a/DT dosing/NN schedule/NN of/IN cerivastatin/NN sodium/NN given/VBN at/IN bedtime/NN and/CC cholestyramine/NN given/VBN before/IN the/DT evening/NN meal/NN would/MD not/RB result/VB in/IN a/DT significant/JJ decrease/NN in/IN the/DT clinical/JJ effect/NN of/IN cerivastatin/NN sodium/NN ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (PRP it)) (VP (MD would) (VP (VB be) (VP (VBN expected) (SBAR (IN that) (S (NP (NP (DT a) (NN dosing) (NN schedule)) (PP (IN of) (NP (NP (NN cerivastatin) (NN sodium)) (VP (VBN given) (PP (IN at) (NP (NP (NN bedtime)) (CC and) (NP (NN cholestyramine))))))) (VP (VBN given) (PP (IN before) (NP (DT the) (NN evening) (NN meal))))) (VP (MD would) (RB not) (VP (VB result) (PP (IN in) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (NP (DT the) (JJ clinical) (NN effect)) (PP (IN of) (NP (NN cerivastatin) (NN sodium))))))))))))))) (. .))))

Sentence Id: DrugDDI.d169.s7
DIGOXIN/NN :/: Plasma/NN digoxin/NN levels/NNS and/CC digoxin/NN clearance/NN at/IN steady-state/NN were/VBD not/RB affected/VBN by/IN co-administration/NN of/IN 0.2/CD mg/NN cerivastatin/NN sodium/NN ./.

(ROOT (S1 (S (NP (NP (NN DIGOXIN)) (: :) (S (NP (NP (NN Plasma) (NN digoxin) (NNS levels)) (CC and) (NP (NP (NN digoxin) (NN clearance)) (PP (IN at) (NP (NN steady-state))))) (VP (VBD were) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (NN co-administration)) (PP (IN of) (NP (ADJP (CD 0.2) (NN mg)) (NN cerivastatin) (NN sodium)))))))) (. .)))))

Sentence Id: DrugDDI.d169.s8
Cerivastatin/NN plasma/NN concentrations/NNS were/VBD also/RB not/RB affected/VBN by/IN co-administration/NN of/IN digoxin/NN ./.

(ROOT (S1 (S (S (NP (NN Cerivastatin) (NN plasma) (NNS concentrations)) (VP (VBD were) (ADVP (RB also)) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (NN co-administration)) (PP (IN of) (NP (NN digoxin)))))))) (. .))))

Sentence Id: DrugDDI.d169.s9
WARFARIN/NN :/: Co-/NN administration/NN of/IN warfarin/NN and/CC cerivastatin/NN to/TO healthy/JJ volunteers/NNS did/VBD not/RB result/VB in/IN any/DT changes/NNS in/IN prothrombin/NN time/NN or/CC clotting/NN factor/NN VII/NN when/WRB compared/VBN to/TO co-administration/NN of/IN warfarin/NN and/CC placebo/NN ./.

(ROOT (S1 (S (NP (NP (NN WARFARIN)) (: :) (S (NP (NP (NN Co-) (NN administration)) (PP (IN of) (NP (NP (NN warfarin)) (CC and) (NP (NN cerivastatin)))) (PP (TO to) (NP (JJ healthy) (NNS volunteers)))) (VP (VBD did) (RB not) (VP (VB result) (PP (IN in) (NP (NP (DT any) (NNS changes)) (PP (IN in) (NP (NP (NN prothrombin) (NN time)) (CC or) (NP (NN clotting) (NN factor) (NN VII))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NP (NN co-administration)) (PP (IN of) (NP (NP (NN warfarin)) (CC and) (NP (NN placebo))))))))))) (. .)))))

Sentence Id: DrugDDI.d169.s10
The/DT AUC/NN and/CC Cmax/NN of/IN both/DT the/DT (/-LRB- R/NN )/-RRB- and/CC (/-LRB- S/NN )/-RRB- isomers/NNS of/IN warfarin/NN were/VBD unaffected/VBN by/IN concurrent/JJ dosing/NN of/IN 0.3/CD mg/NN cerivastatin/NN sodium/NN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NP (NN AUC)) (CC and) (NP (NN Cmax))) (PP (IN of) (NP (NP (DT both) (NP (NP (DT the)) (PRN (-LRB- -LRB-) (NP (NN R)) (-RRB- -RRB-)) (CC and) (PRN (-LRB- -LRB-) (NP (NN S)) (-RRB- -RRB-))) (NNS isomers)) (PP (IN of) (NP (NN warfarin)))))) (VP (VBD were) (VP (VBN unaffected) (PP (IN by) (NP (NP (JJ concurrent) (NN dosing)) (PP (IN of) (NP (ADJP (CD 0.3) (NN mg)) (NN cerivastatin) (NN sodium)))))))) (. .))))

Sentence Id: DrugDDI.d169.s11
Co-administration/NN of/IN warfarin/NN and/CC cerivastatin/NN did/VBD not/RB alter/VB the/DT pharmacokinetics/NNS of/IN cerivastatin/NN sodium/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NP (NN warfarin)) (CC and) (NP (NN cerivastatin))))) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN cerivastatin) (NN sodium))))))) (. .))))

Sentence Id: DrugDDI.d169.s12
ERYTHROMYCIN/NN :/: In/IN hypercholesterolemic/JJ patients/NNS ,/, steady-state/JJ cerivastatin/NN AUC/NN and/CC Cmax/NN increased/VBD approximately/RB 50/CD %/NN and/CC 24/CD %/NN respectively/RB after/IN 10/CD days/NNS with/IN co-administration/NN of/IN erythromycin/NN ,/, a/DT known/JJ inhibitor/NN of/IN cytochrome/NN P450/NN 3A4/NN ./.

(ROOT (S1 (S (NP (NP (NN ERYTHROMYCIN)) (: :) (S (PP (IN In) (NP (JJ hypercholesterolemic) (NNS patients))) (, ,) (NP (NP (JJ steady-state) (NN cerivastatin) (NN AUC)) (CC and) (NP (NN Cmax))) (VP (VBD increased) (NP (NP (QP (RB approximately) (CD 50)) (NN %)) (CC and) (NP (CD 24) (NN %))) (ADVP (RB respectively)) (PP (IN after) (NP (NP (CD 10) (NNS days)) (PP (IN with) (NP (NP (NN co-administration)) (PP (IN of) (NP (NP (NN erythromycin)) (, ,) (NP (NP (DT a) (JJ known) (NN inhibitor)) (PP (IN of) (NP (NN cytochrome) (NN P450) (NN 3A4)))))))))))) (. .)))))

Sentence Id: DrugDDI.d169.s13
OTHER/JJ CONCOMITANT/JJ THERAPY/NN :/: Although/IN specific/JJ interaction/NN studies/NNS were/VBD not/RB performed/VBN ,/, in/IN clinical/JJ studies/NNS ,/, cerivastatin/NN sodium/NN was/VBD used/VBN concomitantly/RB with/IN angiotensin-/NN converting/NN enzyme/NN (/-LRB- ACE/NN )/-RRB- inhibitors/NNS ,/, betablockers/NNS ,/, calcium-channel/NN blockers/NNS ,/, diuretics/NN ,/, and/CC nonsteroidal/JJ anti-inflammatory/JJ drugs/NNS (/-LRB- NSAIDs/NNS )/-RRB- without/IN evidence/NN of/IN clinically/RB significant/JJ adverse/JJ interactions/NNS ./.

(ROOT (S1 (S (NP (NP (JJ OTHER) (JJ CONCOMITANT) (NN THERAPY)) (: :) (S (PP (IN Although) (NP (NP (JJ specific) (NN interaction) (NNS studies)) (VP (VBD were) (RB not) (VP (VBN performed) (, ,) (PP (IN in) (NP (JJ clinical) (NNS studies))))))) (, ,) (NP (NN cerivastatin) (NN sodium)) (VP (VBD was) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NN angiotensin-) (NN converting) (NN enzyme) (-LRB- -LRB-) (NN ACE) (-RRB- -RRB-) (NNS inhibitors)) (, ,) (NP (NNS betablockers)) (, ,) (NP (NN calcium-channel) (NNS blockers)) (, ,) (NP (NN diuretics)) (, ,) (CC and) (NP (NP (JJ nonsteroidal) (JJ anti-inflammatory) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NNS NSAIDs)) (-RRB- -RRB-))))) (PP (IN without) (NP (NP (NN evidence)) (PP (IN of) (NP (ADJP (RB clinically) (JJ significant)) (JJ adverse) (NNS interactions)))))))) (. .)))))

Sentence Id: DrugDDI.d125.s0
Although/IN clinical/JJ studies/NNS have/VBP not/RB established/VBN a/DT cause/NN and/CC effect/NN relationship/NN ,/, physicians/NNS should/MD be/VB aware/NN that/IN variable/JJ effects/NNS an/DT blood/NN coagulation/NN have/VBP been/VBN reported/VBN very/RB rarely/RB in/IN patients/NNS receiving/VBG oral/JJ anticoagulants/NNS and/CC chlordiazepoxide/NN ./.

(ROOT (S1 (S (SBAR (IN Although) (S (NP (JJ clinical) (NNS studies)) (VP (VBP have) (RB not) (VP (VBN established) (NP (NP (DT a) (NN cause)) (CC and) (NP (NN effect)) (NP (NN relationship))))))) (, ,) (NP (NNS physicians)) (VP (MD should) (VP (VB be) (NP (NN aware)) (SBAR (IN that) (S (NP (NP (JJ variable) (NNS effects)) (NP (DT an) (NN blood) (NN coagulation))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (ADVP (RB very) (RB rarely)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (JJ oral) (NNS anticoagulants)) (CC and) (NP (NN chlordiazepoxide))))))))))))) (. .))))

Sentence Id: DrugDDI.d125.s1
The/DT concomitant/JJ use/NN of/IN alcohol/NN or/CC other/JJ central/JJ nervous/JJ system/NN depressants/NNS may/MD have/VB an/DT additive/JJ effect/NN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN alcohol)) (CC or) (NP (JJ other) (JJ central) (JJ nervous) (NN system)) (NP (NNS depressants))))) (VP (MD may) (VP (VB have) (NP (DT an) (JJ additive) (NN effect))))) (. .))))

Sentence Id: DrugDDI.d261.s0
The/DT administration/NN of/IN local/JJ anesthetic/JJ solutions/NNS containing/VBG epinephrine/NN or/CC norepinephrine/NN to/TO patients/NNS receiving/VBG monoamine/NN oxidase/NN inhibitors/NNS ,/, tricyclic/JJ antidepressants/NNS or/CC phenothiazines/NNS may/MD produce/VB severe/JJ ,/, prolonged/JJ hypotension/NN or/CC hypertension/NN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NP (JJ local) (JJ anesthetic) (NNS solutions)) (VP (VBG containing) (NP (NP (NN epinephrine)) (CC or) (NP (NN norepinephrine)))))) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NP (NN monoamine) (NN oxidase)) (NNS inhibitors)) (, ,) (NP (JJ tricyclic) (NNS antidepressants)) (CC or) (NP (NNS phenothiazines))))))) (VP (MD may) (VP (VB produce) (NP (ADJP (ADJP (JJ severe)) (, ,) (ADJP (JJ prolonged))) (NP (NN hypotension)) (CC or) (NP (NN hypertension)))))) (. .))))

Sentence Id: DrugDDI.d261.s3
Concurrent/JJ administration/NN of/IN vasopressor/JJ drugs/NNS (/-LRB- for/IN the/DT treatment/NN of/IN hypotension/NN related/JJ to/TO obstetric/JJ blocks/NNS )/-RRB- and/CC ergot-type/JJ oxytocic/JJ drugs/NNS may/MD cause/VB severe/JJ ,/, persistent/JJ hypertension/NN or/CC cerebrovascular/JJ accidents/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Concurrent) (NN administration)) (PP (IN of) (NP (NP (NP (JJ vasopressor) (NNS drugs)) (PRN (-LRB- -LRB-) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN hypotension))) (ADJP (JJ related) (PP (TO to) (NP (JJ obstetric) (NNS blocks)))))) (-RRB- -RRB-))) (CC and) (NP (JJ ergot-type) (JJ oxytocic) (NNS drugs))))) (VP (MD may) (VP (VB cause) (NP (NP (JJ severe) (, ,) (JJ persistent) (NN hypertension)) (CC or) (NP (JJ cerebrovascular) (NN accidents)))))) (. .))))

Sentence Id: DrugDDI.d261.s4
The/DT para-aminobenzoic/JJ acid/NN metabolite/NN of/IN chloroprocaine/NN inhibits/VBZ the/DT action/NN of/IN sulfonamides/NNS ./.

(ROOT (S1 (S (S (NP (NP (DT The) (JJ para-aminobenzoic) (NN acid) (NN metabolite)) (PP (IN of) (NP (NN chloroprocaine)))) (VP (VBZ inhibits) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NNS sulfonamides)))))) (. .))))

Sentence Id: DrugDDI.d261.s5
Therefore/RB ,/, chloroprocaine/NN should/MD not/RB be/VB used/VBN in/IN any/DT condition/NN in/IN which/WDT a/DT sulfonamide/NN drug/NN is/VBZ being/VBG employed/VBN ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN chloroprocaine)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (PP (IN in) (NP (NP (DT any) (NN condition)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT a) (NN sulfonamide) (NN drug)) (VP (VBZ is) (VP (VBG being) (VP (VBN employed)))))))))))) (. .))))

Sentence Id: DrugDDI.d354.s0
When/WRB given/VBN concurrently/RB the/DT following/JJ drugs/NNS may/MD interact/VB with/IN thiazide/NN diuretics/NNS ./.

(ROOT (S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN given) (ADVP (RB concurrently))))) (NP (DT the) (JJ following) (NNS drugs)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NN thiazide) (NNS diuretics)))))) (. .))))

Sentence Id: DrugDDI.d354.s1
-/CC Alcohol/NN ,/, barbiturates/NNS ,/, or/CC narcotics/NNS :/: Potentiation/NN of/IN otthostatic/JJ hypotension/NN may/MD occur/VB ./.

(ROOT (S1 (S (S (NP (NP (CC -) (NP (NN Alcohol)) (, ,) (NP (NNS barbiturates)) (, ,) (CC or) (NP (NNS narcotics))) (: :) (NP (NP (NN Potentiation)) (PP (IN of) (NP (JJ otthostatic) (NN hypotension))))) (VP (MD may) (VP (VB occur)))) (. .))))

Sentence Id: DrugDDI.d354.s3
-/CC Antidiabetic/JJ drugs/NNS :/: (/-LRB- Oral/JJ agents/NNS and/CC insulin/NN )/-RRB- Dosage/NN adjustment/NN of/IN the/DT antidiabetic/JJ drug/NN may/MD be/VB required/VBN ./.

(ROOT (S1 (S (S (NP (NP (CC -) (NP (NP (JJ Antidiabetic) (NNS drugs) (: :)) (PRN (-LRB- -LRB-) (NP (NP (JJ Oral) (NNS agents)) (CC and) (NP (NN insulin))) (-RRB- -RRB-))) (NN Dosage) (NN adjustment)) (PP (IN of) (NP (DT the) (JJ antidiabetic) (NN drug)))) (VP (MD may) (VP (VB be) (VP (VBN required))))) (. .))))

Sentence Id: DrugDDI.d354.s5
-/CC Other/JJ antihypertensive/JJ drugs/NNS :/: Additive/JJ effect/NN or/CC potentiation/NN ./.

(ROOT (S1 (S (NP (NP (CC -) (JJ Other) (JJ antihypertensive) (NNS drugs)) (: :) (NP (NP (JJ Additive) (NN effect)) (CC or) (NP (NN potentiation))) (. .)))))

Sentence Id: DrugDDI.d354.s7
-/CC Cholestyramine/NN and/CC colestipol/NN resins/NNS :/: Cholestytamine/NN and/CC colestipol/NN resins/NNS have/VBP the/DT potential/NN of/IN binding/NN thiazide/NN diuretics/NNS and/CC reducing/VBG diuretic/JJ absorption/NN from/IN the/DT gastrointestinal/JJ tract/NN ./.

(ROOT (S1 (S (NP (NP (CC -) (NP (NN Cholestyramine)) (CC and) (NP (NN colestipol)) (NP (NNS resins))) (: :) (S (NP (NP (NP (NN Cholestytamine)) (CC and) (NP (NN colestipol))) (NNS resins)) (VP (VP (VBP have) (NP (NP (DT the) (NN potential)) (PP (IN of) (NP (NN binding) (NN thiazide) (NNS diuretics))))) (CC and) (VP (VBG reducing) (NP (NP (JJ diuretic) (NN absorption)) (PP (IN from) (NP (DT the) (JJ gastrointestinal) (NN tract))))))) (. .)))))

Sentence Id: DrugDDI.d354.s9
-/: Corticosteroids/NNS ,/, ACTH/NN :/: Intensified/JJ electrolyte/NN depletion/NN ,/, particularly/RB hypokalemia/NN ./.

(ROOT (S1 (S (S (PRN (: -) (NP (NNS Corticosteroids)) (, ,) (NP (NN ACTH)) (: :) (NP (JJ Intensified) (NN electrolyte) (NN depletion)) (, ,) (NP (ADVP (RB particularly)) (NP (NN hypokalemia))))) (. .))))

Sentence Id: DrugDDI.d354.s11
-/CC Pressor/NN amines/NNS (/-LRB- e.g./FW ,/, norepinephrine/NN )/-RRB- :/: Possible/JJ decreased/VBD response/NN to/TO pressor/JJ amines/NNS but/CC not/RB sufficient/JJ to/TO preclude/VB their/PRP$ use/NN ./.

(ROOT (S1 (S (NP (NP (NP (CC -) (NN Pressor) (NNS amines)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN norepinephrine))) (-RRB- -RRB-))) (: :) (S (NP (JJ Possible)) (VP (VP (VBD decreased) (NP (NP (NN response)) (PP (TO to) (NP (JJ pressor) (NNS amines))))) (CC but) (RB not) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB preclude) (NP (PRP$ their) (NN use)))))))) (. .)))))

Sentence Id: DrugDDI.d354.s13
-/CC Skeletal/JJ muscle/NN relaxants/NNS ,/, nondepolarizing/JJ (/-LRB- e.g./FW ,/, tubocurarine/NN )/-RRB- :/: Possible/JJ increased/VBN responsiveness/NN to/TO the/DT muscle/NN relaxant/NN ./.

(ROOT (S1 (S (NP (NP (CC -) (NP (JJ Skeletal) (NN muscle) (NNS relaxants)) (, ,) (NP (NP (JJ nondepolarizing)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN tubocurarine))) (-RRB- -RRB-)))) (: :) (NP (NP (JJ Possible) (VBN increased) (NN responsiveness)) (PP (TO to) (NP (DT the) (NN muscle) (NN relaxant)))) (. .)))))

Sentence Id: DrugDDI.d354.s15
-/CC Lithium/NN :/: Generally/RB should/MD not/RB be/VB given/VBN with/IN diuretics/NN ./.

(ROOT (S1 (S (S (NP (CC -) (NP (NN Lithium) (: :)) (ADVP (RB Generally))) (VP (MD should) (RB not) (VP (VB be) (VP (VBN given) (PP (IN with) (NP (NN diuretics))))))) (. .))))

Sentence Id: DrugDDI.d354.s16
Diuretic/JJ agents/NNS reduce/VBP the/DT renal/JJ clearance/NN of/IN lithium/NN and/CC add/VBP a/DT high/JJ risk/NN of/IN lithium/NN toxicity/NN ./.

(ROOT (S1 (S (S (NP (JJ Diuretic) (NNS agents)) (VP (VP (VBP reduce) (NP (NP (DT the) (JJ renal) (NN clearance)) (PP (IN of) (NP (NN lithium))))) (CC and) (VP (VBP add) (NP (NP (DT a) (JJ high) (NN risk)) (PP (IN of) (NP (NN lithium) (NN toxicity))))))) (. .))))

Sentence Id: DrugDDI.d354.s17
Refer/VBP to/TO the/DT package/JJ insert/NN for/IN lithium/NN preparation/NN s/NNS before/IN use/NN of/IN such/JJ preparations/NNS with/IN chlorothiazide/NN ./.

(ROOT (S1 (S (S (VP (VBP Refer) (PP (TO to) (NP (NP (DT the) (JJ package) (NN insert)) (PP (IN for) (NP (NP (NN lithium) (NN preparation) (NNS s)) (PP (IN before) (NP (NP (NN use)) (PP (IN of) (NP (NP (JJ such) (NNS preparations)) (PP (IN with) (NP (NN chlorothiazide))))))))))))) (. .))))

Sentence Id: DrugDDI.d354.s19
-/CC Non-steroidal/JJ Anti-inflammatory/JJ Drugs/NNS :/: In/IN some/DT patients/NNS ,/, the/DT administration/NN of/IN a/DT non-steroidal/JJ anti-inflammatory/JJ agent/NN can/MD reduce/VB the/DT diuretic/JJ ,/, natriuretic/JJ ,/, and/CC antihypertensive/JJ effects/NNS of/IN loop/NN ,/, potassium/NN -sparing/NN and/CC thiazide/NN diuretics/NNS ./.

(ROOT (S1 (S (NP (NP (CC -) (JJ Non-steroidal) (JJ Anti-inflammatory) (NNS Drugs)) (: :) (S (PP (IN In) (NP (DT some) (NNS patients))) (, ,) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (DT a) (JJ non-steroidal) (JJ anti-inflammatory) (NN agent)))) (VP (MD can) (VP (VB reduce) (NP (NP (DT the) (ADJP (ADJP (JJ diuretic)) (, ,) (ADJP (JJ natriuretic)) (, ,) (CC and) (ADJP (JJ antihypertensive))) (NNS effects)) (PP (IN of) (NP (NP (NN loop)) (, ,) (NP (NN potassium) (NN -sparing)) (CC and) (NP (NN thiazide) (NNS diuretics)))))))) (. .)))))

Sentence Id: DrugDDI.d354.s20
Therefore/RB ,/, when/WRB chlorothiazide/NN and/CC non-steroidal/JJ anti-inflammatory/JJ agents/NNS are/VBP used/VBN concomitantly/RB ,/, the/DT patient/NN should/MD be/VB observed/VBN closely/RB to/TO determine/VB if/IN the/DT desired/JJ effect/NN of/IN the/DT diuretic/NN is/VBZ obtained/VBN ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN chlorothiazide)) (CC and) (NP (JJ non-steroidal) (JJ anti-inflammatory) (NNS agents))) (VP (VBP are) (VP (VBN used) (ADVP (RB concomitantly)))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (NP (DT the) (JJ desired) (NN effect)) (PP (IN of) (NP (DT the) (NN diuretic)))) (VP (VBZ is) (VP (VBN obtained)))))))))))) (. .))))

Sentence Id: DrugDDI.d354.s22
-/CC Drug/NN /Laboratory/NN Test/NN Interactions/NNS :/: Thiazides/NNS should/MD be/VB discontinued/VBN before/IN carrying/VBG out/RP tests/NNS for/IN parathyroid/JJ function/NN ./.

(ROOT (S1 (S (NP (NP (CC -) (NN Drug) (NN /Laboratory) (NN Test) (NNS Interactions)) (: :) (S (NP (NNS Thiazides)) (VP (MD should) (VP (VB be) (VP (VBN discontinued) (PP (IN before) (S (VP (VBG carrying) (PRT (RP out)) (NP (NP (NNS tests)) (PP (IN for) (NP (JJ parathyroid) (NN function))))))))))) (. .)))))

Sentence Id: DrugDDI.d113.s0
Interactions/NNS for/IN vitamin/NN D/NN analogues/NNS (/-LRB- Vitamin/NN D2/NN ,/, Vitamin/NN D3/NN ,/, Calcitriol/NN ,/, and/CC Calcidiol/NN )/-RRB- :/: Cholestyramine/NN :/: Cholestyramine/NN has/VBZ been/VBN reported/VBN to/TO reduce/VB intestinal/JJ absorption/NN of/IN fat/JJ soluble/JJ vitamins/NNS ;/: ./.

(ROOT (S1 (S (NP (NP (NP (NNS Interactions)) (PP (IN for) (NP (NP (NN vitamin) (NN D) (NNS analogues)) (PRN (-LRB- -LRB-) (NP (NP (NN Vitamin) (NN D2)) (, ,) (NP (NN Vitamin) (NN D3)) (, ,) (NP (NN Calcitriol)) (, ,) (CC and) (NP (NN Calcidiol))) (-RRB- -RRB-))))) (: :) (NP (NP (NN Cholestyramine)) (: :) (S (NP (NN Cholestyramine)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB reduce) (NP (NP (JJ intestinal) (NN absorption)) (PP (IN of) (NP (JJ fat) (JJ soluble) (NNS vitamins))))))))))) (: ;)) (. .)))))

Sentence Id: DrugDDI.d113.s1
as/IN such/JJ it/PRP may/MD impair/VB intestinal/JJ absorption/NN of/IN any/DT of/IN vitamin/NN D/NN ./.

(ROOT (S1 (S (S (PP (IN as) (NP (JJ such))) (NP (PRP it)) (VP (MD may) (VP (VB impair) (NP (NP (JJ intestinal) (NN absorption)) (PP (IN of) (NP (NP (DT any)) (PP (IN of) (NP (NN vitamin) (NN D))))))))) (. .))))

Sentence Id: DrugDDI.d113.s2
Phenytoin/NN //: Phenobarbital/NN :/: The/DT coadministration/NN of/IN phenytoin/NN or/CC phenobarbital/NN will/MD not/RB affect/VB plasma/NN concentrations/NNS of/IN vitamin/NN D/NN ,/, but/CC may/MD reduce/VB endogenous/JJ plasma/NN levels/NNS of/IN calcitriol/NN /ergocalcitriol/NN by/IN accelerating/VBG metabolism/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Phenytoin)) (: /) (NP (NN Phenobarbital)) (: :) (NP (NP (DT The) (NN coadministration)) (PP (IN of) (NP (NP (NN phenytoin)) (CC or) (NP (NN phenobarbital)))))) (VP (MD will) (RB not) (VP (VB affect) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN vitamin) (NN D))))) (, ,) (CC but) (VP (MD may) (VP (VB reduce) (NP (NP (JJ endogenous) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN calcitriol) (NN /ergocalcitriol)))) (PP (IN by) (S (VP (VBG accelerating) (NP (NN metabolism))))))))) (. .))))

Sentence Id: DrugDDI.d113.s3
Since/IN blood/NN level/NN of/IN calcitriol/NN /ergocalcitriol/NN will/MD be/VB reduced/VBN ,/, higher/JJR doses/NNS of/IN Rocaltrol/NN may/MD be/VB necessary/JJ if/IN these/DT drugs/NNS are/VBP administered/VBN simultaneously/RB ./.

(ROOT (S1 (S (S (SBAR (IN Since) (S (NP (NP (NN blood) (NN level)) (PP (IN of) (NP (NN calcitriol) (NN /ergocalcitriol)))) (VP (MD will) (VP (VB be) (VP (VBN reduced)))))) (, ,) (NP (NP (JJR higher) (NNS doses)) (PP (IN of) (NP (NN Rocaltrol)))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary)) (SBAR (IN if) (S (NP (DT these) (NNS drugs)) (VP (VBP are) (VP (VBN administered) (ADVP (RB simultaneously))))))))) (. .))))

Sentence Id: DrugDDI.d113.s4
Thiazides/NNS :/: Thiazides/NNS are/VBP known/VBN to/TO induce/VB hypercalcemia/NN by/IN the/DT reduction/NN of/IN calcium/NN excretion/NN in/IN urine/NN ./.

(ROOT (S1 (S (NP (NP (NNS Thiazides)) (: :) (S (NP (NNS Thiazides)) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB induce) (NP (NN hypercalcemia)) (PP (IN by) (NP (NP (DT the) (NN reduction)) (PP (IN of) (NP (NN calcium) (NN excretion))) (PP (IN in) (NP (NN urine))))))))))) (. .)))))

Sentence Id: DrugDDI.d113.s5
Some/DT reports/NNS have/VBP shown/VBN that/IN the/DT concomitant/JJ administration/NN of/IN thiazides/NNS with/IN vitamin/NN D/NN causes/VBZ hypercalcemia/NN ./.

(ROOT (S1 (S (S (NP (DT Some) (NNS reports)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NNS thiazides))) (PP (IN with) (NP (NN vitamin) (NN D)))) (VP (VBZ causes) (NP (NN hypercalcemia)))))))) (. .))))

Sentence Id: DrugDDI.d113.s7
Digitalis/NN :/: Vitamin/NN D/NN dosage/NN must/MD be/VB determined/VBN with/IN care/NN in/IN patients/NNS undergoing/VBG treatment/NN with/IN digitalis/NN ,/, as/IN hypercalcemia/NN in/IN such/JJ patients/NNS may/MD precipitate/VB cardiac/JJ arrhythmias/NNS ./.

(ROOT (S1 (S (NP (NP (NN Digitalis)) (: :) (S (NP (NN Vitamin) (NN D) (NN dosage)) (VP (MD must) (VP (VB be) (VP (VBN determined) (PP (IN with) (NP (NP (NN care)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (NP (NN treatment)) (PP (IN with) (NP (NN digitalis))))))))) (, ,) (SBAR (IN as) (S (NP (NP (NN hypercalcemia)) (PP (IN in) (NP (JJ such) (NNS patients)))) (VP (MD may) (VP (VB precipitate) (NP (JJ cardiac) (NNS arrhythmias)))))))))) (. .)))))

Sentence Id: DrugDDI.d113.s8
Ketoconazole/NN :/: Ketoconazole/NN may/MD inhibit/VBP both/CC synthetic/JJ and/CC catabolic/JJ enzymes/NNS of/IN vitamin/NN D/NN ./.

(ROOT (S1 (S (NP (NP (NN Ketoconazole)) (: :) (S (NP (NN Ketoconazole)) (VP (MD may) (VP (VBP inhibit) (NP (NP (ADJP (CC both) (ADJP (JJ synthetic)) (CC and) (ADJP (JJ catabolic))) (NNS enzymes)) (PP (IN of) (NP (NN vitamin) (NN D))))))) (. .)))))

Sentence Id: DrugDDI.d113.s9
Reductions/NNS in/IN serum/NN endogenous/JJ vitamin/NN D/NN concentrations/NNS have/VBP been/VBN observed/VBN following/VBG the/DT administration/NN of/IN 300/CD mg/day/NN to/TO 1200/CD mg/day/NN ketoconazole/NN for/IN a/DT week/NN to/TO healthy/JJ men/NNS ./.

(ROOT (S1 (S (S (NP (NP (NNS Reductions)) (PP (IN in) (NP (NN serum) (NP (JJ endogenous) (NN vitamin) (NN D)) (NNS concentrations)))) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (CD 300) (NN mg/day))) (PP (TO to) (NP (NP (ADJP (CD 1200) (NN mg/day)) (NN ketoconazole)) (PP (IN for) (NP (NP (DT a) (NN week)) (PP (TO to) (NP (JJ healthy) (NNS men))))))))))))) (. .))))

Sentence Id: DrugDDI.d113.s10
However/RB ,/, in/FW vivo/FW drug/NN interaction/NN studies/NNS of/IN ketoconazole/NN with/IN vitamin/NN D/NN have/VBP not/RB been/VBN investigated/VBN ./.

(ROOT (S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (ADJP (FW in) (FW vivo)) (NN drug) (NN interaction) (NNS studies)) (PP (IN of) (NP (NN ketoconazole))) (PP (IN with) (NP (NN vitamin) (NN D)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN investigated))))) (. .))))

Sentence Id: DrugDDI.d113.s11
Corticosteroids/NNS :/: A/DT relationship/NN of/IN functional/JJ antagonism/NN exists/VBZ between/IN vitamin/NN D/NN analogues/NNS ,/, which/WDT promote/VBP calcium/NN absorption/NN ,/, and/CC corticosteroids/NNS ,/, which/WDT inhibit/VBP calcium/NN absorption/NN ./.

(ROOT (S1 (S (NP (NP (NNS Corticosteroids)) (: :) (S (NP (NP (DT A) (NN relationship)) (PP (IN of) (NP (JJ functional) (NN antagonism)))) (VP (VBZ exists) (PP (IN between) (NP (NP (NP (NP (NN vitamin) (NN D) (NNS analogues)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP promote) (NP (NN calcium) (NN absorption))))) (, ,)) (CC and) (NP (NNS corticosteroids))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP inhibit) (NP (NN calcium) (NN absorption))))))))) (. .)))))

Sentence Id: DrugDDI.d113.s12
Phosphate-Binding/JJ Agents/NNS :/: Since/IN vitamin/NN D/NN also/RB has/VBZ an/DT effect/NN on/IN phosphate/NN transport/NN in/IN the/DT intestine/NN ,/, kidneys/NN and/CC bones/NN ,/, the/DT dosage/NN of/IN phosphate-binding/JJ agents/NNS must/MD be/VB adjusted/VBN in/IN accordance/NN with/IN the/DT serum/NN phosphate/NN concentration/NN ./.

(ROOT (S1 (S (NP (NP (JJ Phosphate-Binding) (NNS Agents)) (: :) (S (SBAR (IN Since) (S (NP (NN vitamin) (NN D)) (ADVP (RB also)) (VP (VBZ has) (NP (NP (DT an) (NN effect)) (PP (IN on) (NP (NN phosphate) (NN transport)))) (PP (IN in) (NP (DT the) (NP (NP (NN intestine)) (, ,) (NP (NN kidneys)) (CC and) (NP (NN bones)))))))) (, ,) (NP (NP (DT the) (NN dosage)) (PP (IN of) (NP (JJ phosphate-binding) (NNS agents)))) (VP (MD must) (VP (VB be) (VP (VBN adjusted) (PP (IN in) (NP (NP (NN accordance)) (PP (IN with) (NP (DT the) (NN serum) (NN phosphate) (NN concentration))))))))) (. .)))))

Sentence Id: DrugDDI.d113.s13
Vitamin/NN D/NN :/: The/DT coadministration/NN of/IN any/DT of/IN the/DT vitamin/NN D/NN analogues/NNS should/MD be/VB avoided/VBN as/IN this/DT could/MD create/VB possible/JJ additive/JJ effects/NNS and/CC hypercalcemia/NN ./.

(ROOT (S1 (S (NP (NP (NN Vitamin) (NN D)) (: :) (S (NP (NP (DT The) (NN coadministration)) (PP (IN of) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (NN vitamin) (NN D) (NNS analogues)))))) (VP (MD should) (VP (VB be) (VP (VBN avoided) (SBAR (IN as) (S (NP (DT this)) (VP (MD could) (VP (VB create) (NP (NP (JJ possible) (JJ additive) (NNS effects)) (CC and) (NP (NN hypercalcemia))))))))))) (. .)))))

Sentence Id: DrugDDI.d113.s14
Calcium/NN Supplements/NNS :/: Uncontrolled/JJ intake/NN of/IN additional/JJ calcium-containing/JJ preparations/NNS should/MD be/VB avoided/VBN ./.

(ROOT (S1 (S (S (NP (NN Calcium) (NNS Supplements)) (: :) (NP (NP (JJ Uncontrolled) (NN intake)) (PP (IN of) (NP (JJ additional) (JJ calcium-containing) (NNS preparations)))) (VP (MD should) (VP (VB be) (VP (VBN avoided))))) (. .))))

Sentence Id: DrugDDI.d113.s15
Magnesium/NN :/: Magnesium-containing/JJ preparations/NNS (/-LRB- eg/FW ,/, antacids/NNS )/-RRB- may/MD cause/VB hypermagnesemia/NN and/CC should/MD therefore/RB not/RB be/VB taken/VBN during/IN therapy/NN with/IN vitamin/NN D/NN by/IN patients/NNS on/IN chronic/JJ renal/JJ dialysis/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Magnesium)) (: :) (NP (NP (JJ Magnesium-containing) (NNS preparations)) (PRN (-LRB- -LRB-) (PP (FW eg)) (, ,) (NP (NNS antacids)) (-RRB- -RRB-)))) (VP (VP (MD may) (VP (VB cause) (NP (NN hypermagnesemia)))) (CC and) (VP (MD should) (ADVP (RB therefore)) (RB not) (VP (VB be) (VP (VBN taken) (PP (IN during) (NP (NP (NN therapy)) (PP (IN with) (NP (NN vitamin) (NN D))))) (PP (IN by) (NP (NP (NNS patients)) (PP (IN on) (NP (JJ chronic) (JJ renal) (NN dialysis)))))))))) (. .))))

Sentence Id: DrugDDI.d462.s0
Elevated/JJ plasma/NN levels/NNS of/IN theophylline/NN have/VBP been/VBN reported/VBN with/IN concomitant/JJ use/NN of/IN some/DT quinolones/NNS ./.

(ROOT (S1 (S (S (NP (NP (JJ Elevated) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN theophylline)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (DT some) (NNS quinolones))))))))) (. .))))

Sentence Id: DrugDDI.d462.s1
There/EX have/VBP been/VBN reports/NNS of/IN theophylline/NN -related/JJ side-effects/NNS in/IN patients/NNS on/IN concomitant/JJ theophylline/NN -quinolone/NN therapy/NN ./.

(ROOT (S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (NNS reports)) (PP (IN of) (NP (NP (NN theophylline) (JJ -related) (NNS side-effects)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (JJ concomitant) (NN theophylline) (NN -quinolone) (NN therapy))))))))))) (. .))))

Sentence Id: DrugDDI.d462.s2
Therefore/RB ,/, monitoring/NN of/IN theophylline/NN plasma/NN levels/NNS should/MD be/VB considered/VBN and/CC dosage/NN of/IN theophylline/NN adjusted/VBN as/IN required/VBN ./.

(ROOT (S1 (S (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN monitoring)) (PP (IN of) (NP (NN theophylline) (NN plasma) (NNS levels)))) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (CC and) (S (NP (NP (NN dosage)) (PP (IN of) (NP (NN theophylline)))) (VP (VBN adjusted) (PP (IN as) (NP (VBN required)))))) (. .))))

Sentence Id: DrugDDI.d462.s3
Quinolones/NNS have/VBP also/RB been/VBN shown/VBN to/TO interfere/VB with/IN the/DT metabolism/NN of/IN caffeine/NN ./.

(ROOT (S1 (S (S (NP (NNS Quinolones)) (VP (VBP have) (ADVP (RB also)) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN caffeine)))))))))))) (. .))))

Sentence Id: DrugDDI.d462.s4
This/DT may/MD lead/VB to/TO reduced/VBN clearance/NN of/IN caffeine/NN and/CC a/DT prolongation/NN of/IN its/PRP$ plasma/NN half-life/NN ./.

(ROOT (S1 (S (S (NP (DT This)) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (NP (VBN reduced) (NN clearance)) (PP (IN of) (NP (NN caffeine)))) (CC and) (NP (NP (DT a) (NN prolongation)) (PP (IN of) (NP (PRP$ its) (NN plasma) (NN half-life))))))))) (. .))))

Sentence Id: DrugDDI.d462.s5
Although/IN this/DT interaction/NN has/VBZ not/RB been/VBN reported/VBN with/IN cinoxacin/NN ,/, caution/NN should/MD be/VB exercised/VBN when/WRB cinoxacin/NN is/VBZ given/VBN concomitantly/RB with/IN caffeine-containing/JJ products/NNS ./.

(ROOT (S1 (S (S (SBAR (IN Although) (S (NP (DT this) (NN interaction)) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NN cinoxacin)))))))) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (NP (NN cinoxacin)) (VP (VBZ is) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (JJ caffeine-containing) (NNS products))))))))))) (. .))))

Sentence Id: DrugDDI.d462.s6
Antacids/NNS or/CC sucralfate/NN substantially/RB interfere/VBP with/IN the/DT absorption/NN of/IN some/DT quinolones/NNS ,/, resulting/VBG in/IN low/JJ urine/NN levels/NNS ./.

(ROOT (S1 (S (S (NP (NP (NNS Antacids)) (CC or) (NP (NN sucralfate))) (ADVP (RB substantially)) (VP (VBP interfere) (PP (IN with) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (DT some) (NNS quinolones))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (JJ low) (NN urine) (NNS levels))))))) (. .))))

Sentence Id: DrugDDI.d462.s7
Also/RB ,/, concomitant/JJ administration/NN of/IN quinolones/NNS with/IN products/NNS containing/VBG iron/NN ,/, multivitamins/NN containing/NN zinc/NN ,/, or/CC Videx/NN (/-LRB- didanosine/NN )/-RRB- chewable//NN buffer/NN ed/NN tablets/NNS or/CC the/DT pediatric/JJ powder/NN for/IN oral/JJ solution/NN may/MD result/VB in/IN low/JJ urine/NN levels/NNS ./.

(ROOT (S1 (S (ADVP (RB Also)) (, ,) (NP (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NNS quinolones)) (PP (IN with) (NP (NP (NNS products)) (VP (VBG containing) (NP (NP (NN iron)) (, ,) (NP (NN multivitamins) (NN containing) (NN zinc)) (, ,) (CC or) (NP (NP (NN Videx)) (PRN (-LRB- -LRB-) (NP (NN didanosine)) (-RRB- -RRB-))) (NP (NN chewable/) (NN buffer) (NN ed) (NNS tablets))))))))) (CC or) (NP (NP (DT the) (JJ pediatric) (NN powder)) (PP (IN for) (NP (JJ oral) (NN solution))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (JJ low) (NN urine) (NNS levels))))) (. .))))

Sentence Id: DrugDDI.d462.s8
Quinolones/NNS ,/, including/VBG cinoxacin/NN ,/, may/MD enhance/VB the/DT effects/NNS of/IN oral/JJ anticoagulants/NNS ,/, such/JJ as/IN warfarin/NN or/CC its/PRP$ derivatives/NNS ./.

(ROOT (S1 (S (S (NP (NP (NNS Quinolones)) (, ,) (PP (VBG including) (NP (NN cinoxacin))) (, ,)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ oral) (NNS anticoagulants)))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN warfarin)) (CC or) (NP (PRP$ its) (NNS derivatives))))))) (. .))))

Sentence Id: DrugDDI.d462.s10
Seizures/NNS have/VBP been/VBN reported/VBN in/IN patients/NNS taking/VBG another/DT quinolone/NN class/NN antimicrobial/NN and/CC the/DT nonsteroidal/JJ anti-inflammatory/JJ drug/NN fenbufen/VBN concurrently/RB ./.

(ROOT (S1 (S (S (NP (NNS Seizures)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (DT another) (NP (NN quinolone) (NN class) (NN antimicrobial)) (CC and) (NP (DT the) (JJ nonsteroidal) (JJ anti-inflammatory) (NN drug))) (VP (VBN fenbufen) (ADVP (RB concurrently))))))))))) (. .))))

Sentence Id: DrugDDI.d462.s11
Animal/NN studies/NNS also/RB suggest/VBP an/DT increased/VBN potential/NN for/IN seizures/NNS when/WRB these/DT 2/CD drugs/NNS are/VBP given/VBN concomitantly/RB ./.

(ROOT (S1 (S (S (NP (NN Animal) (NNS studies)) (ADVP (RB also)) (VP (VBP suggest) (NP (NP (DT an) (VBN increased) (NN potential)) (PP (IN for) (NP (NNS seizures)))) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (CD 2) (NNS drugs)) (VP (VBP are) (VP (VBN given) (ADVP (RB concomitantly)))))))) (. .))))

Sentence Id: DrugDDI.d462.s12
Fenbufen/NN is/VBZ not/RB approved/JJ in/IN the/DT United/JJ States/NNS at/IN this/DT time/NN ./.

(ROOT (S1 (S (S (NP (NN Fenbufen)) (VP (VBZ is) (RB not) (ADJP (JJ approved)) (PP (IN in) (NP (DT the) (JJ United) (NNS States))) (PP (IN at) (NP (DT this) (NN time))))) (. .))))

Sentence Id: DrugDDI.d462.s13
Physicians/NNS are/VBP provided/VBN this/DT information/NN to/TO increase/VB awareness/NN of/IN the/DT potential/NN for/IN serious/JJ interactions/NNS when/WRB cinoxacin/NN and/CC certain/JJ nonsteroidal/JJ anti-inflammatory/JJ agents/NNS are/VBP administered/VBN concomitantly/RB ./.

(ROOT (S1 (S (S (NP (NNS Physicians)) (VP (VBP are) (VP (VBN provided) (NP (DT this) (NN information)) (S (VP (TO to) (VP (VB increase) (NP (NP (NN awareness)) (PP (IN of) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (JJ serious) (NNS interactions)))))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN cinoxacin)) (CC and) (NP (JJ certain) (JJ nonsteroidal) (JJ anti-inflammatory) (NNS agents))) (VP (VBP are) (VP (VBN administered) (ADVP (RB concomitantly)))))))))))) (. .))))

Sentence Id: DrugDDI.d462.s14
Elevated/JJ cyclosporine/NN serum/NN levels/NNS have/VBP been/VBN reported/VBN with/IN the/DT concomitant/JJ use/NN of/IN quinolones/NN and/CC cyclosporine/NN ./.

(ROOT (S1 (S (S (NP (JJ Elevated) (NN cyclosporine) (NN serum) (NNS levels)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NP (DT the) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN quinolones)) (CC and) (NP (NN cyclosporine)))))))))) (. .))))

Sentence Id: DrugDDI.d12.s0
Plasma/NN levels/NNS of/IN anticonvulsant/JJ agent/NN s/NNS may/MD become/VB subtherapeutic/JJ during/IN cisplatin/NN therapy/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Plasma) (NNS levels)) (PP (IN of) (NP (JJ anticonvulsant) (NN agent) (NNS s)))) (VP (MD may) (VP (VB become) (ADJP (JJ subtherapeutic)) (PP (IN during) (NP (NN cisplatin) (NN therapy)))))) (. .))))

Sentence Id: DrugDDI.d12.s1
In/IN a/DT randomized/JJ trial/NN in/IN advanced/JJ ovarian/JJ cancer/NN ,/, response/NN duration/NN was/VBD adversely/RB affected/VBN when/WRB pyridoxine/NN was/VBD used/VBN in/IN combination/NN with/IN altretamine/NN (/-LRB- hexamethylmelamine/NN )/-RRB- and/CC cisplatin/NN .1/NN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (NP (DT a) (JJ randomized) (NN trial)) (PP (IN in) (NP (JJ advanced) (JJ ovarian) (NN cancer))))) (, ,) (NP (NN response) (NN duration)) (VP (VBD was) (VP (ADVP (RB adversely)) (VBN affected) (SBAR (WHADVP (WRB when)) (S (NP (NN pyridoxine)) (VP (VBD was) (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NP (NN altretamine)) (PRN (-LRB- -LRB-) (NP (NN hexamethylmelamine)) (-RRB- -RRB-))) (CC and) (NP (NN cisplatin) (NN .1))))))))))))) (. .))))

Sentence Id: DrugDDI.d430.s0
Central/JJ nervous/JJ system/NN depressant/JJ (/-LRB- CNS/NN )/-RRB- drugs/NNS including/VBG alcohol/NN ,/, antidepressants/NNS ,/, antihistamines/NNS ,/, antipsychotics/NNS ,/, blood/NN pressure/NN medications/NNS (/-LRB- reserpine/NN ,/, methyldopa/NN ,/, beta-blockers/NN )/-RRB- ,/, motion/NN sickness/NN medications/NNS ,/, muscle/NN relaxants/NNS ,/, narcotics/NNS ,/, sedatives/NNS ,/, sleeping/JJ pills/NNS and/CC tranquilizers/NNS ./.

(ROOT (S1 (S (S (NP (NP (NP (JJ Central) (JJ nervous) (NN system) (JJ depressant)) (PRN (-LRB- -LRB-) (NP (NN CNS)) (-RRB- -RRB-))) (NNS drugs)) (VP (VBG including) (NP (NP (NN alcohol)) (, ,) (NP (NP (NNS antidepressants)) (, ,) (NP (NNS antihistamines)) (, ,) (NP (NNS antipsychotics)) (, ,) (NP (NP (NN blood) (NN pressure) (NNS medications)) (PRN (-LRB- -LRB-) (NP (NP (NN reserpine)) (, ,) (NP (NN methyldopa)) (, ,) (NP (NN beta-blockers))) (-RRB- -RRB-))) (, ,) (NP (NN motion) (NN sickness) (NNS medications)) (, ,) (NP (NN muscle) (NNS relaxants)) (, ,) (NP (NNS narcotics)) (, ,) (NP (NNS sedatives)) (, ,) (NP (JJ sleeping) (NNS pills)) (CC and) (NP (NNS tranquilizers)))))) (. .))))

Sentence Id: DrugDDI.d425.s0
Amantadine/NN ,/, tricyclic/JJ antidepressants/NNS ,/, and/CC MAOIs/NN may/MD increase/VB anticholinergic/JJ effect/NN of/IN clidinium/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Amantadine)) (, ,) (NP (JJ tricyclic) (NNS antidepressants)) (, ,) (CC and) (NP (NN MAOIs))) (VP (MD may) (VP (VB increase) (NP (NP (JJ anticholinergic) (NN effect)) (PP (IN of) (NP (NN clidinium))))))) (. .))))

Sentence Id: DrugDDI.d425.s1
Clidinium/NN may/MD decrease/VB the/DT effect/NN of/IN phenothiazines/NNS ,/, levodopa/NN ,/, and/CC ketoconazole/NN ./.

(ROOT (S1 (S (S (NP (NN Clidinium)) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NNS phenothiazines)) (, ,) (NP (NN levodopa)) (, ,) (CC and) (NP (NN ketoconazole)))))))) (. .))))

Sentence Id: DrugDDI.d40.s0
Clindamycin/NN has/VBZ been/VBN shown/VBN to/TO have/VBP neuromuscular/JJ blocking/NN properties/NNS that/WDT may/MD enhance/VB the/DT action/NN of/IN other/JJ neuromuscular/NN blocking/VBG agents/NNS ./.

(ROOT (S1 (S (S (NP (NN Clindamycin)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VBP have) (NP (NP (JJ neuromuscular) (NN blocking) (NNS properties)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (JJ other) (NN neuromuscular) (VBG blocking) (NNS agents)))))))))))))))) (. .))))

Sentence Id: DrugDDI.d40.s2
Antagonism/NN has/VBZ been/VBN demonstrated/VBN between/IN clindamycin/NN and/CC erythromycin/NN in/FW vitro/FW ./.

(ROOT (S1 (S (S (NP (NN Antagonism)) (VP (VBZ has) (VP (VBN been) (VP (VBN demonstrated) (PP (IN between) (NP (NP (NN clindamycin)) (CC and) (NP (NN erythromycin)))) (ADVP (FW in) (FW vitro)))))) (. .))))

Sentence Id: DrugDDI.d40.s3
Because/IN of/IN possible/JJ clinical/JJ significance/NN ,/, these/DT two/CD drugs/NNS should/MD not/RB be/VB administered/VBN concurrently/RB ./.

(ROOT (S1 (S (S (PP (IN Because) (PP (IN of) (NP (JJ possible) (JJ clinical) (NN significance)))) (, ,) (NP (DT these) (CD two) (NNS drugs)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (ADVP (RB concurrently)))))) (. .))))

Sentence Id: DrugDDI.d119.s0
Alcohol/NN (/-LRB- increases/VBZ bioavailability/NN by/IN 50/CD %/NN )/-RRB- ,/, cimetidine/NN ,/, and/CC valproates/NN ./.

(ROOT (S1 (S (S (NP (NP (NP (NN Alcohol)) (PRN (-LRB- -LRB-) (S (VP (VBZ increases) (NP (NN bioavailability)) (PP (IN by) (NP (CD 50) (NN %))))) (-RRB- -RRB-))) (, ,) (NP (NN cimetidine)) (, ,) (CC and) (NP (NN valproates)))) (. .))))

Sentence Id: DrugDDI.d118.s0
Although/IN no/DT clinical/JJ drug-drug/JJ interaction/NN studies/NNS have/VBP been/VBN conducted/VBN to/TO date/NN ,/, on/IN the/DT basis/NN of/IN the/DT in/FW vitro/FW studies/NNS ,/, cytochrome/NN p450/NN inhibitors/NNS and/CC inducers/NNS are/VBP unlikely/JJ to/TO affect/VB the/DT metabolism/NN of/IN clofarabine/NN ./.

(ROOT (S1 (S (S (SBAR (IN Although) (S (NP (DT no) (JJ clinical) (JJ drug-drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted) (PP (TO to) (NP (NN date)))))))) (, ,) (PP (IN on) (DT the) (NN basis) (IN of) (NP (DT the) (ADJP (FW in) (FW vitro)) (NNS studies))) (, ,) (NP (NP (NN cytochrome) (NN p450) (NNS inhibitors)) (CC and) (NP (NNS inducers))) (VP (VBP are) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VB affect) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN clofarabine)))))))))) (. .))))

Sentence Id: DrugDDI.d118.s1
The/DT effect/NN of/IN clofarabine/NN on/IN the/DT metabolism/NN of/IN cytochrome/NN p450/NN substrates/NNS has/VBZ not/RB been/VBN studied/VBN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN clofarabine))) (PP (IN on) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN cytochrome) (NN p450) (NNS substrates)))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .))))

Sentence Id: DrugDDI.d118.s2
Drug/NN /Laboratory/NN Tests/NNS Interactions/NNS :/: There/EX are/VBP no/RB known/VBN clinically/RB significant/JJ interactions/NNS of/IN CLOLAR/NN @/NN with/IN other/JJ medications/NNS or/CC laboratory/NN tests/NNS ./.

(ROOT (S1 (S (NP (NP (NN Drug) (NN /Laboratory) (NNS Tests) (NNS Interactions)) (: :) (S (NP (EX There)) (VP (VBP are) (ADVP (RB no)) (VP (VBN known) (NP (NP (ADJP (RB clinically) (JJ significant)) (NNS interactions)) (PP (IN of) (NP (NN CLOLAR) (NN @))) (PP (IN with) (NP (NP (JJ other) (NNS medications)) (CC or) (NP (NN laboratory) (NNS tests)))))))) (. .)))))

Sentence Id: DrugDDI.d118.s3
No/DT formal/JJ drug/NN /laboratory/NN test/NN interaction/NN studies/NNS have/VBP been/VBN conducted/VBN with/IN CLOLAR/JJ @/NN ./.

(ROOT (S1 (S (S (NP (DT No) (JJ formal) (NN drug) (NN /laboratory) (NN test) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted) (PP (IN with) (NP (JJ CLOLAR) (NN @))))))) (. .))))

Sentence Id: DrugDDI.d558.s0
Preliminary/JJ data/NNS which/WDT suggest/VBP that/IN dapsone/NN may/MD inhibit/VB the/DT anti-inflammatory/JJ activity/NN of/IN Lamprene/NN have/VBP not/RB been/VBN confirmed/VBN ./.

(ROOT (S1 (S (S (NP (NP (JJ Preliminary) (NNS data)) (SBAR (WHNP (WDT which)) (S (VP (VBP suggest) (SBAR (IN that) (S (NP (NN dapsone)) (VP (MD may) (VP (VB inhibit) (NP (NP (DT the) (JJ anti-inflammatory) (NN activity)) (PP (IN of) (NP (NN Lamprene)))))))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN confirmed))))) (. .))))

Sentence Id: DrugDDI.d558.s1
If/IN leprosy/NN -associated/JJ inflammatory/JJ reactions/NNS develop/VBP in/IN patients/NNS being/VBG treated/VBN with/IN dapsone/NN and/CC clofazimine/NN ,/, it/PRP is/VBZ still/RB advisable/JJ to/TO continue/VBP treatment/NN with/IN both/DT drugs/NNS ./.

(ROOT (S1 (S (S (SBAR (IN If) (S (NP (NN leprosy) (JJ -associated) (JJ inflammatory) (NNS reactions)) (VP (VBP develop) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (NP (NN dapsone)) (CC and) (NP (NN clofazimine))))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADVP (RB still)) (ADJP (JJ advisable) (S (VP (TO to) (VP (VBP continue) (NP (NP (NN treatment)) (PP (IN with) (NP (DT both) (NNS drugs)))))))))) (. .))))

Sentence Id: DrugDDI.d467.s0
Tablet/NN :/: If/IN a/DT patient/NN receiving/VBG clonidine/NN hydrochloride/NN is/VBZ also/RB taking/VBG tricyclic/JJ antidepressants/NNS ,/, the/DT effect/NN of/IN clonidine/NN may/MD be/VB reduced/VBN ,/, thus/RB necessitating/VBG an/DT increase/NN in/IN dosage/NN ./.

(ROOT (S1 (S (NP (NP (NN Tablet)) (: :) (S (SBAR (IN If) (S (NP (NP (DT a) (NN patient)) (VP (VBG receiving) (NP (NN clonidine) (NN hydrochloride)))) (VP (VBZ is) (ADVP (RB also)) (VP (VBG taking) (NP (JJ tricyclic) (NNS antidepressants)))))) (, ,) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN clonidine)))) (VP (MD may) (VP (VB be) (VP (VBN reduced))) (, ,) (S (ADVP (RB thus)) (VP (VBG necessitating) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN dosage)))))))) (. .)))))

Sentence Id: DrugDDI.d467.s1
Clonidine/NN hydrochloride/NN may/MD enhance/VB the/DT CNS-depressive/JJ effects/NNS of/IN alcohol/NN ,/, barbiturates/NNS or/CC other/JJ sedatives/NNS ./.

(ROOT (S1 (S (S (NP (NN Clonidine) (NN hydrochloride)) (VP (MD may) (VP (VB enhance) (NP (NP (NP (DT the) (JJ CNS-depressive) (NNS effects)) (PP (IN of) (NP (NN alcohol)))) (, ,) (NP (NP (NNS barbiturates)) (CC or) (NP (JJ other) (NNS sedatives))))))) (. .))))

Sentence Id: DrugDDI.d467.s2
Amitriptyline/NN in/IN combination/NN with/IN clonidine/NN enhances/VBZ the/DT manifestation/NN of/IN corneal/NN lesions/NNS in/IN rats/NNS Epidural/JJ Injection/NN Clonidine/NN may/MD potentiate/VB the/DT CNS-depressive/JJ effect/NN of/IN alcohol/NN ,/, barbiturates/NNS or/CC other/JJ sedating/JJ drugs/NNS ./.

(ROOT (S1 (S (S (S (NP (NP (NN Amitriptyline)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN clonidine)))))) (VP (VBZ enhances) (NP (NP (DT the) (NN manifestation)) (PP (IN of) (NP (NN corneal) (NNS lesions))) (PP (IN in) (NP (NNS rats)))))) (S (NP (NP (JJ Epidural) (NN Injection)) (NN Clonidine)) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (JJ CNS-depressive) (NN effect)) (PP (IN of) (NP (NP (NN alcohol)) (, ,) (NP (NNS barbiturates)) (CC or) (NP (JJ other) (JJ sedating) (NNS drugs))))))))) (. .))))

Sentence Id: DrugDDI.d467.s3
Narcotic/JJ analgesics/NNS may/MD potentiate/VB the/DT hypotensive/JJ effects/NNS of/IN clonidine/NN ./.

(ROOT (S1 (S (S (NP (JJ Narcotic) (NNS analgesics)) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (JJ hypotensive) (NNS effects)) (PP (IN of) (NP (NN clonidine))))))) (. .))))

Sentence Id: DrugDDI.d467.s4
Tricyclic/JJ antidepressants/NNS may/MD antagonize/VB the/DT hypotensive/JJ effects/NNS of/IN clonidine/NN ./.

(ROOT (S1 (S (S (NP (JJ Tricyclic) (NNS antidepressants)) (VP (MD may) (VP (VB antagonize) (NP (NP (DT the) (JJ hypotensive) (NNS effects)) (PP (IN of) (NP (NN clonidine))))))) (. .))))

Sentence Id: DrugDDI.d467.s5
The/DT effects/NNS of/IN tricyclic/JJ antidepressants/NNS on/IN clonidine/NN s/NN analgesic/JJ actions/NNS are/VBP not/RB known/VBN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (JJ tricyclic) (NNS antidepressants))) (PP (IN on) (NP (NN clonidine) (NN s) (JJ analgesic) (NNS actions)))) (VP (VBP are) (RB not) (VP (VBN known)))) (. .))))

Sentence Id: DrugDDI.d467.s6
Beta/NN blockers/NNS may/MD exacerbate/VB the/DT hypertensive/JJ response/NN seen/VBN with/IN clonidine/NN withdrawl/NN ./.

(ROOT (S1 (S (S (NP (NN Beta) (NNS blockers)) (VP (MD may) (VP (VB exacerbate) (NP (NP (DT the) (JJ hypertensive) (NN response)) (VP (VBN seen) (PP (IN with) (NP (NN clonidine) (NN withdrawl)))))))) (. .))))

Sentence Id: DrugDDI.d467.s7
Also/RB ,/, due/JJ to/TO the/DT potential/NN for/IN additive/JJ effects/NNS such/JJ as/IN bradycardia/NN and/CC AV/NN block/NN ,/, caution/NN is/VBZ warranted/VBN in/IN patients/NNS receiving/VBG clonidine/NN with/IN agents/NNS known/VBN to/TO affect/VB sinus/NN node/NN function/NN or/CC AV/NN nodal/JJ conduction/NN (/-LRB- e.g./FW ,/, digitalis/NN ,/, calcium/NN channel/NN blockers/NNS ,/, and/CC beta-blockers/NNS ./. )/-RRB- ./.

(ROOT (S1 (S (ADVP (RB Also)) (, ,) (PP (JJ due) (TO to) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NP (JJ additive) (NNS effects)) (PP (JJ such) (IN as) (NP (NP (NN bradycardia)) (CC and) (NP (NN AV) (NN block)))))))) (, ,) (NP (NN caution)) (VP (VBZ is) (VP (VBN warranted) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN clonidine)) (PP (IN with) (NP (NP (NNS agents)) (VP (VBN known) (S (VP (TO to) (VP (VB affect) (NP (NP (NP (NN sinus) (NN node)) (NN function)) (CC or) (NP (NP (NN AV) (JJ nodal) (NN conduction)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN digitalis)) (, ,) (NP (NN calcium) (NN channel) (NNS blockers)) (, ,) (CC and) (NP (NNS beta-blockers)) (. .))) (-RRB- -RRB-)))))))))))))))) (. .))))

Sentence Id: DrugDDI.d467.s8
There/EX is/VBZ one/CD reported/VBN case/NN of/IN a/DT patient/NN with/IN acute/JJ delirium/NN associated/VBN with/IN the/DT simultaneous/JJ use/NN of/IN fluphenazine/NN and/CC oral/JJ clonidine/NN ./.

(ROOT (S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (NP (CD one) (VBN reported) (NN case)) (PP (IN of) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (JJ acute) (NN delirium)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (JJ simultaneous) (NN use)) (PP (IN of) (NP (NP (NN fluphenazine)) (CC and) (NP (JJ oral) (NN clonidine)))))))))))))) (. .))))

Sentence Id: DrugDDI.d467.s9
Symptoms/NNS resolved/VBN when/WRB clonidine/NN was/VBD withdrawn/VBN and/CC recurred/VBN when/WRB the/DT patient/NN was/VBD rechallenged/VBN with/IN clonidine/NN ./.

(ROOT (S1 (S (S (NP (NNS Symptoms)) (VP (VP (VBN resolved) (SBAR (WHADVP (WRB when)) (S (NP (NN clonidine)) (VP (VBD was) (VP (VBN withdrawn)))))) (CC and) (VP (VBN recurred) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN patient)) (VP (VBD was) (VP (VBN rechallenged) (PP (IN with) (NP (NN clonidine)))))))))) (. .))))

Sentence Id: DrugDDI.d467.s10
Epidural/JJ clonidine/NN may/MD prolong/VB the/DT duration/NN of/IN pharmacologic/JJ effects/NNS of/IN epidural/JJ local/JJ anesthetics/NN ,/, including/VBG both/CC sensory/NN and/CC motor/NN blockade/NN ./.

(ROOT (S1 (S (S (NP (JJ Epidural) (NN clonidine)) (VP (MD may) (VP (VB prolong) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (JJ pharmacologic) (NNS effects)) (PP (IN of) (NP (JJ epidural) (JJ local) (NN anesthetics))) (, ,) (PP (VBG including) (NP (CC both) (NP (NN sensory)) (CC and) (NP (NN motor)) (NP (NN blockade)))))))))) (. .))))

Sentence Id: DrugDDI.d474.s0
Colchicine/NN is/VBZ inhibited/VBN by/IN acidifying/JJ agents/NNS ./.

(ROOT (S1 (S (S (NP (NN Colchicine)) (VP (VBZ is) (VP (VBN inhibited) (PP (IN by) (NP (JJ acidifying) (NNS agents)))))) (. .))))

Sentence Id: DrugDDI.d474.s1
The/DT action/NN of/IN colchicine/NN is/VBZ potentiated/VBN by/IN alkalinizing/NN agents/NNS ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN action)) (PP (IN of) (NP (NN colchicine)))) (VP (VBZ is) (VP (VBN potentiated) (PP (IN by) (NP (NN alkalinizing) (NNS agents)))))) (. .))))

Sentence Id: DrugDDI.d474.s2
Colchicine/NN may/MD increase/VB sensitivity/NN to/TO the/DT CNS/NN depressants/NNS ./.

(ROOT (S1 (S (S (NP (NN Colchicine)) (VP (MD may) (VP (VB increase) (NP (NP (NN sensitivity)) (PP (TO to) (NP (DT the) (NN CNS) (NNS depressants))))))) (. .))))

Sentence Id: DrugDDI.d474.s3
Response/NN to/TO sympathomimetic/JJ agents/NNS may/MD be/VB enhanced/VBN by/IN colchicine/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Response)) (PP (TO to) (NP (JJ sympathomimetic) (NNS agents)))) (VP (MD may) (VP (VB be) (VP (VBN enhanced) (PP (IN by) (NP (NN colchicine))))))) (. .))))

Sentence Id: DrugDDI.d469.s0
Corticotropin/NN may/MD accentuate/VB the/DT electrolyte/NN loss/NN associated/VBN with/IN diuretic/JJ therapy/NN ./.

(ROOT (S1 (S (S (NP (NN Corticotropin)) (VP (MD may) (VP (VB accentuate) (NP (NP (DT the) (NN electrolyte) (NN loss)) (VP (VBN associated) (PP (IN with) (NP (JJ diuretic) (NN therapy)))))))) (. .))))

Sentence Id: DrugDDI.d191.s1
Drugs/NNS that/WDT induce/VBP hepatic/JJ enzymes/NNS such/JJ as/IN phenobarbital/NN ,/, phenytoin/NN and/CC rifampin/NN may/MD increase/VB the/DT clearance/NN of/IN corticosteroids/NNS and/CC may/MD require/VB increases/NNS in/IN corticosteroid/NN dose/NN to/TO achieve/VB the/DT desired/JJ response/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP induce) (NP (NP (JJ hepatic) (NNS enzymes)) (PP (JJ such) (IN as) (NP (NP (NN phenobarbital)) (, ,) (NP (NN phenytoin)) (CC and) (NP (NN rifampin))))))))) (VP (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NNS corticosteroids)))))) (CC and) (VP (MD may) (VP (VB require) (NP (NP (NNS increases)) (PP (IN in) (NP (NN corticosteroid) (NN dose)))) (S (VP (TO to) (VP (VB achieve) (NP (DT the) (JJ desired) (NN response))))))))) (. .))))

Sentence Id: DrugDDI.d191.s2
Drugs/NNS such/JJ as/IN troleandomycin/NN and/CC ketoconazole/NN may/MD inhibit/VB the/DT metabolism/NN of/IN corticosteroids/NNS and/CC thus/RB decrease/VB their/PRP$ clearance/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Drugs)) (PP (JJ such) (IN as) (NP (NP (NN troleandomycin)) (CC and) (NP (NN ketoconazole))))) (VP (MD may) (VP (VP (VB inhibit) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NNS corticosteroids))))) (CC and) (ADVP (RB thus)) (VP (VB decrease) (NP (PRP$ their) (NN clearance)))))) (. .))))

Sentence Id: DrugDDI.d191.s3
Therefore/RB ,/, the/DT dose/NN of/IN corticosteroid/NN should/MD be/VB titrated/VBN to/TO avoid/VB steroid/NN toxicity/NN ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN corticosteroid)))) (VP (MD should) (VP (VB be) (VP (VBN titrated) (S (VP (TO to) (VP (VB avoid) (NP (NN steroid) (NN toxicity))))))))) (. .))))

Sentence Id: DrugDDI.d191.s4
Corticosteroids/NNS may/MD increase/VB the/DT clearance/NN of/IN chronic/JJ high/JJ dose/NN aspirin/NN ./.

(ROOT (S1 (S (S (NP (NNS Corticosteroids)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (JJ chronic) (JJ high) (NN dose) (NN aspirin))))))) (. .))))

Sentence Id: DrugDDI.d191.s5
This/DT could/MD lead/VB to/TO decreased/VBN salicylate/NN serum/NN levels/NNS or/CC increase/VBP the/DT risk/NN of/IN salicylate/NN toxicity/NN when/WRB corticosteroid/NN is/VBZ withdrawn/VBN ./.

(ROOT (S1 (S (S (NP (DT This)) (VP (VP (MD could) (VP (VB lead) (PP (TO to) (NP (VBN decreased) (NN salicylate) (NN serum) (NNS levels))))) (CC or) (VP (VBP increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN salicylate) (NN toxicity)))) (SBAR (WHADVP (WRB when)) (S (NP (NN corticosteroid)) (VP (VBZ is) (VP (VBN withdrawn)))))))) (. .))))

Sentence Id: DrugDDI.d191.s6
Aspirin/NN should/MD be/VB used/VBN cautiously/RB in/IN conjunction/NN with/IN cortico-steroids/NNS in/IN patients/NNS suffering/VBG from/IN hypopro-thrombinemia/NN ./.

(ROOT (S1 (S (S (NP (NN Aspirin)) (VP (MD should) (VP (VB be) (VP (VBN used) (ADVP (RB cautiously)) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (NNS cortico-steroids)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG suffering) (PP (IN from) (NP (NN hypopro-thrombinemia)))))))))))))) (. .))))

Sentence Id: DrugDDI.d191.s7
The/DT effect/NN of/IN corticosteroids/NNS on/IN oral/JJ anticoagulants/NNS is/VBZ variable/NN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NNS corticosteroids))) (PP (IN on) (NP (JJ oral) (NNS anticoagulants)))) (VP (VBZ is) (NP (NN variable)))) (. .))))

Sentence Id: DrugDDI.d191.s8
There/EX are/VBP reports/NNS of/IN enhanced/VBN as/RB well/RB as/IN diminished/VBN effects/NNS of/IN anticoagulants/NNS when/WRB given/VBN concurrently/RB with/IN corticosteroids/NNS ./.

(ROOT (S1 (S (S (NP (EX There)) (VP (VBP are) (NP (NP (NNS reports)) (PP (IN of) (NP (NP (VBN enhanced)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (VBN diminished) (NNS effects)) (PP (IN of) (NP (NNS anticoagulants))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (ADVP (RB concurrently)) (PP (IN with) (NP (NNS corticosteroids)))))))) (. .))))

Sentence Id: DrugDDI.d25.s0
Drug/NN Interaction/NN During/IN Pregnancy/NN :/: Cromolyn/NN sodium/NN and/CC isoproterenol/NN were/VBD studied/VBN following/VBG subcutaneous/JJ injections/NNS in/IN pregnant/JJ mice/NNS ./.

(ROOT (S1 (S (S (NP (NP (NN Drug) (NN Interaction)) (PP (IN During) (NP (NN Pregnancy)))) (: :) (NP (NN Cromolyn) (NP (NP (NN sodium)) (CC and) (NP (NN isoproterenol)))) (VP (VBD were) (VP (VBN studied) (PP (VBG following) (NP (NP (JJ subcutaneous) (NNS injections)) (PP (IN in) (NP (JJ pregnant) (NNS mice)))))))) (. .))))

Sentence Id: DrugDDI.d25.s1
Cromolyn/NN sodium/NN alone/RB in/IN doses/NNS up/RB to/TO 540/CD mg/kg/day/NN (/-LRB- approximately/RB 340/CD times/NNS the/DT maximum/JJ recommended/VBN daily/JJ inhalation/NN dose/NN in/IN adults/NNS on/IN a/DT mg/m2/JJ basis/NN )/-RRB- did/VBD not/RB cause/VB significant/JJ increases/NNS in/IN resorptions/NNS or/CC major/JJ malformations/NNS ./.

(ROOT (S1 (S (S (NP (NP (NP (NN Cromolyn) (NN sodium)) (ADVP (RB alone))) (PP (IN in) (NP (NP (NNS doses)) (NP (NP (QP (RB up) (TO to) (CD 540)) (NN mg/kg/day)) (-LRB- -LRB-) (NP (QP (RB approximately) (CD 340) (NNS times)) (NP (NP (DT the) (JJ maximum) (VBN recommended) (JJ daily) (NN inhalation) (NN dose)) (PP (IN in) (NP (NP (NNS adults)) (PP (IN on) (NP (DT a) (JJ mg/m2) (NN basis))))))) (-RRB- -RRB-))))) (VP (VBD did) (RB not) (VP (VB cause) (NP (NP (JJ significant) (NNS increases)) (PP (IN in) (NP (NP (NNS resorptions)) (CC or) (NP (JJ major) (NNS malformations)))))))) (. .))))

Sentence Id: DrugDDI.d25.s2
Isoproterenol/NN alone/RB at/IN a/DT dose/NN of/IN 2.7/CD mg/kg/day/NN (/-LRB- approximately/RB 7/CD times/NNS the/DT maximum/JJ recommended/VBN daily/JJ inhalation/NN dose/NN in/IN adults/NNS on/IN a/DT mg/m2/JJ basis/NN )/-RRB- increased/VBD both/CC resorptions/NNS and/CC malformations/NNS ./.

(ROOT (S1 (S (S (NP (NP (NN Isoproterenol)) (ADVP (RB alone)) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (NP (CD 2.7) (NN mg/kg/day)) (-LRB- -LRB-) (NP (QP (RB approximately) (CD 7) (NNS times)) (NP (NP (DT the) (JJ maximum) (VBN recommended) (JJ daily) (NN inhalation) (NN dose)) (PP (IN in) (NP (NNS adults))))) (PP (IN on) (NP (DT a) (JJ mg/m2) (NN basis))) (-RRB- -RRB-)))))) (VP (VBD increased) (NP (CC both) (NP (NNS resorptions)) (CC and) (NP (NNS malformations))))) (. .))))

Sentence Id: DrugDDI.d25.s3
The/DT addition/NN of/IN 540/CD mg/kg/day/NN of/IN cromolyn/NN sodium/NN (/-LRB- approximately/RB 340/CD times/NNS the/DT maximum/JJ recommended/VBN daily/JJ inhalation/NN dose/NN in/IN adults/NNS on/IN a/DT mg/m2/NN basis/NN )/-RRB- to/TO 2.7/CD mg/kg/day/NN of/IN isoproterenol/NN (/-LRB- approximately/RB 7/CD times/NNS the/DT maximum/JJ recommended/VBN daily/JJ inhalation/NN dose/NN in/IN adults/NNS on/IN a/DT mg/m2/NN basis/NN )/-RRB- appears/VBZ to/TO have/VB increased/VBD the/DT incidence/NN of/IN both/CC resorptions/NNS and/CC malformations/NNS ./.

(ROOT (S1 (S (NP (NP (DT The) (NN addition)) (PP (IN of) (NP (NP (NP (CD 540) (NN mg/kg/day)) (PP (IN of) (NP (NN cromolyn) (NN sodium)))) (-LRB- -LRB-) (NP (QP (RB approximately) (CD 340) (NNS times)) (NP (NP (NP (DT the) (JJ maximum) (VBN recommended) (JJ daily) (NN inhalation) (NN dose)) (PP (IN in) (NP (NNS adults)))) (PP (IN on) (NP (DT a) (NN mg/m2) (NN basis))))) (-RRB- -RRB-))) (PP (TO to) (NP (NP (NP (CD 2.7) (NN mg/kg/day)) (PP (IN of) (NP (NN isoproterenol)))) (-LRB- -LRB-) (NP (QP (RB approximately) (CD 7) (NNS times)) (NP (NP (NP (DT the) (JJ maximum) (VBN recommended) (JJ daily) (NN inhalation) (NN dose)) (PP (IN in) (NP (NNS adults)))) (PP (IN on) (NP (DT a) (NN mg/m2) (NN basis))))) (-RRB- -RRB-)))) (VP (VBZ appears) (S (VP (TO to) (VP (VB have) (VP (VBD increased) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (CC both) (NP (NNS resorptions)) (CC and) (NP (NNS malformations)))))))))) (. .))))

Sentence Id: DrugDDI.d230.s0
May/MD interact/VB with/IN wthionamide/NN (/-LRB- Trecator-SC/NN )/-RRB- and/CC isoniazid/NN (/-LRB- Nydrazid/NN )/-RRB- ./.

(ROOT (S1 (S (S (VP (MD May) (VP (VB interact) (PP (IN with) (NP (NP (NP (NN wthionamide)) (PRN (-LRB- -LRB-) (NP (NN Trecator-SC)) (-RRB- -RRB-))) (CC and) (NP (NP (NN isoniazid)) (PRN (-LRB- -LRB-) (NP (NN Nydrazid)) (-RRB- -RRB-)))))))) (. .))))

Sentence Id: DrugDDI.d168.s0
Warfarin/JJ Concomitant/JJ administration/NN of/IN daptomycin/NN (/-LRB- 6/CD mg/kg/NN once/RB every/DT 24/CD hours/NNS for/IN 5/CD days/NNS )/-RRB- and/CC warfarin/NN (/-LRB- 25/CD mg/NN single/JJ oral/JJ dose/NN )/-RRB- had/VBD no/DT significant/JJ effect/NN on/IN the/DT pharmacokinetics/NNS of/IN either/DT drug/NN ,/, and/CC the/DT INR/NN was/VBD not/RB significantly/RB altered/VBN ./.

(ROOT (S1 (S (S (S (NP (NP (JJ Warfarin) (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NP (NN daptomycin)) (PRN (-LRB- -LRB-) (NP (CD 6) (NN mg/kg) (RB once) (NP (DT every) (CD 24) (NNS hours)) (PP (IN for) (NP (CD 5) (NNS days)))) (-RRB- -RRB-))) (CC and) (NP (NP (NN warfarin)) (PRN (-LRB- -LRB-) (NP (CD 25) (NN mg) (JJ single) (JJ oral) (NN dose)) (-RRB- -RRB-)))))) (VP (VBD had) (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (DT either) (NN drug))))))) (, ,) (CC and) (S (NP (DT the) (NN INR)) (VP (VBD was) (RB not) (ADVP (RB significantly)) (VP (VBN altered))))) (. .))))

Sentence Id: DrugDDI.d168.s1
As/IN experience/VBP with/IN the/DT concomitant/JJ administration/NN of/IN daptomycin/NN and/CC warfarin/NN is/VBZ limited/JJ to/TO volunteer/NN studies/NNS ,/, anticoagulant/JJ activity/NN in/IN patients/NNS receiving/VBG daptomycin/NN and/CC warfarin/NN should/MD be/VB monitored/VBN for/IN the/DT first/JJ several/JJ days/NNS after/IN initiating/VBG therapy/NN with/IN Fentanyl/NN ./.

(ROOT (S1 (S (SBAR (IN As) (S (NP (NP (VBP experience)) (PP (IN with) (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN daptomycin)) (CC and) (NP (NN warfarin))))))) (VP (VBZ is) (ADJP (JJ limited) (PP (TO to) (NP (NN volunteer) (NNS studies))))))) (, ,) (NP (NP (JJ anticoagulant) (NN activity)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN daptomycin)) (CC and) (NP (NN warfarin))))))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (PP (IN for) (NP (NP (DT the) (JJ first) (JJ several) (NNS days)) (PP (IN after) (S (VP (VBG initiating) (NP (NP (NN therapy)) (PP (IN with) (NP (NN Fentanyl)))))))))))) (. .))))

Sentence Id: DrugDDI.d168.s2
HMG-CoA/NN Reductase/NN Inhibitors/NNS Inhibitors/NNS of/IN HMG-CoA/NN reductase/NN may/MD cause/VB myopathy/NN ,/, which/WDT is/VBZ manifested/VBN as/IN muscle/NN pain/NN or/CC weakness/NN associated/VBN with/IN elevated/JJ levels/NNS of/IN CPK/NN ./.

(ROOT (S1 (S (S (NP (NP (NP (NN HMG-CoA) (NN Reductase) (NNS Inhibitors)) (NNS Inhibitors)) (PP (IN of) (NP (NN HMG-CoA) (NN reductase)))) (VP (MD may) (VP (VB cause) (NP (NP (NN myopathy)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN manifested) (PP (IN as) (NP (NP (NP (NN muscle) (NN pain)) (CC or) (NP (NN weakness))) (VP (VBN associated) (PP (IN with) (NP (NP (JJ elevated) (NNS levels)) (PP (IN of) (NP (NN CPK)))))))))))))))) (. .))))

Sentence Id: DrugDDI.d168.s3
There/EX were/VBD no/DT reports/NNS of/IN skeletal/JJ myopathy/NN in/IN a/DT placebo-controlled/JJ Phase/NN :/: I/NN trial/NN in/IN which/WDT 10/CD healthy/JJ subjects/NNS on/IN stable/JJ simvastatin/NN therapy/NN were/VBD treated/VBN concurrently/RB with/IN daptomycin/NN (/-LRB- 4/CD mg/kg/NN once/RB every/DT 24/CD hours/NNS )/-RRB- for/IN 14/CD days/NNS ./.

(ROOT (S1 (S (S (NP (EX There)) (VP (VBD were) (NP (NP (DT no) (NNS reports)) (PP (IN of) (NP (JJ skeletal) (NN myopathy)))) (PP (IN in) (NP (NP (DT a) (JJ placebo-controlled) (NN Phase) (: :) (NN I) (NN trial)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (CD 10) (JJ healthy) (NNS subjects)) (PP (IN on) (NP (JJ stable) (NN simvastatin) (NN therapy)))) (VP (VBD were) (VP (VBN treated) (ADVP (RB concurrently)) (PP (IN with) (NP (NP (NN daptomycin)) (PRN (-LRB- -LRB-) (NP (CD 4) (NN mg/kg) (RB once) (NP (DT every) (CD 24) (NNS hours))) (-RRB- -RRB-)))) (PP (IN for) (NP (CD 14) (NNS days))))))))))) (. .))))

Sentence Id: DrugDDI.d168.s4
Experience/VBP with/IN co-administration/NN of/IN HMG-CoA/NN reduc-tase/NN inhibitors/NNS and/CC Fentanyl/NN in/IN patients/NNS is/VBZ limited/VBN ,/, therefore/RB ,/, consideration/NN should/MD be/VB given/VBN to/TO temporarily/RB suspending/JJ use/NN of/IN HMG-CoA/NN reductase/NN inhibitors/NNS in/IN patients/NNS receiving/VBG Fentanyl/NN ./.

(ROOT (S1 (S (S (VP (VBP Experience) (SBAR (IN with) (S (NP (NP (NN co-administration)) (PP (IN of) (NP (NP (NN HMG-CoA) (NN reduc-tase) (NNS inhibitors)) (CC and) (NP (NN Fentanyl)))) (PP (IN in) (NP (NNS patients)))) (VP (VBZ is) (VP (VBN limited))))) (, ,) (S (ADVP (RB therefore)) (, ,) (NP (NN consideration)) (VP (MD should) (VP (VB be) (VP (VBN given) (PP (TO to) (NP (NP (ADJP (RB temporarily) (JJ suspending)) (NN use)) (PP (IN of) (NP (NN HMG-CoA) (NN reductase) (NNS inhibitors))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN Fentanyl))))))))))))) (. .))))

Sentence Id: DrugDDI.d51.s0
Use/NN of/IN Cerubidine/NN in/IN a/DT patient/NN who/WP has/VBZ previously/RB received/VBN doxorubicin/NN increases/VBZ the/DT risk/NN of/IN cardiotoxicity/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Use)) (PP (IN of) (NP (NN Cerubidine))) (PP (IN in) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBZ has) (ADVP (RB previously)) (VP (VBN received) (NP (NN doxorubicin))))))))) (VP (VBZ increases) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN cardiotoxicity)))))) (. .))))

Sentence Id: DrugDDI.d51.s1
Cerubidine/NN should/MD not/RB be/VB used/VBN in/IN patients/NNS who/WP have/VBP previously/RB received/VBN the/DT recommended/VBN maximum/JJ cumulative/JJ doses/NNS of/IN doxorubicin/NN or/CC Cerubidine/NN ./.

(ROOT (S1 (S (S (NP (NN Cerubidine)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP have) (ADVP (RB previously)) (VP (VBN received) (NP (NP (DT the) (VBN recommended) (JJ maximum) (JJ cumulative) (NNS doses)) (PP (IN of) (NP (NP (NN doxorubicin)) (CC or) (NP (NN Cerubidine))))))))))))))) (. .))))

Sentence Id: DrugDDI.d51.s2
Cyclophosphamide/NN used/VBN concurrently/RB with/IN Cerubidine/NN may/MD also/RB result/VB in/IN increased/VBN cardiotoxicity/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Cyclophosphamide)) (VP (VBN used) (ADVP (RB concurrently)) (PP (IN with) (NP (NN Cerubidine))))) (VP (MD may) (ADVP (RB also)) (VP (VB result) (PP (IN in) (NP (VBN increased) (NN cardiotoxicity)))))) (. .))))

Sentence Id: DrugDDI.d51.s3
Dosage/JJ reduction/NN of/IN Cerubidine/NN may/MD be/VB required/VBN when/WRB used/VBN concurrently/RB with/IN other/JJ myelosuppressive/JJ agents/NNS ./.

(ROOT (S1 (S (S (NP (NP (JJ Dosage) (NN reduction)) (PP (IN of) (NP (NN Cerubidine)))) (VP (MD may) (VP (VB be) (VP (VBN required) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (ADVP (RB concurrently)) (PP (IN with) (NP (JJ other) (JJ myelosuppressive) (NNS agents)))))))))) (. .))))

Sentence Id: DrugDDI.d51.s4
Hepatotoxic/JJ medications/NNS ,/, such/JJ as/IN high-dose/JJ methotrexate/NN ,/, may/MD impair/VB liver/NN function/NN and/CC increase/VB the/DT risk/NN of/IN toxicity/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Hepatotoxic) (NNS medications)) (, ,) (PP (JJ such) (IN as) (NP (JJ high-dose) (NN methotrexate))) (, ,)) (VP (MD may) (VP (VP (VB impair) (NP (NN liver) (NN function))) (CC and) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN toxicity)))))))) (. .))))

Sentence Id: DrugDDI.d157.s0
Drug/NN interaction/NN studies/NNS with/IN decitabine/NN have/VBP not/RB been/VBN conducted/VBN ./.

(ROOT (S1 (S (S (NP (NP (NN Drug) (NN interaction) (NNS studies)) (PP (IN with) (NP (NN decitabine)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN conducted))))) (. .))))

Sentence Id: DrugDDI.d157.s1
In/FW vitro/FW studies/NNS in/IN human/JJ liver/NN microsomes/NNS suggest/VBP that/IN decitabine/NN is/VBZ unlikely/JJ to/TO inhibit/VB or/CC induce/VB cytochrome/NN P450/NN enzymes/NNS ./.

(ROOT (S1 (S (S (NP (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (PP (IN in) (NP (JJ human) (NN liver) (NNS microsomes)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN decitabine)) (VP (VBZ is) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VP (VB inhibit)) (CC or) (VP (VB induce) (NP (NN cytochrome) (NN P450) (NNS enzymes)))))))))))) (. .))))

Sentence Id: DrugDDI.d157.s2
In/FW vitro/FW metabolism/NN studies/NNS have/VBP suggested/VBN that/IN decitabine/NN is/VBZ not/RB a/DT substrate/NN for/IN the/DT human/JJ liver/NN cytochrome/NN P450/NN enzyme/NN s/NN ./.

(ROOT (S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NN metabolism) (NNS studies)) (VP (VBP have) (VP (VBN suggested) (SBAR (IN that) (S (NP (NN decitabine)) (VP (VBZ is) (RB not) (NP (NP (DT a) (NN substrate)) (PP (IN for) (NP (DT the) (NP (JJ human) (NN liver) (NN cytochrome) (NN P450)) (NN enzyme) (NN s)))))))))) (. .))))

Sentence Id: DrugDDI.d157.s3
As/IN plasma/NN protein/NN binding/NN of/IN decitabine/NN is/VBZ negligible/JJ (/-LRB- 1/CD %/NN )/-RRB- ,/, interactions/NNS due/JJ to/TO displacement/NN of/IN more/RBR highly/RB protein/NN bound/JJ drugs/NNS from/IN plasma/NN proteins/NNS are/VBP not/RB expected/VBN ./.

(ROOT (S1 (S (S (SBAR (IN As) (S (NP (NP (NN plasma) (NN protein) (NN binding)) (PP (IN of) (NP (NN decitabine)))) (VP (VBZ is) (ADJP (ADJP (JJ negligible)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN %)) (-RRB- -RRB-)))))) (, ,) (NP (NP (NNS interactions)) (ADJP (JJ due) (PP (TO to) (NP (NP (NN displacement)) (PP (IN of) (NP (ADJP (RBR more) (RB highly) (NN protein) (JJ bound)) (NNS drugs))) (PP (IN from) (NP (NN plasma) (NNS proteins))))))) (VP (VBP are) (RB not) (VP (VBN expected)))) (. .))))

Sentence Id: DrugDDI.d492.s0
Because/IN the/DT tetracyclines/NNS have/VBP been/VBN shown/VBN to/TO depress/VB plasma/NN prothrombin/NN activity/NN ,/, patients/NNS who/WP are/VBP on/IN anticoagulant/NN therapy/NN may/MD require/VB downward/JJ adjustment/NN of/IN their/PRP$ anticoagulant/JJ dosage/NN ./.

(ROOT (S1 (S (S (SBAR (IN Because) (S (NP (DT the) (NNS tetracyclines)) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB depress) (NP (NN plasma) (NN prothrombin) (NN activity)))))))))) (, ,) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (PP (IN on) (NP (NN anticoagulant) (NN therapy))))))) (VP (MD may) (VP (VB require) (NP (NP (JJ downward) (NN adjustment)) (PP (IN of) (NP (PRP$ their) (JJ anticoagulant) (NN dosage))))))) (. .))))

Sentence Id: DrugDDI.d492.s1
Since/IN bacteriostat/NN ic/NN drugs/NNS ,/, such/JJ as/IN the/DT tetracycline/NN class/NN of/IN antibiotics/NNS ,/, may/MD interfere/VB with/IN the/DT bactericidal/JJ action/NN of/IN penicillins/NNS ,/, it/PRP is/VBZ not/RB advisable/JJ to/TO administer/VB these/DT drugs/NNS concomitantly/RB ./.

(ROOT (S1 (S (S (SBAR (IN Since) (S (NP (NP (NN bacteriostat) (NN ic) (NNS drugs)) (, ,) (PP (JJ such) (IN as) (NP (NP (DT the) (NN tetracycline) (NN class)) (PP (IN of) (NP (NNS antibiotics))))) (, ,)) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (JJ bactericidal) (NN action)) (PP (IN of) (NP (NNS penicillins))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (RB not) (ADJP (JJ advisable) (S (VP (TO to) (VP (VB administer) (NP (DT these) (NNS drugs)) (ADVP (RB concomitantly)))))))) (. .))))

Sentence Id: DrugDDI.d492.s2
Concurrent/JJ use/NN of/IN tetracyclines/NNS with/IN oral/JJ contraceptives/NNS may/MD render/VB oral/JJ contraceptives/NNS less/CC effect/VB ive/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (NP (NNS tetracyclines)) (PP (IN with) (NP (JJ oral) (NNS contraceptives)))))) (VP (MD may) (VP (VP (VB render) (NP (JJ oral) (NNS contraceptives))) (CC less) (VP (VB effect) (NP (NN ive)))))) (. .))))

Sentence Id: DrugDDI.d392.s1
Drugs/NNS Metabolized/VBN by/IN P450/NN 2D6/NN :/: The/DT biochemical/JJ activity/NN of/IN the/DT drug/NN metabolizing/NN isozyme/NN cytochrome/NN P450/NN 2D6/NN (/-LRB- debrisoquin/NN hydroxylase/NN )/-RRB- is/VBZ reduced/VBN in/IN a/DT subset/NN of/IN the/DT caucasian/NN population/NN (/-LRB- about/RB 7/CD to/TO 10/CD %/NN of/IN caucasians/NNS are/VBP so/RB called/VBN poor/JJ metabolizers/NNS )/-RRB- ;/: ./.

(ROOT (S1 (S (NP (NP (NP (NNS Drugs)) (VP (VBN Metabolized) (PP (IN by) (NP (NN P450) (NN 2D6))))) (: :) (S (NP (NP (DT The) (JJ biochemical) (NN activity)) (PP (IN of) (NP (NP (DT the) (NN drug) (NN metabolizing) (NN isozyme) (NN cytochrome) (NN P450) (NN 2D6)) (PRN (-LRB- -LRB-) (NP (NN debrisoquin) (NN hydroxylase)) (-RRB- -RRB-))))) (VP (VBZ is) (VP (VBN reduced) (PP (IN in) (NP (NP (DT a) (NN subset)) (PP (IN of) (NP (DT the) (NN caucasian) (NN population))))) (PRN (-LRB- -LRB-) (S (NP (NP (QP (RB about) (CD 7) (TO to) (CD 10)) (NN %)) (PP (IN of) (NP (NNS caucasians)))) (VP (VBP are) (NP (ADJP (RB so) (VBN called)) (JJ poor) (NNS metabolizers)))) (-RRB- -RRB-)))) (: ;)) (. .)))))

Sentence Id: DrugDDI.d392.s2
reliable/JJ estimates/NNS of/IN the/DT prevalence/NN of/IN reduced/VBN P450/NN 2D6/NN isozyme/NN activity/NN among/IN Asian/JJ ,/, African/JJ and/CC other/JJ populations/NNS are/VBP not/RB yet/RB available/JJ ./.

(ROOT (S1 (S (S (NP (NP (JJ reliable) (NNS estimates)) (PP (IN of) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (VBN reduced) (NN P450) (NN 2D6) (NN isozyme) (NN activity))) (PP (IN among) (NP (ADJP (ADJP (JJ Asian)) (, ,) (ADJP (JJ African)) (CC and) (ADJP (JJ other))) (NNS populations)))))) (VP (VBP are) (RB not) (ADVP (RB yet)) (ADJP (JJ available)))) (. .))))

Sentence Id: DrugDDI.d392.s3
Poor/JJ metabolizers/NNS have/VBP higher/JJR than/IN expected/VBN plasma/NN concentrations/NNS of/IN tricyclic/JJ antidepressants/NNS (/-LRB- TCAs/NNS )/-RRB- when/WRB given/VBN usual/JJ doses/NNS ./.

(ROOT (S1 (S (S (NP (JJ Poor) (NNS metabolizers)) (VP (VBP have) (NP (NP (JJR higher) (IN than) (VBN expected) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (JJ tricyclic) (NNS antidepressants)) (PRN (-LRB- -LRB-) (NP (NNS TCAs)) (-RRB- -RRB-))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (NP (JJ usual) (NNS doses))))))) (. .))))

Sentence Id: DrugDDI.d392.s4
Depending/VBG on/IN the/DT traction/NN of/IN drug/NN metabolized/VBN by/IN P450/NN 2D6/NN ,/, the/DT increase/NN in/IN plasma/NN concentration/NN may/MD be/VB small/JJ ,/, or/CC quite/RB large/JJ (/-LRB- 8/CD fold/JJ increase/NN in/IN plasma/NN AUC/NN of/IN the/DT TCA/NN )./NN

(ROOT (S1 (S (PP (VBG Depending) (PP (IN on) (NP (NP (DT the) (NN traction)) (PP (IN of) (NP (NP (NN drug)) (VP (VBN metabolized) (PP (IN by) (NP (NN P450) (NN 2D6))))))))) (, ,) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NN plasma) (NN concentration)))) (VP (MD may) (VP (VB be) (ADJP (ADJP (JJ small)) (, ,) (CC or) (RB quite) (ADJP (JJ large))))) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 8) (JJ fold)) (NN increase)) (PP (IN in) (NP (NP (NN plasma) (NN AUC)) (PP (IN of) (NP (DT the) (NN TCA) (NN -RRB-.))))))))))

Sentence Id: DrugDDI.d392.s5
In/IN addition/NN ,/, certain/JJ drugs/NNS inhibit/VB the/DT activity/NN of/IN this/DT isozyme/NN and/CC make/VB normal/JJ metabolizers/NNS resemble/VBP p.o./NN

(ROOT (S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (JJ certain) (NNS drugs)) (VP (VP (VB inhibit) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT this) (NN isozyme))))) (CC and) (VP (VB make) (NP (JJ normal) (NNS metabolizers)))) (VP (VBP resemble) (NP (NN p.o.))))))

Sentence Id: DrugDDI.d392.s7
An/DT individual/JJ who/WP is/VBZ stable/JJ on/IN a/DT given/JJ dose/NN of/IN TCA/NN may/MD become/VB abruptly/RB toxic/JJ when/WRB given/VBN one/CD of/IN these/DT inhibiting/JJ drugs/NNS as/IN concomitant/JJ therapy/NN ./.

(ROOT (S1 (S (S (NP (NP (DT An) (JJ individual)) (SBAR (WHNP (WP who)) (S (VP (VBZ is) (ADJP (JJ stable) (PP (IN on) (NP (NP (DT a) (JJ given) (NN dose)) (PP (IN of) (NP (NN TCA)))))))))) (VP (MD may) (VP (VB become) (ADJP (RB abruptly) (JJ toxic)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT these) (JJ inhibiting) (NNS drugs)) (PP (IN as) (NP (JJ concomitant) (NN therapy)))))))))))) (. .))))

Sentence Id: DrugDDI.d392.s8
The/DT drugs/NNS that/WDT inhibit/VBP cytochrome/NN P450/NN 2D6/NN include/VBP some/DT that/WDT are/VBP not/RB metabolized/VBN by/IN the/DT enzyme/NN (/-LRB- quinidine/NN ;/: ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (NN cytochrome) (NN P450) (NN 2D6)))))) (VP (VBP include) (NP (NP (DT some)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (RB not) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (NN enzyme) (-LRB- -LRB-) (NN quinidine) (: ;)))))))))) (. .))))

Sentence Id: DrugDDI.d392.s9
cimetidine/NN )/-RRB- and/CC many/JJ that/WDT are/VBP substrates/NNS for/IN P450/NN 2D6/NN (/-LRB- many/JJ other/JJ antidepressants/NNS ,/, phenothiazines/NNS ,/, and/CC the/DT Type/NN 1C/NN antiarrhythrnics/NNS propatenone/NN and/CC flecainide/NN )/-RRB- ./.

(ROOT (S1 (S (NP (NP (NP (NN cimetidine) (-RRB- -RRB-)) (CC and) (NP (NP (JJ many)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NNS substrates)) (PP (IN for) (NP (NN P450) (NN 2D6)))) (PRN (-LRB- -LRB-) (NP (NP (JJ many) (JJ other) (NNS antidepressants)) (, ,) (NP (NNS phenothiazines)) (, ,) (CC and) (NP (NP (DT the) (NN Type) (NN 1C) (NNS antiarrhythrnics)) (NP (NP (NN propatenone)) (CC and) (NP (NN flecainide))))) (-RRB- -RRB-))))))) (. .)))))

Sentence Id: DrugDDI.d392.s10
While/IN all/PDT the/DT selective/JJ serotonin/NN reuptake/NN inhibitors/NNS (/-LRB- SSRIs/NN )/-RRB- ,/, e.g./FW ,/, fluoxetine/NN ,/, seriraline/NN ,/, and/CC paroxetine/NN ,/, inhibit/VBP P450/NN 2D6/NN ,/, they/PRP may/MD vary/VB in/IN the/DT extent/NN of/IN inhibition/NN ./.

(ROOT (S1 (S (S (SBAR (IN While) (S (NP (NP (NP (PDT all) (DT the) (JJ selective) (NN serotonin) (NN reuptake) (NNS inhibitors)) (PRN (-LRB- -LRB-) (NP (NN SSRIs)) (-RRB- -RRB-))) (, ,) (PP (FW e.g.) (, ,) (NP (NP (NN fluoxetine)) (, ,) (NP (NN seriraline)) (, ,) (CC and) (NP (NN paroxetine)))) (, ,)) (VP (VBP inhibit) (NP (NN P450) (NN 2D6))))) (, ,) (NP (PRP they)) (VP (MD may) (VP (VB vary) (PP (IN in) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NN inhibition)))))))) (. .))))

Sentence Id: DrugDDI.d392.s12
Nevertheless/RB ,/, caution/NN is/VBZ indicated/VBN in/IN the/DT co-administration/NN of/IN T/NN .A./NNS with/IN any/DT of/IN the/DT SSRIs/NNS and/CC also/RB in/IN switching/NN from/IN one/CD class/NN to/TO the/DT other/JJ ./.

(ROOT (S1 (S (ADVP (RB Nevertheless)) (, ,) (NP (NN caution)) (VP (VBZ is) (VP (VBN indicated) (PP (PP (IN in) (NP (NP (DT the) (NN co-administration)) (PP (IN of) (NP (NN T) (NNS .A.))) (PP (IN with) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (NNS SSRIs))))))) (CC and) (ADVP (RB also)) (PP (IN in) (NP (NP (NN switching)) (PP (IN from) (NP (CD one) (NN class))) (PP (TO to) (NP (DT the) (JJ other)))))))) (. .))))

Sentence Id: DrugDDI.d392.s13
Of/IN particular/JJ importance/NN ,/, sufficient/JJ time/NN must/MD elapse/VB before/IN initiating/VBG TCA/NN treatment/NN in/IN a/DT patient/NN being/VBG withdrawn/NN from/IN fluoxetine/NN ,/, given/IN the/DT long/JJ half-life/NN of/IN the/DT parent/JJ and/CC active/JJ metabolite/NN (/-LRB- at/IN least/JJS 5/CD weeks/NNS may/MD be/VB necessary/JJ )./NN

(ROOT (S1 (S (PP (IN Of) (NP (JJ particular) (NN importance))) (, ,) (S (NP (JJ sufficient) (NN time)) (VP (MD must) (VP (VB elapse) (PP (IN before) (S (VP (VBG initiating) (NP (NN TCA) (NN treatment))))) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBG being) (NP (NP (NN withdrawn)) (PP (IN from) (NP (NN fluoxetine))))))) (, ,) (SBAR (IN given) (S (NP (NP (DT the) (JJ long) (NN half-life)) (PP (IN of) (NP (DT the) (ADJP (ADJP (JJ parent)) (CC and) (ADJP (JJ active))) (NN metabolite) (-LRB- -LRB-) (QP (IN at) (JJS least) (CD 5)) (NNS weeks)))) (VP (MD may) (VP (VB be) (NP (JJ necessary) (NN -RRB-.))))))))))))

Sentence Id: DrugDDI.d392.s14
Concomitant/JJ use/NN of/IN tricyclic/JJ antidepressants/NNS with/IN drugs/NNS that/WDT can/MD inhibit/VB cytochrome/NN P450/NN 2D6/NN may/MD require/VB lower/JJR doses/NNS than/IN usually/RB prescribed/VBN for/IN either/CC the/DT tricyclic/JJ antidepressant/JJ or/CC the/DT other/JJ drug/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NP (JJ tricyclic) (NNS antidepressants)) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB inhibit) (NP (NN cytochrome) (NN P450) (NN 2D6))))))))))) (VP (MD may) (VP (VB require) (NP (NP (JJR lower) (NNS doses)) (VP (ADVP (IN than) (RB usually)) (VBN prescribed) (PP (IN for) (NP (CC either) (NP (DT the) (JJ tricyclic) (JJ antidepressant)) (CC or) (NP (DT the) (JJ other) (NN drug))))))))) (. .))))

Sentence Id: DrugDDI.d392.s15
Furthermore/RB ,/, whenever/RB one/CD of/IN these/DT other/JJ drugs/NNS is/VBZ withdrawn/VBN from/IN co-therapy/NN ,/, an/DT increased/VBN dose/NN of/IN tricyclic/JJ antidepressant/JJ may/MD be/VB required/VBN ./.

(ROOT (S1 (S (S (ADVP (RB Furthermore)) (, ,) (S (ADVP (RB whenever)) (NP (NP (CD one)) (PP (IN of) (NP (DT these) (JJ other) (NNS drugs)))) (VP (VBZ is) (VP (VBN withdrawn) (PP (IN from) (NP (NN co-therapy)))))) (, ,) (NP (NP (DT an) (VBN increased) (NN dose)) (PP (IN of) (NP (JJ tricyclic) (JJ antidepressant)))) (VP (MD may) (VP (VB be) (VP (VBN required))))) (. .))))

Sentence Id: DrugDDI.d392.s16
It/PRP is/VBZ desirable/JJ to/TO monitor/VB TCA/NN plasma/NN levels/NNS whenever/RB a/DT TCA/NN is/VBZ going/JJ to/TO be/VB co-administered/VBN with/IN another/DT drug/NN known/VBN to/TO be/VB an/DT inhibitor/NN of/IN P450/NN 2D6/NN ./.

(ROOT (S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ desirable)) (S (VP (TO to) (VP (VB monitor) (NP (NN TCA) (NN plasma) (NNS levels)) (S (ADVP (RB whenever)) (NP (DT a) (NN TCA)) (VP (VBZ is) (ADJP (JJ going) (S (VP (TO to) (VP (VB be) (VP (VBN co-administered) (PP (IN with) (NP (NP (DT another) (NN drug)) (VP (VBN known) (S (VP (TO to) (VP (VB be) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN P450) (NN 2D6)))))))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d392.s18
Close/JJ supervision/NN and/CC careful/JJ adjustment/NN of/IN dosage/NN are/VBP required/VBN when/WRB this/DT drug/NN is/VBZ given/VBN concomitantly/RB with/IN anticholinergic/JJ or/CC sympathomimetic/JJ drugs/NNS ./.

(ROOT (S1 (S (S (NP (NP (NP (JJ Close) (NN supervision)) (CC and) (NP (JJ careful) (NN adjustment))) (PP (IN of) (NP (NN dosage)))) (VP (VBP are) (VP (VBN required) (SBAR (WHADVP (WRB when)) (S (NP (DT this) (NN drug)) (VP (VBZ is) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (ADJP (ADJP (JJ anticholinergic)) (CC or) (ADJP (JJ sympathomimetic))) (NNS drugs)))))))))) (. .))))

Sentence Id: DrugDDI.d392.s20
Clinical/JJ experience/VBP in/IN the/DT concurrent/JJ administration/NN of/IN ECT/NN and/CC antidepressant/JJ drugs/NNS is/VBZ limited/VBN ./.

(ROOT (S1 (S (S (NP (JJ Clinical)) (VP (VBP experience) (SBAR (IN in) (S (NP (NP (DT the) (JJ concurrent) (NN administration)) (PP (IN of) (NP (NP (NN ECT)) (CC and) (NP (JJ antidepressant) (NNS drugs))))) (VP (VBZ is) (VP (VBN limited))))))) (. .))))

Sentence Id: DrugDDI.d392.s23
If/IN desipramine/NN hydrochloride/NN is/VBZ to/TO be/VB combined/VBN with/IN other/JJ psychotropic/JJ agents/NNS such/JJ as/IN tranquilizers/NNS or/CC sedative/JJ //: hypnotics/NNS ,/, careful/JJ consideration/NN should/MD be/VB given/VBN to/TO the/DT pharmacology/NN of/IN the/DT agents/NNS employed/VBN since/IN the/DT sedative/JJ effects/NNS of/IN desipramine/NN and/CC benzodiazepines/NN (/-LRB- e.g./FW ,/, chlordiazepoxide/NN or/CC diazepam/NN )/-RRB- are/VBP additive/JJ ./.

(ROOT (S1 (S (SBAR (IN If) (S (NP (NN desipramine) (NN hydrochloride)) (VP (VBZ is) (S (VP (TO to) (VP (VB be) (VP (VBN combined) (PP (IN with) (NP (NP (JJ other) (JJ psychotropic) (NNS agents)) (PP (JJ such) (IN as) (NP (NP (NNS tranquilizers)) (CC or) (NP (ADJP (ADJP (JJ sedative)) (: /)) (NNS hypnotics))))))))))))) (, ,) (NP (JJ careful) (NN consideration)) (VP (MD should) (VP (VB be) (VP (VBN given) (PP (TO to) (NP (NP (DT the) (NN pharmacology)) (PP (IN of) (NP (NP (DT the) (NNS agents)) (VP (VBN employed) (SBAR (IN since) (S (NP (NP (DT the) (JJ sedative) (NNS effects)) (PP (IN of) (NP (NP (NP (NN desipramine)) (CC and) (NP (NN benzodiazepines))) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN chlordiazepoxide)) (CC or) (NP (NN diazepam)))) (-RRB- -RRB-))))) (VP (VBP are) (ADJP (JJ additive))))))))))))) (. .))))

Sentence Id: DrugDDI.d392.s24
Both/CC the/DT sedative/JJ and/CC anticholinergic/JJ effects/NNS of/IN the/DT major/JJ tranquilizers/NNS are/VBP also/RB additive/JJ to/TO those/DT of/IN desipramine/NN ./.

(ROOT (S1 (S (S (NP (NP (CC Both) (DT the) (ADJP (ADJP (JJ sedative)) (CC and) (ADJP (JJ anticholinergic))) (NNS effects)) (PP (IN of) (NP (DT the) (JJ major) (NNS tranquilizers)))) (VP (VBP are) (ADVP (RB also)) (ADJP (JJ additive) (PP (TO to) (NP (NP (DT those)) (PP (IN of) (NP (NN desipramine)))))))) (. .))))

Sentence Id: DrugDDI.d392.s26
Concurrent/JJ administration/NN of/IN cimetidine/NN and/CC tricyclic/JJ antidepressants/NNS can/MD produce/VBP clinically/RB significant/JJ increases/NNS in/IN the/DT plasma/NN levels/NNS of/IN the/DT tricyclic/JJ antidepressants/NNS ./.

(ROOT (S1 (S (S (NP (NP (JJ Concurrent) (NN administration)) (PP (IN of) (NP (NP (NN cimetidine)) (CC and) (NP (JJ tricyclic) (NNS antidepressants))))) (VP (MD can) (VP (VBP produce) (NP (NP (ADJP (RB clinically) (JJ significant)) (NNS increases)) (PP (IN in) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (DT the) (JJ tricyclic) (NNS antidepressants))))))))) (. .))))

Sentence Id: DrugDDI.d392.s27
Conversely/RB ,/, decreases/NNS in/IN plasma/NN levels/NNS of/IN the/DT tricyclic/JJ antidepressants/NNS have/VBP been/VBN reported/VBN upon/IN discontinuation/NN of/IN cimetidine/NN which/WDT may/MD result/VB in/IN the/DT loss/NN of/IN the/DT therapeutic/JJ efficacy/NN of/IN the/DT tricyclic/JJ antidepressant/JJ 6/CD ./.

(ROOT (S1 (S (S (ADVP (RB Conversely)) (, ,) (NP (NP (NNS decreases)) (PP (IN in) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (DT the) (JJ tricyclic) (NNS antidepressants)))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN upon) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NP (NN cimetidine)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT the) (NN loss)) (PP (IN of) (NP (NP (DT the) (JJ therapeutic) (NN efficacy)) (PP (IN of) (NP (DT the) (JJ tricyclic) (JJ antidepressant) (CD 6))))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d392.s28
There/EX have/VBP been/VBN greater/JJR than/IN two-fold/JJ increases/NNS of/IN previously/RB stable/JJ plasma/NN levels/NNS of/IN tricyclic/JJ antidepressants/NNS when/WRB fluoxetine/NN has/VBZ been/VBN administered/VBN in/IN combination/NN with/IN these/DT agents/NNS ./.

(ROOT (S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (ADJP (ADJP (JJR greater)) (PP (IN than) (NP (NP (JJ two-fold) (NNS increases)) (PP (IN of) (NP (NP (ADJP (RB previously) (JJ stable)) (NN plasma) (NNS levels)) (PP (IN of) (NP (JJ tricyclic) (NNS antidepressants)))))))) (SBAR (WHADVP (WRB when)) (S (NP (NN fluoxetine)) (VP (VBZ has) (VP (VBN been) (VP (VBN administered) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (DT these) (NNS agents))))))))))))) (. .))))

Sentence Id: DrugDDI.d298.s0
General/JJ :/: In/FW vitro/FW studies/NNS in/IN human/JJ liver/NN microsomes/NNS demonstrated/VBD no/DT evidence/NN of/IN cytochrome/NN P450-mediated/JJ drug/NN interactions/NNS that/WDT are/VBP likely/JJ to/TO be/VB of/IN clinical/JJ relevance/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ General) (ADJP (: :) (ADJP (FW In) (FW vitro))) (NNS studies)) (PP (IN in) (NP (JJ human) (NN liver) (NNS microsomes)))) (VP (VBD demonstrated) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (NN cytochrome) (JJ P450-mediated) (NN drug) (NNS interactions)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (JJ likely) (S (VP (TO to) (VP (VB be) (PP (IN of) (NP (JJ clinical) (NN relevance))))))))))))))) (. .))))

Sentence Id: DrugDDI.d298.s1
Anesthetics/NNS //: Sedatives/NNS //: Hypnotics/NNS //: Opioids/NNS Co-administration/NN of/IN PRECEDEX/NN with/IN anesthetics/NNS ,/, sedatives/NNS ,/, hypnotics/NNS ,/, and/CC opioids/NNS is/VBZ likely/JJ to/TO lead/VB to/TO an/DT enhancement/NN of/IN effects/NNS ./.

(ROOT (S1 (S (S (NP (NP (NP (NP (NNS Anesthetics)) (: /) (NP (NNS Sedatives)) (: /) (NP (NNS Hypnotics)) (: /) (NP (NNS Opioids))) (NN Co-administration)) (PP (IN of) (NP (NN PRECEDEX))) (PP (IN with) (NP (NP (NNS anesthetics)) (, ,) (NP (NNS sedatives)) (, ,) (NP (NNS hypnotics)) (, ,) (CC and) (NP (NNS opioids))))) (VP (VBZ is) (ADJP (JJ likely) (S (VP (TO to) (VP (VB lead) (PP (TO to) (NP (NP (DT an) (NN enhancement)) (PP (IN of) (NP (NNS effects))))))))))) (. .))))

Sentence Id: DrugDDI.d298.s2
Specific/JJ studies/NNS have/VBP confirmed/VBN these/DT effects/NNS with/IN sevoflurane/NN ,/, isoflurane/NN ,/, propofol/NN ,/, alfentanil/NN ,/, and/CC midazolam/NN ./.

(ROOT (S1 (S (S (NP (JJ Specific) (NNS studies)) (VP (VBP have) (VP (VBN confirmed) (NP (DT these) (NNS effects)) (PP (IN with) (NP (NP (NN sevoflurane)) (, ,) (NP (NN isoflurane)) (, ,) (NP (NN propofol)) (, ,) (NP (NN alfentanil)) (, ,) (CC and) (NP (NN midazolam))))))) (. .))))

Sentence Id: DrugDDI.d298.s3
No/DT pharmacokinetic/JJ interactions/NNS between/IN dexmedetomidine/NN and/CC isoflurane/NN ,/, propofol/NN ,/, alfentanil/NN ,/, and/CC midazolam/NN have/VBP been/VBN demonstrated/VBN ./.

(ROOT (S1 (S (S (NP (NP (DT No) (JJ pharmacokinetic) (NNS interactions)) (PP (IN between) (NP (NP (NN dexmedetomidine)) (CC and) (NP (NN isoflurane)) (, ,) (NP (NN propofol)) (, ,) (NP (NN alfentanil)) (, ,) (CC and) (NP (NN midazolam))))) (VP (VBP have) (VP (VBN been) (VP (VBN demonstrated))))) (. .))))

Sentence Id: DrugDDI.d298.s4
However/RB ,/, due/IN to/TO possible/JJ pharmacodynamic/JJ interactions/NNS ,/, when/WRB co-administered/VBN with/IN PRECEDEX/NN ,/, a/DT reduction/NN in/IN dosage/NN of/IN PRECEDEX/NN on/IN the/DT concomitant/JJ anesthetic/NN ,/, sedative/JJ ,/, hypnotic/JJ or/CC opioid/JJ may/MD be/VB required/VBN ./.

(ROOT (S1 (S (ADVP (RB However)) (, ,) (PP (IN due) (PP (TO to) (NP (JJ possible) (JJ pharmacodynamic) (NNS interactions)))) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN co-administered) (PP (IN with) (NP (NN PRECEDEX)))))) (, ,) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NP (NN dosage)) (PP (IN of) (NP (NN PRECEDEX))))) (PP (IN on) (NP (NP (DT the) (JJ concomitant) (NN anesthetic)) (, ,) (ADJP (ADJP (JJ sedative)) (, ,) (ADJP (JJ hypnotic)) (CC or) (ADJP (JJ opioid)))))) (VP (MD may) (VP (VB be) (VP (VBN required)))) (. .))))

Sentence Id: DrugDDI.d298.s5
Neuromuscular/JJ Blockers/NNS :/: In/IN one/CD study/NN of/IN 10/CD healthy/JJ volunteers/NNS ,/, administration/NN of/IN PRECEDEX/NN for/IN 45/CD minutes/NNS at/IN a/DT plasma/NN concentration/NN of/IN 1/CD (/-LRB- one/CD )/-RRB- ng/mL/NN resulted/VBD in/IN no/DT clinically/RB meaningful/JJ increases/NNS in/IN the/DT magnitude/NN or/CC neuromuscular/JJ blockade/NN associated/VBN with/IN rocuronium/NN administration/NN ./.

(ROOT (S1 (S (NP (NP (JJ Neuromuscular) (NNS Blockers)) (: :) (S (PP (IN In) (NP (NP (CD one) (NN study)) (PP (IN of) (NP (CD 10) (JJ healthy) (NNS volunteers))))) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (NN PRECEDEX))) (PP (IN for) (NP (CD 45) (NNS minutes))) (PP (IN at) (NP (NP (DT a) (NN plasma) (NN concentration)) (PP (IN of) (NP (CD 1) (-LRB- -LRB-) (CD one) (-RRB- -RRB-) (NN ng/mL)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT no) (ADJP (RB clinically) (JJ meaningful)) (NNS increases)) (PP (IN in) (NP (NP (NP (DT the) (NN magnitude)) (CC or) (NP (JJ neuromuscular) (NN blockade))) (VP (VBN associated) (PP (IN with) (NP (NN rocuronium) (NN administration)))))))))) (. .)))))

Sentence Id: DrugDDI.d15.s0
May/MD interact/VB anticoagulants/NNS (/-LRB- altered/JJ hypo-prothrombinemic/JJ effect/NN )/-RRB- ,/, barbiturates/NNS ,/, rifampin/NN and/CC other/JJ inducers/NNS of/IN hepatic/JJ microsomal/JJ enzyme/NN oxidation/NN system/NN (/-LRB- decreased/VBN effect/NN of/IN diethylstilbestrol/NN )/-RRB- ,/, corticosteroids/NNS (/-LRB- increased/VBN effect/NN of/IN corticosteroids/NNS )/-RRB- ./.

(ROOT (S1 (S (S (VP (MD May) (VP (VB interact) (NP (NP (NP (NNS anticoagulants)) (PRN (-LRB- -LRB-) (NP (JJ altered) (JJ hypo-prothrombinemic) (NN effect)) (-RRB- -RRB-))) (, ,) (NP (NNS barbiturates)) (, ,) (NP (NP (NP (NN rifampin)) (CC and) (NP (JJ other) (NNS inducers))) (PP (IN of) (NP (NP (JJ hepatic) (JJ microsomal) (NN enzyme) (NN oxidation) (NN system)) (PRN (-LRB- -LRB-) (NP (NP (VBN decreased) (NN effect)) (PP (IN of) (NP (NN diethylstilbestrol)))) (-RRB- -RRB-))))) (, ,) (NP (NP (NNS corticosteroids)) (PRN (-LRB- -LRB-) (NP (NP (VBN increased) (NN effect)) (PP (IN of) (NP (NNS corticosteroids)))) (-RRB- -RRB-))))))) (. .))))

Sentence Id: DrugDDI.d62.s0
Administration/NN of/IN thiazide/NN diuretics/NNS to/TO hypoparathyroid/JJ patients/NNS who/WP are/VBP concurrently/RB being/VBG treated/VBN with/IN dihydrotachysterol/NN may/MD cause/VB hypercalcemia/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN thiazide) (NNS diuretics))) (PP (TO to) (NP (NP (JJ hypoparathyroid) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (ADVP (RB concurrently)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (NN dihydrotachysterol))))))))))) (VP (MD may) (VP (VB cause) (NP (NN hypercalcemia))))) (. .))))

Sentence Id: DrugDDI.d337.s0
Diphenhydramine/NN hydrochloride/NN has/VBZ additive/JJ effects/NNS with/IN alcohol/NN and/CC other/JJ CNS/NN depressants/NNS (/-LRB- hypnotics/NN ,/, sedatives/NNS ,/, tranquilizers/NNS ,/, etc/NN )./CD

(ROOT (S1 (S (NP (NN Diphenhydramine) (NN hydrochloride)) (VP (VBZ has) (NP (JJ additive) (NNS effects)) (PP (IN with) (NP (NP (NN alcohol)) (CC and) (NP (NP (NP (JJ other) (NN CNS) (NNS depressants)) (PRN (-LRB- -LRB-) (NP (NN hypnotics)))) (, ,) (NP (NNS sedatives)) (, ,) (NP (NNS tranquilizers)) (, ,) (NP (NN etc) (CD -RRB-.)))))))))

Sentence Id: DrugDDI.d337.s1
MAO/NN inhibitors/NNS prolong/VBP and/CC intensify/VB the/DT anticholinergic/JJ (/-LRB- drying/NN )/-RRB- effects/NNS of/IN antihistamines/NNS ./.

(ROOT (S1 (S (S (NP (NN MAO) (NNS inhibitors)) (VP (VP (VBP prolong)) (CC and) (VP (VB intensify) (NP (NP (DT the) (ADJP (ADJP (JJ anticholinergic)) (PRN (-LRB- -LRB-) (NP (NN drying)) (-RRB- -RRB-))) (NNS effects)) (PP (IN of) (NP (NNS antihistamines))))))) (. .))))

Sentence Id: DrugDDI.d189.s0
CNS/NN depression/NN @/NN producing/NN medications/NNS -/CC concurrent/JJ use/NN may/MD potentiate/VB the/DT effects/NNS of/IN either/CC these/DT medications/NNS or/CC diphenidol/NN ;/: ./.

(ROOT (S1 (S (S (NP (NP (NN CNS) (NN depression) (NN @) (NN producing) (NNS medications)) (CC -) (NP (JJ concurrent) (NN use))) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (CC either) (DT these) (NP (NNS medications)) (CC or) (NP (NN diphenidol))))))) (: ;)) (. .))))

Sentence Id: DrugDDI.d189.s1
anticholinergics/NN or/CC other/JJ medications/NNS with/IN anticholinergic/JJ activity/NN -/CC anticholinergic/JJ effects/NNS may/MD be/VB potentiated/VBN when/WRB these/DT medications/NNS are/VBP used/VBN concurrently/RB with/IN diphenidol/NN ;/: ./.

(ROOT (S1 (S (S (NP (NP (NP (NP (NN anticholinergics)) (CC or) (NP (JJ other) (NNS medications))) (PP (IN with) (NP (JJ anticholinergic) (NN activity)))) (CC -) (NP (JJ anticholinergic) (NNS effects))) (VP (MD may) (VP (VB be) (VP (VBN potentiated) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (NNS medications)) (VP (VBP are) (VP (VBN used) (ADVP (RB concurrently)) (PP (IN with) (NP (NN diphenidol)))))))))) (: ;)) (. .))))

Sentence Id: DrugDDI.d189.s2
apomorphine/NN -/CC prior/JJ ingestion/NN of/IN diphenidol/NN may/MD decrease/VB the/DT emetic/JJ response/NN to/TO apomorphine/NN in/IN the/DT treatment/NN of/IN poisoning/NN ./.

(ROOT (S1 (S (S (NP (NP (NP (NN apomorphine)) (CC -) (NP (JJ prior) (NN ingestion))) (PP (IN of) (NP (NN diphenidol)))) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (JJ emetic) (NN response)) (PP (TO to) (NP (NN apomorphine))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN poisoning))))))))) (. .))))

Sentence Id: DrugDDI.d448.s0
Known/JJ drug/NN interactions/NNS include/VBP barbiturates/NNS ,/, tranquilizers/NNS ,/, and/CC alcohol/NN ./.

(ROOT (S1 (S (S (NP (JJ Known) (NN drug) (NNS interactions)) (VP (VBP include) (NP (NP (NNS barbiturates)) (, ,) (NP (NNS tranquilizers)) (, ,) (CC and) (NP (NN alcohol))))) (. .))))

Sentence Id: DrugDDI.d448.s1
Diphenoxylate/NN HCl/NN and/CC atropine/NN sulfate/NN may/MD interact/VB with/IN MAO/NN inhibitors/NNS In/IN studies/NNS with/IN male/JJ rats/NNS ,/, diphenoxylate/NN hydrochloride/NN was/VBD found/VBN to/TO inhibit/VB the/DT hepatic/JJ microsomal/JJ enzyme/NN system/NN at/IN a/DT dose/NN of/IN 2/CD mg/kg/day/NN ./.

(ROOT (S1 (S (S (S (NP (NP (NN Diphenoxylate) (NN HCl)) (CC and) (NP (NN atropine) (NN sulfate))) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NN MAO) (NNS inhibitors))) (PP (IN In) (NP (NP (NNS studies)) (PP (IN with) (NP (JJ male) (NNS rats)))))))) (, ,) (NP (NN diphenoxylate) (NN hydrochloride)) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB inhibit) (NP (DT the) (JJ hepatic) (JJ microsomal) (NN enzyme) (NN system)) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 2) (NN mg/kg/day))))))))))) (. .))))

Sentence Id: DrugDDI.d448.s2
Therefore/RB ,/, diphenoxylate/NN has/VBZ the/DT potential/NN to/TO prolong/VB the/DT biological/JJ half-lives/NNS of/IN drugs/NNS for/IN which/WDT the/DT rate/NN of/IN elimination/NN is/VBZ dependent/JJ on/IN the/DT microsomal/JJ drug/NN metabolizing/NN enzyme/NN system/NN ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN diphenoxylate)) (VP (VBZ has) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VB prolong) (NP (NP (DT the) (JJ biological) (NNS half-lives)) (PP (IN of) (NP (NP (NNS drugs)) (SBAR (WHPP (IN for) (WHNP (WDT which))) (S (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NN elimination)))) (VP (VBZ is) (ADJP (JJ dependent) (PP (IN on) (NP (DT the) (JJ microsomal) (NN drug) (NN metabolizing) (NN enzyme) (NN system)))))))))))))))) (. .))))

Sentence Id: DrugDDI.d383.s0
Disulfiram/NN appears/VBZ to/TO decrease/VB the/DT rate/NN at/IN which/WDT certain/JJ drugs/NNS are/VBP metabolized/VBN and/CC therefore/RB may/MD increase/VB the/DT blood/NN levels/NNS and/CC the/DT possibility/NN of/IN clinical/JJ toxicity/NN of/IN drugs/NNS given/VBN concomitantly/RB ./.

(ROOT (S1 (S (S (NP (NN Disulfiram)) (VP (VP (VBZ appears) (S (VP (TO to) (VP (VB decrease) (NP (NP (DT the) (NN rate)) (SBAR (WHPP (IN at) (WHNP (WDT which))) (S (NP (JJ certain) (NNS drugs)) (VP (VBP are) (VP (VBN metabolized)))))))))) (CC and) (ADVP (RB therefore)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN blood) (NNS levels)) (CC and) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NP (JJ clinical) (NN toxicity)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBN given) (ADVP (RB concomitantly))))))))))))) (. .))))

Sentence Id: DrugDDI.d383.s1
DISULFIRAM/NN SHOULD/MD BE/VB USED/VBN WITH/IN CAUTION/NN IN/IN THOSE/DT PATIENTS/NNS REVEIVING/VBG PHENYTOIN/NN AND/CC ITS/PRP$ CONGENER/NN S/NNS ./.

(ROOT (S1 (S (S (NP (NN DISULFIRAM)) (VP (MD SHOULD) (VP (VB BE) (VP (VBN USED) (PP (IN WITH) (NP (NP (NN CAUTION)) (PP (IN IN) (NP (NP (DT THOSE) (NNS PATIENTS)) (VP (VBG REVEIVING) (NP (NP (NN PHENYTOIN)) (CC AND) (NP (PRP$ ITS) (NN CONGENER) (NNS S)))))))))))) (. .))))

Sentence Id: DrugDDI.d383.s2
SINCE/IN THE/DT CONCOMITANT/JJ ADMINISTRATION/NN OF/IN THESE/DT TWO/CD DRUGS/NNS CAN/MD LEAD/VB TO/TO PHENYTOIN/NN INTOXICATION/NN ,/, PRIOR/JJ TO/TO ADMINISTERING/VBG DISULFIRAM/NN TO/TO A/DT PATIENT/NN ON/IN PHENYTOIN/NN THERAPY/NN ,/, A/DT BASELINE/NN PHENYTOIN/NN SERUM/NN LEVEL/NN SHOULD/MD BE/VB OBTAINED/VBN ./.

(ROOT (S1 (S (SBAR (IN SINCE) (S (NP (NP (DT THE) (JJ CONCOMITANT) (NN ADMINISTRATION)) (PP (IN OF) (NP (DT THESE) (CD TWO) (NNS DRUGS)))) (VP (MD CAN) (VP (VB LEAD) (PP (TO TO) (NP (NN PHENYTOIN) (NN INTOXICATION))))))) (, ,) (PP (JJ PRIOR) (TO TO) (S (VP (VBG ADMINISTERING) (NP (NN DISULFIRAM)) (PP (TO TO) (NP (NP (DT A) (NN PATIENT)) (PP (IN ON) (NP (NN PHENYTOIN) (NN THERAPY)))))))) (, ,) (NP (DT A) (NN BASELINE) (NN PHENYTOIN) (NN SERUM) (NN LEVEL)) (VP (MD SHOULD) (VP (VB BE) (VP (VBN OBTAINED)))) (. .))))

Sentence Id: DrugDDI.d383.s4
SERUM/NN LEVELS/NNS OF/IN PHENYTOIN/NN SHOULD/MD BE/VB DETERMINED/VBN ON/IN DIFFERENT/JJ DAYS/NNS FOR/IN EVIDENCE/NN OF/IN AN/DT INCREASE/NN OR/CC FOR/IN A/DT CONTINUING/VBG RISE/NN IN/IN LEVELS/NNS ./.

(ROOT (S1 (S (S (NP (NP (NN SERUM) (NNS LEVELS)) (PP (IN OF) (NP (NN PHENYTOIN)))) (VP (MD SHOULD) (VP (VB BE) (VP (VBN DETERMINED) (PP (IN ON) (NP (NP (JJ DIFFERENT) (NNS DAYS)) (PP (PP (IN FOR) (NP (NP (NN EVIDENCE)) (PP (IN OF) (NP (DT AN) (NN INCREASE))))) (CC OR) (PP (IN FOR) (NP (NP (DT A) (VBG CONTINUING) (NN RISE)) (PP (IN IN) (NP (NNS LEVELS)))))))))))) (. .))))

Sentence Id: DrugDDI.d383.s6
It/PRP may/MD be/VB necessary/JJ to/TO adjust/VB the/DT dosage/NN of/IN oral/JJ anticoagulants/NNS upon/IN beginning/NN or/CC stopping/JJ disulfiram/NN ./. since/IN disulfiram/NN may/MD prolong/VB prothrombin/NN time/NN ./.

(ROOT (S1 (S (S (NP (PRP It)) (VP (MD may) (VP (VB be) (ADJP (JJ necessary) (S (S (VP (TO to) (VP (VB adjust) (NP (NP (DT the) (NN dosage)) (PP (IN of) (NP (JJ oral) (NNS anticoagulants)))) (PP (IN upon) (NP (NP (NN beginning)) (CC or) (NP (JJ stopping) (NN disulfiram))))))) (. .))) (SBAR (IN since) (S (NP (NN disulfiram)) (VP (MD may) (VP (VB prolong) (NP (NN prothrombin) (NN time))))))))) (. .))))

Sentence Id: DrugDDI.d383.s7
Patients/NNS taking/VBG isoniazid/NN when/WRB disulfiram/NN is/VBZ given/VBN should/MD be/VB observed/VBN for/IN the/DT appearance/NN of/IN unsteady/NN gait/NN or/CC marked/JJ changes/NNS in/IN mental/JJ status/NN ;/: ./.

(ROOT (S1 (S (S (NP (NP (NNS Patients)) (VP (VBG taking) (NP (NP (NN isoniazid)) (SBAR (WHADVP (WRB when)) (S (NP (NN disulfiram)) (VP (VBZ is) (VP (VBN given)))))))) (VP (MD should) (VP (VB be) (VP (VBN observed) (PP (IN for) (NP (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (NN unsteady) (NN gait)))) (CC or) (NP (NP (JJ marked) (NNS changes)) (PP (IN in) (NP (JJ mental) (NN status))))))))) (: ;)) (. .))))

Sentence Id: DrugDDI.d383.s8
the/DT disulfiram/NN should/MD be/VB discontinued/VBN if/IN such/JJ signs/NNS appear/VBP ./.

(ROOT (S1 (S (S (NP (DT the) (NN disulfiram)) (VP (MD should) (VP (VB be) (VP (VBN discontinued) (SBAR (IN if) (S (NP (JJ such) (NNS signs)) (VP (VBP appear)))))))) (. .))))

Sentence Id: DrugDDI.d383.s9
In/IN rats/NNS ,/, simultaneous/JJ ingestion/NN of/IN disulfiram/NN and/CC nitrite/NN in/IN the/DT diet/NN for/IN 78/CD weeks/NNS has/VBZ been/VBN reported/VBN to/TO cause/VB tumors/NNS ,/, and/CC it/PRP has/VBZ been/VBN suggested/VBN that/IN disulfiram/NN may/MD react/VB with/IN nitrites/NNS in/IN the/DT rat/NN stomach/NN to/TO form/VB a/DT nitrosamine/NN ,/, which/WDT is/VBZ tumorigenic/JJ ./.

(ROOT (S1 (S (S (S (PP (IN In) (NP (NNS rats))) (, ,) (NP (NP (JJ simultaneous) (NN ingestion)) (PP (IN of) (NP (NP (NN disulfiram)) (CC and) (NP (NN nitrite)))) (PP (IN in) (NP (NP (DT the) (NN diet)) (PP (IN for) (NP (CD 78) (NNS weeks)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB cause) (NP (NNS tumors))))))))) (, ,) (CC and) (S (NP (PRP it)) (VP (VBZ has) (VP (VBN been) (VP (VBN suggested) (SBAR (IN that) (S (NP (NN disulfiram)) (VP (MD may) (VP (VB react) (PP (IN with) (NP (NP (NNS nitrites)) (PP (IN in) (NP (DT the) (NN rat) (NN stomach))))) (S (VP (TO to) (VP (VB form) (NP (NP (DT a) (NN nitrosamine)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADJP (JJ tumorigenic)))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d383.s10
Disulfiram/NN alone/RB in/IN the/DT rat/NN @/NN s/NN diet/NN did/VBD not/RB lead/VB to/TO such/JJ tumors/NNS ./.

(ROOT (S1 (S (S (NP (NP (NN Disulfiram)) (ADVP (RB alone)) (PP (IN in) (NP (DT the) (NN rat) (NN @) (NN s) (NN diet)))) (VP (VBD did) (RB not) (VP (VB lead) (PP (TO to) (NP (JJ such) (NNS tumors)))))) (. .))))

Sentence Id: DrugDDI.d106.s0
There/EX have/VBP been/VBN no/DT formal/JJ clinical/JJ studies/NNS to/TO evaluate/VB the/DT drug/NN interactions/NNS of/IN TAXOTERE/NN with/IN other/JJ medications/NNS ./.

(ROOT (S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (DT no) (JJ formal) (JJ clinical) (NNS studies)) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN drug) (NNS interactions)) (PP (IN of) (NP (NN TAXOTERE))) (PP (IN with) (NP (JJ other) (NNS medications)))))))))) (. .))))

Sentence Id: DrugDDI.d106.s1
In/FW vitro/FW studies/NNS have/VBP shown/VBN that/IN the/DT metabolism/NN of/IN docetaxel/NN may/MD be/VB modified/VBN by/IN the/DT concomitant/JJ administration/NN of/IN compounds/NNS that/WDT induce/VBP ,/, inhibit/VBP ,/, or/CC are/VBP metabolized/VBN by/IN cytochrome/NN P450/NN 3A4/NN ,/, such/JJ as/IN cyclosporine/NN ,/, terfenadine/NN ,/, ketoconazole/NN ,/, erythromycin/NN ,/, and/CC troleandomycin/NN ./.

(ROOT (S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN docetaxel)))) (VP (MD may) (VP (VB be) (VP (VBN modified) (PP (IN by) (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NNS compounds)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBP induce)) (, ,) (VP (VBP inhibit)) (, ,) (CC or) (VP (VBP are) (VP (VBN metabolized) (PP (IN by) (NP (NN cytochrome) (NN P450) (NN 3A4)))))))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN cyclosporine)) (, ,) (NP (NN terfenadine)) (, ,) (NP (NN ketoconazole)) (, ,) (NP (NN erythromycin)) (, ,) (CC and) (NP (NN troleandomycin)))))))))))))))) (. .))))

Sentence Id: DrugDDI.d106.s2
Caution/NN should/MD be/VB exercised/VBN with/IN these/DT drugs/NNS when/WRB treating/VBG patients/NNS receiving/VBG TAXOTERE/NN as/IN there/EX is/VBZ a/DT potential/NN for/IN a/DT significant/JJ interaction/NN ./.

(ROOT (S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (PP (IN with) (NP (DT these) (NNS drugs))) (SBAR (WHADVP (WRB when)) (S (VP (VBG treating) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN TAXOTERE) (SBAR (IN as) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (NN potential)) (PP (IN for) (NP (DT a) (JJ significant) (NN interaction))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d212.s0
Clinical/JJ trials/NNS have/VBP indicated/VBN that/IN Pulmozyme/NN can/MD be/VB effectively/RB and/CC safely/RB used/VBN in/IN conjunction/NN with/IN standard/JJ cystic/JJ fibrosis/NN therapies/NNS including/VBG oral/JJ ,/, inhaled/JJ and/or/CC parenteral/JJ antibiotics/NNS ,/, bronchodilators/NNS ,/, enzyme/NN supplements/NNS ,/, vitamins/NNS ,/, oral/JJ or/CC inhaled/JJ corticosteroids/NNS ,/, and/CC analgesics/NNS ./.

(ROOT (S1 (S (S (NP (JJ Clinical) (NNS trials)) (VP (VBP have) (VP (VBN indicated) (SBAR (IN that) (S (NP (NN Pulmozyme)) (VP (MD can) (VP (VB be) (ADVP (ADVP (RB effectively)) (CC and) (ADVP (RB safely))) (VP (VBN used) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (NP (JJ standard) (JJ cystic) (NN fibrosis)) (NNS therapies)) (PP (VBG including) (NP (NP (ADJP (ADJP (JJ oral)) (, ,) (ADJP (JJ inhaled)) (CC and/or) (ADJP (JJ parenteral))) (NNS antibiotics)) (, ,) (NP (NNS bronchodilators)) (, ,) (NP (NN enzyme) (NNS supplements)) (, ,) (NP (NNS vitamins)) (, ,) (NP (JJ oral) (CC or) (JJ inhaled) (NNS corticosteroids)) (, ,) (CC and) (NP (NNS analgesics)))))))))))))))) (. .))))

Sentence Id: DrugDDI.d43.s0
Prior/JJ administration/NN of/IN succinylcholine/NN has/VBZ no/DT clinically/RB important/JJ effect/NN on/IN the/DT neuromuscular/JJ blocking/NN action/NN of/IN NUROMAX/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Prior) (NN administration)) (PP (IN of) (NP (NN succinylcholine)))) (VP (VBZ has) (NP (DT no) (ADJP (RB clinically) (JJ important)) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ neuromuscular) (NN blocking) (NN action)) (PP (IN of) (NP (NN NUROMAX))))))) (. .))))

Sentence Id: DrugDDI.d43.s1
The/DT use/NN of/IN NUROMAX/NN before/IN succinylcholine/NN to/TO attenuate/VB some/DT of/IN the/DT side/JJ effects/NNS of/IN succinylcholine/NN has/VBZ not/RB been/VBN studied/VBN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NN NUROMAX))) (PP (IN before) (NP (NP (NN succinylcholine)) (VP (TO to) (VP (VB attenuate) (NP (NP (DT some)) (PP (IN of) (NP (NP (DT the) (JJ side) (NNS effects)) (PP (IN of) (NP (NN succinylcholine))))))))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .))))

Sentence Id: DrugDDI.d43.s2
There/EX are/VBP no/DT clinical/JJ data/NNS on/IN concomitant/JJ use/NN of/IN NUROMAX/NN and/CC other/JJ nondepolarizing/JJ neuromuscular/NN blocking/NN agents/NNS ./.

(ROOT (S1 (S (S (NP (EX There)) (VP (VBP are) (NP (NP (DT no) (JJ clinical) (NNS data)) (PP (IN on) (NP (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NN NUROMAX)))) (CC and) (NP (JJ other) (JJ nondepolarizing) (NN neuromuscular) (NN blocking) (NNS agents))))))) (. .))))

Sentence Id: DrugDDI.d43.s3
Isoflurane/NN ,/, enflurane/NN ,/, and/CC halothane/NN decrease/VBP the/DT ED50/NN of/IN NUROMAX/NN by/IN 30/CD %/NN to/TO 45/CD %./NN

(ROOT (S1 (S (NP (NP (NN Isoflurane)) (, ,) (NP (NN enflurane)) (, ,) (CC and) (NP (NN halothane))) (VP (VBP decrease) (NP (NP (DT the) (NN ED50)) (PP (IN of) (NP (NN NUROMAX)))) (PP (IN by) (NP (CD 30) (NN %))) (PP (TO to) (NP (CD 45) (NN %.)))))))

Sentence Id: DrugDDI.d43.s5
Other/JJ drugs/NNS which/WDT may/MD enhance/VB the/DT neuromuscular/JJ blocking/NN action/NN of/IN nondepolarizing/NN agent/NN s/NNS such/JJ as/IN NUROMAX/NN include/VBP certain/JJ antibiotics/NNS (/-LRB- e./FW g./FW ,/, aminoglycosides/NNS ,/, tetracyclines/NNS ,/, bacitracin/NN ,/, polymyxins/NNS ,/, lincomycin/NN ,/, clindamycin/NN ,/, colistin/NN ,/, and/CC sodium/NN colistimethate/NN )/-RRB- ,/, magnesium/NN salt/NN s/NNS ,/, lithium/NN ,/, local/JJ anesthetics/NNS ,/, procainamide/NN ,/, and/CC quinidine/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Other) (NNS drugs)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (JJ neuromuscular) (NN blocking) (NN action)) (PP (IN of) (NP (NP (NN nondepolarizing) (NN agent) (NNS s)) (PP (JJ such) (IN as) (NP (NN NUROMAX))))))))))) (VP (VBP include) (NP (NP (NP (JJ certain) (NNS antibiotics)) (PRN (-LRB- -LRB-) (FRAG (NP (FW e.) (FW g.)) (, ,) (NP (NNS aminoglycosides)) (, ,) (NP (NNS tetracyclines)) (, ,) (NP (NN bacitracin)) (, ,) (NP (NP (NNS polymyxins)) (, ,) (NP (NN lincomycin)) (, ,) (NP (NN clindamycin)) (, ,) (NP (NN colistin)) (, ,) (CC and) (NP (NN sodium) (NN colistimethate)))) (-RRB- -RRB-))) (, ,) (NP (NN magnesium) (NN salt) (NNS s)) (, ,) (NP (NN lithium)) (, ,) (NP (JJ local) (NNS anesthetics)) (, ,) (NP (NN procainamide)) (, ,) (CC and) (NP (NN quinidine))))) (. .))))

Sentence Id: DrugDDI.d43.s6
As/IN with/IN some/DT other/JJ nondepolarizing/JJ neuromuscular/JJ blocking/NN agents/NNS ,/, the/DT time/NN of/IN onset/NN of/IN neuromuscular/JJ block/NN induced/VBN by/IN NUROMAX/NN is/VBZ lengthened/VBN and/CC the/DT duration/NN of/IN block/NN is/VBZ shortened/VBD in/IN patients/NNS receiving/VBG phenytoin/NN or/CC carbamazepine/NN ./.

(ROOT (S1 (S (S (S (PP (IN As) (PP (IN with) (NP (DT some) (JJ other) (JJ nondepolarizing) (JJ neuromuscular) (NN blocking) (NNS agents)))) (, ,) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NP (NN onset)) (PP (IN of) (NP (NP (JJ neuromuscular) (NN block)) (VP (VBN induced) (PP (IN by) (NP (NN NUROMAX))))))))) (VP (VBZ is) (VP (VBN lengthened)))) (CC and) (S (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NN block)))) (VP (VBZ is) (VP (VBD shortened) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN phenytoin)) (CC or) (NP (NN carbamazepine)))))))))) (. .))))

Sentence Id: DrugDDI.d55.s0
Administration/NN of/IN doxapram/NN to/TO patients/NNS who/WP are/VBP receiving/VBG sympathomimetic/NN or/CC monoamine/NN oxidase/NN inhibiting/NN drugs/NNS may/MD result/VB in/IN an/DT additive/JJ pressor/JJ effect/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN doxapram))) (PP (TO to) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (VP (VBG receiving) (NP (NP (NP (NN sympathomimetic)) (CC or) (NP (NN monoamine) (NN oxidase))) (NN inhibiting) (NNS drugs))))))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (DT an) (JJ additive) (JJ pressor) (NN effect)))))) (. .))))

Sentence Id: DrugDDI.d55.s1
In/IN patients/NNS who/WP have/VBP received/VBN muscle/NN relaxants/NNS ,/, doxapram/NN may/MD temporarily/RB mask/VB the/DT residual/JJ effects/NNS of/IN muscle/NN relaxant/NN drugs/NNS ./.

(ROOT (S1 (S (S (PP (IN In) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP have) (VP (VBN received) (NP (NN muscle) (NNS relaxants)))))))) (, ,) (NP (NN doxapram)) (VP (MD may) (ADVP (RB temporarily)) (VP (VB mask) (NP (NP (DT the) (JJ residual) (NNS effects)) (PP (IN of) (NP (NN muscle) (NN relaxant) (NNS drugs))))))) (. .))))

Sentence Id: DrugDDI.d55.s2
In/IN patients/NNS who/WP have/VBP received/VBN general/JJ anesthesia/NN utilizing/VBG a/DT volatile/JJ agent/NN known/VBN to/TO sensitize/VB the/DT myocardium/NN to/TO catecholamines/NNS ,/, administration/NN of/IN doxapram/NN should/MD be/VB delayed/VBN until/IN the/DT volatile/JJ agent/NN has/VBZ been/VBN excreted/VBN in/IN order/NN to/TO lessen/VB the/DT potential/NN for/IN arrhythmias/NNS ,/, including/VBG ventricular/JJ tachycardia/NN and/CC ventricular/JJ fibrillation/NN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP have) (VP (VBN received) (NP (NP (JJ general) (NN anesthesia)) (VP (VBG utilizing) (NP (NP (DT a) (JJ volatile) (NN agent)) (VP (VBN known) (S (VP (TO to) (VP (VB sensitize) (NP (NP (DT the) (NN myocardium)) (PP (TO to) (NP (NNS catecholamines))))))))))))))))) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (NN doxapram)))) (VP (MD should) (VP (VB be) (VP (VBN delayed) (SBAR (IN until) (S (NP (DT the) (JJ volatile) (NN agent)) (VP (VBZ has) (VP (VBN been) (VP (VBN excreted) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB lessen) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NP (NNS arrhythmias)) (, ,) (PP (VBG including) (NP (NP (JJ ventricular) (NN tachycardia)) (CC and) (NP (JJ ventricular) (NN fibrillation)))))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d93.s0
Drug/NN interaction/NN studies/NNS with/IN Xigris/NN have/VBP not/RB been/VBN performed/VBN in/IN patients/NNS with/IN severe/JJ sepsis/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Drug) (NN interaction) (NNS studies)) (PP (IN with) (NP (NN Xigris)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN performed) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ severe) (NN sepsis))))))))) (. .))))

Sentence Id: DrugDDI.d93.s1
However/RB ,/, since/IN there/EX is/VBZ an/DT increased/VBN risk/NN of/IN bleeding/JJ with/IN Xigris/NN ,/, caution/NN should/MD be/VB employed/VBN when/WRB Xigris/NN is/VBZ used/VBN with/IN other/JJ drugs/NNS that/WDT affect/VBP hemostasis/NN ./.

(ROOT (S1 (S (S (ADVP (RB However)) (, ,) (SBAR (IN since) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (JJ bleeding))) (PP (IN with) (NP (NN Xigris))))))) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN employed) (SBAR (WHADVP (WRB when)) (S (NP (NN Xigris)) (VP (VBZ is) (VP (VBN used) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP affect) (NP (NN hemostasis))))))))))))))) (. .))))

Sentence Id: DrugDDI.d93.s2
Approximately/RB 2/3/CD of/IN the/DT patients/NNS in/IN the/DT Phase/NN 3/CD study/NN received/VBD either/DT prophylactic/JJ low/JJ dose/NN heparin/NN (/-LRB- unfractionated/JJ heparin/NN up/RB to/TO 15,000/CD units/day/NN )/-RRB- or/CC prophylactic/JJ doses/NNS of/IN low/JJ molecular/JJ weight/NN heparins/NNS as/IN indicated/VBN in/IN the/DT prescribing/JJ information/NN for/IN the/DT specific/JJ products/NNS ./.

(ROOT (S1 (S (S (NP (NP (RB Approximately) (CD 2/3)) (PP (IN of) (NP (NP (DT the) (NNS patients)) (PP (IN in) (NP (DT the) (NN Phase) (CD 3) (NN study)))))) (VP (VBD received) (NP (NP (NP (DT either) (JJ prophylactic) (JJ low) (NN dose) (NN heparin)) (PRN (-LRB- -LRB-) (NP (NP (JJ unfractionated) (NN heparin)) (ADJP (QP (RB up) (TO to) (CD 15,000)) (NN units/day))) (-RRB- -RRB-))) (CC or) (NP (NP (JJ prophylactic) (NNS doses)) (PP (IN of) (NP (NP (JJ low) (JJ molecular) (NN weight) (NNS heparins)) (SBAR (IN as) (S (VP (VBN indicated) (PP (IN in) (NP (NP (DT the) (JJ prescribing) (NN information)) (PP (IN for) (NP (DT the) (JJ specific) (NNS products)))))))))))))) (. .))))

Sentence Id: DrugDDI.d93.s3
Concomitant/JJ use/NN of/IN prophylactic/JJ low/JJ dose/NN heparin/NN did/VBD not/RB appear/VB to/TO affect/VB safety/NN ,/, however/RB ,/, its/PRP$ effects/NNS on/IN the/DT efficacy/NN of/IN Xigris/NN have/VBP not/RB been/VBN evaluated/VBN in/IN an/DT adequate/JJ and/CC well-controlled/JJ clinical/JJ trial/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (JJ prophylactic) (JJ low) (NN dose) (NN heparin)))) (VP (VBD did) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB affect) (NP (NN safety)) (, ,) (S (ADVP (RB however)) (, ,) (NP (NP (PRP$ its) (NNS effects)) (PP (IN on) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NN Xigris)))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN evaluated) (PP (IN in) (NP (DT an) (ADJP (ADJP (JJ adequate)) (CC and) (ADJP (JJ well-controlled))) (JJ clinical) (NN trial))))))))))))) (. .))))

Sentence Id: DrugDDI.d93.s4
Drug/NN /Laboratory/NN Test/NN Interaction/NN Because/IN Xigris/NN may/MD affect/VB the/DT APTT/NN assay/NN ,/, Xigris/NN present/NN in/IN plasma/NN samples/NNS may/MD interfere/VB with/IN one-stage/JJ coagulation/NN assays/NNS based/VBN on/IN the/DT APTT/NN (/-LRB- such/JJ as/IN factor/NN VIII/NN ,/, IX/NN ,/, and/CC XI/NN assays/NNS )./CD

(ROOT (S1 (S (NP (NN Drug) (NN /Laboratory) (NN Test) (NN Interaction)) (SBAR (IN Because) (S (NP (NN Xigris)) (VP (MD may) (VP (VB affect) (NP (DT the) (NN APTT) (NN assay)))))) (, ,) (S (NP (NP (NN Xigris) (NN present)) (PP (IN in) (NP (NN plasma) (NNS samples)))) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (NP (JJ one-stage) (NN coagulation) (NNS assays)) (VP (VBN based) (PP (IN on) (NP (DT the) (NN APTT)))) (-LRB- -LRB-) (PP (JJ such) (IN as) (NP (NN factor) (NN VIII)))) (, ,) (NP (NN IX)) (, ,) (CC and) (NP (NN XI) (NNS assays) (CD -RRB-.))))))))))

Sentence Id: DrugDDI.d93.s6
Xigris/NN present/JJ in/IN plasma/NN samples/NNS does/VBZ not/RB interfere/VB with/IN one-stage/JJ factor/NN assays/NNS based/VBN on/IN the/DT PT/NN (/-LRB- such/JJ as/IN factor/NN II/CD ,/, V/NN ,/, VII/NN ,/, and/CC X/NN assays/NNS )./NN

(ROOT (S1 (S (NP (NP (NN Xigris)) (ADJP (JJ present) (PP (IN in) (NP (NN plasma) (NNS samples))))) (VP (VBZ does) (RB not) (VP (VB interfere) (PP (IN with) (NP (NP (JJ one-stage) (NN factor) (NNS assays)) (VP (VBN based) (PP (IN on) (NP (DT the) (NN PT) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NP (NN factor) (CD II)) (, ,) (NP (NN V)) (, ,) (NP (NN VII)) (, ,) (CC and) (NP (NN X) (NNS assays)))))) (NN -RRB-.)))))))))))

Sentence Id: DrugDDI.d522.s1
Steroids/NNS enhance/VBP the/DT renal/JJ toxicity/NN of/IN edetate/NN calcium/NN disodium/NN in/IN animals./NN 7/CD Edetate/NN calcium/NN disodium/NN interferes/VBZ with/IN the/DT action/NN of/IN zinc/NN insulin/NN preparations/NNS by/IN chelating/NN the/DT zinc/NN ./. 7/CD ./.

(ROOT (S1 (S (S (NP (NNS Steroids)) (VP (VBP enhance) (NP (NP (DT the) (JJ renal) (NN toxicity)) (PP (IN of) (NP (NN edetate) (NN calcium) (NN disodium))) (SBAR (IN in) (S (NP (NN animals.) (CD 7) (NN Edetate) (NN calcium) (NN disodium)) (VP (VBZ interferes) (PP (IN with) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NN zinc) (NN insulin) (NNS preparations))))) (PP (IN by) (S (VP (NN chelating) (NP (DT the) (NN zinc)))))))) (. .) (CD 7)))) (. .))))

Sentence Id: DrugDDI.d496.s0
Efavirenz/NN has/VBZ been/VBN shown/VBN in/FW vivo/FW to/TO induce/VB CYP3A4/NN ./.

(ROOT (S1 (S (S (NP (NN Efavirenz)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (ADVP (FW in) (FW vivo)) (S (VP (TO to) (VP (VB induce) (NP (NN CYP3A4))))))))) (. .))))

Sentence Id: DrugDDI.d496.s1
Other/JJ compounds/NNS that/WDT are/VBP substrates/NNS of/IN CYP3A4/NN may/MD have/VBP decreased/VBN plasma/NN concentrations/NNS when/WRB coadministered/VBN with/IN SUSTIVA/NN (/-LRB- efavirenz/NN )/-RRB- ./.

(ROOT (S1 (S (S (NP (NP (JJ Other) (NNS compounds)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NNS substrates)) (PP (IN of) (NP (NN CYP3A4)))))))) (VP (MD may) (VP (VBP have) (NP (VBN decreased) (NN plasma) (NNS concentrations)) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NP (NN SUSTIVA)) (PRN (-LRB- -LRB-) (NP (NN efavirenz)) (-RRB- -RRB-)))))))))) (. .))))

Sentence Id: DrugDDI.d496.s2
In/FW vitro/FW studies/NNS have/VBP demonstrated/VBN that/IN efavirenz/NN inhibits/VBZ 2C9/NN ,/, 2C19/NN ,/, and/CC 3A4/NN isozymes/NNS in/IN the/DT range/NN of/IN observed/VBN efavirenz/NN plasma/NN concentrations/NNS ./.

(ROOT (S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP have) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NN efavirenz)) (VP (VBZ inhibits) (NP (NP (NN 2C9)) (, ,) (NP (NN 2C19)) (, ,) (CC and) (NP (NN 3A4) (NNS isozymes))) (PP (IN in) (NP (NP (DT the) (NN range)) (PP (IN of) (NP (VBN observed) (NN efavirenz) (NN plasma) (NNS concentrations))))))))))) (. .))))

Sentence Id: DrugDDI.d496.s3
Coadministration/NN of/IN efavirenz/NN with/IN drugs/NNS primarily/RB metabolized/VBN by/IN these/DT isozymes/NNS may/MD result/VB in/IN altered/JJ plasma/NN concentrations/NNS of/IN the/DT coadministered/JJ drug/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN efavirenz))) (PP (IN with) (NP (NP (NNS drugs)) (VP (ADVP (RB primarily)) (VBN metabolized) (PP (IN by) (NP (DT these) (NNS isozymes))))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (JJ altered) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (DT the) (JJ coadministered) (NN drug)))))))) (. .))))

Sentence Id: DrugDDI.d496.s4
Therefore/RB ,/, appropriate/JJ dose/NN adjustments/NNS may/MD be/VB necessary/JJ for/IN these/DT drugs/NNS ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (JJ appropriate) (NN dose) (NNS adjustments)) (VP (MD may) (VP (VB be) (ADJP (JJ necessary) (PP (IN for) (NP (DT these) (NNS drugs))))))) (. .))))

Sentence Id: DrugDDI.d496.s5
Drugs/NNS which/WDT induce/VBP CYP3A4/NN activity/NN (/-LRB- eg/NN ,/, phenobarbital/NN ,/, rifampin/NN ,/, rifabutin/NN )/-RRB- would/MD be/VB expected/VBN to/TO increase/VB the/DT clearance/NN of/IN efavirenz/NN resulting/VBG in/IN lowered/JJ plasma/NN concentrations/NNS ./.

(ROOT (S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT which)) (S (VP (VBP induce) (NP (NP (NN CYP3A4) (NN activity)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN phenobarbital)) (, ,) (NP (NN rifampin)) (, ,) (NP (NN rifabutin))) (-RRB- -RRB-))))))) (VP (MD would) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NP (NN efavirenz)) (VP (VBG resulting) (PP (IN in) (NP (JJ lowered) (NN plasma) (NNS concentrations)))))))))))))) (. .))))

Sentence Id: DrugDDI.d496.s6
Drug/NN interactions/NNS with/IN SUSTIVA/NN are/VBP summarized/VBN in/IN Table/NN 5/CD ./.

(ROOT (S1 (S (S (NP (NP (NN Drug) (NNS interactions)) (PP (IN with) (NP (NN SUSTIVA)))) (VP (VBP are) (VP (VBN summarized) (PP (IN in) (NP (NN Table) (CD 5)))))) (. .))))

Sentence Id: DrugDDI.d496.s7
Table/JJ 5a/NN :/: Drugs/NNS That/WDT Should/MD Not/RB Be/VB Coadministered/VBN With/IN SUSTIVA/NN ./.

(ROOT (S1 (S (NP (NP (JJ Table) (NN 5a)) (: :) (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT That)) (S (VP (MD Should) (RB Not) (VP (VB Be) (VP (VBN Coadministered) (PP (IN With) (NP (NN SUSTIVA))))))))) (. .)))))

Sentence Id: DrugDDI.d496.s8
Drug/NN Class/NN ./.

(ROOT (S1 (S (NP (NP (NN Drug) (NN Class)) (. .)))))

Sentence Id: DrugDDI.d496.s9
Drugs/NNS Within/IN Class/NN Not/RB To/TO Be/VB Coadministered/VBN With/IN SUSTIVA/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Drugs)) (PP (IN Within) (NP (NN Class)))) (VP (RB Not) (TO To) (VP (VB Be) (VP (VBN Coadministered) (PP (IN With) (NP (NN SUSTIVA))))))) (. .))))

Sentence Id: DrugDDI.d496.s10
Antihistamines/NNS Benzodiazepines/NN GI/NN Motility/NN Agents/NNS Anti-Migraine/JJ Antifungal/JJ ./.

(ROOT (S1 (S (S (NP (NNS Antihistamines)) (VP (NN Benzodiazepines) (NP (NN GI) (NN Motility) (NNS Agents) (JJ Anti-Migraine) (JJ Antifungal)))) (. .))))

Sentence Id: DrugDDI.d496.s11
astemizole/NN midazolam/NNS ,/, triazolam/NN cisapride/NN ergot/NN derivatives/NNS voriconazole/NN ./.

(ROOT (S1 (S (S (NP (NP (NN astemizole) (NNS midazolam)) (, ,) (NP (NN triazolam) (NN cisapride) (NN ergot) (NNS derivatives))) (NP (NN voriconazole))) (. .))))

Sentence Id: DrugDDI.d496.s14
Drug/NN Name/NN ./.

(ROOT (S1 (S (NP (NP (NN Drug) (NN Name)) (. .)))))

Sentence Id: DrugDDI.d496.s17
Atazanavir/NN ./.

(ROOT (S1 (S (NP (NP (NN Atazanavir)) (. .)))))

Sentence Id: DrugDDI.d496.s19
When/WRB coadministered/VBN with/IN SUSTIVA/NN in/IN treatment-naive/JJ patients/NNS ,/, the/DT recommended/VBN dose/NN of/IN atazanavir/NN is/VBZ 300/CD mg/NN with/IN ritonavir/NN 100/CD mg/NN and/CC SUSTIVA/NN 600/CD mg/NN (/-LRB- all/DT once/RB daily/JJ )./NN

(ROOT (S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN coadministered) (PP (IN with) (NP (NP (NN SUSTIVA)) (PP (IN in) (NP (JJ treatment-naive) (NNS patients)))))))) (, ,) (NP (NP (DT the) (VBN recommended) (NN dose)) (PP (IN of) (NP (NN atazanavir)))) (VP (VBZ is) (NP (NP (CD 300) (NN mg)) (PP (IN with) (NP (NP (NP (NN ritonavir) (CD 100) (NN mg)) (CC and) (NP (NN SUSTIVA) (CD 600) (NN mg))) (PRN (-LRB- -LRB-) (NP (DT all) (ADJP (RB once) (JJ daily)) (NN -RRB-.))))))))))

Sentence Id: DrugDDI.d496.s20
Dosing/NN recommendations/NNS for/IN SUSTIVA/NN and/CC atazanavir/NN in/IN treatment-experienced/JJ patients/NNS have/VBP not/RB been/VBN established/VBN ./.

(ROOT (S1 (S (S (NP (NP (NN Dosing) (NNS recommendations)) (PP (IN for) (NP (NP (NP (NN SUSTIVA)) (CC and) (NP (NN atazanavir))) (PP (IN in) (NP (JJ treatment-experienced) (NNS patients)))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN established))))) (. .))))

Sentence Id: DrugDDI.d496.s22
Drug/NN Name/NN ./.

(ROOT (S1 (S (NP (NP (NN Drug) (NN Name)) (. .)))))

Sentence Id: DrugDDI.d496.s25
Clarithromycin/NN ./.

(ROOT (S1 (S (NP (NP (NN Clarithromycin)) (. .)))))

Sentence Id: DrugDDI.d496.s26
@/NN @/NN clarithromycin/NN concentration/NN ./.

(ROOT (S1 (S (NP (NP (NN @) (NN @) (NN clarithromycin) (NN concentration)) (. .)))))

Sentence Id: DrugDDI.d496.s27
Plasma/NN concentrations/NNS decreased/VBD by/IN SUSTIVA/NN ;/: ./.

(ROOT (S1 (S (S (NP (NN Plasma) (NNS concentrations)) (VP (VBD decreased) (PP (IN by) (NP (NN SUSTIVA)))) (: ;)) (. .))))

Sentence Id: DrugDDI.d496.s29
In/IN uninfected/JJ volunteers/NNS ,/, 46/CD %/NN developed/VBD rash/NN while/IN receiving/VBG SUSTIVA/NN and/CC clarithromycin/NN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (JJ uninfected) (NNS volunteers))) (, ,) (NP (CD 46) (NN %)) (VP (VBD developed) (NP (NN rash)) (PP (IN while) (S (VP (VBG receiving) (NP (NP (NN SUSTIVA)) (CC and) (NP (NN clarithromycin)))))))) (. .))))

Sentence Id: DrugDDI.d496.s30
No/DT dose/NN adjustment/NN of/IN SUSTIVA/NN is/VBZ recommended/VBN when/WRB given/VBN with/IN clarithromycin/NN ./.

(ROOT (S1 (S (S (NP (NP (DT No) (NN dose) (NN adjustment)) (PP (IN of) (NP (NN SUSTIVA)))) (VP (VBZ is) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN with) (NP (NN clarithromycin))))))))) (. .))))

Sentence Id: DrugDDI.d496.s31
Alternatives/NNS to/TO clarithromycin/NN ,/, such/JJ as/IN azithromycin/NN ,/, should/MD be/VB considered/VBN ./.

(ROOT (S1 (S (S (NP (NP (NNS Alternatives)) (PP (TO to) (NP (NN clarithromycin))) (, ,) (PP (JJ such) (IN as) (NP (NN azithromycin))) (, ,)) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (. .))))

Sentence Id: DrugDDI.d496.s32
Other/JJ macrolide/NN antibiotics/NNS ,/, such/JJ as/IN erythromycin/NN ,/, have/VBP not/RB been/VBN studied/VBN in/IN combination/NN with/IN SUSTIVA/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Other) (NN macrolide) (NNS antibiotics)) (, ,) (PP (JJ such) (IN as) (NP (NN erythromycin))) (, ,)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN studied) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN SUSTIVA))))))))) (. .))))

Sentence Id: DrugDDI.d496.s35
Indinavir/NN ./.

(ROOT (S1 (S (NP (NP (NN Indinavir)) (. .)))))

Sentence Id: DrugDDI.d496.s36
@/NN @/NN indinavir/NN concentration/NN ./.

(ROOT (S1 (S (NP (NP (NN @) (NN @) (NN indinavir) (NN concentration)) (. .)))))

Sentence Id: DrugDDI.d496.s37
The/DT optimal/JJ dose/NN of/IN indinavir/NN ,/, when/WRB given/VBN in/IN combination/NN with/IN SUSTIVA/NN ,/, is/VBZ not/RB known/VBN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (JJ optimal) (NN dose)) (PP (IN of) (NP (NN indinavir))) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN SUSTIVA)))))))) (, ,)) (VP (VBZ is) (RB not) (VP (VBN known)))) (. .))))

Sentence Id: DrugDDI.d496.s38
Increasing/VBG the/DT indinavir/NN dose/NN to/TO 1000/CD mg/NN every/DT 8/CD hours/NNS does/VBZ not/RB compensate/VB for/IN the/DT increased/VBN indinavir/NN metabolism/NN due/JJ to/TO SUSTIVA/NN ./.

(ROOT (S1 (S (S (NP (VBG Increasing) (NP (NP (DT the) (NN indinavir) (NN dose) (TO to) (CD 1000) (NN mg)) (NP (DT every) (CD 8) (NNS hours)))) (VP (VBZ does) (RB not) (VP (VB compensate) (PP (IN for) (NP (NP (DT the) (VBN increased) (NN indinavir) (NN metabolism)) (ADJP (JJ due) (PP (TO to) (NP (NN SUSTIVA))))))))) (. .))))

Sentence Id: DrugDDI.d496.s39
When/WRB indinavir/NN at/IN an/DT increased/VBN dose/NN (/-LRB- 1000/CD mg/NN every/DT 8/CD hours/NNS )/-RRB- was/VBD given/VBN with/IN SUSTIVA/NN (/-LRB- 600/CD mg/NN once/RB daily/JJ )/-RRB- ,/, the/DT indinavir/JJ AUC/NN and/CC Cmin/NN were/VBD decreased/VBN on/IN average/NN by/IN 33-46/CD %/NN and/CC 39-57/CD %/NN ,/, respectively/RB ,/, compared/VBN to/TO when/WRB indinavir/NN (/-LRB- 800/CD mg/NN every/DT 8/CD hours/NNS )/-RRB- was/VBD given/VBN alone/RB ./.

(ROOT (S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NN indinavir)) (PP (IN at) (NP (NP (DT an) (VBN increased) (NN dose)) (PRN (-LRB- -LRB-) (NP (NP (CD 1000) (NN mg)) (NP (DT every) (CD 8) (NNS hours))) (-RRB- -RRB-))))) (VP (VBD was) (VP (VBN given) (PP (IN with) (NP (NP (NN SUSTIVA)) (PRN (-LRB- -LRB-) (NP (NP (CD 600) (NN mg)) (ADJP (RB once) (JJ daily))) (-RRB- -RRB-)))))))) (, ,) (NP (NP (DT the) (JJ indinavir) (NN AUC)) (CC and) (NP (NN Cmin))) (VP (VBD were) (VP (VBN decreased) (PP (IN on) (NP (NN average))) (PP (IN by) (NP (NP (CD 33-46) (NN %)) (CC and) (NP (CD 39-57) (NN %)) (, ,) (ADVP (RB respectively)))) (, ,) (PP (VBN compared) (PP (TO to) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN indinavir)) (PRN (-LRB- -LRB-) (NP (CD 800) (NN mg) (NP (DT every) (CD 8) (NNS hours))) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (ADVP (RB alone)))))))))) (. .))))

Sentence Id: DrugDDI.d496.s40
Lopinavir/NN //: ritonavir/NN ./.

(ROOT (S1 (S (S (NP (NN Lopinavir)) (: /) (NP (NN ritonavir))) (. .))))

Sentence Id: DrugDDI.d496.s41
@/NN @/NN lopinavir/NN concentration/NN ./.

(ROOT (S1 (S (NP (NP (NN @) (NN @) (NN lopinavir) (NN concentration)) (. .)))))

Sentence Id: DrugDDI.d496.s42
A/DT dose/NN increase/NN of/IN lopinavir/NN //: ritonavir/NN to/TO 533/133/CD mg/NN (/-LRB- 4/CD capsules/NNS or/CC 6.5/CD mL/NN )/-RRB- twice/RB daily/RB taken/VBN with/IN food/NN is/VBZ recommended/VBN when/WRB used/VBN in/IN combination/NN with/IN SUSTIVA/NN ./.

(ROOT (S1 (S (S (NP (NP (NP (DT A) (NN dose) (NN increase)) (PP (IN of) (NP (NN lopinavir)))) (: /) (NP (NP (NP (NP (NN ritonavir) (TO to) (CD 533/133) (NN mg)) (PRN (-LRB- -LRB-) (NP (CD 4) (NNS capsules) (CC or) (CD 6.5) (NN mL)) (-RRB- -RRB-))) (ADVP (RB twice) (RB daily))) (VP (VBN taken) (PP (IN with) (NP (NN food)))))) (VP (VBZ is) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN SUSTIVA))))))))))) (. .))))

Sentence Id: DrugDDI.d496.s43
Methadone/NN ./.

(ROOT (S1 (S (NP (NP (NN Methadone)) (. .)))))

Sentence Id: DrugDDI.d496.s44
@/NN @/NN methadone/NN concentration/NN ./.

(ROOT (S1 (S (NP (NP (NN @) (NN @) (NN methadone) (NN concentration)) (. .)))))

Sentence Id: DrugDDI.d496.s45
Coadministration/NN in/IN HIV-infected/JJ individuals/NNS with/IN a/DT history/NN of/IN injection/NN drug/NN use/NN resulted/VBD in/IN decreased/VBN plasma/NN levels/NNS of/IN methadone/NN and/CC signs/NNS of/IN opiate/NN withdrawal/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Coadministration)) (PP (IN in) (NP (JJ HIV-infected) (NNS individuals))) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NN injection) (NN drug) (NN use)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (VBN decreased) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN methadone)))) (CC and) (NP (NP (NNS signs)) (PP (IN of) (NP (NN opiate) (NN withdrawal)))))))) (. .))))

Sentence Id: DrugDDI.d496.s48
Ethinyl/NN estradiol/NN ./.

(ROOT (S1 (S (NP (NP (NN Ethinyl) (NN estradiol)) (. .)))))

Sentence Id: DrugDDI.d496.s49
@/NN @/NN ethinyl/NN estradiol/NN concentration/NN ./.

(ROOT (S1 (S (S (NP (NN @) (NN @) (NN ethinyl) (NN estradiol)) (NP (NN concentration))) (. .))))

Sentence Id: DrugDDI.d496.s50
Plasma/NN concentrations/NNS increased/VBD by/IN SUSTIVA/NN (/-LRB- efavirenz/NN )/-RRB- ;/: ./.

(ROOT (S1 (S (S (NP (NN Plasma) (NNS concentrations)) (VP (VBD increased) (PP (IN by) (NP (NP (NN SUSTIVA)) (PRN (-LRB- -LRB-) (NP (NN efavirenz)) (-RRB- -RRB-))))) (: ;)) (. .))))

Sentence Id: DrugDDI.d496.s52
Because/IN the/DT potential/JJ interaction/NN of/IN efavirenz/NN with/IN oral/JJ contraceptives/NNS has/VBZ not/RB been/VBN fully/RB characterized/VBN ,/, a/DT reliable/JJ method/NN of/IN barrier/NN contraception/NN should/MD be/VB used/VBN in/IN addition/NN to/TO oral/JJ contraceptives/NNS ./.

(ROOT (S1 (S (S (SBAR (IN Because) (S (NP (NP (DT the) (JJ potential) (NN interaction)) (PP (IN of) (NP (NN efavirenz))) (PP (IN with) (NP (JJ oral) (NNS contraceptives)))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB fully)) (VP (VBN characterized)))))) (, ,) (NP (NP (DT a) (JJ reliable) (NN method)) (PP (IN of) (NP (NN barrier) (NN contraception)))) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (NP (JJ oral) (NNS contraceptives))))))))) (. .))))

Sentence Id: DrugDDI.d496.s53
Rifabutin/NN ./.

(ROOT (S1 (S (NP (NP (NN Rifabutin)) (. .)))))

Sentence Id: DrugDDI.d496.s54
@/NN @/NN rifabutin/NN concentration/NN ./.

(ROOT (S1 (S (NP (NP (NN @) (NN @) (NN rifabutin) (NN concentration)) (. .)))))

Sentence Id: DrugDDI.d496.s55
Increase/NN daily/JJ dose/NN of/IN rifabutin/NN by/IN 50/CD %./NN

(ROOT (S1 (S (NP (NP (NN Increase) (JJ daily) (NN dose)) (PP (IN of) (NP (NN rifabutin))) (PP (IN by) (NP (CD 50) (NN %.)))))))

Sentence Id: DrugDDI.d496.s56
Consider/VB doubling/VBG the/DT rifabutin/NN dose/NN in/IN regimens/NNS where/WRB rifabutin/NN is/VBZ given/VBN 2/CD or/CC 3/CD times/NNS a/DT week/NN ./.

(ROOT (S1 (S (S (NP (VB Consider)) (VP (VBG doubling) (NP (DT the) (NN rifabutin) (NN dose)) (PP (IN in) (NP (NP (NNS regimens)) (SBAR (WHADVP (WRB where)) (S (NP (NN rifabutin)) (VP (VBZ is) (VP (VBN given) (NP (NP (QP (CD 2) (CC or) (CD 3)) (NNS times)) (NP (DT a) (NN week))))))))))) (. .))))

Sentence Id: DrugDDI.d496.s57
Rifampin/NN ./.

(ROOT (S1 (S (NP (NP (NN Rifampin)) (. .)))))

Sentence Id: DrugDDI.d496.s58
@/NN @/NN efavirenz/NN concentration/NN ./.

(ROOT (S1 (S (NP (NP (NN @) (NN @) (NN efavirenz) (NN concentration)) (. .)))))

Sentence Id: DrugDDI.d496.s59
Clinical/JJ significance/NN of/IN reduced/VBN efavirenz/NN concentrations/NNS unknown/JJ ./.

(ROOT (S1 (S (S (NP (NP (JJ Clinical) (NN significance)) (PP (IN of) (NP (VBN reduced) (NN efavirenz) (NNS concentrations)))) (VP (JJ unknown))) (. .))))

Sentence Id: DrugDDI.d496.s60
Ritonavir/NN ./.

(ROOT (S1 (S (NP (NP (NN Ritonavir)) (. .)))))

Sentence Id: DrugDDI.d496.s61
@/NN @/NN ritonavir/NN concentration/NN ./.

(ROOT (S1 (S (NP (NP (NN @) (NN @) (NN ritonavir) (NN concentration)) (. .)))))

Sentence Id: DrugDDI.d496.s63
Monitoring/NN of/IN liver/NN enzymes/NNS is/VBZ recommended/VBN when/WRB SUSTIVA/NN is/VBZ used/VBN in/IN combination/NN with/IN ritonavir/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Monitoring)) (PP (IN of) (NP (NN liver) (NNS enzymes)))) (VP (VBZ is) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (NP (NN SUSTIVA)) (VP (VBZ is) (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN ritonavir)))))))))))) (. .))))

Sentence Id: DrugDDI.d496.s64
@/NN @/NN efavirenz/NN concentration/NN ./.

(ROOT (S1 (S (NP (NP (NN @) (NN @) (NN efavirenz) (NN concentration)) (. .)))))

Sentence Id: DrugDDI.d496.s65
Saquinavir/NN ./.

(ROOT (S1 (S (NP (NP (NN Saquinavir)) (. .)))))

Sentence Id: DrugDDI.d496.s66
@/NN @/NN saquinavir/NN concentration/NN ./.

(ROOT (S1 (S (NP (NP (NN @) (NN @) (NN saquinavir) (NN concentration)) (. .)))))

Sentence Id: DrugDDI.d496.s67
Should/MD not/RB be/VB used/VBN as/IN sole/JJ protease/NN inhibitor/NN in/IN combination/NN with/IN SUSTIVA/NN ./.

(ROOT (S1 (S (S (VP (MD Should) (RB not) (VP (VB be) (VP (VBN used) (PP (IN as) (NP (NP (JJ sole) (NN protease) (NN inhibitor)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN SUSTIVA))))))))))) (. .))))

Sentence Id: DrugDDI.d496.s68
Sertraline/NN ./.

(ROOT (S1 (S (NP (NP (NN Sertraline)) (. .)))))

Sentence Id: DrugDDI.d496.s69
@/NN @/NN sertraline/NN concentration/NN ./.

(ROOT (S1 (S (NP (NP (NN @) (NN @) (NN sertraline) (NN concentration)) (. .)))))

Sentence Id: DrugDDI.d496.s71
Other/JJ Potentially/RB Clinically/RB Significant/JJ Drug/NN or/CC Herbal/NN Product/NN Interactions/NNS With/IN SUSTIVAb/NN ./.

(ROOT (S1 (S (S (NP (JJ Other) (ADJP (RB Potentially) (RB Clinically) (JJ Significant)) (NN Drug) (CC or) (NN Herbal) (NN Product)) (VP (NNS Interactions) (PP (IN With) (NP (NN SUSTIVAb))))) (. .))))

Sentence Id: DrugDDI.d496.s72
Anticoagulants/NNS :/: Warfarin/NN ./.

(ROOT (S1 (S (S (NP (NNS Anticoagulants)) (: :) (NP (NN Warfarin))) (. .))))

Sentence Id: DrugDDI.d496.s73
Plasma/NN concentrations/NNS and/CC effects/NNS potentially/RB increased/VBN or/CC decreased/VBN by/IN SUSTIVA/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Plasma) (NNS concentrations)) (CC and) (NP (NNS effects))) (ADVP (RB potentially)) (VP (VP (VBN increased)) (CC or) (VP (VBN decreased) (PP (IN by) (NP (NN SUSTIVA)))))) (. .))))

Sentence Id: DrugDDI.d496.s74
Anticonvulsants/NNS :/: Phenytoin/NN Phenobarbital/NN Carbamazepine/NN ./.

(ROOT (S1 (S (S (NP (NNS Anticonvulsants)) (: :) (NP (NN Phenytoin) (NN Phenobarbital) (NN Carbamazepine))) (. .))))

Sentence Id: DrugDDI.d496.s75
Potential/JJ for/IN reduction/NN in/IN anticonvulsant/JJ and/or/CC efavirenz/NN plasma/NN levels/NNS ;/: ./.

(ROOT (S1 (S (S (ADJP (JJ Potential) (PP (IN for) (NP (NP (NN reduction)) (PP (IN in) (NP (JJ anticonvulsant) (CC and/or) (NN efavirenz) (NN plasma) (NNS levels))) (: ;))))) (. .))))

Sentence Id: DrugDDI.d496.s76
periodic/JJ monitoring/NN of/IN anticonvulsant/JJ plasma/NN levels/NNS should/MD be/VB conducted/VBN ./.

(ROOT (S1 (S (S (NP (NP (JJ periodic) (NN monitoring)) (PP (IN of) (NP (JJ anticonvulsant) (NN plasma) (NNS levels)))) (VP (MD should) (VP (VB be) (VP (VBN conducted))))) (. .))))

Sentence Id: DrugDDI.d496.s77
Antifungals/NNS :/: Itraconazole/NN Ketoconazole/NN ./.

(ROOT (S1 (S (S (NP (NNS Antifungals)) (: :) (NP (NN Itraconazole) (NN Ketoconazole))) (. .))))

Sentence Id: DrugDDI.d496.s78
Drug/NN interaction/NN studies/NNS with/IN SUSTIVA/NNP and/CC these/DT imidazole/JJ and/CC triazole/JJ antifungals/NNS have/VBP not/RB been/VBN conducted/VBN ./.

(ROOT (S1 (S (S (NP (NP (NN Drug) (NN interaction) (NNS studies)) (PP (IN with) (NP (NNP SUSTIVA) (CC and) (DT these) (ADJP (ADJP (JJ imidazole)) (CC and) (ADJP (JJ triazole))) (NNS antifungals)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN conducted))))) (. .))))

Sentence Id: DrugDDI.d496.s79
SUSTIVA/NN has/VBZ the/DT potential/NN to/TO decrease/NN plasma/NN concentrations/NNS of/IN itraconazole/NN and/CC ketoconazole/NN ./.

(ROOT (S1 (S (S (NP (NN SUSTIVA)) (VP (VBZ has) (NP (NP (DT the) (NN potential)) (PP (TO to) (NP (NP (NN decrease) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NN itraconazole)) (CC and) (NP (NN ketoconazole))))))))) (. .))))

Sentence Id: DrugDDI.d496.s80
Anti-HIV/NN protease/NN inhibitors/NNS :/: Saquinavir/NN //: ritonavir/NN combination/NN ./.

(ROOT (S1 (S (S (NP (NN Anti-HIV) (NN protease) (NNS inhibitors)) (: :) (NP (NN Saquinavir)) (: /) (NP (NN ritonavir) (NN combination))) (. .))))

Sentence Id: DrugDDI.d496.s82
Amprenavir/NN ./.

(ROOT (S1 (S (NP (NP (NN Amprenavir)) (. .)))))

Sentence Id: DrugDDI.d496.s83
SUSTIVAhas/NNS the/DT potential/NN to/TO decrease/NN serum/NN concentrations/NNS of/IN amprenavir/NN ./.

(ROOT (S1 (S (S (VP (NNS SUSTIVAhas) (NP (DT the) (NN potential)) (PP (TO to) (NP (NP (NN decrease) (NN serum) (NNS concentrations)) (PP (IN of) (NP (NN amprenavir))))))) (. .))))

Sentence Id: DrugDDI.d496.s84
Non-nucleoside/JJ reverse/NN transcriptase/NN inhibitors/NNS ./.

(ROOT (S1 (S (NP (NP (JJ Non-nucleoside) (NN reverse) (NN transcriptase) (NNS inhibitors)) (. .)))))

Sentence Id: DrugDDI.d496.s86
St./NN John/NN @/NN s/NN wort/NN (/-LRB- Hypericum/NN perforatum/NN )/-RRB- ./.

(ROOT (S1 (S (NP (NP (NP (NN St.) (NN John) (NN @) (NN s) (NN wort)) (PRN (-LRB- -LRB-) (NP (NN Hypericum) (NN perforatum)) (-RRB- -RRB-))) (. .)))))

Sentence Id: DrugDDI.d496.s87
Expected/VBN to/TO substantially/RB decrease/VB plasma/NN levels/NNS of/IN efavirenz/NN ;/: has/VBZ not/RB been/VBN studied/VBN in/IN combination/NN with/IN SUSTIVA/NN ./.

(ROOT (S1 (S (S (S (VP (VBN Expected) (S (VP (TO to) (ADVP (RB substantially)) (VP (VB decrease) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NN efavirenz))))))))) (: ;) (S (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN SUSTIVA)))))))))) (. .))))

Sentence Id: DrugDDI.d496.s90
Other/JJ Drugs/NNS :/: Based/NN on/IN the/DT results/NNS of/IN drug/NN interaction/NN studies/NNS ,/, no/DT dosage/JJ adjustment/NN is/VBZ recommended/VBN when/WRB SUSTIVA/NN (/-LRB- efavirenz/NN )/-RRB- is/VBZ given/VBN with/IN the/DT following/NN :/: aluminum//NN magnesium/NN hydroxide/NN antacids/NNS ,/, azithromycin/NN ,/, cetirizine/NN ,/, famotidine/NN ,/, fluconazole/NN ,/, lamivudine/NN ,/, lorazepam/NN ,/, nelfinavir/NN ,/, paroxetine/NN ,/, and/CC zidovudine/NN ./.

(ROOT (S1 (S (NP (NP (JJ Other) (NNS Drugs)) (: :) (S (NP (NP (NN Based)) (PP (IN on) (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (NP (NN drug) (NN interaction) (NNS studies)) (, ,) (NP (DT no) (JJ dosage) (NN adjustment))))))) (VP (VBZ is) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN SUSTIVA)) (PRN (-LRB- -LRB-) (NP (NN efavirenz)) (-RRB- -RRB-))) (VP (VBZ is) (VP (VBN given) (PP (IN with) (NP (NP (DT the) (NN following)) (: :) (NP (NP (NN aluminum/) (NN magnesium) (NN hydroxide) (NNS antacids)) (, ,) (NP (NP (NN azithromycin)) (, ,) (NP (NN cetirizine)) (, ,) (NP (NN famotidine)) (, ,) (NP (NN fluconazole)) (, ,) (NP (NN lamivudine)) (, ,) (NP (NN lorazepam)) (, ,) (NP (NN nelfinavir)) (, ,) (NP (NN paroxetine)) (, ,) (CC and) (NP (NN zidovudine))))))))))))) (. .)))))

Sentence Id: DrugDDI.d496.s91
Specific/JJ drug/NN interaction/NN studies/NNS have/VBP not/RB been/VBN performed/VBN with/IN SUSTIVA/NN and/CC NRTIs/NN other/JJ than/IN lamivudine/NN and/CC zidovudine/NN ./.

(ROOT (S1 (S (S (NP (JJ Specific) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN performed) (PP (IN with) (NP (NP (NN SUSTIVA)) (CC and) (NP (NN NRTIs)) (CONJP (JJ other) (IN than)) (NP (NP (NN lamivudine)) (CC and) (NP (NN zidovudine))))))))) (. .))))

Sentence Id: DrugDDI.d496.s92
Clinically/RB significant/JJ interactions/NNS would/MD not/RB be/VB expected/VBN since/IN the/DT NRTIs/NNS are/VBP metabolized/VBN via/IN a/DT different/JJ route/NN than/IN efavirenz/NN and/CC would/MD be/VB unlikely/JJ to/TO compete/VB for/IN the/DT same/JJ metabolic/JJ enzymes/NNS and/CC elimination/NN pathways/NNS ./.

(ROOT (S1 (S (S (NP (ADJP (RB Clinically) (JJ significant)) (NNS interactions)) (VP (VP (MD would) (RB not) (VP (VB be) (VP (VBN expected) (SBAR (IN since) (S (NP (DT the) (NNS NRTIs)) (VP (VBP are) (VP (VBN metabolized) (PP (IN via) (NP (NP (DT a) (JJ different) (NN route)) (PP (IN than) (NP (NN efavirenz)))))))))))) (CC and) (VP (MD would) (VP (VB be) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VB compete) (PP (IN for) (NP (NP (DT the) (JJ same) (JJ metabolic) (NNS enzymes)) (CC and) (NP (NN elimination) (NNS pathways)))))))))))) (. .))))

Sentence Id: DrugDDI.d578.s0
Inhibitors/NNS of/IN CYP3A4/NN -Eplerenone/NN metabolism/NN is/VBZ predominantly/RB mediated/VBN via/IN CYP3A4/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Inhibitors)) (PP (IN of) (NP (NN CYP3A4) (NN -Eplerenone) (NN metabolism)))) (VP (VBZ is) (ADVP (RB predominantly)) (VP (VBN mediated) (PP (IN via) (NP (NN CYP3A4)))))) (. .))))

Sentence Id: DrugDDI.d578.s1
A/DT pharmacokinetic/JJ study/NN evaluating/VBG the/DT administration/NN of/IN a/DT single/JJ dose/NN of/IN INSPRA/NN 100/CD mg/NN with/IN ketoconazole/NN 200/CD mg/NN BID/NN ,/, a/DT potent/JJ inhibitor/NN of/IN the/DT CYP3A4/NN pathway/NN ,/, showed/VBD a/DT 1.7-fold/JJ increase/NN in/IN Cmax/NN of/IN eplerenone/NN and/CC a/DT 5.4-fold/JJ increase/NN in/IN AUC/NN of/IN eplerenone/NN ./.

(ROOT (S1 (S (NP (NP (DT A) (JJ pharmacokinetic) (NN study)) (VP (VBG evaluating) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NP (NN INSPRA) (CD 100) (NN mg)) (PP (IN with) (NP (NP (NN ketoconazole) (CD 200) (NN mg) (NN BID)) (, ,) (NP (NP (DT a) (JJ potent) (NN inhibitor)) (PP (IN of) (NP (DT the) (NN CYP3A4) (NN pathway)))) (, ,)))))))))) (VP (VBD showed) (NP (NP (NP (DT a) (JJ 1.7-fold) (NN increase)) (PP (IN in) (NP (NP (NN Cmax)) (PP (IN of) (NP (NN eplerenone)))))) (CC and) (NP (NP (DT a) (JJ 5.4-fold) (NN increase)) (PP (IN in) (NP (NP (NN AUC)) (PP (IN of) (NP (NN eplerenone)))))))) (. .))))

Sentence Id: DrugDDI.d578.s2
INSPRA/NN should/MD not/RB be/VB used/VBN with/IN drugs/NNS described/VBN as/IN strong/JJ inhibitors/NNS of/IN CYP3A4/NN in/IN their/PRP$ labeling/NN ./.

(ROOT (S1 (S (S (NP (NN INSPRA)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NP (NNS drugs)) (VP (VBN described) (PP (IN as) (NP (NP (JJ strong) (NNS inhibitors)) (PP (IN of) (NP (NN CYP3A4))))) (PP (IN in) (NP (PRP$ their) (NN labeling)))))))))) (. .))))

Sentence Id: DrugDDI.d578.s3
Administration/NN of/IN eplerenone/NN with/IN other/JJ CYP3A4/JJ inhibitors/NNS (/-LRB- e.g./FW ,/, erythromycin/NN 500/CD mg/NN BID/NN ,/, verapamil/NN 240/NN mg/NN QD/NN ,/, saquinavir/NN 1200/CD mg/NN TID/NN ,/, fluconazole/NN 200/CD mg/NN QD/NN )/-RRB- resulted/VBD in/IN increases/NNS in/IN Cmax/NN of/IN eplerenone/NN ranging/VBG from/IN 1.4-/NN to/TO 1.6-/JJ fold/NN and/CC AUC/NN from/IN 2.0-/NN to/TO 2.9-/NN fold/NN ./.

(ROOT (S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN eplerenone))) (PP (IN with) (NP (NP (JJ other) (JJ CYP3A4) (NNS inhibitors)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NP (NN erythromycin) (CD 500) (NN mg)) (NP (NN BID))) (, ,) (NP (NN verapamil) (NN 240) (NN mg) (NN QD)) (, ,) (NP (NP (NN saquinavir) (CD 1200) (NN mg)) (NP (NN TID))) (, ,) (NP (NN fluconazole) (CD 200) (NN mg)))) (NP (NN QD)) (-RRB- -RRB-))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (NP (NN Cmax)) (PP (IN of) (NP (NP (NN eplerenone)) (VP (VBG ranging) (PP (IN from) (NP (NN 1.4-))) (PP (TO to) (NP (JJ 1.6-) (NN fold))))))) (CC and) (NP (NP (NN AUC)) (PP (IN from) (NP (NP (NN 2.0-)) (PP (TO to) (NP (NN 2.9-) (NN fold))))))))))) (. .))))

Sentence Id: DrugDDI.d578.s4
ACE/NN Inhibitors/NNS and/CC Angiotensin/NN II/NN Receptor/NN Antagonists/NNS (/-LRB- Congestive/JJ Heart/NN Failure/NN Post-Myocardial/JJ Infarction/NN )/-RRB- -/: In/FW EPHESUS/FW ,/, 3020/CD (/-LRB- 91/CD %/NN )/-RRB- patients/NNS receiving/VBG INSPRA/FW 25/CD to/TO 50/CD mg/NN also/RB received/VBD ACE/NN inhibitors/NNS or/CC angiotensin/NN II/NN receptor/NN antagonists/NNS (/-LRB- ACEI/ARB)./CD

(ROOT (S1 (S (NP (NP (NP (NP (NN ACE) (NNS Inhibitors)) (CC and) (NP (NN Angiotensin) (NN II) (NN Receptor) (NNS Antagonists))) (PRN (-LRB- -LRB-) (NP (NP (JJ Congestive) (NN Heart) (NN Failure)) (JJ Post-Myocardial) (NN Infarction)) (-RRB- -RRB-))) (: -) (S (ADVP (FW In) (FW EPHESUS)) (, ,) (NP (NP (CD 3020) (PRN (-LRB- -LRB-) (NP (CD 91) (NN %)) (-RRB- -RRB-)) (NNS patients)) (VP (VBG receiving) (NP (QP (FW INSPRA) (CD 25) (TO to) (CD 50)) (NN mg)))) (ADVP (RB also)) (VP (VBD received) (NP (NP (NN ACE) (NNS inhibitors)) (CC or) (NP (NN angiotensin) (NN II) (NN receptor) (NNS antagonists))))) (-LRB- -LRB-) (CD ACEI/ARB-RRB-.)))))

Sentence Id: DrugDDI.d578.s6
ACE/NN Inhibitors/NNS and/CC Angiotensin/NN II/NN Receptor/NN Antagonists/NNS (/-LRB- Hypertension/NN )/-RRB- -/: In/IN clinical/JJ studies/NNS of/IN patients/NNS with/IN hypertension/NN ,/, the/DT addition/NN of/IN INSPRA/NN 50/CD to/TO 100/CD mg/NN to/TO ACE/NN inhibitors/NNS and/CC angiotensin/NN II/NN receptor/NN antagonists/NNS increased/VBD mean/NN serum/NN potassium/NN slightly/RB (/-LRB- about/RB 0.09-0.13/CD mEq/L/NN )./NN

(ROOT (S1 (S (NP (NP (NP (NP (NN ACE) (NNS Inhibitors)) (CC and) (NP (NN Angiotensin) (NN II) (NN Receptor) (NNS Antagonists))) (PRN (-LRB- -LRB-) (NP (NN Hypertension)) (-RRB- -RRB-))) (: -) (S (PP (IN In) (NP (NP (JJ clinical) (NNS studies)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NN hypertension))))))) (, ,) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NN INSPRA) (CD 50) (TO to) (CD 100) (NN mg))) (PP (TO to) (NP (NP (NN ACE) (NNS inhibitors)) (CC and) (NP (NN angiotensin) (NN II) (NN receptor) (NNS antagonists))))) (VP (VBD increased) (NP (NN mean) (NN serum) (NN potassium)) (ADVP (RB slightly)) (-LRB- -LRB-) (NP (ADJP (QP (RB about) (CD 0.09-0.13)) (NN mEq/L)) (NN -RRB-.))))))))

Sentence Id: DrugDDI.d578.s7
In/IN a/DT study/NN in/IN diabetics/NNS with/IN microalbuminuria/NN INSPRA/NN 200/CD mg/NN combined/VBN with/IN the/DT ACE/NN inhibitor/NN enalapril/NN 10/CD mg/NN increased/VBD the/DT frequency/NN of/IN hyperkalemia/NN (/-LRB- serum/NN potassium/NN 5.5/CD mEq/L/NN )/-RRB- from/IN 17/CD %/NN on/IN enalapril/NN alone/RB to/TO 38/CD %./NN

(ROOT (S1 (S (PP (IN In) (NP (NP (DT a) (NN study)) (PP (IN in) (NP (NP (NNS diabetics)) (PP (IN with) (NP (NP (NN microalbuminuria) (NN INSPRA) (CD 200) (NN mg)) (VP (VBN combined) (PP (IN with) (NP (NP (DT the) (NN ACE) (NN inhibitor) (NN enalapril)) (ADJP (CD 10) (NN mg))))))))))) (VP (VBD increased) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NP (NN hyperkalemia)) (PRN (-LRB- -LRB-) (NP (NN serum) (NN potassium) (CD 5.5) (NN mEq/L)) (-RRB- -RRB-))))) (PP (IN from) (NP (NP (CD 17) (NN %)) (PP (IN on) (NP (NP (NN enalapril)) (ADVP (RB alone)))))) (PP (TO to) (NP (CD 38) (NN %.)))))))

Sentence Id: DrugDDI.d578.s8
Lithium/NN -A/NN drug/NN interaction/NN study/NN of/IN eplerenone/NN with/IN lithium/NN has/VBZ not/RB been/VBN conducted/VBN ./.

(ROOT (S1 (S (S (NP (NP (NN Lithium) (NN -A) (NN drug) (NN interaction) (NN study)) (PP (IN of) (NP (NN eplerenone))) (PP (IN with) (NP (NN lithium)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN conducted))))) (. .))))

Sentence Id: DrugDDI.d578.s9
Lithium/NN toxicity/NN has/VBZ been/VBN reported/VBN in/IN patients/NNS receiving/VBG lithium/NN concomitantly/RB with/IN diuretics/NNS and/CC ACE/NN inhibitors/NNS ./.

(ROOT (S1 (S (S (NP (NN Lithium) (NN toxicity)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN lithium)) (PP (ADVP (RB concomitantly)) (IN with) (NP (NP (NNS diuretics)) (CC and) (NP (NN ACE) (NNS inhibitors)))))))))))) (. .))))

Sentence Id: DrugDDI.d578.s10
Serum/NN lithium/NN levels/NNS should/MD be/VB monitored/VBN frequently/RB if/IN INSPRA/NN is/VBZ administered/VBN concomitantly/RB with/IN lithium/NN ./.

(ROOT (S1 (S (S (NP (NN Serum) (NN lithium) (NNS levels)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB frequently)) (SBAR (IN if) (S (NP (NN INSPRA)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN lithium))))))))))) (. .))))

Sentence Id: DrugDDI.d578.s11
Nonsteroidal/JJ Anti-Inflammatory/JJ Drugs/NNS (/-LRB- NSAIDs/NNS )/-RRB- -A/NN drug/NN interaction/NN study/NN of/IN eplerenone/NN with/IN an/DT NSAID/NN has/VBZ not/RB been/VBN conducted/VBN ./.

(ROOT (S1 (S (S (NP (NP (NP (NP (JJ Nonsteroidal) (JJ Anti-Inflammatory) (NNS Drugs)) (PRN (-LRB- -LRB-) (NP (NNS NSAIDs)) (-RRB- -RRB-))) (NN -A) (NN drug) (NN interaction) (NN study)) (PP (IN of) (NP (NN eplerenone))) (PP (IN with) (NP (DT an) (NN NSAID)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN conducted))))) (. .))))

Sentence Id: DrugDDI.d578.s12
The/DT administration/NN of/IN other/JJ potassium-sparing/JJ antihypertensives/NNS with/IN NSAIDs/NNS has/VBZ been/VBN shown/VBN to/TO reduce/VB the/DT antihypertensive/JJ effect/NN in/IN some/DT patients/NNS and/CC result/VB in/IN severe/JJ hyperkalemia/NN in/IN patients/NNS with/IN impaired/JJ renal/JJ function/NN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NP (JJ other) (JJ potassium-sparing) (NNS antihypertensives)) (PP (IN with) (NP (NNS NSAIDs)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VP (VB reduce) (NP (DT the) (JJ antihypertensive) (NN effect)) (PP (IN in) (NP (DT some) (NNS patients)))) (CC and) (VP (VB result) (PP (IN in) (NP (JJ severe) (NN hyperkalemia))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ impaired) (JJ renal) (NN function))))))))))))) (. .))))

Sentence Id: DrugDDI.d578.s13
Therefore/RB ,/, when/WRB INSPRA/NN and/CC NSAIDs/NN are/VBP used/VBN concomitantly/RB ,/, patients/NNS should/MD be/VB observed/VBN to/TO determine/VB whether/IN the/DT desired/JJ effect/NN on/IN blood/NN pressure/NN is/VBZ obtained/VBN ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN INSPRA)) (CC and) (NP (NN NSAIDs))) (VP (VBP are) (VP (VBN used) (ADVP (RB concomitantly)))))) (, ,) (NP (NNS patients)) (VP (MD should) (VP (VB be) (VP (VBN observed) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (DT the) (JJ desired) (NN effect)) (PP (IN on) (NP (NN blood) (NN pressure)))) (VP (VBZ is) (VP (VBN obtained)))))))))))) (. .))))

Sentence Id: DrugDDI.d145.s0
Co-treatment/NN with/IN the/DT potent/JJ CYP3A4/NN inhibitor/NN ketoconazole/NN increases/VBZ erlotinib/NN AUC/NN by/IN 2/3/CD ./.

(ROOT (S1 (S (S (NP (NP (NN Co-treatment)) (PP (IN with) (NP (DT the) (JJ potent) (NN CYP3A4) (NN inhibitor) (NN ketoconazole)))) (VP (VBZ increases) (NP (NN erlotinib) (NN AUC)) (PP (IN by) (NP (CD 2/3))))) (. .))))

Sentence Id: DrugDDI.d145.s1
Caution/NN should/MD be/VB used/VBN when/WRB administering/VBG or/CC taking/VBG TARCEVA/NN with/IN ketoconazole/NN and/CC other/JJ strong/JJ CYP3A4/NN inhibitors/NNS such/JJ as/IN ,/, but/CC not/RB limited/JJ to/TO ,/, atazanavir/NN ,/, clarithromycin/NN ,/, indinavir/NN ,/, itraconazole/NN ,/, nefazodone/NN ,/, nelfinavir/NN ,/, ritonavir/NN ,/, saquinavir/NN ,/, telithromycin/NN ,/, troleandomycin/NN (/-LRB- TAO/CD )/-RRB- ,/, and/CC voriconazole/NN ./.

(ROOT (S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (CC or) (NP (NP (VBG taking) (NN TARCEVA)) (PP (IN with) (NP (NN ketoconazole)))) (CC and) (NP (NP (JJ other) (JJ strong) (NN CYP3A4) (NNS inhibitors)) (PP (JJ such) (IN as) (NP (, ,) (CONJP (CC but) (RB not)) (NP (ADJP (JJ limited) (PP (TO to))) (, ,) (NN atazanavir) (, ,) (NN clarithromycin) (, ,) (NN indinavir) (, ,) (NN itraconazole) (, ,) (NN nefazodone) (, ,) (NN nelfinavir) (, ,) (NN ritonavir) (, ,) (NN saquinavir) (, ,) (NN telithromycin) (, ,) (NN troleandomycin) (-LRB- -LRB-) (CD TAO) (-RRB- -RRB-)) (, ,) (CC and) (NP (NN voriconazole))))))))))))) (. .))))

Sentence Id: DrugDDI.d145.s2
Pre-treatment/NN with/IN the/DT CYP3A4/NN inducer/NN rifampicin/NN decreased/VBD erlotinib/NN AUC/NN by/IN about/RB 2/3/CD ./.

(ROOT (S1 (S (S (NP (NP (NN Pre-treatment)) (PP (IN with) (NP (DT the) (NN CYP3A4) (NN inducer) (NN rifampicin)))) (VP (VBD decreased) (NP (NN erlotinib) (NN AUC)) (PP (IN by) (NP (RB about) (CD 2/3))))) (. .))))

Sentence Id: DrugDDI.d145.s3
Alternate/JJ treatments/NNS lacking/VBG CYP3A4/NN inducing/NN activity/NN should/MD be/VB considered/VBN ./.

(ROOT (S1 (S (S (NP (NP (JJ Alternate) (NNS treatments)) (VP (VBG lacking) (NP (NN CYP3A4) (NN inducing) (NN activity)))) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (. .))))

Sentence Id: DrugDDI.d145.s4
If/IN an/DT alternative/JJ treatment/NN is/VBZ unavailable/JJ ,/, a/DT TARCEVA/NN dose/NN greater/JJR than/IN 150/CD mg/NN should/MD be/VB considered/VBN for/IN NSCLC/NN patients/NNS ,/, and/CC greater/JJR than/IN 100/CD mg/NN considered/VBN for/IN pancreatic/JJ cancer/NN patients/NNS ./.

(ROOT (S1 (S (S (SBAR (IN If) (S (NP (DT an) (JJ alternative) (NN treatment)) (VP (VBZ is) (ADJP (JJ unavailable))))) (, ,) (NP (NP (DT a) (NN TARCEVA) (NN dose)) (ADJP (QP (JJR greater) (IN than) (CD 150)) (NN mg))) (VP (MD should) (VP (VB be) (VP (VBN considered) (PP (IN for) (NP (NP (NP (NN NSCLC) (NNS patients)) (, ,) (CC and) (NP (ADJP (JJR greater) (PP (IN than) (NP (CD 100) (NN mg)))))) (VP (VBN considered) (PP (IN for) (NP (JJ pancreatic) (NN cancer) (NNS patients)))))))))) (. .))))

Sentence Id: DrugDDI.d145.s5
If/IN the/DT TARCEVA/NN dose/NN is/VBZ adjusted/VBN upward/NN ,/, the/DT dose/NN will/MD need/VBP to/TO be/VB reduced/VBN upon/IN discontinuation/NN of/IN rifampicin/NN or/CC other/JJ inducers/NNS ./.

(ROOT (S1 (S (S (SBAR (IN If) (S (NP (DT the) (NN TARCEVA) (NN dose)) (VP (VBZ is) (VP (VBN adjusted) (S (NP (NN upward))))))) (, ,) (NP (DT the) (NN dose)) (VP (MD will) (VP (VBP need) (S (VP (TO to) (VP (VB be) (VP (VBN reduced) (PP (IN upon) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NP (NN rifampicin)) (CC or) (NP (JJ other) (NNS inducers))))))))))))) (. .))))

Sentence Id: DrugDDI.d145.s6
Other/JJ CYP3A4/NN inducers/NNS include/VBP ,/, but/CC are/VBP not/RB limited/JJ to/TO ,/, rifabutin/NN ,/, rifapentine/NN ,/, phenytoin/NN ,/, carbamazepine/NN ,/, phenobarbital/NN and/CC St./NN Johns/NNP Wort/NNP ./.

(ROOT (S1 (S (S (NP (JJ Other) (NN CYP3A4) (NNS inducers)) (VP (VP (VBP include)) (, ,) (CC but) (VP (VBP are) (RB not) (ADJP (JJ limited) (PP (TO to) (NP (, ,) (NP (NN rifabutin)) (, ,) (NP (NN rifapentine)) (, ,) (NP (NN phenytoin)) (, ,) (NP (NN carbamazepine)) (, ,) (NP (NN phenobarbital)) (CC and) (NP (NN St.)) (NP (NNP Johns) (NNP Wort)))))))) (. .))))

Sentence Id: DrugDDI.d145.s7
Hepatotoxicity/NN Asymptomatic/JJ increases/NNS in/IN liver/NN transaminases/NNS have/VBP been/VBN observed/VBN in/IN TARCEVA/NN treated/JJ patients/NNS ;/: ./.

(ROOT (S1 (S (S (NP (NP (NN Hepatotoxicity) (JJ Asymptomatic) (NNS increases)) (PP (IN in) (NP (NN liver) (NNS transaminases)))) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (PP (IN in) (NP (NN TARCEVA) (JJ treated) (NNS patients)))))) (: ;)) (. .))))

Sentence Id: DrugDDI.d145.s8
therefore/RB ,/, periodic/JJ liver/NN function/NN testing/NN (/-LRB- transaminases/NN ,/, bilirubin/NN ,/, and/CC alkaline/NN phosphatase/NN )/-RRB- should/MD be/VB considered/VBN ./.

(ROOT (S1 (S (S (ADVP (RB therefore)) (, ,) (NP (NP (JJ periodic) (NN liver) (NN function) (NN testing)) (PRN (-LRB- -LRB-) (NP (NP (NN transaminases)) (, ,) (NP (NN bilirubin)) (, ,) (CC and) (NP (NN alkaline) (NN phosphatase))) (-RRB- -RRB-))) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (. .))))

Sentence Id: DrugDDI.d145.s9
Dose/NN reduction/NN or/CC interruption/NN of/IN TARCEVA/NN should/MD be/VB considered/VBN if/IN changes/NNS in/IN liver/NN function/NN are/VBP severe/JJ ./.

(ROOT (S1 (S (S (NP (NP (NN Dose) (NN reduction)) (CC or) (NP (NP (NN interruption)) (PP (IN of) (NP (NN TARCEVA))))) (VP (MD should) (VP (VB be) (VP (VBN considered) (SBAR (IN if) (S (NP (NP (NNS changes)) (PP (IN in) (NP (NN liver) (NN function)))) (VP (VBP are) (ADJP (JJ severe))))))))) (. .))))

Sentence Id: DrugDDI.d145.s10
Patients/NNS with/IN Hepatic/JJ Impairment/NN :/: In/FW vitro/FW and/CC in/FW vivo/FW evidence/NN suggest/VBP that/IN erlotinib/NN is/VBZ cleared/VBN primarily/RB by/IN the/DT liver/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Patients)) (PP (IN with) (NP (JJ Hepatic) (NN Impairment)))) (: :) (NP (ADJP (ADJP (FW In) (FW vitro)) (CC and) (ADJP (FW in) (FW vivo))) (NN evidence)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN erlotinib)) (VP (VBZ is) (VP (VBN cleared) (ADVP (RB primarily)) (PP (IN by) (NP (DT the) (NN liver))))))))) (. .))))

Sentence Id: DrugDDI.d145.s11
Therefore/RB ,/, erlotinib/NN exposure/NN may/MD be/VB increased/VBN in/IN patients/NNS with/IN hepatic/JJ dysfunction/NN ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN erlotinib) (NN exposure)) (VP (MD may) (VP (VB be) (VP (VBN increased) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ hepatic) (NN dysfunction))))))))) (. .))))

Sentence Id: DrugDDI.d145.s12
Elevated/JJ International/NNP Normalized/VBN Ratio/NN and/CC Potential/JJ Bleeding/JJ International/NNP Normalized/VBN Ratio/NN (/-LRB- INR/NN )/-RRB- elevations/NNS and/CC infrequent/JJ reports/NNS of/IN bleeding/JJ events/NNS including/VBG gastrointestinal/JJ and/CC non-gastrointestinal/JJ bleedings/NNS have/VBP been/VBN reported/VBN in/IN clinical/JJ studies/NNS ,/, some/DT associated/VBN with/IN concomitant/JJ warfarin/NN administration/NN ./.

(ROOT (S1 (S (S (NP (NP (NP (NP (JJ Elevated) (NNP International) (VBN Normalized) (NN Ratio)) (CC and) (NP (NP (JJ Potential) (JJ Bleeding) (NNP International) (VBN Normalized) (NN Ratio)) (PRN (-LRB- -LRB-) (NP (NN INR)) (-RRB- -RRB-)))) (NNS elevations)) (CC and) (NP (NP (JJ infrequent) (NNS reports)) (PP (IN of) (NP (NP (JJ bleeding) (NNS events)) (PP (VBG including) (NP (ADJP (ADJP (JJ gastrointestinal)) (CC and) (ADJP (JJ non-gastrointestinal))) (NNS bleedings))))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (JJ clinical) (NNS studies)) (, ,) (NP (NP (DT some)) (VP (VBN associated) (PP (IN with) (NP (JJ concomitant) (NN warfarin) (NN administration))))))))))) (. .))))

Sentence Id: DrugDDI.d145.s13
Patients/NNS taking/VBG warfarin/NN or/CC other/JJ coumarin-derivative/JJ anticoagulants/NNS should/MD be/VB monitored/VBN regularly/RB for/IN changes/NNS in/IN prothrombin/NN time/NN or/CC INR/NN ./.

(ROOT (S1 (S (S (NP (NP (NP (NNS Patients)) (VP (VBG taking) (NP (NN warfarin)))) (CC or) (NP (JJ other) (JJ coumarin-derivative) (NNS anticoagulants))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB regularly)) (PP (IN for) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (NN prothrombin) (NN time)) (CC or) (NP (NN INR)))))))))) (. .))))

Sentence Id: DrugDDI.d124.s0
When/WRB ertapenem/NN is/VBZ co-administered/VBN with/IN probenecid/NN (/-LRB- 500/CD mg/NN p.o./NN every/DT 6/CD hours/NNS )/-RRB- ,/, probenecid/NN competes/VBZ for/IN active/JJ tubular/JJ secretion/NN and/CC reduces/VBZ the/DT renal/JJ clearance/NN of/IN ertapenem/NN ./.

(ROOT (S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN ertapenem)) (VP (VBZ is) (VP (VBN co-administered) (PP (IN with) (NP (NP (NN probenecid)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 500) (NN mg)) (NN p.o.)) (NP (DT every) (CD 6) (NNS hours))) (-RRB- -RRB-)))))))) (, ,) (NP (NN probenecid)) (VP (VP (VBZ competes) (PP (IN for) (NP (JJ active) (JJ tubular) (NN secretion)))) (CC and) (VP (VBZ reduces) (NP (NP (DT the) (JJ renal) (NN clearance)) (PP (IN of) (NP (NN ertapenem))))))) (. .))))

Sentence Id: DrugDDI.d124.s1
Based/VBN on/IN total/JJ ertapenem/NN concentrations/NNS ,/, probenecid/NN increased/VBD the/DT AUC/NN by/IN 25/CD %/NN and/CC reduced/VBD the/DT plasma/NN and/CC renal/JJ clearances/NNS by/IN 20/CD %/NN and/CC 35/CD %/NN ,/, respectively/RB ./.

(ROOT (S1 (S (S (PP (VBN Based) (PP (IN on) (NP (JJ total) (NN ertapenem) (NNS concentrations)))) (, ,) (NP (NN probenecid)) (VP (VP (VBD increased) (NP (DT the) (NN AUC)) (PP (IN by) (NP (CD 25) (NN %)))) (CC and) (VP (VBD reduced) (NP (DT the) (NN plasma) (CC and) (JJ renal) (NNS clearances)) (PP (IN by) (NP (NP (CD 20) (NN %)) (CC and) (NP (CD 35) (NN %)) (, ,) (ADVP (RB respectively))))))) (. .))))

Sentence Id: DrugDDI.d124.s3
Because/IN of/IN the/DT small/JJ effect/NN on/IN half-life/NN ,/, the/DT coadministration/NN with/IN probenecid/NN to/TO extend/VB the/DT half-life/NN of/IN ertapenem/NN is/VBZ not/RB recommended/VBN ./.

(ROOT (S1 (S (S (PP (IN Because) (PP (IN of) (NP (NP (DT the) (JJ small) (NN effect)) (PP (IN on) (NP (NN half-life)))))) (, ,) (NP (NP (DT the) (NN coadministration)) (PP (IN with) (NP (NN probenecid))) (S (VP (TO to) (VP (VB extend) (NP (NP (DT the) (NN half-life)) (PP (IN of) (NP (NN ertapenem)))))))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .))))

Sentence Id: DrugDDI.d124.s4
In/FW vitro/FW studies/NNS indicate/VBP that/IN ertapenem/NN does/VBZ not/RB inhibit/VB P-/NN glycoprotein/NN -mediated/JJ transport/NN of/IN digoxin/NN or/CC vinblastine/NN and/CC that/IN ertapenem/NN is/VBZ not/RB a/DT substrate/NN for/IN P-/NN glycoprotein/NN -mediated/JJ transport/NN ./.

(ROOT (S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP indicate) (SBAR (SBAR (IN that) (S (NP (NN ertapenem)) (VP (VBZ does) (RB not) (VP (VB inhibit) (NP (NP (NN P-) (NN glycoprotein) (JJ -mediated) (NN transport)) (PP (IN of) (NP (NP (NN digoxin)) (CC or) (NP (NN vinblastine))))))))) (CC and) (SBAR (IN that) (S (NP (NN ertapenem)) (VP (VBZ is) (RB not) (NP (NP (DT a) (NN substrate)) (PP (IN for) (NP (ADJP (NN P-) (NN glycoprotein) (JJ -mediated)) (NN transport)))))))))) (. .))))

Sentence Id: DrugDDI.d124.s5
In/FW vitro/FW studies/NNS in/IN human/JJ liver/NN microsomes/NNS indicate/VBP that/IN ertapenem/NN does/VBZ not/RB inhibit/VB metabolism/NN mediated/VBN by/IN any/DT of/IN the/DT following/JJ six/CD cytochrome/NN p450/NN (/-LRB- CYP/NN )/-RRB- isoforms/NNS :/: 1A2/NN ,/, 2C9/NN ,/, 2C19/NN ,/, 2D6/NN ,/, 2E1/NN and/CC 3A4/NN ./.

(ROOT (S1 (S (S (NP (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (PP (IN in) (NP (JJ human) (NN liver) (NNS microsomes)))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN ertapenem)) (VP (VBZ does) (RB not) (VP (VB inhibit) (NP (NP (NN metabolism)) (VP (VBN mediated) (PP (IN by) (NP (NP (DT any)) (PP (IN of) (NP (NP (DT the) (JJ following) (NP (NP (CD six) (NN cytochrome) (NN p450)) (PRN (-LRB- -LRB-) (NP (NN CYP)) (-RRB- -RRB-))) (NNS isoforms)) (: :) (NP (NP (NN 1A2)) (, ,) (NP (NN 2C9)) (, ,) (NP (NN 2C19)) (, ,) (NP (NN 2D6)) (, ,) (NP (NN 2E1)) (CC and) (NP (NN 3A4))))))))))))))) (. .))))

Sentence Id: DrugDDI.d124.s6
Drug/NN interactions/NNS caused/VBN by/IN inhibition/NN of/IN P-/NN glycoprotein/NN -mediated/JJ drug/NN clearance/NN or/CC CYP/NN -mediated/JJ drug/NN clearance/NN with/IN the/DT listed/JJ isoforms/NNS are/VBP unlikely/JJ ./.

(ROOT (S1 (S (S (NP (NP (NN Drug) (NNS interactions)) (VP (VBN caused) (PP (IN by) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (ADJP (NN P-) (NN glycoprotein) (JJ -mediated)) (NN drug) (NN clearance)) (CC or) (NP (ADJP (NN CYP) (JJ -mediated)) (NN drug) (NN clearance)))) (PP (IN with) (NP (DT the) (JJ listed) (NNS isoforms))))))) (VP (VBP are) (ADJP (JJ unlikely)))) (. .))))

Sentence Id: DrugDDI.d124.s7
Other/JJ than/IN with/IN probenecid/NN ,/, no/DT specific/JJ clinical/JJ drug/NN interaction/NN studies/NNS have/VBP been/VBN conducted/VBN ./.

(ROOT (S1 (S (S (ADVP (JJ Other) (PP (IN than) (PP (IN with) (NP (NN probenecid))))) (, ,) (NP (DT no) (JJ specific) (JJ clinical) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted))))) (. .))))

Sentence Id: DrugDDI.d388.s1
Drug/NN and/CC Laboratory/NN Test/NN Interactions/NNS 1/CD ./.

(ROOT (S1 (S (S (NP (NP (NN Drug)) (CC and) (NP (NN Laboratory) (NN Test) (NNS Interactions))) (NP (CD 1))) (. .))))

Sentence Id: DrugDDI.d388.s4
increased/VBN factors/NNS II/CD ,/, VII/NN antigen/NN ,/, VIII/NN antigen/NN ,/, VIII/NN coagulant/NN activity/NN ,/, IX/NN ,/, X/NN ,/, XII/NN ,/, VII-X/NN complex/NN ,/, II-VII-X/NN complex/NN ,/, and/CC beta-thromboglobulin/NN ;/: ./.

(ROOT (S1 (S (NP (NP (NP (VBN increased) (NNS factors) (NP (CD II))) (, ,) (NP (NP (NN VII) (NN antigen)) (, ,) (NP (NN VIII) (NN antigen)) (, ,) (NP (NN VIII) (NN coagulant) (NN activity)) (, ,) (NP (NN IX)) (, ,) (NP (NN X)) (, ,) (NP (NN XII)) (, ,) (NP (NN VII-X) (NN complex)) (, ,) (NP (NN II-VII-X) (NN complex)) (, ,) (CC and) (NP (NN beta-thromboglobulin))) (: ;)) (. .)))))

Sentence Id: DrugDDI.d388.s5
decreased/VBN levels/NNS of/IN anti-factor/NN Xa/NN and/CC antithrombin/NN III/CD ,/, decreased/VBD antithrombin/NN III/CD activity/NN ;/: ./.

(ROOT (S1 (S (S (NP (NP (VBN decreased) (NNS levels)) (PP (IN of) (NP (NP (NN anti-factor) (NN Xa)) (CC and) (NP (NN antithrombin) (CD III)))) (, ,)) (VP (VBD decreased) (NP (NN antithrombin) (CD III) (NN activity))) (: ;)) (. .))))

Sentence Id: DrugDDI.d388.s6
increased/VBN levels/NNS of/IN fibrinogen/NN and/CC fibrinogen/NN activity/NN ;/: ./.

(ROOT (S1 (S (NP (NP (NP (VBN increased) (NNS levels)) (PP (IN of) (NP (NP (NN fibrinogen)) (CC and) (NP (NN fibrinogen)) (NP (NN activity)))) (: ;)) (. .)))))

Sentence Id: DrugDDI.d388.s9
Increased/VBN thyroid-binding/JJ globulin/NN (/-LRB- TBG/NN )/-RRB- leading/VBG to/TO increased/VBN circulating/JJ total/JJ thyroid/NN hormone/NN levels/NNS ,/, as/IN measured/VBN by/IN protein-bound/JJ iodine/NN (/-LRB- PBI/NN )/-RRB- ,/, T4/NN levels/NNS (/-LRB- by/IN column/NN or/CC by/IN radioimmunoassay/NN )/-RRB- or/CC T3/NN levels/NNS by/IN radioimmunoassay/NN ./.

(ROOT (S1 (S (S (VP (VBN Increased) (NP (NP (NP (JJ thyroid-binding) (NN globulin)) (PRN (-LRB- -LRB-) (NP (NN TBG)) (-RRB- -RRB-))) (VP (VBG leading) (PP (TO to) (NP (VBN increased) (JJ circulating) (JJ total) (NN thyroid) (NN hormone) (NNS levels))))) (, ,) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (NP (NP (JJ protein-bound) (NN iodine)) (PRN (-LRB- -LRB-) (NP (NN PBI)) (-RRB- -RRB-))) (, ,) (NP (NP (NN T4) (NNS levels)) (PRN (-LRB- -LRB-) (PP (PP (IN by) (NP (NN column))) (CC or) (PP (IN by) (NP (NN radioimmunoassay)))) (-RRB- -RRB-))) (CC or) (NP (NN T3) (NNS levels)))) (PP (IN by) (NP (NN radioimmunoassay)))))))) (. .))))

Sentence Id: DrugDDI.d388.s11
Free/JJ T4/NN and/CC T3/NN concentrations/NNS are/VBP unaltered/JJ ./.

(ROOT (S1 (S (S (NP (JJ Free) (NP (NP (NN T4)) (CC and) (NP (NN T3))) (NNS concentrations)) (VP (VBP are) (ADJP (JJ unaltered)))) (. .))))

Sentence Id: DrugDDI.d388.s12
Patients/NNS on/IN thyroid/NN replacement/NN therapy/NN may/MD require/VBP higher/JJR doses/NNS of/IN thyroid/NN hormone/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Patients)) (PP (IN on) (NP (NN thyroid) (NN replacement) (NN therapy)))) (VP (MD may) (VP (VBP require) (NP (NP (JJR higher) (NNS doses)) (PP (IN of) (NP (NN thyroid) (NN hormone))))))) (. .))))

Sentence Id: DrugDDI.d388.s14
Other/JJ binding/NN proteins/NNS may/MD be/VB elevated/VBN in/IN serum/NN ,/, i.e./FW ,/, corticosteroid/NN binding/NN globulin/NN (/-LRB- CBG/NN )/-RRB- ,/, sex/NN hormone-binding/NN globulin/NN (/-LRB- SHBG/NN )/-RRB- ,/, leading/VBG to/TO increased/VBN total/JJ circulating/JJ corticosteroids/NNS and/CC sex/NN steroids/NNS ,/, respectively/RB ./.

(ROOT (S1 (S (S (NP (JJ Other) (NN binding) (NNS proteins)) (VP (MD may) (VP (VB be) (VP (VBN elevated) (PP (IN in) (NP (NP (NN serum)) (, ,) (FW i.e.) (, ,) (NP (NP (NN corticosteroid) (NN binding) (NN globulin)) (PRN (-LRB- -LRB-) (NP (NN CBG)) (-RRB- -RRB-))) (, ,) (NP (NP (NN sex) (NN hormone-binding) (NN globulin)) (PRN (-LRB- -LRB-) (NP (NN SHBG)) (-RRB- -RRB-))))))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (NP (VBN increased) (JJ total) (JJ circulating) (NNS corticosteroids)) (CC and) (NP (NN sex) (NNS steroids)))) (, ,) (ADVP (RB respectively)))))) (. .))))

Sentence Id: DrugDDI.d388.s16
Other/JJ plasma/NN proteins/NNS may/MD be/VB increased/VBN (/-LRB- angiotensinogen/NN /renin/NN substrate/NN ,/, alpha-1-antitrypsin/JJ ,/, ceruloplasmin/NN )/-RRB- ./.

(ROOT (S1 (S (S (NP (JJ Other) (NN plasma) (NNS proteins)) (VP (MD may) (VP (VB be) (VP (VBN increased) (PRN (-LRB- -LRB-) (NP (NP (NN angiotensinogen) (NN /renin) (NN substrate)) (, ,) (NP (ADJP (JJ alpha-1-antitrypsin))) (, ,) (NP (NN ceruloplasmin))) (-RRB- -RRB-)))))) (. .))))

Sentence Id: DrugDDI.d388.s18
Increased/VBN plasma/NN HDL/NN and/CC HDL2/NN cholesterol/NN subfraction/NN concentrations/NNS ,/, reduced/VBD LDL/NN cholesterol/NN concentration/NN ,/, increased/VBD triglyceride/NN levels/NNS ./.

(ROOT (S1 (S (S (NP (VBN Increased) (NN plasma) (NN HDL) (CC and) (NN HDL2) (NN cholesterol) (NN subfraction) (NNS concentrations)) (, ,) (VP (VP (VBD reduced) (NP (NN LDL) (NN cholesterol) (NN concentration))) (, ,) (VP (VBD increased) (NP (NN triglyceride) (NNS levels))))) (. .))))

Sentence Id: DrugDDI.d217.s1
However/RB ,/, it/PRP was/VBD observed/VBN that/IN the/DT pharmacokinetics/NNS of/IN ENBREL/NN @/NN was/VBD unaltered/JJ by/IN concomitant/JJ methotrexate/NN in/IN rheumatoid/JJ arthritis/NN patients/NNS ./.

(ROOT (S1 (S (S (ADVP (RB However)) (, ,) (NP (PRP it)) (VP (VBD was) (VP (VBN observed) (SBAR (IN that) (S (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN ENBREL) (NN @)))) (VP (VBD was) (ADJP (JJ unaltered) (PP (IN by) (NP (NP (JJ concomitant) (NN methotrexate)) (PP (IN in) (NP (NP (JJ rheumatoid) (NN arthritis)) (NNS patients)))))))))))) (. .))))

Sentence Id: DrugDDI.d217.s2
In/IN a/DT study/NN in/IN which/WDT patients/NNS with/IN active/JJ RA/NN were/VBD treated/VBN for/IN up/RB to/TO 24/CD weeks/NNS with/IN concurrent/JJ ENBREL/NN @/NN and/CC anakinra/NN therapy/NN ,/, a/DT 7/CD %/NN rate/NN of/IN serious/JJ infections/NNS was/VBD observed/VBN ,/, which/WDT was/VBD higher/JJR than/IN that/DT observed/VBN with/IN ENBREL/NN @/NN alone/RB (/-LRB- 0%)./JJ

(ROOT (S1 (S (PP (IN In) (NP (NP (DT a) (NN study)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (NNS patients)) (PP (IN with) (NP (JJ active) (NN RA)))) (VP (VBD were) (VP (VBN treated) (PP (IN for) (NP (QP (RB up) (TO to) (CD 24)) (NNS weeks))) (PP (IN with) (NP (NP (JJ concurrent) (NN ENBREL) (NN @)) (CC and) (NP (NN anakinra) (NN therapy)))))))))) (, ,) (NP (NP (DT a) (ADJP (CD 7) (NN %)) (NN rate)) (PP (IN of) (NP (JJ serious) (NNS infections)))) (VP (VBD was) (VP (VBN observed) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (NP (DT that)) (VP (VBN observed) (PP (IN with) (NP (NP (NN ENBREL) (NN @)) (ADVP (RB alone)))))))) (PRN (-LRB- -LRB-) (NP (JJ 0%-RRB-.)))))))))))

Sentence Id: DrugDDI.d217.s3
Two/CD percent/NN of/IN patients/NNS treated/VBN concurrently/RB with/IN ENBREL/NN @/NN and/CC anakinra/NN developed/VBD neutropenia/NN (/-LRB- ANC/NN 1/CD x/NN 109/L/NN )/-RRB- ./.

(ROOT (S1 (S (S (NP (NP (CD Two) (NN percent)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN treated) (ADVP (RB concurrently)) (PP (IN with) (NP (NP (NN ENBREL) (NN @)) (CC and) (NP (NN anakinra)))))))) (VP (VBD developed) (NP (NP (NN neutropenia)) (PRN (-LRB- -LRB-) (NP (NN ANC) (CD 1) (NN x) (NN 109/L)) (-RRB- -RRB-))))) (. .))))

Sentence Id: DrugDDI.d217.s4
Patients/NNS in/IN a/DT clinical/JJ study/NN who/WP were/VBD on/IN established/JJ therapy/NN with/IN sulfasalazine/NN ,/, to/TO which/WDT ENBREL/NN was/VBD added/VBN ,/, were/VBD noted/VBN to/TO develop/VB a/DT mild/JJ decrease/NN in/IN mean/NN neutrophil/NN counts/NNS in/IN comparison/NN to/TO groups/NNS treated/VBN with/IN either/CC ENBREL/NN CI/CD or/CC sulfasalazine/NN alone/RB ./.

(ROOT (S1 (S (S (NP (NP (NNS Patients)) (PP (IN in) (NP (DT a) (JJ clinical) (NN study))) (SBAR (WHNP (WP who)) (S (VP (VBD were) (PP (IN on) (NP (NP (JJ established) (NN therapy)) (PP (IN with) (NP (NP (NN sulfasalazine)) (, ,) (SBAR (WHPP (TO to) (WHNP (WDT which))) (S (NP (NN ENBREL)) (VP (VBD was) (VP (VBN added))))) (, ,))))))))) (VP (VBD were) (VP (VBN noted) (S (VP (TO to) (VP (VB develop) (NP (NP (DT a) (JJ mild) (NN decrease)) (PP (IN in) (NP (NP (NN mean) (NN neutrophil) (NNS counts)) (PP (IN in) (NP (NP (NN comparison)) (PP (TO to) (NP (NP (NNS groups)) (VP (VBN treated) (PP (IN with) (NP (CC either) (NP (NN ENBREL) (CD CI)) (CC or) (NP (NN sulfasalazine)))) (ADVP (RB alone)))))))))))))))) (. .))))

Sentence Id: DrugDDI.d174.s0
Dicumarol/NN and/CC warfarin/NN may/MD decrease/VB hypoprothrombinemic/JJ effect/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Dicumarol)) (CC and) (NP (NN warfarin))) (VP (MD may) (VP (VB decrease) (NP (JJ hypoprothrombinemic) (NN effect))))) (. .))))

Sentence Id: DrugDDI.d174.s1
Other/JJ depressasnts/NNS such/JJ as/IN alcohol/NN ,/, barbiturates/NNS ,/, and/CC MAOIs/NNS may/MD enhance/VB CNS/NN depression/NN when/WRB administered/VBN with/IN ethchlorvynol/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Other) (NNS depressasnts)) (PP (JJ such) (IN as) (NP (NP (NN alcohol)) (, ,) (NP (NNS barbiturates)) (, ,) (CC and) (NP (NNS MAOIs))))) (VP (MD may) (VP (VB enhance) (NP (NN CNS) (NN depression)) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN with) (NP (NN ethchlorvynol))))))))) (. .))))

Sentence Id: DrugDDI.d9.s0
Certain/JJ endocrine/NN and/CC liver/NN function/NN tests/NNS may/MD be/VB affected/VBN by/IN estrogen/NN -containing/JJ oral/JJ contraceptives/NNS ./.

(ROOT (S1 (S (S (NP (NP (JJ Certain) (NN endocrine)) (CC and) (NP (NN liver) (NN function) (NNS tests))) (VP (MD may) (VP (VB be) (VP (VBN affected) (PP (IN by) (NP (ADJP (NN estrogen) (JJ -containing)) (JJ oral) (NNS contraceptives))))))) (. .))))

Sentence Id: DrugDDI.d9.s1
The/DT following/JJ similar/JJ changes/NNS may/MD be/VB expected/VBN with/IN larger/JJR doses/NNS of/IN estrogen/NN :/: Increased/VBN sulfobromophthalein/NN retention/NN ;/: ./.

(ROOT (S1 (S (S (NP (DT The) (JJ following) (JJ similar) (NNS changes)) (VP (MD may) (VP (VB be) (VP (VBN expected) (PP (IN with) (NP (NP (JJR larger) (NNS doses)) (PP (IN of) (NP (NN estrogen)))))))) (: :) (NP (VBN Increased) (NN sulfobromophthalein) (NN retention)) (: ;)) (. .))))

Sentence Id: DrugDDI.d9.s2
increased/VBN prothrombin/NN and/CC factors/NNS VII/NN ,/, VIII/NN ,/, IX/NN ,/, and/CC X/NN ;/: ./.

(ROOT (S1 (S (S (VP (VBN increased) (NP (NP (NN prothrombin)) (CC and) (NP (NP (NP (NNS factors) (NN VII)) (, ,) (NP (NN VIII)) (, ,) (NP (NN IX)) (, ,) (CC and) (NP (NN X))) (: ;))))) (. .))))

Sentence Id: DrugDDI.d9.s3
decreased/VBN antithrombin/NN 3/CD ;/: ./.

(ROOT (S1 (S (S (VP (VBN decreased) (NP (NN antithrombin) (CD 3))) (: ;)) (. .))))

Sentence Id: DrugDDI.d9.s4
increased/VBN norepinephrine/NN -induced/JJ platel/NNP et/FW aggregation/NN ;/: ./.

(ROOT (S1 (S (S (NP (VBN increased) (NN norepinephrine)) (VP (JJ -induced) (NP (NNP platel) (FW et) (NP (NN aggregation)))) (: ;)) (. .))))

Sentence Id: DrugDDI.d9.s5
increased/VBN thyroid/NN binding/NN globulin/NN (/-LRB- TBG/NN )/-RRB- leading/VBG to/TO increased/VBN circulating/VBG total/JJ thyroid/NN hormone/NN ,/, as/IN measured/VBN by/IN PBI/NN ,/, T4/NN by/IN column/NN ,/, or/CC T4/NN by/IN radioimmunoassay/NN ./.

(ROOT (S1 (S (S (NP (NP (VBN increased) (NN thyroid) (NN binding) (NN globulin)) (PRN (-LRB- -LRB-) (NP (NN TBG)) (-RRB- -RRB-))) (VP (VBG leading) (PP (TO to) (NP (VBN increased) (VBG circulating) (JJ total) (NN thyroid) (NN hormone))) (, ,) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (NP (NN PBI)) (, ,) (NP (NP (NN T4)) (PP (IN by) (NP (NN column)))) (, ,) (CC or) (NP (NN T4)))) (PP (IN by) (NP (NN radioimmunoassay)))))))) (. .))))

Sentence Id: DrugDDI.d9.s11
increased/VBN serum/NN triglyceride/NN and/CC phospholipid/NN concentration/NN ./.

(ROOT (S1 (S (S (VP (VBN increased) (NP (NP (NN serum) (NN triglyceride)) (CC and) (NP (NN phospholipid) (NN concentration))))) (. .))))

Sentence Id: DrugDDI.d132.s0
Ethinyl/NN estradiol/NN :/: Substrate/NN of/IN CYP3A4/NN (/-LRB- major/JJ )/-RRB- ,/, 3A5-7/NN (/-LRB- minor/JJ )/-RRB- ;/: ./.

(ROOT (S1 (S (NP (NP (NN Ethinyl) (NN estradiol)) (: :) (NP (NP (NP (NN Substrate)) (PP (IN of) (NP (NP (NN CYP3A4)) (PRN (-LRB- -LRB-) (NP (JJ major)) (-RRB- -RRB-))))) (, ,) (NP (NP (NN 3A5-7)) (PRN (-LRB- -LRB-) (NP (JJ minor)) (-RRB- -RRB-))) (: ;)) (. .)))))

Sentence Id: DrugDDI.d132.s1
Inhibits/VBZ CYP1A2/NN (/-LRB- weak/JJ )/-RRB- ,/, 2B6/NN (/-LRB- weak/JJ )/-RRB- ,/, 2C19/NN (/-LRB- weak/JJ )/-RRB- ,/, 3A4/NN (/-LRB- weak)./NN

(ROOT (S1 (S (SINV (VBZ Inhibits) (NP (NP (NP (NN CYP1A2)) (PRN (-LRB- -LRB-) (NP (JJ weak)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NN 2B6)) (PRN (-LRB- -LRB-) (NP (JJ weak)) (-RRB- -RRB-))) (, ,) (NP (NP (NN 2C19)) (PRN (-LRB- -LRB-) (NP (JJ weak)) (-RRB- -RRB-))) (, ,) (NP (NN 3A4)) (-LRB- -LRB-) (NP (NN weak-RRB-.))))))))

Sentence Id: DrugDDI.d132.s2
Acetaminophen/NN :/: May/MD increase/VB plasma/NN concentration/NN of/IN synthetic/JJ estrogens/NNS ,/, possibly/RB by/IN inhibiting/VBG conjugation/NN ./.

(ROOT (S1 (S (S (NP (NN Acetaminophen) (: :)) (VP (MD May) (VP (VB increase) (NP (NP (NN plasma) (NN concentration)) (PP (IN of) (NP (JJ synthetic) (NNS estrogens)))) (, ,) (PP (ADVP (RB possibly)) (IN by) (S (VP (VBG inhibiting) (NP (NN conjugation)))))))) (. .))))

Sentence Id: DrugDDI.d132.s3
Combination/NN hormonal/JJ contraceptives/NNS may/MD also/RB decrease/VB the/DT plasma/NN concentration/NN of/IN acetaminophen/NN ./.

(ROOT (S1 (S (S (NP (NN Combination) (JJ hormonal) (NNS contraceptives)) (VP (MD may) (ADVP (RB also)) (VP (VB decrease) (NP (NP (DT the) (NN plasma) (NN concentration)) (PP (IN of) (NP (NN acetaminophen))))))) (. .))))

Sentence Id: DrugDDI.d132.s4
Acitretin/NN :/: Interferes/VBZ with/IN the/DT contraceptive/JJ effect/NN of/IN microdosed/JJ progestin/NN -containing/JJ minipill/NN preparations/NNS ./.

(ROOT (S1 (S (S (NP (NN Acitretin) (: :)) (VP (VBZ Interferes) (PP (IN with) (NP (NP (DT the) (JJ contraceptive) (NN effect)) (PP (IN of) (NP (JJ microdosed) (NN progestin) (JJ -containing) (NN minipill) (NNS preparations))))))) (. .))))

Sentence Id: DrugDDI.d132.s5
The/DT effect/NN on/IN other/JJ progestational/JJ contraceptives/NNS (/-LRB- eg/FW ,/, implants/NNS ,/, injectables/NNS )/-RRB- is/VBZ unknown/JJ ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN on) (NP (NP (JJ other) (JJ progestational) (NNS contraceptives)) (PRN (-LRB- -LRB-) (PP (FW eg) (, ,) (NP (NNS implants))) (, ,) (NP (NNS injectables)) (-RRB- -RRB-))))) (VP (VBZ is) (ADJP (JJ unknown)))) (. .))))

Sentence Id: DrugDDI.d132.s6
Aminoglutethimide/NN :/: May/MD increase/VBP CYP/NN metabolism/NN of/IN progestins/NNS leading/VBG to/TO possible/JJ decrease/NN in/IN contraceptive/JJ effectiveness/NN ./.

(ROOT (S1 (S (S (NP (NN Aminoglutethimide) (: :)) (VP (MD May) (VP (VBP increase) (NP (NP (NN CYP) (NN metabolism)) (PP (IN of) (NP (NP (NNS progestins)) (VP (VBG leading) (PP (TO to) (NP (NP (JJ possible) (NN decrease)) (PP (IN in) (NP (JJ contraceptive) (NN effectiveness)))))))))))) (. .))))

Sentence Id: DrugDDI.d132.s7
Use/NN of/IN a/DT nonhormonal/JJ contraceptive/JJ product/NN is/VBZ recommended/VBN ./.

(ROOT (S1 (S (S (NP (NP (NN Use)) (PP (IN of) (NP (DT a) (JJ nonhormonal) (JJ contraceptive) (NN product)))) (VP (VBZ is) (VP (VBN recommended)))) (. .))))

Sentence Id: DrugDDI.d132.s8
Antibiotics/NNS (/-LRB- ampicillin/NN ,/, tetracycline/NN )/-RRB- :/: Pregnancy/NN has/VBZ been/VBN reported/VBN following/VBG concomitant/JJ use/NN ,/, however/RB ,/, pharmacokinetic/JJ studies/NNS have/VBP not/RB shown/VBN consistent/JJ effects/NNS with/IN these/DT antibiotics/NNS on/IN plasma/NN concentrations/NNS of/IN synthetic/JJ steroids/NNS ./.

(ROOT (S1 (S (S (NP (NP (NP (NNS Antibiotics)) (PRN (-LRB- -LRB-) (NP (NP (NN ampicillin)) (, ,) (NP (NN tetracycline))) (-RRB- -RRB-))) (: :) (S (NP (NN Pregnancy)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (VBG following) (NP (JJ concomitant) (NN use)))))))) (, ,) (ADVP (RB however)) (, ,) (NP (JJ pharmacokinetic) (NNS studies)) (VP (VBP have) (RB not) (VP (VBN shown) (NP (NP (JJ consistent) (NNS effects)) (PP (IN with) (NP (DT these) (NNS antibiotics))) (PP (IN on) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (JJ synthetic) (NNS steroids))))))))) (. .))))

Sentence Id: DrugDDI.d132.s9
Use/NN of/IN a/DT nonhormonal/JJ contraceptive/JJ product/NN is/VBZ recommended/VBN ./.

(ROOT (S1 (S (S (NP (NP (NN Use)) (PP (IN of) (NP (DT a) (JJ nonhormonal) (JJ contraceptive) (NN product)))) (VP (VBZ is) (VP (VBN recommended)))) (. .))))

Sentence Id: DrugDDI.d132.s10
Anticoagulants/NNS :/: Combination/NN hormonal/JJ contraceptives/NNS may/MD increase/VB or/CC decrease/VB the/DT effects/NNS of/IN coumarin/NN derivatives/NNS ./.

(ROOT (S1 (S (NP (NP (NNS Anticoagulants)) (: :) (S (NP (NN Combination) (JJ hormonal) (NNS contraceptives)) (VP (MD may) (VP (VP (VB increase)) (CC or) (VP (VB decrease) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN coumarin) (NNS derivatives)))))))) (. .)))))

Sentence Id: DrugDDI.d132.s11
Combination/NN hormonal/JJ contraceptives/NNS may/MD also/RB increase/VB risk/NN of/IN thromboembolic/JJ disorders/NNS ./.

(ROOT (S1 (S (S (NP (NN Combination) (JJ hormonal) (NNS contraceptives)) (VP (MD may) (ADVP (RB also)) (VP (VB increase) (NP (NP (NN risk)) (PP (IN of) (NP (JJ thromboembolic) (NNS disorders))))))) (. .))))

Sentence Id: DrugDDI.d132.s12
Anticonvulsants/NNS (/-LRB- carbamazepine/NN ,/, felbamate/NN ,/, phenobarbital/NN ,/, phenytoin/NN ,/, topiramate/NN )/-RRB- :/: Increase/NN the/DT metabolism/NN of/IN ethinyl/NN estradiol/NN and/or/CC some/DT progestins/NNS ,/, leading/VBG to/TO possible/JJ decrease/NN in/IN contraceptive/JJ effectiveness/NN ./.

(ROOT (S1 (S (NP (NP (NP (NNS Anticonvulsants)) (PRN (-LRB- -LRB-) (NP (NP (NN carbamazepine)) (, ,) (NP (NN felbamate)) (, ,) (NP (NN phenobarbital)) (, ,) (NP (NN phenytoin)) (, ,) (NP (NN topiramate))) (-RRB- -RRB-))) (: :) (NP (NP (NP (NN Increase)) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN ethinyl) (NN estradiol))))) (CC and/or) (NP (NP (DT some) (NNS progestins)) (, ,) (VP (VBG leading) (PP (TO to) (NP (NP (JJ possible) (NN decrease)) (PP (IN in) (NP (JJ contraceptive) (NN effectiveness)))))))) (. .)))))

Sentence Id: DrugDDI.d132.s13
Use/NN of/IN a/DT nonhormonal/JJ contraceptive/JJ product/NN is/VBZ recommended/VBN ./.

(ROOT (S1 (S (S (NP (NP (NN Use)) (PP (IN of) (NP (DT a) (JJ nonhormonal) (JJ contraceptive) (NN product)))) (VP (VBZ is) (VP (VBN recommended)))) (. .))))

Sentence Id: DrugDDI.d132.s14
Ascorbic/JJ acid/NN :/: Doses/NNS of/IN ascorbic/JJ acid/NN (/-LRB- vitamin/NN C/NN )/-RRB- 1/CD g/day/NN have/VBP been/VBN reported/VBN to/TO increase/VB plasma/NN concentration/NN of/IN synthetic/JJ estrogens/NNS by/IN ~47/CD %/NN ,/, possibly/RB by/IN inhibiting/VBG conjugation/NN ;/: ./.

(ROOT (S1 (S (NP (NP (JJ Ascorbic) (NN acid)) (: :) (S (NP (NP (NNS Doses)) (PP (IN of) (NP (NP (NP (JJ ascorbic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN vitamin) (NN C)) (-RRB- -RRB-))) (CD 1) (NN g/day)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB increase) (NP (NP (NN plasma) (NN concentration)) (PP (IN of) (NP (JJ synthetic) (NNS estrogens)))) (PP (IN by) (NP (CD ~47) (NN %))) (, ,) (PP (ADVP (RB possibly)) (IN by) (S (VP (VBG inhibiting) (NP (NN conjugation))))))))))) (: ;)) (. .)))))

Sentence Id: DrugDDI.d132.s16
Atorvastatin/NN :/: Atorvastatin/NN increases/VBZ the/DT AUC/NN for/IN norethindrone/NN and/CC ethinyl/NN estradiol/NN ./.

(ROOT (S1 (S (NP (NP (NN Atorvastatin)) (: :) (S (NP (NN Atorvastatin)) (VP (VBZ increases) (NP (NP (DT the) (NN AUC)) (PP (IN for) (NP (NP (NN norethindrone)) (CC and) (NP (NN ethinyl) (NN estradiol))))))) (. .)))))

Sentence Id: DrugDDI.d132.s17
Benzodiazepines/NNS :/: Combination/NN hormonal/JJ contraceptives/NNS may/MD decrease/VB the/DT clearance/NN of/IN some/DT benzodiazepines/NNS (/-LRB- alprazolam/NN ,/, chlordiazepoxide/NN ,/, diazepam/NN )/-RRB- and/CC increase/VB the/DT clearance/NN of/IN others/NNS (/-LRB- lorazepam/NN ,/, oxazepam/NN ,/, temazepam/NN )/-RRB- ./.

(ROOT (S1 (S (NP (NP (NNS Benzodiazepines)) (: :) (S (NP (NN Combination) (JJ hormonal) (NNS contraceptives)) (VP (MD may) (VP (VP (VP (VB decrease) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NP (DT some) (NNS benzodiazepines)) (PRN (-LRB- -LRB-) (NP (NP (NN alprazolam)) (, ,) (NP (NN chlordiazepoxide)) (, ,) (NP (NN diazepam))) (-RRB- -RRB-)))))) (CC and) (VP (VB increase) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NNS others)))))) (PRN (-LRB- -LRB-) (NP (NP (NN lorazepam)) (, ,) (NP (NN oxazepam)) (, ,) (NP (NN temazepam))) (-RRB- -RRB-))))) (. .)))))

Sentence Id: DrugDDI.d132.s18
Clofibric/JJ acid/NN :/: Combination/NN hormonal/JJ contraceptives/NNS may/MD increase/VB the/DT clearance/NN of/IN clofibric/JJ acid/NN ./.

(ROOT (S1 (S (S (NP (JJ Clofibric) (NN acid) (: :) (NN Combination) (JJ hormonal) (NNS contraceptives)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (JJ clofibric) (NN acid))))))) (. .))))

Sentence Id: DrugDDI.d132.s19
Cyclosporine/NN :/: Combination/NN hormonal/JJ contraceptives/NNS may/MD inhibit/VB the/DT metabolism/NN of/IN cyclosporine/NN ,/, leading/VBG to/TO increased/VBN plasma/NN concentrations/NNS ;/: ./.

(ROOT (S1 (S (S (NP (NN Cyclosporine) (: :) (NN Combination) (JJ hormonal) (NNS contraceptives)) (VP (MD may) (VP (VB inhibit) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN cyclosporine)))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (VBN increased) (NN plasma) (NNS concentrations))))))) (: ;)) (. .))))

Sentence Id: DrugDDI.d132.s20
monitor/VB cyclosporine/NN levels/NNS ./.

(ROOT (S1 (S (S (VP (VB monitor) (NP (NN cyclosporine) (NNS levels)))) (. .))))

Sentence Id: DrugDDI.d132.s21
CYP3A4/JJ inducers/NNS :/: CYP3A4/NN inducers/NNS may/MD decrease/VB the/DT levels/effects/NNS of/IN ethinyl/NN estradiol/NN ./.

(ROOT (S1 (S (NP (NP (JJ CYP3A4) (NNS inducers)) (: :) (S (NP (NN CYP3A4) (NNS inducers)) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NNS levels/effects)) (PP (IN of) (NP (NN ethinyl) (NN estradiol))))))) (. .)))))

Sentence Id: DrugDDI.d132.s22
Example/NN inducers/NNS include/VBP aminoglutethimide/NN ,/, carbamazepine/NN ,/, nafcillin/NN ,/, nevirapine/NN ,/, phenobarbital/NN ,/, phenytoin/NN ,/, and/CC rifamycins/NN ./.

(ROOT (S1 (S (S (NP (NN Example) (NNS inducers)) (VP (VBP include) (NP (NP (NN aminoglutethimide)) (, ,) (NP (NP (NN carbamazepine)) (, ,) (NP (NN nafcillin)) (, ,) (NP (NN nevirapine)) (, ,) (NP (NN phenobarbital)) (, ,) (NP (NN phenytoin)) (, ,) (CC and) (NP (NN rifamycins)))))) (. .))))

Sentence Id: DrugDDI.d132.s23
Griseofulvin/NN :/: Griseofulvin/NN may/MD induce/VB the/DT metabolism/NN of/IN combination/NN hormonal/JJ contraceptives/NNS causing/VBG menstrual/JJ changes/NNS ;/: ./.

(ROOT (S1 (S (S (NP (NN Griseofulvin) (: :) (NN Griseofulvin)) (VP (MD may) (VP (VB induce) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (NN combination) (JJ hormonal) (NNS contraceptives)) (VP (VBG causing) (NP (JJ menstrual) (NNS changes)))))))) (: ;)) (. .))))

Sentence Id: DrugDDI.d132.s25
Use/NN of/IN barrier/NN form/NN of/IN contraception/NN is/VBZ suggested/VBN while/IN on/IN griseofulvin/NN therapy/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Use)) (PP (IN of) (NP (NP (NN barrier) (NN form)) (PP (IN of) (NP (NN contraception)))))) (VP (VBZ is) (VP (VBN suggested) (PP (IN while) (PP (IN on) (NP (NN griseofulvin) (NN therapy))))))) (. .))))

Sentence Id: DrugDDI.d132.s26
Morphine/NN :/: Combination/NN hormonal/JJ contraceptives/NNS may/MD increase/VB the/DT clearance/NN of/IN morphine/NN ./.

(ROOT (S1 (S (S (NP (NN Morphine) (: :) (NN Combination) (JJ hormonal) (NNS contraceptives)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN morphine))))))) (. .))))

Sentence Id: DrugDDI.d132.s27
Non-nucleoside/JJ reverse/NN transcriptase/NN inhibitors/NNS (/-LRB- NNRTIs/NN )/-RRB- :/: Nevirapine/NN may/MD decrease/VB plasma/NN levels/NNS of/IN combination/NN hormonal/JJ contraceptives/NNS ;/: ./.

(ROOT (S1 (S (NP (NP (NP (JJ Non-nucleoside) (NN reverse) (NN transcriptase) (NNS inhibitors)) (PRN (-LRB- -LRB-) (NP (NN NNRTIs)) (-RRB- -RRB-))) (: :) (S (NP (NN Nevirapine)) (VP (MD may) (VP (VB decrease) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NN combination) (JJ hormonal) (NNS contraceptives)))))) (: ;)) (. .)))))

Sentence Id: DrugDDI.d132.s28
use/NN of/IN a/DT nonhormonal/JJ contraceptive/JJ product/NN is/VBZ recommended/VBN ./.

(ROOT (S1 (S (S (NP (NP (NN use)) (PP (IN of) (NP (DT a) (JJ nonhormonal) (JJ contraceptive) (NN product)))) (VP (VBZ is) (VP (VBN recommended)))) (. .))))

Sentence Id: DrugDDI.d132.s29
No/NN data/NNS for/IN delavirdine/NN ;/: ./.

(ROOT (S1 (S (S (NP (NN No)) (VP (NNS data) (PP (IN for) (NP (NN delavirdine)))) (: ;)) (. .))))

Sentence Id: DrugDDI.d132.s30
incomplete/JJ data/NNS for/IN efavirenz/NN ./.

(ROOT (S1 (S (NP (NP (JJ incomplete) (NNS data)) (PP (IN for) (NP (NN efavirenz))) (. .)))))

Sentence Id: DrugDDI.d132.s31
Prednisolone/NN :/: Ethinyl/NN estradiol/NN may/MD inhibit/VB the/DT metabolism/NN of/IN prednisolone/NN ,/, leading/VBG to/TO increased/VBN plasma/NN concentrations/NNS ./.

(ROOT (S1 (S (S (NP (NN Prednisolone) (: :) (NN Ethinyl) (NN estradiol)) (VP (MD may) (VP (VB inhibit) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN prednisolone)))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (VBN increased) (NN plasma) (NNS concentrations)))))))) (. .))))

Sentence Id: DrugDDI.d132.s32
Protease/NN inhibitors/NNS :/: Amprenavir/NN ,/, lopinavir/NN ,/, nelfinavir/NN ,/, and/CC ritonavir/NN have/VBP been/VBN shown/VBN to/TO decrease/VB plasma/NN levels/NNS of/IN combination/NN hormonal/JJ contraceptives/NNS ;/: ./.

(ROOT (S1 (S (S (NP (NP (NN Protease) (NNS inhibitors)) (: :) (NP (NP (NN Amprenavir)) (, ,) (NP (NN lopinavir)) (, ,) (NP (NN nelfinavir)) (, ,) (CC and) (NP (NN ritonavir)))) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB decrease) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NN combination) (JJ hormonal) (NNS contraceptives)))))))))) (: ;)) (. .))))

Sentence Id: DrugDDI.d132.s33
use/NN of/IN a/DT nonhormonal/JJ contraceptive/JJ product/NN is/VBZ recommended/VBN ./.

(ROOT (S1 (S (S (NP (NP (NN use)) (PP (IN of) (NP (DT a) (JJ nonhormonal) (JJ contraceptive) (NN product)))) (VP (VBZ is) (VP (VBN recommended)))) (. .))))

Sentence Id: DrugDDI.d132.s34
Indinavir/NN has/VBZ been/VBN shown/VBN to/TO increase/VB plasma/NN levels/NNS of/IN combination/NN hormonal/JJ contraceptives/NNS ./.

(ROOT (S1 (S (S (NP (NN Indinavir)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB increase) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NN combination) (JJ hormonal) (NNS contraceptives))))))))))) (. .))))

Sentence Id: DrugDDI.d132.s35
No/DT data/NNS for/IN saquinavir/NN ./.

(ROOT (S1 (S (S (NP (DT No) (NNS data)) (PP (IN for) (NP (NN saquinavir)))) (. .))))

Sentence Id: DrugDDI.d132.s36
Rifampin/NN :/: Rifampin/NN increases/VBZ the/DT metabolism/NN of/IN ethinyl/NN estradiol/NN and/CC some/DT progestins/NNS (/-LRB- norethindrone/NN )/-RRB- resulting/VBG in/IN decreased/VBN contraceptive/JJ effectiveness/NN and/CC increased/VBN menstrual/JJ irregularities/NNS ./.

(ROOT (S1 (S (S (NP (NP (NN Rifampin)) (: :) (NP (NN Rifampin))) (VP (VBZ increases) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (NN ethinyl) (NN estradiol)) (CC and) (NP (NP (NP (DT some) (NNS progestins)) (PRN (-LRB- -LRB-) (NP (NN norethindrone)) (-RRB- -RRB-))) (VP (VBG resulting) (PP (IN in) (NP (NP (VBN decreased) (JJ contraceptive) (NN effectiveness)) (CC and) (NP (VBN increased) (JJ menstrual) (NNS irregularities))))))))))) (. .))))

Sentence Id: DrugDDI.d132.s37
Use/NN of/IN a/DT nonhormonal/JJ contraceptive/JJ product/NN is/VBZ recommended/VBN ./.

(ROOT (S1 (S (S (NP (NP (NN Use)) (PP (IN of) (NP (DT a) (JJ nonhormonal) (JJ contraceptive) (NN product)))) (VP (VBZ is) (VP (VBN recommended)))) (. .))))

Sentence Id: DrugDDI.d132.s38
Salicylic/JJ acid/NN :/: Combination/NN hormonal/JJ contraceptives/NNS may/MD increase/VB the/DT clearance/NN of/IN salicylic/JJ acid/NN ./.

(ROOT (S1 (S (S (NP (JJ Salicylic) (NN acid) (: :) (NN Combination) (JJ hormonal) (NNS contraceptives)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (JJ salicylic) (NN acid))))))) (. .))))

Sentence Id: DrugDDI.d132.s39
Selegiline/NN :/: Combination/NN hormonal/JJ contraceptives/NNS may/MD increase/VB the/DT serum/NN concentration/NN of/IN selegiline/NN ./.

(ROOT (S1 (S (S (NP (NN Selegiline) (: :) (NN Combination) (JJ hormonal) (NNS contraceptives)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN serum) (NN concentration)) (PP (IN of) (NP (NN selegiline))))))) (. .))))

Sentence Id: DrugDDI.d132.s40
Theophylline/NN :/: Ethinyl/NN estradiol/NN may/MD inhibit/VB the/DT metabolism/NN of/IN theophylline/NN ,/, leading/VBG to/TO increased/VBN plasma/NN concentrations/NNS ./.

(ROOT (S1 (S (S (NP (NP (NN Theophylline)) (: :) (NP (NN Ethinyl) (NN estradiol))) (VP (MD may) (VP (VB inhibit) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN theophylline)))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (VBN increased) (NN plasma) (NNS concentrations)))))))) (. .))))

Sentence Id: DrugDDI.d132.s41
Tricyclic/JJ antidepressants/NNS (/-LRB- amitriptyline/NN ,/, imipramine/NN ,/, nortriptyline/NN )/-RRB- :/: Metabolism/NN may/MD be/VB inhibited/VBN by/IN combination/NN hormonal/JJ contraceptives/NNS ,/, increasing/VBG plasma/NN levels/NNS of/IN antidepressant/JJ ;/: ./.

(ROOT (S1 (S (NP (NP (NP (JJ Tricyclic) (NNS antidepressants)) (PRN (-LRB- -LRB-) (NP (NP (NN amitriptyline)) (, ,) (NP (NN imipramine)) (, ,) (NP (NN nortriptyline))) (-RRB- -RRB-))) (: :) (S (NP (NN Metabolism)) (VP (MD may) (VP (VB be) (VP (VBN inhibited) (PP (IN by) (NP (NN combination) (JJ hormonal) (NNS contraceptives))) (, ,) (S (VP (VBG increasing) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (JJ antidepressant) (: ;)))))))))) (. .)))))

Sentence Id: DrugDDI.d132.s43
ETHANOL/NN //: NUTRITION/NN //: HERB/NN INTERACTIONS/NNS :/: Food/NN :/: CNS/NN effects/NNS of/IN caffeine/NN may/MD be/VB enhanced/VBN if/IN combination/NN hormonal/JJ contraceptives/NNS are/VBP used/VBN concurrently/RB with/IN caffeine/NN ./.

(ROOT (S1 (S (S (NP (NP (NN ETHANOL)) (: /) (NP (NN NUTRITION)) (: /) (NP (NN HERB) (NNS INTERACTIONS)) (: :) (NP (NN Food)) (: :) (NP (NP (NN CNS) (NNS effects)) (PP (IN of) (NP (NN caffeine))))) (VP (MD may) (VP (VB be) (VP (VBN enhanced) (SBAR (IN if) (S (NP (NN combination) (JJ hormonal) (NNS contraceptives)) (VP (VBP are) (VP (VBN used) (ADVP (RB concurrently)) (PP (IN with) (NP (NN caffeine))))))))))) (. .))))

Sentence Id: DrugDDI.d132.s44
Grapefruit/NN juice/NN increases/VBZ ethinyl/NN estradiol/NN concentrations/NNS and/CC would/MD be/VB expected/VBN to/TO increase/VB progesterone/NN serum/NN levels/NNS as/IN well/NN ;/: ./.

(ROOT (S1 (S (S (NP (NN Grapefruit) (NN juice)) (VP (VP (VBZ increases) (NP (NN ethinyl) (NN estradiol) (NNS concentrations))) (CC and) (VP (MD would) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB increase) (NP (NN progesterone) (NN serum) (NNS levels)) (PP (IN as) (NP (NN well)))))))))) (: ;)) (. .))))

Sentence Id: DrugDDI.d132.s46
Herb/Nutraceutical/NN :/: St/JJ Johns/NNP wort/NN may/MD decrease/VB the/DT effectiveness/NN of/IN combination/NN hormonal/JJ contraceptives/NNS by/IN inducing/VBG hepatic/JJ enzymes/NNS ./.

(ROOT (S1 (S (S (NP (NP (NN Herb/Nutraceutical)) (: :) (NP (JJ St) (NNP Johns) (NN wort))) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (NN combination) (JJ hormonal) (NNS contraceptives)))) (PP (IN by) (S (VP (VBG inducing) (NP (JJ hepatic) (NNS enzymes)))))))) (. .))))

Sentence Id: DrugDDI.d132.s47
Avoid/VB dong/JJ quai/NN and/CC black/JJ cohosh/NN (/-LRB- have/VB estrogen/NN activity/NN )./RB

(ROOT (S1 (S (VP (VB Avoid) (NP (NP (JJ dong) (NN quai)) (CC and) (NP (JJ black) (NN cohosh))) (-LRB- -LRB-) (S (VP (VB have) (NP (NN estrogen) (NN activity)) (ADVP (RB -RRB-.))))))))

Sentence Id: DrugDDI.d132.s48
Avoid/VB saw/VB palmetto/NN ,/, red/JJ clover/NN ,/, ginseng/NN ./.

(ROOT (S1 (S (S (VP (VB Avoid) (S (VP (VB saw) (NP (NP (NN palmetto)) (, ,) (NP (JJ red) (NN clover)) (, ,) (NP (NN ginseng))))))) (. .))))

Sentence Id: DrugDDI.d411.s0
CYP3A4/JJ Inhibitors/NNS @/NN Felodipine/NN is/VBZ metabolized/VBN by/IN CYP3A4/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ CYP3A4) (NNS Inhibitors)) (NN @) (NN Felodipine)) (VP (VBZ is) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP3A4)))))) (. .))))

Sentence Id: DrugDDI.d411.s1
Co-administration/NN of/IN CYP3A4/JJ inhibitors/NNS (/-LRB- eg/NN ,/, ketoconazole/NN ,/, itraconazole/NN ,/, erythromycin/NN ,/, grapefruit/NN juice/NN ,/, cimetidine/NN )/-RRB- with/IN felodipine/NN may/MD lead/VB to/TO several-/JJ fold/JJ increases/NNS in/IN the/DT plasma/NN levels/NNS of/IN felodipine/NN ,/, either/CC due/JJ to/TO an/DT increase/NN in/IN bioavailability/NN or/CC due/JJ to/TO a/DT decrease/NN in/IN metabolism/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NP (JJ CYP3A4) (NNS inhibitors)) (PRN (-LRB- -LRB-) (NP (NN eg)) (, ,) (NP (NP (NN ketoconazole)) (, ,) (NP (NN itraconazole)) (, ,) (NP (NN erythromycin)) (, ,) (NP (NN grapefruit) (NN juice)) (, ,) (NP (NN cimetidine))) (-RRB- -RRB-)))) (PP (IN with) (NP (NN felodipine)))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (JJ several-) (JJ fold) (NNS increases)) (PP (IN in) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NN felodipine)) (, ,) (ADJP (CC either) (ADJP (JJ due) (PP (TO to) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN bioavailability)))))) (CC or) (ADJP (JJ due) (PP (TO to) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NN metabolism)))))))))))))))) (. .))))

Sentence Id: DrugDDI.d411.s3
These/DT effects/NNS have/VBP been/VBN observed/VBN with/IN co-administration/NN of/IN itraconazole/NN (/-LRB- a/DT potent/JJ CYP3A4/NN inhibitor/NN )./NN

(ROOT (S1 (S (NP (DT These) (NNS effects)) (VP (VP (VBP have) (VP (VBN been) (VP (VBN observed) (PP (IN with) (NP (NP (NN co-administration)) (PP (IN of) (NP (NN itraconazole)))))))) (-LRB- -LRB-) (NP (DT a) (JJ potent) (NN CYP3A4) (NN inhibitor) (NN -RRB-.))))))

Sentence Id: DrugDDI.d411.s4
Caution/NN should/MD be/VB used/VBN when/WRB CYP3A4/JJ inhibitors/NNS are/VBP co-administered/VBN with/IN felodipine/NN ./.

(ROOT (S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN used))) (SBAR (WHADVP (WRB when)) (S (NP (JJ CYP3A4) (NNS inhibitors)) (VP (VBP are) (VP (VBN co-administered) (PP (IN with) (NP (NN felodipine))))))))) (. .))))

Sentence Id: DrugDDI.d411.s5
A/DT conservative/JJ approach/NN to/TO dosing/NN felodipine/NN should/MD be/VB taken/VBN ./.

(ROOT (S1 (S (S (NP (NP (DT A) (JJ conservative) (NN approach)) (PP (TO to) (NP (NN dosing) (NN felodipine)))) (VP (MD should) (VP (VB be) (VP (VBN taken))))) (. .))))

Sentence Id: DrugDDI.d411.s6
The/DT following/JJ specific/JJ interactions/NNS have/VBP been/VBN reported/VBN :/: Itraconazole/NN @/NN Co-administration/NN of/IN another/DT extended/VBN release/NN formulation/NN of/IN felodipine/NN with/IN itraconazole/NN resulted/VBD in/IN approximately/RB 8-fold/JJ increase/NN in/IN the/DT AUC/NN ,/, more/JJR than/IN 6-/CD fold/NN increase/NN in/IN the/DT Cmax/NN ,/, and/CC 2-fold/JJ prolongation/NN in/IN the/DT half-/JJ life/NN of/IN felodipine/NN ./.

(ROOT (S1 (S (S (NP (DT The) (JJ following) (JJ specific) (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN reported))))) (: :) (S (NP (NP (NN Itraconazole) (NN @) (NN Co-administration)) (PP (IN of) (NP (NP (DT another) (VBN extended) (NN release) (NN formulation)) (PP (IN of) (NP (NN felodipine))))) (PP (IN with) (NP (NN itraconazole)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (ADJP (RB approximately) (JJ 8-fold)) (NN increase)) (PP (IN in) (NP (DT the) (NN AUC)))) (, ,) (NP (NP (QP (JJR more) (IN than) (CD 6-)) (NN fold) (NN increase)) (PP (IN in) (NP (DT the) (NN Cmax)))) (, ,) (CC and) (NP (NP (JJ 2-fold) (NN prolongation)) (PP (IN in) (NP (NP (DT the) (JJ half-) (NN life)) (PP (IN of) (NP (NN felodipine)))))))))) (. .))))

Sentence Id: DrugDDI.d411.s7
Erythromycin/NN @/NN Co-administration/NN of/IN felodipine/NN (/-LRB- PLENDIL/NN )/-RRB- with/IN erythromycin/NN resulted/VBD in/IN approximately/RB 2.5-/CD fold/JJ increase/NN in/IN the/DT AUC/NN and/CC Cmax/NN ,/, and/CC about/RB 2-/CD fold/NN prolongation/NN in/IN the/DT half-/JJ life/NN of/IN felodipine/NN ./.

(ROOT (S1 (S (NP (NP (NN Erythromycin) (NN @) (NN Co-administration)) (PP (IN of) (NP (NP (NN felodipine)) (PRN (-LRB- -LRB-) (NP (NN PLENDIL)) (-RRB- -RRB-)))) (PP (IN with) (NP (NN erythromycin)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (ADJP (QP (RB approximately) (CD 2.5-)) (JJ fold)) (NN increase)) (PP (IN in) (NP (DT the) (NP (NP (NN AUC)) (CC and) (NP (NN Cmax)))))) (, ,) (CC and) (NP (NP (ADJP (QP (RB about) (CD 2-)) (NN fold)) (NN prolongation)) (PP (IN in) (NP (NP (DT the) (JJ half-) (NN life)) (PP (IN of) (NP (NN felodipine))))))))) (. .))))

Sentence Id: DrugDDI.d411.s8
Grapefruit/NN juice/NN @/NN Co-administration/NN of/IN felodipine/NN with/IN grapefruit/NN juice/NN resulted/VBD in/IN more/JJR than/IN 2-fold/JJ increase/NN in/IN the/DT AUC/NN and/CC Cmax/NN ,/, but/CC no/DT prolongation/NN in/IN the/DT half-/JJ life/NN of/IN felodipine/NN ./.

(ROOT (S1 (S (NP (NP (NN Grapefruit) (NN juice) (NN @) (NN Co-administration)) (PP (IN of) (NP (NN felodipine))) (PP (IN with) (NP (NN grapefruit) (NN juice)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (ADJP (JJR more) (IN than) (JJ 2-fold)) (NN increase)) (PP (IN in) (NP (DT the) (NP (NN AUC)) (CC and) (NP (NN Cmax))))) (, ,) (CC but) (NP (NP (DT no) (NN prolongation)) (PP (IN in) (NP (NP (DT the) (JJ half-) (NN life)) (PP (IN of) (NP (NN felodipine))))))))) (. .))))

Sentence Id: DrugDDI.d411.s9
Cimetidine/NN @/NN Co-administration/NN of/IN felodipine/NN with/IN cimetidine/NN (/-LRB- a/DT non-specific/JJ CYP-450/NN inhibitor/NN )/-RRB- resulted/VBD in/IN an/DT increase/NN of/IN approximately/RB 50/CD %/NN in/IN the/DT AUC/NN and/CC the/DT Cmax/NN ,/, of/IN felodipine/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Cimetidine) (NN @) (NN Co-administration)) (PP (IN of) (NP (NN felodipine))) (PP (IN with) (NP (NP (NN cimetidine)) (PRN (-LRB- -LRB-) (NP (DT a) (JJ non-specific) (NN CYP-450) (NN inhibitor)) (-RRB- -RRB-))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (QP (RB approximately) (CD 50)) (NN %))) (PP (IN in) (NP (DT the) (NP (NN AUC)) (CC and) (NP (NP (DT the) (NN Cmax)) (, ,) (PP (IN of) (NP (NN felodipine)))))))))) (. .))))

Sentence Id: DrugDDI.d411.s10
Beta-Blocking/JJ Agents/NNS @/NN :/: A/DT pharmacokinetic/JJ study/NN of/IN felodipine/NN in/IN conjunction/NN with/IN metoprolol/NN demonstrated/VBD no/DT significant/JJ effects/NNS on/IN the/DT pharmacokinetics/NNS of/IN felodipine/NN ./.

(ROOT (S1 (S (NP (NP (JJ Beta-Blocking) (NNS Agents) (NN @)) (: :) (S (NP (NP (DT A) (JJ pharmacokinetic) (NN study)) (PP (IN of) (NP (NN felodipine))) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NN metoprolol)))))) (VP (VBD demonstrated) (NP (NP (DT no) (JJ significant) (NNS effects)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN felodipine)))))))) (. .)))))

Sentence Id: DrugDDI.d411.s11
The/DT AUC/NN and/CC Cmax/NN of/IN metoprolol/NN ,/, however/RB ,/, were/VBD increased/VBN approximately/RB 31/CD and/CC 38/CD %/NN ,/, respectively/RB ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NP (NN AUC)) (CC and) (NP (NN Cmax))) (PP (IN of) (NP (NN metoprolol)))) (, ,) (ADVP (RB however)) (, ,) (VP (VBD were) (VP (VBN increased) (NP (QP (RB approximately) (CD 31) (CC and) (CD 38)) (NN %)) (, ,) (ADVP (RB respectively))))) (. .))))

Sentence Id: DrugDDI.d411.s12
In/IN controlled/JJ clinical/JJ trials/NNS ,/, however/RB ,/, beta/NN blockers/NNS including/VBG metoprolol/NN were/VBD concurrently/RB administered/VBN with/IN felodipine/NN and/CC were/VBD well/RB tolerated/VBN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (JJ controlled) (JJ clinical) (NNS trials))) (, ,) (ADVP (RB however)) (, ,) (NP (NP (NN beta) (NNS blockers)) (PP (VBG including) (NP (NN metoprolol)))) (VP (VP (VBD were) (VP (ADVP (RB concurrently)) (VBN administered) (PP (IN with) (NP (NN felodipine))))) (CC and) (VP (VBD were) (VP (ADVP (RB well)) (VBN tolerated))))) (. .))))

Sentence Id: DrugDDI.d411.s13
Digoxin/NN @/NN :/: When/WRB given/VBN concomitantly/RB with/IN PLENDIL/NN the/DT pharmacokinetics/NNS of/IN digoxin/NN in/IN patients/NNS with/IN heart/NN failure/NN were/VBD not/RB significantly/RB altered/VBN ./.

(ROOT (S1 (S (NP (NP (NN Digoxin) (NN @)) (: :) (S (SBAR (WHADVP (WRB When)) (S (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN PLENDIL)))))) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN digoxin))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN heart) (NN failure)))))) (VP (VBD were) (RB not) (ADVP (RB significantly)) (VP (VBN altered)))) (. .)))))

Sentence Id: DrugDDI.d411.s14
Anticonvulsants/NNS @/NN :/: In/IN a/DT pharmacokinetic/JJ study/NN ,/, maximum/JJ plasma/NN concentrations/NNS of/IN felodipine/NN were/VBD considerably/RB lower/JJR in/IN epileptic/JJ patients/NNS on/IN long-term/JJ anticonvulsant/JJ therapy/NN (/-LRB- eg/NN ,/, phenytoin/NN ,/, carbamazepine/NN ,/, or/CC phenobarbital/NN )/-RRB- than/IN in/IN healthy/JJ volunteers/NNS ./.

(ROOT (S1 (S (NP (NP (NNS Anticonvulsants) (NN @)) (: :) (S (PP (IN In) (NP (DT a) (JJ pharmacokinetic) (NN study))) (, ,) (NP (NP (JJ maximum) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN felodipine)))) (VP (VBD were) (ADJP (ADJP (RB considerably) (JJR lower)) (PP (IN in) (NP (NP (JJ epileptic) (NNS patients)) (PP (IN on) (NP (NP (JJ long-term) (JJ anticonvulsant) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN phenytoin)) (, ,) (NP (NN carbamazepine)) (, ,) (CC or) (NP (NN phenobarbital))) (-RRB- -RRB-)))))) (PP (IN than) (PP (IN in) (NP (JJ healthy) (NNS volunteers))))))) (. .)))))

Sentence Id: DrugDDI.d411.s15
In/IN such/JJ patients/NNS ,/, the/DT mean/JJ area/NN under/IN the/DT felodipine/NN plasma/NN concentration-time/NN curve/NN was/VBD also/RB reduced/VBN to/TO approximately/RB 6/CD %/NN of/IN that/DT observed/VBN in/IN healthy/JJ volunteers/NNS ./.

(ROOT (S1 (S (S (PP (IN In) (NP (JJ such) (NNS patients))) (, ,) (NP (NP (DT the) (JJ mean) (NN area)) (PP (IN under) (NP (DT the) (NN felodipine) (NN plasma) (NN concentration-time) (NN curve)))) (VP (VBD was) (ADVP (RB also)) (VP (VBN reduced) (PP (TO to) (NP (NP (QP (RB approximately) (CD 6)) (NN %)) (PP (IN of) (NP (NP (DT that)) (VP (VBN observed) (PP (IN in) (NP (JJ healthy) (NNS volunteers))))))))))) (. .))))

Sentence Id: DrugDDI.d411.s16
Since/IN a/DT clinically/RB significant/JJ interaction/NN may/MD be/VB anticipated/VBN ,/, alternative/JJ antihypertensive/JJ therapy/NN should/MD be/VB considered/VBN in/IN these/DT patients/NNS ./.

(ROOT (S1 (S (S (SBAR (IN Since) (S (NP (DT a) (ADJP (RB clinically) (JJ significant)) (NN interaction)) (VP (MD may) (VP (VB be) (VP (VBN anticipated)))))) (, ,) (NP (JJ alternative) (JJ antihypertensive) (NN therapy)) (VP (MD should) (VP (VB be) (VP (VBN considered) (PP (IN in) (NP (DT these) (NNS patients))))))) (. .))))

Sentence Id: DrugDDI.d411.s17
Tacrolimus/NN @/NN Felodipine/NN may/MD increase/VB the/DT blood/NN concentration/NN of/IN tacrolimus/NN ./.

(ROOT (S1 (S (S (NP (NN Tacrolimus) (NN @) (NN Felodipine)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN blood) (NN concentration)) (PP (IN of) (NP (NN tacrolimus))))))) (. .))))

Sentence Id: DrugDDI.d411.s18
When/WRB given/VBN concomitantly/RB with/IN felodipine/NN ,/, the/DT tacrolimus/NN blood/NN concentration/NN should/MD be/VB followed/VBN and/CC the/DT tacrolimus/NN dose/NN may/MD need/VBP to/TO be/VB adjusted/VBN ./.

(ROOT (S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN felodipine)))))) (, ,) (S (S (NP (DT the) (NN tacrolimus) (NN blood) (NN concentration)) (VP (MD should) (VP (VB be) (VP (VBN followed))))) (CC and) (S (NP (DT the) (NN tacrolimus) (NN dose)) (VP (MD may) (VP (VBP need) (S (VP (TO to) (VP (VB be) (VP (VBN adjusted)))))))))) (. .))))

Sentence Id: DrugDDI.d411.s19
Other/JJ Concomitant/JJ Therapy/NN @/NN :/: In/IN healthy/JJ subjects/NNS there/EX were/VBD no/DT clinically/RB significant/JJ interactions/NNS when/WRB felodipine/NN was/VBD given/VBN concomitantly/RB with/IN indomethacin/NN or/CC spironolactone/NN ./.

(ROOT (S1 (S (NP (NP (JJ Other) (JJ Concomitant) (NN Therapy) (NN @)) (: :) (S (PP (IN In) (NP (JJ healthy) (NNS subjects))) (NP (EX there)) (VP (VBD were) (NP (DT no) (ADJP (RB clinically) (JJ significant)) (NNS interactions)) (SBAR (WHADVP (WRB when)) (S (NP (NN felodipine)) (VP (VBD was) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NN indomethacin)) (CC or) (NP (NN spironolactone)))))))))) (. .)))))

Sentence Id: DrugDDI.d210.s0
Fenfluramine/NN may/MD increase/VB slightly/RB the/DT effect/NN of/IN antihypertensive/JJ drugs/NNS ,/, e.g./FW ,/, guanethidine/NN ,/, methyldopa/NN ,/, reserpine/NN ./.

(ROOT (S1 (S (S (NP (NN Fenfluramine)) (VP (MD may) (VP (VB increase) (ADVP (RB slightly)) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ antihypertensive) (NNS drugs)))) (, ,) (PP (FW e.g.) (, ,) (NP (NP (NN guanethidine)) (, ,) (NP (NN methyldopa)) (, ,) (NP (NN reserpine))))))) (. .))))

Sentence Id: DrugDDI.d210.s1
Other/JJ CNS/NN depressant/NN drugs/NNS should/MD be/VB used/VBN with/IN caution/NN in/IN patients/NNS taking/VBG fenfluramine/NN ,/, since/IN the/DT effects/NNS may/MD be/VB additive/JJ ./.

(ROOT (S1 (S (S (NP (JJ Other) (NN CNS) (NN depressant) (NNS drugs)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN fenfluramine))))) (, ,) (SBAR (IN since) (S (NP (DT the) (NNS effects)) (VP (MD may) (VP (VB be) (ADJP (JJ additive)))))))))) (. .))))

Sentence Id: DrugDDI.d199.s0
Oral/JJ Anticoagulants/NNS CAUTION/NN SHOULD/MD BE/VB EXERCISED/VBN WHEN/WRB COUMARIN/NN ANTICOAGULANT/NN S/NNS ARE/VBP GIVEN/VBN IN/IN CONJUNCTION/NN WITH/IN TRICOR/NN ./.

(ROOT (S1 (S (S (NP (JJ Oral) (NNS Anticoagulants) (NN CAUTION)) (VP (MD SHOULD) (VP (VB BE) (VP (VBN EXERCISED) (SBAR (WHADVP (WRB WHEN)) (S (NP (NN COUMARIN) (NN ANTICOAGULANT) (NNS S)) (VP (VBP ARE) (VP (VBN GIVEN) (PP (IN IN) (NP (NP (NN CONJUNCTION)) (PP (IN WITH) (NP (NN TRICOR))))))))))))) (. .))))

Sentence Id: DrugDDI.d199.s1
THE/DT DOSAGE/NN OF/IN THE/DT ANTICOAGULANTS/NNS SHOULD/MD BE/VB REDUCED/VBN TO/TO MAINTAIN/VB THE/DT PROTHROMBIN/NN TIME/INR/NN AT/IN THE/DT DESIRED/JJ LEVEL/NN TO/TO PREVENT/VB BLEEDING/JJ COMPLICATIONS/NNS ./.

(ROOT (S1 (S (S (NP (NP (DT THE) (NN DOSAGE)) (PP (IN OF) (NP (DT THE) (NNS ANTICOAGULANTS)))) (VP (MD SHOULD) (VP (VB BE) (VP (VBN REDUCED) (S (VP (TO TO) (VP (VB MAINTAIN) (NP (NP (DT THE) (NN PROTHROMBIN) (NN TIME/INR)) (PP (IN AT) (NP (DT THE) (JJ DESIRED) (NN LEVEL))) (S (VP (TO TO) (VP (VB PREVENT) (NP (JJ BLEEDING) (NNS COMPLICATIONS))))))))))))) (. .))))

Sentence Id: DrugDDI.d199.s3
HMG-CoA/NN reductase/NN inhibitors/NNS The/DT combined/JJ use/NN of/IN TRICOR/NN and/CC HMG-CoA/NN reductase/NN inhibitors/NNS should/MD be/VB avoided/VBN unless/IN the/DT benefit/NN of/IN further/JJ alterations/NNS in/IN lipid/NN levels/NNS is/VBZ likely/JJ to/TO outweigh/VB the/DT increased/VBN risk/NN of/IN this/DT drug/NN combination/NN ./.

(ROOT (S1 (S (S (NP (NN HMG-CoA) (NN reductase) (NNS inhibitors) (NP (NP (DT The) (JJ combined) (NN use)) (PP (IN of) (NP (NN TRICOR)))) (CC and) (NP (NN HMG-CoA) (NN reductase) (NNS inhibitors))) (VP (MD should) (VP (VB be) (VP (VBN avoided) (SBAR (IN unless) (S (NP (NP (DT the) (NN benefit)) (PP (IN of) (NP (JJ further) (NNS alterations))) (PP (IN in) (NP (NN lipid) (NNS levels)))) (VP (VBZ is) (ADJP (JJ likely) (S (VP (TO to) (VP (VB outweigh) (NP (NP (DT the) (VBN increased) (NN risk)) (PP (IN of) (NP (DT this) (NN drug) (NN combination))))))))))))))) (. .))))

Sentence Id: DrugDDI.d199.s4
Resins/NNS :/: Since/IN bile/JJ acid/NN sequestrants/NNS may/MD bind/VB other/JJ drugs/NNS given/VBN concurrently/RB ,/, patients/NNS should/MD take/VB TRICOR/NN at/IN least/JJS 1/CD hour/NN before/IN or/CC 4-6/CD hours/NNS after/IN a/DT bile/JJ acid/NN binding/NN resin/NN to/TO avoid/VB impeding/VBG its/PRP$ absorption/NN ./.

(ROOT (S1 (S (NP (NP (NNS Resins)) (: :) (S (SBAR (IN Since) (S (NP (JJ bile) (NN acid) (NNS sequestrants)) (VP (MD may) (VP (VB bind) (NP (NP (JJ other) (NNS drugs)) (VP (VBN given) (ADVP (RB concurrently)))))))) (, ,) (NP (NNS patients)) (VP (MD should) (VP (VB take) (NP (NN TRICOR)) (PP (NP (QP (IN at) (JJS least) (CD 1)) (NN hour)) (IN before) (NP (NP (CC or) (CD 4-6) (NNS hours)) (PP (IN after) (NP (NP (DT a) (JJ bile) (NN acid) (NN binding) (NN resin)) (S (VP (TO to) (VP (VB avoid) (S (VP (VBG impeding) (NP (PRP$ its) (NN absorption)))))))))))))) (. .)))))

Sentence Id: DrugDDI.d199.s5
Cyclosporine/NN :/: Because/IN cyclosporine/NN can/MD produce/VB nephrotoxicity/NN with/IN decreases/NNS in/IN creatinine/NN clearance/NN and/CC rises/VBZ in/IN serum/NN creatinine/NN ,/, and/CC because/IN renal/JJ excretion/NN is/VBZ the/DT primary/JJ elimination/NN route/NN of/IN fibrate/JJ drugs/NNS including/VBG TRICOR/NN ,/, there/EX is/VBZ a/DT risk/NN that/IN an/DT interaction/NN will/MD lead/VB to/TO deterioration/NN ./.

(ROOT (S1 (S (NP (NP (NN Cyclosporine)) (: :) (S (SBAR (SBAR (IN Because) (S (NP (NN cyclosporine)) (VP (VP (MD can) (VP (VB produce) (NP (NN nephrotoxicity)) (PP (IN with) (NP (NP (NNS decreases)) (PP (IN in) (NP (NN creatinine) (NN clearance))))))) (CC and) (VP (VBZ rises) (PP (IN in) (NP (NN serum) (NN creatinine))))))) (, ,) (CC and) (SBAR (IN because) (S (NP (JJ renal) (NN excretion)) (VP (VBZ is) (NP (NP (DT the) (JJ primary) (NN elimination) (NN route)) (PP (IN of) (NP (NP (JJ fibrate) (NNS drugs)) (PP (VBG including) (NP (NN TRICOR)))))))))) (, ,) (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (NN risk)) (SBAR (IN that) (S (NP (DT an) (NN interaction)) (VP (MD will) (VP (VB lead) (PP (TO to) (NP (NN deterioration)))))))))) (. .)))))

Sentence Id: DrugDDI.d199.s6
The/DT benefits/NNS and/CC risks/NNS of/IN using/VBG TRICOR/NN with/IN immunosuppressants/NNS and/CC other/JJ potentially/RB nephrotoxic/JJ agents/NNS should/MD be/VB carefully/RB considered/VBN ,/, and/CC the/DT lowest/JJS effective/JJ dose/NN employed/VBN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NP (NNS benefits)) (CC and) (NP (NNS risks))) (PP (IN of) (NP (VBG using) (NN TRICOR))) (PP (IN with) (NP (NP (NNS immunosuppressants)) (CC and) (NP (JJ other) (ADJP (RB potentially) (JJ nephrotoxic)) (NNS agents))))) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN considered))))) (, ,) (CC and) (S (NP (DT the) (JJS lowest) (JJ effective) (NN dose)) (VP (VBN employed))) (. .))))

Sentence Id: DrugDDI.d199.s8
@/NN Drug-drug/JJ interactions/NNS In/FW vitro/FW studies/NNS using/VBG human/JJ liver/NN microsomes/NNS indicate/VBP that/IN fenofibrate/NN and/CC fenofibric/JJ acid/NN are/VBP not/RB inhibitors/NNS of/IN cytochrome/NN (/-LRB- CYP/NN )/-RRB- P450/NN isoforms/NNS CYP3A4/NN ,/, CYP2D6/NN ,/, CYP2E1/NN ,/, or/CC CYP1A2/NN ./.

(ROOT (S1 (S (NP (NP (NN @) (JJ Drug-drug) (NNS interactions)) (S (NP (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBG using) (NP (JJ human) (NN liver) (NNS microsomes)))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN fenofibrate)) (CC and) (NP (JJ fenofibric) (NN acid))) (VP (VBP are) (RB not) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (NN cytochrome) (-LRB- -LRB-) (NN CYP) (-RRB- -RRB-) (NN P450) (NNS isoforms) (NP (NP (NN CYP3A4)) (, ,) (NP (NN CYP2D6)) (, ,) (NP (NN CYP2E1)) (, ,) (CC or) (NP (NN CYP1A2))))))))))) (. .)))))

Sentence Id: DrugDDI.d199.s9
They/PRP are/VBP weak/JJ inhibitors/NNS of/IN CYP2C19/NN and/CC CYP2A6/NN ,/, and/CC mild-to-moderate/JJ inhibitors/NNS of/IN CYP2C9/NN at/IN therapeutic/JJ concentrations/NNS ./.

(ROOT (S1 (S (S (NP (PRP They)) (VP (VBP are) (NP (NP (NP (JJ weak) (NNS inhibitors)) (PP (IN of) (NP (NP (NN CYP2C19)) (CC and) (NP (NN CYP2A6))))) (, ,) (CC and) (NP (NP (JJ mild-to-moderate) (NNS inhibitors)) (PP (IN of) (NP (NN CYP2C9))))) (PP (IN at) (NP (JJ therapeutic) (NNS concentrations))))) (. .))))

Sentence Id: DrugDDI.d199.s10
Potentiation/NN of/IN coumarin-type/NN anticoagulants/NNS has/VBZ been/VBN observed/VBN with/IN prolongation/NN of/IN the/DT prothrombin/NN time/INR/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Potentiation)) (PP (IN of) (NP (NN coumarin-type) (NNS anticoagulants)))) (VP (VBZ has) (VP (VBN been) (VP (VBN observed) (PP (IN with) (NP (NP (NN prolongation)) (PP (IN of) (NP (DT the) (NN prothrombin) (NN time/INR))))))))) (. .))))

Sentence Id: DrugDDI.d199.s11
Bile/JJ acid/NN sequestrants/NNS have/VBP been/VBN shown/VBN to/TO bind/VB other/JJ drugs/NNS given/VBN concurrently/RB ./.

(ROOT (S1 (S (S (NP (JJ Bile) (NN acid) (NNS sequestrants)) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB bind) (NP (NP (JJ other) (NNS drugs)) (VP (VBN given) (ADVP (RB concurrently))))))))))) (. .))))

Sentence Id: DrugDDI.d199.s12
Therefore/RB ,/, fenofibrate/NN should/MD be/VB taken/VBN at/IN least/JJS 1/CD hour/NN before/IN or/CC 4-6/CD hours/NNS after/IN a/DT bile/JJ acid/NN binding/NN resin/NN to/TO avoid/VB impeding/VBG its/PRP$ absorption/NN ./.

(ROOT (S1 (S (ADVP (RB Therefore)) (, ,) (NP (NN fenofibrate)) (VP (MD should) (VP (VB be) (VP (VBN taken) (PP (NP (QP (IN at) (JJS least) (CD 1)) (NN hour)) (IN before) (NP (CC or) (CD 4-6) (NNS hours))) (PP (IN after) (NP (NP (DT a) (JJ bile) (NN acid) (NN binding) (NN resin)) (S (VP (TO to) (VP (VB avoid) (S (VP (VBG impeding) (NP (PRP$ its) (NN absorption)))))))))))) (. .))))

Sentence Id: DrugDDI.d199.s13
Concomitant/JJ administration/NN of/IN fenofibrate/NN (/-LRB- equivalent/JJ to/TO 145mg/NN TRICOR/NN )/-RRB- with/IN pravastatin/NN (/-LRB- 40/CD mg/NN )/-RRB- once/RB daily/JJ for/IN 10/CD days/NNS has/VBZ been/VBN shown/VBN to/TO increase/VB the/DT mean/NN Cmax/NN and/CC AUC/NN values/NNS for/IN pravastatin/NN by/IN 36/CD %/NN (/-LRB- range/NN from/IN 69/CD %/NN decrease/NN to/TO 321/CD %/NN increase/NN )/-RRB- and/CC 28/CD %/NN (/-LRB- range/NN from/IN 54/CD %/NN decrease/NN to/TO 128/CD %/NN increase/NN )/-RRB- ,/, respectively/RB ,/, and/CC for/IN 3/CD @/NN -hydroxy-iso-/JJ pravastatin/NN by/IN 55/CD %/NN (/-LRB- range/NN from/IN 32/CD %/NN decrease/NN to/TO 314/CD %/NN increase/NN )/-RRB- and/CC 39/CD %/NN (/-LRB- range/NN from/IN 24/CD %/NN decrease/NN to/TO 261/CD %/NN increase/NN )/-RRB- ,/, respectively/RB in/IN 23/CD healthy/JJ adults/NNS ./.

(ROOT (S1 (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN fenofibrate)) (PRN (-LRB- -LRB-) (ADJP (JJ equivalent) (PP (TO to) (NP (NN 145mg) (NN TRICOR)))) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (NP (NN pravastatin)) (PRN (-LRB- -LRB-) (NP (CD 40) (NN mg)) (-RRB- -RRB-))) (ADJP (RB once) (JJ daily) (PP (IN for) (NP (CD 10) (NNS days))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NN mean) (NN Cmax) (CC and) (NN AUC) (NNS values)) (PP (PP (IN for) (NP (NP (NN pravastatin)) (PP (IN by) (NP (NP (NP (CD 36) (NN %)) (PRN (-LRB- -LRB-) (NP (NN range)) (PP (IN from) (NP (NP (ADJP (CD 69) (NN %)) (NN decrease)) (PP (TO to) (NP (ADJP (CD 321) (NN %)) (NN increase))))) (-RRB- -RRB-))) (CC and) (NP (NP (CD 28) (NN %)) (PRN (-LRB- -LRB-) (NP (NN range)) (PP (IN from) (NP (NP (ADJP (CD 54) (NN %)) (NN decrease)) (PP (TO to) (NP (ADJP (CD 128) (NN %)) (NN increase))))) (-RRB- -RRB-))) (, ,) (ADVP (RB respectively)))))) (, ,) (CC and) (PP (IN for) (NP (CD 3) (NN @) (JJ -hydroxy-iso-) (NN pravastatin))))) (PP (IN by) (NP (NP (NP (CD 55) (NN %)) (PRN (-LRB- -LRB-) (NP (NN range)) (PP (IN from) (NP (NP (ADJP (CD 32) (NN %)) (NN decrease)) (PP (TO to) (NP (ADJP (CD 314) (NN %)) (NN increase))))) (-RRB- -RRB-))) (CC and) (NP (NP (CD 39) (NN %)) (PRN (-LRB- -LRB-) (NP (NN range)) (PP (IN from) (NP (NP (ADJP (CD 24) (NN %)) (NN decrease)) (PP (TO to) (NP (ADJP (CD 261) (NN %)) (NN increase))))) (-RRB- -RRB-))) (, ,) (ADVP (RB respectively)))) (PP (IN in) (NP (CD 23) (JJ healthy) (NNS adults))))))))) (. .))))

Sentence Id: DrugDDI.d199.s14
A/DT single/JJ dose/NN of/IN pravastatin/NN had/VBD no/DT clinically/RB important/JJ effect/NN on/IN the/DT pharmacokinetics/NNS of/IN fenofibric/JJ acid/NN ./.

(ROOT (S1 (S (S (NP (NP (DT A) (JJ single) (NN dose)) (PP (IN of) (NP (NN pravastatin)))) (VP (VBD had) (NP (DT no) (ADJP (RB clinically) (JJ important)) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (JJ fenofibric) (NN acid))))))) (. .))))

Sentence Id: DrugDDI.d199.s15
Concomitant/JJ administration/NN of/IN fenofibrate/NN (/-LRB- equivalent/JJ to/TO 145/CD mg/NN TRICOR/NN )/-RRB- with/IN atorvastatin/NN (/-LRB- 20/CD mg/NN )/-RRB- once/RB daily/RB for/IN 10/CD days/NNS resulted/VBD in/IN approximately/RB 17/CD %/NN decrease/NN (/-LRB- range/NN from/IN 67/CD %/NN decrease/NN to/TO 44/CD %/NN increase/NN )/-RRB- in/IN atorvastatin/NN AUC/NN values/NNS in/IN 22/CD healthy/JJ males/NNS ./.

(ROOT (S1 (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN fenofibrate)) (PRN (-LRB- -LRB-) (ADJP (JJ equivalent) (PP (TO to) (NP (ADJP (CD 145) (NN mg)) (NN TRICOR)))) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (NP (NN atorvastatin)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN mg)) (-RRB- -RRB-))) (ADVP (RB once) (RB daily) (PP (IN for) (NP (CD 10) (NNS days))))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (ADJP (QP (RB approximately) (CD 17)) (NN %)) (NN decrease)) (PRN (-LRB- -LRB-) (NP (NN range)) (PP (IN from) (NP (NP (ADJP (CD 67) (NN %)) (NN decrease)) (PP (TO to) (NP (ADJP (CD 44) (NN %)) (NN increase))))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NN atorvastatin) (NN AUC) (NNS values)) (PP (IN in) (NP (CD 22) (JJ healthy) (NNS males)))))))) (. .))))

Sentence Id: DrugDDI.d199.s16
The/DT atorvastatin/NN Cmax/NN values/NNS were/VBD not/RB significantly/RB affected/VBN by/IN fenofibrate/NN ./.

(ROOT (S1 (S (S (NP (DT The) (NN atorvastatin) (NN Cmax) (NNS values)) (VP (VBD were) (RB not) (ADVP (RB significantly)) (VP (VBN affected) (PP (IN by) (NP (NN fenofibrate)))))) (. .))))

Sentence Id: DrugDDI.d199.s17
The/DT pharmacokinetics/NNS of/IN fenofibric/JJ acid/NN were/VBD not/RB significantly/RB affected/VBN by/IN atorvastatin/NN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NNS pharmacokinetics)) (PP (IN of) (NP (JJ fenofibric) (NN acid)))) (VP (VBD were) (RB not) (ADVP (RB significantly)) (VP (VBN affected) (PP (IN by) (NP (NN atorvastatin)))))) (. .))))

Sentence Id: DrugDDI.d95.s0
Drug/NN Interaction/NN with/IN Erythromycin/NN and/CC Ketoconazole/NN Fexofenadine/NN has/VBZ been/VBN shown/VBN to/TO exhibit/VB minimal/JJ (/-LRB- ca./FW 5/CD %/NN )/-RRB- metabolism/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Drug) (NN Interaction)) (PP (IN with) (NP (NP (NN Erythromycin)) (CC and) (NP (NN Ketoconazole)) (NP (NN Fexofenadine))))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB exhibit) (NP (ADJP (ADJP (JJ minimal)) (PRN (-LRB- -LRB-) (PP (FW ca.)) (NP (CD 5) (NN %)) (-RRB- -RRB-))) (NN metabolism))))))))) (. .))))

Sentence Id: DrugDDI.d95.s1
However/RB ,/, co/NN @/NN administration/NN of/IN fexofenadine/NN hydrochloride/NN with/IN either/CC ketoconazole/NN or/CC erythromycin/NN led/VBD to/TO increased/VBN plasma/NN concentrations/NNS of/IN fexofenadine/NN ./.

(ROOT (S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (NN co) (NN @) (NN administration)) (PP (IN of) (NP (NN fexofenadine) (NN hydrochloride))) (PP (IN with) (NP (CC either) (NP (NN ketoconazole)) (CC or) (NP (NN erythromycin))))) (VP (VBD led) (PP (TO to) (NP (NP (VBN increased) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN fexofenadine))))))) (. .))))

Sentence Id: DrugDDI.d95.s2
Fexofenadine/NN had/VBD no/DT effect/NN on/IN the/DT pharmacokinetics/NNS of/IN either/CC erythromycin/NN or/CC ketoconazole/NN ./.

(ROOT (S1 (S (S (NP (NN Fexofenadine)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (CC either) (NP (NN erythromycin)) (CC or) (NP (NN ketoconazole)))))))) (. .))))

Sentence Id: DrugDDI.d95.s3
In/IN 2/CD separate/JJ studies/NNS ,/, fexofenadine/NN hydrochloride/NN 120/CD mg/NN twice/RB daily/RB (/-LRB- 240/CD mg/NN total/JJ daily/JJ dose/NN )/-RRB- was/VBD co-administered/VBN with/IN either/CC erythromycin/NN 500/CD mg/NN every/DT 8/CD hours/NNS or/CC ketoconazole/NN 400/CD mg/NN once/RB daily/JJ under/IN steady-state/JJ conditions/NNS to/TO healthy/JJ volunteers/NNS (/-LRB- n=24/NN ,/, each/DT study/NN )./NN

(ROOT (S1 (S (PP (IN In) (NP (CD 2) (JJ separate) (NNS studies))) (, ,) (NP (NP (NP (NN fexofenadine) (NN hydrochloride) (CD 120) (NN mg)) (ADVP (RB twice) (RB daily))) (PRN (-LRB- -LRB-) (NP (CD 240) (NN mg) (JJ total) (JJ daily) (NN dose)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN co-administered) (PP (IN with) (NP (CC either) (NP (NP (NN erythromycin) (CD 500) (NN mg)) (NP (DT every) (CD 8) (NNS hours))) (CC or) (NP (NP (NN ketoconazole) (CD 400) (NN mg)) (ADJP (RB once) (JJ daily))))) (PP (IN under) (NP (NP (JJ steady-state) (NNS conditions)) (PP (TO to) (NP (JJ healthy) (NNS volunteers))))))) (PRN (-LRB- -LRB-) (NP (NP (NN n=24)) (, ,) (NP (DT each) (NN study) (NN -RRB-.)))))))

Sentence Id: DrugDDI.d95.s4
No/DT differences/NNS in/IN adverse/JJ events/NNS or/CC QTc/NN interval/NN were/VBD observed/VBN when/WRB subjects/NNS were/VBD administered/VBN fexofenadine/NN hydrochloride/NN alone/RB or/CC in/IN combination/NN with/IN either/CC erythromycin/NN or/CC ketoconazole/NN ./.

(ROOT (S1 (S (S (NP (NP (DT No) (NNS differences)) (PP (IN in) (NP (NP (JJ adverse) (NNS events)) (CC or) (NP (NN QTc) (NN interval))))) (VP (VBD were) (VP (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (NNS subjects)) (VP (VBD were) (VP (VBN administered) (NP (NN fexofenadine) (NN hydrochloride)) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (CC either) (NP (NN erythromycin)) (CC or) (NP (NN ketoconazole)))))))))))))) (. .))))

Sentence Id: DrugDDI.d95.s5
The/DT findings/NNS of/IN these/DT studies/NNS are/VBP summarized/VBN in/IN the/DT following/VBG table/NN :/: Effects/NNS on/IN steady-state/JJ fexofenadine/NN pharmacokinetics/NNS after/IN 7/CD days/NNS of/IN co-administration/NN with/IN fexofenadine/NN hydrochloride/NN 120/CD mg/NN every/DT 12/CD hours/NNS (/-LRB- two/CD times/NNS the/DT recommended/VBN twice/RB daily/JJ dose/NN )/-RRB- in/IN healthy/JJ volunteers/NNS (/-LRB- n=24/NN )/-RRB- ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NNS findings)) (PP (IN of) (NP (DT these) (NNS studies)))) (VP (VBP are) (VP (VBN summarized) (PP (IN in) (NP (DT the) (VBG following) (NN table)))))) (: :) (NP (NP (NNS Effects)) (PP (IN on) (NP (NP (JJ steady-state) (NN fexofenadine) (NNS pharmacokinetics)) (PP (IN after) (NP (NP (CD 7) (NNS days)) (PP (IN of) (NP (NP (NN co-administration)) (PP (IN with) (NP (NP (NP (NN fexofenadine) (NN hydrochloride) (CD 120) (NN mg)) (NP (NP (DT every) (CD 12) (NNS hours)) (PRN (-LRB- -LRB-) (NP (NP (CD two) (NNS times)) (NP (DT the) (VBN recommended) (ADJP (RB twice) (JJ daily)) (NN dose))) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (JJ healthy) (NNS volunteers)) (PRN (-LRB- -LRB-) (NP (NN n=24)) (-RRB- -RRB-))))))))))))) (. .))))

Sentence Id: DrugDDI.d95.s6
Concomitant/JJ Drug/NN ./.

(ROOT (S1 (S (NP (NP (JJ Concomitant) (NN Drug)) (. .)))))

Sentence Id: DrugDDI.d95.s9
Erythromycin/NN (/-LRB- 500/CD mg/NN every/DT 8/CD hrs/NNS )/-RRB- ./.

(ROOT (S1 (S (NP (NP (NP (NN Erythromycin)) (PRN (-LRB- -LRB-) (NP (CD 500) (NN mg) (NP (DT every) (CD 8) (NNS hrs))) (-RRB- -RRB-))) (. .)))))

Sentence Id: DrugDDI.d95.s12
Ketoconazole/NN (/-LRB- 400/CD mg/NN once/RB daily/JJ )/-RRB- ./.

(ROOT (S1 (S (NP (NP (NP (NN Ketoconazole)) (PRN (-LRB- -LRB-) (NP (NP (CD 400) (NN mg)) (ADJP (RB once) (JJ daily))) (-RRB- -RRB-))) (. .)))))

Sentence Id: DrugDDI.d95.s17
These/DT studies/NNS indicate/VBP that/IN ketoconazole/NN or/CC erythromycin/NN co-administration/NN enhances/VBZ fexofenadine/NN gastrointestinal/JJ absorption/NN ./.

(ROOT (S1 (S (S (NP (DT These) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN ketoconazole)) (CC or) (NP (NN erythromycin)) (NP (NN co-administration))) (VP (VBZ enhances) (NP (NN fexofenadine) (JJ gastrointestinal) (NN absorption))))))) (. .))))

Sentence Id: DrugDDI.d95.s18
This/DT observed/VBN increase/NN in/IN the/DT bioavailability/NN of/IN fexofenadine/NN may/MD be/VB due/JJ to/TO transport-related/JJ effects/NNS ,/, such/JJ as/IN p-/NN glycoprotein/NN ./. in/FW vivo/FW animal/NN studies/NNS also/RB suggest/VBP that/IN in/IN addition/NN to/TO enhancing/VBG absorption/NN ,/, ketoconazole/NN decreases/VBZ fexofenadine/NN gastrointestinal/JJ secretion/NN ,/, while/IN erythromycin/NN may/MD also/RB decrease/VB biliary/JJ excretion/NN ./.

(ROOT (S1 (S (S (S (NP (NP (DT This) (VBN observed) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (NN fexofenadine)))))) (VP (MD may) (VP (VB be) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ transport-related) (NNS effects)) (, ,) (PP (JJ such) (IN as) (NP (NN p-) (NN glycoprotein)))))))) (. .)) (NP (FW in) (FW vivo) (NN animal) (NNS studies)) (ADVP (RB also)) (VP (VBP suggest) (SBAR (IN that) (S (PP (IN in) (NN addition) (TO to) (S (VP (VBG enhancing) (NP (NN absorption))))) (, ,) (NP (NN ketoconazole)) (VP (VBZ decreases) (NP (NN fexofenadine) (JJ gastrointestinal) (NN secretion)) (, ,) (SBAR (IN while) (S (NP (NN erythromycin)) (VP (MD may) (ADVP (RB also)) (VP (VB decrease) (NP (JJ biliary) (NN excretion))))))))))) (. .))))

Sentence Id: DrugDDI.d95.s19
Drug/NN Interactions/NNS with/IN Antacids/NNS Administration/NN of/IN 120/CD mg/NN of/IN fexofenadine/NN hydrochloride/NN (/-LRB- 2/CD x/CC 60/CD mg/NN capsule/JJ )/-RRB- within/IN 15/CD minutes/NNS of/IN an/DT aluminum/NN and/CC magnesium/NN containing/VBG antacid/JJ (/-LRB- Maalox/NN @/NN )/-RRB- decreased/VBN fexofenadine/NN AUC/NN by/IN 41/CD %/NN and/CC cmax/NN by/IN 43/CD %./NN

(ROOT (S1 (S (NP (NP (NN Drug) (NNS Interactions)) (PP (IN with) (NP (NP (NNS Antacids) (NN Administration)) (PP (IN of) (NP (NP (CD 120) (NN mg)) (PP (IN of) (NP (NP (NN fexofenadine) (NN hydrochloride)) (PRN (-LRB- -LRB-) (NP (CD 2) (CC x) (CD 60) (NN mg) (JJ capsule)) (-RRB- -RRB-)))))))) (PP (IN within) (NP (NP (CD 15) (NNS minutes)) (PP (IN of) (NP (NP (DT an) (NP (NN aluminum)) (CC and) (NP (NN magnesium))) (VP (VBG containing) (NP (NP (NP (ADJP (ADJP (JJ antacid)) (PRN (-LRB- -LRB-) (NP (NN Maalox) (NN @)) (-RRB- -RRB-))) (VBN decreased) (NN fexofenadine) (NN AUC)) (PP (IN by) (NP (CD 41) (NN %)))) (CC and) (NP (NP (NN cmax)) (PP (IN by) (NP (CD 43) (NN %.))))))))))))))

Sentence Id: DrugDDI.d95.s20
ALLEGRA/NN should/MD not/RB be/VB taken/VBN closely/RB in/IN time/NN with/IN aluminum/NN and/CC magnesium/NN containing/VBG antacids/NNS ./.

(ROOT (S1 (S (S (NP (NN ALLEGRA)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN taken) (ADVP (RB closely)) (PP (IN in) (NP (NN time))) (PP (IN with) (NP (NP (NP (NN aluminum)) (CC and) (NP (NN magnesium))) (VP (VBG containing) (NP (NNS antacids))))))))) (. .))))

Sentence Id: DrugDDI.d95.s21
Interactions/NNS with/IN Fruit/NN Juices/NNS Fruit/NN juices/NNS such/JJ as/IN grapefruit/NN ,/, orange/NN and/CC apple/NN may/MD reduce/VB the/DT bioavailability/NN and/CC exposure/NN of/IN fexofenadine/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Interactions)) (PP (IN with) (NP (NP (NN Fruit) (NNS Juices) (NN Fruit) (NNS juices)) (PP (JJ such) (IN as) (NP (NP (NN grapefruit)) (, ,) (NP (NN orange)) (CC and) (NP (NN apple))))))) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (NP (NN bioavailability)) (CC and) (NP (NN exposure))) (PP (IN of) (NP (NN fexofenadine))))))) (. .))))

Sentence Id: DrugDDI.d95.s23
The/DT size/NN of/IN wheal/NN and/CC flare/NN were/VBD significantly/RB larger/JJR when/WRB fexofenadine/NN hydrochloride/NN was/VBD administered/VBN with/IN either/CC grapefruit/NN or/CC orange/NN juices/NNS compared/VBN to/TO water/NN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN size)) (PP (IN of) (NP (NP (NN wheal)) (CC and) (NP (NN flare))))) (VP (VBD were) (ADJP (RB significantly) (JJR larger)) (SBAR (WHADVP (WRB when)) (S (NP (NN fexofenadine) (NN hydrochloride)) (VP (VBD was) (VP (VBN administered) (PP (IN with) (NP (CC either) (NP (NN grapefruit)) (CC or) (NP (NN orange)) (NP (NNS juices)))) (PP (VBN compared) (PP (TO to) (NP (NN water)))))))))) (. .))))

Sentence Id: DrugDDI.d95.s26
In/IN addition/NN ,/, based/VBN on/IN the/DT population/NN pharmacokinetics/NNS analysis/NN of/IN the/DT combined/JJ data/NNS from/IN grapefruit/NN and/CC orange/NN juices/NNS studies/NNS with/IN the/DT data/NNS from/IN a/DT bioequivalence/NN study/NN ,/, the/DT bioavailability/NN of/IN fexofenadine/NN was/VBD reduced/VBN by/IN 36/CD %./NN

(ROOT (S1 (S (PP (IN In) (NP (NN addition))) (, ,) (PP (VBN based) (PP (IN on) (NP (DT the) (NN population) (NNS pharmacokinetics)))) (NP (NP (NN analysis)) (PP (IN of) (NP (NP (DT the) (JJ combined) (NNS data)) (PP (IN from) (NP (NP (NP (NP (NN grapefruit)) (CC and) (NP (NN orange)) (NP (NNS juices))) (NNS studies)) (PP (IN with) (NP (NP (DT the) (NNS data)) (PP (IN from) (NP (NP (DT a) (NN bioequivalence) (NN study)) (, ,) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (NN fexofenadine))))))))))))) (VP (VBD was) (VP (VBN reduced) (PP (IN by) (NP (CD 36) (NN %.))))))))

Sentence Id: DrugDDI.d95.s27
Therefore/RB ,/, to/TO maximize/VB the/DT effects/NNS of/IN fexofenadine/NN ,/, it/PRP is/VBZ recommended/VBN that/IN ALLEGRA/NN should/MD be/VB taken/VBN with/IN water/NN ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (S (VP (TO to) (VP (VB maximize) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN fexofenadine))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NN ALLEGRA)) (VP (MD should) (VP (VB be) (VP (VBN taken) (PP (IN with) (NP (NN water))))))))))) (. .))))

Sentence Id: DrugDDI.d433.s0
Androgens/NNS may/MD increase/VB sensitivity/NN to/TO oral/JJ anticoagulahts/NNS ./.

(ROOT (S1 (S (S (NP (NNS Androgens)) (VP (MD may) (VP (VB increase) (NP (NP (NN sensitivity)) (PP (TO to) (NP (JJ oral) (NNS anticoagulahts))))))) (. .))))

Sentence Id: DrugDDI.d433.s1
Dosage/NN of/IN the/DT anticoagulant/NN may/MD require/VB reduction/NN in/IN order/NN to/TO maintain/VB satisfactory/JJ therapeutic/JJ hypoprothrombinemia/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Dosage)) (PP (IN of) (NP (DT the) (NN anticoagulant)))) (VP (MD may) (VP (VB require) (NP (NN reduction))) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB maintain) (NP (JJ satisfactory) (JJ therapeutic) (NN hypoprothrombinemia)))))))) (. .))))

Sentence Id: DrugDDI.d433.s2
Concurrent/JJ administration/NN of/IN oxyphenbutazone/NN and/CC androgens/NNS may/MD result/VB in/IN elevated/JJ serum/NN levels/NNS of/IN oxyphenbutazone/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Concurrent) (NN administration)) (PP (IN of) (NP (NP (NN oxyphenbutazone)) (CC and) (NP (NNS androgens))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (JJ elevated) (NN serum) (NNS levels)) (PP (IN of) (NP (NN oxyphenbutazone)))))))) (. .))))

Sentence Id: DrugDDI.d433.s3
In/IN diabetic/JJ patients/NNS ,/, the/DT metabolic/JJ effects/NNS of/IN androgens/NNS may/MD decrease/VB blood/NN glucose/NN and/CC therefore/RB ,/, insulin/NN requirements/NNS ./.

(ROOT (S1 (S (S (PP (IN In) (NP (JJ diabetic) (NNS patients))) (, ,) (NP (NP (DT the) (JJ metabolic) (NNS effects)) (PP (IN of) (NP (NNS androgens)))) (VP (MD may) (VP (VP (VB decrease) (NP (NN blood) (NN glucose))) (CC and) (ADVP (RB therefore)) (, ,) (NP (NN insulin) (NNS requirements))))) (. .))))

Sentence Id: DrugDDI.d332.s0
Antacids/NNS :/: Administration/NN of/IN flurbiprofen/NN to/TO volunteers/NNS under/IN fasting/JJ conditions/NNS ,/, or/CC with/IN antacid/JJ suspension/NN yielded/VBD similar/JJ serum/NN flurbiprofen/NN time/NN profiles/NNS in/IN young/JJ subjects/NNS (/-LRB- n=12)./NN

(ROOT (S1 (S (NP (NP (NNS Antacids)) (: :) (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN flurbiprofen))) (PP (TO to) (NP (NP (NNS volunteers)) (PP (PP (IN under) (NP (JJ fasting) (NNS conditions))) (, ,) (CC or) (PP (IN with) (NP (JJ antacid) (NN suspension))))))) (VP (VBD yielded) (NP (JJ similar) (NN serum) (NN flurbiprofen) (NN time) (NNS profiles)) (PP (IN in) (NP (JJ young) (NNS subjects))) (-LRB- -LRB-) (NP (NN n=12-RRB-.))))))))

Sentence Id: DrugDDI.d332.s1
In/IN geriatric/JJ subjects/NNS (/-LRB- n=7/NN )/-RRB- there/EX was/VBD a/DT reduction/NN in/IN the/DT rate/NN but/CC not/RB the/DT extent/NN of/IN flurbiprofen/NN absorption/NN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (NP (JJ geriatric) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (NN n=7)) (-RRB- -RRB-)))) (NP (EX there)) (VP (VBD was) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NN rate)) (CONJP (CC but) (RB not)) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NN flurbiprofen) (NN absorption))))))))) (. .))))

Sentence Id: DrugDDI.d332.s2
Anticoagulants/NNS :/: Flurbiprofen/NN like/IN other/JJ nonsteroidal/JJ anti-inflammatory/JJ drugs/NNS ,/, has/VBZ been/VBN shown/VBN to/TO affect/VB bleeding/JJ parameters/NNS in/IN patients/NNS receiving/VBG anti-coagulants/NNS ,/, and/CC serious/JJ clinical/JJ bleeding/JJ has/VBZ been/VBN reported/VBN ./.

(ROOT (S1 (S (NP (NP (NNS Anticoagulants)) (: :) (S (S (NP (NP (NN Flurbiprofen)) (PP (IN like) (NP (JJ other) (JJ nonsteroidal) (JJ anti-inflammatory) (NNS drugs))) (, ,)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB affect) (NP (NP (JJ bleeding) (NNS parameters)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NNS anti-coagulants))))))))))))) (, ,) (CC and) (S (NP (JJ serious) (JJ clinical) (JJ bleeding)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported)))))) (. .)))))

Sentence Id: DrugDDI.d332.s3
The/DT physician/NN should/MD be/VB cautious/JJ when/WRB administering/VBG flurbiprofen/NN to/TO patients/NNS taking/VBG anticoagulants/NNS ./.

(ROOT (S1 (S (S (NP (DT The) (NN physician)) (VP (MD should) (VP (VB be) (ADJP (JJ cautious))) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NN flurbiprofen)) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NNS anticoagulants)))))))))) (. .))))

Sentence Id: DrugDDI.d332.s4
Aspirin/NN :/: Concurrent/JJ administration/NN of/IN aspirin/NN and/CC flurbiprofen/NN resulted/VBD in/IN 50/CD %/NN lower/JJR serum/NN flurbiprofen/NN concentrations/NNS ./.

(ROOT (S1 (S (S (NP (NN Aspirin)) (: :) (NP (NP (JJ Concurrent) (NN administration)) (PP (IN of) (NP (NP (NN aspirin)) (CC and) (NP (NN flurbiprofen))))) (VP (VBD resulted) (PP (IN in) (NP (ADJP (NP (CD 50) (NN %)) (JJR lower)) (NN serum) (NN flurbiprofen) (NNS concentrations))))) (. .))))

Sentence Id: DrugDDI.d332.s5
This/DT effect/NN of/IN aspirin/NN (/-LRB- which/WDT also/RB lowers/VBZ serum/NN concentrations/NNS of/IN other/JJ nonsteroidal/JJ anti-inflammatory/JJ drugs/NNS given/VBN with/IN it/PRP )/-RRB- has/VBZ been/VBN demonstrated/VBN in/IN patients/NNS with/IN rheumatoid/JJ arthritis/NN (/-LRB- n=/NN 15/CD )/-RRB- as/RB well/RB as/IN normal/JJ volunteers/NNS (/-LRB- n=/NN 16/CD )./NN

(ROOT (S1 (S (NP (NP (DT This) (NN effect)) (PP (IN of) (NP (NN aspirin))) (-LRB- -LRB-) (SBAR (WHNP (WDT which)) (S (ADVP (RB also)) (VP (VBZ lowers) (NP (NP (NN serum) (NNS concentrations)) (PP (IN of) (NP (NP (JJ other) (JJ nonsteroidal) (JJ anti-inflammatory) (NNS drugs)) (VP (VBN given) (PP (IN with) (NP (PRP it)))))))))) (-RRB- -RRB-)) (VP (VBZ has) (VP (VBN been) (VP (VBN demonstrated) (PP (IN in) (NP (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ rheumatoid) (NN arthritis)) (PRN (-LRB- -LRB-) (NP (NN n=) (CD 15)) (-RRB- -RRB-))))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ normal) (NNS volunteers)) (PRN (-LRB- -LRB-) (NP (NN n=) (CD 16) (NN -RRB-.))))))))))))

Sentence Id: DrugDDI.d332.s6
Concurrent/JJ use/NN of/IN flurbiprofen/NN and/CC aspirin/NN is/VBZ therefore/RB not/RB recommended/VBN ./.

(ROOT (S1 (S (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (NP (NN flurbiprofen)) (CC and) (NP (NN aspirin))))) (VP (VBZ is) (ADVP (RB therefore)) (RB not) (VP (VBN recommended)))) (. .))))

Sentence Id: DrugDDI.d332.s7
Beta-adrenergic/JJ Blocking/NN Agents/NNS :/: The/DT effect/NN of/IN flurbiprofen/NN on/IN blood/NN pressure/NN response/NN to/TO propranolol/NN and/CC atenolol/NN was/VBD evaluated/VBN in/IN men/NNS with/IN mild/JJ uncomplicated/JJ hypertension/NN (/-LRB- n/NN =/JJ 10/CD )./NN

(ROOT (S1 (S (NP (NP (JJ Beta-adrenergic) (NN Blocking) (NNS Agents)) (: :) (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN flurbiprofen))) (PP (IN on) (NP (NP (NN blood) (NN pressure) (NN response)) (PP (TO to) (NP (NP (NN propranolol)) (CC and) (NP (NN atenolol))))))) (VP (VBD was) (VP (VBN evaluated) (PP (IN in) (NP (NP (NNS men)) (PP (IN with) (NP (NP (JJ mild) (JJ uncomplicated) (NN hypertension)) (PRN (-LRB- -LRB-) (NP (NP (NN n)) (ADJP (JJ =) (NP (CD 10) (NN -RRB-.))))))))))))))))

Sentence Id: DrugDDI.d332.s8
Flurbiprofen/NN pretreatment/NN attenuated/VBD the/DT hypotensive/JJ effect/NN of/IN a/DT single/JJ dose/NN of/IN propranolol/NN but/CC not/RB atenolol/NN ./.

(ROOT (S1 (S (S (NP (NN Flurbiprofen) (NN pretreatment)) (VP (VBD attenuated) (NP (NP (DT the) (JJ hypotensive) (NN effect)) (PP (IN of) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NP (NN propranolol)) (CONJP (CC but) (RB not)) (NP (NN atenolol))))))))) (. .))))

Sentence Id: DrugDDI.d332.s9
Flurbiprofen/NN did/VBD not/RB appear/VB to/TO affect/VB the/DT beta-blocker/JJ -mediated/JJ reduction/NN in/IN heart/NN rate/NN ./.

(ROOT (S1 (S (S (NP (NN Flurbiprofen)) (VP (VBD did) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB affect) (NP (NP (DT the) (JJ beta-blocker) (JJ -mediated) (NN reduction)) (PP (IN in) (NP (NN heart) (NN rate)))))))))) (. .))))

Sentence Id: DrugDDI.d332.s10
Flurbiprofen/NN did/VBD not/RB affect/VB the/DT pharmacokinetic/JJ profile/NN of/IN either/DT drug/NN ,/, and/CC the/DT mechanism/NN under/IN lying/VBG the/DT interference/NN with/IN propranolol/NN s/NN hypotensive/JJ effect/NN is/VBZ unknown/JJ ./.

(ROOT (S1 (S (S (S (NP (NN Flurbiprofen)) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (DT the) (JJ pharmacokinetic) (NN profile)) (PP (IN of) (NP (DT either) (NN drug))))))) (, ,) (CC and) (S (NP (NP (DT the) (NN mechanism)) (PP (IN under) (S (VP (VBG lying) (NP (NP (DT the) (NN interference)) (PP (IN with) (NP (NN propranolol) (NN s) (JJ hypotensive) (NN effect)))))))) (VP (VBZ is) (ADJP (JJ unknown))))) (. .))))

Sentence Id: DrugDDI.d332.s11
Patients/NNS taking/VBG both/CC flurbiprofen/NN and/CC a/DT beta-blocker/NN should/MD be/VB monitored/VBN to/TO ensure/VB that/IN a/DT satisfactory/JJ hypotensive/JJ effect/NN is/VBZ achieved/VBN ./.

(ROOT (S1 (S (S (NP (NP (NNS Patients)) (VP (VBG taking) (NP (CC both) (NP (NN flurbiprofen)) (CC and) (NP (DT a) (NN beta-blocker))))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (S (VP (TO to) (VP (VB ensure) (SBAR (IN that) (S (NP (DT a) (JJ satisfactory) (JJ hypotensive) (NN effect)) (VP (VBZ is) (VP (VBN achieved)))))))))))) (. .))))

Sentence Id: DrugDDI.d332.s12
Cimetidine/NN ,/, Ranitidine/NN :/: In/IN normal/JJ volunteers/NNS (/-LRB- n=9/NN )/-RRB- ,/, pretreatment/NN with/IN cimetidine/NN or/CC ranitidine/NN did/VBD not/RB affect/VB flurbiprofen/NN pharmacokinetics/NNS except/IN that/IN a/DT small/JJ (/-LRB- 13/CD %/NN )/-RRB- but/CC statistically/RB significant/JJ increase/NN in/IN the/DT area/NN under/IN the/DT serum/NN concentration/NN curve/NN of/IN flurbiprofen/NN resulted/VBD with/IN cimetidine/NN ./.

(ROOT (S1 (S (NP (NP (NP (NN Cimetidine)) (, ,) (NP (NN Ranitidine))) (: :) (S (PP (IN In) (NP (NP (JJ normal) (NNS volunteers)) (PRN (-LRB- -LRB-) (NP (NN n=9)) (-RRB- -RRB-)))) (, ,) (NP (NP (NN pretreatment)) (PP (IN with) (NP (NP (NN cimetidine)) (CC or) (NP (NN ranitidine))))) (VP (VBD did) (RB not) (VP (VB affect) (NP (NN flurbiprofen) (NNS pharmacokinetics)) (PP (IN except) (SBAR (IN that) (S (NP (NP (DT a) (ADJP (ADJP (JJ small) (PRN (-LRB- -LRB-) (NP (CD 13) (NN %)) (-RRB- -RRB-))) (CC but) (ADJP (RB statistically) (JJ significant))) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN area)) (PP (IN under) (NP (NP (DT the) (NN serum) (NN concentration) (NN curve)) (PP (IN of) (NP (NN flurbiprofen)))))))) (VP (VBD resulted) (PP (IN with) (NP (NN cimetidine)))))))))) (. .)))))

Sentence Id: DrugDDI.d332.s13
Digoxin/NN :/: Studies/NNS of/IN concomitant/JJ administration/NN of/IN flurbiprofen/NN and/CC digoxin/NN to/TO healthy/JJ men/NNS (/-LRB- n=/NN 14/CD )/-RRB- did/VBD not/RB show/VB a/DT change/NN in/IN the/DT steady/JJ state/NN serum/NN levels/NNS of/IN either/DT drug/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Digoxin)) (: :) (NP (NP (NNS Studies)) (PP (IN of) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN flurbiprofen)))))) (CC and) (NP (NP (NN digoxin)) (PP (TO to) (NP (NP (JJ healthy) (NNS men)) (PRN (-LRB- -LRB-) (NP (NN n=) (CD 14)) (-RRB- -RRB-)))))) (VP (VBD did) (RB not) (VP (VB show) (NP (NP (DT a) (NN change)) (PP (IN in) (NP (NP (DT the) (JJ steady) (NN state) (NN serum) (NNS levels)) (PP (IN of) (NP (DT either) (NN drug))))))))) (. .))))

Sentence Id: DrugDDI.d332.s14
Diuretics/NN :/: Studies/NNS in/IN normal/JJ volunteers/NNS have/VBP shown/VBN that/IN flurbiprofen/NN like/IN other/JJ nonsteroidal/JJ anti-inflammatory/JJ drugs/NNS ,/, can/MD interfere/VB with/IN the/DT effects/NNS of/IN furosemide/NN ./.

(ROOT (S1 (S (NP (NP (NN Diuretics)) (: :) (S (NP (NP (NNS Studies)) (PP (IN in) (NP (JJ normal) (NNS volunteers)))) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN flurbiprofen)) (PP (IN like) (NP (JJ other) (JJ nonsteroidal) (JJ anti-inflammatory) (NNS drugs))) (, ,) (VP (MD can) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN furosemide)))))))))))) (. .)))))

Sentence Id: DrugDDI.d332.s15
Although/IN results/NNS have/VBP varied/VBD from/IN study/NN to/TO study/NN ,/, effects/NNS have/VBP been/VBN shown/VBN on/IN furosemide-stimulated/JJ diuresis/NN ,/, natriuresis/NN ,/, and/CC kaliuresis/NN ./.

(ROOT (S1 (S (S (SBAR (IN Although) (S (NP (NNS results)) (VP (VBP have) (VP (VBD varied) (PP (IN from) (NP (NP (NN study)) (TO to) (NP (NN study)))))))) (, ,) (NP (NNS effects)) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (PP (IN on) (NP (NP (JJ furosemide-stimulated) (NN diuresis)) (, ,) (NP (NN natriuresis)) (, ,) (CC and) (NP (NN kaliuresis)))))))) (. .))))

Sentence Id: DrugDDI.d332.s16
Other/JJ nonsteroidal/JJ anti-inflammatory/JJ drugs/NNS that/WDT inhibit/VBP prostaglandin/NN synthesis/NN have/VBP been/VBN shown/VBN to/TO interfere/VB with/IN thiazide/NN diuretics/NNS in/IN some/DT studies/NNS and/CC with/IN potassium-sparing/JJ diuretics/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Other) (JJ nonsteroidal) (JJ anti-inflammatory) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (NN prostaglandin) (NN synthesis)))))) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB interfere) (PP (PP (IN with) (NP (NN thiazide) (NNS diuretics))) (PP (IN in) (NP (DT some) (NNS studies))) (CC and) (PP (IN with) (NP (JJ potassium-sparing) (NN diuretics))))))))))) (. .))))

Sentence Id: DrugDDI.d332.s17
Patients/NNS receiving/VBG flurbiprofen/NN and/CC furosemide/NN or/CC other/JJ diuretics/NNS should/MD be/VB observed/VBN closely/RB to/TO determine/VB if/IN the/DT desired/JJ effect/NN is/VBZ obtained/VBN ./.

(ROOT (S1 (S (S (NP (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NP (NN flurbiprofen)) (CC and) (NP (NN furosemide))))) (CC or) (NP (JJ other) (NNS diuretics))) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (DT the) (JJ desired) (NN effect)) (VP (VBZ is) (VP (VBN obtained)))))))))))) (. .))))

Sentence Id: DrugDDI.d332.s18
Oral/JJ Hypoglycemic/JJ Agents/NNS :/: In/IN one/CD study/NN ,/, flurbiprofen/NN was/VBD given/VBN to/TO adult/JJ diabetics/NNS who/WP were/VBD already/RB receiving/VBG glyburide/NN (/-LRB- n=4/NN )/-RRB- ,/, metformin/NN (/-LRB- n=2/NN )/-RRB- chlorpropamide/NN with/IN phenformin/NN (/-LRB- n=/NN 3/CD )/-RRB- or/CC glyburide/NN with/IN phenformin/NN (/-LRB- n=6)./CD

(ROOT (S1 (S (NP (NP (JJ Oral) (JJ Hypoglycemic) (NNS Agents)) (: :) (S (PP (IN In) (NP (CD one) (NN study))) (, ,) (NP (NN flurbiprofen)) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (JJ adult) (NNS diabetics)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG receiving) (NP (NP (NP (NN glyburide)) (PRN (-LRB- -LRB-) (NP (NN n=4)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NP (NP (NN metformin)) (PRN (-LRB- -LRB-) (NP (NN n=2)) (-RRB- -RRB-))) (NN chlorpropamide)) (PP (IN with) (NP (NN phenformin)))) (PRN (-LRB- -LRB-) (NP (NN n=) (CD 3)) (-RRB- -RRB-))) (CC or) (NP (NP (NN glyburide)) (PP (IN with) (NP (NN phenformin) (-LRB- -LRB-) (CD n=6-RRB-.))))))))))))))))))

Sentence Id: DrugDDI.d332.s19
Although/IN there/EX was/VBD a/DT slight/JJ reduction/NN in/IN blood/NN sugar/NN concentrations/NNS during/IN concomitant/JJ administration/NN of/IN flurbiprofen/NN and/CC hypoglycemic/JJ agents/NNS ,/, there/EX were/VBD no/DT signs/NNS or/CC symptoms/NNS of/IN hypoglycemia/NN ./.

(ROOT (S1 (S (S (SBAR (IN Although) (S (NP (EX there)) (VP (VBD was) (NP (NP (DT a) (JJ slight) (NN reduction)) (PP (IN in) (NP (NN blood) (NN sugar) (NNS concentrations)))) (PP (IN during) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN flurbiprofen)) (CC and) (NP (JJ hypoglycemic) (NNS agents))))))))) (, ,) (NP (EX there)) (VP (VBD were) (NP (NP (DT no) (NP (NNS signs)) (CC or) (NP (NNS symptoms))) (PP (IN of) (NP (NN hypoglycemia)))))) (. .))))

Sentence Id: DrugDDI.d561.s0
Diuretics/NN :/: Patients/NNS on/IN diuretics/NN ,/, especially/RB those/DT with/IN intravascular/JJ volume/NN depletion/NN ,/, may/MD occasionally/RB experience/VBP an/DT excessive/JJ reduction/NN of/IN blood/NN pressure/NN after/IN initiation/NN of/IN therapy/NN with/IN fosinopril/NN sodium/NN ./.

(ROOT (S1 (S (NP (NP (NN Diuretics)) (: :) (S (NP (NP (NP (NNS Patients)) (PP (IN on) (NP (NN diuretics)))) (, ,) (ADVP (RB especially)) (NP (NP (DT those)) (PP (IN with) (NP (JJ intravascular) (NN volume) (NN depletion)))) (, ,)) (VP (MD may) (ADVP (RB occasionally)) (VP (VBP experience) (NP (NP (DT an) (JJ excessive) (NN reduction)) (PP (IN of) (NP (NN blood) (NN pressure))) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (NP (NN therapy)) (PP (IN with) (NP (NN fosinopril) (NN sodium))))))))))) (. .)))))

Sentence Id: DrugDDI.d561.s1
The/DT possibility/NN of/IN hypotensive/JJ effects/NNS can/MD be/VB minimized/VBN by/IN either/CC discontinuing/VBG the/DT diuretic/JJ or/CC increasing/VBG salt/NN intake/NN prior/RB to/TO initiation/NN of/IN treatment/NN with/IN fosinopril/NN sodium/NN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (NP (JJ hypotensive) (NNS effects)))) (VP (MD can) (VP (VB be) (VP (VBN minimized) (PP (IN by) (S (VP (CC either) (VP (VBG discontinuing) (NP (DT the) (JJ diuretic))) (CC or) (VP (VBG increasing) (NP (NP (NN salt) (NN intake)) (ADVP (ADVP (RB prior)) (PP (TO to) (NP (NP (NN initiation)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN with) (NP (NN fosinopril) (NN sodium))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d561.s3
Potassium/NN Supplement/NN s/NNS and/CC Potassium-Sparing/JJ Diuretics/NNS :/: Fosinopril/NN sodium/NN can/MD attenuate/VB potassium/NN loss/NN caused/VBN by/IN thiazide/NN diuretics/NNS ./.

(ROOT (S1 (S (NP (NP (NP (NN Potassium) (NN Supplement) (NNS s)) (CC and) (NP (JJ Potassium-Sparing) (NNS Diuretics))) (: :) (S (NP (NN Fosinopril) (NN sodium)) (VP (MD can) (VP (VB attenuate) (NP (NP (NN potassium) (NN loss)) (VP (VBN caused) (PP (IN by) (NP (NN thiazide) (NNS diuretics)))))))) (. .)))))

Sentence Id: DrugDDI.d561.s4
Potassium-sparing/JJ diuretics/NNS (/-LRB- spironolactone/NN ,/, amiloride/NN ,/, triamterene/NN ,/, and/CC others/NNS )/-RRB- or/CC potassium/NN supplement/NN s/NNS can/MD increase/VB the/DT risk/NN of/IN hyperkalemia/NN ./.

(ROOT (S1 (S (S (NP (NP (NP (JJ Potassium-sparing) (NNS diuretics)) (PRN (-LRB- -LRB-) (NP (NP (NN spironolactone)) (, ,) (NP (NN amiloride)) (, ,) (NP (NN triamterene)) (, ,) (CC and) (NP (NNS others))) (-RRB- -RRB-))) (CC or) (NP (NN potassium) (NN supplement) (NNS s))) (VP (MD can) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN hyperkalemia))))))) (. .))))

Sentence Id: DrugDDI.d561.s6
Lithium/NN :/: Increased/VBN serum/NN lithium/NN levels/NNS and/CC symptoms/NNS of/IN lithium/NN toxicity/NN have/VBP been/VBN reported/VBN in/IN patients/NNS receiving/VBG ACE/NN inhibitors/NNS during/IN therapy/NN with/IN lithium/NN ./.

(ROOT (S1 (S (NP (NP (NN Lithium)) (: :) (S (NP (NP (NP (VBN Increased) (NN serum) (NN lithium) (NNS levels)) (CC and) (NP (NNS symptoms))) (PP (IN of) (NP (NN lithium) (NN toxicity)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN ACE) (NNS inhibitors)) (PP (IN during) (NP (NP (NN therapy)) (PP (IN with) (NP (NN lithium)))))))))))) (. .)))))

Sentence Id: DrugDDI.d561.s7
These/DT drugs/NNS should/MD be/VB coadministered/VBN with/IN caution/NN ,/, and/CC frequent/JJ monitoring/NN of/IN serum/NN lithium/NN levels/NNS is/VBZ recommended/VBN ./.

(ROOT (S1 (S (S (S (NP (DT These) (NNS drugs)) (VP (MD should) (VP (VB be) (VP (VBN coadministered) (PP (IN with) (NP (NN caution))))))) (, ,) (CC and) (S (NP (NP (JJ frequent) (NN monitoring)) (PP (IN of) (NP (NN serum) (NN lithium) (NNS levels)))) (VP (VBZ is) (VP (VBN recommended))))) (. .))))

Sentence Id: DrugDDI.d561.s8
If/IN a/DT diuretic/NN is/VBZ also/RB used/VBN ,/, the/DT risk/NN of/IN lithium/NN toxicity/NN may/MD be/VB increased/VBN ./.

(ROOT (S1 (S (S (SBAR (IN If) (S (NP (DT a) (NN diuretic)) (VP (VBZ is) (ADVP (RB also)) (VP (VBN used))))) (, ,) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN lithium) (NN toxicity)))) (VP (MD may) (VP (VB be) (VP (VBN increased))))) (. .))))

Sentence Id: DrugDDI.d561.s9
Antacids/NNS :/: In/IN a/DT clinical/JJ pharmacology/NN study/NN ,/, coadministration/NN of/IN an/DT antacid/JJ (/-LRB- aluminum/NN hydroxide/NN ,/, magnesium/NN hydroxide/NN ,/, and/CC simethicone/NN )/-RRB- with/IN fosinopril/NN reduced/VBD serum/NN levels/NNS and/CC urinary/JJ excretion/NN of/IN fosinoprilat/NN as/IN compared/VBN with/IN fosinopril/NN administered/VBN alone/RB ,/, suggesting/VBG that/IN antacids/NNS may/MD impair/VB absorption/NN of/IN fosinopril/NN ./.

(ROOT (S1 (S (NP (NP (NNS Antacids)) (: :) (S (PP (IN In) (NP (DT a) (JJ clinical) (NN pharmacology) (NN study))) (, ,) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (DT an) (JJ antacid)) (PRN (-LRB- -LRB-) (NP (NP (NN aluminum) (NN hydroxide)) (, ,) (NP (NN magnesium) (NN hydroxide)) (, ,) (CC and) (NP (NN simethicone))) (-RRB- -RRB-)))) (PP (IN with) (NP (NN fosinopril)))) (VP (VBD reduced) (NP (NP (NN serum) (NNS levels)) (CC and) (NP (NP (JJ urinary) (NN excretion)) (PP (IN of) (NP (NN fosinoprilat))))) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (NP (NN fosinopril)) (VP (VBN administered) (ADVP (RB alone)))))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NNS antacids)) (VP (MD may) (VP (VB impair) (NP (NP (NN absorption)) (PP (IN of) (NP (NN fosinopril)))))))))))) (. .)))))

Sentence Id: DrugDDI.d561.s11
Other/JJ :/: Neither/CC fosinopril/NN sodium/NN nor/CC its/PRP$ metabolites/NNS have/VBP been/VBN found/VBN to/TO interact/VB with/IN food/NN ./.

(ROOT (S1 (S (S (NP (JJ Other) (: :) (CC Neither) (NP (NN fosinopril) (NN sodium)) (CC nor) (NP (PRP$ its) (NNS metabolites))) (VP (VBP have) (VP (VBN been) (VP (VBN found) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (NN food)))))))))) (. .))))

Sentence Id: DrugDDI.d561.s12
In/IN separate/JJ single/JJ or/CC multiple/JJ dose/NN pharmacokinetic/JJ interaction/NN studies/NNS with/IN chlorthalidone/NN ,/, nifedipine/NN ,/, propanolol/NN ,/, hydrochlorothiazide/NN ,/, cimetidine/NN ,/, metoclopramide/NN ,/, propantheline/NN ,/, digoxin/NN ,/, and/CC warfarin/NN ,/, the/DT bioavailability/NN of/IN fosinoprilat/NN was/VBD not/RB altered/VBN by/IN coadministration/NN of/IN fosinopril/NN with/IN any/DT one/CD of/IN these/DT drugs/NNS ./.

(ROOT (S1 (S (S (PP (IN In) (NP (NP (JJ separate) (ADJP (ADJP (JJ single)) (CC or) (ADJP (JJ multiple))) (NN dose) (JJ pharmacokinetic) (NN interaction) (NNS studies)) (PP (IN with) (NP (NP (NN chlorthalidone)) (, ,) (NP (NN nifedipine)) (, ,) (NP (NN propanolol)) (, ,) (NP (NN hydrochlorothiazide)) (, ,) (NP (NN cimetidine)) (, ,) (NP (NN metoclopramide)) (, ,) (NP (NN propantheline)) (, ,) (NP (NN digoxin)) (, ,) (CC and) (NP (NN warfarin)))))) (, ,) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (NN fosinoprilat)))) (VP (VBD was) (RB not) (VP (VBN altered) (PP (IN by) (NP (NP (NN coadministration)) (PP (IN of) (NP (NN fosinopril))) (PP (IN with) (NP (NP (DT any) (CD one)) (PP (IN of) (NP (DT these) (NNS drugs)))))))))) (. .))))

Sentence Id: DrugDDI.d561.s13
In/IN a/DT study/NN with/IN concomitant/JJ administration/NN of/IN aspirin/NN and/CC fosinopril/NN sodium/NN ,/, the/DT bioavailability/NN of/IN unbound/JJ fosinoprilat/NN was/VBD not/RB altered/VBN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (NP (DT a) (NN study)) (PP (IN with) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN aspirin)) (CC and) (NP (NN fosinopril)) (NP (NN sodium)))))))) (, ,) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (JJ unbound) (NN fosinoprilat)))) (VP (VBD was) (RB not) (VP (VBN altered)))) (. .))))

Sentence Id: DrugDDI.d561.s14
In/IN a/DT pharmacokinetic/JJ interaction/NN study/NN with/IN warfarin/NN ,/, bioavailability/NN parameters/NNS ,/, the/DT degree/NN of/IN protein/NN binding/NN ,/, and/CC the/DT anticoagulant/JJ effect/NN (/-LRB- measured/VBN by/IN prothrombin/NN time/NN )/-RRB- of/IN warfarin/NN were/VBD not/RB significantly/RB changed/VBN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (NP (DT a) (JJ pharmacokinetic) (NN interaction) (NN study)) (PP (IN with) (NP (NN warfarin))))) (, ,) (NP (NP (NN bioavailability) (NNS parameters)) (, ,) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NN protein) (NN binding)))) (, ,) (CC and) (NP (NP (NP (DT the) (JJ anticoagulant) (NN effect)) (PRN (-LRB- -LRB-) (VP (VBN measured) (PP (IN by) (NP (NN prothrombin) (NN time)))) (-RRB- -RRB-))) (PP (IN of) (NP (NN warfarin))))) (VP (VBD were) (RB not) (ADVP (RB significantly)) (VP (VBN changed)))) (. .))))

Sentence Id: DrugDDI.d561.s15
Drug/NN /Laboratory/NN Test/NN Interaction/NN Fosinopril/NN may/MD cause/VB a/DT false/JJ low/JJ measurement/NN of/IN serum/NN digoxin/NN levels/NNS with/IN the/DT Digi-/NN Tab/NN @/NN RIA/NN Kit/NN for/IN Digoxin/NN ./.

(ROOT (S1 (S (S (NP (NN Drug) (NN /Laboratory) (NN Test) (NN Interaction) (NN Fosinopril)) (VP (MD may) (VP (VB cause) (NP (NP (DT a) (JJ false) (JJ low) (NN measurement)) (PP (IN of) (NP (NN serum) (NN digoxin) (NNS levels)))) (PP (IN with) (NP (NP (DT the) (NN Digi-) (NN Tab) (NN @) (NN RIA) (NN Kit)) (PP (IN for) (NP (NN Digoxin)))))))) (. .))))

Sentence Id: DrugDDI.d466.s0
No/DT drugs/NNS are/VBP known/VBN to/TO interfere/VB with/IN the/DT conversion/NN of/IN fosphenytoin/NN to/TO phenytoin/NN ./.

(ROOT (S1 (S (S (NP (DT No) (NNS drugs)) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN conversion)) (PP (IN of) (NP (NN fosphenytoin))) (PP (TO to) (NP (NN phenytoin))))))))))) (. .))))

Sentence Id: DrugDDI.d466.s1
Conversion/NN could/MD be/VB affected/VBN by/IN alterations/NNS in/IN the/DT level/NN of/IN phosphatase/NN activity/NN ,/, but/CC given/IN the/DT abundance/NN and/CC wide/JJ distribution/NN of/IN phosphatases/NNS in/IN the/DT body/NN it/PRP is/VBZ unlikely/JJ that/IN drugs/NNS would/MD affect/VB this/DT activity/NN enough/RB to/TO affect/VB conversion/NN of/IN fosphenytoin/NN to/TO phenytoin/NN ./.

(ROOT (S1 (S (S (S (NP (NN Conversion)) (VP (MD could) (VP (VB be) (VP (VBN affected) (PP (IN by) (NP (NP (NNS alterations)) (PP (IN in) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN phosphatase) (NN activity))))))))))) (, ,) (CC but) (S (PP (IN given) (NP (NP (DT the) (NP (NN abundance)) (CC and) (NP (JJ wide) (NN distribution))) (PP (IN of) (NP (NNS phosphatases))) (PP (IN in) (NP (DT the) (NN body))))) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ unlikely) (SBAR (IN that) (S (NP (NNS drugs)) (VP (MD would) (VP (VB affect) (NP (NP (DT this) (NN activity)) (SBAR (ADVP (RB enough)) (S (VP (TO to) (VP (VB affect) (NP (NP (NN conversion)) (PP (IN of) (NP (NN fosphenytoin))) (PP (TO to) (NP (NN phenytoin))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d466.s2
Drugs/NNS highly/RB bound/VBN to/TO albumin/NN could/MD increase/VB the/DT unbound/JJ fraction/NN of/IN fosphenytoin/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Drugs)) (VP (ADVP (RB highly)) (VBN bound) (PP (TO to) (NP (NN albumin))))) (VP (MD could) (VP (VB increase) (NP (NP (DT the) (JJ unbound) (NN fraction)) (PP (IN of) (NP (NN fosphenytoin))))))) (. .))))

Sentence Id: DrugDDI.d466.s3
Although/IN ,/, it/PRP is/VBZ unknown/JJ whether/IN this/DT could/MD result/VB in/IN clinically/RB significant/JJ effects/NNS ,/, caution/NN is/VBZ advised/VBN when/WRB administering/VBG Cerebyx/NN with/IN other/JJ drugs/NNS that/WDT significantly/RB bind/VBP to/TO serum/NN albumin/NN ./.

(ROOT (S1 (S (S (SBAR (IN Although) (, ,) (S (NP (PRP it)) (VP (VBZ is) (ADJP (JJ unknown)) (SBAR (IN whether) (S (NP (DT this)) (VP (MD could) (VP (VB result) (PP (IN in) (NP (ADJP (RB clinically) (JJ significant)) (NNS effects)))))))))) (, ,) (NP (NN caution)) (VP (VBZ is) (VP (VBN advised) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NN Cerebyx)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (ADVP (RB significantly)) (VP (VBP bind) (PP (TO to) (NP (NN serum) (NN albumin)))))))))))))) (. .))))

Sentence Id: DrugDDI.d466.s4
The/DT pharmacokinetics/NNS and/CC protein/NN binding/NN of/IN fosphenytoin/NN ,/, phenytoin/NN ,/, and/CC diazepam/NN were/VBD not/RB altered/VBN when/WRB diazepam/NN and/CC Cerebyx/NN were/VBD concurrently/RB administered/VBN in/IN single/JJ submaximal/JJ doses/NNS ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NP (NNS pharmacokinetics)) (CC and) (NP (NN protein) (NN binding))) (PP (IN of) (NP (NP (NN fosphenytoin)) (, ,) (NP (NN phenytoin)) (, ,) (CC and) (NP (NN diazepam))))) (VP (VBD were) (RB not) (VP (VBN altered)) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN diazepam)) (CC and) (NP (NN Cerebyx))) (VP (VBD were) (ADVP (RB concurrently)) (VP (VBN administered) (PP (IN in) (NP (JJ single) (JJ submaximal) (NNS doses))))))))) (. .))))

Sentence Id: DrugDDI.d466.s5
The/DT most/RBS significant/JJ drug/NN interactions/NNS following/VBG administration/NN of/IN Cerebyx/NN are/VBP expected/VBN to/TO occur/VB with/IN drugs/NNS that/WDT interact/VBP with/IN phenytoin/NN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (ADJP (RBS most) (JJ significant)) (NN drug) (NNS interactions)) (VP (VBG following) (NP (NP (NN administration)) (PP (IN of) (NP (NN Cerebyx)))))) (VP (VBP are) (VP (VBN expected) (S (VP (TO to) (VP (VB occur) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP interact) (PP (IN with) (NP (NN phenytoin)))))))))))))) (. .))))

Sentence Id: DrugDDI.d466.s6
Phenytoin/NN is/VBZ extensively/RB bound/VBN to/TO serum/NN plasma/NN proteins/NNS and/CC is/VBZ prone/JJ to/TO competitive/JJ displacement/NN ./.

(ROOT (S1 (S (S (NP (NN Phenytoin)) (VP (VP (VBZ is) (ADVP (RB extensively)) (VP (VBN bound) (PP (TO to) (NP (NN serum) (NN plasma) (NNS proteins))))) (CC and) (VP (VBZ is) (ADJP (JJ prone) (PP (TO to) (NP (JJ competitive) (NN displacement))))))) (. .))))

Sentence Id: DrugDDI.d466.s7
Phenytoin/NN is/VBZ metabolized/VBN by/IN hepatic/JJ cytochrome/NN P450/NN enzyme/NN s/NN and/CC is/VBZ particularly/RB susceptible/JJ to/TO inhibitory/JJ drug/NN interactions/NNS because/IN it/PRP is/VBZ subject/JJ to/TO saturable/JJ metabolism/NN ./.

(ROOT (S1 (S (S (NP (NN Phenytoin)) (VP (VP (VBZ is) (VP (VBN metabolized) (PP (IN by) (NP (NP (JJ hepatic) (NN cytochrome) (NN P450)) (NN enzyme) (NN s))))) (CC and) (VP (VBZ is) (ADJP (RB particularly) (JJ susceptible) (PP (TO to) (NP (JJ inhibitory) (NN drug) (NNS interactions)))) (SBAR (IN because) (S (NP (PRP it)) (VP (VBZ is) (ADJP (JJ subject) (PP (TO to) (NP (JJ saturable) (NN metabolism)))))))))) (. .))))

Sentence Id: DrugDDI.d466.s8
Inhibition/NN of/IN metabolism/NN may/MD produce/VB significant/JJ increases/NNS in/IN circulating/VBG phenytoin/NN concentrations/NNS and/CC enhance/VB the/DT risk/NN of/IN drug/NN toxicity/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NN metabolism)))) (VP (MD may) (VP (VP (VB produce) (NP (NP (JJ significant) (NNS increases)) (PP (IN in) (NP (VBG circulating) (NN phenytoin) (NNS concentrations))))) (CC and) (VP (VB enhance) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN drug) (NN toxicity)))))))) (. .))))

Sentence Id: DrugDDI.d466.s9
Phenytoin/NN is/VBZ a/DT potent/JJ inducer/NN of/IN hepatic/JJ drug-metabolizing/JJ enzymes/NNS ./.

(ROOT (S1 (S (S (NP (NN Phenytoin)) (VP (VBZ is) (NP (NP (DT a) (JJ potent) (NN inducer)) (PP (IN of) (NP (JJ hepatic) (JJ drug-metabolizing) (NNS enzymes)))))) (. .))))

Sentence Id: DrugDDI.d466.s10
The/DT most/RBS commonly/RB occurring/VBG drug/NN interactions/NNS are/VBP listed/VBN below/IN :/: -/CC Drugs/NNS that/WDT may/MD increase/VB plasma/NN phenytoin/NN concentrations/NNS include/VBP :/: acute/JJ alcohol/NN intake/NN ,/, amiodarone/NN ,/, chboramphenicol/NN ,/, chlordiazepoxide/NN ,/, cimetidine/NN ,/, diazepam/NN ,/, dicumarol/NN ,/, disulfiram/NN ,/, estrogens/NNS ,/, ethosuximide/NN ,/, fluoxetine/NN ,/, H2-antagonists/NN ,/, halothane/NN ,/, isoniazid/NN ,/, methylphenidate/NN ,/, phenothiazines/NNS ,/, phenylbutazone/NN ,/, salicylates/NNS ,/, succinimides/NNS ,/, sulfonamides/NNS ,/, tolbutamide/NN ,/, trazodone/NN ./.

(ROOT (S1 (S (S (ADVP (DT The) (RBS most) (RB commonly)) (VP (VBG occurring) (S (NP (NN drug) (NNS interactions)) (VP (VBP are) (VP (VBN listed) (PP (IN below) (: :) (NP (NP (CC -) (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB increase) (S (NP (NN plasma) (NN phenytoin) (NNS concentrations)) (VP (VBP include) (: :) (NP (NP (NP (NP (JJ acute) (NN alcohol) (NN intake)) (, ,) (NP (NN amiodarone)) (, ,) (NP (NN chboramphenicol)) (, ,) (NP (NN chlordiazepoxide)) (, ,) (NP (NN cimetidine)) (, ,) (NP (NN diazepam)) (, ,) (NP (NN dicumarol)) (, ,) (NP (NN disulfiram)) (, ,) (NP (NNS estrogens)) (, ,) (NP (NN ethosuximide)) (, ,) (NP (NN fluoxetine)) (, ,)) (NN H2-antagonists)) (, ,) (NP (NN halothane)) (, ,) (NP (NN isoniazid)) (, ,) (NP (NN methylphenidate)) (, ,) (NP (NP (NNS phenothiazines)) (, ,) (NP (NN phenylbutazone)) (, ,) (NP (NNS salicylates)) (, ,) (NP (NNS succinimides)) (, ,) (NP (NNS sulfonamides))) (, ,) (NP (NN tolbutamide)) (, ,) (NP (NN trazodone)))))))))))))))) (. .))))

Sentence Id: DrugDDI.d466.s12
-/CC Drugs/NNS that/WDT may/MD decrease/VB plasma/NN phenytoin/NN concentrations/NNS include/VBP :/: carbamazepine/NN ,/, chronic/JJ alcohol/NN abuse/NN ,/, reserpine/NN ./.

(ROOT (S1 (S (S (NP (NP (CC -) (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB decrease) (NP (NN plasma) (NN phenytoin) (NNS concentrations))))))) (VP (VBP include) (: :) (NP (NP (NN carbamazepine)) (, ,) (NP (JJ chronic) (NN alcohol) (NN abuse)) (, ,) (NP (NN reserpine))))) (. .))))

Sentence Id: DrugDDI.d466.s14
-/CC Drugs/NNS that/WDT may/MD either/RB increase/VB or/CC decrease/VB plasma/NN phenytoin/NN concentrations/NNS include/VBP :/: phenobarbital/NN ,/, vaiproic/JJ acid/NN ,/, and/CC sodium/NN valproate/NN ./.

(ROOT (S1 (S (S (NP (NP (CC -) (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (ADVP (RB either)) (VP (VP (VB increase)) (CC or) (VP (VB decrease) (NP (NN plasma) (NN phenytoin) (NNS concentrations)))))))) (VP (VBP include) (: :) (NP (NP (NN phenobarbital)) (, ,) (NP (JJ vaiproic) (NN acid)) (, ,) (CC and) (NP (NN sodium) (NN valproate))))) (. .))))

Sentence Id: DrugDDI.d466.s15
Similarly/RB ,/, the/DT effects/NNS of/IN phenytoin/NN on/IN phenobarbital/NN ,/, valproic/JJ acid/NN and/CC sodium/NN plasma/NN valproate/NN concentrations/NNS are/VBP unpredictable/JJ ./.

(ROOT (S1 (S (S (ADVP (RB Similarly)) (, ,) (NP (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN phenytoin))) (PP (IN on) (NP (NN phenobarbital)))) (, ,) (NP (NP (JJ valproic) (NN acid)) (CC and) (NP (NN sodium) (NN plasma) (NN valproate) (NNS concentrations)))) (VP (VBP are) (ADJP (JJ unpredictable)))) (. .))))

Sentence Id: DrugDDI.d466.s17
-/CC Although/IN not/RB a/DT true/JJ drug/NN interaction/NN ,/, tricyclic/JJ antidepressants/NNS may/MD precipitate/VB seizures/NNS in/IN susceptible/JJ patients/NNS and/CC Cerebyx/NN dosage/NN may/MD need/VBP to/TO be/VB adjusted/VBN ./.

(ROOT (S1 (S (S (S (CC -) (SBAR (IN Although) (FRAG (RB not) (NP (DT a) (JJ true) (NN drug) (NN interaction)))) (, ,) (NP (JJ tricyclic) (NNS antidepressants)) (VP (MD may) (VP (VB precipitate) (NP (NP (NNS seizures)) (PP (IN in) (NP (JJ susceptible) (NNS patients))))))) (CC and) (S (NP (NN Cerebyx) (NN dosage)) (VP (MD may) (VP (VBP need) (S (VP (TO to) (VP (VB be) (VP (VBN adjusted))))))))) (. .))))

Sentence Id: DrugDDI.d466.s19
-/CC Drugs/NNS whose/WP$ efficacy/NN is/VBZ impaired/VBN by/IN phenytoin/NN include/VBP :/: anticoagulants/NNS ,/, corticosteroids/NNS ,/, coumarin/NN ,/, digitoxin/NN ,/, doxycycline/NN ,/, estrogens/NNS ,/, furosemide/NN ,/, oral/JJ contraceptives/NNS ,/, rifampin/NN ,/, quinidine/NN ,/, theophylline/NN ,/, vitamin/NN D/NN ./.

(ROOT (S1 (S (CC -) (NP (NP (NNS Drugs)) (SBAR (WHNP (WP$ whose) (NN efficacy)) (S (VP (VBZ is) (VP (VBN impaired) (PP (IN by) (NP (NN phenytoin))))) (VP (VBP include) (: :) (NP (NP (NNS anticoagulants)) (, ,) (NP (NNS corticosteroids)) (, ,) (NP (NP (NN coumarin)) (, ,) (NP (NN digitoxin)) (, ,) (NP (NN doxycycline)) (, ,) (NP (NNS estrogens)) (, ,) (NP (NN furosemide)) (, ,) (NP (JJ oral) (NNS contraceptives)) (, ,) (NP (NN rifampin)) (, ,) (NP (NN quinidine)) (, ,) (NP (NN theophylline)) (, ,) (NP (NN vitamin) (NN D)))))))) (. .))))

Sentence Id: DrugDDI.d466.s20
Monitoring/NN of/IN plasma/NN phenytoin/NN concentrations/NNS may/MD be/VB helpful/JJ when/WRB possible/JJ drug/NN interactions/NNS are/VBP suspected/VBN ./.

(ROOT (S1 (S (S (NP (NP (NN Monitoring)) (PP (IN of) (NP (NN plasma) (NN phenytoin) (NNS concentrations)))) (VP (MD may) (VP (VB be) (ADJP (JJ helpful) (SBAR (WHADVP (WRB when)) (S (NP (JJ possible) (NN drug) (NNS interactions)) (VP (VBP are) (VP (VBN suspected))))))))) (. .))))

Sentence Id: DrugDDI.d466.s21
Drug/NN /Laboratory/NN Test/NN Interactions/NNS Phenytoin/NN may/MD decrease/VB serum/NN concentrations/NNS of/IN 14/CD ./.

(ROOT (S1 (S (S (NP (NN Drug) (NN /Laboratory) (NN Test) (NNS Interactions) (NP (NN Phenytoin))) (VP (MD may) (VP (VB decrease) (NP (NP (NN serum) (NNS concentrations)) (PP (IN of) (NP (CD 14))))))) (. .))))

Sentence Id: DrugDDI.d466.s22
It/PRP may/MD also/RB produce/VB artifactually/RB low/JJ results/NNS in/IN dexamethasone/NN or/CC metyrapone/NN tests/NNS ./.

(ROOT (S1 (S (S (NP (PRP It)) (VP (MD may) (ADVP (RB also)) (VP (VB produce) (NP (ADJP (RB artifactually) (JJ low)) (NNS results)) (PP (IN in) (NP (NP (NN dexamethasone)) (CC or) (NP (NN metyrapone) (NNS tests))))))) (. .))))

Sentence Id: DrugDDI.d466.s23
Phenytoin/NN may/MD also/RB cause/VB increased/VBN serum/NN concentrations/NNS of/IN glucose/NN ,/, alkaline/NN phosphatase/NN ,/, and/CC gamma/NN glutamyl/NN transpeptidase/NN (/-LRB- GGT)./NN

(ROOT (S1 (S (NP (NN Phenytoin)) (VP (MD may) (ADVP (RB also)) (VP (VB cause) (NP (NP (VBN increased) (NN serum) (NNS concentrations)) (PP (IN of) (NP (NP (NN glucose)) (, ,) (NP (NN alkaline) (NN phosphatase)) (, ,) (CC and) (NP (NP (NN gamma) (NN glutamyl) (NN transpeptidase)) (PRN (-LRB- -LRB-) (NP (NN GGT-RRB-.))))))))))))

Sentence Id: DrugDDI.d466.s24
Care/NN should/MD be/VB taken/VBN when/WRB using/VBG immunoanalytical/JJ methods/NNS to/TO measure/VB plasma/NN phenytoin/NN concentrations/NNS following/VBG Cerebyx/NN administration/NN ./.

(ROOT (S1 (S (S (NP (NN Care)) (VP (MD should) (VP (VB be) (VP (VBN taken) (SBAR (WHADVP (WRB when)) (S (VP (VBG using) (NP (JJ immunoanalytical) (NNS methods)) (S (VP (TO to) (VP (VB measure) (NP (NN plasma) (NN phenytoin) (NNS concentrations)) (PP (VBG following) (NP (NN Cerebyx) (NN administration))))))))))))) (. .))))

Sentence Id: DrugDDI.d281.s0
No/DT drug/NN interactions/NNS have/VBP been/VBN observed/VBN with/IN the/DT Vitrasert/JJ Implant/NN ./.

(ROOT (S1 (S (S (NP (DT No) (NN drug) (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (PP (IN with) (NP (DT the) (JJ Vitrasert) (NN Implant))))))) (. .))))

Sentence Id: DrugDDI.d281.s1
There/EX is/VBZ limited/VBN experience/VBP with/IN use/NN of/IN retinal/JJ tamponades/NNS in/IN conjunction/NN with/IN the/DT Vitrasert/NN Implant/NN ./.

(ROOT (S1 (S (S (NP (EX There)) (VP (VBZ is) (VP (VBN limited) (PP (VBP experience) (PP (IN with) (NP (NP (NN use)) (PP (IN of) (NP (JJ retinal) (NNS tamponades))) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (DT the) (NN Vitrasert) (NN Implant))))))))))) (. .))))

Sentence Id: DrugDDI.d178.s0
Substances/NNS that/WDT are/VBP inducers/NNS of/IN CYP3A4/NN activity/NN increase/VBP the/DT metabolism/NN of/IN gefitinib/NN and/CC decrease/VBP its/PRP$ plasma/NN concentrations/NNS ./.

(ROOT (S1 (S (S (NP (NP (NNS Substances)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NNS inducers)) (PP (IN of) (NP (NN CYP3A4) (NN activity)))))))) (VP (VP (VBP increase) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN gefitinib))))) (CC and) (VP (VBP decrease) (NP (PRP$ its) (NN plasma) (NNS concentrations))))) (. .))))

Sentence Id: DrugDDI.d178.s1
In/IN patients/NNS receiving/VBG a/DT potent/JJ CYP3A4/NN inducer/NN such/JJ as/IN rifampicin/NN or/CC phenytoin/NN ,/, a/DT dose/NN increase/NN to/TO 500/CD mg/NN daily/RB should/MD be/VB considered/VBN in/IN the/DT absence/NN of/IN severe/JJ adverse/JJ drug/NN reaction/NN ,/, and/CC clinical/JJ response/NN and/CC adverse/JJ events/NNS should/MD be/VB carefully/RB monitored/VBN (/-LRB- see/VB CLINICAL/JJ PHARMACOLOGY-Pharmacokinetics-Drug-Drug/JJ Interactions/NNS and/CC DOSAGE/NN AND/CC ADMINISTRATION-Dosage/JJ Adjustment/JJ sections/NNS )./NN

(ROOT (S1 (S (PP (IN In) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (DT a) (JJ potent) (NN CYP3A4) (NN inducer)) (CONJP (JJ such) (IN as)) (NP (NP (NN rifampicin)) (CC or) (NP (NN phenytoin))))))) (, ,) (S (S (NP (NP (DT a) (NN dose) (NN increase)) (PP (TO to) (NP (NP (CD 500) (NN mg)) (ADVP (RB daily))))) (VP (MD should) (VP (VB be) (VP (VBN considered) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ severe) (JJ adverse) (NN drug) (NN reaction))))))))) (, ,) (CC and) (S (NP (NP (JJ clinical) (NN response)) (CC and) (NP (JJ adverse) (NNS events))) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN monitored)) (-LRB- -LRB-) (S (VP (VB see) (NP (NP (JJ CLINICAL) (JJ PHARMACOLOGY-Pharmacokinetics-Drug-Drug) (NNS Interactions)) (CC and) (NP (NP (NN DOSAGE)) (CC AND) (NP (JJ ADMINISTRATION-Dosage) (JJ Adjustment) (NNS sections)) (NP (NN -RRB-.)))))))))))))

Sentence Id: DrugDDI.d178.s2
International/NNP Normalized/VBN Ratio/NN (/-LRB- INR/NN )/-RRB- elevations/NNS and/or/CC bleeding/JJ events/NNS have/VBP been/VBN reported/VBN in/IN some/DT patients/NNS taking/VBG warfarin/NN while/IN on/IN IRESSA/NN therapy/NN ./.

(ROOT (S1 (S (S (NP (NP (NP (NNP International)) (VBN Normalized) (NN Ratio) (-LRB- -LRB-) (NN INR) (-RRB- -RRB-) (NNS elevations)) (CC and/or) (NP (JJ bleeding) (NNS events))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (DT some) (NNS patients)) (VP (VBG taking) (NP (NN warfarin)) (PP (IN while) (PP (IN on) (NP (NN IRESSA) (NN therapy))))))))))) (. .))))

Sentence Id: DrugDDI.d178.s3
Patients/NNS taking/VBG warfarin/NN should/MD be/VB monitored/VBN regularly/RB for/IN changes/NNS in/IN prothrombin/NN time/NN or/CC INR/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Patients)) (VP (VBG taking) (NP (NN warfarin)))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB regularly)) (PP (IN for) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (NN prothrombin) (NN time)) (CC or) (NP (NN INR)))))))))) (. .))))

Sentence Id: DrugDDI.d178.s4
Substances/NNS that/WDT are/VBP potent/JJ inhibitors/NNS of/IN CYP3A4/NN activity/NN (/-LRB- eg/NN ,/, ketoconazole/NN and/CC itraconazole/NN )/-RRB- decrease/VBP gefitinib/NN metabolism/NN and/CC increase/VBP gefitinib/NN plasma/NN concentrations/NNS ./.

(ROOT (S1 (S (S (NP (NP (NP (NNS Substances)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (JJ potent) (NNS inhibitors)) (PP (IN of) (NP (NN CYP3A4) (NN activity)))))))) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN ketoconazole)) (CC and) (NP (NN itraconazole))) (-RRB- -RRB-))) (VP (VP (VBP decrease) (NP (NN gefitinib) (NN metabolism))) (CC and) (VP (VBP increase) (NP (NN gefitinib) (NN plasma) (NNS concentrations))))) (. .))))

Sentence Id: DrugDDI.d178.s6
therefore/RB ,/, caution/NN should/MD be/VB used/VBN when/WRB administering/VBG CYP3A4/JJ inhibitors/NNS with/IN IRESSA/NN ./.

(ROOT (S1 (S (S (ADVP (RB therefore)) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN used))) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (JJ CYP3A4) (NNS inhibitors)) (PP (IN with) (NP (NN IRESSA)))))))) (. .))))

Sentence Id: DrugDDI.d178.s7
Drugs/NNS that/WDT cause/VBP significant/JJ sustained/JJ elevation/NN in/IN gastric/JJ pH/NN (/-LRB- histamine/NN H2-receptor/NN antagonists/NNS such/JJ as/IN ranitidine/NN or/CC cimetidine/NN )/-RRB- may/MD reduce/VB plasma/NN concentrations/NNS of/IN IRESSA/NN and/CC therefore/RB potentially/RB may/MD reduce/VB efficacy/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP cause) (NP (NP (JJ significant) (JJ sustained) (NN elevation)) (PP (IN in) (NP (NP (JJ gastric) (NN pH)) (PRN (-LRB- -LRB-) (NP (NP (NN histamine) (NN H2-receptor) (NNS antagonists)) (PP (JJ such) (IN as) (NP (NP (NN ranitidine)) (CC or) (NP (NN cimetidine))))) (-RRB- -RRB-))))))))) (VP (VP (MD may) (VP (VB reduce) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN IRESSA)))))) (CC and) (ADVP (RB therefore)) (ADVP (RB potentially)) (VP (MD may) (VP (VB reduce) (NP (NN efficacy)))))) (. .))))

Sentence Id: DrugDDI.d178.s8
Phase/NN II/CD clinical/JJ trial/NN data/NNS ,/, where/WRB IRESSA/NN and/CC vinorelbine/NN have/VBP been/VBN used/VBN concomitantly/RB ,/, indicate/VBP that/IN IRESSA/NN may/MD exacerbate/VB the/DT neutropenic/JJ effect/NN of/IN vinorelbine/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Phase) (CD II) (JJ clinical) (NN trial) (NNS data)) (, ,) (SBAR (WHADVP (WRB where)) (S (NP (NP (NN IRESSA)) (CC and) (NP (NN vinorelbine))) (VP (VBP have) (VP (VBN been) (VP (VBN used) (ADVP (RB concomitantly))))))) (, ,)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN IRESSA)) (VP (MD may) (VP (VB exacerbate) (NP (NP (DT the) (JJ neutropenic) (NN effect)) (PP (IN of) (NP (NN vinorelbine)))))))))) (. .))))

Sentence Id: DrugDDI.d147.s1
For/IN information/NN on/IN the/DT pharmacokinetics/NNS of/IN Gemzar/NN and/CC cisplatin/NN in/IN combination/NN ,/, see/VB Drug/NN Interactions/NNS under/IN CLINICAL/JJ PHARMACOLOGY/NN section/NN ./.

(ROOT (S1 (S (PP (IN For) (NP (NP (NN information)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN Gemzar)) (CC and) (NP (NN cisplatin)))) (PP (IN in) (NP (NN combination))))))) (, ,) (VP (VB see) (NP (NN Drug) (NNS Interactions)) (PP (IN under) (NP (JJ CLINICAL) (NN PHARMACOLOGY) (NN section)))) (. .))))

Sentence Id: DrugDDI.d57.s4
increased/VBN creatine/NN ./.

(ROOT (S1 (S (S (VP (VBN increased) (NP (NN creatine)))) (. .))))

Sentence Id: DrugDDI.d57.s7
phosphokinase/NN ./.

(ROOT (S1 (S (NP (NP (NN phosphokinase)) (. .)))))

Sentence Id: DrugDDI.d57.s8
antibody/NN ./.

(ROOT (S1 (S (NP (NP (NN antibody)) (. .)))))

Sentence Id: DrugDDI.d57.s10
increased/VBN bilirubin/NN ./.

(ROOT (S1 (S (S (VP (VBN increased) (NP (NN bilirubin)))) (. .))))

Sentence Id: DrugDDI.d57.s13
increased/VBD liver/NN ./.

(ROOT (S1 (S (S (VP (VBD increased) (NP (NN liver)))) (. .))))

Sentence Id: DrugDDI.d57.s16
transaminases/NNS (/-LRB- AST/NN ./.

(ROOT (S1 (S (NP (NP (NP (NNS transaminases)) (PRN (-LRB- -LRB-) (NP (NN AST)))) (. .)))))

Sentence Id: DrugDDI.d465.s0
Many/JJ other/JJ medicines/NNS may/MD increase/VB or/CC decrease/VB the/DT effects/NNS of/IN glimepiride/NN or/CC affect/VB your/NN condition/NN ./.

(ROOT (S1 (S (S (NP (JJ Many) (JJ other) (NNS medicines)) (VP (MD may) (VP (VP (VB increase)) (CC or) (VP (VB decrease) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN glimepiride))))) (CC or) (VP (VB affect) (NP (NN your) (NN condition)))))) (. .))))

Sentence Id: DrugDDI.d465.s1
Before/IN taking/VBG glimepiride/NN ,/, tell/NN your/NN doctor/NN if/IN you/NN are/VBP taking/VBG any/DT of/IN the/DT following/JJ medicines/NNS :/: -/CC aspirin/NN or/CC another/DT salicylate/NN such/JJ as/IN magnesium/NN //: choline/NN salicylate/NN (/-LRB- Trilisate/NN )/-RRB- ,/, salsalate/NN (/-LRB- Disalcid/NN ,/, others/NNS )/-RRB- ,/, choline/NN salicylate/NN (/-LRB- Arthropan/NNP )/-RRB- ,/, magnesium/NN salicylate/NN (/-LRB- Magan/NNP )/-RRB- ,/, or/CC bismuth/NN subsalicylate/NN (/-LRB- Pepto-Bismol/NN )/-RRB- ;/: ./.

(ROOT (S1 (S (PP (IN Before) (NP (VBG taking) (NN glimepiride))) (, ,) (NP (NP (NN tell) (NN your) (NN doctor)) (PP (IN if) (NP (NN you)))) (VP (VBP are) (VP (VBG taking) (NP (NP (DT any)) (PP (IN of) (NP (NP (DT the) (JJ following) (NNS medicines)) (: :) (NP (CC -) (NP (NP (NN aspirin)) (CC or) (NP (NP (DT another) (NN salicylate)) (PP (JJ such) (IN as) (NP (NN magnesium)))) (: /) (NP (NP (NN choline) (NN salicylate)) (PRN (-LRB- -LRB-) (NP (NN Trilisate)) (-RRB- -RRB-))) (, ,) (NP (NP (NN salsalate)) (PRN (-LRB- -LRB-) (NP (NN Disalcid)) (, ,) (NP (NNS others)) (-RRB- -RRB-))) (, ,) (NP (NP (NN choline) (NN salicylate)) (PRN (-LRB- -LRB-) (NP (NNP Arthropan)) (-RRB- -RRB-))) (, ,) (NP (NP (NN magnesium) (NN salicylate)) (PRN (-LRB- -LRB-) (NP (NNP Magan)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (NN bismuth) (NN subsalicylate)) (PRN (-LRB- -LRB-) (NP (NN Pepto-Bismol)) (-RRB- -RRB-))))) (: ;)))))) (. .))))

Sentence Id: DrugDDI.d465.s2
-/CC a/DT nonsteroidal/JJ anti-inflammatory/JJ drug/NN (/-LRB- NSAID/NN )/-RRB- such/JJ as/IN ibuprofen/NN (/-LRB- Motrin/NNP ,/, Advil/NNP ,/, Nuprin/NNP ,/, others/NNS )/-RRB- ,/, ketoprofen/NN (/-LRB- Orudis/NNP ,/, Orudis/NNP KT/NNP ,/, Oruvail/NNP )/-RRB- ,/, diclofenac/NN (/-LRB- Voltaren/NNP ,/, Cataflam/NNP )/-RRB- ,/, etodolac/NN (/-LRB- Lodine/NN )/-RRB- ,/, indomethacin/NN (/-LRB- Indocin/NNP )/-RRB- ,/, nabumetone/NN (/-LRB- Relafen/NNP )/-RRB- ,/, oxaprozin/NN (/-LRB- Daypro/NNP )/-RRB- ,/, and/CC naproxen/NN (/-LRB- Anaprox/NN ,/, Naprosyn/NNP ,/, Aleve/NNP )/-RRB- ;/: ./.

(ROOT (S1 (S (NP (NP (NP (CC -) (NP (ADJP (NP (DT a) (JJ nonsteroidal) (JJ anti-inflammatory) (NN drug)) (-LRB- -LRB-) (NN NSAID) (-RRB- -RRB-) (JJ such) (PP (IN as) (NP (NN ibuprofen))))) (PRN (-LRB- -LRB-) (NP (NNP Motrin) (, ,) (NNP Advil) (, ,) (NNP Nuprin)) (, ,) (NP (NNS others)) (-RRB- -RRB-)) (, ,) (NP (NP (NP (NN ketoprofen)) (PRN (-LRB- -LRB-) (NP (NNP Orudis) (, ,) (NNP Orudis) (NNP KT) (, ,) (NNP Oruvail)) (-RRB- -RRB-))) (, ,) (NP (NP (NN diclofenac)) (PRN (-LRB- -LRB-) (NP (NNP Voltaren) (, ,) (NNP Cataflam)) (-RRB- -RRB-))) (, ,) (NP (NP (NN etodolac)) (PRN (-LRB- -LRB-) (NP (NN Lodine)) (-RRB- -RRB-))) (, ,) (NP (NP (NN indomethacin)) (PRN (-LRB- -LRB-) (NP (NNP Indocin)) (-RRB- -RRB-))) (, ,) (NP (NP (NN nabumetone)) (PRN (-LRB- -LRB-) (NP (NNP Relafen)) (-RRB- -RRB-))) (, ,) (NP (NP (NN oxaprozin)) (PRN (-LRB- -LRB-) (NP (NNP Daypro)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NN naproxen)))) (PRN (-LRB- -LRB-) (NP (NN Anaprox)) (, ,) (NP (NNP Naprosyn) (, ,) (NNP Aleve)) (-RRB- -RRB-)) (: ;)) (. .)))))

Sentence Id: DrugDDI.d465.s3
-/CC a/DT sulfa-based/JJ drug/NN such/JJ as/IN sulfamethoxazole-trimethoprim/NN (/-LRB- Bactrim/NNP ,/, Septra/NNP )/-RRB- ,/, sulfisoxazole/NN (/-LRB- Gantrisin/NN )/-RRB- ,/, or/CC sulfasalazine/NN (/-LRB- Azulfidine/NN )/-RRB- ;/: ./.

(ROOT (S1 (S (NP (NP (NP (CC -) (DT a) (JJ sulfa-based) (NN drug)) (PP (JJ such) (IN as) (NP (NP (NP (NN sulfamethoxazole-trimethoprim)) (PRN (-LRB- -LRB-) (NP (NNP Bactrim) (, ,) (NNP Septra)) (-RRB- -RRB-))) (, ,) (NP (NP (NN sulfisoxazole)) (PRN (-LRB- -LRB-) (NP (NN Gantrisin)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (NN sulfasalazine)) (PRN (-LRB- -LRB-) (NP (NN Azulfidine)) (-RRB- -RRB-))))) (: ;)) (. .)))))

Sentence Id: DrugDDI.d465.s4
-/CC a/DT monoamine/NN oxidase/NN inhibitor/NN (/-LRB- MAOI/NN )/-RRB- such/JJ as/IN isocarboxazid/NN (/-LRB- Marplan/NN )/-RRB- ,/, tranylcypromine/NN (/-LRB- Parnate/NN )/-RRB- ,/, or/CC phenelzine/NN (/-LRB- Nardil/NN )/-RRB- ;/: ./.

(ROOT (S1 (S (NP (CC -) (NP (NP (NP (DT a) (NN monoamine) (NN oxidase) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NN MAOI)) (-RRB- -RRB-))) (PP (JJ such) (IN as) (NP (NP (NP (NN isocarboxazid)) (PRN (-LRB- -LRB-) (NP (NN Marplan)) (-RRB- -RRB-))) (, ,) (NP (NP (NN tranylcypromine)) (PRN (-LRB- -LRB-) (NP (NN Parnate)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (NN phenelzine)) (PRN (-LRB- -LRB-) (NP (NN Nardil)) (-RRB- -RRB-))))) (: ;)) (. .)))))

Sentence Id: DrugDDI.d465.s5
-/CC a/DT beta-blocker/NN such/JJ as/IN propranolol/NN (/-LRB- Inderal/NN )/-RRB- ,/, atenolol/NN (/-LRB- Tenormin/NN )/-RRB- ,/, acebutolol/NN (/-LRB- Sectral/NN )/-RRB- ,/, metoprolol/NN (/-LRB- Lopressor/NN )/-RRB- ,/, and/CC others/NNS ;/: ./.

(ROOT (S1 (S (NP (NP (CC -) (NP (NP (DT a) (NN beta-blocker)) (PP (JJ such) (IN as) (NP (NP (NP (NN propranolol)) (PRN (-LRB- -LRB-) (NP (NN Inderal)) (-RRB- -RRB-))) (, ,) (NP (NP (NN atenolol)) (PRN (-LRB- -LRB-) (NP (NN Tenormin)) (-RRB- -RRB-))) (, ,) (NP (NP (NN acebutolol)) (PRN (-LRB- -LRB-) (NP (NN Sectral)) (-RRB- -RRB-))) (, ,) (NP (NP (NN metoprolol)) (PRN (-LRB- -LRB-) (NP (NN Lopressor)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNS others)))) (: ;))) (. .)))))

Sentence Id: DrugDDI.d465.s6
-/CC a/DT diuretic/JJ (/-LRB- water/NN pill/NN )/-RRB- such/JJ as/IN hydrochlorothiazide/NN (/-LRB- HCTZ/NN ,/, Hydrodiuril/NN )/-RRB- ,/, chlorothiazide/NN (/-LRB- Diuril/NN )/-RRB- ,/, and/CC others/NNS ;/: ./.

(ROOT (S1 (S (NP (NP (NP (NP (CC -) (DT a) (JJ diuretic)) (PRN (-LRB- -LRB-) (NP (NN water) (NN pill)) (-RRB- -RRB-))) (PP (JJ such) (IN as) (NP (NP (NP (NN hydrochlorothiazide)) (PRN (-LRB- -LRB-) (NP (NP (NN HCTZ)) (, ,) (NP (NN Hydrodiuril))) (-RRB- -RRB-))) (, ,) (NP (NP (NN chlorothiazide)) (PRN (-LRB- -LRB-) (NP (NN Diuril)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNS others)))) (: ;)) (. .)))))

Sentence Id: DrugDDI.d465.s7
-/CC a/DT steroid/NN medicine/NN such/JJ as/IN prednisone/NN (/-LRB- Deltasone/NNP ,/, Orasone/NNP ,/, others/NNS )/-RRB- ,/, methylprednisolone/NN (/-LRB- Medrol/NN ,/, others/NNS )/-RRB- ,/, prednisolone/NN (/-LRB- Prelone/NNP ,/, Pediapred/NNP ,/, others/NNS )/-RRB- ,/, and/CC others/NNS ;/: ./.

(ROOT (S1 (S (NP (NP (NP (CC -) (DT a) (NN steroid) (NN medicine)) (PP (JJ such) (IN as) (NP (NP (NP (NN prednisone)) (PRN (-LRB- -LRB-) (NP (NNP Deltasone) (, ,) (NNP Orasone)) (, ,) (NP (NNS others)) (-RRB- -RRB-))) (, ,) (NP (NP (NN methylprednisolone)) (PRN (-LRB- -LRB-) (NP (NN Medrol)) (, ,) (NP (NNS others)) (-RRB- -RRB-))) (, ,) (NP (NP (NN prednisolone)) (PRN (-LRB- -LRB-) (NP (NNP Prelone) (, ,) (NNP Pediapred)) (, ,) (NP (NNS others)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNS others)))) (: ;)) (. .)))))

Sentence Id: DrugDDI.d465.s8
-/CC a/DT phenothiazine/JJ such/JJ as/IN chlorpromazine/NN (/-LRB- Thorazine/NN )/-RRB- ,/, fluphenazine/NN (/-LRB- Prolixin/NNP ,/, Permitil/NNP )/-RRB- ,/, prochlorperazine/NN (/-LRB- Compazine/NN )/-RRB- ,/, promethazine/NN (/-LRB- Phenergan/NNP )/-RRB- ,/, and/CC others/NNS ;/: ./.

(ROOT (S1 (S (NP (CC -) (NP (NP (DT a) (JJ phenothiazine) (JJ such)) (PP (IN as) (NP (NP (NP (NN chlorpromazine)) (PRN (-LRB- -LRB-) (NP (NN Thorazine)) (-RRB- -RRB-))) (, ,) (NP (NP (NN fluphenazine)) (PRN (-LRB- -LRB-) (NP (NNP Prolixin) (, ,) (NNP Permitil)) (-RRB- -RRB-))) (, ,) (NP (NP (NN prochlorperazine)) (PRN (-LRB- -LRB-) (NP (NN Compazine)) (-RRB- -RRB-))) (, ,) (NP (NP (NN promethazine)) (PRN (-LRB- -LRB-) (NP (NNP Phenergan)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNS others)))) (: ;)) (. .)))))

Sentence Id: DrugDDI.d465.s9
-/CC phenytoin/NN (/-LRB- Dilantin/NN )/-RRB- ;/: ./.

(ROOT (S1 (S (S (CC -) (NP (NP (NN phenytoin)) (PRN (-LRB- -LRB-) (NP (NN Dilantin)) (-RRB- -RRB-))) (: ;)) (. .))))

Sentence Id: DrugDDI.d465.s10
-/CC isoniazid/NN (/-LRB- Nydrazid/NN )/-RRB- ;/: ./.

(ROOT (S1 (S (S (CC -) (NP (NP (NN isoniazid)) (PRN (-LRB- -LRB-) (NP (NN Nydrazid)) (-RRB- -RRB-))) (: ;)) (. .))))

Sentence Id: DrugDDI.d465.s11
-/CC rifampin/NN (/-LRB- Rifadin/NNP ,/, Rifamate/NNP )/-RRB- ;/: ./.

(ROOT (S1 (S (S (CC -) (NP (NP (NN rifampin)) (PRN (-LRB- -LRB-) (NP (NNP Rifadin) (, ,) (NNP Rifamate)) (-RRB- -RRB-))) (: ;)) (. .))))

Sentence Id: DrugDDI.d465.s12
or/CC -/CC over-the-counter/JJ cough/NN ,/, cold/NN ,/, allergy/NN ,/, or/CC weight/NN loss/NN medications/NNS ./.

(ROOT (S1 (S (S (NP (NP (CC or)) (CC -) (NP (JJ over-the-counter) (NP (NP (NN cough)) (, ,) (NP (NN cold)) (, ,) (NP (NN allergy)) (, ,) (CC or) (NP (NN weight) (NN loss))) (NNS medications)))) (. .))))

Sentence Id: DrugDDI.d465.s13
You/NN may/MD require/VB a/DT dosage/JJ adjustment/NN or/CC special/JJ monitoring/NN if/IN you/RB are/VBP taking/VBG any/DT of/IN the/DT medicines/NNS listed/VBN above/RB ./.

(ROOT (S1 (S (S (NP (NN You)) (VP (MD may) (VP (VB require) (NP (NP (DT a) (JJ dosage) (NN adjustment)) (CC or) (NP (JJ special) (NN monitoring))) (SBAR (IN if) (S (ADVP (RB you)) (VP (VBP are) (VP (VBG taking) (NP (NP (DT any)) (PP (IN of) (NP (NP (DT the) (NNS medicines)) (VP (VBN listed) (ADVP (RB above))))))))))))) (. .))))

Sentence Id: DrugDDI.d465.s14
Drugs/NNS other/JJ than/IN those/DT listed/VBN here/RB may/MD also/RB interact/VB with/IN glimepiride/NN or/CC affect/VB your/NN condition/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Drugs)) (ADJP (JJ other) (PP (IN than) (NP (NP (DT those)) (VP (VBN listed) (ADVP (RB here))))))) (VP (MD may) (ADVP (RB also)) (VP (VP (VB interact) (PP (IN with) (NP (NN glimepiride)))) (CC or) (VP (VB affect) (NP (NN your) (NN condition)))))) (. .))))

Sentence Id: DrugDDI.d465.s15
Talk/NN to/TO your/NN doctor/NN and/CC pharmacist/VBP before/IN taking/VBG any/DT prescription/NN or/CC over-the-counter/NN medicines/NNS ,/, including/VBG herbal/JJ products/NNS ./.

(ROOT (S1 (S (S (VP (VP (NP (NN Talk)) (PP (TO to) (NP (NN your) (NN doctor)))) (CC and) (VP (VBP pharmacist) (PP (IN before) (S (VP (VBG taking) (NP (NP (DT any) (NN prescription) (CC or) (NN over-the-counter) (NNS medicines)) (, ,) (PP (VBG including) (NP (JJ herbal) (NNS products)))))))))) (. .))))

Sentence Id: DrugDDI.d244.s0
The/DT use/NN of/IN codeine/NN may/MD result/VB in/IN additive/JJ CNS/NN depressant/NN effects/NNS when/WRB coadministered/VBN with/IN alcohol/NN ,/, antihistamines/NNS ,/, psychotropics/NNS or/CC other/JJ drugs/NNS that/WDT produce/VBP CNS/NN depression/NN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NN codeine)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (JJ additive) (NN CNS) (NN depressant) (NNS effects)) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NP (NP (NN alcohol)) (, ,) (NP (NNS antihistamines)) (, ,) (NP (NNS psychotropics)) (CC or) (NP (JJ other) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (VBP produce) (NP (NN CNS) (NN depression))))))))))))))) (. .))))

Sentence Id: DrugDDI.d244.s1
Serious/JJ toxicity/NN may/MD result/VB if/IN dextromethorphan/NN is/VBZ coadministered/VBN with/IN monoamine/NN oxidase/NN inhibitors/NNS (/-LRB- MAOIs)./NN

(ROOT (S1 (S (NP (JJ Serious) (NN toxicity)) (VP (MD may) (VP (VB result) (SBAR (IN if) (S (NP (NN dextromethorphan)) (VP (VBZ is) (VP (VBN coadministered) (PP (IN with) (NP (NP (NN monoamine) (NN oxidase) (NNS inhibitors)) (PRN (-LRB- -LRB-) (NP (NN MAOIs-RRB-.))))))))))))))

Sentence Id: DrugDDI.d244.s2
The/DT use/NN of/IN dextromethorphan/NN hydrobromide/NN may/MD result/VB in/IN additive/JJ CNS/NN depressant/NN effects/NNS when/WRB coadministered/VBN with/IN alcohol/NN ,/, antihistamines/NNS ,/, psychotropics/NNS or/CC other/JJ drugs/NNS that/WDT produce/VBP CNS/NN depression/NN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NN dextromethorphan) (NN hydrobromide)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (JJ additive) (NN CNS) (NN depressant) (NNS effects)) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NP (NN alcohol)) (, ,) (NP (NNS antihistamines)) (, ,) (NP (NNS psychotropics)) (CC or) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP produce) (NP (NN CNS) (NN depression)))))))))))))))) (. .))))

Sentence Id: DrugDDI.d184.s0
Calcium/NN Supplements//NN Antacids/NNS ./.

(ROOT (S1 (S (NP (NP (NN Calcium) (NN Supplements/) (NNS Antacids)) (. .)))))

Sentence Id: DrugDDI.d184.s1
Products/NNS containing/VBG calcium/NN and/CC other/JJ multivalent/JJ cations/NNS (/-LRB- such/JJ as/IN aluminum/NN ,/, magnesium/NN ,/, iron/NN )/-RRB- are/VBP likely/JJ to/TO interfere/VB with/IN absorption/NN of/IN Ibandronate/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Products)) (VP (VBG containing) (NP (NP (NN calcium)) (CC and) (NP (NP (JJ other) (JJ multivalent) (NNS cations)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NP (NN aluminum)) (, ,) (NP (NN magnesium)) (, ,) (NP (NN iron))))) (-RRB- -RRB-)))))) (VP (VBP are) (ADJP (JJ likely) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (NP (NN absorption)) (PP (IN of) (NP (NN Ibandronate))))))))))) (. .))))

Sentence Id: DrugDDI.d184.s2
Ibandronate/NN should/MD be/VB taken/VBN at/IN least/JJS 60/CD minutes/NNS before/IN any/DT oral/JJ medications/NNS containing/VBG multivalent/JJ cations/NNS (/-LRB- including/VBG antacids/NNS ,/, supplements/NNS or/CC vitamins/NNS )/-RRB- ./.

(ROOT (S1 (S (S (NP (NN Ibandronate)) (VP (MD should) (VP (VB be) (VP (VBN taken) (PP (NP (QP (IN at) (JJS least) (CD 60)) (NNS minutes)) (IN before) (NP (NP (DT any) (JJ oral) (NNS medications)) (VP (VBG containing) (NP (NP (JJ multivalent) (NNS cations)) (PRN (-LRB- -LRB-) (PP (VBG including) (NP (NP (NNS antacids)) (, ,) (NP (NNS supplements)) (CC or) (NP (NNS vitamins)))) (-RRB- -RRB-)))))))))) (. .))))

Sentence Id: DrugDDI.d184.s3
H2/NN Blockers/NNS and/CC Proton/NN Pump/NN Inhibitors/NNS (/-LRB- PPIs/NN )/-RRB- ./.

(ROOT (S1 (S (S (NP (NP (NN H2) (NNS Blockers)) (CC and) (NP (NP (NN Proton) (NN Pump) (NNS Inhibitors)) (PRN (-LRB- -LRB-) (NP (NN PPIs)) (-RRB- -RRB-))))) (. .))))

Sentence Id: DrugDDI.d184.s4
Of/IN over/IN 3500/CD patients/NNS enrolled/VBN in/IN the/DT Ibandronate/JJ osteoporosis/NN Treatment/NN and/CC Prevention/NN Studies/NNS ,/, 15/CD %/NN used/VBN anti-peptic/JJ agents/NNS (/-LRB- primarily/RB H2/NN blockers/NN and/CC PPIs/NN )./NN

(ROOT (S1 (S (PP (IN Of) (IN over) (NP (NP (CD 3500) (NNS patients)) (VP (VBN enrolled) (PP (IN in) (NP (NP (DT the) (JJ Ibandronate) (NN osteoporosis) (NN Treatment)) (CC and) (NP (NN Prevention)) (NP (NNS Studies))))))) (, ,) (NP (ADJP (NP (CD 15) (NN %)) (VBN used)) (JJ anti-peptic) (NNS agents)) (-LRB- -LRB-) (NP (ADVP (RB primarily)) (NP (NP (NN H2) (NN blockers)) (CC and) (NP (NN PPIs) (NN -RRB-.)))))))

Sentence Id: DrugDDI.d184.s5
Among/IN these/DT patients/NNS ,/, the/DT incidence/NN of/IN upper/JJ gastrointestinal/JJ adverse/JJ experiences/NNS in/IN the/DT patients/NNS treated/VBN with/IN Ibandronate/NN was/VBD similar/JJ to/TO that/DT in/IN placebo-treated/JJ patients/NNS ./.

(ROOT (S1 (S (S (PP (IN Among) (NP (DT these) (NNS patients))) (, ,) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (JJ upper) (JJ gastrointestinal) (JJ adverse) (NNS experiences))) (PP (IN in) (NP (NP (DT the) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NN Ibandronate))))))) (VP (VBD was) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN in) (NP (JJ placebo-treated) (NNS patients)))))))) (. .))))

Sentence Id: DrugDDI.d184.s6
Similarly/RB ,/, of/IN over/IN 1600/CD patients/NNS enrolled/VBN in/IN a/DT study/NN comparing/VBG once-monthly/JJ with/IN daily/JJ dosing/NN regimens/NNS of/IN ibandronate/NN ,/, 14/CD %/NN of/IN patients/NNS used/VBN anti-peptic/JJ agents/NNS ./.

(ROOT (S1 (S (S (ADVP (RB Similarly)) (, ,) (NP (QP (IN of) (IN over) (CD 1600)) (NNS patients)) (VP (VBN enrolled) (PP (IN in) (NP (NP (DT a) (NN study)) (VP (VBG comparing) (NP (ADJP (JJ once-monthly) (PP (IN with) (NP (NP (JJ daily) (NN dosing) (NNS regimens)) (PP (IN of) (NP (NP (NN ibandronate)) (, ,) (NP (NP (CD 14) (NN %)) (PP (IN of) (NP (NNS patients))))))))) (VBN used) (JJ anti-peptic) (NNS agents))))))) (. .))))

Sentence Id: DrugDDI.d184.s7
Among/IN these/DT patients/NNS ,/, the/DT incidence/NN of/IN upper/JJ gastrointestinal/JJ adverse/JJ experiences/NNS in/IN the/DT patients/NNS treated/VBN with/IN Ibandronate/NN 150/CD mg/NN once/RB monthly/RB was/VBD similar/JJ to/TO that/DT in/IN patients/NNS treated/VBN with/IN Ibandronate/NN 2.5/CD mg/NN once/RB daily/RB ./.

(ROOT (S1 (S (S (PP (IN Among) (NP (DT these) (NNS patients))) (, ,) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (JJ upper) (JJ gastrointestinal) (JJ adverse) (NNS experiences))) (PP (IN in) (NP (NP (DT the) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NN Ibandronate) (CD 150) (NN mg))) (ADVP (RB once) (RB monthly)))))) (VP (VBD was) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NN Ibandronate) (CD 2.5) (NN mg)) (ADVP (RB once) (RB daily)))))))))))) (. .))))

Sentence Id: DrugDDI.d184.s8
Aspirin/NN //: Nonsteroidal/JJ Antiinflammatory/JJ Drug/NN s/NNS (/-LRB- NSAIDs/NNS )/-RRB- ./.

(ROOT (S1 (S (NP (NP (NN Aspirin)) (: /) (NP (NP (JJ Nonsteroidal) (JJ Antiinflammatory) (NN Drug) (NNS s)) (PRN (-LRB- -LRB-) (NP (NNS NSAIDs)) (-RRB- -RRB-))) (. .)))))

Sentence Id: DrugDDI.d184.s9
In/IN the/DT large/JJ ,/, placebo-controlled/JJ osteoporosis/NN Treatment/NN Study/NN ,/, aspirin/NN and/CC nonsteroidal/JJ anti-inflammatory/JJ drugs/NNS were/VBD taken/VBN by/IN 62/CD %/NN of/IN the/DT 2946/CD patients/NNS ./.

(ROOT (S1 (S (S (PP (IN In) (NP (DT the) (ADJP (ADJP (JJ large)) (, ,) (ADJP (JJ placebo-controlled))) (NN osteoporosis) (NN Treatment) (NN Study))) (, ,) (NP (NP (NN aspirin)) (CC and) (NP (JJ nonsteroidal) (JJ anti-inflammatory) (NNS drugs))) (VP (VBD were) (VP (VBN taken) (PP (IN by) (NP (NP (CD 62) (NN %)) (PP (IN of) (NP (DT the) (CD 2946) (NNS patients)))))))) (. .))))

Sentence Id: DrugDDI.d184.s10
Among/IN aspirin/NN or/CC NSAID/NN users/NNS ,/, the/DT incidence/NN of/IN upper/JJ gastrointestinal/JJ adverse/JJ events/NNS in/IN patients/NNS treated/VBN with/IN ibandronate/NN 2.5/CD mg/NN daily/RB (/-LRB- 28.9/CD %/NN )/-RRB- was/VBD similar/JJ to/TO that/DT in/IN placebo-treated/JJ patients/NNS (/-LRB- 30.7%)./NN

(ROOT (S1 (S (PP (IN Among) (NP (NN aspirin) (CC or) (NN NSAID) (NNS users))) (, ,) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (JJ upper) (JJ gastrointestinal) (JJ adverse) (NNS events)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NN ibandronate) (CD 2.5) (NN mg) (RB daily)) (PRN (-LRB- -LRB-) (NP (CD 28.9) (NN %)) (-RRB- -RRB-)))))))))) (VP (VBD was) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN in) (NP (JJ placebo-treated) (NNS patients))))))) (PRN (-LRB- -LRB-) (NP (NN 30.7%-RRB-.))))))

Sentence Id: DrugDDI.d184.s11
Similarly/RB ,/, in/IN the/DT 1-year/JJ monthly/JJ comparison/NN study/NN ,/, aspirin/NN and/CC nonsteroidal/JJ anti-inflammatory/JJ drugs/NNS were/VBD taken/VBN by/IN 39/CD %/NN of/IN the/DT 1602/CD patients/NNS ./.

(ROOT (S1 (S (S (ADVP (RB Similarly)) (, ,) (PP (IN in) (NP (DT the) (JJ 1-year) (JJ monthly) (NN comparison) (NN study))) (, ,) (NP (NP (NN aspirin)) (CC and) (NP (JJ nonsteroidal) (JJ anti-inflammatory) (NNS drugs))) (VP (VBD were) (VP (VBN taken) (PP (IN by) (NP (NP (CD 39) (NN %)) (PP (IN of) (NP (DT the) (CD 1602) (NNS patients)))))))) (. .))))

Sentence Id: DrugDDI.d184.s12
The/DT incidence/NN of/IN upper/JJ gastrointestinal/JJ events/NNS in/IN patients/NNS concomitantly/RB taking/VBG aspirin/NN or/CC NSAIDs/NN was/VBD similar/JJ in/IN patients/NNS taking/VBG ibandronate/NN 2.5/CD mg/NN daily/RB (/-LRB- 21.7/CD %/NN )/-RRB- and/CC 150/CD mg/NN once/RB monthly/RB (/-LRB- 22.0%)./CD

(ROOT (S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NP (JJ upper) (JJ gastrointestinal) (NNS events)) (PP (IN in) (NP (NP (NNS patients)) (VP (ADVP (RB concomitantly)) (VBG taking) (NP (NP (NN aspirin)) (CC or) (NP (NN NSAIDs))))))))) (VP (VBD was) (ADJP (JJ similar)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (NP (NP (NN ibandronate) (CD 2.5) (NN mg)) (ADVP (RB daily))) (PRN (-LRB- -LRB-) (NP (CD 21.7) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 150) (NN mg)) (ADVP (RB once) (RB monthly))))))) (PRN (-LRB- -LRB-) (NP (CD 22.0%-RRB-.)))))))

Sentence Id: DrugDDI.d184.s13
However/RB ,/, since/IN aspirin/NN ,/, NSAIDs/NN ,/, and/CC bisphosphonates/NNS are/VBP all/DT associated/VBN with/IN gastrointestinal/JJ irritation/NN ,/, caution/NN should/MD be/VB exercised/VBN in/IN the/DT concomitant/JJ use/NN of/IN aspirin/NN or/CC NSAIDs/NN with/IN Ibandronate/NN ./.

(ROOT (S1 (S (ADVP (RB However)) (, ,) (SBAR (IN since) (S (NP (NP (NN aspirin)) (, ,) (NP (NN NSAIDs)) (, ,) (CC and) (NP (NNS bisphosphonates))) (VP (VBP are) (NP (NP (DT all)) (VP (VBN associated) (PP (IN with) (NP (JJ gastrointestinal) (NN irritation)))))))) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (PP (IN in) (NP (NP (DT the) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN aspirin)) (CC or) (NP (NN NSAIDs)))) (PP (IN with) (NP (NN Ibandronate)))))))) (. .))))

Sentence Id: DrugDDI.d184.s14
Drug/NN /Laboratory/NN Test/NN Interactions/NNS ./.

(ROOT (S1 (S (NP (NP (NN Drug) (NN /Laboratory) (NN Test) (NNS Interactions)) (. .)))))

Sentence Id: DrugDDI.d184.s15
Bisphosphonates/NNS are/VBP known/VBN to/TO interfere/VB with/IN the/DT use/NN of/IN bone-imaging/JJ agents/NNS ./.

(ROOT (S1 (S (S (NP (NNS Bisphosphonates)) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ bone-imaging) (NNS agents))))))))))) (. .))))

Sentence Id: DrugDDI.d184.s16
Specific/JJ studies/NNS with/IN ibandronate/NN have/VBP not/RB been/VBN performed/VBN ./.

(ROOT (S1 (S (S (NP (NP (JJ Specific) (NNS studies)) (PP (IN with) (NP (NN ibandronate)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN performed))))) (. .))))

Sentence Id: DrugDDI.d246.s1
No/DT evaluation/NN of/IN EXTRANEAL/JJ s/NN effects/NNS on/IN the/DT cytochrome/NN P450/NN system/NN was/VBD conducted/VBN ./.

(ROOT (S1 (S (S (NP (NP (DT No) (NN evaluation)) (PP (IN of) (NP (NP (JJ EXTRANEAL) (NN s) (NNS effects)) (PP (IN on) (NP (DT the) (NN cytochrome) (NN P450) (NN system)))))) (VP (VBD was) (VP (VBN conducted)))) (. .))))

Sentence Id: DrugDDI.d246.s2
As/IN with/IN other/JJ dialysis/NN solutions/NNS ,/, blood/NN concentrations/NNS of/IN dialyzable/JJ drugs/NNS may/MD be/VB reduced/VBN by/IN dialysis/NN ./.

(ROOT (S1 (S (S (PP (IN As) (PP (IN with) (NP (JJ other) (NN dialysis) (NNS solutions)))) (, ,) (NP (NP (NN blood) (NNS concentrations)) (PP (IN of) (NP (JJ dialyzable) (NNS drugs)))) (VP (MD may) (VP (VB be) (VP (VBN reduced) (PP (IN by) (NP (NN dialysis))))))) (. .))))

Sentence Id: DrugDDI.d246.s3
Dosage/JJ adjustment/NN of/IN concomitant/JJ medications/NNS may/MD be/VB necessary/JJ ./.

(ROOT (S1 (S (S (NP (NP (JJ Dosage) (NN adjustment)) (PP (IN of) (NP (JJ concomitant) (NNS medications)))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary))))) (. .))))

Sentence Id: DrugDDI.d246.s4
In/IN patients/NNS using/VBG cardiac/JJ glycosides/NNS (/-LRB- digoxin/NN and/CC others/NNS )/-RRB- ,/, plasma/NN levels/NNS of/IN calcium/NN ,/, potassium/NN and/CC magnesium/NN must/MD be/VB carefully/RB monitored/VBN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (NP (NNS patients)) (VP (VBG using) (NP (NP (JJ cardiac) (NNS glycosides)) (PRN (-LRB- -LRB-) (NP (NP (NN digoxin)) (CC and) (NP (NNS others))) (-RRB- -RRB-)))))) (, ,) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NN calcium)) (, ,) (NP (NN potassium)) (CC and) (NP (NN magnesium))))) (VP (MD must) (VP (VB be) (ADVP (RB carefully)) (VP (VBN monitored))))) (. .))))

Sentence Id: DrugDDI.d246.s5
Insulin/NN :/: A/DT clinical/JJ study/NN in/IN 6/CD insulin-dependent/JJ diabetic/JJ patients/NNS demonstrated/VBD no/DT effect/NN of/IN EXTRANEAL/NN on/IN insulin/NN absorption/NN from/IN the/DT peritoneal/JJ cavity/NN or/CC on/IN insulin/NN s/NN ability/NN to/TO control/VB blood/NN glucose/NN when/WRB insulin/NN was/VBD administered/VBN intraperitoneally/RB with/IN EXTRANEAL/NN ./.

(ROOT (S1 (S (NP (NP (NN Insulin)) (: :) (S (NP (NP (DT A) (JJ clinical) (NN study)) (PP (IN in) (NP (CD 6) (JJ insulin-dependent) (JJ diabetic) (NNS patients)))) (VP (VBD demonstrated) (NP (NP (DT no) (NN effect)) (PP (IN of) (NP (NN EXTRANEAL))) (PP (PP (IN on) (NP (NP (NN insulin) (NN absorption)) (PP (IN from) (NP (DT the) (JJ peritoneal) (NN cavity))))) (CC or) (PP (IN on) (NP (NP (NN insulin) (NN s) (NN ability)) (S (VP (TO to) (VP (VB control) (NP (NN blood) (NN glucose)) (SBAR (WHADVP (WRB when)) (S (NP (NN insulin)) (VP (VBD was) (VP (VBN administered) (ADVP (RB intraperitoneally)) (PP (IN with) (NP (NN EXTRANEAL)))))))))))))))) (. .)))))

Sentence Id: DrugDDI.d246.s6
However/RB ,/, appropriate/JJ monitoring/NN of/IN blood/NN glucose/NN should/MD be/VB performed/VBN when/WRB initiating/VBG EXTRANEAL/NN in/IN diabetic/JJ patients/NNS and/CC insulin/NN dosage/NN should/MD be/VB adjusted/VBN if/IN needed/VBN ./.

(ROOT (S1 (S (S (ADVP (RB However)) (, ,) (S (NP (NP (JJ appropriate) (NN monitoring)) (PP (IN of) (NP (NN blood) (NN glucose)))) (VP (MD should) (VP (VB be) (VP (VBN performed))) (SBAR (WHADVP (WRB when)) (S (VP (VBG initiating) (NP (NP (NN EXTRANEAL)) (PP (IN in) (NP (JJ diabetic) (NNS patients))))))))) (CC and) (S (NP (NN insulin) (NN dosage)) (VP (MD should) (VP (VB be) (VP (VBN adjusted) (SBAR (IN if) (S (VP (VBN needed))))))))) (. .))))

Sentence Id: DrugDDI.d246.s7
Heparin/NN :/: No/DT human/JJ drug/NN interaction/NN studies/NNS with/IN heparin/NN were/VBD conducted/VBN ./.

(ROOT (S1 (S (S (NP (NN Heparin)) (: :) (NP (NP (DT No) (JJ human) (NN drug) (NN interaction) (NNS studies)) (PP (IN with) (NP (NN heparin)))) (VP (VBD were) (VP (VBN conducted)))) (. .))))

Sentence Id: DrugDDI.d246.s8
In/FW vitro/FW studies/NNS demonstrated/VBD no/DT evidence/NN of/IN incompatibility/NN of/IN heparin/NN with/IN EXTRANEAL/NN ./.

(ROOT (S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBD demonstrated) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (NN incompatibility)) (PP (IN of) (NP (NN heparin))) (PP (IN with) (NP (NN EXTRANEAL)))))))) (. .))))

Sentence Id: DrugDDI.d246.s9
Antibiotics/NNS :/: No/DT human/JJ drug/NN interaction/NN studies/NNS with/IN antibiotics/NNS were/VBD conducted/VBN ./.

(ROOT (S1 (S (S (NP (NNS Antibiotics)) (: :) (NP (NP (DT No) (JJ human) (NN drug) (NN interaction) (NNS studies)) (PP (IN with) (NP (NNS antibiotics)))) (VP (VBD were) (VP (VBN conducted)))) (. .))))

Sentence Id: DrugDDI.d246.s10
In/FW vitro/FW studies/NNS evaluating/VBG the/DT minimum/JJ inhibitory/JJ concentration/NN (/-LRB- MIC/NN )/-RRB- of/IN vancomycin/NN ,/, cefazolin/NN ,/, ampicillin/NN ,/, ampicillin/NN /flucoxacillin/NN ,/, ceftazidime/NN ,/, gentamicin/NN ,/, and/CC amphotericin/NN demonstrated/VBD no/DT evidence/NN of/IN incompatibility/NN of/IN these/DT antibiotics/NNS with/IN EXTRANEAL/NN ./.

(ROOT (S1 (S (NP (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBG evaluating) (NP (NP (NP (DT the) (JJ minimum) (JJ inhibitory) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NN MIC)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NN vancomycin)) (, ,) (NP (NN cefazolin)) (, ,) (NP (NN ampicillin)) (, ,) (NP (NN ampicillin) (NN /flucoxacillin)) (, ,) (NP (NN ceftazidime)) (, ,) (NP (NN gentamicin)) (, ,) (CC and) (NP (NN amphotericin))))))) (VP (VBD demonstrated) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (NN incompatibility)) (PP (IN of) (NP (DT these) (NNS antibiotics))) (PP (IN with) (NP (NN EXTRANEAL))))))) (. .))))

Sentence Id: DrugDDI.d246.s11
Drug/NN /Laboratory/NN Test/NN Interactions/NNS Blood/NN Glucose/NN Blood/NN glucose/NN measurement/NN must/MD be/VB done/VBN with/IN a/DT glucose/NN -specific/JJ method/NN to/TO prevent/VB maltose/NN interference/NN with/IN test/NN results/NNS ./.

(ROOT (S1 (S (S (NP (NP (NN Drug) (NN /Laboratory) (NN Test) (NNS Interactions)) (NN Blood) (NN Glucose) (NN Blood) (NN glucose) (NN measurement)) (VP (MD must) (VP (VB be) (VP (VBN done) (PP (IN with) (NP (NP (DT a) (ADJP (NN glucose) (JJ -specific)) (NN method)) (S (VP (TO to) (VP (VB prevent) (NP (NP (NN maltose) (NN interference)) (PP (IN with) (NP (NN test) (NNS results))))))))))))) (. .))))

Sentence Id: DrugDDI.d246.s12
Since/IN falsely/RB elevated/JJ glucose/NN levels/NNS have/VBP been/VBN observed/VBN with/IN blood/NN glucose/NN monitoring/NN devices/NNS and/CC test/NN strips/NNS that/WDT use/VBP glucose/NN dehydrogenase/NN pyrroloquinolinequinone/NN (/-LRB- GDH/CD PQQ/NN )/-RRB- -based/JJ methods/NNS ,/, GDH/CD PQQ-based/JJ methods/NNS should/MD not/RB be/VB used/VBN to/TO measure/VB glucose/NN levels/NNS in/IN patients/NNS administered/VBN EXTRANEAL/NN ./. ./.

(ROOT (S1 (S (S (SBAR (IN Since) (S (NP (ADJP (RB falsely) (JJ elevated)) (NN glucose) (NNS levels)) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (PP (IN with) (NP (NP (NP (NN blood) (NN glucose) (NN monitoring) (NNS devices)) (CC and) (NP (NN test) (NNS strips))) (SBAR (WHNP (WDT that)) (S (VP (VBP use) (NP (ADJP (NP (NP (NN glucose) (NN dehydrogenase) (NN pyrroloquinolinequinone)) (PRN (-LRB- -LRB-) (NP (CD GDH) (NN PQQ)) (-RRB- -RRB-))) (JJ -based)) (NNS methods)))))))))))) (, ,) (NP (CD GDH) (JJ PQQ-based) (NNS methods)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (S (VP (TO to) (VP (VB measure) (NP (NN glucose) (NNS levels)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN administered) (S (NP (NN EXTRANEAL)))))))))))) (. .)) (. .))))

Sentence Id: DrugDDI.d246.s13
Serum/NN Amylase/NN :/: An/DT apparent/JJ decrease/NN in/IN serum/NN amylase/NN activity/NN has/VBZ been/VBN observed/VBN in/IN patients/NNS administered/VBN EXTRANEAL/NN ./.

(ROOT (S1 (S (NP (NP (NN Serum) (NN Amylase)) (: :) (S (NP (NP (DT An) (JJ apparent) (NN decrease)) (PP (IN in) (NP (NN serum) (NN amylase) (NN activity)))) (VP (VBZ has) (VP (VBN been) (VP (VBN observed) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN administered) (NP (NN EXTRANEAL))))))))) (. .)))))

Sentence Id: DrugDDI.d246.s14
Preliminary/JJ investigations/NNS indicate/VBP that/IN icodextrin/NN and/CC its/PRP$ metabolites/NNS interfere/VBP with/IN enzymatic-based/JJ amylase/NN assays/NNS ,/, resulting/VBG in/IN inaccurately/RB low/JJ values/NNS ./.

(ROOT (S1 (S (S (NP (JJ Preliminary) (NNS investigations)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN icodextrin)) (CC and) (NP (PRP$ its) (NNS metabolites))) (VP (VBP interfere) (PP (IN with) (NP (JJ enzymatic-based) (NN amylase) (NNS assays))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (ADJP (RB inaccurately) (JJ low)) (NNS values)))))))))) (. .))))

Sentence Id: DrugDDI.d246.s15
This/DT should/MD be/VB taken/VBN into/IN account/NN when/WRB evaluating/VBG serum/NN amylase/NN levels/NNS for/IN diagnosis/NN or/CC monitoring/NN of/IN pancreatitis/NN in/IN patients/NNS using/VBG EXTRANEAL/NN ./.

(ROOT (S1 (S (S (NP (DT This)) (VP (MD should) (VP (VB be) (VP (VBN taken) (PP (IN into) (NP (NN account))) (SBAR (WHADVP (WRB when)) (S (VP (VBG evaluating) (NP (NN serum) (NN amylase) (NNS levels)) (PP (IN for) (NP (NP (NN diagnosis)) (CC or) (NP (NP (NN monitoring)) (PP (IN of) (NP (NN pancreatitis))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG using) (NP (NN EXTRANEAL))))))))))))))) (. .))))

Sentence Id: DrugDDI.d470.s0
The/DT physician/NN should/MD be/VB alert/JJ for/IN possible/JJ combined/JJ drug/NN actions/NNS ,/, desirable/JJ or/CC undesirable/JJ ,/, involving/VBG ifosfamide/NN even/RB though/IN ifosfamide/NN has/VBZ been/VBN used/VBN successfully/RB concurrently/RB with/IN other/JJ drugs/NNS ,/, including/VBG other/JJ cytotoxic/JJ drugs/NNS ./.

(ROOT (S1 (S (S (NP (DT The) (NN physician)) (VP (MD should) (VP (VB be) (ADJP (JJ alert) (PP (IN for) (NP (NP (JJ possible) (JJ combined) (NN drug) (NNS actions)) (, ,) (ADJP (ADJP (JJ desirable)) (CC or) (ADJP (JJ undesirable))) (, ,) (VP (VBG involving) (NP (NN ifosfamide)))))) (SBAR (RB even) (IN though) (S (NP (NN ifosfamide)) (VP (VBZ has) (VP (VBN been) (VP (VBN used) (ADVP (RB successfully)) (PP (ADVP (RB concurrently)) (IN with) (NP (NP (JJ other) (NNS drugs)) (, ,) (PP (VBG including) (NP (JJ other) (JJ cytotoxic) (NNS drugs))))))))))))) (. .))))

Sentence Id: DrugDDI.d188.s0
In/IN occasional/JJ susceptible/JJ patients/NNS or/CC in/IN those/DT receiving/VBG anticholinergic/JJ drugs/NNS (/-LRB- including/VBG antiparkinsonism/NN agents/NNS )/-RRB- in/IN addition/NN ,/, the/DT atropine/JJ -like/JJ effects/NNS may/MD become/VB more/RBR pronounced/JJ (/-LRB- e.g./FW ,/, paralytic/JJ ileus/NN )./NN

(ROOT (S1 (S (S (PP (PP (IN In) (NP (JJ occasional) (JJ susceptible) (NNS patients))) (CC or) (PP (IN in) (NP (NP (DT those)) (VP (VBG receiving) (NP (NP (JJ anticholinergic) (NNS drugs)) (PRN (-LRB- -LRB-) (VP (VBG including) (NP (NN antiparkinsonism) (NNS agents))) (-RRB- -RRB-))) (PP (IN in) (NP (NN addition))))))) (, ,) (NP (DT the) (JJ atropine) (JJ -like) (NNS effects)) (VP (MD may) (VP (VB become) (ADJP (RBR more) (JJ pronounced))))) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (JJ paralytic) (NN ileus) (NN -RRB-.)))))))

Sentence Id: DrugDDI.d188.s1
Close/JJ supervision/NN and/CC careful/JJ adjustment/NN of/IN dosage/NN is/VBZ required/VBN when/WRB this/DT drug/NN is/VBZ administered/VBN concomitantly/RB with/IN anticholinergic/JJ drugs/NNS ./.

(ROOT (S1 (S (S (NP (NP (NP (JJ Close) (NN supervision)) (CC and) (NP (JJ careful) (NN adjustment))) (PP (IN of) (NP (NN dosage)))) (VP (VBZ is) (VP (VBN required) (SBAR (WHADVP (WRB when)) (S (NP (DT this) (NN drug)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (JJ anticholinergic) (NNS drugs)))))))))) (. .))))

Sentence Id: DrugDDI.d188.s2
Avoid/VB the/DT use/NN of/IN preparations/NNS such/JJ as/IN decongestants/NNS and/CC local/JJ anesthetics/NNS which/WDT contain/VBP any/DT sympathomimetic/JJ amine/NN (/-LRB- e.g./FW ,/, epinephrine/NN ,/, norepinephrine/NN )/-RRB- ,/, since/IN it/PRP has/VBZ been/VBN reported/VBN that/IN tricyclic/JJ antidepressants/NNS can/MD potentiate/VB the/DT effects/NNS of/IN catecholamines/NNS ./.

(ROOT (S1 (S (S (VP (VB Avoid) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNS preparations))) (PP (JJ such) (IN as) (NP (NP (NP (NNS decongestants)) (CC and) (NP (JJ local) (NNS anesthetics))) (SBAR (WHNP (WDT which)) (S (VP (VBP contain) (NP (NP (DT any) (JJ sympathomimetic) (NN amine)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN epinephrine)) (, ,) (NP (NN norepinephrine))) (-RRB- -RRB-))) (, ,) (SBAR (IN since) (S (NP (PRP it)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (SBAR (IN that) (S (NP (JJ tricyclic) (NNS antidepressants)) (VP (MD can) (VP (VB potentiate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNS catecholamines))))))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d188.s3
Caution/NN should/MD be/VB exercised/VBN when/WRB imipramine/NN hydrochloride/NN is/VBZ used/VBN with/IN agents/NNS that/IN lower/JJR blood/NN pressure/NN ./.

(ROOT (S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (NP (NN imipramine) (NN hydrochloride)) (VP (VBZ is) (VP (VBN used) (PP (IN with) (NP (NP (NNS agents)) (PP (IN that) (NP (JJR lower) (NN blood) (NN pressure))))))))))))) (. .))))

Sentence Id: DrugDDI.d188.s4
Imipramine/NN hydrochloride/NN may/MD potentiate/VB the/DT effects/NNS of/IN CNS/NN depressant/NN drugs/NNS ./.

(ROOT (S1 (S (S (NP (NN Imipramine) (NN hydrochloride)) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN CNS) (NN depressant) (NNS drugs))))))) (. .))))

Sentence Id: DrugDDI.d188.s5
The/DT plasma/NN concentration/NN of/IN imipramine/NN may/MD increase/VB when/WRB the/DT drug/NN is/VBZ given/VBN concomitantly/RB with/IN hepatic/JJ enzyme/NN inhibitors/NNS (/-LRB- e.g./FW ,/, cimetidine/NN ,/, fluoxetine/NN )/-RRB- and/CC decrease/VB by/IN concomitant/JJ administration/NN of/IN hepatic/JJ enzyme/NN inducers/NNS (/-LRB- e.g./FW ,/, barbiturates/NNS ,/, phenytoin/NN )/-RRB- ,/, and/CC adjustment/NN of/IN the/DT dosage/NN of/IN imipramine/NN may/MD therefore/RB be/VB necessary/JJ ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN plasma) (NN concentration)) (PP (IN of) (NP (NN imipramine)))) (VP (MD may) (VP (VP (VB increase) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN drug)) (VP (VBZ is) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (JJ hepatic) (NN enzyme) (NNS inhibitors)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN cimetidine)) (, ,) (NP (NN fluoxetine))) (-RRB- -RRB-))))))))) (CC and) (VP (VB decrease) (PP (IN by) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (JJ hepatic) (NN enzyme) (NNS inducers)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NNS barbiturates)) (, ,) (NP (NN phenytoin))) (-RRB- -RRB-)))))))))) (, ,) (CC and) (S (NP (NP (NN adjustment)) (PP (IN of) (NP (NP (DT the) (NN dosage)) (PP (IN of) (NP (NN imipramine)))))) (VP (MD may) (ADVP (RB therefore)) (VP (VB be) (ADJP (JJ necessary))))) (. .))))

Sentence Id: DrugDDI.d188.s6
Drugs/NNS Metabolized/VBN by/IN P450/NN 2D6/NN :/: The/DT biochemical/JJ activity/NN of/IN the/DT drug/NN metabolizing/NN isozyme/NN cytochrome/NN P450/NN 2D6/NN (/-LRB- debrisoquin/NN hydroxylase/NN )/-RRB- is/VBZ reduced/VBN in/IN a/DT subset/NN of/IN the/DT caucasian/NN population/NN (/-LRB- about/RB 7/CD to/TO 10/CD %/NN of/IN caucasians/NNS are/VBP so/RB called/VBN poor/JJ metabolizers/NNS )/-RRB- ;/: ./.

(ROOT (S1 (S (NP (NP (NP (NNS Drugs)) (VP (VBN Metabolized) (PP (IN by) (NP (NN P450) (NN 2D6))))) (: :) (S (NP (NP (DT The) (JJ biochemical) (NN activity)) (PP (IN of) (NP (NP (DT the) (NN drug) (NN metabolizing) (NN isozyme) (NN cytochrome) (NN P450) (NN 2D6)) (PRN (-LRB- -LRB-) (NP (NN debrisoquin) (NN hydroxylase)) (-RRB- -RRB-))))) (VP (VBZ is) (VP (VBN reduced) (PP (IN in) (NP (NP (DT a) (NN subset)) (PP (IN of) (NP (DT the) (NN caucasian) (NN population))))) (PRN (-LRB- -LRB-) (S (NP (NP (QP (RB about) (CD 7) (TO to) (CD 10)) (NN %)) (PP (IN of) (NP (NNS caucasians)))) (VP (VBP are) (NP (ADJP (RB so) (VBN called)) (JJ poor) (NNS metabolizers)))) (-RRB- -RRB-)))) (: ;)) (. .)))))

Sentence Id: DrugDDI.d188.s7
reliable/JJ estimates/NNS of/IN the/DT prevalence/NN of/IN reduced/VBN P450/NN 2D6/NN isozyme/NN activity/NN among/IN Asian/JJ ,/, African/JJ and/CC other/JJ populations/NNS are/VBP not/RB yet/RB available/JJ ./.

(ROOT (S1 (S (S (NP (NP (JJ reliable) (NNS estimates)) (PP (IN of) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (VBN reduced) (NN P450) (NN 2D6) (NN isozyme) (NN activity))) (PP (IN among) (NP (ADJP (ADJP (JJ Asian)) (, ,) (ADJP (JJ African)) (CC and) (ADJP (JJ other))) (NNS populations)))))) (VP (VBP are) (RB not) (ADVP (RB yet)) (ADJP (JJ available)))) (. .))))

Sentence Id: DrugDDI.d188.s8
Poor/JJ metabolizers/NNS have/VBP higher/JJR than/IN expected/VBN plasma/NN concentrations/NNS of/IN tricyclic/JJ antidepressants/NNS (/-LRB- TCAs/NNS )/-RRB- when/WRB given/VBN usual/JJ doses/NNS ./.

(ROOT (S1 (S (S (NP (JJ Poor) (NNS metabolizers)) (VP (VBP have) (NP (NP (JJR higher) (IN than) (VBN expected) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (JJ tricyclic) (NNS antidepressants)) (PRN (-LRB- -LRB-) (NP (NNS TCAs)) (-RRB- -RRB-))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (NP (JJ usual) (NNS doses))))))) (. .))))

Sentence Id: DrugDDI.d188.s9
Depending/VBG on/IN the/DT fraction/NN of/IN drug/NN metabolized/VBN by/IN P450/NN 2D6/NN ,/, the/DT increase/NN in/IN plasma/NN concentration/NN may/MD be/VB small/JJ ,/, or/CC quite/RB large/JJ (/-LRB- 8-fold/JJ increase/NN in/IN plasma/NN AUC/NN of/IN the/DT TCA/NN )./NN

(ROOT (S1 (S (PP (VBG Depending) (PP (IN on) (NP (NP (DT the) (NN fraction)) (PP (IN of) (NP (NP (NN drug)) (VP (VBN metabolized) (PP (IN by) (NP (NN P450) (NN 2D6))))))))) (, ,) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NN plasma) (NN concentration)))) (VP (MD may) (VP (VB be) (ADJP (ADJP (JJ small)) (, ,) (CC or) (RB quite) (ADJP (JJ large))))) (PRN (-LRB- -LRB-) (NP (NP (JJ 8-fold) (NN increase)) (PP (IN in) (NP (NP (NN plasma) (NN AUC)) (PP (IN of) (NP (DT the) (NN TCA) (NN -RRB-.))))))))))

Sentence Id: DrugDDI.d188.s10
In/IN addition/NN ,/, certain/JJ drugs/NNS inhibit/VB the/DT activity/NN of/IN this/DT isozyme/NN and/CC make/VB normal/JJ metabolizers/NNS resemble/VBP p.o./NN

(ROOT (S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (JJ certain) (NNS drugs)) (VP (VP (VB inhibit) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT this) (NN isozyme))))) (CC and) (VP (VB make) (NP (JJ normal) (NNS metabolizers)))) (VP (VBP resemble) (NP (NN p.o.))))))

Sentence Id: DrugDDI.d188.s12
An/DT individual/JJ who/WP is/VBZ stable/JJ on/IN a/DT given/JJ dose/NN of/IN TCA/NN may/MD become/VB abruptly/RB toxic/JJ when/WRB given/VBN one/CD of/IN these/DT inhibiting/JJ drugs/NNS as/IN concomitant/JJ therapy/NN ./.

(ROOT (S1 (S (S (NP (NP (DT An) (JJ individual)) (SBAR (WHNP (WP who)) (S (VP (VBZ is) (ADJP (JJ stable) (PP (IN on) (NP (NP (DT a) (JJ given) (NN dose)) (PP (IN of) (NP (NN TCA)))))))))) (VP (MD may) (VP (VB become) (ADJP (RB abruptly) (JJ toxic)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT these) (JJ inhibiting) (NNS drugs)) (PP (IN as) (NP (JJ concomitant) (NN therapy)))))))))))) (. .))))

Sentence Id: DrugDDI.d188.s13
The/DT drugs/NNS that/WDT inhibit/VBP cytochrome/NN P450/NN 2D6/NN include/VBP some/DT that/WDT are/VBP not/RB metabolized/VBN by/IN the/DT enzyme/NN (/-LRB- quinidine/NN ;/: ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (NN cytochrome) (NN P450) (NN 2D6)))))) (VP (VBP include) (NP (NP (DT some)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (RB not) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (NN enzyme) (-LRB- -LRB-) (NN quinidine) (: ;)))))))))) (. .))))

Sentence Id: DrugDDI.d188.s14
cimetidine/NN )/-RRB- and/CC many/JJ that/WDT are/VBP substrates/NNS for/IN P450/NN 2D6/NN (/-LRB- many/JJ other/JJ antidepressants/NNS ,/, phenothiazines/NNS ,/, and/CC the/DT Type/NN 1C/NN antiarrhythmics/NNS propafenone/NN and/CC flecainide/NN )/-RRB- ./.

(ROOT (S1 (S (NP (NP (NP (NN cimetidine) (-RRB- -RRB-)) (CC and) (NP (NP (JJ many)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NNS substrates)) (PP (IN for) (NP (NN P450) (NN 2D6)))) (PRN (-LRB- -LRB-) (NP (NP (JJ many) (JJ other) (NNS antidepressants)) (, ,) (NP (NNS phenothiazines)) (, ,) (CC and) (NP (NP (DT the) (NN Type) (NN 1C) (NNS antiarrhythmics)) (NP (NP (NN propafenone)) (CC and) (NP (NN flecainide))))) (-RRB- -RRB-))))))) (. .)))))

Sentence Id: DrugDDI.d188.s15
While/IN all/PDT the/DT selective/JJ serotonin/NN reuptake/NN inhibitors/NNS (/-LRB- SSRIs/NN )/-RRB- ,/, e./FW g./FW ,/, fluoxetine/NN ,/, sertraline/NN ,/, and/CC paroxetine/NN ,/, inhibit/VBP P450/NN 2D6/NN ,/, they/PRP may/MD vary/VB in/IN the/DT extent/NN of/IN inhibition/NN ./.

(ROOT (S1 (S (S (SBAR (IN While) (S (NP (NP (NP (PDT all) (DT the) (JJ selective) (NN serotonin) (NN reuptake) (NNS inhibitors)) (PRN (-LRB- -LRB-) (NP (NN SSRIs)) (-RRB- -RRB-))) (, ,) (NP (FW e.) (FW g.) (, ,) (NP (NN fluoxetine)) (, ,) (NP (NN sertraline)) (, ,) (CC and) (NP (NN paroxetine))) (, ,)) (VP (VBP inhibit) (NP (NN P450) (NN 2D6))))) (, ,) (NP (PRP they)) (VP (MD may) (VP (VB vary) (PP (IN in) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NN inhibition)))))))) (. .))))

Sentence Id: DrugDDI.d188.s18
Of/IN particular/JJ importance/NN ,/, sufficient/JJ time/NN must/MD elapse/VB before/IN initiating/VBG TCA/NN treatment/NN in/IN a/DT patient/NN being/VBG withdrawn/NN from/IN fluoxetine/NN ,/, given/IN the/DT long/JJ half-life/NN of/IN the/DT parent/JJ and/CC active/JJ metabolite/NN (/-LRB- at/IN least/JJS 5/CD weeks/NNS may/MD be/VB necessary/JJ )./NN

(ROOT (S1 (S (PP (IN Of) (NP (JJ particular) (NN importance))) (, ,) (S (NP (JJ sufficient) (NN time)) (VP (MD must) (VP (VB elapse) (PP (IN before) (S (VP (VBG initiating) (NP (NN TCA) (NN treatment))))) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBG being) (NP (NP (NN withdrawn)) (PP (IN from) (NP (NN fluoxetine))))))) (, ,) (SBAR (IN given) (S (NP (NP (DT the) (JJ long) (NN half-life)) (PP (IN of) (NP (DT the) (ADJP (ADJP (JJ parent)) (CC and) (ADJP (JJ active))) (NN metabolite) (-LRB- -LRB-) (QP (IN at) (JJS least) (CD 5)) (NNS weeks)))) (VP (MD may) (VP (VB be) (NP (JJ necessary) (NN -RRB-.))))))))))))

Sentence Id: DrugDDI.d188.s19
Concomitant/JJ use/NN of/IN tricyclic/JJ antidepressants/NNS with/IN drugs/NNS that/WDT can/MD inhibit/VB cytochrome/NN P450/NN 2D6/NN may/MD require/VB lower/JJR doses/NNS than/IN usually/RB prescribed/VBN for/IN either/CC the/DT tricyclic/JJ antidepressant/JJ or/CC the/DT other/JJ drug/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NP (JJ tricyclic) (NNS antidepressants)) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB inhibit) (NP (NN cytochrome) (NN P450) (NN 2D6))))))))))) (VP (MD may) (VP (VB require) (NP (NP (JJR lower) (NNS doses)) (VP (ADVP (IN than) (RB usually)) (VBN prescribed) (PP (IN for) (NP (CC either) (NP (DT the) (JJ tricyclic) (JJ antidepressant)) (CC or) (NP (DT the) (JJ other) (NN drug))))))))) (. .))))

Sentence Id: DrugDDI.d188.s20
Furthermore/RB ,/, whenever/RB one/CD of/IN these/DT other/JJ drugs/NNS is/VBZ withdrawn/VBN from/IN cotherapy/NN ,/, an/DT increased/VBN dose/NN of/IN tricyclic/JJ antidepressant/JJ may/MD be/VB required/VBN ./.

(ROOT (S1 (S (S (ADVP (RB Furthermore)) (, ,) (S (ADVP (RB whenever)) (NP (NP (CD one)) (PP (IN of) (NP (DT these) (JJ other) (NNS drugs)))) (VP (VBZ is) (VP (VBN withdrawn) (PP (IN from) (NP (NN cotherapy)))))) (, ,) (NP (NP (DT an) (VBN increased) (NN dose)) (PP (IN of) (NP (JJ tricyclic) (JJ antidepressant)))) (VP (MD may) (VP (VB be) (VP (VBN required))))) (. .))))

Sentence Id: DrugDDI.d188.s21
It/PRP is/VBZ desirable/JJ to/TO monitor/VB TCA/NN plasma/NN levels/NNS whenever/RB a/DT TCA/NN is/VBZ going/JJ to/TO be/VB co-administered/VBN with/IN another/DT drug/NN known/VBN to/TO be/VB an/DT inhibitor/NN of/IN P450/NN 2D6/NN ./.

(ROOT (S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ desirable)) (S (VP (TO to) (VP (VB monitor) (NP (NN TCA) (NN plasma) (NNS levels)) (S (ADVP (RB whenever)) (NP (DT a) (NN TCA)) (VP (VBZ is) (ADJP (JJ going) (S (VP (TO to) (VP (VB be) (VP (VBN co-administered) (PP (IN with) (NP (NP (DT another) (NN drug)) (VP (VBN known) (S (VP (TO to) (VP (VB be) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN P450) (NN 2D6)))))))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d83.s0
In/IN normal/JJ volunteers/NNS receiving/VBG indomethacin/NN ,/, the/DT administration/NN of/IN diflunisal/NN decreased/VBD the/DT renal/JJ clearance/NN and/CC significantly/RB increased/VBD the/DT plasma/NN levels/NNS of/IN indomethacin/NN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (NP (JJ normal) (NNS volunteers)) (VP (VBG receiving) (NP (NN indomethacin))))) (, ,) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NN diflunisal)))) (VP (VP (VBD decreased) (NP (DT the) (JJ renal) (NN clearance))) (CC and) (VP (ADVP (RB significantly)) (VBD increased) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN indomethacin))))))) (. .))))

Sentence Id: DrugDDI.d83.s1
In/IN some/DT patients/NNS ,/, combined/JJ use/NN of/IN INDOCIN/NN and/CC diflunisal/NN has/VBZ been/VBN associated/VBN with/IN fatal/JJ gastrointestinal/JJ hemorrhage/NN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (DT some) (NNS patients))) (, ,) (NP (NP (JJ combined) (NN use)) (PP (IN of) (NP (NP (NN INDOCIN)) (CC and) (NP (NN diflunisal))))) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (JJ fatal) (JJ gastrointestinal) (NN hemorrhage))))))) (. .))))

Sentence Id: DrugDDI.d83.s2
Therefore/RB ,/, diflunisal/NN and/CC INDOCIN/NN should/MD not/RB be/VB used/VBN concomitantly/RB ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN diflunisal)) (CC and) (NP (NN INDOCIN))) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (ADVP (RB concomitantly)))))) (. .))))

Sentence Id: DrugDDI.d83.s3
In/IN a/DT study/NN in/IN normal/JJ volunteers/NNS ,/, it/PRP was/VBD found/VBN that/IN chronic/JJ concurrent/JJ administration/NN of/IN 3.6/CD g/NN of/IN aspirin/NN per/IN day/NN decreases/VBZ indomethacin/NN blood/NN levels/NNS approximately/RB 20/CD %./NN

(ROOT (S1 (S (S (PP (IN In) (NP (NP (DT a) (NN study)) (PP (IN in) (NP (JJ normal) (NNS volunteers))))) (, ,) (NP (PRP it)) (VP (VBD was) (VP (VBN found) (SBAR (IN that) (S (NP (NP (JJ chronic) (JJ concurrent) (NN administration)) (PP (IN of) (NP (NP (CD 3.6) (NN g)) (PP (IN of) (NP (NN aspirin))))) (PP (IN per) (NP (NN day)))) (VP (VBZ decreases) (NP (NN indomethacin) (NN blood) (NNS levels)))))))) (NP (QP (RB approximately) (CD 20)) (NN %.)))))

Sentence Id: DrugDDI.d83.s4
The/DT concomitant/JJ use/NN of/IN INDOCIN/NN with/IN other/JJ NSAIDs/NNS is/VBZ not/RB recommended/VBN due/JJ to/TO the/DT increased/VBN possibility/NN of/IN gastrointestinal/JJ toxicity/NN ,/, with/IN little/JJ or/CC no/DT increase/NN in/IN efficacy/NN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NN INDOCIN))) (PP (IN with) (NP (JJ other) (NNS NSAIDs)))) (VP (VBZ is) (RB not) (VP (VBN recommended) (PP (JJ due) (TO to) (NP (NP (DT the) (VBN increased) (NN possibility)) (PP (IN of) (NP (JJ gastrointestinal) (NN toxicity))))) (, ,) (PP (IN with) (NP (NP (ADJP (JJ little))) (CC or) (NP (DT no)) (NP (NP (NN increase)) (PP (IN in) (NP (NN efficacy))))))))) (. .))))

Sentence Id: DrugDDI.d83.s5
Clinical/JJ studies/NNS have/VBP shown/VBN that/IN INDOCIN/NN does/VBZ not/RB influence/VB the/DT hypoprothrombinemia/NN produced/VBN by/IN anticoagulants/NNS ./.

(ROOT (S1 (S (S (NP (JJ Clinical) (NNS studies)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN INDOCIN)) (VP (VBZ does) (RB not) (VP (VB influence) (NP (NP (DT the) (NN hypoprothrombinemia)) (VP (VBN produced) (PP (IN by) (NP (NNS anticoagulants)))))))))))) (. .))))

Sentence Id: DrugDDI.d83.s6
However/RB ,/, when/WRB any/DT additional/JJ drug/NN ,/, including/VBG INDOCIN/NN ,/, is/VBZ added/VBN to/TO the/DT treatment/NN of/IN patients/NNS on/IN anticoagulant/NN therapy/NN ,/, the/DT patients/NNS should/MD be/VB observed/VBN for/IN alterations/NNS of/IN the/DT prothrombin/NN time/NN ./.

(ROOT (S1 (S (S (ADVP (RB However)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (DT any) (JJ additional) (NN drug)) (, ,) (PP (VBG including) (NP (NN INDOCIN))) (, ,)) (VP (VBZ is) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN on) (NP (NN anticoagulant) (NN therapy))))))))))) (, ,) (NP (DT the) (NNS patients)) (VP (MD should) (VP (VB be) (VP (VBN observed) (PP (IN for) (NP (NP (NNS alterations)) (PP (IN of) (NP (DT the) (NN prothrombin) (NN time))))))))) (. .))))

Sentence Id: DrugDDI.d83.s7
In/IN post-marketing/JJ experience/VBP ,/, bleeding/JJ has/VBZ been/VBN reported/VBN in/IN patients/NNS on/IN concomitant/JJ treatment/NN with/IN anticoagulants/NNS and/CC INDOCIN/NN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (JJ post-marketing) (VBP experience))) (, ,) (NP (JJ bleeding)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (NP (JJ concomitant) (NN treatment)) (PP (IN with) (NP (NP (NNS anticoagulants)) (CC and) (NP (NN INDOCIN)))))))))))) (. .))))

Sentence Id: DrugDDI.d83.s8
Caution/NN should/MD be/VB exercised/VBN when/WRB INDOCIN/NN and/CC anticoagulants/NNS are/VBP administered/VBN concomitantly/RB ./.

(ROOT (S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN INDOCIN)) (CC and) (NP (NNS anticoagulants))) (VP (VBP are) (VP (VBN administered) (ADVP (RB concomitantly)))))))))) (. .))))

Sentence Id: DrugDDI.d83.s9
When/WRB INDOCIN/NN is/VBZ given/VBN to/TO patients/NNS receiving/VBG probenecid/NN ,/, the/DT plasma/NN levels/NNS of/IN indomethacin/NN are/VBP likely/JJ to/TO be/VB increased/VBN ./.

(ROOT (S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN INDOCIN)) (VP (VBZ is) (VP (VBN given) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN probenecid))))))))) (, ,) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN indomethacin)))) (VP (VBP are) (ADJP (JJ likely) (S (VP (TO to) (VP (VB be) (VP (VBN increased)))))))) (. .))))

Sentence Id: DrugDDI.d83.s10
Therefore/RB ,/, a/DT lower/RBR total/JJ daily/JJ dosage/NN of/IN INDOCIN/NN may/MD produce/VB a/DT satisfactory/JJ therapeutic/JJ effect/NN ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT a) (ADJP (RBR lower) (JJ total)) (JJ daily) (NN dosage)) (PP (IN of) (NP (NN INDOCIN)))) (VP (MD may) (VP (VB produce) (NP (DT a) (JJ satisfactory) (JJ therapeutic) (NN effect))))) (. .))))

Sentence Id: DrugDDI.d83.s11
When/WRB increases/NNS in/IN the/DT dose/NN of/IN INDOCIN/NN are/VBP made/VBN ,/, they/PRP should/MD be/VB made/VBN carefully/RB and/CC in/IN small/JJ increments/NNS ./.

(ROOT (S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NNS increases)) (PP (IN in) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN INDOCIN)))))) (VP (VBP are) (VP (VBN made))))) (, ,) (NP (PRP they)) (VP (MD should) (VP (VB be) (VP (VBN made) (UCP (ADVP (RB carefully)) (CC and) (PP (IN in) (NP (JJ small) (NNS increments)))))))) (. .))))

Sentence Id: DrugDDI.d83.s12
Caution/NN should/MD be/VB used/VBN if/IN INDOCIN/NN is/VBZ administered/VBN simultaneously/RB with/IN methotrexate/NN ./.

(ROOT (S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (SBAR (IN if) (S (NP (NN INDOCIN)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB simultaneously)) (PP (IN with) (NP (NN methotrexate))))))))))) (. .))))

Sentence Id: DrugDDI.d83.s13
INDOCIN/NN has/VBZ been/VBN reported/VBN to/TO decrease/VB the/DT tubular/JJ secretion/NN of/IN methotrexate/NN and/CC to/TO potentiate/VB its/PRP$ toxicity/NN ./.

(ROOT (S1 (S (S (NP (NN INDOCIN)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (VP (TO to) (VP (VB decrease) (NP (NP (DT the) (JJ tubular) (NN secretion)) (PP (IN of) (NP (NN methotrexate)))))) (CC and) (VP (TO to) (VP (VB potentiate) (NP (PRP$ its) (NN toxicity)))))))))) (. .))))

Sentence Id: DrugDDI.d83.s14
Administration/NN of/IN non-steroidal/JJ anti-inflammatory/JJ drugs/NNS concomitantly/RB with/IN cyclosporine/NN has/VBZ been/VBN associated/VBN with/IN an/DT increase/NN in/IN cyclosporine-induced/JJ toxicity/NN ,/, possibly/RB due/JJ to/TO decreased/VBN synthesis/NN of/IN renal/JJ prostacyclin/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Administration)) (PP (IN of) (NP (NP (JJ non-steroidal) (JJ anti-inflammatory) (NNS drugs)) (PP (ADVP (RB concomitantly)) (IN with) (NP (NN cyclosporine)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ cyclosporine-induced) (NN toxicity))))) (, ,) (PP (ADVP (RB possibly)) (JJ due) (TO to) (NP (NP (VBN decreased) (NN synthesis)) (PP (IN of) (NP (JJ renal) (NN prostacyclin))))))))) (. .))))

Sentence Id: DrugDDI.d83.s15
NSAIDs/NN should/MD be/VB used/VBN with/IN caution/NN in/IN patients/NNS taking/VBG cyclosporine/NN ,/, and/CC renal/JJ function/NN should/MD be/VB carefully/RB monitored/VBN ./.

(ROOT (S1 (S (S (S (NP (NN NSAIDs)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN cyclosporine))))))))) (, ,) (CC and) (S (NP (JJ renal) (NN function)) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN monitored)))))) (. .))))

Sentence Id: DrugDDI.d83.s16
Capsules/NNS INDOCIN/NN 50/CD mg/NN t.i.d./RB produced/VBD a/DT clinically/RB relevant/JJ elevation/NN of/IN plasma/NN lithium/NN and/CC reduction/NN in/IN renal/JJ lithium/NN clearance/NN in/IN psychiatric/JJ patients/NNS and/CC normal/JJ subjects/NNS with/IN steady/JJ state/NN plasma/NN lithium/NN concentrations/NNS ./.

(ROOT (S1 (S (NP (NP (NNS Capsules)) (NP (NN INDOCIN) (CD 50) (NN mg))) (ADVP (RB t.i.d.)) (VP (VBD produced) (NP (NP (NP (DT a) (ADJP (RB clinically) (JJ relevant)) (NN elevation)) (PP (IN of) (NP (NN plasma) (NN lithium)))) (CC and) (NP (NP (NN reduction)) (PP (IN in) (NP (NP (JJ renal) (NN lithium) (NN clearance)) (PP (IN in) (NP (NP (NP (JJ psychiatric) (NNS patients)) (CC and) (NP (JJ normal) (NNS subjects))) (PP (IN with) (NP (JJ steady) (NN state) (NN plasma) (NN lithium) (NNS concentrations)))))))))) (. .))))

Sentence Id: DrugDDI.d83.s17
This/DT effect/NN has/VBZ been/VBN attributed/VBN to/TO inhibition/NN of/IN prostaglandin/NN synthesis/NN ./.

(ROOT (S1 (S (S (NP (DT This) (NN effect)) (VP (VBZ has) (VP (VBN been) (VP (VBN attributed) (PP (TO to) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN prostaglandin) (NN synthesis))))))))) (. .))))

Sentence Id: DrugDDI.d83.s18
As/IN a/DT consequence/NN ,/, when/WRB INDOCIN/NN and/CC lithium/NN are/VBP given/VBN concomitantly/RB ,/, the/DT patient/NN should/MD be/VB carefully/RB observed/VBN for/IN signs/NNS of/IN lithium/NN toxicity/NN ./.

(ROOT (S1 (S (S (PP (IN As) (NP (DT a) (NN consequence))) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN INDOCIN)) (CC and) (NP (NN lithium))) (VP (VBP are) (VP (VBN given) (ADVP (RB concomitantly)))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN observed) (PP (IN for) (NP (NP (NNS signs)) (PP (IN of) (NP (NN lithium) (NN toxicity))))))))) (. .))))

Sentence Id: DrugDDI.d83.s19
(/-LRB- Read/VBN circulars/NNS for/IN lithium/NN preparation/NN s/NNS before/IN use/NN of/IN such/JJ concomitant/JJ therapy./NN )/-RRB- ./.

(ROOT (S1 (S (S (PRN (-LRB- -LRB-) (NP (NP (VBN Read) (NNS circulars)) (PP (IN for) (NP (NP (NN lithium) (NN preparation) (NNS s)) (PP (IN before) (NP (NP (NN use)) (PP (IN of) (NP (JJ such) (JJ concomitant) (NN therapy.)))))))) (-RRB- -RRB-))) (. .))))

Sentence Id: DrugDDI.d83.s20
In/IN addition/NN ,/, the/DT frequency/NN of/IN monitoring/VBG serum/NN lithium/NN concentration/NN should/MD be/VB increased/VBN at/IN the/DT outset/NN of/IN such/JJ combination/NN drug/NN treatment/NN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (DT the) (NN frequency)) (PP (IN of) (S (VP (VBG monitoring) (NP (NN serum) (NN lithium) (NN concentration)))))) (VP (MD should) (VP (VB be) (VP (VBN increased) (PP (IN at) (NP (NP (DT the) (NN outset)) (PP (IN of) (NP (JJ such) (NN combination) (NN drug) (NN treatment))))))))) (. .))))

Sentence Id: DrugDDI.d83.s21
INDOCIN/NN given/VBN concomitantly/RB with/IN digoxin/NN has/VBZ been/VBN reported/VBN to/TO increase/VB the/DT serum/NN concentration/NN and/CC prolong/VB the/DT half-life/NN of/IN digoxin/NN ./.

(ROOT (S1 (S (S (NP (NP (NN INDOCIN)) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN digoxin))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VP (VB increase) (NP (DT the) (NN serum) (NN concentration))) (CC and) (VP (VB prolong) (NP (NP (DT the) (NN half-life)) (PP (IN of) (NP (NN digoxin)))))))))))) (. .))))

Sentence Id: DrugDDI.d83.s22
Therefore/RB ,/, when/WRB INDOCIN/NN and/CC digoxin/NN are/VBP used/VBN concomitantly/RB ,/, serum/NN digoxin/NN levels/NNS should/MD be/VB closely/RB monitored/VBN ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN INDOCIN)) (CC and) (NP (NN digoxin))) (VP (VBP are) (VP (VBN used) (ADVP (RB concomitantly)))))) (, ,) (NP (NN serum) (NN digoxin) (NNS levels)) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored))))) (. .))))

Sentence Id: DrugDDI.d83.s23
In/IN some/DT patients/NNS ,/, the/DT administration/NN of/IN INDOCIN/NN can/MD reduce/VB the/DT diuretic/JJ ,/, natriuretic/JJ ,/, and/CC antihypertensive/JJ effects/NNS of/IN loop/NN ,/, potassium/NN -sparing/NN ,/, and/CC thiazide/NN diuretics/NNS ./.

(ROOT (S1 (S (S (PP (IN In) (NP (DT some) (NNS patients))) (, ,) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NN INDOCIN)))) (VP (MD can) (VP (VB reduce) (NP (NP (DT the) (ADJP (ADJP (JJ diuretic)) (, ,) (ADJP (JJ natriuretic)) (, ,) (CC and) (ADJP (JJ antihypertensive))) (NNS effects)) (PP (IN of) (NP (NP (NN loop)) (, ,) (NP (NN potassium) (NN -sparing)) (, ,) (CC and) (NP (NN thiazide) (NNS diuretics)))))))) (. .))))

Sentence Id: DrugDDI.d83.s24
Therefore/RB ,/, when/IN INDOCIN/NN and/CC INDOCIN/NN ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (PP (IN when) (NP (NP (NN INDOCIN)) (CC and) (NP (NN INDOCIN))))) (. .))))

Sentence Id: DrugDDI.d83.s25
(/-LRB- Indomethacin/NN )/-RRB- diuretics/NNS are/VBP used/VBN concomitantly/RB ,/, the/DT patient/NN should/MD be/VB observed/VBN closely/RB to/TO determine/VB if/IN the/DT desired/JJ effect/NN of/IN the/DT diuretic/NN is/VBZ obtained/VBN ./.

(ROOT (S1 (S (S (NP (-LRB- -LRB-) (NN Indomethacin) (-RRB- -RRB-) (NNS diuretics)) (VP (VBP are) (VP (VBN used) (ADVP (RB concomitantly))) (, ,) (S (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (NP (DT the) (JJ desired) (NN effect)) (PP (IN of) (NP (DT the) (NN diuretic)))) (VP (VBZ is) (VP (VBN obtained)))))))))))))) (. .))))

Sentence Id: DrugDDI.d83.s26
INDOCIN/NN reduces/VBZ basal/JJ plasma/NN renin/NN activity/NN (/-LRB- PRA/NN )/-RRB- ,/, as/RB well/RB as/IN those/DT elevations/NNS of/IN PRA/NN induced/VBN by/IN furosemide/NN administration/NN ,/, or/CC salt/NN or/CC volume/NN depletion/NN ./.

(ROOT (S1 (S (S (NP (NN INDOCIN)) (VP (VBZ reduces) (NP (NP (NP (JJ basal) (NN plasma) (NN renin) (NN activity)) (PRN (-LRB- -LRB-) (NP (NN PRA)) (-RRB- -RRB-))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT those) (NNS elevations)) (PP (IN of) (NP (NP (NN PRA)) (VP (VBN induced) (PP (IN by) (NP (NP (NN furosemide) (NN administration)) (, ,) (CC or) (NP (NN salt)) (CC or) (NP (NN volume) (NN depletion))))))))))) (. .))))

Sentence Id: DrugDDI.d83.s28
It/PRP has/VBZ been/VBN reported/VBN that/IN the/DT addition/NN of/IN triamterene/NN to/TO a/DT maintenance/NN schedule/NN of/IN INDOCIN/NN resulted/VBD in/IN reversible/JJ acute/JJ renal/JJ failure/NN in/IN two/CD of/IN four/CD healthy/JJ volunteers/NNS ./.

(ROOT (S1 (S (S (NP (PRP It)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (SBAR (IN that) (S (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NN triamterene))) (PP (TO to) (NP (NP (DT a) (NN maintenance) (NN schedule)) (PP (IN of) (NP (NN INDOCIN)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ reversible) (JJ acute) (JJ renal) (NN failure)) (PP (IN in) (NP (NP (CD two)) (PP (IN of) (NP (CD four) (JJ healthy) (NNS volunteers)))))))))))))) (. .))))

Sentence Id: DrugDDI.d83.s29
INDOCIN/NN and/CC triamterene/NN should/MD not/RB be/VB administered/VBN together/RB ./.

(ROOT (S1 (S (S (NP (NP (NN INDOCIN)) (CC and) (NP (NN triamterene))) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (ADVP (RB together)))))) (. .))))

Sentence Id: DrugDDI.d83.s30
INDOCIN/NN and/CC potassium-sparing/JJ diuretics/NNS each/DT may/MD be/VB associated/VBN with/IN increased/VBN serum/NN potassium/NN levels/NNS ./.

(ROOT (S1 (S (S (NP (NP (NN INDOCIN)) (CC and) (NP (NP (JJ potassium-sparing) (NNS diuretics)) (NP (DT each)))) (VP (MD may) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (VBN increased) (NN serum) (NN potassium) (NNS levels))))))) (. .))))

Sentence Id: DrugDDI.d83.s31
The/DT potential/JJ effects/NNS of/IN INDOCIN/JJ and/CC potassium-sparing/JJ diuretics/NNS on/IN potassium/NN kinetics/NNS and/CC renal/JJ function/NN should/MD be/VB considered/VBN when/WRB these/DT agents/NNS are/VBP administered/VBN concurrently/RB ./.

(ROOT (S1 (S (S (NP (NP (DT The) (JJ potential) (NNS effects)) (PP (IN of) (NP (ADJP (ADJP (JJ INDOCIN)) (CC and) (ADJP (JJ potassium-sparing))) (NNS diuretics))) (PP (IN on) (NP (NP (NN potassium) (NNS kinetics)) (CC and) (NP (JJ renal) (NN function))))) (VP (MD should) (VP (VB be) (VP (VBN considered) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (NNS agents)) (VP (VBP are) (VP (VBN administered) (ADVP (RB concurrently)))))))))) (. .))))

Sentence Id: DrugDDI.d83.s32
Most/JJS of/IN the/DT above/JJ effects/NNS concerning/VBG diuretics/NNS have/VBP been/VBN attributed/VBN ,/, at/IN least/JJS in/IN part/NN ,/, to/TO mechanisms/NNS involving/VBG inhibition/NN of/IN prostaglandin/NN synthesis/NN by/IN INDOCIN/NN ./.

(ROOT (S1 (S (S (NP (NP (JJS Most)) (PP (IN of) (NP (NP (DT the) (JJ above) (NNS effects)) (VP (VBG concerning) (NP (NNS diuretics)))))) (VP (VBP have) (VP (VBN been) (VP (VBN attributed) (, ,) (PP (ADVP (IN at) (JJS least)) (IN in) (NP (NN part))) (, ,) (PP (TO to) (NP (NP (NNS mechanisms)) (VP (VBG involving) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN prostaglandin) (NN synthesis))) (PP (IN by) (NP (NN INDOCIN))))))))))) (. .))))

Sentence Id: DrugDDI.d83.s33
Blunting/NN of/IN the/DT antihypertensive/JJ effect/NN of/IN beta-adrenoceptor/NN blocking/NN agent/NN s/NNS by/IN non-steroidal/JJ antiinflammatory/JJ drugs/NNS including/VBG INDOCIN/NN has/VBZ been/VBN reported/VBN ./.

(ROOT (S1 (S (S (NP (NP (NN Blunting)) (PP (IN of) (NP (NP (DT the) (JJ antihypertensive) (NN effect)) (PP (IN of) (NP (NN beta-adrenoceptor) (NN blocking) (NN agent) (NNS s))))) (PP (IN by) (NP (NP (JJ non-steroidal) (JJ antiinflammatory) (NNS drugs)) (PP (VBG including) (NP (NN INDOCIN)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported))))) (. .))))

Sentence Id: DrugDDI.d83.s35
INDOCIN/NN can/MD reduce/VB the/DT antihypertensive/JJ effects/NNS of/IN captopril/NN and/CC losartan/NN ./.

(ROOT (S1 (S (S (NP (NN INDOCIN)) (VP (MD can) (VP (VB reduce) (NP (NP (DT the) (JJ antihypertensive) (NNS effects)) (PP (IN of) (NP (NP (NN captopril)) (CC and) (NP (NN losartan)))))))) (. .))))

Sentence Id: DrugDDI.d83.s36
False-negative/JJ results/NNS in/IN the/DT dexamethasone/NN suppression/NN test/NN (/-LRB- DST/NN )/-RRB- in/IN patients/NNS being/VBG treated/VBN with/IN INDOCIN/NN have/VBP been/VBN reported/VBN ./.

(ROOT (S1 (S (S (NP (NP (JJ False-negative) (NNS results)) (PP (IN in) (NP (NP (NP (DT the) (NN dexamethasone) (NN suppression) (NN test)) (PRN (-LRB- -LRB-) (NP (NN DST)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (NN INDOCIN)))))))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported))))) (. .))))

Sentence Id: DrugDDI.d395.s0
A/DT number/NN of/IN substances/NNS affect/VBP glucose/NN metabolism/NN and/CC may/MD require/VBP insulin/NN dose/NN adjustment/NN and/CC particularly/RB close/JJ monitoring/NN ./.

(ROOT (S1 (S (S (NP (NP (DT A) (NN number)) (PP (IN of) (NP (NNS substances)))) (VP (VP (VBP affect) (NP (NN glucose) (NN metabolism))) (CC and) (VP (MD may) (VP (VBP require) (NP (NP (NN insulin) (NN dose) (NN adjustment)) (CC and) (ADVP (RB particularly)) (NP (JJ close) (NN monitoring))))))) (. .))))

Sentence Id: DrugDDI.d395.s1
@/NN @/NN @/NN The/DT following/NN are/VBP examples/NNS of/IN substances/NNS that/WDT may/MD increase/VB the/DT blood-glucose-lowering/JJ effect/NN and/CC susceptibility/NN to/TO hypoglycemia/NN :/: oral/JJ antidiabetic/JJ products/NNS ,/, ACE/NN inhibitors/NNS ,/, disopyramide/NN ,/, fibrates/NNS ,/, fluoxetine/NN ,/, monoamine/NN oxidase/NN (/-LRB- MAO/NN )/-RRB- inhibitors/NNS ,/, propoxyphene/NN ,/, salicylates/NNS ,/, somatostatin/NN analog/NN (/-LRB- e.g./FW ,/, octreotide/NN )/-RRB- ,/, sulfonamide/NN antibiotics/NNS ./.

(ROOT (S1 (S (S (NP (NN @) (NN @) (NN @) (NP (DT The) (NN following))) (VP (VBP are) (NP (NP (NP (NNS examples)) (PP (IN of) (NP (NP (NNS substances)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB increase) (NP (NP (DT the) (JJ blood-glucose-lowering) (NN effect)) (CC and) (NP (NP (NN susceptibility)) (PP (TO to) (NP (NN hypoglycemia)))))))))))) (: :) (NP (NP (JJ oral) (JJ antidiabetic) (NNS products)) (, ,) (NP (NN ACE) (NNS inhibitors)) (, ,) (NP (NN disopyramide)) (, ,) (NP (NNS fibrates)) (, ,) (NP (NN fluoxetine)) (, ,) (NP (NN monoamine) (NN oxidase) (-LRB- -LRB-) (NN MAO) (-RRB- -RRB-) (NNS inhibitors)) (, ,) (NP (NN propoxyphene)) (, ,) (NP (NNS salicylates)) (, ,) (NP (NN somatostatin) (NN analog)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN octreotide))) (-RRB- -RRB-)) (, ,) (NP (NN sulfonamide) (NNS antibiotics)))))) (. .))))

Sentence Id: DrugDDI.d395.s2
@/NN @/NN @/NN The/DT following/VBG are/VBP examples/NNS of/IN substances/NNS that/WDT may/MD reduce/VB the/DT blood-glucose-lowering/JJ effect/NN :/: corticosteroids/NNS ,/, niacin/NN ,/, danazol/NN ,/, diuretics/NN ,/, sympathomimetic/JJ agents/NNS (/-LRB- e.g./FW ,/, epinephrine/NN ,/, salbutamol/NN ,/, terbutaline/NN )/-RRB- ,/, isoniazid/NN ,/, phenothiazine/JJ derivatives/NNS ,/, somatropin/NN ,/, thyroid/NN hormones/NNS ,/, estrogens/NNS ,/, progestogens/NNS (/-LRB- e.g./FW ,/, in/IN oral/JJ contraceptives/NNS )/-RRB- ./.

(ROOT (S1 (S (S (NP (NP (NN @) (NN @) (NN @)) (NP (DT The) (VBG following))) (VP (VBP are) (NP (NP (NP (NNS examples)) (PP (IN of) (NP (NNS substances))) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB reduce) (NP (DT the) (JJ blood-glucose-lowering) (NN effect))))))) (: :) (NP (NP (NNS corticosteroids)) (, ,) (NP (NN niacin)) (, ,) (NP (NN danazol)) (, ,) (NP (NN diuretics)) (, ,) (NP (NP (JJ sympathomimetic) (NNS agents)) (PRN (-LRB- -LRB-) (NP (FW e.g.) (, ,) (NP (NN epinephrine)) (, ,) (NP (NN salbutamol)) (, ,) (NP (NN terbutaline))) (-RRB- -RRB-))) (, ,) (NP (NN isoniazid)) (, ,) (NP (JJ phenothiazine) (NNS derivatives)) (, ,) (NP (NN somatropin)) (, ,) (NP (NN thyroid) (NNS hormones)) (, ,) (NP (NNS estrogens)) (, ,) (NP (NNS progestogens)))) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (PP (IN in) (NP (JJ oral) (NNS contraceptives))) (-RRB- -RRB-)))) (. .))))

Sentence Id: DrugDDI.d395.s3
@/NN @/NN @/NN Beta-blockers/NN ,/, clonidine/NN ,/, lithium/NN salt/NN s/NN ,/, and/CC alcohol/NN may/MD either/CC potentiate/VB or/CC weaken/VB the/DT blood-glucose-lowering/JJ effect/NN of/IN insulin/NN ./.

(ROOT (S1 (S (S (NP (NP (NN @) (NN @) (NN @) (NN Beta-blockers)) (, ,) (NP (NN clonidine)) (, ,) (NP (NN lithium) (NN salt) (NN s)) (, ,) (CC and) (NP (NN alcohol))) (VP (MD may) (VP (CC either) (VP (VB potentiate)) (CC or) (VP (VB weaken) (NP (NP (DT the) (JJ blood-glucose-lowering) (NN effect)) (PP (IN of) (NP (NN insulin)))))))) (. .))))

Sentence Id: DrugDDI.d395.s4
Pentamidine/NN may/MD cause/VB hypoglycemia/NN ,/, which/WDT may/MD sometimes/RB be/VB followed/VBN by/IN hyperglycemia/NN ./.

(ROOT (S1 (S (S (NP (NN Pentamidine)) (VP (MD may) (VP (VB cause) (NP (NP (NN hypoglycemia)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (ADVP (RB sometimes)) (VP (VB be) (VP (VBN followed) (PP (IN by) (NP (NN hyperglycemia)))))))))))) (. .))))

Sentence Id: DrugDDI.d395.s5
@/NN @/NN @/NN :/: In/IN addition/NN ,/, under/IN the/DT influence/NN of/IN sympatholytic/JJ medicinal/NN products/NNS such/JJ as/IN beta-blockers/NN ,/, clonidine/NN ,/, guanethidine/NN ,/, and/CC reserpine/NN ,/, the/DT signs/NNS of/IN hypoglycemia/NN may/MD be/VB reduced/VBN or/CC absent/JJ ./.

(ROOT (S1 (S (NP (NP (NN @) (NN @) (NN @)) (: :) (S (PP (IN In) (NP (NN addition))) (, ,) (PP (IN under) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NP (JJ sympatholytic) (NN medicinal) (NNS products)) (PP (JJ such) (IN as) (NP (NP (NN beta-blockers)) (, ,) (NP (NN clonidine)) (, ,) (NP (NN guanethidine)) (, ,) (CC and) (NP (NN reserpine)))))))) (, ,) (NP (NP (DT the) (NNS signs)) (PP (IN of) (NP (NN hypoglycemia)))) (VP (MD may) (VP (VB be) (VP (VBN reduced) (UCP (CC or) (ADJP (JJ absent))))))) (. .)))))

Sentence Id: DrugDDI.d395.s6
Mixing/NN of/IN Insulins/NNS ./.

(ROOT (S1 (S (NP (NP (NN Mixing)) (PP (IN of) (NP (NNS Insulins))) (. .)))))

Sentence Id: DrugDDI.d395.s7
@/NN @/NN @/NN :/: A/DT clinical/JJ study/NN in/IN healthy/JJ male/JJ volunteers/NNS (/-LRB- n=24/NN )/-RRB- demonstrated/VBD that/IN mixing/NN NovoLog/NN with/IN NPH/NN human/JJ insulin/NN immediately/RB before/IN injection/NN produced/VBD some/DT attenuation/NN in/IN the/DT peak/JJ concentration/NN of/IN NovoLog/NN ,/, but/CC that/IN the/DT time/NN to/TO peak/NN and/CC the/DT total/JJ bioavailability/NN of/IN NovoLog/NN were/VBD not/RB significantly/RB affected/VBN ./.

(ROOT (S1 (S (NP (NP (NN @) (NN @) (NN @)) (: :) (S (NP (NP (DT A) (JJ clinical) (NN study)) (PP (IN in) (NP (NP (JJ healthy) (JJ male) (NNS volunteers)) (PRN (-LRB- -LRB-) (NP (NN n=24)) (-RRB- -RRB-))))) (VP (VBD demonstrated) (SBAR (SBAR (IN that) (S (NP (NP (NN mixing) (NN NovoLog)) (PP (IN with) (NP (NN NPH) (JJ human) (NN insulin))) (PP (ADVP (RB immediately)) (IN before) (NP (NN injection)))) (VP (VBD produced) (NP (DT some) (NN attenuation)) (PP (IN in) (NP (NP (DT the) (JJ peak) (NN concentration)) (PP (IN of) (NP (NN NovoLog)))))))) (, ,) (CC but) (SBAR (IN that) (S (NP (NP (NP (DT the) (NN time)) (PP (TO to) (NP (NN peak)))) (CC and) (NP (NP (DT the) (JJ total) (NN bioavailability)) (PP (IN of) (NP (NN NovoLog))))) (VP (VBD were) (RB not) (ADVP (RB significantly)) (VP (VBN affected)))))))) (. .)))))

Sentence Id: DrugDDI.d395.s8
If/IN NovoLog/NN is/VBZ mixed/VBN with/IN NPH/NN human/JJ insulin/NN ,/, NovoLog/NN should/MD be/VB drawn/VBN into/IN the/DT syringe/NN first/JJ ./.

(ROOT (S1 (S (S (SBAR (IN If) (S (NP (NN NovoLog)) (VP (VBZ is) (VP (VBN mixed) (PP (IN with) (NP (NN NPH) (JJ human) (NN insulin))))))) (, ,) (NP (NN NovoLog)) (VP (MD should) (VP (VB be) (VP (VBN drawn) (PP (IN into) (NP (DT the) (NN syringe) (JJ first))))))) (. .))))

Sentence Id: DrugDDI.d395.s10
Because/IN there/EX are/VBP no/DT data/NNS on/IN the/DT compatibility/NN of/IN NovoLog/NN and/CC crystalline/JJ zinc/NN insulin/NN preparation/NN s/NNS ,/, NovoLog/NN should/MD not/RB be/VB mixed/VBN with/IN these/DT preparations/NNS ./.

(ROOT (S1 (S (S (SBAR (IN Because) (S (NP (EX there)) (VP (VBP are) (NP (NP (DT no) (NNS data)) (PP (IN on) (NP (NP (DT the) (NN compatibility)) (PP (IN of) (NP (NP (NP (NN NovoLog)) (CC and) (NP (JJ crystalline) (NN zinc) (NN insulin) (NN preparation))) (NNS s))))))))) (, ,) (NP (NN NovoLog)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN mixed) (PP (IN with) (NP (DT these) (NNS preparations))))))) (. .))))

Sentence Id: DrugDDI.d395.s11
@/NN @/NN @/NN :/: The/DT effects/NNS of/IN mixing/JJ NovoLog/NN with/IN insulins/NNS of/IN animal/NN source/NN or/CC insulin/NN preparations/NNS produced/VBN by/IN other/JJ manufacturers/NNS have/VBP not/RB been/VBN studied/VBN ./.

(ROOT (S1 (S (NP (NP (NN @) (NN @) (NN @)) (: :) (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (JJ mixing) (NN NovoLog)) (PP (IN with) (NP (NP (NNS insulins)) (PP (IN of) (NP (NP (NN animal) (NN source) (CC or) (NN insulin) (NNS preparations)) (VP (VBN produced) (PP (IN by) (NP (JJ other) (NNS manufacturers))))))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))))

Sentence Id: DrugDDI.d395.s13
@/NN @/NN @/NN :/: When/WRB used/VBN in/IN external/JJ subcutaneous/JJ infusion/NN pumps/VBZ for/IN insulin/NN ,/, NovoLog/NN should/MD not/RB be/VB mixed/VBN with/IN any/DT other/JJ insulins/NNS or/CC diluent/NN ./.

(ROOT (S1 (S (NP (NP (NN @) (NN @) (NN @)) (: :) (S (SBAR (WHADVP (WRB When)) (S (VP (VBN used) (PP (IN in) (NP (NP (JJ external) (JJ subcutaneous) (NN infusion) (VBZ pumps)) (PP (IN for) (NP (NN insulin)))))))) (, ,) (NP (NN NovoLog)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN mixed) (PP (IN with) (NP (NP (DT any) (JJ other) (NNS insulins)) (CC or) (NP (NN diluent)))))))) (. .)))))

Sentence Id: DrugDDI.d396.s0
No/DT significant/JJ drug/NN -drug/NN pharmacokinetic/JJ (/-LRB- or/CC pharmacodynamic/JJ )/-RRB- interactions/NNS have/VBP been/VBN found/VBN in/IN interaction/NN studies/NNS with/IN hydrochlorothiazide/NN ,/, digoxin/NN ,/, warfarin/NN ,/, and/CC nifedipine/NN ./.

(ROOT (S1 (S (S (NP (DT No) (JJ significant) (NN drug) (NN -drug) (ADJP (ADJP (JJ pharmacokinetic)) (-LRB- -LRB-) (CC or) (ADJP (JJ pharmacodynamic)) (-RRB- -RRB-)) (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN found) (PP (IN in) (NP (NP (NN interaction) (NNS studies)) (PP (IN with) (NP (NP (NN hydrochlorothiazide)) (, ,) (NP (NN digoxin)) (, ,) (NP (NN warfarin)) (, ,) (CC and) (NP (NN nifedipine)))))))))) (. .))))

Sentence Id: DrugDDI.d396.s1
In/FW vitro/FW studies/NNS show/VBP significant/JJ inhibition/NN of/IN the/DT formation/NN of/IN oxidized/VBN irbesartan/NN metabolites/NNS with/IN the/DT known/JJ cytochrome/NN CYP/NN 2C9/NN substrates/inhibitors/NN sulphenazole/NN ,/, tolbutamide/NN and/CC nifedipine/NN ./.

(ROOT (S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP show) (NP (NP (JJ significant) (NN inhibition)) (PP (IN of) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (NP (VBN oxidized) (NN irbesartan) (NNS metabolites)) (PP (IN with) (NP (NP (DT the) (JJ known) (NN cytochrome) (NN CYP) (NN 2C9) (NN substrates/inhibitors) (NN sulphenazole)) (, ,) (NP (NN tolbutamide)) (CC and) (NP (NN nifedipine))))))))))) (. .))))

Sentence Id: DrugDDI.d396.s2
However/RB ,/, in/IN clinical/JJ studies/NNS the/DT consequences/NNS of/IN concomitant/JJ irbesartan/NN on/IN the/DT pharmacodynamics/NNS of/IN warfarin/NN were/VBD negligible/JJ ./.

(ROOT (S1 (S (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (JJ clinical) (NNS studies))) (NP (NP (DT the) (NNS consequences)) (PP (IN of) (NP (JJ concomitant) (NN irbesartan))) (PP (IN on) (NP (NP (DT the) (NNS pharmacodynamics)) (PP (IN of) (NP (NN warfarin)))))) (VP (VBD were) (ADJP (JJ negligible)))) (. .))))

Sentence Id: DrugDDI.d396.s3
Based/VBN on/IN in/FW vitro/FW data/NNS ,/, no/DT interaction/NN would/MD be/VB expected/VBN with/IN drugs/NNS whose/WP$ metabolism/NN is/VBZ dependent/JJ upon/IN cytochrome/NN P450/NN isozymes/NNS 1A1/NN ,/, 1A2,2A6,2B6,2D6,2E1/NN ,/, or/CC 3A4/NN ./.

(ROOT (S1 (S (S (PP (VBN Based) (PP (IN on) (NP (ADJP (FW in) (FW vitro)) (NNS data)))) (, ,) (NP (DT no) (NN interaction)) (VP (MD would) (VP (VB be) (VP (VBN expected) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WP$ whose) (NN metabolism)) (S (VP (VBZ is) (ADJP (JJ dependent) (PP (IN upon) (NP (NP (NN cytochrome) (NN P450) (NNS isozymes) (NN 1A1)) (, ,) (NP (NN 1A2,2A6,2B6,2D6,2E1)) (, ,) (CC or) (NP (NN 3A4)))))))))))))) (. .))))

Sentence Id: DrugDDI.d396.s4
In/IN separate/JJ studies/NNS of/IN patients/NNS receiving/VBG maintenance/NN doses/NNS of/IN warfarin/NN ,/, hydrochlorothiazide/NN ,/, or/CC digoxin/NN ,/, irbesartan/NN administration/NN for/IN 7/CD days/NNS had/VBD no/DT effect/NN on/IN the/DT pharmacodynamics/NNS of/IN warfarin/NN (/-LRB- prothrombin/NN time/NN )/-RRB- or/CC pharmacokinetics/NNS of/IN digoxin/NN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (NP (JJ separate) (NNS studies)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN maintenance) (NNS doses)) (PP (IN of) (NP (NP (NN warfarin)) (, ,) (NP (NN hydrochlorothiazide)) (, ,) (CC or) (NP (NN digoxin)))))))))) (, ,) (NP (NP (NN irbesartan) (NN administration)) (PP (IN for) (NP (CD 7) (NNS days)))) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NP (NP (DT the) (NNS pharmacodynamics)) (PP (IN of) (NP (NN warfarin))) (PRN (-LRB- -LRB-) (NP (NN prothrombin) (NN time)) (-RRB- -RRB-))) (CC or) (NP (NNS pharmacokinetics))) (PP (IN of) (NP (NN digoxin))))))) (. .))))

Sentence Id: DrugDDI.d396.s5
The/DT pharmacokinetics/NNS of/IN irbesartan/NN were/VBD not/RB affected/VBN by/IN coadministration/NN of/IN nifedipine/NN or/CC hydrochlorothiazide/NN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NNS pharmacokinetics)) (PP (IN of) (NP (NN irbesartan)))) (VP (VBD were) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NN nifedipine)) (CC or) (NP (NN hydrochlorothiazide))))))))) (. .))))

Sentence Id: DrugDDI.d177.s0
The/DT adverse/JJ effects/NNS of/IN CAMPTOSAR/NN ,/, such/JJ as/IN myelosuppression/NN and/CC diarrhea/NN ,/, would/MD be/VB expected/VBN to/TO be/VB exacerbated/JJ by/IN other/JJ antineoplastic/JJ agents/NNS having/VBG similar/JJ adverse/JJ effects/NNS ./.

(ROOT (S1 (S (S (NP (NP (DT The) (JJ adverse) (NNS effects)) (PP (IN of) (NP (NN CAMPTOSAR))) (, ,) (ADJP (JJ such) (PP (IN as) (NP (NP (NN myelosuppression)) (CC and) (NP (NN diarrhea))))) (, ,)) (VP (MD would) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB be) (ADJP (JJ exacerbated) (PP (IN by) (NP (NP (JJ other) (JJ antineoplastic) (NNS agents)) (VP (VBG having) (NP (JJ similar) (JJ adverse) (NNS effects))))))))))))) (. .))))

Sentence Id: DrugDDI.d177.s1
Patients/NNS who/WP have/VBP previously/RB received/VBN pelvic//NN abdominal/JJ irradiation/NN are/VBP at/IN increased/VBN risk/NN of/IN severe/JJ myelosuppression/NN following/VBG the/DT administration/NN of/IN CAMPTOSAR/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBP have) (ADVP (RB previously)) (VP (VBN received) (NP (NN pelvic/) (JJ abdominal) (NN irradiation))))))) (VP (VBP are) (PP (IN at) (NP (NP (VBN increased) (NN risk)) (PP (IN of) (NP (JJ severe) (NN myelosuppression))))) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NN CAMPTOSAR))))))) (. .))))

Sentence Id: DrugDDI.d177.s2
The/DT concurrent/JJ administration/NN of/IN CAMPTOSAR/NN with/IN irradiation/NN has/VBZ not/RB been/VBN adequately/RB studied/VBN and/CC is/VBZ not/RB recommended/VBN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (JJ concurrent) (NN administration)) (PP (IN of) (NP (NN CAMPTOSAR))) (PP (IN with) (NP (NN irradiation)))) (VP (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB adequately)) (VP (VBN studied)))) (CC and) (VP (VBZ is) (RB not) (VP (VBN recommended))))) (. .))))

Sentence Id: DrugDDI.d177.s3
Lymphocytopenia/NN has/VBZ been/VBN reported/VBN in/IN patients/NNS receiving/VBG CAMPTOSAR/NN ,/, and/CC it/PRP is/VBZ possible/JJ that/IN the/DT administration/NN of/IN dexamethasone/NN as/IN antiemetic/JJ prophylaxis/NNS may/MD have/VB enhanced/VBD the/DT likelihood/NN of/IN this/DT effect/NN ./.

(ROOT (S1 (S (S (S (NP (NN Lymphocytopenia)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN CAMPTOSAR))))))))) (, ,) (CC and) (S (NP (PRP it)) (VP (VBZ is) (ADJP (JJ possible)) (SBAR (IN that) (S (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (NN dexamethasone)) (PP (IN as) (NP (JJ antiemetic) (NNS prophylaxis)))))) (VP (MD may) (VP (VB have) (VP (VBD enhanced) (NP (NP (DT the) (NN likelihood)) (PP (IN of) (NP (DT this) (NN effect)))))))))))) (. .))))

Sentence Id: DrugDDI.d177.s5
Hyperglycemia/NN has/VBZ also/RB been/VBN reported/VBN in/IN patients/NNS receiving/VBG CAMPTOSAR/NN ./.

(ROOT (S1 (S (S (NP (NN Hyperglycemia)) (VP (VBZ has) (ADVP (RB also)) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN CAMPTOSAR))))))))) (. .))))

Sentence Id: DrugDDI.d177.s6
Usually/RB ,/, this/DT has/VBZ been/VBN observed/VBN in/IN patients/NNS with/IN a/DT history/NN of/IN diabetes/NN mellitus/NN or/CC evidence/NN of/IN glucose/NN intolerance/NN prior/JJ to/TO administration/NN of/IN CAMPTOSAR/NN ./.

(ROOT (S1 (S (S (ADVP (RB Usually)) (, ,) (NP (DT this)) (VP (VBZ has) (VP (VBN been) (VP (VBN observed) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NN diabetes) (NN mellitus)))) (CC or) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (NN glucose) (NN intolerance)) (ADJP (JJ prior) (PP (TO to) (NP (NP (NN administration)) (PP (IN of) (NP (NN CAMPTOSAR))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d177.s7
It/PRP is/VBZ probable/JJ that/IN dexamethasone/NN ,/, given/VBN as/IN antiemetic/NN prophylaxis/NN ,/, contributed/VBD to/TO hyperglycemia/NN in/IN some/DT patients/NNS ./.

(ROOT (S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ probable)) (SBAR (IN that) (S (NP (NP (NN dexamethasone)) (, ,) (VP (VBN given) (PP (IN as) (NP (NN antiemetic) (NN prophylaxis)))) (, ,)) (VP (VBD contributed) (PP (TO to) (NP (NP (NN hyperglycemia)) (PP (IN in) (NP (DT some) (NNS patients)))))))))) (. .))))

Sentence Id: DrugDDI.d177.s8
The/DT incidence/NN of/IN akathisia/NN in/IN clinical/JJ trials/NNS of/IN the/DT weekly/JJ dosage/NN schedule/NN was/VBD greater/JJR (/-LRB- 8.5/CD %/NN ,/, 4/47/CD patients/NNS )/-RRB- when/WRB prochlorperazine/NN was/VBD administered/VBN on/IN the/DT same/JJ day/NN as/IN CAMPTOSAR/NN than/IN when/WRB these/DT drugs/NNS were/VBD given/VBN on/IN separate/JJ days/NNS (/-LRB- 1.3/CD %/NN ,/, 1/80/NN patients/NNS )./CD

(ROOT (S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NN akathisia))) (PP (IN in) (NP (NP (JJ clinical) (NNS trials)) (PP (IN of) (NP (DT the) (JJ weekly) (NN dosage) (NN schedule)))))) (VP (VBD was) (ADJP (ADJP (JJR greater) (PRN (-LRB- -LRB-) (NP (NP (CD 8.5) (NN %)) (, ,) (NP (CD 4/47) (NNS patients))) (-RRB- -RRB-))) (SBAR (WHADVP (WRB when)) (S (NP (NN prochlorperazine)) (VP (VBD was) (VP (VBN administered) (PP (IN on) (NP (DT the) (JJ same) (NN day))) (PP (IN as) (NP (NN CAMPTOSAR))))))) (PP (IN than) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (NNS drugs)) (VP (VBD were) (VP (VBN given) (PP (IN on) (NP (NP (JJ separate) (NNS days)) (PRN (-LRB- -LRB-) (NP (CD 1.3) (NN %)) (, ,) (NP (NN 1/80) (NNS patients) (CD -RRB-.)))))))))))))))

Sentence Id: DrugDDI.d177.s9
The/DT 8.5/CD %/NN incidence/NN of/IN akathisia/NN ,/, however/RB ,/, is/VBZ within/IN the/DT range/NN reported/VBN for/IN use/NN of/IN prochlorperazine/NN when/WRB given/VBN as/IN a/DT premedication/NN for/IN other/JJ chemotherapies/NNS ./.

(ROOT (S1 (S (S (NP (NP (DT The) (ADJP (CD 8.5) (NN %)) (NN incidence)) (PP (IN of) (NP (NN akathisia)))) (, ,) (ADVP (RB however)) (, ,) (VP (VBZ is) (PP (IN within) (NP (NP (DT the) (NN range)) (VP (VBN reported) (PP (IN for) (NP (NP (NN use)) (PP (IN of) (NP (NN prochlorperazine)))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN as) (NP (NP (DT a) (NN premedication)) (PP (IN for) (NP (JJ other) (NNS chemotherapies)))))))))) (. .))))

Sentence Id: DrugDDI.d177.s10
It/PRP would/MD be/VB expected/VBN that/IN laxative/JJ use/NN during/IN therapy/NN with/IN CAMPTOSAR/NN would/MD worsen/VB the/DT incidence/NN or/CC severity/NN of/IN diarrhea/NN ,/, but/CC this/DT has/VBZ not/RB been/VBN studied/VBN ./.

(ROOT (S1 (S (S (NP (PRP It)) (VP (MD would) (VP (VB be) (VP (VBN expected) (SBAR (IN that) (S (S (NP (NP (JJ laxative) (NN use)) (PP (IN during) (NP (NN therapy))) (PP (IN with) (NP (NN CAMPTOSAR)))) (VP (MD would) (VP (VB worsen) (NP (NP (DT the) (NP (NN incidence)) (CC or) (NP (NN severity))) (PP (IN of) (NP (NN diarrhea))))))) (, ,) (CC but) (S (NP (DT this)) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))))))))) (. .))))

Sentence Id: DrugDDI.d177.s11
In/IN view/NN of/IN the/DT potential/JJ risk/NN of/IN dehydration/NN secondary/JJ to/TO vomiting/NN and/or/CC diarrhea/NN induced/VBN by/IN CAMPTOSAR/NN ,/, the/DT physician/NN may/MD wish/VB to/TO withhold/JJ diuretics/NNS during/IN dosing/NN with/IN CAMPTOSAR/NN and/CC ,/, certainly/RB ,/, during/IN periods/NNS of/IN active/JJ vomiting/NN or/CC diarrhea/NN ./.

(ROOT (S1 (S (PP (IN In) (NP (NP (NN view)) (PP (IN of) (NP (NP (DT the) (JJ potential) (NN risk)) (PP (IN of) (NP (NP (NN dehydration)) (ADJP (JJ secondary) (PP (TO to) (NP (NP (NP (NN vomiting)) (CC and/or) (NP (NN diarrhea))) (VP (VBN induced) (PP (IN by) (NP (NN CAMPTOSAR))))))))))))) (, ,) (NP (DT the) (NN physician)) (VP (MD may) (VP (VP (VB wish) (PP (TO to) (NP (JJ withhold) (NNS diuretics))) (PP (IN during) (NP (NP (NN dosing)) (PP (IN with) (NP (NN CAMPTOSAR)))))) (CC and) (, ,) (ADVP (RB certainly)) (, ,) (PP (IN during) (NP (NP (NNS periods)) (PP (IN of) (NP (JJ active) (NP (NN vomiting)) (CC or) (NP (NN diarrhea)))))))) (. .))))

Sentence Id: DrugDDI.d177.s12
Drug-Laboratory/JJ Test/NN Interactions/NNS :/: There/EX are/VBP no/DT known/JJ interactions/NNS between/IN CAMPTOSAR/NN and/CC laboratory/NN tests/NNS ./.

(ROOT (S1 (S (S (NP (JJ Drug-Laboratory) (NN Test) (NNS Interactions)) (: :) (NP (EX There)) (VP (VBP are) (NP (NP (DT no) (JJ known) (NNS interactions)) (PP (IN between) (NP (NP (NN CAMPTOSAR)) (CC and) (NP (NN laboratory) (NNS tests))))))) (. .))))

Sentence Id: DrugDDI.d171.s0
Isoflurane/NN potentiates/VBZ the/DT muscle/NN relaxant/JJ effect/NN of/IN all/DT muscle/NN relaxants/NNS ,/, most/RBS notably/RB nondepolarizing/VBG muscle/NN relaxants/NNS ,/, and/CC MAC/NN (/-LRB- minimum/JJ alveolar/JJ concentration/NN )/-RRB- is/VBZ reduced/VBN by/IN concomitant/JJ administration/NN of/IN N/NN span/NN class=/NN c13/NN 2O/NN ./.

(ROOT (S1 (S (S (S (NP (NN Isoflurane)) (VP (VBZ potentiates) (NP (NP (DT the) (NN muscle) (JJ relaxant) (NN effect)) (PP (IN of) (NP (DT all) (NN muscle) (NNS relaxants)))) (, ,) (S (ADVP (RBS most) (RB notably)) (VP (VBG nondepolarizing) (NP (NN muscle) (NNS relaxants)))))) (, ,) (CC and) (S (NP (NP (NN MAC)) (PRN (-LRB- -LRB-) (NP (JJ minimum) (JJ alveolar) (NN concentration)) (-RRB- -RRB-))) (VP (VBZ is) (VP (VBN reduced) (PP (IN by) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN N) (NN span) (NN class=) (NN c13) (NN 2O))))))))) (. .))))

Sentence Id: DrugDDI.d250.s0
The/DT vasodilating/JJ effects/NNS of/IN isosorbide/NN dinitrate/NN may/MD be/VB additive/JJ with/IN those/DT of/IN other/JJ vasodilators/NNS ./.

(ROOT (S1 (S (S (NP (NP (DT The) (JJ vasodilating) (NNS effects)) (PP (IN of) (NP (NN isosorbide) (NN dinitrate)))) (VP (MD may) (VP (VB be) (ADJP (JJ additive) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (JJ other) (NNS vasodilators))))))))) (. .))))

Sentence Id: DrugDDI.d250.s1
Alcohol/NN ,/, in/IN particular/JJ ,/, has/VBZ been/VBN found/VBN to/TO exhibit/VBP additive/JJ effects/NNS of/IN this/DT variety/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Alcohol)) (, ,) (PP (IN in) (NP (JJ particular))) (, ,)) (VP (VBZ has) (VP (VBN been) (VP (VBN found) (S (VP (TO to) (VP (VBP exhibit) (NP (NP (JJ additive) (NNS effects)) (PP (IN of) (NP (DT this) (NN variety))))))))))) (. .))))

Sentence Id: DrugDDI.d347.s0
The/DT following/JJ drug/NN interactions/NNS were/VBD studied/VBN with/IN ketoprofen/NN doses/NNS of/IN 200/CD mg/day/NN ./.

(ROOT (S1 (S (S (NP (DT The) (JJ following) (NN drug) (NNS interactions)) (VP (VBD were) (VP (VBN studied) (PP (IN with) (NP (NP (NN ketoprofen) (NNS doses)) (PP (IN of) (NP (CD 200) (NN mg/day)))))))) (. .))))

Sentence Id: DrugDDI.d347.s1
The/DT possibility/NN of/IN increased/VBN interaction/NN should/MD be/VB kept/VBN in/IN mind/NN when/WRB Orudis/NN doses/NNS greater/JJR than/IN 50/CD mg/NN as/IN a/DT single/JJ dose/NN or/CC 200/CD mg/NN of/IN ketoprofen/NN per/IN day/NN are/VBP used/VBN concomitantly/RB with/IN highly/RB bound/VBN drugs/NNS ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (NP (VBN increased) (NN interaction)))) (VP (MD should) (VP (VB be) (VP (VBN kept) (PP (IN in) (NP (NN mind))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN Orudis) (NNS doses)) (ADJP (JJR greater) (PP (IN than) (NP (NP (NP (CD 50) (NN mg)) (PP (IN as) (NP (DT a) (JJ single) (NN dose)))) (CC or) (NP (NP (CD 200) (NN mg)) (PP (IN of) (NP (NN ketoprofen))) (PP (IN per) (NP (NN day)))))))) (VP (VBP are) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (ADJP (RB highly) (VBN bound)) (NNS drugs))))))))))) (. .))))

Sentence Id: DrugDDI.d347.s3
Antacids/NNS :/: Concomitant/JJ administration/NN of/IN magnesium/NN hydroxide/NN and/CC aluminum/NN hydroxide/NN does/VBZ not/RB interfere/VB with/IN the/DT rate/NN or/CC extent/NN of/IN the/DT absorption/NN of/IN ketoprofen/NN administered/VBN as/IN Orudis/NN ./.

(ROOT (S1 (S (NP (NP (NNS Antacids)) (: :) (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN magnesium) (NN hydroxide)) (CC and) (NP (NN aluminum) (NN hydroxide))))) (VP (VBZ does) (RB not) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NP (NN rate)) (CC or) (NP (NN extent))) (PP (IN of) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NP (NN ketoprofen)) (VP (VBN administered) (PP (IN as) (NP (NN Orudis))))))))))))) (. .)))))

Sentence Id: DrugDDI.d347.s5
Aspirin/NN :/: Ketoprofen/NN does/VBZ not/RB alter/VB aspirin/NN absorption/NN ;/: ./.

(ROOT (S1 (S (S (NP (NN Aspirin) (: :) (NN Ketoprofen)) (VP (VBZ does) (RB not) (VP (VB alter) (NP (NN aspirin) (NN absorption)))) (: ;)) (. .))))

Sentence Id: DrugDDI.d347.s6
however/RB ,/, in/IN a/DT study/NN of/IN 12/CD normal/JJ subjects/NNS ,/, concurrent/JJ administration/NN of/IN aspirin/NN decreased/VBD ketoprofen/NN protein/NN binding/NN and/CC increased/VBN ketoprofen/NN plasma/NN clearance/NN from/IN 0.07/CD L/kg/h/NN without/IN aspirin/NN to/TO 0.11/NN L/kg/h/NN with/IN aspirin/NN ./.

(ROOT (S1 (S (ADVP (RB however)) (, ,) (PP (IN in) (NP (NP (DT a) (NN study)) (PP (IN of) (NP (CD 12) (JJ normal) (NNS subjects))))) (, ,) (NP (NP (JJ concurrent) (NN administration)) (PP (IN of) (NP (NN aspirin)))) (VP (VBD decreased) (NP (NP (NN ketoprofen) (NN protein) (NN binding)) (CC and) (NP (VBN increased) (NN ketoprofen) (NN plasma) (NN clearance))) (PP (IN from) (NP (CD 0.07) (NN L/kg/h))) (PP (IN without) (NP (NN aspirin))) (PP (TO to) (NP (NP (NN 0.11) (NN L/kg/h)) (PP (IN with) (NP (NN aspirin)))))) (. .))))

Sentence Id: DrugDDI.d347.s8
Therefore/RB ,/, concurrent/JJ use/NN of/IN aspirin/NN and/CC ketoprofen/NN is/VBZ not/RB recommended/VBN ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (JJ concurrent) (NN use)) (PP (IN of) (NP (NP (NN aspirin)) (CC and) (NP (NN ketoprofen))))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .))))

Sentence Id: DrugDDI.d347.s10
Diuretic/JJ :/: Hydrochlorothiazide/NN ,/, given/VBN concomitantly/RB with/IN ketoprofen/NN ,/, produces/VBZ a/DT reduction/NN in/IN urinary/JJ potassium/NN and/CC chloride/NN excretion/NN compared/VBN to/TO hydrochlorothiazide/NN alone/RB ./.

(ROOT (S1 (S (S (NP (JJ Diuretic) (: :) (NP (NN Hydrochlorothiazide)) (, ,) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN ketoprofen)))) (, ,)) (VP (VBZ produces) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (JJ urinary) (NN potassium) (CC and) (NN chloride) (NN excretion)))) (PP (VBN compared) (PP (TO to) (NP (NP (NN hydrochlorothiazide)) (ADVP (RB alone))))))) (. .))))

Sentence Id: DrugDDI.d347.s11
Patients/NNS taking/VBG diuretics/NNS are/VBP at/IN a/DT greater/JJR risk/NN of/IN developing/VBG renal/JJ failure/NN secondary/JJ to/TO a/DT decrease/NN in/IN renal/JJ blood/NN flow/NN caused/VBN by/IN prostaglandin/NN inhibition/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Patients)) (VP (VBG taking) (NP (NNS diuretics)))) (VP (VBP are) (PP (IN at) (NP (NP (DT a) (JJR greater) (NN risk)) (PP (IN of) (S (VP (VBG developing) (NP (NP (JJ renal) (NN failure)) (ADJP (JJ secondary) (PP (TO to) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (JJ renal) (NN blood) (NN flow)) (VP (VBN caused) (PP (IN by) (NP (NN prostaglandin) (NN inhibition))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d347.s13
Digoxin/NN :/: In/IN a/DT study/NN in/IN 12/CD patients/NNS with/IN congestive/JJ heart/NN failure/NN where/WRB ketoprofen/NN and/CC digoxin/NN were/VBD concomitantly/RB administered/VBN ,/, ketoprofen/NN did/VBD not/RB alter/VB the/DT serum/NN levels/NNS of/IN digoxin/NN ./.

(ROOT (S1 (S (NP (NP (NN Digoxin)) (: :) (S (PP (IN In) (NP (NP (DT a) (NN study)) (PP (IN in) (NP (NP (CD 12) (NNS patients)) (PP (IN with) (NP (NP (JJ congestive) (NN heart) (NN failure)) (SBAR (WHADVP (WRB where)) (S (NP (NP (NN ketoprofen)) (CC and) (NP (NN digoxin))) (VP (VBD were) (ADVP (RB concomitantly)) (VP (VBN administered))))))))))) (, ,) (NP (NN ketoprofen)) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (NN serum) (NNS levels)) (PP (IN of) (NP (NN digoxin))))))) (. .)))))

Sentence Id: DrugDDI.d347.s15
Warfarin/NN :/: In/IN a/DT short-term/JJ controlled/JJ study/NN in/IN 14/CD normal/JJ volunteers/NNS ,/, ketoprofen/NN did/VBD not/RB significantly/RB interfere/VB with/IN the/DT effect/NN of/IN warfarin/NN on/IN prothrombin/NN time/NN ./.

(ROOT (S1 (S (S (NP (NN Warfarin)) (: :) (PP (IN In) (NP (NP (DT a) (JJ short-term) (JJ controlled) (NN study)) (PP (IN in) (NP (CD 14) (JJ normal) (NNS volunteers))))) (, ,) (NP (NN ketoprofen)) (VP (VBD did) (RB not) (ADVP (RB significantly)) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN warfarin))) (PP (IN on) (NP (NN prothrombin) (NN time)))))))) (. .))))

Sentence Id: DrugDDI.d347.s16
Bleeding/JJ from/IN a/DT number/NN of/IN sites/NNS may/MD be/VB a/DT complication/NN of/IN warfarin/NN treatment/NN and/CC GI/JJ bleeding/JJ a/DT complication/NN of/IN ketoprofen/NN treatment/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Bleeding)) (PP (IN from) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NNS sites)))))) (VP (MD may) (VP (VB be) (NP (NP (NP (DT a) (NN complication)) (PP (IN of) (NP (NN warfarin) (NN treatment)))) (CC and) (NP (JJ GI) (JJ bleeding)) (NP (NP (DT a) (NN complication)) (PP (IN of) (NP (NN ketoprofen) (NN treatment)))))))) (. .))))

Sentence Id: DrugDDI.d347.s17
Because/IN prostaglandina/NNS play/VBP an/DT important/JJ role/NN in/IN hemostasis/NN and/CC ketoprofen/NN has/VBZ an/DT effect/NN on/IN platelet/NN function/NN as/IN well/NN ,/, concurent/JJ therapy/NN with/IN ketoprofen/NN and/CC warfarin/NN requires/VBZ close/JJ monitoring/NN of/IN patients/NNS on/IN both/DT drugs/NNS ./.

(ROOT (S1 (S (S (SBAR (IN Because) (S (NP (NNS prostaglandina)) (VP (VBP play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (NN hemostasis)) (CC and) (NP (NN ketoprofen))))))) (VP (VBZ has) (NP (NP (DT an) (NN effect)) (PP (IN on) (NP (NN platelet) (NN function)))) (PP (IN as) (NP (NN well))))) (, ,) (S (NP (NP (JJ concurent) (NN therapy)) (PP (IN with) (NP (NP (NN ketoprofen)) (CC and) (NP (NN warfarin))))) (VP (VBZ requires) (NP (NP (JJ close) (NN monitoring)) (PP (IN of) (NP (NNS patients))) (PP (IN on) (NP (DT both) (NNS drugs)))))) (. .))))

Sentence Id: DrugDDI.d347.s19
Probenecid/NN :/: Probenecid/NN increases/VBZ both/CC free/JJ and/CC bound/JJ ketoprofen/NN by/IN reducing/VBG the/DT plasma/NN clearance/NN of/IN ketoprofen/NN to/TO about/RB one-third/CD ,/, as/RB well/RB as/IN decreasing/VBG its/PRP$ protein/NN binding/NN ./.

(ROOT (S1 (S (NP (NP (NN Probenecid)) (: :) (S (NP (NN Probenecid)) (VP (VBZ increases) (NP (ADJP (CC both) (ADJP (JJ free)) (CC and) (ADJP (JJ bound))) (NN ketoprofen)) (PP (IN by) (S (VP (VP (VBG reducing) (NP (NP (DT the) (NN plasma) (NN clearance)) (PP (IN of) (NP (NN ketoprofen))) (PP (TO to) (NP (RB about) (CD one-third))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (VP (VBG decreasing) (NP (PRP$ its) (NN protein) (NN binding)))))))) (. .)))))

Sentence Id: DrugDDI.d347.s20
Therefore/RB ,/, the/DT combination/NN of/IN ketoprofen/NN and/CC probenecid/NN is/VBZ not/RB recommended/VBN ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (NN ketoprofen)) (CC and) (NP (NN probenecid))))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .))))

Sentence Id: DrugDDI.d347.s22
Methotrexate/NN :/: Ketoprofen/NN ,/, like/IN other/JJ NSAIDs/NNS ,/, may/MD cause/VB changes/NNS in/IN the/DT elimination/NN of/IN methotrexate/NN leading/VBG to/TO elevated/JJ serum/NN levels/NNS of/IN the/DT drug/NN and/CC increased/VBN toxicity/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Methotrexate)) (: :) (NP (NN Ketoprofen))) (, ,) (PP (IN like) (NP (JJ other) (NNS NSAIDs))) (, ,) (VP (MD may) (VP (VB cause) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (DT the) (NN elimination)) (PP (IN of) (NP (NP (NN methotrexate)) (VP (VBG leading) (PP (TO to) (NP (NP (JJ elevated) (NN serum) (NNS levels)) (PP (IN of) (NP (NP (DT the) (NN drug)) (CC and) (NP (VBN increased) (NN toxicity))))))))))))))) (. .))))

Sentence Id: DrugDDI.d347.s24
Lithium/NN :/: Nonsteroidal/JJ anti-inflammatory/JJ agents/NNS have/VBP been/VBN reported/VBN to/TO increase/VB steadystate/JJ plasma/NN lithium/NN levels/NNS ./.

(ROOT (S1 (S (NP (NP (NN Lithium)) (: :) (S (NP (JJ Nonsteroidal) (JJ anti-inflammatory) (NNS agents)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB increase) (NP (JJ steadystate) (NN plasma) (NN lithium) (NNS levels))))))))) (. .)))))

Sentence Id: DrugDDI.d347.s25
It/PRP is/VBZ recommended/VBN that/IN plasma/NN lithium/NN levels/NNS be/VB monitored/VBN when/WRB ketoprofen/NN is/VBZ coadministered/VBN with/IN lithium/NN ./.

(ROOT (S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NN plasma) (NN lithium) (NNS levels)) (VP (VB be) (VP (VBN monitored) (SBAR (WHADVP (WRB when)) (S (NP (NN ketoprofen)) (VP (VBZ is) (VP (VBN coadministered) (PP (IN with) (NP (NN lithium)))))))))))))) (. .))))

Sentence Id: DrugDDI.d347.s26
DRUG/NN /LABORATORY/NN TEST/NN INTERACTIONS/NNS :/: EFFECT/NN ON/IN BLOOD/NN COAGULATION/NN Ketoprofen/NN decreases/VBZ platelet/NN adhesion/NN and/CC aggregation/NN ./.

(ROOT (S1 (S (NP (NP (NN DRUG) (NN /LABORATORY) (NN TEST) (NNS INTERACTIONS)) (: :) (S (NP (NP (NN EFFECT)) (PP (IN ON) (NP (NN BLOOD) (NN COAGULATION) (NN Ketoprofen)))) (VP (VBZ decreases) (NP (NP (NN platelet) (NN adhesion)) (CC and) (NP (NN aggregation))))) (. .)))))

Sentence Id: DrugDDI.d334.s0
Ketorolac/NN is/VBZ highly/RB bound/VBN to/TO human/JJ plasma/NN protein/NN (/-LRB- mean/NN 99.2/CD %)./NN

(ROOT (S1 (S (NP (NN Ketorolac)) (VP (VBZ is) (ADVP (RB highly)) (VP (VBN bound) (PP (TO to) (NP (JJ human) (NN plasma) (NN protein) (-LRB- -LRB-) (NN mean) (CD 99.2) (NN %-RRB-.))))))))

Sentence Id: DrugDDI.d334.s1
Warfarin/NN ,/, Digoxin/NN ,/, Salicylate/NN ,/, and/CC Heparin/NN :/: The/DT in/FW vitro/FW binding/NN of/IN warfarin/NN to/TO plasma/NN proteins/NNS is/VBZ only/RB slightly/RB reduced/VBN by/IN ketorolac/NN tromethamine/NN (/-LRB- 99.5/CD %/NN control/NN vs/CC 99.3/CD %/NN )/-RRB- when/WRB ketorolac/NN plasma/NN concentrations/NNS reach/VBP 5/CD to10/CD m/NN g/mL/NN ./.

(ROOT (S1 (S (NP (NP (NP (NN Warfarin)) (, ,) (NP (NN Digoxin)) (, ,) (NP (NN Salicylate)) (, ,) (CC and) (NP (NN Heparin))) (: :) (S (NP (NP (DT The) (ADJP (FW in) (FW vitro)) (NN binding)) (PP (IN of) (NP (NN warfarin))) (PP (TO to) (NP (NN plasma) (NNS proteins)))) (VP (VBZ is) (ADVP (RB only) (RB slightly)) (VP (VBN reduced) (PP (IN by) (NP (NP (NN ketorolac) (NN tromethamine)) (PRN (-LRB- -LRB-) (NP (CD 99.5) (NN %) (NN control) (CC vs) (CD 99.3) (NN %)) (-RRB- -RRB-)))) (SBAR (WHADVP (WRB when)) (S (NP (NN ketorolac) (NN plasma) (NNS concentrations)) (VP (VBP reach) (NP (CD 5) (ADJP (CD to10) (NN m)) (NN g/mL)))))))) (. .)))))

Sentence Id: DrugDDI.d334.s2
Ketorolac/NN does/VBZ not/RB alter/VB digoxin/NN protein/NN binding/NN ./.

(ROOT (S1 (S (S (NP (NN Ketorolac)) (VP (VBZ does) (RB not) (VP (VB alter) (NP (NN digoxin) (NN protein) (NN binding))))) (. .))))

Sentence Id: DrugDDI.d334.s3
In/FW vitro/FW studies/NNS indicate/VBP that/IN ,/, at/IN therapeutic/JJ concentrations/NNS of/IN salicylate/NN (/-LRB- 300/CD m/NN g/mL/NN )/-RRB- ,/, the/DT binding/NN of/IN ketorolac/NN was/VBD reduced/VBN from/IN approximately/RB 99.2/CD %/NN to/TO 97.5/CD %/NN ,/, representing/VBG a/DT potential/JJ twofold/JJ increase/NN in/IN unbound/JJ ketorolac/NN plasma/NN levels/NNS ./.

(ROOT (S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (, ,) (PP (IN at) (NP (NP (NP (JJ therapeutic) (NNS concentrations)) (PP (IN of) (NP (NN salicylate)))) (PRN (-LRB- -LRB-) (NP (CD 300) (NN m) (NN g/mL)) (-RRB- -RRB-)))) (, ,) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (NN ketorolac)))) (VP (VBD was) (VP (VBN reduced) (PP (IN from) (NP (QP (RB approximately) (CD 99.2) (NN %) (TO to) (CD 97.5)) (NN %))) (, ,) (S (VP (VBG representing) (NP (NP (DT a) (JJ potential) (JJ twofold) (NN increase)) (PP (IN in) (NP (JJ unbound) (NN ketorolac) (NN plasma) (NNS levels)))))))))))) (. .))))

Sentence Id: DrugDDI.d334.s4
Therapeutic/JJ concentrations/NNS of/IN digoxin/NN ,/, warfarin/NN ,/, ibuprofen/NN ,/, naproxen/NN ,/, piroxicam/NN ,/, acetaminophen/NN ,/, phenytoin/NN andtolbutamide/NN did/VBD not/RB alter/VB ketorolac/NN tromethamine/NN protein/NN binding/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Therapeutic) (NNS concentrations)) (PP (IN of) (NP (NP (NN digoxin)) (, ,) (NP (NN warfarin)) (, ,) (NP (NN ibuprofen)) (, ,) (NP (NN naproxen)) (, ,) (NP (NN piroxicam)) (, ,) (NP (NN acetaminophen)) (, ,) (NP (NN phenytoin) (NN andtolbutamide))))) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (NN ketorolac) (NN tromethamine)) (NN protein) (NN binding))))) (. .))))

Sentence Id: DrugDDI.d334.s5
In/IN a/DT study/NN involving/VBG 12/CD adult/JJ volunteers/NNS ,/, TORADOLORAL/NN was/VBD coadministered/VBN with/IN a/DT single/JJ dose/NN of/IN 25/CD mg/NN warfarin/NN ,/, causing/VBG no/DT significant/JJ changes/NNS in/IN pharmacokinetics/NNS or/CC pharmacodynamics/NNS of/IN warfarin/NN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (NP (DT a) (NN study)) (VP (VBG involving) (NP (CD 12) (JJ adult) (NNS volunteers))))) (, ,) (NP (NN TORADOLORAL)) (VP (VBD was) (VP (VBN coadministered) (PP (IN with) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (ADJP (CD 25) (NN mg)) (NN warfarin))))) (, ,) (S (VP (VBG causing) (NP (NP (DT no) (JJ significant) (NNS changes)) (PP (IN in) (NP (NP (NP (NNS pharmacokinetics)) (CC or) (NP (NNS pharmacodynamics))) (PP (IN of) (NP (NN warfarin))))))))))) (. .))))

Sentence Id: DrugDDI.d334.s6
In/IN another/DT study/NN ,/, TORADOLIV/IM/NN was/VBD given/VBN with/IN two/CD doses/NNS of/IN 5000/CD U/NN of/IN heparin/NN to/TO 11/CD healthy/JJ volunteers/NNS ,/, resulting/VBG in/IN a/DT mean/NN template/NN bleeding/JJ time/NN of/IN 6.4/CD minutes/NNS (/-LRB- 3.2/CD to/TO 11.4/CD min/NN )/-RRB- compared/VBN to/TO a/DT mean/NN of/IN 6.0/CD minutes/NNS (/-LRB- 3.4/CD to/TO 7.5/CD min/NN )/-RRB- for/IN heparin/NN alone/RB and/CC 5.1/CD minutes/NNS (/-LRB- 3.5/CD to/TO 8.5/CD min/NN )/-RRB- for/IN placebo/NN ./.

(ROOT (S1 (S (PP (IN In) (NP (DT another) (NN study))) (, ,) (NP (NN TORADOLIV/IM)) (VP (VBD was) (VP (VBN given) (PP (IN with) (NP (NP (CD two) (NNS doses)) (PP (IN of) (NP (NP (CD 5000) (NN U)) (PP (IN of) (NP (NN heparin))) (PP (TO to) (NP (CD 11) (JJ healthy) (NNS volunteers))))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (DT a) (NN mean) (NN template) (JJ bleeding) (NN time)) (PP (IN of) (NP (NP (NP (CD 6.4) (NNS minutes)) (PRN (-LRB- -LRB-) (NP (QP (CD 3.2) (TO to) (CD 11.4)) (NN min)) (-RRB- -RRB-))) (VP (VBN compared) (PP (TO to) (NP (DT a) (NN mean))) (PP (IN of) (NP (NP (NP (NP (NP (CD 6.0) (NNS minutes)) (PRN (-LRB- -LRB-) (NP (QP (CD 3.4) (TO to) (CD 7.5)) (NN min)) (-RRB- -RRB-))) (PP (IN for) (NP (NN heparin)))) (ADVP (RB alone))) (CC and) (NP (NP (CD 5.1) (NNS minutes)) (PRN (-LRB- -LRB-) (NP (QP (CD 3.5) (TO to) (CD 8.5)) (NN min)) (-RRB- -RRB-)))))))) (PP (IN for) (NP (NN placebo))))))))) (. .))))

Sentence Id: DrugDDI.d334.s7
Although/IN these/DT results/NNS do/VBP not/RB indicate/VB a/DT significant/JJ interaction/NN between/IN TORADOL/NN and/CC warfarin/NN or/CC heparin/NN ,/, the/DT administration/NN of/IN TORADOL/NN to/TO patients/NNS taking/VBG anticoagulants/NNS should/MD be/VB done/VBN extremely/RB cautiously/RB ,/, and/CC patients/NNS should/MD be/VB closely/RB monitored/VBN ./.

(ROOT (S1 (S (S (S (SBAR (IN Although) (S (NP (DT these) (NNS results)) (VP (VBP do) (RB not) (VP (VB indicate) (NP (NP (DT a) (JJ significant) (NN interaction)) (PP (IN between) (NP (NP (NN TORADOL)) (CC and) (NP (NP (NN warfarin)) (CC or) (NP (NN heparin)))))))))) (, ,) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NN TORADOL))) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NNS anticoagulants)))))) (VP (MD should) (VP (VB be) (VP (VBN done) (ADVP (RB extremely) (RB cautiously)))))) (, ,) (CC and) (S (NP (NNS patients)) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored)))))) (. .))))

Sentence Id: DrugDDI.d334.s8
Furosemide/NN TORADOLIV/NN /IM/NN reduced/VBD the/DT diuretic/JJ response/NN to/TO furosemide/NN in/IN normovolemic/JJ healthy/JJ subjects/NNS by/IN approximately/RB 20/CD %/NN (/-LRB- mean/JJ sodium/NN and/CC urinary/JJ output/NN decreased/VBD 17/CD %)./NN

(ROOT (S1 (S (S (NP (NN Furosemide) (NN TORADOLIV) (NN /IM)) (VP (VBD reduced) (NP (NP (DT the) (JJ diuretic) (NN response)) (PP (TO to) (NP (NN furosemide))) (PP (IN in) (NP (JJ normovolemic) (JJ healthy) (NNS subjects)))) (PP (IN by) (NP (QP (RB approximately) (CD 20)) (NN %))) (-LRB- -LRB-) (NP (JJ mean) (NN sodium)))) (CC and) (S (NP (JJ urinary) (NN output)) (VP (VBD decreased) (NP (CD 17) (NN %-RRB-.)))))))

Sentence Id: DrugDDI.d334.s9
Probenecid/NN Concomitant/JJ administration/NN of/IN TORADOLORAL/NN and/CC probenecid/NN resulted/VBD in/IN decreased/VBN clearance/NN of/IN ketorolac/NN and/CC significant/JJ increases/NNS in/IN ketorolac/NN plasma/NN levels/NNS (/-LRB- total/JJ AUC/NN increased/VBD approximately/RB threefold/RB from/IN 5.4/CD to/TO 17.8/CD m/NN g/h/mL/NN )/-RRB- and/CC terminal/JJ half-life/NN increased/VBD approximately/RB twofold/RB from/IN 6.6/CD to/TO 15.1/CD hours/NNS ./.

(ROOT (S1 (S (S (S (NP (NP (NP (NN Probenecid)) (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN TORADOLORAL)) (CC and) (NP (NN probenecid))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (VBN decreased) (NN clearance)) (PP (IN of) (NP (NN ketorolac)))) (CC and) (NP (NP (JJ significant) (NNS increases)) (PP (IN in) (NP (NP (NN ketorolac) (NN plasma) (NNS levels)) (PRN (-LRB- -LRB-) (NP (NP (JJ total) (NN AUC)) (VP (VBD increased) (ADVP (RB approximately) (RB threefold)) (PP (IN from) (NP (ADJP (QP (CD 5.4) (TO to) (CD 17.8)) (NN m)) (NN g/h/mL))))) (-RRB- -RRB-))))))))) (CC and) (S (NP (JJ terminal) (NN half-life)) (VP (VBD increased) (ADVP (RB approximately) (RB twofold)) (PP (IN from) (NP (QP (CD 6.6) (TO to) (CD 15.1)) (NNS hours)))))) (. .))))

Sentence Id: DrugDDI.d334.s10
Therefore/RB ,/, concomitant/JJ use/NN of/IN TORADOL/NN and/CC probenecid/NN is/VBZ contraindicated/VBN ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN TORADOL)) (CC and) (NP (NN probenecid))))) (VP (VBZ is) (VP (VBN contraindicated)))) (. .))))

Sentence Id: DrugDDI.d334.s11
Lithium/NN Inhibition/NN of/IN renal/JJ lithium/NN clearance/NN ,/, leading/VBG to/TO an/DT increase/NN in/IN plasma/NN lithium/NN concentration/NN ,/, has/VBZ been/VBN reported/VBN with/IN some/DT prostaglandin/NN synthesis-inhibiting/JJ drugs/NNS ./.

(ROOT (S1 (S (S (NP (NP (NN Lithium) (NN Inhibition)) (PP (IN of) (NP (NP (JJ renal) (NN lithium) (NN clearance)) (, ,) (VP (VBG leading) (PP (TO to) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN plasma) (NN lithium) (NN concentration)))))) (, ,)))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (DT some) (NN prostaglandin) (JJ synthesis-inhibiting) (NNS drugs))))))) (. .))))

Sentence Id: DrugDDI.d334.s12
The/DT effect/NN of/IN TORADOL/NN on/IN plasma/NN lithium/NN has/VBZ not/RB been/VBN studied/VBN ,/, but/CC cases/NNS of/IN increased/VBN lithium/NN plasma/NN levels/NNS during/IN TORADOL/NN therapy/NN have/VBP been/VBN reported/VBN ./.

(ROOT (S1 (S (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN TORADOL))) (PP (IN on) (NP (NN plasma) (NN lithium)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))) (, ,) (CC but) (S (NP (NP (NNS cases)) (PP (IN of) (NP (NP (VBN increased) (NN lithium) (NN plasma) (NNS levels)) (PP (IN during) (NP (NN TORADOL) (NN therapy)))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported)))))) (. .))))

Sentence Id: DrugDDI.d334.s13
Methotrexate/NN Concomitant/JJ administration/NN of/IN methotrexate/NN and/CC some/DT NSAIDs/NNS has/VBZ been/VBN reported/VBN to/TO reduce/VB the/DT clearance/NN of/IN methotrexate/NN ,/, enhancing/VBG the/DT toxicity/NN of/IN methotrexate/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Methotrexate) (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN methotrexate)) (CC and) (NP (DT some) (NNS NSAIDs))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB reduce) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN methotrexate))))))))) (, ,) (S (VP (VBG enhancing) (NP (NP (DT the) (NN toxicity)) (PP (IN of) (NP (NN methotrexate)))))))) (. .))))

Sentence Id: DrugDDI.d334.s14
The/DT effect/NN of/IN TORADOL/NN on/IN methotrexate/NN clearance/NN has/VBZ not/RB been/VBN studied/VBN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN TORADOL))) (PP (IN on) (NP (NN methotrexate) (NN clearance)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .))))

Sentence Id: DrugDDI.d334.s15
Nondepolarizing/JJ Muscle/NN Relaxants/NNS :/: In/FW postmarketing/FW experience/VBP there/EX have/VBP been/VBN reports/NNS of/IN a/DT possible/JJ interaction/NN between/IN TORADOLIV/IM/NN and/CC nondepolarizing/JJ muscle/NN relaxants/NNS that/WDT resulted/VBD in/IN apnea/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Nondepolarizing) (NN Muscle) (NNS Relaxants)) (: :) (ADVP (FW In) (FW postmarketing))) (VP (VBP experience) (S (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (NP (NNS reports)) (PP (IN of) (NP (NP (DT a) (JJ possible) (NN interaction)) (PP (IN between) (NP (NP (NN TORADOLIV/IM)) (CC and) (NP (JJ nondepolarizing) (NN muscle) (NNS relaxants)))))) (SBAR (WHNP (WDT that)) (S (VP (VBD resulted) (PP (IN in) (NP (NN apnea)))))))))))) (. .))))

Sentence Id: DrugDDI.d334.s16
The/DT concurrent/JJ use/NN of/IN TORADOL/NN with/IN muscle/NN relaxants/NNS has/VBZ not/RB been/VBN formally/RB studied/VBN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (JJ concurrent) (NN use)) (PP (IN of) (NP (NN TORADOL))) (PP (IN with) (NP (NN muscle) (NNS relaxants)))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB formally)) (VP (VBN studied))))) (. .))))

Sentence Id: DrugDDI.d334.s17
ACE/NN Inhibitors/NNS Concomitant/JJ use/NN of/IN ACE/NN inhibitors/NNS may/MD increase/VB the/DT risk/NN of/IN renal/JJ impairment/NN ,/, particularly/RB in/IN volume-depleted/JJ patients/NNS ./.

(ROOT (S1 (S (S (NP (NP (NP (NN ACE) (NNS Inhibitors)) (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN ACE) (NNS inhibitors)))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ renal) (NN impairment)))) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (JJ volume-depleted) (NNS patients)))))) (. .))))

Sentence Id: DrugDDI.d334.s18
Antiepileptic/JJ Drugs/NNS Sporadic/JJ cases/NNS of/IN seizures/NNS have/VBP been/VBN reported/VBN during/IN concomitant/JJ use/NN of/IN TORADOL/NN and/CC antiepileptic/JJ drugs/NNS (/-LRB- phenytoin/NN ,/, carbamazepine/NN )/-RRB- ./.

(ROOT (S1 (S (S (NP (NP (JJ Antiepileptic) (NNS Drugs)) (NP (NP (JJ Sporadic) (NNS cases)) (PP (IN of) (NP (NNS seizures))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN during) (NP (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NN TORADOL)))) (CC and) (NP (NP (JJ antiepileptic) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NP (NN phenytoin)) (, ,) (NP (NN carbamazepine))) (-RRB- -RRB-))))))))) (. .))))

Sentence Id: DrugDDI.d334.s19
Psychoactive/JJ Drugs/NNS Hallucinations/NNS have/VBP been/VBN reported/VBN when/WRB TORADOL/NN was/VBD used/VBN in/IN patients/NNS taking/VBG psychoactive/JJ drugs/NNS (/-LRB- fluoxetine/NN ,/, thiothixene/NN ,/, alprazolam/NN )/-RRB- ./.

(ROOT (S1 (S (S (NP (NP (JJ Psychoactive) (NNS Drugs)) (NP (NNS Hallucinations))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (SBAR (WHADVP (WRB when)) (S (NP (NN TORADOL)) (VP (VBD was) (VP (VBN used) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (JJ psychoactive) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NP (NN fluoxetine)) (, ,) (NP (NN thiothixene)) (, ,) (NP (NN alprazolam))) (-RRB- -RRB-)))))))))))))) (. .))))

Sentence Id: DrugDDI.d334.s20
Morphine/NN TORADOLIV/IM/NN has/VBZ been/VBN administered/VBN concurrently/RB with/IN morphine/NN in/IN several/JJ clinical/JJ trials/NNS of/IN postoperative/JJ pain/NN without/IN evidence/NN of/IN adverse/JJ interactions/NNS ./.

(ROOT (S1 (S (S (NP (NN Morphine) (NN TORADOLIV/IM)) (VP (VBZ has) (VP (VBN been) (VP (VBN administered) (ADVP (RB concurrently)) (PP (IN with) (NP (NN morphine))) (PP (IN in) (NP (NP (JJ several) (JJ clinical) (NNS trials)) (PP (IN of) (NP (JJ postoperative) (NN pain))) (PP (IN without) (NP (NP (NN evidence)) (PP (IN of) (NP (JJ adverse) (NNS interactions))))))))))) (. .))))

Sentence Id: DrugDDI.d334.s21
Do/VBP not/RB mix/NN TORADOL/NN and/CC morphine/NN in/IN the/DT same/JJ syringe/NN ./.

(ROOT (S1 (S (S (VP (VBP Do) (RB not) (NP (NN mix) (NP (NP (NN TORADOL)) (CC and) (NP (NN morphine)))) (PP (IN in) (NP (DT the) (JJ same) (NN syringe))))) (. .))))

Sentence Id: DrugDDI.d334.s22
There/EX is/VBZ no/DT evidence/NN in/IN animal/JJ or/CC human/JJ studies/NNS that/IN TORADOL/NN induces/VBZ or/CC inhibits/VBZ hepatic/JJ enzymes/NNS capable/JJ of/IN metabolizing/VBG itself/PRP or/CC other/JJ drugs/NNS ./.

(ROOT (S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (NP (DT no) (NN evidence)) (PP (IN in) (NP (ADJP (ADJP (JJ animal)) (CC or) (ADJP (JJ human))) (NNS studies))) (SBAR (IN that) (S (NP (NN TORADOL)) (VP (VP (VBZ induces)) (CC or) (VP (VBZ inhibits) (NP (NP (JJ hepatic) (NNS enzymes)) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG metabolizing) (NP (NP (PRP itself)) (CC or) (NP (JJ other) (NNS drugs))))))))))))))) (. .))))

Sentence Id: DrugDDI.d415.s0
Medroxyprogesterone/NN Acetate/NN -/CC L-histidine/NN was/VBD observed/VBN to/TO enhance/VBP (/-LRB- in/IN tissue/NN culture/NN )/-RRB- the/DT effect/NN of/IN medroxyprogesterone/NN acetate/NN in/IN reducing/VBG the/DT number/NN of/IN human/JJ breast/NN cancer/NN cells/NNS that/WDT were/VBD in/IN the/DT S/NN phase/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Medroxyprogesterone) (NN Acetate)) (CC -) (NP (NN L-histidine))) (VP (VBD was) (VP (VBN observed) (S (VP (TO to) (VP (VBP enhance) (PRN (-LRB- -LRB-) (PP (IN in) (NP (NN tissue) (NN culture))) (-RRB- -RRB-)) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN medroxyprogesterone) (NN acetate))) (PP (IN in) (S (VP (VBG reducing) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (JJ human) (NN breast) (NN cancer) (NNS cells)) (SBAR (WHNP (WDT that)) (S (VP (VBD were) (PP (IN in) (NP (DT the) (NN S) (NN phase))))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d415.s1
H1/NN and/CC H2/NN Blockers/NNS -/: Although/IN not/RB reported/VBN ,/, L-histidine/NN ,/, via/IN its/PRP$ metabolism/NN to/TO histamine/NN ,/, might/MD decrease/VB the/DT efficacy/NN of/IN H1/NN and/CC H2/NN blockers/NN ./.

(ROOT (S1 (S (NP (NP (NP (NP (NN H1)) (CC and) (NP (NN H2))) (NNS Blockers)) (: -) (S (SBAR (IN Although) (S (VP (RB not) (VBN reported)))) (, ,) (NP (NN L-histidine)) (, ,) (PP (IN via) (NP (NP (PRP$ its) (NN metabolism)) (PP (TO to) (NP (NN histamine))))) (, ,) (VP (MD might) (VP (VB decrease) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NP (NN H1)) (CC and) (NP (NN H2)) (NP (NN blockers)))))))) (. .)))))

Sentence Id: DrugDDI.d201.s0
Effects/NNS of/IN Lapatinib/NN on/IN Drug/NN Metabolizing/NN Enzymes/NNS and/CC Drug/NN Transport/NN Systems/NNS Lapatinib/NN inhibits/VBZ CYP3A4/NN and/CC CYP2C8/NN in/FW vitro/FW at/IN clinically/RB relevant/JJ concentrations/NNS ./.

(ROOT (S1 (S (S (NP (NP (NNS Effects)) (PP (IN of) (NP (NN Lapatinib))) (PP (IN on) (NP (NP (NN Drug) (NN Metabolizing) (NNS Enzymes)) (CC and) (NP (NN Drug) (NN Transport) (NNS Systems)) (NP (NN Lapatinib))))) (VP (VBZ inhibits) (NP (NP (NN CYP3A4)) (CC and) (NP (NN CYP2C8))) (ADVP (FW in) (FW vitro)) (PP (IN at) (NP (ADJP (RB clinically) (JJ relevant)) (NNS concentrations))))) (. .))))

Sentence Id: DrugDDI.d201.s1
Caution/NN should/MD be/VB exercised/VBN and/CC dose/NN reduction/NN of/IN the/DT concomitant/JJ substrate/NN drug/NN should/MD be/VB considered/VBN when/IN dosing/NN lapatinib/NN concurrently/RB with/IN medications/NNS with/IN narrow/JJ therapeutic/JJ windows/NNS that/WDT are/VBP substrates/NNS of/IN CYP3A4/NN or/CC CYP2C8/NN ./.

(ROOT (S1 (S (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised))))) (CC and) (S (NP (NP (NN dose) (NN reduction)) (PP (IN of) (NP (DT the) (JJ concomitant) (NN substrate) (NN drug)))) (VP (MD should) (VP (VB be) (VP (VBN considered) (PP (IN when) (NP (NP (NN dosing) (NN lapatinib)) (PP (ADVP (RB concurrently)) (IN with) (NP (NP (NNS medications)) (PP (IN with) (NP (NP (ADJP (ADJP (JJ narrow)) (ADJP (JJ therapeutic))) (NNS windows)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NNS substrates)) (PP (IN of) (NP (NP (NN CYP3A4)) (CC or) (NP (NN CYP2C8))))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d201.s2
Lapatinib/NN did/VBD not/RB significantly/RB inhibit/VB the/DT following/JJ enzymes/NNS in/IN human/JJ liver/NN microsomes/NNS :/: CYP1A2/NN ,/, CYP2C9/NN ,/, CYP2C19/NN ,/, and/CC CYP2D6/NN or/CC UGT/NN enzymes/NNS in/FW vitro/FW ,/, however/RB ,/, the/DT clinical/JJ significance/NN is/VBZ unknown/JJ ./.

(ROOT (S1 (S (S (NP (NN Lapatinib)) (VP (VBD did) (RB not) (ADVP (RB significantly)) (VP (VB inhibit) (NP (NP (NP (NP (DT the) (JJ following) (NNS enzymes)) (PP (IN in) (NP (JJ human) (NN liver) (NNS microsomes)))) (: :) (NP (NP (NN CYP1A2)) (, ,) (NP (NN CYP2C9)) (, ,) (NP (NN CYP2C19)) (, ,) (CC and) (NP (NN CYP2D6)))) (CC or) (NP (NN UGT) (NNS enzymes))) (ADVP (FW in) (FW vitro))))) (, ,) (S (ADVP (RB however)) (, ,) (NP (DT the) (JJ clinical) (NN significance)) (VP (VBZ is) (ADJP (JJ unknown)))) (. .))))

Sentence Id: DrugDDI.d201.s3
Lapatinib/NN inhibits/VBZ human/JJ P-/NN glycoprotein/NN ./.

(ROOT (S1 (S (S (NP (NN Lapatinib)) (VP (VBZ inhibits) (NP (JJ human) (NN P-) (NN glycoprotein)))) (. .))))

Sentence Id: DrugDDI.d201.s4
If/IN TYKERB/NN is/VBZ administered/VBN with/IN drugs/NNS that/WDT are/VBP substrates/NNS of/IN Pgp/NN ,/, increased/VBN concentrations/NNS of/IN the/DT substrate/JJ drug/NN are/VBP likely/JJ ,/, and/CC caution/NN should/MD be/VB exercised/VBN ./.

(ROOT (S1 (S (S (SBAR (IN If) (S (NP (NN TYKERB)) (VP (VBZ is) (VP (VBN administered) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NNS substrates)) (PP (IN of) (NP (NN Pgp))))))))))))) (, ,) (S (S (NP (NP (VBN increased) (NNS concentrations)) (PP (IN of) (NP (DT the) (JJ substrate) (NN drug)))) (VP (VBP are) (ADJP (JJ likely)))) (, ,) (CC and) (S (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised))))))) (. .))))

Sentence Id: DrugDDI.d201.s5
Drugs/NNS that/WDT Inhibit/VBP or/CC Induce/VBP Cytochrome/NN P450/NN 3A4/NN Enzymes/NNS Lapatinib/NN undergoes/VBZ extensive/JJ metabolism/NN by/IN CYP3A4/NN ,/, and/CC concomitant/JJ administration/NN of/IN strong/JJ inhibitors/NNS or/CC inducers/NNS of/IN CYP3A4/NN alter/VB lapatinib/NN concentrations/NNS significantly/RB ./.

(ROOT (S1 (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBP Inhibit)) (CC or) (VP (VBP Induce) (NP (NP (NP (NN Cytochrome) (NN P450) (NN 3A4)) (NNS Enzymes)) (S (S (NP (NN Lapatinib)) (VP (VBZ undergoes) (NP (JJ extensive) (NN metabolism)) (PP (IN by) (NP (NN CYP3A4))))) (, ,) (CC and) (S (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (JJ strong) (NNS inhibitors)) (CC or) (NP (NP (NNS inducers)) (PP (IN of) (NP (NN CYP3A4))))))) (VP (VB alter) (NP (NN lapatinib) (NNS concentrations)) (ADVP (RB significantly)))))))))) (. .)))))

Sentence Id: DrugDDI.d201.s6
Dose/NN adjustment/NN of/IN lapatinib/NN should/MD be/VB considered/VBN for/IN patients/NNS who/WP must/MD receive/VBP concomitant/JJ strong/JJ inhibitors/NNS or/CC concomitant/JJ strong/JJ inducers/NNS of/IN CYP3A4/JJ enzymes/NNS ./.

(ROOT (S1 (S (S (NP (NP (NN Dose) (NN adjustment)) (PP (IN of) (NP (NN lapatinib)))) (VP (MD should) (VP (VB be) (VP (VBN considered) (PP (IN for) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (MD must) (VP (VBP receive) (NP (NP (NP (JJ concomitant) (JJ strong) (NNS inhibitors)) (CC or) (NP (JJ concomitant) (JJ strong) (NNS inducers))) (PP (IN of) (NP (JJ CYP3A4) (NNS enzymes)))))))))))))) (. .))))

Sentence Id: DrugDDI.d201.s7
Ketoconazole/NN :/: In/IN healthy/JJ subjects/NNS receiving/VBG ketoconazole/NN ,/, a/DT CYP3A4/NN inhibitor/NN ,/, at/IN 200/CD mg/NN twice/RB daily/RB for/IN 7/CD days/NNS ,/, systemic/JJ exposure/NN (/-LRB- AUC/NN )/-RRB- to/TO lapatinib/NN was/VBD increased/VBN to/TO approximately/RB 3.6-fold/NN of/IN control/NN and/CC half-life/NN increased/VBD to/TO 1.7-fold/NN of/IN control/NN ./.

(ROOT (S1 (S (NP (NP (NN Ketoconazole)) (: :) (S (PP (IN In) (NP (NP (JJ healthy) (NNS subjects)) (VP (VBG receiving) (NP (NP (NN ketoconazole)) (, ,) (NP (DT a) (NN CYP3A4) (NN inhibitor)) (, ,)) (PP (IN at) (NP (NP (CD 200) (NN mg)) (ADVP (RB twice) (RB daily) (PP (IN for) (NP (CD 7) (NNS days))))))))) (, ,) (NP (NP (NP (JJ systemic) (NN exposure)) (PRN (-LRB- -LRB-) (NP (NN AUC)) (-RRB- -RRB-))) (PP (TO to) (NP (NN lapatinib)))) (VP (VBD was) (VP (VBN increased) (PP (TO to) (NP (NP (RB approximately) (NN 3.6-fold)) (PP (IN of) (NP (NP (NN control)) (CC and) (NP (NN half-life)))) (VP (VBD increased) (PP (TO to) (NP (NP (NN 1.7-fold)) (PP (IN of) (NP (NN control))))))))))) (. .)))))

Sentence Id: DrugDDI.d201.s8
Carbamazepine/NN :/: In/IN healthy/JJ subjects/NNS receiving/VBG the/DT CYP3A4/NN inducer/NN ,/, carbamazepine/NN ,/, at/IN 100/CD mg/NN twice/RB daily/JJ for/IN 3/CD days/NNS and/CC 200/CD mg/NN twice/RB daily/JJ for/IN 17/CD days/NNS ,/, systemic/JJ exposure/NN (/-LRB- AUC/NN )/-RRB- to/TO lapatinib/NN was/VBD decreased/VBN approximately/RB 72/CD %./NN

(ROOT (S1 (S (NP (NP (NN Carbamazepine)) (: :) (S (PP (IN In) (NP (NP (JJ healthy) (NNS subjects)) (VP (VBG receiving) (NP (NP (DT the) (NN CYP3A4) (NN inducer)) (, ,) (NP (NN carbamazepine)) (, ,)) (PP (IN at) (NP (NP (NP (CD 100) (NN mg)) (ADJP (RB twice) (JJ daily) (PP (IN for) (NP (CD 3) (NNS days))))) (CC and) (NP (NP (CD 200) (NN mg)) (ADJP (RB twice) (JJ daily) (PP (IN for) (NP (CD 17) (NNS days)))))))))) (, ,) (NP (NP (NP (JJ systemic) (NN exposure)) (PRN (-LRB- -LRB-) (NP (NN AUC)) (-RRB- -RRB-))) (PP (TO to) (NP (NN lapatinib)))) (VP (VBD was) (VP (VBN decreased) (NP (QP (RB approximately) (CD 72)) (NN %.)))))))))

Sentence Id: DrugDDI.d201.s9
Drugs/NNS that/WDT Inhibit/VBP Drug/NN Transport/NN Systems/NNS Lapatinib/NN is/VBZ a/DT substrate/NN of/IN the/DT efflux/NN transporter/NN P-glycoprotein/NN (/-LRB- Pgp/NN ,/, ABCB1/NN )/-RRB- ./.

(ROOT (S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP Inhibit) (NP (NP (NN Drug) (NN Transport) (NNS Systems)) (NN Lapatinib)))))) (VP (VBZ is) (NP (NP (DT a) (NN substrate)) (PP (IN of) (NP (NP (DT the) (NN efflux) (NN transporter) (NN P-glycoprotein)) (PRN (-LRB- -LRB-) (NP (NP (NN Pgp)) (, ,) (NP (NN ABCB1))) (-RRB- -RRB-))))))) (. .))))

Sentence Id: DrugDDI.d201.s10
If/IN TYKERB/NN is/VBZ administered/VBN with/IN drugs/NNS that/WDT inhibit/VBP Pgp/NN ,/, increased/VBN concentrations/NNS of/IN lapatinib/NN are/VBP likely/JJ ,/, and/CC caution/NN should/MD be/VB exercised/VBN ./.

(ROOT (S1 (S (S (SBAR (IN If) (S (NP (NN TYKERB)) (VP (VBZ is) (VP (VBN administered) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (NN Pgp))))))))))) (, ,) (S (S (NP (NP (VBN increased) (NNS concentrations)) (PP (IN of) (NP (NN lapatinib)))) (VP (VBP are) (ADJP (JJ likely)))) (, ,) (CC and) (S (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised))))))) (. .))))

Sentence Id: DrugDDI.d201.s11
Other/JJ Chemotherapy/NN Agents/NNS :/: In/IN a/DT separate/JJ study/NN ,/, concomitant/JJ administration/NN of/IN lapatinib/NN with/IN capecitabine/NN did/VBD not/RB meaningfully/RB alter/VB the/DT pharmacokinetics/NNS of/IN either/DT agent/NN (/-LRB- or/CC the/DT metabolites/NNS of/IN capecitabine/NN )/-RRB- ./.

(ROOT (S1 (S (NP (NP (JJ Other) (NN Chemotherapy) (NNS Agents)) (: :) (S (PP (IN In) (NP (DT a) (JJ separate) (NN study))) (, ,) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN lapatinib))) (PP (IN with) (NP (NN capecitabine)))) (VP (VBD did) (RB not) (ADVP (RB meaningfully)) (VP (VB alter) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (DT either) (NN agent)))) (PRN (-LRB- -LRB-) (CC or) (NP (NP (DT the) (NNS metabolites)) (PP (IN of) (NP (NN capecitabine)))) (-RRB- -RRB-))))) (. .)))))

Sentence Id: DrugDDI.d581.s0
Cholestyramine/NN and/CC Charcoal/NN Administration/NN of/IN cholestyramine/NN or/CC activated/VBN charcoal/NN in/IN patients/NNS (/-LRB- n=13/NN )/-RRB- and/CC volunteers/NNS (/-LRB- n=96/CD )/-RRB- resulted/VBD in/IN a/DT rapid/JJ and/CC significant/JJ decrease/NN in/IN plasma/NN M1/NN (/-LRB- the/DT active/JJ metabolite/NN of/IN leflunomide/NN )/-RRB- concentration/NN ./.

(ROOT (S1 (S (S (NP (NP (NP (NN Cholestyramine)) (CC and) (NP (NN Charcoal) (NN Administration))) (PP (IN of) (NP (NP (NN cholestyramine)) (CC or) (NP (VBN activated) (NN charcoal)))) (PP (IN in) (NP (NP (NP (NNS patients)) (PRN (-LRB- -LRB-) (NP (NN n=13)) (-RRB- -RRB-))) (CC and) (NP (NP (NNS volunteers)) (PRN (-LRB- -LRB-) (NP (CD n=96)) (-RRB- -RRB-)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (ADJP (ADJP (JJ rapid)) (CC and) (ADJP (JJ significant))) (NN decrease)) (PP (IN in) (NP (NN plasma) (NP (NP (NN M1)) (PRN (-LRB- -LRB-) (NP (NP (DT the) (JJ active) (NN metabolite)) (PP (IN of) (NP (NN leflunomide)))) (-RRB- -RRB-))) (NN concentration))))))) (. .))))

Sentence Id: DrugDDI.d581.s1
Hepatotoxic/JJ Drugs/NNS Increased/VBN side/NN effects/NNS may/MD occur/VB when/WRB leflunomide/NN is/VBZ given/VBN concomitantly/RB with/IN hepatotoxic/JJ substances/NNS ./.

(ROOT (S1 (S (S (NP (NP (JJ Hepatotoxic) (NNS Drugs)) (VBN Increased) (NN side) (NNS effects)) (VP (MD may) (VP (VB occur) (SBAR (WHADVP (WRB when)) (S (NP (NN leflunomide)) (VP (VBZ is) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (JJ hepatotoxic) (NNS substances)))))))))) (. .))))

Sentence Id: DrugDDI.d581.s2
This/DT is/VBZ also/RB to/TO be/VB considered/VBN when/WRB leflunomide/NN treatment/NN is/VBZ followed/VBN by/IN such/JJ drugs/NNS without/IN a/DT drug/NN elimination/NN procedure/NN ./.

(ROOT (S1 (S (S (NP (DT This)) (VP (VBZ is) (ADVP (RB also)) (S (VP (TO to) (VP (VB be) (VP (VBN considered) (SBAR (WHADVP (WRB when)) (S (NP (NN leflunomide) (NN treatment)) (VP (VBZ is) (VP (VBN followed) (PP (IN by) (NP (JJ such) (NNS drugs))) (PP (IN without) (NP (DT a) (NN drug) (NN elimination) (NN procedure))))))))))))) (. .))))

Sentence Id: DrugDDI.d581.s3
In/IN a/DT small/JJ (/-LRB- n=30/NN )/-RRB- combination/NN study/NN of/IN ARAVA/NN with/IN methotrexate/NN ,/, a/DT 2-/CD to/TO 3-fold/JJ elevation/NN in/IN liver/NN enzymes/NNS was/VBD seen/VBN in/IN 5/CD of/IN 30/CD patients/NNS ./.

(ROOT (S1 (S (S (PP (IN In) (NP (NP (DT a) (ADJP (ADJP (JJ small)) (PRN (-LRB- -LRB-) (NP (NN n=30)) (-RRB- -RRB-))) (NN combination) (NN study)) (PP (IN of) (NP (NN ARAVA))) (PP (IN with) (NP (NN methotrexate))))) (, ,) (NP (NP (DT a) (ADJP (CD 2-) (TO to) (JJ 3-fold)) (NN elevation)) (PP (IN in) (NP (NN liver) (NNS enzymes)))) (VP (VBD was) (VP (VBN seen) (PP (IN in) (NP (NP (CD 5)) (PP (IN of) (NP (CD 30) (NNS patients)))))))) (. .))))

Sentence Id: DrugDDI.d581.s4
All/DT elevations/NNS resolved/VBN ,/, 2/CD with/IN continuation/NN of/IN both/DT drugs/NNS and/CC 3/CD after/IN discontinuation/NN of/IN leflunomide/NN ./.

(ROOT (S1 (S (S (NP (DT All) (NNS elevations)) (VP (VBN resolved) (, ,) (NP (NP (NP (CD 2)) (PP (IN with) (NP (NP (NN continuation)) (PP (IN of) (NP (DT both) (NNS drugs)))))) (CC and) (NP (NP (CD 3)) (PP (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NN leflunomide))))))))) (. .))))

Sentence Id: DrugDDI.d581.s6
All/DT of/IN these/DT also/RB resolved/VBN ,/, 2/CD with/IN continuation/NN of/IN both/DT drugs/NNS and/CC 3/CD after/IN discontinuation/NN of/IN leflunomide/NN ./.

(ROOT (S1 (S (S (NP (NP (DT All)) (PP (IN of) (NP (DT these)))) (ADVP (RB also)) (VP (VBN resolved) (, ,) (NP (NP (NP (CD 2)) (PP (IN with) (NP (NP (NN continuation)) (PP (IN of) (NP (DT both) (NNS drugs)))))) (CC and) (NP (NP (CD 3)) (PP (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NN leflunomide))))))))) (. .))))

Sentence Id: DrugDDI.d581.s7
Three/CD patients/NNS met/NN ACR/NN criteria/NNS for/IN liver/NN biopsy/NN (/-LRB- 1/CD :/: Roegnik/NNP Grade/NN I/CD ,/, 2/CD :/: Roegnik/NNP Grade/NN IIIa/NN )./NN

(ROOT (S1 (S (NP (NP (NP (CD Three) (NNS patients) (NN met) (NN ACR) (NNS criteria)) (PP (IN for) (NP (NN liver) (NN biopsy)))) (-LRB- -LRB-) (NP (CD 1) (: :) (NP (NP (NNP Roegnik)) (NP (NN Grade) (CD I) (, ,) (CD 2))) (: :) (NP (NP (NNP Roegnik)) (NP (NN Grade) (NN IIIa) (NN -RRB-.))))))))

Sentence Id: DrugDDI.d581.s9
NSAIDs/NNS :/: In/IN in/FW vitro/FW studies/NNS ,/, M1/NN was/VBD shown/VBN to/TO cause/VB increases/NNS ranging/VBG from/IN 13/CD -/CC 50/CD %/NN in/IN the/DT free/JJ fraction/NN of/IN diclofenac/NN and/CC ibuprofen/NN at/IN concentrations/NNS in/IN the/DT clinical/JJ range/NN ./.

(ROOT (S1 (S (NP (NP (NNS NSAIDs)) (: :) (S (PP (IN In) (NP (ADJP (FW in) (FW vitro)) (NNS studies))) (, ,) (NP (NN M1)) (VP (VBD was) (VP (VBN shown) (S (VP (TO to) (VP (VB cause) (NP (NP (NNS increases)) (VP (VBG ranging) (PP (IN from) (NP (QP (CD 13) (CC -) (CD 50)) (NN %))) (PP (IN in) (NP (NP (DT the) (JJ free) (NN fraction)) (PP (IN of) (NP (NP (NP (NN diclofenac)) (CC and) (NP (NN ibuprofen))) (PP (IN at) (NP (NP (NNS concentrations)) (PP (IN in) (NP (DT the) (JJ clinical) (NN range))))))))))))))))) (. .)))))

Sentence Id: DrugDDI.d581.s11
however/RB ,/, there/EX was/VBD extensive/JJ concomitant/JJ use/NN of/IN NSAIDs/NN in/IN clinical/JJ studies/NNS and/CC no/DT differential/JJ effect/NN was/VBD observed/VBN ./.

(ROOT (S1 (S (S (ADVP (RB however)) (, ,) (S (NP (EX there)) (VP (VBD was) (NP (NP (JJ extensive) (JJ concomitant) (NN use)) (PP (IN of) (NP (NN NSAIDs))) (PP (IN in) (NP (JJ clinical) (NNS studies)))))) (CC and) (S (NP (DT no) (JJ differential) (NN effect)) (VP (VBD was) (VP (VBN observed))))) (. .))))

Sentence Id: DrugDDI.d581.s12
Tolbutamide/NN :/: In/IN in/FW vitro/FW studies/NNS ,/, M1/NN was/VBD shown/VBN to/TO cause/VB increases/NNS ranging/VBG from/IN 13/CD -/CC 50/CD %/NN in/IN the/DT free/JJ fraction/NN of/IN tolbutamide/NN at/IN concentrations/NNS in/IN the/DT clinical/JJ range/NN ./.

(ROOT (S1 (S (NP (NP (NN Tolbutamide)) (: :) (S (PP (IN In) (NP (ADJP (FW in) (FW vitro)) (NNS studies))) (, ,) (NP (NN M1)) (VP (VBD was) (VP (VBN shown) (S (VP (TO to) (VP (VB cause) (NP (NP (NNS increases)) (VP (VBG ranging) (PP (IN from) (NP (QP (CD 13) (CC -) (CD 50)) (NN %))) (PP (IN in) (NP (NP (DT the) (JJ free) (NN fraction)) (PP (IN of) (NP (NN tolbutamide))))) (PP (IN at) (NP (NP (NNS concentrations)) (PP (IN in) (NP (DT the) (JJ clinical) (NN range))))))))))))) (. .)))))

Sentence Id: DrugDDI.d581.s14
Rifampin/NN Following/VBG concomitant/JJ administration/NN of/IN a/DT single/JJ dose/NN of/IN ARAVA/NN to/TO subjects/NNS receiving/VBG multiple/JJ doses/NNS of/IN rifampin/NN ,/, M1/NN peak/NN levels/NNS were/VBD increased/VBN (/-LRB- ~40/CD %/NN )/-RRB- over/IN those/DT seen/VBN when/WRB ARAVA/NN was/VBD given/VBN alone/RB ./.

(ROOT (S1 (S (S (S (NP (NN Rifampin)) (VP (VBG Following) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NN ARAVA)))))) (PP (TO to) (NP (NP (NNS subjects)) (VP (VBG receiving) (NP (NP (JJ multiple) (NNS doses)) (PP (IN of) (NP (NN rifampin))))))))) (, ,) (S (NP (NN M1) (NN peak) (NNS levels)) (VP (VBD were) (VP (VBN increased) (PRN (-LRB- -LRB-) (NP (CD ~40) (NN %)) (-RRB- -RRB-)) (PP (IN over) (NP (NP (DT those)) (VP (VBN seen) (SBAR (WHADVP (WRB when)) (S (NP (NN ARAVA)) (VP (VBD was) (VP (VBN given) (ADVP (RB alone))))))))))))) (. .))))

Sentence Id: DrugDDI.d581.s15
Because/IN of/IN the/DT potential/NN for/IN ARAVA/NN levels/NNS to/TO continue/VBP to/TO increase/VB with/IN multiple/JJ dosing/NN ,/, caution/NN should/MD be/VB used/VBN if/IN patients/NNS are/VBP to/TO be/VB receiving/VBG both/CC ARAVA/NN and/CC rifampin/NN ./.

(ROOT (S1 (S (S (PP (IN Because) (PP (IN of) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NN ARAVA) (NNS levels))) (S (VP (TO to) (VP (VBP continue) (S (VP (TO to) (VP (VB increase) (PP (IN with) (NP (JJ multiple) (NN dosing)))))))))))) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (SBAR (IN if) (S (NP (NNS patients)) (VP (VBP are) (S (VP (TO to) (VP (VB be) (VP (VBG receiving) (NP (CC both) (NP (NN ARAVA)) (CC and) (NP (NN rifampin)))))))))))))) (. .))))

Sentence Id: DrugDDI.d581.s16
Warfarin/JJ Increased/VBN INR/NN (/-LRB- International/NNP Normalized/VBN Ratio/NN )/-RRB- when/WRB ARAVA/NN and/CC warfarin/NN were/VBD co-administered/VBN has/VBZ been/VBN rarely/RB reported/VBN ./.

(ROOT (S1 (S (S (NP (NP (NP (JJ Warfarin) (VBN Increased) (NN INR)) (PRN (-LRB- -LRB-) (NP (NP (NNP International)) (VBN Normalized) (NN Ratio)) (-RRB- -RRB-))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN ARAVA)) (CC and) (NP (NN warfarin))) (VP (VBD were) (VP (VBN co-administered)))))) (VP (VBZ has) (VP (VBN been) (ADVP (RB rarely)) (VP (VBN reported))))) (. .))))

Sentence Id: DrugDDI.d379.s0
Clinical/JJ interaction/NN studies/NNS with/IN cimetidine/NN and/CC warfarin/NN indicated/VBD that/IN the/DT coadministration/NN of/IN Femara/NN with/IN these/DT drugs/NNS does/VBZ not/RB result/VB in/IN clinically-/JJ significant/JJ drug/NN interactions/NNS ./.

(ROOT (S1 (S (S (NP (NP (JJ Clinical) (NN interaction) (NNS studies)) (PP (IN with) (NP (NP (NN cimetidine)) (CC and) (NP (NN warfarin))))) (VP (VBD indicated) (SBAR (IN that) (S (NP (NP (DT the) (NN coadministration)) (PP (IN of) (NP (NN Femara))) (PP (IN with) (NP (DT these) (NNS drugs)))) (VP (VBZ does) (RB not) (VP (VB result) (PP (IN in) (NP (JJ clinically-) (JJ significant) (NN drug) (NNS interactions))))))))) (. .))))

Sentence Id: DrugDDI.d379.s1
(/-LRB- See/VB CLINICAL/JJ PHARMACOLOGY/NN )/-RRB- Coadministration/NN of/IN Femara/NN and/CC tamoxifen/NN 20/CD mg/NN daily/RB resulted/VBD in/IN a/DT reduction/NN of/IN letrozole/NN plasma/NN levels/NNS by/IN 38/CD %/NN on/IN average/NN ./.

(ROOT (S1 (S (NP (NP (S (-LRB- -LRB-) (VP (VB See) (NP (JJ CLINICAL) (NN PHARMACOLOGY))) (-RRB- -RRB-)) (NP (NN Coadministration)) (PP (IN of) (NP (NN Femara)))) (CC and) (NP (NP (NN tamoxifen) (CD 20) (NN mg)) (ADVP (RB daily)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (NN letrozole) (NN plasma) (NNS levels))) (PP (IN by) (NP (NP (CD 38) (NN %)) (PP (IN on) (NP (NN average)))))))) (. .))))

Sentence Id: DrugDDI.d379.s2
There/EX is/VBZ no/DT clinical/JJ experience/VBP to/TO date/VB on/IN the/DT use/NN of/IN Femara/NN in/IN combination/NN with/IN other/JJ anticancer/JJ agents/NNS ./.

(ROOT (S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (NP (DT no) (JJ clinical) (VBP experience)) (S (VP (TO to) (VP (VB date) (PP (IN on) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN Femara))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ other) (JJ anticancer) (NNS agents))))))))))))) (. .))))

Sentence Id: DrugDDI.d379.s3
Drug/NN /Laboratory/NN Test-Interactions/NN None/NN observed/VBN ./.

(ROOT (S1 (S (S (NP (NN Drug) (NN /Laboratory) (NN Test-Interactions) (NN None)) (VP (VBN observed))) (. .))))

Sentence Id: DrugDDI.d341.s0
Folic/JJ acid/NN in/IN large/JJ amounts/NNS may/MD counteract/VB the/DT antiepileptic/JJ effect/NN of/IN phenobarbital/NN ,/, phenytoin/NN and/CC primidone/NN ,/, and/CC increase/VB the/DT frequency/NN of/IN seizures/NNS in/IN susceptible/JJ pediatric/JJ patients/NNS ./.

(ROOT (S1 (S (S (NP (NP (JJ Folic) (NN acid)) (PP (IN in) (NP (JJ large) (NNS amounts)))) (VP (MD may) (VP (VP (VB counteract) (NP (NP (DT the) (JJ antiepileptic) (NN effect)) (PP (IN of) (NP (NP (NN phenobarbital)) (, ,) (NP (NN phenytoin)) (CC and) (NP (NN primidone)))))) (, ,) (CC and) (VP (VB increase) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NNS seizures))) (PP (IN in) (NP (JJ susceptible) (JJ pediatric) (NNS patients)))))))) (. .))))

Sentence Id: DrugDDI.d341.s1
Preliminary/JJ animal/JJ and/CC human/JJ studies/NNS have/VBP shown/VBN that/IN small/JJ quantities/NNS of/IN systemically/RB administered/VBN leucovorin/NN enter/VBP the/DT CSF/NN primarily/RB as/IN 5-methyltetrahydro-folate/NN and/CC ,/, in/IN humans/NNS ,/, remain/VBP 1/CD to/TO 3/CD orders/NNS of/IN magnitude/NN lower/JJR than/IN the/DT usual/JJ methotrexate/NN concentrations/NNS following/VBG intrathecal/JJ administration/NN ./.

(ROOT (S1 (S (S (NP (JJ Preliminary) (ADJP (ADJP (JJ animal)) (CC and) (ADJP (JJ human))) (NNS studies)) (VP (VBP have) (VP (VBN shown) (PP (IN that) (S (NP (NP (JJ small) (NNS quantities)) (PP (IN of) (NP (ADJP (RB systemically) (VBN administered)) (NN leucovorin)))) (VP (VP (VBP enter) (NP (DT the) (NN CSF)) (PP (ADVP (RB primarily)) (IN as) (NP (NN 5-methyltetrahydro-folate)))) (CC and) (, ,) (PP (IN in) (NP (NNS humans))) (, ,) (VP (VBP remain) (NP (NP (QP (CD 1) (TO to) (CD 3)) (NNS orders)) (PP (IN of) (NP (NN magnitude))) (ADJP (JJR lower) (PP (IN than) (NP (NP (DT the) (JJ usual) (NN methotrexate) (NNS concentrations)) (VP (VBG following) (NP (JJ intrathecal) (NN administration)))))))))))))) (. .))))

Sentence Id: DrugDDI.d341.s2
However/RB ,/, high/JJ doses/NNS of/IN leucovorin/NN may/MD reduce/VB the/DT efficacy/NN of/IN intrathecally/RB administered/VBN methotrexate/NN ./.

(ROOT (S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NN leucovorin)))) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (ADJP (RB intrathecally) (VBN administered)) (NN methotrexate))))))) (. .))))

Sentence Id: DrugDDI.d341.s3
Leucovorin/NN may/MD enhance/VB the/DT toxicity/NN of/IN 5-/CD fluorouracil/NN ./.

(ROOT (S1 (S (S (NP (NN Leucovorin)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NN toxicity)) (PP (IN of) (NP (CD 5-) (NN fluorouracil))))))) (. .))))

Sentence Id: DrugDDI.d484.s0
Although/IN BETAGAN/NN used/VBN alone/RB has/VBZ little/JJ or/CC no/DT effect/NN on/IN pupil/NN size/NN ,/, mydriasis/NNS resulting/VBG from/IN concomitant/JJ therapy/NN with/IN BETAGAN/NN and/CC epinephrine/NN may/MD occur/VB ./.

(ROOT (S1 (S (S (SBAR (IN Although) (S (NP (NP (NN BETAGAN)) (VP (VBN used) (ADVP (RB alone)))) (VP (VBZ has) (NP (NP (ADJP (JJ little))) (CC or) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NN pupil) (NN size)))))))) (, ,) (NP (NP (NNS mydriasis)) (VP (VBG resulting) (PP (IN from) (NP (NP (JJ concomitant) (NN therapy)) (PP (IN with) (NP (NP (NN BETAGAN)) (CC and) (NP (NN epinephrine)))))))) (VP (MD may) (VP (VB occur)))) (. .))))

Sentence Id: DrugDDI.d484.s1
Close/JJ observation/NN of/IN the/DT patient/NN is/VBZ recommended/VBN when/WRB a/DT beta-blocker/NN is/VBZ administered/VBN to/TO patients/NNS receiving/VBG catecholamine-depleting/JJ drugs/NNS such/JJ as/IN reserpine/NN ,/, because/IN of/IN possible/JJ additive/JJ effects/NNS and/CC the/DT production/NN of/IN hypotension/NN and/or/CC marked/JJ bradycardia/NN ,/, which/WDT may/MD produce/VB vertigo/NN ,/, syncope/NN or/CC postural/JJ hypotension/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Close) (NN observation)) (PP (IN of) (NP (DT the) (NN patient)))) (VP (VBZ is) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (NP (DT a) (NN beta-blocker)) (VP (VBZ is) (VP (VBN administered) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (JJ catecholamine-depleting) (NNS drugs)) (PP (JJ such) (IN as) (NP (NN reserpine))) (, ,) (PP (IN because) (PP (IN of) (NP (NP (JJ possible) (JJ additive) (NNS effects)) (CC and) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NP (NN hypotension)) (CC and/or) (NP (JJ marked) (NN bradycardia)))))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB produce) (NP (NP (NN vertigo)) (, ,) (NP (NN syncope)) (CC or) (NP (JJ postural) (NN hypotension)))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d484.s2
Patients/NNS receiving/VBG beta-adrenergic/JJ blocking/NN agents/NNS along/IN with/IN either/CC oral/JJ or/CC intravenous/JJ calcium/NN antagonist/NN s/NN should/MD be/VB monitored/VBN for/IN possible/JJ atrioventricular/JJ conduction/NN disturbances/NNS ,/, left/JJ ventricular/NN failure/NN and/CC hypotension/NN ./.

(ROOT (S1 (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (JJ beta-adrenergic) (NN blocking) (NNS agents)) (PP (IN along) (PP (IN with) (NP (ADJP (CC either) (ADJP (JJ oral)) (CC or) (ADJP (JJ intravenous))) (NN calcium) (NN antagonist) (NN s)))))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (PP (IN for) (NP (NP (JJ possible) (JJ atrioventricular) (NN conduction) (NNS disturbances)) (, ,) (NP (NP (JJ left) (NN ventricular)) (NN failure)) (CC and) (NP (NN hypotension))))))) (. .))))

Sentence Id: DrugDDI.d484.s4
The/DT concomitant/JJ use/NN of/IN beta-adrenergic/JJ blocking/NN agents/NNS with/IN digitalis/NN and/CC calcium/NN antagonist/NN s/NN may/MD have/VB additive/JJ effects/NNS on/IN prolonging/VBG atrioventricular/JJ conduction/NN time/NN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (JJ beta-adrenergic) (NN blocking) (NNS agents)) (PP (IN with) (NP (NP (NN digitalis)) (CC and) (NP (NN calcium) (NN antagonist) (NN s))))))) (VP (MD may) (VP (VB have) (NP (JJ additive) (NNS effects)) (PP (IN on) (S (VP (VBG prolonging) (NP (JJ atrioventricular) (NN conduction) (NN time)))))))) (. .))))

Sentence Id: DrugDDI.d484.s5
Phenothiazine/JJ -related/JJ compounds/NNS and/CC beta-adrenergic/JJ blocking/NN agents/NNS may/MD have/VB additive/JJ hypotensite/JJ effects/NNS due/JJ to/TO the/DT inhibition/NN of/IN each/DT other/JJ @/NN s/NN metabolism/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Phenothiazine) (JJ -related) (NNS compounds)) (CC and) (NP (JJ beta-adrenergic) (NN blocking) (NNS agents))) (VP (MD may) (VP (VB have) (NP (JJ additive) (JJ hypotensite) (NNS effects)) (PP (JJ due) (TO to) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (DT each) (JJ other) (NN @) (NN s) (NN metabolism)))))))) (. .))))

Sentence Id: DrugDDI.d112.s0
No/DT significant/JJ drug-drug/JJ pharmacokinetic/JJ interactions/NNS have/VBP been/VBN found/VBN in/IN interaction/NN studies/NNS with/IN hydrochlorothiazide/NN ,/, digoxin/NN ,/, warfarin/NN ,/, cimetidine/NN and/CC phenobarbital/NN ./.

(ROOT (S1 (S (S (NP (DT No) (JJ significant) (JJ drug-drug) (JJ pharmacokinetic) (NNS interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN found) (PP (IN in) (NP (NP (NN interaction) (NNS studies)) (PP (IN with) (NP (NP (NN hydrochlorothiazide)) (, ,) (NP (NN digoxin)) (, ,) (NP (NN warfarin)) (, ,) (NP (NN cimetidine)) (CC and) (NP (NN phenobarbital)))))))))) (. .))))

Sentence Id: DrugDDI.d112.s1
Rifampin/NN ,/, an/DT inducer/NN of/IN drug/NN metabolism/NN ,/, decreased/VBD the/DT concentrations/NNS of/IN losartan/NN and/CC its/PRP$ active/JJ metabolite/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Rifampin)) (, ,) (NP (NP (DT an) (NN inducer)) (PP (IN of) (NP (NN drug) (NN metabolism)))) (, ,)) (VP (VBD decreased) (NP (NP (DT the) (NNS concentrations)) (PP (IN of) (NP (NP (NN losartan)) (CC and) (NP (PRP$ its) (JJ active) (NN metabolite))))))) (. .))))

Sentence Id: DrugDDI.d112.s2
In/IN humans/NNS ,/, two/CD inhibitors/NNS of/IN P450/NN 3A4/NN have/VBP been/VBN studied/VBN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (NNS humans))) (, ,) (NP (NP (CD two) (NNS inhibitors)) (PP (IN of) (NP (NN P450) (NN 3A4)))) (VP (VBP have) (VP (VBN been) (VP (VBN studied))))) (. .))))

Sentence Id: DrugDDI.d112.s3
Ketoconazole/NN did/VBD not/RB affect/VB the/DT conversion/NN of/IN losartan/NN to/TO the/DT active/JJ metabolite/NN after/IN intravenous/JJ administration/NN of/IN losartan/NN ,/, and/CC erythromycin/NN had/VBD no/DT clinically/RB significant/JJ effect/NN after/IN oral/JJ administration/NN ./.

(ROOT (S1 (S (S (S (NP (NN Ketoconazole)) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (DT the) (NN conversion)) (PP (IN of) (NP (NN losartan))) (PP (TO to) (NP (NP (DT the) (JJ active) (NN metabolite)) (PP (IN after) (NP (NP (JJ intravenous) (NN administration)) (PP (IN of) (NP (NN losartan))))))))))) (, ,) (CC and) (S (NP (NN erythromycin)) (VP (VBD had) (NP (DT no) (ADJP (RB clinically) (JJ significant)) (NN effect)) (PP (IN after) (NP (JJ oral) (NN administration)))))) (. .))))

Sentence Id: DrugDDI.d112.s4
Fluconazole/NN ,/, an/DT inhibitor/NN of/IN P450/NN 2C9/NNS ,/, decreased/VBD active/JJ metabolite/NN concentration/NN and/CC increased/VBD losartan/NN concentration/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Fluconazole)) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN P450) (NNS 2C9)))) (, ,)) (VP (VP (VBD decreased) (NP (JJ active) (NN metabolite) (NN concentration))) (CC and) (VP (VBD increased) (NP (NN losartan) (NN concentration))))) (. .))))

Sentence Id: DrugDDI.d112.s5
The/DT pharmacodynamic/JJ consequences/NNS of/IN concomitant/JJ use/NN of/IN losartan/NN and/CC inhibitors/NNS of/IN P450/NN 2C9/NNS have/VBP not/RB been/VBN examined/VBN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (JJ pharmacodynamic) (NNS consequences)) (PP (IN of) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN losartan)) (CC and) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (NN P450) (NNS 2C9))))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN examined))))) (. .))))

Sentence Id: DrugDDI.d112.s6
Subjects/NNS who/WP do/VBP not/RB metabolize/VB losartan/NN to/TO active/JJ metabolite/NN have/VBP been/VBN shown/VBN to/TO have/VB a/DT specific/JJ ,/, rare/JJ defect/NN in/IN cytochrome/NN P450/NN 2C9/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Subjects)) (SBAR (WHNP (WP who)) (S (VP (VBP do) (RB not) (VP (VB metabolize) (NP (NP (NN losartan)) (PP (TO to) (NP (JJ active) (NN metabolite))))))))) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB have) (NP (DT a) (ADJP (ADJP (JJ specific)) (, ,) (ADJP (JJ rare))) (NN defect)) (PP (IN in) (NP (NN cytochrome) (NN P450) (NN 2C9)))))))))) (. .))))

Sentence Id: DrugDDI.d112.s7
These/DT data/NNS suggest/VBP that/IN the/DT conversion/NN of/IN losartan/NN to/TO its/PRP$ active/JJ metabolite/NN is/VBZ mediated/VBN primarily/RB by/IN P450/NN 2C9/NN and/CC not/RB P450/NN 3A4/NN ./.

(ROOT (S1 (S (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN conversion)) (PP (IN of) (NP (NN losartan))) (PP (TO to) (NP (PRP$ its) (JJ active) (NN metabolite)))) (VP (VP (VBZ is) (VP (VBN mediated) (ADVP (RB primarily)) (PP (IN by) (NP (NN P450) (NN 2C9))))) (CC and) (VP (ADVP (RB not)) (NP (NN P450) (NN 3A4)))))))) (. .))))

Sentence Id: DrugDDI.d112.s8
As/IN with/IN other/JJ drugs/NNS that/WDT block/VBP angiotensin/NN II/CD or/CC its/PRP$ effects/NNS ,/, concomitant/JJ use/NN of/IN potassium-sparing/JJ diuretics/NNS (/-LRB- e.g./FW ,/, spironolactone/NN ,/, triamterene/NN ,/, amiloride/NN )/-RRB- ,/, potassium/NN supplement/NN s/NNS ,/, or/CC salt/NN substitutes/VBZ containing/VBG potassium/NN may/MD lead/VB to/TO increases/NNS in/IN serum/NN potassium/NN ./.

(ROOT (S1 (S (PP (IN As) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP block) (NP (NP (NN angiotensin) (CD II)) (CC or) (NP (PRP$ its) (NNS effects))))))))) (, ,) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NP (JJ potassium-sparing) (NNS diuretics)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN spironolactone)) (, ,) (NP (NN triamterene)) (, ,) (NP (NN amiloride)))) (-RRB- -RRB-))) (, ,) (NP (NN potassium) (NN supplement) (NNS s)) (, ,) (CC or) (NP (NP (NN salt) (VBZ substitutes)) (VP (VBG containing) (NP (NN potassium))))))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (NNS increases)) (PP (IN in) (NP (NN serum) (NN potassium))))))) (. .))))

Sentence Id: DrugDDI.d112.s9
As/IN with/IN other/JJ antihypertensive/JJ agents/NNS ,/, the/DT antihypertensive/JJ effect/NN of/IN losartan/NN may/MD be/VB blunted/VBN by/IN the/DT non-steroidal/JJ anti-inflammatory/JJ drug/NN indomethacin/NN ./.

(ROOT (S1 (S (S (PP (IN As) (PP (IN with) (NP (JJ other) (JJ antihypertensive) (NNS agents)))) (, ,) (NP (NP (DT the) (JJ antihypertensive) (NN effect)) (PP (IN of) (NP (NN losartan)))) (VP (MD may) (VP (VB be) (VP (VBN blunted) (PP (IN by) (NP (NP (DT the) (JJ non-steroidal) (JJ anti-inflammatory) (NN drug)) (NN indomethacin))))))) (. .))))

Sentence Id: DrugDDI.d464.s0
When/WRB administered/VBN concurrently/RB ,/, the/DT following/VBG drugs/NNS may/MD interact/VB with/IN beta-adrenergic/JJ receptor/NN blocking/NN agents/NNS :/: Anesthetics/NN ,/, general/JJ :/: exaggeration/NN of/IN the/DT hypotension/NN induced/VBN by/IN general/JJ anesthetics/NNS ./.

(ROOT (S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN administered) (ADVP (RB concurrently))))) (, ,) (NP (DT the) (VBG following) (NNS drugs)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NP (JJ beta-adrenergic) (NN receptor) (NN blocking) (NNS agents)) (: :) (NP (NP (NN Anesthetics)) (, ,) (NP (ADJP (JJ general))) (: :) (NP (NP (NN exaggeration)) (PP (IN of) (NP (NP (DT the) (NN hypotension)) (VP (VBN induced) (PP (IN by) (NP (JJ general) (NNS anesthetics))))))))))))) (. .))))

Sentence Id: DrugDDI.d464.s1
Antidiabetic/JJ drugs/NNS (/-LRB- oral/JJ agents/NNS and/CC insulin/NN )/-RRB- :/: hypoglycemia/NN or/CC hyperglycemia/NN ;/: ./.

(ROOT (S1 (S (S (NP (NP (NP (JJ Antidiabetic) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NP (JJ oral) (NNS agents)) (CC and) (NP (NN insulin))) (-RRB- -RRB-))) (: :) (NP (NP (NN hypoglycemia)) (CC or) (NP (NN hyperglycemia))) (: ;))) (. .))))

Sentence Id: DrugDDI.d464.s2
adjust/VB dosage/NN of/IN antidiabetic/JJ drug/NN accordingly/RB ./.

(ROOT (S1 (S (S (VP (VB adjust) (NP (NP (NN dosage)) (PP (IN of) (NP (JJ antidiabetic) (NN drug)))) (ADVP (RB accordingly)))) (. .))))

Sentence Id: DrugDDI.d464.s3
Catecholamine-depleting/JJ drugs/NNS (/-LRB- e.g./FW ,/, reserpine/NN )/-RRB- :/: additive/JJ effect/NN ;/: ./.

(ROOT (S1 (S (S (NP (NP (JJ Catecholamine-depleting) (NNS drugs)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN reserpine))) (-RRB- -RRB-))) (: :) (NP (JJ additive) (NN effect)) (: ;)) (. .))))

Sentence Id: DrugDDI.d464.s5
Response/NN to/TO Treatment/NN for/IN Anaphylactic/JJ Reaction/NN :/: While/IN taking/VBG beta-blockers/NN ,/, patients/NNS with/IN a/DT history/NN of/IN severe/JJ anaphylactic/JJ reaction/NN to/TO a/DT variety/NN of/IN allergens/NNS may/MD be/VB more/RBR reactive/JJ to/TO repeated/JJ challenge/NN ,/, either/CC accidental/JJ ,/, diagnostic/JJ ,/, or/CC therapeutic/JJ ./.

(ROOT (S1 (S (NP (NP (NP (NN Response)) (PP (TO to) (NP (NP (NN Treatment)) (PP (IN for) (NP (JJ Anaphylactic) (NN Reaction)))))) (: :) (S (SBAR (IN While) (S (VP (VBG taking) (NP (NN beta-blockers))))) (, ,) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NP (JJ severe) (JJ anaphylactic) (NN reaction)) (PP (TO to) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NNS allergens)))))))))) (VP (MD may) (VP (VB be) (ADJP (ADJP (RBR more) (JJ reactive) (PP (TO to) (NP (JJ repeated) (NN challenge)))) (, ,) (CC either) (ADJP (JJ accidental)) (, ,) (ADJP (JJ diagnostic)) (, ,) (CC or) (ADJP (JJ therapeutic)))))) (. .)))))

Sentence Id: DrugDDI.d464.s6
Such/JJ patients/NNS may/MD be/VB unresponsive/JJ to/TO the/DT usual/JJ doses/NNS of/IN epinephrine/NN used/VBN to/TO treat/VB allergic/JJ reaction/NN ./.

(ROOT (S1 (S (S (NP (JJ Such) (NNS patients)) (VP (MD may) (VP (VB be) (ADJP (JJ unresponsive) (PP (TO to) (NP (NP (DT the) (JJ usual) (NNS doses)) (PP (IN of) (NP (NN epinephrine))) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (JJ allergic) (NN reaction)))))))))))) (. .))))

Sentence Id: DrugDDI.d485.s0
Elevated/JJ plasma/NN levels/NNS of/IN theophylline/NN have/VBP been/VBN reported/VBN with/IN concomitant/JJ quinolone/NN use/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Elevated) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN theophylline)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (JJ concomitant) (NN quinolone) (NN use))))))) (. .))))

Sentence Id: DrugDDI.d485.s1
There/EX have/VBP been/VBN reports/NNS of/IN theophylline/NN -related/JJ side/JJ effects/NNS in/IN patients/NNS on/IN concomitant/JJ therapy/NN with/IN quinolones/NNS and/CC theophylline/NN ./.

(ROOT (S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (NNS reports)) (PP (IN of) (NP (NP (ADJP (NN theophylline) (JJ -related)) (JJ side) (NNS effects)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (NP (JJ concomitant) (NN therapy)) (PP (IN with) (NP (NP (NNS quinolones)) (CC and) (NP (NN theophylline)))))))))))))) (. .))))

Sentence Id: DrugDDI.d485.s2
Therefore/RB ,/, monitoring/NN of/IN theophylline/NN plasma/NN levels/NNS should/MD be/VB considered/VBN and/CC dosage/NN of/IN theophylline/NN adjusted/VBN ,/, as/IN required/VBN ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN monitoring)) (PP (IN of) (NP (NN theophylline) (NN plasma) (NNS levels)))) (VP (MD should) (VP (VB be) (VP (VP (VBN considered)) (CC and) (VP (NP (NP (NN dosage)) (PP (IN of) (NP (NP (NN theophylline)) (VP (VBN adjusted))))) (, ,) (SBAR (IN as) (S (VP (VBN required))))))))) (. .))))

Sentence Id: DrugDDI.d485.s3
Quinolones/NNS have/VBP been/VBN shown/VBN to/TO interfere/VB with/IN the/DT metabolism/NN of/IN caffeine/NN ./.

(ROOT (S1 (S (S (NP (NNS Quinolones)) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN caffeine)))))))))))) (. .))))

Sentence Id: DrugDDI.d485.s4
This/DT may/MD lead/VB to/TO reduced/VBN clearance/NN of/IN caffeine/NN and/CC the/DT prolongation/NN of/IN its/PRP$ plasma/NN half-life/NN ./.

(ROOT (S1 (S (S (NP (DT This)) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (NP (VBN reduced) (NN clearance)) (PP (IN of) (NP (NN caffeine)))) (CC and) (NP (NP (DT the) (NN prolongation)) (PP (IN of) (NP (PRP$ its) (NN plasma) (NN half-life))))))))) (. .))))

Sentence Id: DrugDDI.d485.s5
Quinolones/NNS ,/, including/VBG nalidixic/JJ acid/NN ,/, may/MD enhance/VB the/DT effects/NNS of/IN the/DT oral/JJ anticoagulant/NN warfarin/NN or/CC its/PRP$ derivatives/NNS ./.

(ROOT (S1 (S (S (NP (NP (NNS Quinolones)) (, ,) (PP (VBG including) (NP (JJ nalidixic) (NN acid))) (, ,)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (DT the) (JJ oral) (NN anticoagulant) (NN warfarin)) (CC or) (NP (PRP$ its) (NNS derivatives)))))))) (. .))))

Sentence Id: DrugDDI.d485.s7
Nitrofurantoin/NN interferes/VBZ with/IN the/DT therapeutic/JJ action/NN of/IN nalidixic/JJ acid/NN ./.

(ROOT (S1 (S (S (NP (NN Nitrofurantoin)) (VP (VBZ interferes) (PP (IN with) (NP (NP (DT the) (JJ therapeutic) (NN action)) (PP (IN of) (NP (JJ nalidixic) (NN acid))))))) (. .))))

Sentence Id: DrugDDI.d485.s8
Antacids/NNS containing/VBG magnesium/NN ,/, aluminum/NN ,/, or/CC calcium/NN ;/: ./.

(ROOT (S1 (S (S (NP (NNS Antacids)) (VP (VBG containing) (NP (NP (NN magnesium)) (, ,) (NP (NN aluminum)) (, ,) (CC or) (NP (NN calcium)))) (: ;)) (. .))))

Sentence Id: DrugDDI.d485.s9
sucralfate/VBP or/CC divalent/JJ or/CC trivalent/JJ cations/NNS such/JJ as/IN iron/NN ;/: ./.

(ROOT (S1 (S (S (VP (VBP sucralfate) (NP (NP (ADJP (CC or) (ADJP (JJ divalent)) (CC or) (ADJP (JJ trivalent))) (NNS cations)) (PP (JJ such) (IN as) (NP (NN iron) (: ;)))))) (. .))))

Sentence Id: DrugDDI.d485.s10
multivitamins/NNS containing/VBG zinc/NN ;/: ./.

(ROOT (S1 (S (S (NP (NNS multivitamins)) (VP (VBG containing) (NP (NN zinc))) (: ;)) (. .))))

Sentence Id: DrugDDI.d485.s11
and/CC Videx/NN @/NN ,/, (/-LRB- Didanosine/NN )/-RRB- ,/, chewable//NN buffer/NN ed/NN tablets/NNS or/CC the/DT pediatric/JJ powder/NN for/IN oral/JJ solution/NN may/MD substantially/RB interfere/VB with/IN the/DT absorption/NN of/IN quinolones/NNS ,/, resulting/VBG in/IN systemic/JJ levels/NNS considerably/RB lower/JJR than/IN desired/VBN ./.

(ROOT (S1 (S (S (NP (CC and) (NP (NP (NN Videx) (NN @)) (, ,) (NP (-LRB- -LRB-) (NN Didanosine) (-RRB- -RRB-)) (, ,) (NP (NN chewable/) (NN buffer) (NN ed) (NNS tablets))) (CC or) (NP (NP (DT the) (JJ pediatric) (NN powder)) (PP (IN for) (NP (JJ oral) (NN solution))))) (VP (MD may) (ADVP (RB substantially)) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NNS quinolones))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (JJ systemic) (NNS levels)) (ADJP (ADJP (RB considerably) (JJR lower)) (SBAR (IN than) (S (VP (VBN desired)))))))))))) (. .))))

Sentence Id: DrugDDI.d485.s12
These/DT agents/NNS should/MD not/RB be/VB taken/VBN within/IN the/DT two/CD hour/NN period/NN before/IN or/CC within/IN the/DT two-hour/JJ period/NN after/IN nalidixic/JJ acid/NN administration/NN ./.

(ROOT (S1 (S (S (NP (DT These) (NNS agents)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN taken) (PP (IN within) (NP (DT the) (ADJP (CD two) (NN hour)) (NN period))) (PP (PP (IN before)) (CC or) (PP (IN within) (NP (DT the) (JJ two-hour) (NN period))) (PP (IN after) (NP (NP (JJ nalidixic) (NN acid)) (NN administration)))))))) (. .))))

Sentence Id: DrugDDI.d485.s13
Elevated/JJ serum/NN levels/NNS of/IN cyclosporine/NN have/VBP been/VBN reported/VBN with/IN the/DT concomitant/JJ use/NN of/IN some/DT quinolones/NN and/CC cyclosporine/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Elevated) (NN serum) (NNS levels)) (PP (IN of) (NP (NN cyclosporine)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NP (DT the) (JJ concomitant) (NN use)) (PP (IN of) (NP (DT some) (NP (NP (NN quinolones)) (CC and) (NP (NN cyclosporine))))))))))) (. .))))

Sentence Id: DrugDDI.d485.s14
Therefore/RB ,/, cyclosporine/NN serum/NN levels/NNS should/MD be/VB monitored/VBN and/CC appropriate/JJ cyclosporine/NN dosage/NN adjustments/NNS made/VBD when/WRB these/DT drugs/NNS are/VBP used/VBN concomitantly/RB ./.

(ROOT (S1 (S (S (S (ADVP (RB Therefore)) (, ,) (NP (NN cyclosporine) (NN serum) (NNS levels)) (VP (MD should) (VP (VB be) (VP (VBN monitored))))) (CC and) (S (NP (JJ appropriate) (NN cyclosporine) (NN dosage) (NNS adjustments)) (VP (VBD made) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (NNS drugs)) (VP (VBP are) (VP (VBN used) (ADVP (RB concomitantly))))))))) (. .))))

Sentence Id: DrugDDI.d249.s0
In/FW vitro/FW drug/NN metabolism/NN studies/NNS indicate/VBP that/IN Starlix/NN is/VBZ predominantly/RB metabolized/VBN by/IN the/DT cytochrome/NN P450/NN isozyme/NN CYP2C9/NN (/-LRB- 70/CD %/NN )/-RRB- and/CC to/TO a/DT lesser/JJR extent/NN CYP3A4/NN (/-LRB- 30%)./NN

(ROOT (S1 (S (NP (ADJP (FW In) (FW vitro)) (NN drug) (NN metabolism) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN Starlix)) (VP (VBZ is) (ADVP (RB predominantly)) (VP (VBN metabolized) (PP (PP (IN by) (NP (NP (DT the) (NN cytochrome) (NN P450) (NN isozyme) (NN CYP2C9)) (PRN (-LRB- -LRB-) (NP (CD 70) (NN %)) (-RRB- -RRB-)))) (CC and) (PP (TO to) (NP (DT a) (JJR lesser) (NN extent))) (NP (NN CYP3A4))) (PRN (-LRB- -LRB-) (NP (NN 30%-RRB-.)))))))))))

Sentence Id: DrugDDI.d249.s1
Starlix/NN is/VBZ a/DT potential/JJ inhibitor/NN of/IN the/DT CYP2C9/NN isoenzyme/NN in/FW vivo/FW as/IN indicated/VBN by/IN its/PRP$ ability/NN to/TO inhibit/VB the/DT in/FW vitro/FW metabolism/NN of/IN tolbutamide/NN ./.

(ROOT (S1 (S (S (NP (NN Starlix)) (VP (VBZ is) (NP (NP (DT a) (JJ potential) (NN inhibitor)) (PP (IN of) (NP (DT the) (NN CYP2C9) (NN isoenzyme)))) (ADVP (FW in) (FW vivo)) (SBAR (IN as) (S (VP (VBN indicated) (PP (IN by) (NP (PRP$ its) (NN ability) (S (VP (TO to) (VP (VB inhibit) (NP (NP (DT the) (ADJP (FW in) (FW vitro)) (NN metabolism)) (PP (IN of) (NP (NN tolbutamide)))))))))))))) (. .))))

Sentence Id: DrugDDI.d249.s2
Inhibition/NN of/IN CYP3A4/JJ metabolic/JJ reactions/NNS was/VBD not/RB detected/VBN in/IN in/FW vitro/FW experiments/NNS ./.

(ROOT (S1 (S (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (JJ CYP3A4) (JJ metabolic) (NNS reactions)))) (VP (VBD was) (RB not) (VP (VBN detected) (PP (IN in) (NP (ADJP (FW in) (FW vitro)) (NNS experiments)))))) (. .))))

Sentence Id: DrugDDI.d249.s3
Glyburide/NN :/: In/IN a/DT randomized/JJ ,/, multiple-dose/JJ crossover/NN study/NN ,/, patients/NNS with/IN Type/NN 2/CD diabetes/NNS were/VBD administered/VBN 120/CD mg/NN Starlix/NN three/CD times/NNS a/DT day/NN before/IN meals/NN for/IN 1/CD day/NN in/IN combination/NN with/IN glyburide/NN 10/CD mg/NN daily/RB ./.

(ROOT (S1 (S (NP (NP (NN Glyburide)) (: :) (S (PP (IN In) (NP (DT a) (ADJP (ADJP (JJ randomized)) (, ,) (ADJP (JJ multiple-dose))) (NN crossover) (NN study))) (, ,) (NP (NP (NNS patients)) (PP (IN with) (NP (NN Type) (CD 2) (NNS diabetes)))) (VP (VBD were) (VP (VBN administered) (NP (NP (CD 120) (NN mg) (NN Starlix) (CD three) (NNS times)) (NP (NP (DT a) (NN day)) (PP (IN before) (NP (NN meals))) (PP (IN for) (NP (CD 1) (NN day))))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NN glyburide) (CD 10) (NN mg)) (ADVP (RB daily))))))))) (. .)))))

Sentence Id: DrugDDI.d249.s5
Metformin/NN :/: When/WRB Starlix/NN 120/CD mg/NN three/CD times/NNS daily/RB before/IN meals/NN was/VBD administered/VBN in/IN combination/NN with/IN metformin/NN 500/CD mg/NN three/CD times/NNS daily/JJ to/TO patients/NNS with/IN Type/NN 2/CD diabetes/NNS ,/, there/EX were/VBD no/DT clinically/RB relevant/JJ changes/NNS in/IN the/DT pharmacokinetics/NNS of/IN either/DT agent/NN ./.

(ROOT (S1 (S (NP (NP (NN Metformin)) (: :) (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NN Starlix) (CD 120) (NN mg)) (ADVP (NP (CD three) (NNS times)) (RB daily) (PP (IN before) (NP (NN meals))))) (VP (VBD was) (VP (VBN administered) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NN metformin) (CD 500) (NN mg) (CD three) (NNS times)) (ADJP (JJ daily) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (NN Type) (CD 2) (NNS diabetes)))))))))))))) (, ,) (NP (EX there)) (VP (VBD were) (NP (NP (DT no) (ADJP (RB clinically) (JJ relevant)) (NNS changes)) (PP (IN in) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (DT either) (NN agent)))))))) (. .)))))

Sentence Id: DrugDDI.d249.s6
Digoxin/NN :/: When/WRB Starlix/NN 120/CD mg/NN before/IN meals/NN was/VBD administered/VBN in/IN combination/NN with/IN a/DT single/JJ 1-mg/JJ dose/NN of/IN digoxin/NN to/TO healthy/JJ volunteers/NNS ,/, there/EX were/VBD no/DT clinically/RB relevant/JJ changes/NNS in/IN the/DT pharmacokinetics/NNS of/IN either/DT agent/NN ./.

(ROOT (S1 (S (NP (NP (NN Digoxin)) (: :) (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NN Starlix) (CD 120) (NN mg)) (PP (IN before) (NP (NN meals)))) (VP (VBD was) (VP (VBN administered) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (DT a) (JJ single) (JJ 1-mg) (NN dose)) (PP (IN of) (NP (NN digoxin))) (PP (TO to) (NP (JJ healthy) (NNS volunteers))))))))))) (, ,) (NP (EX there)) (VP (VBD were) (NP (NP (DT no) (ADJP (RB clinically) (JJ relevant)) (NNS changes)) (PP (IN in) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (DT either) (NN agent)))))))) (. .)))))

Sentence Id: DrugDDI.d249.s7
Warfarin/NN :/: When/WRB healthy/JJ subjects/NNS were/VBD administered/VBN Starlix/NN 120/CD mg/NN three/CD times/NNS daily/RB before/IN meals/NN for/IN four/CD days/NNS in/IN combination/NN with/IN a/DT single/JJ dose/NN of/IN warfarin/NN 30/CD mg/NN on/IN day/NN 2/CD ,/, there/EX were/VBD no/DT alterations/NNS in/IN the/DT pharmacokinetics/NNS of/IN either/DT agent/NN ./.

(ROOT (S1 (S (NP (NP (NN Warfarin)) (: :) (S (SBAR (WHADVP (WRB When)) (S (NP (JJ healthy) (NNS subjects)) (VP (VBD were) (VP (VBN administered) (ADVP (NP (NN Starlix) (CD 120) (NN mg) (CD three) (NNS times)) (RB daily)) (PP (IN before) (NP (NN meals))) (PP (IN for) (NP (NP (CD four) (NNS days)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NP (NN warfarin) (CD 30) (NN mg)) (PP (IN on) (NP (NN day) (CD 2))))))))))))))) (, ,) (NP (EX there)) (VP (VBD were) (NP (DT no) (NNS alterations)) (PP (IN in) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (DT either) (NN agent))))))) (. .)))))

Sentence Id: DrugDDI.d249.s9
Diclofenac/NN :/: Administration/NN of/IN morning/NN and/CC lunch/NN doses/NNS of/IN Starlix/NN 120/CD mg/NN in/IN combination/NN with/IN a/DT single/JJ 75-mg/NN dose/NN of/IN diclofenac/NN in/IN healthy/JJ volunteers/NNS resulted/VBD in/IN no/DT significant/JJ changes/NNS to/TO the/DT pharmacokinetics/NNS of/IN either/DT agent/NN ./.

(ROOT (S1 (S (NP (NP (NN Diclofenac)) (: :) (S (NP (NP (NN Administration)) (PP (IN of) (NP (NP (NP (NP (NN morning)) (CC and) (NP (NN lunch))) (NNS doses)) (PP (IN of) (NP (NP (NN Starlix) (CD 120) (NN mg)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (DT a) (JJ single) (NN 75-mg) (NN dose)) (PP (IN of) (NP (NN diclofenac))) (PP (IN in) (NP (JJ healthy) (NNS volunteers)))))))))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT no) (JJ significant) (NNS changes)) (PP (TO to) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (DT either) (NN agent))))))))) (. .)))))

Sentence Id: DrugDDI.d249.s10
Nateglinide/NN is/VBZ highly/RB bound/VBN to/TO plasma/NN proteins/NNS (/-LRB- 98/CD %/NN )/-RRB- ,/, mainly/RB albumin/NN ./.

(ROOT (S1 (S (S (NP (NN Nateglinide)) (VP (VBZ is) (ADVP (RB highly)) (VP (VBN bound) (PP (TO to) (NP (NP (NP (NN plasma) (NNS proteins)) (PRN (-LRB- -LRB-) (NP (CD 98) (NN %)) (-RRB- -RRB-))) (, ,) (NP (ADVP (RB mainly)) (NP (NN albumin)))))))) (. .))))

Sentence Id: DrugDDI.d249.s11
In/FW vitro/FW displacement/NN studies/NNS with/IN highly/RB protein/NN -bound/JJ drugs/NNS such/JJ as/IN furosemide/NN ,/, propranolol/NN ,/, captopril/NN ,/, nicardipine/NN ,/, pravastatin/NN ,/, glyburide/NN ,/, warfarin/NN ,/, phenytoin/NN ,/, acetylsalicylic/JJ acid/NN ,/, tolbutamide/NN ,/, and/CC metformin/NN showed/VBD no/DT influence/NN on/IN the/DT extent/NN of/IN nateglinide/JJ protein/NN binding/NN ./.

(ROOT (S1 (S (S (NP (NP (ADJP (FW In) (FW vitro)) (NN displacement) (NNS studies)) (PP (IN with) (NP (NP (ADJP (RB highly) (NN protein) (JJ -bound)) (NNS drugs)) (PP (JJ such) (IN as) (NP (NP (NN furosemide)) (, ,) (NP (NN propranolol)) (, ,) (NP (NN captopril)) (, ,) (NP (NN nicardipine)) (, ,) (NP (NN pravastatin)) (, ,) (NP (NN glyburide)) (, ,) (NP (NN warfarin)) (, ,) (NP (NN phenytoin)) (, ,) (NP (JJ acetylsalicylic) (NN acid)) (, ,) (NP (NN tolbutamide)) (, ,) (CC and) (NP (NN metformin))))))) (VP (VBD showed) (NP (NP (DT no) (NN influence)) (PP (IN on) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (JJ nateglinide) (NN protein) (NN binding)))))))) (. .))))

Sentence Id: DrugDDI.d249.s12
Similarly/RB ,/, nateglinide/NN had/VBD no/DT influence/NN on/IN the/DT serum/NN protein/NN binding/NN of/IN propranolol/NN ,/, glyburide/NN ,/, nicardipine/NN ,/, warfarin/NN ,/, phenytoin/NN ,/, acetylsalicylic/JJ acid/NN ,/, and/CC tolbutamide/NN in/FW vitro/FW ./.

(ROOT (S1 (S (ADVP (RB Similarly)) (, ,) (NP (NN nateglinide)) (VP (VBD had) (NP (DT no) (NN influence)) (PP (IN on) (NP (NP (DT the) (NN serum) (NN protein) (NN binding)) (PP (IN of) (NP (NP (NN propranolol)) (, ,) (NP (NN glyburide)) (, ,) (NP (NN nicardipine)) (, ,) (NP (NN warfarin)) (, ,) (NP (NN phenytoin)) (, ,) (NP (JJ acetylsalicylic) (NN acid)) (, ,) (CC and) (NP (NN tolbutamide)))))) (ADVP (FW in) (FW vitro))) (. .))))

Sentence Id: DrugDDI.d249.s14
Certain/JJ drugs/NNS ,/, including/VBG nonsteroidal/JJ anti-inflammatory/JJ agents/NNS (/-LRB- NSAIDs/NNS )/-RRB- ,/, salicylates/NNS ,/, monoamine/NN oxidase/NN inhibitors/NNS ,/, and/CC non-selective/JJ beta-adrenergic-blocking/JJ agents/NNS may/MD potentiate/VB the/DT hypoglycemic/JJ action/NN of/IN Starlix/NN and/CC other/JJ oral/JJ antidiabetic/JJ drugs/NNS ./.

(ROOT (S1 (S (S (NP (NP (JJ Certain) (NNS drugs)) (, ,) (PP (VBG including) (NP (NP (NP (JJ nonsteroidal) (JJ anti-inflammatory) (NNS agents)) (PRN (-LRB- -LRB-) (NP (NNS NSAIDs)) (-RRB- -RRB-))) (, ,) (NP (NNS salicylates)) (, ,) (NP (NP (NN monoamine) (NN oxidase)) (NNS inhibitors)) (, ,) (CC and) (NP (JJ non-selective) (JJ beta-adrenergic-blocking) (NNS agents))))) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (JJ hypoglycemic) (NN action)) (PP (IN of) (NP (NP (NN Starlix)) (CC and) (NP (JJ other) (JJ oral) (JJ antidiabetic) (NNS drugs)))))))) (. .))))

Sentence Id: DrugDDI.d249.s15
Certain/JJ drugs/NNS including/VBG thiazides/NNS ,/, corticosteroids/NNS ,/, thyroid/NN products/NNS ,/, and/CC sympathomimetics/NNS may/MD reduce/VB the/DT hypoglycemic/JJ action/NN of/IN Starlix/NN and/CC other/JJ oral/JJ antidiabetic/JJ drugs/NNS ./.

(ROOT (S1 (S (S (NP (NP (JJ Certain) (NNS drugs)) (PP (VBG including) (NP (NP (NNS thiazides)) (, ,) (NP (NNS corticosteroids)) (, ,) (NP (NN thyroid) (NNS products)) (, ,) (CC and) (NP (NNS sympathomimetics))))) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (JJ hypoglycemic) (NN action)) (PP (IN of) (NP (NP (NN Starlix)) (CC and) (NP (JJ other) (JJ oral) (JJ antidiabetic) (NNS drugs)))))))) (. .))))

Sentence Id: DrugDDI.d249.s16
When/WRB these/DT drugs/NNS are/VBP administered/VBN to/TO or/CC withdrawn/VBN from/IN patients/NNS receiving/VBG Starlix/NN ,/, the/DT patient/NN should/MD be/VB observed/VBN closely/RB for/IN changes/NNS in/IN glycemic/JJ control/NN ./.

(ROOT (S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (DT these) (NNS drugs)) (VP (VBP are) (VP (VP (VBN administered) (PP (TO to))) (CC or) (VP (VBN withdrawn) (PP (IN from) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN Starlix)))))))))) (, ,) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (PP (IN for) (NP (NP (NNS changes)) (PP (IN in) (NP (JJ glycemic) (NN control))))))))) (. .))))

Sentence Id: DrugDDI.d312.s0
In/IN clinical/JJ studies/NNS ,/, Tilade/NN has/VBZ been/VBN co-administered/VBN with/IN other/JJ anti-asthma/NN medications/NNS ,/, including/VBG inhaled/JJ and/CC oral/JJ bronchodilators/NNS ,/, and/CC inhaled/JJ corticosteroids/NNS ,/, with/IN no/DT evidence/NN of/IN increased/VBN frequency/NN of/IN adverse/JJ events/NNS or/CC laboratory/NN abnormalities/NNS ./.

(ROOT (S1 (S (S (PP (IN In) (NP (JJ clinical) (NNS studies))) (, ,) (NP (NN Tilade)) (VP (VBZ has) (VP (VBN been) (VP (VBN co-administered) (PP (IN with) (NP (NP (NP (JJ other) (NN anti-asthma) (NNS medications)) (, ,) (PP (VBG including) (NP (JJ inhaled) (CC and) (JJ oral) (NNS bronchodilators))) (, ,)) (CC and) (NP (JJ inhaled) (NNS corticosteroids)))) (, ,) (PP (IN with) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (VBN increased) (NN frequency)) (PP (IN of) (NP (NP (JJ adverse) (NNS events)) (CC or) (NP (NN laboratory) (NNS abnormalities)))))))))))) (. .))))

Sentence Id: DrugDDI.d336.s0
Caution/NN should/MD be/VB taken/VBN in/IN concurrent/JJ or/CC serial/JJ use/NN of/IN other/JJ neurotoxic/JJ and//NN or/CC nephrotoxic/JJ drugs/NNS because/IN of/IN possible/JJ enhancement/NN of/IN the/DT nephrotoxicity/NN and/or/CC ototoxicity/NN of/IN neomycin/NN ./.

(ROOT (S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN taken) (PP (IN in) (NP (NP (ADJP (ADJP (JJ concurrent)) (CC or) (ADJP (JJ serial))) (NN use)) (PP (IN of) (NP (NP (JJ other) (JJ neurotoxic) (NN and/) (CC or) (JJ nephrotoxic) (NNS drugs)) (PP (IN because) (PP (IN of) (NP (NP (JJ possible) (NN enhancement)) (PP (IN of) (NP (NP (DT the) (NP (NN nephrotoxicity)) (CC and/or) (NP (NN ototoxicity))) (PP (IN of) (NP (NN neomycin)))))))))))))))) (. .))))

Sentence Id: DrugDDI.d336.s1
Caution/NN should/MD also/RB be/VB taken/VBN in/IN concurrent/JJ or/CC serial/JJ use/NN of/IN other/JJ aminoglycosides/NNS and/CC polymyxins/NNS because/IN they/PRP may/MD enhance/VB neomycin/NN @/NN s/NN nephrotoxicity/NN and/or/CC ototoxicity/NN and/CC potentiate/VB neomycin/NN sulfate/NN @/NN s/NN neuromuscular/JJ blocking/VBG effects/NNS ./.

(ROOT (S1 (S (S (NP (NN Caution)) (VP (MD should) (ADVP (RB also)) (VP (VB be) (VP (VBN taken) (PP (IN in) (NP (NP (ADJP (ADJP (JJ concurrent)) (CC or) (ADJP (JJ serial))) (NN use)) (PP (IN of) (NP (NP (JJ other) (NNS aminoglycosides)) (CC and) (NP (NNS polymyxins)))))) (SBAR (IN because) (S (NP (PRP they)) (VP (MD may) (VP (VP (VB enhance) (NP (NP (NN neomycin) (NN @) (NN s) (NN nephrotoxicity)) (CC and/or) (NP (NN ototoxicity)))) (CC and) (VP (VB potentiate) (NP (ADJP (NN neomycin) (NN sulfate) (NN @) (NN s) (JJ neuromuscular)) (VBG blocking) (NNS effects))))))))))) (. .))))

Sentence Id: DrugDDI.d336.s2
Oral/JJ neomycin/NN inhibits/VBZ the/DT gastrointestinal/JJ absorption/NN of/IN penicillin/NN V/NN ,/, oral/JJ vitamin/NN B-12/NN ,/, methotrexate/NN and/CC 5-fluorouracil/NN ./.

(ROOT (S1 (S (S (NP (JJ Oral) (NN neomycin)) (VP (VBZ inhibits) (NP (NP (NP (DT the) (JJ gastrointestinal) (NN absorption)) (PP (IN of) (NP (NN penicillin) (NN V)))) (, ,) (NP (JJ oral) (NN vitamin) (NN B-12)) (, ,) (NP (NP (NN methotrexate)) (CC and) (NP (NN 5-fluorouracil)))))) (. .))))

Sentence Id: DrugDDI.d336.s3
The/DT gastrointestinal/JJ absorption/NN of/IN digoxin/NN also/RB appears/VBZ to/TO be/VB inhibited/VBN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (JJ gastrointestinal) (NN absorption)) (PP (IN of) (NP (NN digoxin)))) (ADVP (RB also)) (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (VP (VBN inhibited))))))) (. .))))

Sentence Id: DrugDDI.d336.s5
Oral/JJ neomycin/NN sulfate/NN may/MD enhance/VB the/DT effect/NN of/IN coumarin/NN in/IN anticoagulants/NNS by/IN decreasing/VBG vitamin/NN K/NN availability/NN ./.

(ROOT (S1 (S (S (NP (JJ Oral) (NN neomycin) (NN sulfate)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN coumarin))) (PP (IN in) (NP (NNS anticoagulants)))) (PP (IN by) (S (VP (VBG decreasing) (NP (NN vitamin) (NN K) (NN availability)))))))) (. .))))

Sentence Id: DrugDDI.d266.s0
Beta-adrenergic/JJ Blocking/NN Agents/NNS :/: Experience/VBP in/IN over/IN 1400/CD patients/NNS in/IN a/DT non-comparative/JJ clinical/JJ trial/NN has/VBZ shown/VBN that/IN concomitant/JJ administration/NN of/IN nifedipine/NN and/CC beta-blocking/JJ agent/NN s/NNS is/VBZ usually/RB well/RB tolerated/VBN ,/, but/CC there/EX have/VBP been/VBN occasional/JJ literature/NN reports/NNS suggesting/VBG that/IN the/DT combination/NN may/MD increase/VBP the/DT likelihood/NN of/IN congestive/JJ heart/NN failure/NN ,/, severe/JJ hypotension/NN or/CC exacerbation/NN of/IN angina/NN ./.

(ROOT (S1 (S (NP (NP (JJ Beta-adrenergic) (NN Blocking) (NNS Agents)) (: :) (S (VP (VBP Experience) (PP (IN in) (NP (QP (IN over) (CD 1400)) (NNS patients))) (SBAR (IN in) (S (NP (DT a) (JJ non-comparative) (JJ clinical) (NN trial)) (VP (VBZ has) (VP (VBN shown) (SBAR (IN that) (S (S (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN nifedipine)) (CC and) (NP (JJ beta-blocking) (NN agent) (NNS s))))) (VP (VBZ is) (ADVP (RB usually)) (VP (ADVP (RB well)) (VBN tolerated)))) (, ,) (CC but) (S (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (NP (JJ occasional) (NN literature) (NNS reports)) (VP (VBG suggesting) (SBAR (IN that) (S (NP (DT the) (NN combination)) (VP (MD may) (VP (VBP increase) (NP (NP (DT the) (NN likelihood)) (PP (IN of) (NP (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (NP (JJ severe) (NN hypotension)) (CC or) (NP (NP (NN exacerbation)) (PP (IN of) (NP (NN angina)))))))))))))))))))))))) (. .)))))

Sentence Id: DrugDDI.d266.s1
Long/JJ Acting/NN Nitrates/NNS :/: Nifedipine/NN may/MD be/VB safely/RB co-administered/VBN with/IN nitrates/NNS ,/, but/CC there/EX have/VBP been/VBN no/DT controlled/JJ studies/NNS to/TO evaluate/VB the/DT antianginal/JJ effectiveness/NN of/IN this/DT combination/NN ./.

(ROOT (S1 (S (NP (NP (JJ Long) (NN Acting) (NNS Nitrates)) (: :) (S (S (NP (NN Nifedipine)) (VP (MD may) (VP (VB be) (ADVP (RB safely)) (VP (VBN co-administered) (PP (IN with) (NP (NNS nitrates))))))) (, ,) (CC but) (S (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (DT no) (JJ controlled) (NNS studies)) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (JJ antianginal) (NN effectiveness)) (PP (IN of) (NP (DT this) (NN combination))))))))))) (. .)))))

Sentence Id: DrugDDI.d266.s2
Digitalis/NN :/: Immediate/JJ Release/NN Capsules/NNS :/: Since/IN there/EX have/VBP been/VBN isolated/VBN reports/NNS of/IN patients/NNS with/IN elevated/JJ digoxin/NN levels/NNS ,/, and/CC there/EX is/VBZ a/DT possible/JJ interaction/NN between/IN digoxin/NN and/CC nifedipine/NN ,/, it/PRP is/VBZ recommended/VBN that/IN digoxin/NN levels/NNS be/VB monitored/VBN when/WRB initiating/VBG ,/, adjusting/VBG ,/, and/CC discontinuing/VBG nifedipine/NN to/TO avoid/VB possible/JJ over-/NN or/CC under-digitalization/NN ./.

(ROOT (S1 (S (NP (NP (NN Digitalis) (: :) (NP (JJ Immediate) (NN Release) (NNS Capsules))) (: :) (S (SBAR (IN Since) (S (S (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (NP (VBN isolated) (NNS reports)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ elevated) (NN digoxin) (NNS levels))))))))) (, ,) (CC and) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (JJ possible) (NN interaction)) (PP (IN between) (NP (NP (NN digoxin)) (CC and) (NP (NN nifedipine))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NN digoxin) (NNS levels)) (VP (VB be) (VP (VBN monitored) (SBAR (WHADVP (WRB when)) (S (VP (VP (VBG initiating)) (, ,) (VP (VBG adjusting)) (, ,) (CC and) (VP (VBG discontinuing) (NP (NN nifedipine)) (S (VP (TO to) (VP (VB avoid) (NP (NP (JJ possible) (NN over-)) (CC or) (NP (NN under-digitalization))))))))))))))))) (. .)))))

Sentence Id: DrugDDI.d266.s3
Extended/JJ Release/NN Tablets/NNS :/: Administration/NN of/IN nifedipine/NN with/IN digoxin/NN increased/VBD digoxin/NN levels/NNS in/IN 9/CD of/IN 12/CD normal/JJ volunteers/NNS ./.

(ROOT (S1 (S (NP (NP (JJ Extended) (NN Release) (NNS Tablets)) (: :) (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN nifedipine))) (PP (IN with) (NP (NN digoxin)))) (VP (VBD increased) (NP (NN digoxin) (NNS levels)) (PP (IN in) (NP (NP (CD 9)) (PP (IN of) (NP (CD 12) (JJ normal) (NNS volunteers))))))) (. .)))))

Sentence Id: DrugDDI.d266.s7
Since/IN there/EX have/VBP been/VBN isolated/VBN reports/NNS of/IN patients/NNS with/IN elevated/JJ digoxin/NN levels/NNS ,/, it/PRP is/VBZ recommended/VBN that/IN digoxin/NN levels/NNS be/VB monitored/VBN when/WRB initiating/VBG ,/, adjusting/VBG ,/, and/CC discontinuing/VBG nifedipine/NN to/TO avoid/VB possible/JJ over-/NN or/CC under-digitalization/NN ./.

(ROOT (S1 (S (S (SBAR (IN Since) (S (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (NP (VBN isolated) (NNS reports)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ elevated) (NN digoxin) (NNS levels)))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NN digoxin) (NNS levels)) (VP (VB be) (VP (VBN monitored) (SBAR (WHADVP (WRB when)) (S (VP (VP (VBG initiating)) (, ,) (VP (VBG adjusting)) (, ,) (CC and) (VP (VBG discontinuing) (NP (NN nifedipine)) (S (VP (TO to) (VP (VB avoid) (NP (NP (JJ possible) (NN over-)) (CC or) (NP (NN under-digitalization))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d266.s8
Quinidine/NN :/: Immediate/JJ Release/NN Capsules/NNS :/: There/EX have/VBP been/VBN rare/JJ reports/NNS of/IN an/DT interaction/NN between/IN quinidine/NN and/CC nifedipine/NN (/-LRB- with/IN a/DT decreased/VBN plasma/NN level/NN of/IN quinidine/NN )/-RRB- ./.

(ROOT (S1 (S (NP (NP (NN Quinidine) (: :) (NP (JJ Immediate) (NN Release) (NNS Capsules))) (: :) (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (JJ rare) (NNS reports)) (PP (IN of) (NP (NP (DT an) (NN interaction)) (PP (IN between) (NP (NP (NN quinidine)) (CC and) (NP (NN nifedipine)))) (-LRB- -LRB-) (PP (IN with) (NP (NP (DT a) (VBN decreased) (NN plasma) (NN level)) (PP (IN of) (NP (NN quinidine))))) (-RRB- -RRB-))))))) (. .)))))

Sentence Id: DrugDDI.d266.s9
Coumarin/NN Anticoagulant/NN s/NNS :/: There/EX have/VBP been/VBN rare/JJ reports/NNS of/IN increased/VBN prothrombin/NN time/NN in/IN patients/NNS taking/VBG coumarin/NN anticoagulant/NN s/NNS to/TO whom/WP nifedipine/NN was/VBD administered/VBN ./.

(ROOT (S1 (S (NP (NP (NN Coumarin) (NN Anticoagulant) (NNS s)) (: :) (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (JJ rare) (NNS reports)) (PP (IN of) (NP (VBN increased) (NN prothrombin) (NN time))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (NN coumarin) (NN anticoagulant) (NNS s)) (SBAR (WHPP (TO to) (WHNP (WP whom))) (S (NP (NN nifedipine)) (VP (VBD was) (VP (VBN administered))))))))))))) (. .)))))

Sentence Id: DrugDDI.d266.s10
However/RB ,/, the/DT relationship/NN to/TO nifedipine/NN therapy/NN is/VBZ uncertain/JJ ./.

(ROOT (S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN relationship)) (PP (TO to) (NP (NN nifedipine) (NN therapy)))) (VP (VBZ is) (ADJP (JJ uncertain)))) (. .))))

Sentence Id: DrugDDI.d266.s11
Cimetidine/NN :/: A/DT study/NN in/IN 6/CD healthy/JJ volunteers/NNS has/VBZ shown/VBN a/DT significant/JJ increase/NN in/IN peak/NN nifedipine/NN plasma/NN levels/NNS (/-LRB- 80/CD %/NN )/-RRB- and/CC area-under-the-curve/JJ (/-LRB- 74/CD %/NN )/-RRB- after/IN a/DT 1/CD week/NN course/NN of/IN cimetidine/NN at/IN 1000/CD mg/NN per/IN day/NN and/CC nifedipine/NN at/IN 40/CD mg/NN per/IN day/NN ./.

(ROOT (S1 (S (NP (NP (NN Cimetidine)) (: :) (S (NP (NP (DT A) (NN study)) (PP (IN in) (NP (CD 6) (JJ healthy) (NNS volunteers)))) (VP (VBZ has) (VP (VBN shown) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (NP (NN peak) (NN nifedipine) (NN plasma) (NNS levels)) (PRN (-LRB- -LRB-) (NP (CD 80) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ area-under-the-curve)) (PRN (-LRB- -LRB-) (NP (CD 74) (NN %)) (-RRB- -RRB-)))))) (PP (IN after) (NP (NP (DT a) (CD 1) (NN week) (NN course)) (PP (IN of) (NP (NP (NN cimetidine)) (PP (IN at) (NP (NP (CD 1000) (NN mg)) (PP (IN per) (NP (NP (NN day)) (CC and) (NP (NN nifedipine)))) (PP (IN at) (NP (NP (CD 40) (NN mg)) (PP (IN per) (NP (NN day)))))))))))))) (. .)))))

Sentence Id: DrugDDI.d266.s12
Ranitidine/NN produced/VBD smaller/JJR ,/, non-significant/JJ increases/NNS ./.

(ROOT (S1 (S (S (NP (NN Ranitidine)) (VP (VBD produced) (NP (ADJP (ADJP (JJR smaller)) (, ,) (ADJP (JJ non-significant))) (NNS increases)))) (. .))))

Sentence Id: DrugDDI.d266.s13
The/DT effect/NN may/MD be/VB mediated/VBN by/IN the/DT known/JJ inhibition/NN of/IN cimetidine/NN on/IN hepatic/JJ cytochrome/NN P-450/NN ,/, the/DT enzyme/NN system/NN probably/RB responsible/JJ for/IN the/DT first-pass/NN metabolism/NN of/IN nifedipine/NN ./.

(ROOT (S1 (S (S (NP (DT The) (NN effect)) (VP (MD may) (VP (VB be) (VP (VBN mediated) (PP (IN by) (NP (NP (DT the) (JJ known) (NN inhibition)) (PP (IN of) (NP (NN cimetidine))) (PP (IN on) (NP (NP (JJ hepatic) (NN cytochrome) (NN P-450)) (, ,) (NP (NP (DT the) (NN enzyme) (NN system)) (ADJP (ADVP (RB probably)) (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN first-pass) (NN metabolism)) (PP (IN of) (NP (NN nifedipine))))))))))))))) (. .))))

Sentence Id: DrugDDI.d266.s14
If/IN nifedipine/NN therapy/NN is/VBZ initiated/VBN in/IN a/DT patient/NN currently/RB receiving/VBG cimetidine/NN ,/, cautious/JJ titration/NN is/VBZ advised/VBN ./.

(ROOT (S1 (S (S (SBAR (IN If) (S (NP (NN nifedipine) (NN therapy)) (VP (VBZ is) (VP (VBN initiated) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (ADVP (RB currently)) (VBG receiving) (NP (NN cimetidine))))))))) (, ,) (NP (JJ cautious) (NN titration)) (VP (VBZ is) (VP (VBN advised)))) (. .))))

Sentence Id: DrugDDI.d234.s0
A/DT 30/CD to/TO 45/CD %/NN increase/NN in/IN AUC/NN and/CC Cmax/NN of/IN nisoldipine/NN was/VBD observed/VBN with/IN concomitant/JJ administration/NN of/IN cimetidine/NN 400/CD mg/NN twice/RB daily/RB ./.

(ROOT (S1 (S (S (NP (NP (DT A) (CD 30) (TO to) (CD 45) (NN %) (NN increase)) (PP (IN in) (NP (NP (NP (NN AUC)) (CC and) (NP (NN Cmax))) (PP (IN of) (NP (NN nisoldipine)))))) (VP (VBD was) (VP (VBN observed) (PP (IN with) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN cimetidine) (CD 400) (NN mg)) (ADVP (RB twice) (RB daily))))))))) (. .))))

Sentence Id: DrugDDI.d234.s1
Ranitidine/NN 150/CD mg/NN twice/RB daily/RB did/VBD not/RB interact/VB significantly/RB with/IN nisoldipine/NN (/-LRB- AUC/NN was/VBD decreased/VBN by/IN 15-20/CD %/NN )./CD

(ROOT (S1 (S (S (NP (NP (NN Ranitidine) (CD 150) (NN mg)) (ADVP (RB twice) (RB daily))) (VP (VBD did) (RB not) (VP (VB interact) (ADVP (RB significantly)) (PP (IN with) (NP (NN nisoldipine)))))) (S (-LRB- -LRB-) (NP (NN AUC)) (VP (VBD was) (VP (VBN decreased) (PP (IN by) (NP (CD 15-20) (NN %) (CD -RRB-.)))))))))

Sentence Id: DrugDDI.d234.s2
No/DT pharmacodynamic/JJ effects/NNS of/IN either/DT histamine/NN H2/NN receptor/NN antagonist/NN were/VBD observed/VBN ./.

(ROOT (S1 (S (S (NP (NP (DT No) (JJ pharmacodynamic) (NNS effects)) (PP (IN of) (NP (DT either) (NN histamine) (NN H2) (NN receptor) (NN antagonist)))) (VP (VBD were) (VP (VBN observed)))) (. .))))

Sentence Id: DrugDDI.d234.s3
Coadministration/NN of/IN phenytoin/NN with/IN 40/CD mg/NN SULAR/NN tablets/NNS in/IN epileptic/JJ patients/NNS lowered/VBD the/DT nisoldipine/NN plasma/NN concentrations/NNS to/TO undetectable/JJ levels/NNS ./.

(ROOT (S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN phenytoin))) (PP (IN with) (NP (NP (CD 40) (NN mg) (NN SULAR) (NNS tablets)) (PP (IN in) (NP (JJ epileptic) (NNS patients)))))) (VP (VBD lowered) (NP (DT the) (NN nisoldipine) (NN plasma) (NNS concentrations)) (PP (TO to) (NP (JJ undetectable) (NNS levels))))) (. .))))

Sentence Id: DrugDDI.d234.s4
Coadministration/NN of/IN SULAR/NN with/IN phenytoin/NN or/CC any/DT known/JJ CYP3A4/NN inducer/NN should/MD be/VB avoided/VBN and/CC alternative/JJ antihypertensive/JJ therapy/NN should/MD be/VB considered/VBN ./.

(ROOT (S1 (S (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN SULAR))) (PP (IN with) (NP (NP (NN phenytoin)) (CC or) (NP (DT any) (JJ known) (NN CYP3A4) (NN inducer))))) (VP (MD should) (VP (VB be) (VP (VBN avoided))))) (CC and) (S (NP (JJ alternative) (JJ antihypertensive) (NN therapy)) (VP (MD should) (VP (VB be) (VP (VBN considered)))))) (. .))))

Sentence Id: DrugDDI.d234.s5
Pharmacokinetic/JJ interactions/NNS between/IN nisoldipine/NN and/CC beta-blockers/NNS (/-LRB- atenolol/NN ,/, propranolol/NN )/-RRB- were/VBD variable/JJ and/CC not/RB significant/JJ ./.

(ROOT (S1 (S (S (NP (NP (JJ Pharmacokinetic) (NNS interactions)) (PP (IN between) (NP (NP (NN nisoldipine)) (CC and) (NP (NP (NNS beta-blockers)) (PRN (-LRB- -LRB-) (NP (NP (NN atenolol)) (, ,) (NP (NN propranolol))) (-RRB- -RRB-)))))) (VP (VBD were) (ADJP (ADJP (JJ variable)) (CC and) (ADJP (RB not) (JJ significant))))) (. .))))

Sentence Id: DrugDDI.d234.s6
Propranolol/NN attenuated/VBD the/DT heart/NN rate/NN increase/NN following/VBG administration/NN of/IN immediate/JJ release/NN nisoldipine/NN ./.

(ROOT (S1 (S (S (NP (NN Propranolol)) (VP (VBD attenuated) (NP (DT the) (NN heart) (NN rate) (NN increase)) (PP (VBG following) (NP (NP (NN administration)) (PP (IN of) (NP (JJ immediate) (NN release) (NN nisoldipine))))))) (. .))))

Sentence Id: DrugDDI.d234.s7
The/DT blood/NN pressure/NN effect/NN of/IN SULAR/NN tended/VBD to/TO be/VB greater/JJR in/IN patients/NNS on/IN atenolol/NN than/IN in/IN patients/NNS on/IN no/DT other/JJ antihypertensive/JJ therapy/NN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN blood) (NN pressure) (NN effect)) (PP (IN of) (NP (NN SULAR)))) (VP (VBD tended) (S (VP (TO to) (VP (VB be) (ADJP (ADJP (JJR greater)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (NN atenolol))))) (PP (IN than) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (DT no) (JJ other) (JJ antihypertensive) (NN therapy)))))))))))) (. .))))

Sentence Id: DrugDDI.d234.s8
Quinidine/NN at/IN 648/CD mg/NN bid/NN decreased/VBD the/DT bioavailability/NN (/-LRB- AUC/NN )/-RRB- of/IN nisoldipine/NN by/IN 26/CD %/NN ,/, but/CC not/RB the/DT peak/JJ concentration/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Quinidine)) (PP (IN at) (NP (ADJP (CD 648) (NN mg)) (NN bid)))) (VP (VBD decreased) (NP (NP (NP (DT the) (NN bioavailability)) (PRN (-LRB- -LRB-) (NP (NN AUC)) (-RRB- -RRB-))) (PP (IN of) (NP (NN nisoldipine)))) (PP (IN by) (NP (CD 26) (NN %))) (, ,) (CONJP (CC but) (RB not)) (NP (DT the) (JJ peak) (NN concentration)))) (. .))))

Sentence Id: DrugDDI.d234.s9
The/DT immediate/JJ release/NN ,/, but/CC not/RB the/DT coat-core/JJ formulation/NN of/IN nisoldipine/NN increased/VBD plasma/NN quinidine/NN concentrations/NNS by/IN about/RB 20/CD %./NN

(ROOT (S1 (S (NP (NP (DT The) (JJ immediate) (NN release)) (, ,) (CONJP (CC but) (RB not)) (S (NP (NP (DT the) (JJ coat-core) (NN formulation)) (PP (IN of) (NP (NN nisoldipine)))) (VP (VBD increased) (NP (NN plasma) (NN quinidine) (NNS concentrations)) (PP (IN by) (NP (QP (RB about) (CD 20)) (NN %.)))))))))

Sentence Id: DrugDDI.d234.s11
No/DT significant/JJ interactions/NNS were/VBD found/VBN between/IN nisoldipine/NN and/CC warfarin/NN or/CC digoxin/NN ./.

(ROOT (S1 (S (S (NP (DT No) (JJ significant) (NNS interactions)) (VP (VBD were) (VP (VBN found) (PP (IN between) (NP (NP (NN nisoldipine)) (CC and) (NP (NN warfarin)) (CC or) (NP (NN digoxin))))))) (. .))))

Sentence Id: DrugDDI.d306.s0
Tizoxanide/NN is/VBZ highly/RB bound/VBN to/TO plasma/NN protein/NN (/-LRB- 99.9/CD %)./NN

(ROOT (S1 (S (NP (NN Tizoxanide)) (VP (VBZ is) (ADVP (RB highly)) (VP (VBN bound) (PP (TO to) (NP (NN plasma) (NN protein))) (PRN (-LRB- -LRB-) (NP (CD 99.9) (NN %-RRB-.))))))))

Sentence Id: DrugDDI.d306.s1
Therefore/RB ,/, caution/NN should/MD be/VB used/VBN when/WRB administering/VBG nitazoxanide/NN concurrently/RB with/IN other/JJ highly/RB plasma/NN protein-bound/JJ drugs/NNS with/IN narrow/JJ therapeutic/JJ indices/NNS ,/, as/IN competition/NN for/IN binding/NN sites/NNS may/MD occur/VB (/-LRB- e.g./FW ,/, warfarin/NN )/-RRB- ./.

(ROOT (S1 (S (ADVP (RB Therefore)) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NP (NN nitazoxanide)) (PP (ADVP (RB concurrently)) (IN with) (NP (JJ other) (ADJP (RB highly) (NN plasma) (JJ protein-bound)) (NNS drugs)))) (PP (IN with) (NP (JJ narrow) (JJ therapeutic) (NNS indices)))))) (, ,) (SBAR (IN as) (S (NP (NP (NN competition)) (PP (IN for) (NP (NN binding) (NNS sites)))) (VP (MD may) (VP (VB occur)))))) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN warfarin))) (-RRB- -RRB-)))) (. .))))

Sentence Id: DrugDDI.d306.s2
In/FW vitro/FW metabolism/NN studies/NNS have/VBP demonstrated/VBN that/IN tizoxanide/NN has/VBZ no/DT significant/JJ inhibitory/JJ effect/NN on/IN cytochrome/NN P450/NN enzymes/NNS ./.

(ROOT (S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NN metabolism) (NNS studies)) (VP (VBP have) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NN tizoxanide)) (VP (VBZ has) (NP (DT no) (JJ significant) (JJ inhibitory) (NN effect)) (PP (IN on) (NP (NN cytochrome) (NN P450) (NNS enzymes))))))))) (. .))))

Sentence Id: DrugDDI.d306.s3
Although/IN no/DT drug-drug/JJ interaction/NN studies/NNS have/VBP been/VBN conducted/VBN in/FW vivo/FW ,/, it/PRP is/VBZ expected/VBN that/IN no/DT significant/JJ interaction/NN would/MD occur/VB when/WRB nitazoxanide/NN is/VBZ co-administered/VBN with/IN drugs/NNS that/WDT either/RB are/VBP metabolized/VBN by/IN or/CC inhibit/VB cytochrome/NN P450/NN enzymes/NNS ./.

(ROOT (S1 (S (SBAR (IN Although) (S (NP (DT no) (JJ drug-drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted) (ADVP (FW in) (FW vivo))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN expected) (SBAR (IN that) (S (NP (DT no) (JJ significant) (NN interaction)) (VP (MD would) (VP (VB occur) (SBAR (WHADVP (WRB when)) (S (NP (NN nitazoxanide)) (VP (VBZ is) (VP (VBN co-administered) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (ADVP (RB either)) (VP (VP (VBP are) (VP (VBN metabolized) (PP (IN by)))) (CC or) (VP (VB inhibit) (NP (NN cytochrome) (NN P450) (NNS enzymes)))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d20.s0
Oxcarbazepine/NN can/MD inhibit/VB CYP2C19/NN and/CC induce/VB CYP3A4/NN /5/NN with/IN potentially/RB important/JJ effects/NNS on/IN plasma/NN concentrations/NNS of/IN other/JJ drugs/NNS ./.

(ROOT (S1 (S (S (NP (NN Oxcarbazepine)) (VP (MD can) (VP (VP (VB inhibit) (NP (NN CYP2C19))) (CC and) (VP (VB induce) (NP (NP (NN CYP3A4) (NN /5)) (PP (IN with) (NP (NP (ADJP (RB potentially) (JJ important)) (NNS effects)) (PP (IN on) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (JJ other) (NNS drugs)))))))))))) (. .))))

Sentence Id: DrugDDI.d20.s1
In/IN addition/NN ,/, several/JJ AED/JJ @/NN s/NNS that/WDT are/VBP cytochrome/NN P450/NN inducers/NNS can/MD decrease/VB plasma/NN concentrations/NNS of/IN oxcarbazepine/NN and/CC MHD/NN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (JJ several) (JJ AED) (NN @) (NNS s)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NN cytochrome) (NN P450) (NNS inducers)))))) (VP (MD can) (VP (VB decrease) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NN oxcarbazepine)) (CC and) (NP (NN MHD)))))))) (. .))))

Sentence Id: DrugDDI.d20.s2
Oxcarbazepine/NN was/VBD evaluated/VBN in/IN human/JJ liver/NN microsomes/NNS to/TO determine/VB its/PRP$ capacity/NN to/TO inhibit/VB the/DT major/JJ cytochrome/NN P450/NN enzymes/NNS responsible/JJ for/IN the/DT metabolism/NN of/IN other/JJ drugs/NNS ./.

(ROOT (S1 (S (S (NP (NN Oxcarbazepine)) (VP (VBD was) (VP (VBN evaluated) (PP (IN in) (NP (JJ human) (NN liver) (NNS microsomes))) (S (VP (TO to) (VP (VB determine) (NP (PRP$ its) (NN capacity) (S (VP (TO to) (VP (VB inhibit) (NP (NP (DT the) (JJ major) (NN cytochrome) (NN P450) (NNS enzymes)) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (JJ other) (NNS drugs))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d20.s3
Results/NNS demonstrate/VBP that/IN oxcarbazepine/NN and/CC its/PRP$ pharmacologically/RB active/JJ 10-monohydroxy/NN metabolite/NN (/-LRB- MHD/NN )/-RRB- have/VBP little/JJ or/CC no/DT capacity/NN to/TO function/VB as/IN inhibitors/NNS for/IN most/JJS of/IN the/DT human/JJ cytochrome/NN P450/NN enzymes/NNS evaluated/VBN (/-LRB- CYP1A2/NN ,/, CYP2A6/NN ,/, CYP2C9/NN ,/, CYP2D6/NN ,/, CYP2E1/NN ,/, CYP4A9/NN and/CC CYP4A11/NN )/-RRB- with/IN the/DT exception/NN of/IN CYP2C19/NN and/CC CYP3A4/NN /5/NN ./.

(ROOT (S1 (S (NP (NNS Results)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (NN oxcarbazepine)) (CC and) (NP (NP (PRP$ its) (ADJP (RB pharmacologically) (JJ active)) (NN 10-monohydroxy) (NN metabolite)) (PRN (-LRB- -LRB-) (NP (NN MHD)) (-RRB- -RRB-)))) (VP (VBP have) (NP (NP (ADJP (JJ little))) (CC or) (NP (DT no) (NN capacity) (S (VP (TO to) (VP (VB function) (PP (IN as) (NP (NP (NNS inhibitors)) (PP (IN for) (NP (NP (JJS most)) (PP (IN of) (NP (NP (DT the) (JJ human) (NN cytochrome) (NN P450) (NNS enzymes)) (VP (VBN evaluated) (PRN (-LRB- -LRB-) (NP (NP (NN CYP1A2)) (, ,) (NP (NN CYP2A6)) (, ,) (NP (NN CYP2C9)) (, ,) (NP (NN CYP2D6)) (, ,) (NP (NN CYP2E1)) (, ,) (NP (NN CYP4A9)) (CC and) (NP (NN CYP4A11))) (-RRB- -RRB-)) (PP (IN with) (NP (NP (DT the) (NN exception)) (PP (IN of) (NP (NP (NN CYP2C19)) (CC and) (NP (NN CYP3A4) (NN /5)))))))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d20.s4
Although/IN inhibition/NN of/IN CYP/NN 3A4/5/NN by/IN OXC/NN and/CC MHD/NN did/VBD occur/VB at/IN high/JJ concentrations/NNS ,/, it/PRP is/VBZ not/RB likely/JJ to/TO be/VB of/IN clinical/JJ significance/NN ./.

(ROOT (S1 (S (S (SBAR (IN Although) (S (NP (NP (NN inhibition)) (PP (IN of) (NP (NN CYP) (NN 3A4/5))) (PP (IN by) (NP (NP (NN OXC)) (CC and) (NP (NN MHD))))) (VP (VBD did) (VP (VB occur) (PP (IN at) (NP (JJ high) (NNS concentrations))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (RB not) (ADJP (JJ likely) (S (VP (TO to) (VP (VB be) (PP (IN of) (NP (JJ clinical) (NN significance))))))))) (. .))))

Sentence Id: DrugDDI.d20.s5
The/DT inhibition/NN of/IN CYP-2C19/NN by/IN OXC/NN and/CC MHD/NN ,/, however/RB ,/, is/VBZ clinically/RB relevant/JJ ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN inhibition)) (PP (IN of) (NP (NN CYP-2C19))) (PP (IN by) (NP (NP (NN OXC)) (CC and) (NP (NN MHD))))) (, ,) (ADVP (RB however)) (, ,) (VP (VBZ is) (ADJP (RB clinically) (JJ relevant)))) (. .))))

Sentence Id: DrugDDI.d20.s6
In/FW vitro/FW ,/, the/DT UDP-glucuronyl/JJ transferase/NN level/NN was/VBD increased/VBN ,/, indicating/VBG induction/NN of/IN this/DT enzyme/NN ./.

(ROOT (S1 (S (S (ADVP (FW In) (FW vitro)) (, ,) (NP (DT the) (JJ UDP-glucuronyl) (NN transferase) (NN level)) (VP (VBD was) (VP (VBN increased) (, ,) (S (VP (VBG indicating) (NP (NP (NN induction)) (PP (IN of) (NP (DT this) (NN enzyme))))))))) (. .))))

Sentence Id: DrugDDI.d20.s7
Increases/NNS of/IN 22/CD %/NN with/IN MHD/NN and/CC 47/CD %/NN with/IN oxcarbazepine/NN were/VBD observed/VBN ./.

(ROOT (S1 (S (S (NP (NP (NNS Increases)) (PP (IN of) (NP (NP (NP (CD 22) (NN %)) (PP (IN with) (NP (NN MHD)))) (CC and) (NP (NP (CD 47) (NN %)) (PP (IN with) (NP (NN oxcarbazepine))))))) (VP (VBD were) (VP (VBN observed)))) (. .))))

Sentence Id: DrugDDI.d20.s8
As/IN MHD/NN ,/, the/DT predominant/JJ plasma/NN substrate/NN ,/, is/VBZ only/RB a/DT weak/JJ inducer/NN of/IN UDP-glucuronyl/NN transferase/NN ,/, it/PRP is/VBZ unlikely/JJ to/TO have/VB an/DT effect/NN on/IN drugs/NNS that/WDT are/VBP mainly/RB eliminated/VBN by/IN conjugation/NN through/IN UDP-glucuronyl/JJ transferase/NN (/-LRB- e.g./FW ,/, valproic/JJ acid/NN ,/, lamotrigine/NN )/-RRB- ./.

(ROOT (S1 (S (SBAR (IN As) (S (NP (NP (NN MHD)) (, ,) (NP (DT the) (JJ predominant) (NN plasma) (NN substrate)) (, ,)) (VP (VBZ is) (ADVP (RB only)) (NP (NP (DT a) (JJ weak) (NN inducer)) (PP (IN of) (NP (NN UDP-glucuronyl) (NN transferase))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VB have) (NP (DT an) (NN effect)) (PP (IN on) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADVP (RB mainly)) (VP (VBN eliminated) (PP (IN by) (NP (NN conjugation))) (PP (IN through) (NP (NP (JJ UDP-glucuronyl) (NN transferase)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (JJ valproic) (NN acid))) (, ,) (NP (NN lamotrigine)) (-RRB- -RRB-))))))))))))))) (. .))))

Sentence Id: DrugDDI.d20.s9
In/IN addition/NN ,/, oxcarbazepine/NN and/CC MHD/NN induce/VBP a/DT subgroup/NN of/IN the/DT cytochrome/NN P450/NN 3A/NN family/NN (/-LRB- CYP3A4/NN and/CC CYP3A5/NN )/-RRB- responsible/JJ for/IN the/DT metabolism/NN of/IN dihydropyridine/NN calcium/NN antagonist/NN s/NN and/CC oral/JJ contraceptives/NNS ,/, resulting/VBG in/IN a/DT lower/JJR plasma/NN concentration/NN of/IN these/DT drugs/NNS ./.

(ROOT (S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NN oxcarbazepine)) (CC and) (NP (NN MHD))) (VP (VBP induce) (NP (NP (DT a) (NN subgroup)) (PP (IN of) (NP (NP (NP (DT the) (NN cytochrome) (NN P450) (NN 3A) (NN family)) (PRN (-LRB- -LRB-) (NP (NP (NN CYP3A4)) (CC and) (NP (NN CYP3A5))) (-RRB- -RRB-))) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (NN dihydropyridine) (NN calcium) (NN antagonist) (NN s)) (CC and) (NP (JJ oral) (NNS contraceptives)))))))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (DT a) (JJR lower) (NN plasma) (NN concentration)) (PP (IN of) (NP (DT these) (NNS drugs))))))))) (. .))))

Sentence Id: DrugDDI.d20.s10
As/IN binding/NN of/IN MHD/NN to/TO plasma/NN proteins/NNS is/VBZ low/JJ (/-LRB- 40/CD %/NN )/-RRB- ,/, clinically/RB significant/JJ interactions/NNS with/IN other/JJ drugs/NNS through/IN competition/NN for/IN protein/NN binding/NN sites/NNS are/VBP unlikely/JJ ./.

(ROOT (S1 (S (S (SBAR (IN As) (S (NP (NP (NN binding)) (PP (IN of) (NP (NN MHD))) (PP (TO to) (NP (NN plasma) (NNS proteins)))) (VP (VBZ is) (ADJP (ADJP (JJ low)) (PRN (-LRB- -LRB-) (NP (CD 40) (NN %)) (-RRB- -RRB-)))))) (, ,) (NP (NP (ADJP (RB clinically) (JJ significant)) (NNS interactions)) (PP (IN with) (NP (JJ other) (NNS drugs))) (PP (IN through) (NP (NP (NN competition)) (PP (IN for) (NP (NN protein) (NN binding) (NNS sites)))))) (VP (VBP are) (ADJP (JJ unlikely)))) (. .))))

Sentence Id: DrugDDI.d20.s11
Antiepileptic/JJ drugs/NNS Potential/JJ interactions/NNS between/IN Trileptal/NNP and/CC other/JJ AEDs/NNS were/VBD assessed/VBN in/IN clinical/JJ studies/NNS ./.

(ROOT (S1 (S (S (NP (NP (JJ Antiepileptic) (NNS drugs)) (NP (NP (JJ Potential) (NNS interactions)) (PP (IN between) (NP (NP (NNP Trileptal)) (CC and) (NP (JJ other) (NNS AEDs)))))) (VP (VBD were) (VP (VBN assessed) (PP (IN in) (NP (JJ clinical) (NNS studies)))))) (. .))))

Sentence Id: DrugDDI.d20.s12
The/DT effect/NN of/IN these/DT interactions/NNS on/IN mean/JJ AUCs/NNS and/CC Cmin/NN are/VBP summarized/VBN in/IN Table/NN 2/CD :/: Table/NN 2/CD :/: Summary/NN of/IN AED/JJ interactions/NNS with/IN Trileptal/NN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (DT these) (NNS interactions))) (PP (IN on) (NP (NP (JJ mean) (NNS AUCs)) (CC and) (NP (NN Cmin))))) (VP (VBP are) (VP (VBN summarized) (PP (IN in) (NP (NP (NN Table) (CD 2) (: :) (NP (NN Table) (CD 2)) (: :) (NP (NN Summary))) (PP (IN of) (NP (NP (JJ AED) (NNS interactions)) (PP (IN with) (NP (NN Trileptal)))))))))) (. .))))

Sentence Id: DrugDDI.d20.s15
Trileptal/JJ dose/NN (/-LRB- mg/day/NN )/-RRB- ./.

(ROOT (S1 (S (S (NP (NP (JJ Trileptal) (NN dose)) (PRN (-LRB- -LRB-) (NP (NN mg/day)) (-RRB- -RRB-)))) (. .))))

Sentence Id: DrugDDI.d20.s16
Influence/NN of/IN Trileptal/NN on/IN AED/JJ Concentration/NN (/-LRB- Mean/NN change/NN ,/, 90/CD %/NN Confidence/NN Interval/NN )/-RRB- ./.

(ROOT (S1 (S (NP (NP (NN Influence)) (PP (IN of) (NP (NN Trileptal))) (PP (IN on) (NP (NP (JJ AED) (NN Concentration)) (PRN (-LRB- -LRB-) (NP (NP (NN Mean) (NN change)) (, ,) (NP (ADJP (CD 90) (NN %)) (NN Confidence) (NN Interval))) (-RRB- -RRB-)))) (. .)))))

Sentence Id: DrugDDI.d20.s18
Carbamazepine/NN ./.

(ROOT (S1 (S (NP (NP (NN Carbamazepine)) (. .)))))

Sentence Id: DrugDDI.d20.s22
Phenobarbital/NN ./.

(ROOT (S1 (S (NP (NP (NN Phenobarbital)) (. .)))))

Sentence Id: DrugDDI.d20.s26
Phenytoin/NN ./.

(ROOT (S1 (S (NP (NP (NN Phenytoin)) (. .)))))

Sentence Id: DrugDDI.d20.s31
Valproic/JJ acid/NN ./.

(ROOT (S1 (S (S (NP (JJ Valproic) (NN acid))) (. .))))

Sentence Id: DrugDDI.d20.s35
1-/CD nc/NN denotes/VBZ a/DT mean/JJ change/NN of/IN less/JJR than/IN 10/CD %/NN 2-/CD Pediatrics/NN 3-/CD Mean/NN increase/NN in/IN adults/NNS at/IN high/JJ Trileptal/NN doses/NNS In/FW vivo/FW ,/, the/DT plasma/NN levels/NNS of/IN phenytoin/NN increased/VBD by/IN up/RB to/TO 40/CD %/NN ,/, when/WRB Trileptal/NN was/VBD given/VBN at/IN doses/NNS above/IN 1200/CD mg/day/NN ./.

(ROOT (S1 (S (S (NP (CD 1-) (NN nc)) (VP (VBZ denotes) (NP (NP (DT a) (JJ mean) (NN change)) (PP (IN of) (NP (NP (QP (JJR less) (IN than) (CD 10)) (NN %) (CD 2-) (NN Pediatrics) (CD 3-) (NN Mean) (NN increase)) (PP (IN in) (NP (NNS adults))) (PP (IN at) (NP (JJ high) (NN Trileptal) (NNS doses)))))) (ADVP (FW In) (FW vivo)))) (, ,) (S (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN phenytoin)))) (VP (VBD increased) (PP (IN by) (NP (QP (RB up) (TO to) (CD 40)) (NN %))) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NN Trileptal)) (VP (VBD was) (VP (VBN given) (PP (IN at) (NP (NP (NNS doses)) (PP (IN above) (NP (CD 1200) (NN mg/day))))))))))) (. .))))

Sentence Id: DrugDDI.d20.s36
Therefore/RB ,/, when/WRB using/VBG doses/NNS of/IN Trileptal/NN greater/JJR than/IN 1200/CD mg/day/NN during/IN adjunctive/JJ therapy/NN ,/, a/DT decrease/NN in/IN the/DT dose/NN of/IN phenytoin/NN may/MD be/VB required/VBN ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBG using) (NP (NP (NNS doses)) (PP (IN of) (NP (NN Trileptal))) (ADJP (QP (JJR greater) (IN than) (CD 1200)) (NN mg/day))) (PP (IN during) (NP (JJ adjunctive) (NN therapy)))))) (, ,) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN phenytoin)))))) (VP (MD may) (VP (VB be) (VP (VBN required))))) (. .))))

Sentence Id: DrugDDI.d20.s37
The/DT increase/NN of/IN phenobarbital/NN level/NN ,/, however/RB ,/, is/VBZ small/JJ (/-LRB- 15/CD %/NN )/-RRB- when/WRB given/VBN with/IN Trileptal/NN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN increase)) (PP (IN of) (NP (NN phenobarbital) (NN level)))) (, ,) (ADVP (RB however)) (, ,) (VP (VBZ is) (ADJP (ADJP (JJ small)) (PRN (-LRB- -LRB-) (NP (CD 15) (NN %)) (-RRB- -RRB-))) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN with) (NP (NN Trileptal)))))))) (. .))))

Sentence Id: DrugDDI.d20.s38
Strong/JJ inducers/NNS of/IN cytochrome/NN P450/NN enzymes/NNS (/-LRB- i.e./FW carbamazepine/NN ,/, phenytoin/NN and/CC phenobarbital/NN )/-RRB- have/VBP been/VBN shown/VBN to/TO decrease/VB the/DT plasma/NN levels/NNS of/IN MHD/NN (/-LRB- 29-40%)./NN

(ROOT (S1 (S (NP (NP (JJ Strong) (NNS inducers)) (PP (IN of) (NP (NP (NN cytochrome) (NN P450) (NNS enzymes)) (PRN (-LRB- -LRB-) (PP (FW i.e.)) (NP (NP (NN carbamazepine)) (, ,) (NP (NN phenytoin)) (CC and) (NP (NN phenobarbital))) (-RRB- -RRB-))))) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB decrease) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN MHD)))) (PRN (-LRB- -LRB-) (NP (NN 29-40%-RRB-.))))))))))))

Sentence Id: DrugDDI.d20.s39
No/DT autoinduction/NN has/VBZ been/VBN observed/VBN with/IN Trileptal/NN ./.

(ROOT (S1 (S (S (NP (DT No) (NN autoinduction)) (VP (VBZ has) (VP (VBN been) (VP (VBN observed) (PP (IN with) (NP (NN Trileptal))))))) (. .))))

Sentence Id: DrugDDI.d20.s40
Hormonal/JJ contraceptives/NNS Co-administration/NN of/IN Trileptal/NN with/IN an/DT oral/JJ contraceptive/NN has/VBZ been/VBN shown/VBN to/TO influence/VB the/DT plasma/NN concentrations/NNS of/IN the/DT two/CD hormonal/JJ components/NNS ,/, ethinylestradiol/NN (/-LRB- EE/NN )/-RRB- and/CC levonorgestrel/NN (/-LRB- LNG)./NN

(ROOT (S1 (S (NP (NP (JJ Hormonal) (NNS contraceptives)) (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NN Trileptal))) (PP (IN with) (NP (DT an) (JJ oral) (NN contraceptive)))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB influence) (NP (NP (DT the) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (DT the) (CD two) (JJ hormonal) (NNS components)) (, ,) (NP (NP (NP (NN ethinylestradiol)) (PRN (-LRB- -LRB-) (NP (NN EE)) (-RRB- -RRB-))) (CC and) (NP (NP (NN levonorgestrel)) (PRN (-LRB- -LRB-) (NP (NN LNG-RRB-.)))))))))))))))))))

Sentence Id: DrugDDI.d20.s43
Therefore/RB ,/, concurrent/JJ use/NN of/IN Trileptal/NN with/IN hormonal/JJ contraceptives/NNS may/MD render/VB these/DT contraceptives/NNS less/RBR effective/JJ ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (JJ concurrent) (NN use)) (PP (IN of) (NP (NN Trileptal))) (PP (IN with) (NP (JJ hormonal) (NNS contraceptives)))) (VP (MD may) (VP (VB render) (S (NP (DT these) (NNS contraceptives)) (ADJP (RBR less) (JJ effective)))))) (. .))))

Sentence Id: DrugDDI.d20.s44
Studies/NNS with/IN other/JJ oral/JJ or/CC implant/JJ contraceptives/NNS have/VBP not/RB been/VBN conducted/VBN ./.

(ROOT (S1 (S (S (NP (NP (NNS Studies)) (PP (IN with) (NP (JJ other) (ADJP (ADJP (JJ oral)) (CC or) (ADJP (JJ implant))) (NNS contraceptives)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN conducted))))) (. .))))

Sentence Id: DrugDDI.d20.s45
Calcium/NN Antagonist/NN s/NN After/IN repeated/JJ co-administration/NN of/IN Trileptal/NN ,/, the/DT AUC/NN of/IN felodipine/NN was/VBD lowered/VBN by/IN 28/CD %/NN [90/CD %/NN CI/NN :/: 20-33/CD ]./NN

(ROOT (S1 (S (PP (NP (NN Calcium) (NN Antagonist) (NN s)) (IN After) (NP (NP (JJ repeated) (NN co-administration)) (PP (IN of) (NP (NN Trileptal))))) (, ,) (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NN felodipine)))) (VP (VBD was) (VP (VBN lowered) (PP (IN by) (NP (NP (CD 28) (NN %)) (NP (ADJP (CD -LSB-90) (NN %)) (NN CI)))))) (: :) (NP (CD 20-33) (NN -RSB-.)))))

Sentence Id: DrugDDI.d20.s46
Verapamil/NN produced/VBD a/DT decrease/NN of/IN 20/CD %/NN [90/CD %/NN CI/CD :/: 18-27/CD ]/-RRB- of/IN the/DT plasma/NN levels/NNS of/IN MHD/NN ./.

(ROOT (S1 (S (S (NP (NN Verapamil)) (VP (VBD produced) (NP (NP (DT a) (NN decrease)) (PP (IN of) (NP (NP (CD 20) (NN %) (CD -LSB-90) (NN %) (CD CI) (: :) (CD 18-27) (-RRB- -RSB-)) (PP (IN of) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN MHD)))))))))) (. .))))

Sentence Id: DrugDDI.d20.s47
Other/JJ drug/NN interactions/NNS Cimetidine/NN ,/, erythromycin/NN and/CC dextropropoxyphene/NN had/VBD no/DT effect/NN on/IN the/DT pharmacokinetics/NNS of/IN MHD/NN ./.

(ROOT (S1 (S (S (NP (JJ Other) (NN drug) (NNS interactions) (NP (NP (NN Cimetidine)) (, ,) (NP (NN erythromycin)) (CC and) (NP (NN dextropropoxyphene)))) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN MHD))))))) (. .))))

Sentence Id: DrugDDI.d20.s48
Results/NNS with/IN warfarin/NN wshow/VBP no/DT evidence/NN of/IN interaction/NN with/IN either/CC single/JJ or/CC repeated/JJ doses/NNS of/IN Trileptal/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Results)) (PP (IN with) (NP (NN warfarin)))) (VP (VBP wshow) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (NN interaction)) (PP (IN with) (NP (NP (ADJP (CC either) (ADJP (JJ single)) (CC or) (ADJP (JJ repeated))) (NNS doses)) (PP (IN of) (NP (NN Trileptal)))))))))) (. .))))

Sentence Id: DrugDDI.d480.s0
In/IN a/DT Phase/NN :/: I/NN trial/NN using/VBG escalating/JJ doses/NNS of/IN TAXOL/NN (/-LRB- 110-200/CD mg/m2/NN )/-RRB- and/CC cisplatin/NN (/-LRB- 50/CD or/CC 75/CD mg/m2/NN )/-RRB- given/VBN as/IN sequential/JJ infusions/NNS ,/, myelosuppression/NN was/VBD more/RBR profound/JJ when/WRB TAXOL/NN was/VBD given/VBN after/IN cisplatin/NN than/IN with/IN the/DT alternate/JJ sequence/NN (/-LRB- ie/FW ,/, TAXOL/NN before/IN cisplatin/NN )/-RRB- ./.

(ROOT (S1 (S (PP (IN In) (NP (NP (DT a) (NN Phase) (: :) (NN I) (NN trial)) (VP (VBG using) (NP (NP (NP (JJ escalating) (NNS doses)) (PP (IN of) (NP (NP (NP (NN TAXOL)) (PRN (-LRB- -LRB-) (NP (CD 110-200) (NN mg/m2)) (-RRB- -RRB-))) (CC and) (NP (NP (NN cisplatin)) (PRN (-LRB- -LRB-) (NP (QP (CD 50) (CC or) (CD 75)) (NN mg/m2)) (-RRB- -RRB-)))))) (VP (VBN given) (PP (IN as) (NP (JJ sequential) (NNS infusions)))))))) (, ,) (NP (NN myelosuppression)) (VP (VBD was) (ADJP (RBR more) (JJ profound)) (SBAR (WHADVP (WRB when)) (S (NP (NN TAXOL)) (VP (VBD was) (VP (VBN given) (PP (IN after) (NP (NN cisplatin))) (PP (IN than) (PP (IN with) (NP (NP (DT the) (JJ alternate) (NN sequence)) (PRN (-LRB- -LRB-) (PP (FW ie)) (, ,) (NP (NP (NN TAXOL)) (PP (IN before) (NP (NN cisplatin)))) (-RRB- -RRB-)))))))))) (. .))))

Sentence Id: DrugDDI.d480.s1
Pharmacokinetic/JJ data/NNS from/IN these/DT patients/NNS demonstrated/VBD a/DT decrease/NN in/IN paclitaxel/NN clearance/NN of/IN approximately/RB 33/CD %/NN when/WRB TAXOL/NN was/VBD administered/VBN following/VBG cisplatin/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Pharmacokinetic) (NNS data)) (PP (IN from) (NP (DT these) (NNS patients)))) (VP (VBD demonstrated) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (NN paclitaxel) (NN clearance)) (PP (IN of) (NP (QP (RB approximately) (CD 33)) (NN %)))))) (SBAR (WHADVP (WRB when)) (S (NP (NN TAXOL)) (VP (VBD was) (VP (VBN administered) (PP (VBG following) (NP (NN cisplatin))))))))) (. .))))

Sentence Id: DrugDDI.d480.s2
The/DT metabolism/NN of/IN TAXOL/NN is/VBZ catalyzed/VBN by/IN cytochrome/NN P450/NN isoen-zymes/NNS CYP2C8/NN and/CC CYP3A4/NN ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN metabolism)) (PP (IN of) (NP (NN TAXOL)))) (VP (VBZ is) (VP (VBN catalyzed) (PP (IN by) (NP (NN cytochrome) (NN P450) (NNS isoen-zymes) (NP (NP (NN CYP2C8)) (CC and) (NP (NN CYP3A4)))))))) (. .))))

Sentence Id: DrugDDI.d480.s3
In/IN the/DT absence/NN of/IN formal/JJ clinical/JJ drug/NN interaction/NN studies/NNS ,/, caution/NN should/MD be/VB exercised/VBN when/WRB administering/VBG TAXOL/NN concomitantly/RB with/IN known/JJ substrates/NNS or/CC inhibitors/NNS of/IN the/DT cytochrome/NN P450/NN isoenzymes/NNS CYP2C8/NN and/CC CYP3A4/NN ./.

(ROOT (S1 (S (S (PP (IN In) (DT the) (NN absence) (IN of) (NP (JJ formal) (JJ clinical) (NN drug) (NN interaction) (NNS studies))) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NP (NN TAXOL)) (ADVP (RB concomitantly))) (PP (IN with) (NP (NP (JJ known) (NNS substrates)) (CC or) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (DT the) (NN cytochrome) (NN P450) (NNS isoenzymes) (NP (NP (NN CYP2C8)) (CC and) (NP (NN CYP3A4))))))))))))))) (. .))))

Sentence Id: DrugDDI.d480.s4
Potential/JJ interactions/NNS between/IN TAXOL/NN ,/, a/DT substrate/NN of/IN CYP3A4/NN ,/, and/CC protease/NN inhibitors/NNS (/-LRB- ritonavir/NN ,/, saquinavir/NN ,/, indinavir/NN ,/, and/CC nelfinavir/NN )/-RRB- ,/, which/WDT are/VBP substrates/NNS and/or/CC inhibitors/NNS of/IN CYP3A4/NN ,/, have/VBP not/RB been/VBN evaluated/VBN in/IN clinical/JJ trials/NNS ./.

(ROOT (S1 (S (S (NP (NP (JJ Potential) (NNS interactions)) (PP (IN between) (NP (NP (NP (NN TAXOL)) (, ,) (NP (NP (DT a) (NN substrate)) (PP (IN of) (NP (NN CYP3A4)))) (, ,)) (CC and) (NP (NP (NN protease) (NNS inhibitors)) (PRN (-LRB- -LRB-) (NP (NP (NN ritonavir)) (, ,) (NP (NN saquinavir)) (, ,) (NP (NN indinavir)) (, ,) (CC and) (NP (NN nelfinavir))) (-RRB- -RRB-))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (NP (NP (NP (NNS substrates)) (CC and/or) (NP (NNS inhibitors))) (PP (IN of) (NP (NN CYP3A4))))))) (, ,)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN evaluated) (PP (IN in) (NP (JJ clinical) (NNS trials))))))) (. .))))

Sentence Id: DrugDDI.d480.s5
Reports/NNS in/IN the/DT literature/NN suggest/VBP that/IN plasma/NN levels/NNS of/IN doxorubicin/NN (/-LRB- and/CC its/PRP$ active/JJ metabolite/NN doxorubicinol/NN )/-RRB- may/MD be/VB increased/VBN when/WRB paclitaxel/NN and/CC doxorubicin/NN are/VBP used/VBN in/IN combination/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Reports)) (PP (IN in) (NP (DT the) (NN literature)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NN doxorubicin)))) (-LRB- -LRB-) (CC and) (NP (PRP$ its) (JJ active) (NN metabolite) (NN doxorubicinol)) (-RRB- -RRB-)) (VP (MD may) (VP (VB be) (VP (VBN increased) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN paclitaxel)) (CC and) (NP (NN doxorubicin))) (VP (VBP are) (VP (VBN used) (PP (IN in) (NP (NN combination)))))))))))))) (. .))))

Sentence Id: DrugDDI.d480.s6
Hematology/NNP :/: TAXOL/NN therapy/NN should/MD not/RB be/VB administered/VBN to/TO patients/NNS with/IN baseline/NN neutrophil/NN counts/NNS of/IN less/JJR than/IN 1,500/CD cells/mm3/NN ./.

(ROOT (S1 (S (NP (NP (NNP Hematology)) (: :) (S (NP (NN TAXOL) (NN therapy)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN baseline) (NN neutrophil) (NNS counts)) (PP (IN of) (NP (QP (JJR less) (IN than) (CD 1,500)) (NN cells/mm3))))))))))) (. .)))))

Sentence Id: DrugDDI.d480.s7
In/IN order/NN to/TO monitor/VB the/DT occurrence/NN of/IN myelotoxicity/NN ,/, it/PRP is/VBZ recommended/VBN that/IN frequent/JJ peripheral/JJ blood/NN cell/NN counts/NNS be/VB performed/VBN on/IN all/DT patients/NNS receiving/VBG TAXOL/NN ./.

(ROOT (S1 (S (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB monitor) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NN myelotoxicity)))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (JJ frequent) (JJ peripheral) (NN blood) (NN cell) (NNS counts)) (VP (VB be) (VP (VBN performed) (PP (IN on) (NP (NP (DT all) (NNS patients)) (VP (VBG receiving) (NP (NN TAXOL)))))))))))) (. .))))

Sentence Id: DrugDDI.d480.s8
Patients/NNS should/MD not/RB be/VB re-treated/VBN with/IN subsequent/JJ cycles/NNS of/IN TAXOL/NN until/IN neutrophils/NNS recover/VBP to/TO a/DT level/NN 1500/CD cells/mm3/NN and/CC platelets/NNS recover/VBP to/TO a/DT level/NN 100,000/CD cells/mm3/NN ./.

(ROOT (S1 (S (S (NP (NNS Patients)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN re-treated) (PP (IN with) (NP (NP (JJ subsequent) (NNS cycles)) (PP (IN of) (NP (NN TAXOL))))) (SBAR (IN until) (S (S (NP (NNS neutrophils)) (VP (VBP recover) (PP (TO to) (NP (NP (DT a) (NN level)) (ADJP (CD 1500) (NN cells/mm3)))))) (CC and) (S (NP (NNS platelets)) (VP (VBP recover) (PP (TO to) (NP (NP (DT a) (NN level)) (ADJP (CD 100,000) (NN cells/mm3)))))))))))) (. .))))

Sentence Id: DrugDDI.d480.s9
In/IN the/DT case/NN of/IN severe/JJ neutropenia/NN (/-LRB- 500/CD cells/mm3/NN for/IN seven/CD days/NNS or/CC more/JJR )/-RRB- during/IN a/DT course/NN of/IN TAXOL/NN therapy/NN ,/, a/DT 20/CD %/NN reduction/NN in/IN dose/NN for/IN subsequent/JJ courses/NNS of/IN therapy/NN is/VBZ recommended/VBN ./.

(ROOT (S1 (S (PP (IN In) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (JJ severe) (NN neutropenia)) (PRN (-LRB- -LRB-) (NP (CD 500) (NN cells/mm3)) (PP (IN for) (NP (NP (CD seven) (NNS days)) (CC or) (NP (JJR more)))) (-RRB- -RRB-)))) (PP (IN during) (NP (NP (DT a) (NN course)) (PP (IN of) (NP (NN TAXOL) (NN therapy))))))) (, ,) (NP (NP (DT a) (CD 20) (NN %) (NN reduction)) (PP (IN in) (NP (NN dose))) (PP (IN for) (NP (NP (JJ subsequent) (NNS courses)) (PP (IN of) (NP (NN therapy)))))) (VP (VBZ is) (VP (VBN recommended))) (. .))))

Sentence Id: DrugDDI.d480.s10
For/IN patients/NNS with/IN advanced/JJ HIV/NN disease/NN and/CC poor-risk/JJ AIDS-related/JJ Kaposi/NN @/NN s/NN sarcoma/NN ,/, TAXOL/NN ,/, at/IN the/DT recommended/VBN dose/NN for/IN this/DT disease/NN ,/, can/MD be/VB initiated/VBN and/CC repeated/VBN if/IN the/DT neutrophil/NN count/NN is/VBZ at/IN least/JJS 1000/CD cells/mm3/NN ./.

(ROOT (S1 (S (S (PP (IN For) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ advanced) (NN HIV) (NN disease)) (CC and) (NP (JJ poor-risk) (JJ AIDS-related) (NN Kaposi) (NN @) (NN s) (NN sarcoma)))))) (, ,) (NP (NP (NN TAXOL)) (, ,) (PP (IN at) (NP (NP (DT the) (VBN recommended) (NN dose)) (PP (IN for) (NP (DT this) (NN disease))))) (, ,)) (VP (MD can) (VP (VB be) (VP (VP (VBN initiated)) (CC and) (VP (VBN repeated) (SBAR (IN if) (S (NP (DT the) (NN neutrophil) (NN count)) (VP (VBZ is) (NP (QP (IN at) (JJS least) (CD 1000)) (NN cells/mm3)))))))))) (. .))))

Sentence Id: DrugDDI.d480.s11
Hypersensitivity/NN Reactions/NNS :/: Patients/NNS with/IN a/DT history/NN of/IN severe/JJ hypersensitivity/NN reactions/NNS to/TO products/NNS containing/VBG Cremophor/NN @/NN EL/NN (/-LRB- eg/NN ,/, cyclosporin/NN for/IN injection/NN concentrate/NN and/CC teniposide/NN for/IN injection/NN concentrate/NN )/-RRB- should/MD not/RB be/VB treated/VBN with/IN TAXOL/NN ./.

(ROOT (S1 (S (NP (NP (NN Hypersensitivity) (NNS Reactions)) (: :) (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NP (JJ severe) (NN hypersensitivity) (NNS reactions)) (PP (TO to) (NP (NP (NNS products)) (VP (VBG containing) (NP (NP (NN Cremophor) (NN @) (NN EL)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NP (NN cyclosporin)) (PP (IN for) (NP (NP (NN injection)) (NP (NN concentrate)) (CC and) (NP (NN teniposide)))) (PP (IN for) (NP (NN injection) (NN concentrate))))) (-RRB- -RRB-))))))))))) (VP (MD should) (RB not) (VP (VB be) (VP (VBN treated) (PP (IN with) (NP (NN TAXOL))))))) (. .)))))

Sentence Id: DrugDDI.d480.s12
In/IN order/NN to/TO avoid/VB the/DT occurrence/NN of/IN severe/JJ hypersensitivity/NN reactions/NNS ,/, all/DT patients/NNS treated/VBN with/IN TAXOL/NN should/MD be/VB premedicated/VBN with/IN corticosteroids/NNS (/-LRB- such/JJ as/IN dexamethasone/NN )/-RRB- ,/, diphen/NN -hydramine/NN and/CC H2/NN antagonists/NNS (/-LRB- such/JJ as/IN cimetidine/NN or/CC ranitidine/NN )/-RRB- ./.

(ROOT (S1 (S (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB avoid) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (JJ severe) (NN hypersensitivity) (NNS reactions)))))))) (, ,) (NP (NP (DT all) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NN TAXOL))))) (VP (MD should) (VP (VB be) (VP (VBN premedicated) (PP (IN with) (NP (NP (NP (NNS corticosteroids)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NN dexamethasone)))) (-RRB- -RRB-))) (, ,) (NP (NN diphen) (NN -hydramine)) (CC and) (NP (NP (NN H2) (NNS antagonists)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NP (NN cimetidine)) (CC or) (NP (NN ranitidine))))) (-RRB- -RRB-))))))))) (. .))))

Sentence Id: DrugDDI.d480.s14
However/RB ,/, severe/JJ reactions/NNS ,/, such/JJ as/IN hypotension/NN requiring/VBG treatment/NN ,/, dyspnea/NN requiring/VBG bronchodilators/NNS ,/, angioedema/NN ,/, or/CC generalized/JJ urticaria/NN require/VBP immediate/JJ discontinuation/NN of/IN TAXOL/NN and/CC aggressive/JJ symptomatic/JJ therapy/NN ./.

(ROOT (S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (JJ severe) (NNS reactions)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN hypotension)) (VP (VBG requiring) (NP (NP (NN treatment)) (, ,) (NP (NP (NN dyspnea)) (VP (VBG requiring) (NP (NNS bronchodilators)))) (, ,) (NP (NN angioedema)) (, ,) (CC or) (NP (JJ generalized) (NN urticaria))))))) (VP (VBP require) (NP (NP (JJ immediate) (NN discontinuation)) (PP (IN of) (NP (NP (NN TAXOL)) (CC and) (NP (JJ aggressive) (JJ symptomatic) (NN therapy))))))) (. .))))

Sentence Id: DrugDDI.d480.s15
Patients/NNS who/WP have/VBP developed/VBN severe/JJ hypersensitivity/NN reactions/NNS should/MD not/RB be/VB rechallenged/VBN with/IN TAXOL/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBP have) (VP (VBN developed) (NP (JJ severe) (NN hypersensitivity) (NNS reactions))))))) (VP (MD should) (RB not) (VP (VB be) (VP (VBN rechallenged) (PP (IN with) (NP (NN TAXOL))))))) (. .))))

Sentence Id: DrugDDI.d480.s16
Cardiovascular/NN :/: Hypotension/NN ,/, bradycardia/NN ,/, and/CC hypertension/NN have/VBP been/VBN observed/VBN during/IN administration/NN of/IN TAXOL/NN ,/, but/CC generally/RB do/VBP not/RB require/VB treatment/NN ./.

(ROOT (S1 (S (NP (NP (NN Cardiovascular)) (: :) (S (S (NP (NP (NN Hypotension)) (, ,) (NP (NN bradycardia)) (, ,) (CC and) (NP (NN hypertension))) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (PP (IN during) (NP (NP (NN administration)) (PP (IN of) (NP (NN TAXOL))))))))) (, ,) (CC but) (S (ADVP (RB generally)) (VP (VBP do) (RB not) (VP (VB require) (NP (NN treatment)))))) (. .)))))

Sentence Id: DrugDDI.d480.s17
Occasionally/RB TAXOL/NN infusions/NNS must/MD be/VB interrupted/VBN or/CC discontinued/VBD because/IN of/IN initial/JJ or/CC recurrent/JJ hypertension/NN ./.

(ROOT (S1 (S (S (ADVP (RB Occasionally)) (NP (NN TAXOL) (NNS infusions)) (VP (VP (MD must) (VP (VB be) (VP (VBN interrupted)))) (CC or) (VP (VBD discontinued) (PP (IN because) (IN of) (NP (ADJP (ADJP (JJ initial)) (CC or) (ADJP (JJ recurrent))) (NN hypertension)))))) (. .))))

Sentence Id: DrugDDI.d480.s18
Frequent/JJ vital/JJ sign/NN monitoring/NN ,/, particularly/RB during/IN the/DT first/JJ hour/NN of/IN TAXOL/NN infusion/NN ,/, is/VBZ recommended/VBN ./.

(ROOT (S1 (S (S (NP (NP (JJ Frequent) (JJ vital) (NN sign) (NN monitoring)) (, ,) (ADVP (RB particularly)) (PP (IN during) (NP (NP (DT the) (JJ first) (NN hour)) (PP (IN of) (NP (NN TAXOL) (NN infusion))))) (, ,)) (VP (VBZ is) (VP (VBN recommended)))) (. .))))

Sentence Id: DrugDDI.d480.s20
Nervous/JJ System/NN :/: Although/IN the/DT occurrence/NN of/IN peripheral/JJ neuropathy/NN is/VBZ frequent/JJ ,/, the/DT development/NN of/IN severe/JJ symptomatology/NN is/VBZ unusual/JJ and/CC requires/VBZ a/DT dose/NN reduction/NN of/IN 20/CD %/NN for/IN all/DT subsequentcourses/NNS of/IN TAXOL/NN ./.

(ROOT (S1 (S (NP (NP (JJ Nervous) (NN System)) (: :) (S (SBAR (IN Although) (S (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (JJ peripheral) (NN neuropathy)))) (VP (VBZ is) (ADJP (JJ frequent))))) (, ,) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ severe) (NN symptomatology)))) (VP (VP (VBZ is) (ADJP (JJ unusual))) (CC and) (VP (VBZ requires) (NP (NP (DT a) (NN dose) (NN reduction)) (PP (IN of) (NP (CD 20) (NN %))) (PP (IN for) (NP (NP (DT all) (NNS subsequentcourses)) (PP (IN of) (NP (NN TAXOL))))))))) (. .)))))

Sentence Id: DrugDDI.d480.s21
TAXOL/NN contains/VBZ dehydrated/JJ alcohol/NN USP/NN ,/, 396/CD mg/mL/NN ;/: ./.

(ROOT (S1 (S (S (NP (NN TAXOL)) (VP (VBZ contains) (NP (NP (JJ dehydrated) (NN alcohol) (NN USP)) (, ,) (NP (CD 396) (NN mg/mL)))) (: ;)) (. .))))

Sentence Id: DrugDDI.d480.s22
consideration/NN should/MD be/VB given/VBN to/TO possible/JJ CNS/NNS and/CC other/JJ effects/NNS of/IN alcohol/NN ./.

(ROOT (S1 (S (S (NP (NN consideration)) (VP (MD should) (VP (VB be) (VP (VBN given) (PP (TO to) (NP (NP (NP (JJ possible) (NNS CNS)) (CC and) (NP (JJ other) (NNS effects))) (PP (IN of) (NP (NN alcohol))))))))) (. .))))

Sentence Id: DrugDDI.d480.s23
Hepatic/JJ :/: There/EX is/VBZ limited/JJ evidence/NN that/IN the/DT myelotoxicity/NN of/IN TAXOL/NN may/MD be/VB exacerbated/JJ in/IN patients/NNS with/IN serum/NN total/JJ bilirubin/NN 2/CD times/NNS ULN/NN ./.

(ROOT (S1 (S (NP (NP (JJ Hepatic)) (: :) (S (NP (EX There)) (VP (VBZ is) (NP (JJ limited) (NN evidence) (SBAR (IN that) (S (NP (NP (DT the) (NN myelotoxicity)) (PP (IN of) (NP (NN TAXOL)))) (VP (MD may) (VP (VB be) (ADJP (JJ exacerbated) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN serum) (JJ total) (NN bilirubin) (CD 2) (NNS times) (NN ULN))))))))))))) (. .)))))

Sentence Id: DrugDDI.d480.s24
Extreme/JJ caution/NN should/MD be/VB exercised/VBN when/WRB administering/VBG TAXOL/NN to/TO such/JJ patients/NNS ,/, with/IN dose/NN reduction/NN as/IN recommended/VBN in/IN DOSAGE/NN AND/CC ADMINISTRATION/NN ,/, Table/NN 17/CD ./.

(ROOT (S1 (S (S (NP (JJ Extreme) (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NP (NN TAXOL)) (PP (TO to) (NP (JJ such) (NNS patients))))))) (, ,) (PP (IN with) (NP (NN dose) (NN reduction))) (SBAR (IN as) (S (VP (VBN recommended) (PP (IN in) (NP (NP (NN DOSAGE)) (CC AND) (NP (NP (NN ADMINISTRATION)) (, ,) (NP (NN Table) (CD 17)))))))))))) (. .))))

Sentence Id: DrugDDI.d480.s27
Recurrence/NN of/IN skin/NN reactions/NNS at/IN a/DT site/NN of/IN previous/JJ extravasation/NN following/VBG administration/NN of/IN TAXOL/NN at/IN a/DT different/JJ site/NN ,/, ie/FW ,/, recall/NN ,/, has/VBZ been/VBN reported/VBN rarely/RB ./.

(ROOT (S1 (S (S (NP (NP (NN Recurrence)) (PP (IN of) (NP (NN skin) (NNS reactions))) (PP (IN at) (NP (NP (DT a) (NN site)) (PP (IN of) (NP (JJ previous) (NN extravasation))) (PP (VBG following) (NP (NP (NN administration)) (PP (IN of) (NP (NN TAXOL))) (PP (IN at) (NP (DT a) (JJ different) (NN site))))))) (, ,) (PP (FW ie) (, ,) (NP (NN recall))) (, ,)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (ADVP (RB rarely)))))) (. .))))

Sentence Id: DrugDDI.d480.s28
Rare/JJ reports/NNS of/IN more/RBR severe/JJ events/NNS such/JJ as/IN phlebitis/NN ,/, cellulitis/NN ,/, induration/NN ,/, skin/NN exfoliation/NN ,/, necrosis/NN ,/, and/CC fibrosis/NN have/VBP been/VBN received/VBN as/IN part/NN of/IN the/DT continuing/VBG surveillance/NN of/IN TAXOL/NN safety/NN ./.

(ROOT (S1 (S (S (NP (NP (JJ Rare) (NNS reports)) (PP (IN of) (NP (NP (ADJP (RBR more) (JJ severe)) (NNS events)) (PP (JJ such) (IN as) (NP (NP (NN phlebitis)) (, ,) (NP (NN cellulitis)) (, ,) (NP (NN induration)) (, ,) (NP (NN skin) (NN exfoliation)) (, ,) (NP (NN necrosis)) (, ,) (CC and) (NP (NN fibrosis))))))) (VP (VBP have) (VP (VBN been) (VP (VBN received) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (NP (DT the) (VBG continuing) (NN surveillance)) (PP (IN of) (NP (NN TAXOL) (NN safety))))))))))) (. .))))

Sentence Id: DrugDDI.d235.s0
Aminoglycosides/NNS :/: The/DT mixing/NN of/IN piperacillin/NN with/IN an/DT aminoglycoside/NN in/IN vitro/FW can/MD result/VB in/IN substantial/JJ inactivation/NN of/IN the/DT aminoglycoside/NN ./.

(ROOT (S1 (S (NP (NP (NNS Aminoglycosides)) (: :) (S (NP (NP (DT The) (NN mixing)) (PP (IN of) (NP (NN piperacillin))) (PP (IN with) (NP (NP (DT an) (NN aminoglycoside)) (PP (IN in) (NP (FW vitro)))))) (VP (MD can) (VP (VB result) (PP (IN in) (NP (NP (JJ substantial) (NN inactivation)) (PP (IN of) (NP (DT the) (NN aminoglycoside)))))))) (. .)))))

Sentence Id: DrugDDI.d235.s1
Vecuronium/NN :/: When/WRB used/VBN in/IN the/DT perioperative/JJ period/NN ,/, piperacillin/NN has/VBZ been/VBN implicated/VBN in/IN the/DT prolongation/NN of/IN the/DT neuromuscular/JJ blockade/NN of/IN vecuronium/NN ./.

(ROOT (S1 (S (NP (NP (NN Vecuronium)) (: :) (S (SBAR (WHADVP (WRB When)) (S (VP (VBN used) (PP (IN in) (NP (DT the) (JJ perioperative) (NN period)))))) (, ,) (NP (NN piperacillin)) (VP (VBZ has) (VP (VBN been) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN prolongation)) (PP (IN of) (NP (NP (DT the) (JJ neuromuscular) (NN blockade)) (PP (IN of) (NP (NN vecuronium))))))))))) (. .)))))

Sentence Id: DrugDDI.d235.s2
Caution/NN is/VBZ indicated/VBN when/WRB piperacillin/NN is/VBZ used/VBN perioperatively/NN ./.

(ROOT (S1 (S (S (NP (NN Caution)) (VP (VBZ is) (VP (VBN indicated) (SBAR (WHADVP (WRB when)) (S (NP (NN piperacillin)) (VP (VBZ is) (VP (VBN used) (NP (NN perioperatively))))))))) (. .))))

Sentence Id: DrugDDI.d235.s3
In/IN one/CD controlled/JJ clinical/JJ study/NN ,/, the/DT ureidopenicillins/NNS ,/, including/VBG piperacillin/NN ,/, were/VBD reported/VBN to/TO prolong/VB the/DT action/NN of/IN vecuronium/NN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (CD one) (JJ controlled) (JJ clinical) (NN study))) (, ,) (NP (NP (DT the) (NNS ureidopenicillins)) (, ,) (PP (VBG including) (NP (NN piperacillin))) (, ,)) (VP (VBD were) (VP (VBN reported) (S (VP (TO to) (VP (VB prolong) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NN vecuronium)))))))))) (. .))))

Sentence Id: DrugDDI.d235.s4
Due/JJ to/TO their/PRP$ similar/JJ mechanism/NN of/IN action/NN ,/, it/PRP is/VBZ expected/VBN that/IN the/DT neuromuscular/JJ blockade/NN produced/VBN by/IN any/DT of/IN the/DT non-depolarizing/JJ muscle/NN relaxants/NNS could/MD be/VB prolonged/VBD in/IN the/DT presence/NN of/IN piperacillin/NN ./.

(ROOT (S1 (S (S (PP (JJ Due) (TO to) (NP (NP (PRP$ their) (JJ similar) (NN mechanism)) (PP (IN of) (NP (NN action))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN expected) (SBAR (IN that) (S (NP (NP (DT the) (JJ neuromuscular) (NN blockade)) (VP (VBN produced) (PP (IN by) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (JJ non-depolarizing) (NN muscle) (NNS relaxants))))))) (VP (MD could) (VP (VB be) (VP (VBD prolonged) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN piperacillin))))))))))))) (. .))))

Sentence Id: DrugDDI.d235.s5
Probenecid/NN :/: The/DT oral/JJ combination/NN of/IN probenecid/NN before/IN intramuscular/JJ injection/NN of/IN PIPRACIL/NN produces/VBZ an/DT increase/NN in/IN piperacillin/JJ peak/JJ serum/NN level/NN of/IN about/RB 30/CD %./NN

(ROOT (S1 (S (NP (NP (NN Probenecid)) (: :) (S (NP (NP (DT The) (JJ oral) (NN combination)) (PP (IN of) (NP (NN probenecid))) (PP (IN before) (NP (NP (JJ intramuscular) (NN injection)) (PP (IN of) (NP (NN PIPRACIL)))))) (VP (VBZ produces) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (JJ piperacillin) (JJ peak) (NN serum) (NN level)) (PP (IN of) (NP (QP (RB about) (CD 30)) (NN %.))))))))))))

Sentence Id: DrugDDI.d235.s6
Anticoagulants/NNS Coagulation/NN parameters/NNS should/MD be/VB tested/VBN more/RBR frequently/RB and/CC monitored/VBN regularly/RB during/IN simultaneous/JJ administration/NN of/IN high/JJ doses/NNS of/IN heparin/NN ,/, oral/JJ anticoagulants/NNS ,/, or/CC other/JJ drugs/NNS that/WDT may/MD affect/VB the/DT blood/NN coagulation/NN system/NN or/CC the/DT thrombocyte/JJ function/NN ./.

(ROOT (S1 (S (S (NP (NNS Anticoagulants) (NN Coagulation) (NNS parameters)) (VP (MD should) (VP (VB be) (VP (VP (VBN tested) (ADVP (RBR more) (RB frequently))) (CC and) (VP (VBN monitored) (ADVP (RB regularly)) (PP (IN during) (NP (NP (NP (JJ simultaneous) (NN administration)) (PP (IN of) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NN heparin)))))) (, ,) (NP (JJ oral) (NNS anticoagulants)) (, ,) (CC or) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB affect) (NP (DT the) (NN blood) (NN coagulation) (NN system))))))) (CC or) (NP (DT the) (JJ thrombocyte) (NN function))))))))) (. .))))

Sentence Id: DrugDDI.d235.s7
Methotrexate/NN Piperacillin/NN sodium/NN may/MD reduce/VB the/DT excretion/NN of/IN methotrexate/NN ./.

(ROOT (S1 (S (S (NP (NN Methotrexate) (NN Piperacillin) (NN sodium)) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (NN excretion)) (PP (IN of) (NP (NN methotrexate))))))) (. .))))

Sentence Id: DrugDDI.d235.s8
Therefore/RB ,/, serum/NN levels/NNS of/IN methotrexate/NN should/MD be/VB monitored/VBN in/IN patients/NNS to/TO avoid/VB drug/NN toxicity/NN ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN serum) (NNS levels)) (PP (IN of) (NP (NN methotrexate)))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (PP (IN in) (NP (NNS patients))))) (S (VP (TO to) (VP (VB avoid) (NP (NN drug) (NN toxicity))))))) (. .))))

Sentence Id: DrugDDI.d235.s9
Drug/NN /Laboratory/NN Test/NN Interactions/NNS :/: As/IN with/IN other/JJ penicillins/NNS ,/, the/DT administration/NN of/IN PIPRACIL/NN may/MD result/VB in/IN a/DT false-positive/JJ reaction/NN for/IN glucose/NN in/IN the/DT urine/NN using/VBG a/DT copper/NN -reduction/NN method/NN ./.

(ROOT (S1 (S (NP (NP (NN Drug) (NN /Laboratory) (NN Test) (NNS Interactions)) (: :) (S (PP (IN As) (PP (IN with) (NP (JJ other) (NNS penicillins)))) (, ,) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NN PIPRACIL)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT a) (JJ false-positive) (NN reaction)) (PP (IN for) (NP (NN glucose))) (PP (IN in) (NP (NP (DT the) (NN urine)) (VP (VBG using) (NP (DT a) (NN copper) (NN -reduction) (NN method)))))))))) (. .)))))

Sentence Id: DrugDDI.d235.s10
It/PRP is/VBZ recommended/VBN that/IN glucose/NN tests/NNS based/VBN on/IN enzymatic/JJ glucose/NN oxidase/NN reactions/NNS be/VB used/VBN ./.

(ROOT (S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NP (NN glucose) (NNS tests)) (VP (VBN based) (PP (IN on) (NP (JJ enzymatic) (NN glucose) (NN oxidase) (NNS reactions))))) (VP (VB be) (VP (VBN used)))))))) (. .))))

Sentence Id: DrugDDI.d235.s11
There/EX have/VBP been/VBN reports/NNS of/IN positive/JJ test/NN results/NNS using/VBG the/DT Bio-Rad/JJ Laboratories/NNS Platelia/NN Aspergillus/NN EIA/NN test/NN in/IN patients/NNS receiving/VBG piperacillin/NN //: tazobactam/NN injection/NN who/WP were/VBD subsequently/RB found/VBN to/TO be/VB free/JJ of/IN Aspergillus/JJ infection/NN ./.

(ROOT (S1 (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (NNS reports)) (PP (IN of) (NP (JJ positive) (NN test) (NNS results)))) (S (VP (VBG using) (NP (NP (DT the) (NP (JJ Bio-Rad) (NNS Laboratories)) (NN Platelia) (NN Aspergillus) (NN EIA) (NN test)) (PP (IN in) (NP (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN piperacillin) (: /) (NN tazobactam) (NN injection)))) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB subsequently)) (VP (VBN found) (S (VP (TO to) (VP (VB be) (ADJP (JJ free) (PP (IN of) (NP (JJ Aspergillus) (NN infection)))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d235.s12
Cross-reactions/NNS with/IN non-Aspergillus/JJ polysaccharides/NNS and/CC polyfuranoses/NNS with/IN the/DT Bio-Rad/JJ Laboratories/NNS Platelia/FW Aspergillus/FW EIA/NN test/NN have/VBP been/VBN reported/VBN ./.

(ROOT (S1 (S (S (NP (NP (NP (NNS Cross-reactions)) (PP (IN with) (NP (JJ non-Aspergillus) (NNS polysaccharides)))) (CC and) (NP (NP (NNS polyfuranoses)) (PP (IN with) (NP (DT the) (JJ Bio-Rad) (NNS Laboratories)))) (NP (ADJP (FW Platelia) (FW Aspergillus)) (NN EIA) (NN test))) (VP (VBP have) (VP (VBN been) (VP (VBN reported))))) (. .))))

Sentence Id: DrugDDI.d235.s13
Therefore/RB ,/, positive/JJ test/NN results/NNS in/IN patients/NNS receiving/VBG piperacillin/NN should/MD be/VB interpreted/VBN cautiously/RB and/CC confirmed/VBN by/IN other/JJ diagnostic/JJ methods/NNS ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (JJ positive) (NN test) (NNS results)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN piperacillin)))))) (VP (MD should) (VP (VB be) (VP (VP (VBN interpreted) (ADVP (RB cautiously))) (CC and) (VP (VBN confirmed) (PP (IN by) (NP (JJ other) (JJ diagnostic) (NNS methods)))))))) (. .))))

Sentence Id: DrugDDI.d253.s0
Effect/NN of/IN other/JJ drugs/NNS on/IN Vardenafil/NN ./.

(ROOT (S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (JJ other) (NNS drugs))) (PP (IN on) (NP (NN Vardenafil))) (. .)))))

Sentence Id: DrugDDI.d253.s1
In/FW vitro/FW studies/NNS :/: Studies/NNS in/IN human/JJ liver/NN microsomes/NNS showed/VBD that/IN vardenafil/NN is/VBZ metabolized/VBN primarily/RB by/IN cytochrome/NN P450/NN (/-LRB- CYP/NN )/-RRB- isoforms/NNS 3A4/5/NN ,/, and/CC to/TO a/DT lesser/JJR degree/NN by/IN CYP2C9/NN ./.

(ROOT (S1 (S (NP (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (: :) (S (NP (NP (NNS Studies)) (PP (IN in) (NP (JJ human) (NN liver) (NNS microsomes)))) (VP (VBD showed) (SBAR (IN that) (S (NP (NN vardenafil)) (VP (VBZ is) (VP (VP (VBN metabolized) (ADVP (RB primarily)) (PP (IN by) (NP (NP (NP (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN CYP)) (-RRB- -RRB-))) (NNS isoforms) (NN 3A4/5)))) (, ,) (CC and) (PP (TO to) (NP (DT a) (JJR lesser) (NN degree))) (PP (IN by) (NP (NN CYP2C9))))))))) (. .)))))

Sentence Id: DrugDDI.d253.s2
Therefore/RB ,/, inhibitors/NNS of/IN these/DT enzymes/NNS are/VBP expected/VBN to/TO reduce/VB vardenafil/NN clearance/NN ./.

(ROOT (S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (DT these) (NNS enzymes)))) (VP (VBP are) (VP (VBN expected) (S (VP (TO to) (VP (VB reduce) (NP (NN vardenafil) (NN clearance)))))))) (. .))))

Sentence Id: DrugDDI.d253.s3
In/FW vivo/FW studies/NNS :/: Cytochrome/NN P450/NN Inhibitors/NNS ./.

(ROOT (S1 (S (S (NP (ADJP (FW In) (FW vivo)) (NNS studies)) (: :) (NP (NN Cytochrome) (NN P450) (NNS Inhibitors))) (. .))))

Sentence Id: DrugDDI.d253.s4
Cimetidine/NN (/-LRB- 400/CD mg/NN b.i.d./NN )/-RRB- had/VBD no/DT effect/NN on/IN vardenafil/NN bioavailability/NN (/-LRB- AUC/NN )/-RRB- and/CC maximum/NN concentration/NN (/-LRB- Cmax/NN )/-RRB- of/IN vardenafil/NN when/WRB co-administered/VBN with/IN 20/CD mg/NN Vardenafil/NN in/IN healthy/JJ volunteers/NNS ./.

(ROOT (S1 (S (S (NP (NP (NN Cimetidine)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 400) (NN mg)) (NN b.i.d.)) (-RRB- -RRB-))) (VP (VBD had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NP (NN vardenafil) (NN bioavailability)) (PRN (-LRB- -LRB-) (NP (NN AUC)) (-RRB- -RRB-))) (CC and) (NP (NP (NN maximum) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NN Cmax)) (-RRB- -RRB-))))) (PP (IN of) (NP (NN vardenafil)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN co-administered) (PP (IN with) (NP (CD 20) (NN mg) (NN Vardenafil))) (PP (IN in) (NP (JJ healthy) (NNS volunteers)))))))) (. .))))

Sentence Id: DrugDDI.d253.s5
Erythromycin/NN (/-LRB- 500/CD mg/NN t.i.d/CD )/-RRB- produced/VBD a/DT 4-fold/JJ increase/NN in/IN vardenafil/NN AUC/NN and/CC a/DT 3-fold/JJ increase/NN in/IN Cmax/NN when/WRB co-administered/VBN with/IN Vardenafil/NN 5/CD mg/NN in/IN healthy/JJ volunteers/NNS ./.

(ROOT (S1 (S (S (NP (NP (NN Erythromycin)) (PRN (-LRB- -LRB-) (NP (CD 500) (NN mg) (CD t.i.d)) (-RRB- -RRB-))) (VP (VBD produced) (NP (NP (NP (DT a) (JJ 4-fold) (NN increase)) (PP (IN in) (NP (NN vardenafil) (NN AUC)))) (CC and) (NP (NP (DT a) (JJ 3-fold) (NN increase)) (PP (IN in) (NP (NN Cmax))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN co-administered) (PP (IN with) (NP (NP (NN Vardenafil) (CD 5) (NN mg)) (PP (IN in) (NP (JJ healthy) (NNS volunteers)))))))))) (. .))))

Sentence Id: DrugDDI.d253.s6
It/PRP is/VBZ recommended/VBN not/RB to/TO exceed/VB a/DT single/JJ 5/CD mg/NN dose/NN of/IN Vardenafil/NN in/IN a/DT 24-hour/JJ period/NN when/WRB used/VBN in/IN combination/NN with/IN erythromycin/NN ./.

(ROOT (S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (S (VP (RB not) (TO to) (VP (VB exceed) (NP (NP (DT a) (JJ single) (ADJP (CD 5) (NN mg)) (NN dose)) (PP (IN of) (NP (NN Vardenafil)))) (PP (IN in) (NP (NP (DT a) (JJ 24-hour) (NN period)) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN erythromycin)))))))))))))))) (. .))))

Sentence Id: DrugDDI.d253.s7
Ketoconazole/NN (/-LRB- 200/CD mg/NN once/RB daily/JJ )/-RRB- produced/VBD a/DT 10-fold/JJ increase/NN in/IN vardenafil/NN AUC/NN and/CC a/DT 4-fold/JJ increase/NN in/IN Cmax/NN when/WRB co-administered/VBN with/IN Vardenafil/NN (/-LRB- 5/CD mg/NN )/-RRB- in/IN healthy/JJ volunteers/NNS ./.

(ROOT (S1 (S (S (NP (NP (NN Ketoconazole)) (PRN (-LRB- -LRB-) (NP (NP (CD 200) (NN mg)) (ADJP (RB once) (JJ daily))) (-RRB- -RRB-))) (VP (VBD produced) (NP (NP (NP (DT a) (JJ 10-fold) (NN increase)) (PP (IN in) (NP (NN vardenafil) (NN AUC)))) (CC and) (NP (NP (DT a) (JJ 4-fold) (NN increase)) (PP (IN in) (NP (NN Cmax))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN co-administered) (PP (IN with) (NP (NP (NP (NN Vardenafil)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN mg)) (-RRB- -RRB-))) (PP (IN in) (NP (JJ healthy) (NNS volunteers)))))))))) (. .))))

Sentence Id: DrugDDI.d253.s8
A/DT 5-mg/JJ Vardenafil/NN dose/NN should/MD not/RB be/VB exceeded/VBD when/WRB used/VBN in/IN combination/NN with/IN 200/CD mg/NN once/IN daily/JJ ketoconazole/NN ./.

(ROOT (S1 (S (S (NP (DT A) (JJ 5-mg) (NN Vardenafil) (NN dose)) (VP (MD should) (RB not) (VP (VB be) (VP (VBD exceeded) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (CD 200) (NN mg)) (PP (IN once) (NP (JJ daily) (NN ketoconazole)))))))))))))) (. .))))

Sentence Id: DrugDDI.d253.s9
Since/IN higher/JJR doses/NNS of/IN ketoconazole/NN (/-LRB- 400/CD mg/NN daily/RB )/-RRB- may/MD result/VB in/IN higher/JJR increases/NNS in/IN Cmax/NN and/CC AUC/NN ,/, a/DT single/JJ 2.5/CD mg/NN dose/NN of/IN Vardenafil/NN should/MD not/RB be/VB exceeded/VBD in/IN a/DT 24-hour/JJ period/NN when/WRB used/VBN in/IN combination/NN with/IN ketoconazole/NN 400/CD mg/NN daily/RB ./.

(ROOT (S1 (S (S (SBAR (IN Since) (S (NP (NP (NP (JJR higher) (NNS doses)) (PP (IN of) (NP (NN ketoconazole)))) (PRN (-LRB- -LRB-) (NP (NP (CD 400) (NN mg)) (ADVP (RB daily))) (-RRB- -RRB-))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (JJR higher) (NNS increases)) (PP (IN in) (NP (NP (NN Cmax)) (CC and) (NP (NN AUC)))))))))) (, ,) (NP (NP (DT a) (JJ single) (ADJP (CD 2.5) (NN mg)) (NN dose)) (PP (IN of) (NP (NN Vardenafil)))) (VP (MD should) (RB not) (VP (VB be) (VP (VBD exceeded) (PP (IN in) (NP (DT a) (JJ 24-hour) (NN period))) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NN ketoconazole) (CD 400) (NN mg)) (ADVP (RB daily))))))))))))) (. .))))

Sentence Id: DrugDDI.d253.s10
HIV/NN Protease/NN Inhibitors/NNS :/: Indinavir/NN (/-LRB- 800/CD mg/NN t.i.d./NN )/-RRB- co-administered/VBN with/IN Vardenafil/NN 10/CD mg/NN resulted/VBD in/IN a/DT 16-fold/JJ increase/NN in/IN vardenafil/NN AUC/NN ,/, a/DT 7-fold/JJ increase/NN in/IN vardenafil/NN Cmax/NN and/CC a/DT 2-fold/JJ increase/NN in/IN vardenafil/NN half-life/NN ./.

(ROOT (S1 (S (S (NP (NP (NP (NN HIV) (NN Protease) (NNS Inhibitors)) (: :) (NP (NP (NN Indinavir)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 800) (NN mg)) (NN t.i.d.)) (-RRB- -RRB-)))) (VP (VBN co-administered) (PP (IN with) (NP (NP (NN Vardenafil)) (ADJP (CD 10) (NN mg)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (JJ 16-fold) (NN increase)) (PP (IN in) (NP (NN vardenafil) (NN AUC)))) (, ,) (NP (NP (DT a) (JJ 7-fold) (NN increase)) (PP (IN in) (NP (NN vardenafil) (NN Cmax)))) (CC and) (NP (NP (DT a) (JJ 2-fold) (NN increase)) (PP (IN in) (NP (NN vardenafil) (NN half-life)))))))) (. .))))

Sentence Id: DrugDDI.d253.s11
It/PRP is/VBZ recommended/VBN not/RB to/TO exceed/VB a/DT single/JJ 2.5/CD mg/NN Vardenafil/NN dose/NN in/IN a/DT 24-hour/JJ period/NN when/WRB used/VBN in/IN combination/NN with/IN indinavir/NN ./.

(ROOT (S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (S (VP (RB not) (TO to) (VP (VB exceed) (NP (DT a) (JJ single) (ADJP (CD 2.5) (NN mg)) (NN Vardenafil) (NN dose)) (PP (IN in) (NP (NP (DT a) (JJ 24-hour) (NN period)) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN indinavir)))))))))))))))) (. .))))

Sentence Id: DrugDDI.d253.s12
Ritonavir/NN (/-LRB- 600/CD mg/NN b.i.d./NN )/-RRB- co-administered/VBN with/IN Vardenafil/NN 5/CD mg/NN resulted/VBD in/IN a/DT 49-fold/JJ increase/NN in/IN vardenafil/NN AUC/NN and/CC a/DT 13-fold/RB increase/NN in/IN vardenafil/NN Cmax/NN ./.

(ROOT (S1 (S (S (NP (NP (NP (NN Ritonavir)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 600) (NN mg)) (NN b.i.d.)) (-RRB- -RRB-))) (VP (VBN co-administered) (PP (IN with) (NP (NN Vardenafil) (CD 5) (NN mg))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (JJ 49-fold) (NN increase)) (PP (IN in) (NP (NN vardenafil) (NN AUC)))) (CC and) (NP (NP (DT a) (ADJP (RB 13-fold)) (NN increase)) (PP (IN in) (NP (NN vardenafil) (NN Cmax)))))))) (. .))))

Sentence Id: DrugDDI.d253.s13
The/DT interaction/NN is/VBZ a/DT consequence/NN of/IN blocking/VBG hepatic/JJ metabolism/NN of/IN vardenafil/NN by/IN ritonavir/NN ,/, a/DT highly/RB potent/JJ CYP3A4/NN inhibitor/NN ,/, which/WDT also/RB inhibits/VBZ CYP2C9/NN ./.

(ROOT (S1 (S (S (NP (DT The) (NN interaction)) (VP (VBZ is) (NP (NP (DT a) (NN consequence)) (PP (IN of) (S (VP (VBG blocking) (NP (NP (JJ hepatic) (NN metabolism)) (PP (IN of) (NP (NN vardenafil)))) (PP (IN by) (NP (NP (NN ritonavir)) (, ,) (NP (NP (DT a) (ADJP (RB highly) (JJ potent)) (NN CYP3A4) (NN inhibitor)) (, ,) (SBAR (WHNP (WDT which)) (S (ADVP (RB also)) (VP (VBZ inhibits) (NP (NN CYP2C9)))))))))))))) (. .))))

Sentence Id: DrugDDI.d253.s14
Ritonavir/NN significantly/RB prolonged/VBD the/DT half-life/NN of/IN vardenafil/NN to/TO 26/CD hours/NNS ./.

(ROOT (S1 (S (S (NP (NN Ritonavir)) (ADVP (RB significantly)) (VP (VBD prolonged) (NP (NP (DT the) (NN half-life)) (PP (IN of) (NP (NN vardenafil))) (PP (TO to) (NP (CD 26) (NNS hours)))))) (. .))))

Sentence Id: DrugDDI.d253.s15
Consequently/RB ,/, it/PRP is/VBZ recommended/VBN not/RB to/TO exceed/VB a/DT single/JJ 2.5/CD mg/NN Vardenafil/NN dose/NN in/IN a/DT 72-hour/JJ period/NN when/WRB used/VBN in/IN combination/NN with/IN ritonavir/NN ./.

(ROOT (S1 (S (S (ADVP (RB Consequently)) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN recommended) (S (VP (RB not) (TO to) (VP (VB exceed) (NP (DT a) (JJ single) (ADJP (CD 2.5) (NN mg)) (NN Vardenafil) (NN dose)) (PP (IN in) (NP (NP (DT a) (JJ 72-hour) (NN period)) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN ritonavir)))))))))))))))) (. .))))

Sentence Id: DrugDDI.d253.s16
Other/JJ Drug/NN Interactions/NNS :/: No/DT pharmacokinetic/JJ interactions/NNS were/VBD observed/VBN between/IN vardenafil/NN and/CC the/DT following/JJ drugs/NNS :/: glyburide/NN ,/, warfarin/NN ,/, digoxin/NN ,/, Maalox/NN ,/, and/CC ranitidine/NN ./.

(ROOT (S1 (S (NP (NP (JJ Other) (NN Drug) (NNS Interactions)) (: :) (S (NP (DT No) (JJ pharmacokinetic) (NNS interactions)) (VP (VBD were) (VP (VBN observed) (PP (IN between) (NP (NP (NN vardenafil)) (CC and) (NP (DT the) (JJ following) (NNS drugs))))))) (: :) (NP (NP (NN glyburide)) (, ,) (NP (NN warfarin)) (, ,) (NP (NN digoxin)) (, ,) (NP (NN Maalox)) (, ,) (CC and) (NP (NN ranitidine))) (. .)))))

Sentence Id: DrugDDI.d253.s17
In/IN the/DT warfarin/JJ study/NN ,/, vardenafil/NN had/VBD no/DT effect/NN on/IN the/DT prothrombin/NN time/NN or/CC other/JJ pharmacodynamic/JJ parameters/NNS ./.

(ROOT (S1 (S (S (PP (IN In) (NP (DT the) (JJ warfarin) (NN study))) (, ,) (NP (NN vardenafil)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN prothrombin) (NN time)) (CC or) (NP (JJ other) (JJ pharmacodynamic) (NNS parameters)))))) (. .))))

Sentence Id: DrugDDI.d253.s18
Effects/NNS of/IN Vardenafil/NN on/IN other/JJ drugs/NNS ./.

(ROOT (S1 (S (S (NP (NP (NNS Effects)) (PP (IN of) (NP (NN Vardenafil))) (PP (IN on) (NP (JJ other) (NNS drugs))))) (. .))))

Sentence Id: DrugDDI.d253.s19
In/FW vitro/FW studies/NNS :/: Vardenafil/NN and/CC its/PRP$ metabolites/NNS had/VBD no/DT effect/NN on/IN CYP1A2/NN ,/, 2A6/NN ,/, and/CC 2E1/NN (/-LRB- Ki/NN 100uM/NN )/-RRB- ./.

(ROOT (S1 (S (NP (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (: :) (S (NP (NP (NN Vardenafil)) (CC and) (NP (PRP$ its) (NNS metabolites))) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NN CYP1A2)) (, ,) (NP (NN 2A6)) (, ,) (CC and) (NP (NP (NN 2E1)) (PRN (-LRB- -LRB-) (NP (NN Ki) (NN 100uM)) (-RRB- -RRB-))))))) (. .)))))

Sentence Id: DrugDDI.d253.s20
Weak/JJ inhibitory/JJ effects/NNS toward/IN other/JJ isoforms/NNS (/-LRB- CYP2C8/NN ,/, 2C9/NN ,/, 2C19/NN ,/, 2D6/NN ,/, 3A4/NN )/-RRB- were/VBD found/VBN ,/, but/CC Ki/NN values/NNS were/VBD in/IN excess/NN of/IN plasma/NN concentrations/NNS achieved/VBN following/VBG dosing/NN ./.

(ROOT (S1 (S (S (S (NP (NP (JJ Weak) (JJ inhibitory) (NNS effects)) (PP (IN toward) (NP (NP (JJ other) (NNS isoforms)) (PRN (-LRB- -LRB-) (NP (NP (NN CYP2C8)) (, ,) (NP (NN 2C9)) (, ,) (NP (NN 2C19)) (, ,) (NP (NN 2D6)) (, ,) (NP (NN 3A4))) (-RRB- -RRB-))))) (VP (VBD were) (VP (VBN found)))) (, ,) (CC but) (S (NP (NN Ki) (NNS values)) (VP (VBD were) (PP (IN in) (NP (NP (NN excess)) (PP (IN of) (NP (NP (NN plasma) (NNS concentrations)) (VP (VBN achieved) (PP (VBG following) (NP (NN dosing))))))))))) (. .))))

Sentence Id: DrugDDI.d253.s21
The/DT most/RBS potent/JJ inhibitory/JJ activity/NN was/VBD observed/VBN for/IN vardenafil/NN metabolite/NN M1/NN ,/, which/WDT had/VBD a/DT Ki/NN of/IN 1.4/CD uM/NN toward/IN CYP3A4/NN ,/, which/WDT is/VBZ about/RB 20/CD times/NNS higher/JJR than/IN the/DT M1/NN Cmax/NN values/NNS after/IN an/DT 80/CD mg/NN Vardenafil/NN dose/NN ./.

(ROOT (S1 (S (S (NP (DT The) (ADJP (RBS most) (JJ potent)) (JJ inhibitory) (NN activity)) (VP (VBD was) (VP (VBN observed) (PP (IN for) (NP (NP (NN vardenafil) (NN metabolite) (NN M1)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD had) (NP (NP (DT a) (NN Ki)) (PP (IN of) (NP (NP (CD 1.4) (NN uM)) (PP (IN toward) (NP (NN CYP3A4))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADJP (ADJP (QP (RB about) (CD 20) (NNS times)) (JJR higher)) (PP (IN than) (NP (NP (DT the) (NN M1) (NN Cmax) (NNS values)) (PP (IN after) (NP (DT an) (ADJP (CD 80) (NN mg)) (NN Vardenafil) (NN dose)))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d253.s22
In/FW vivo/FW studies/NNS :/: Nitrates/NNS :/: The/DT blood/NN pressure/NN lowering/JJ effects/NNS of/IN sublingual/JJ nitrates/NNS (/-LRB- 0.4/CD mg/NN )/-RRB- taken/VBN 1/CD and/CC 4/CD hours/NNS after/IN vardenafil/NN and/CC increases/NNS in/IN heart/NN rate/NN when/WRB taken/VBN at/IN 1/CD ,/, 4/CD and/CC 8/CD hours/NNS were/VBD potentiated/VBN by/IN a/DT 20/CD mg/NN dose/NN of/IN Vardenafil/NN in/IN healthy/JJ middle-aged/JJ subjects/NNS ./.

(ROOT (S1 (S (S (NP (NP (ADJP (FW In) (FW vivo)) (NNS studies)) (: :) (NP (NNS Nitrates)) (: :) (NP (NP (DT The) (NN blood) (NN pressure) (JJ lowering) (NNS effects)) (PP (IN of) (NP (NP (NP (JJ sublingual) (NNS nitrates)) (PRN (-LRB- -LRB-) (NP (CD 0.4) (NN mg)) (-RRB- -RRB-))) (VP (VBN taken) (PP (NP (QP (CD 1) (CC and) (CD 4)) (NNS hours)) (IN after) (NP (NN vardenafil))))))) (CC and) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (NN heart) (NN rate)) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN at) (NP (QP (CD 1) (, ,) (CD 4) (CC and) (CD 8)) (NNS hours)))))))))) (VP (VBD were) (VP (VBN potentiated) (PP (IN by) (NP (NP (DT a) (ADJP (CD 20) (NN mg)) (NN dose)) (PP (IN of) (NP (NP (NN Vardenafil)) (PP (IN in) (NP (JJ healthy) (JJ middle-aged) (NNS subjects)))))))))) (. .))))

Sentence Id: DrugDDI.d253.s23
These/DT effects/NNS were/VBD not/RB observed/VBN when/WRB Vardenafil/NN 20/CD mg/NN was/VBD taken/VBN 24/CD hours/NNS before/IN the/DT NTG/NN ./.

(ROOT (S1 (S (S (NP (DT These) (NNS effects)) (VP (VBD were) (RB not) (VP (VBN observed)) (SBAR (WHADVP (WRB when)) (S (NP (NN Vardenafil) (CD 20) (NN mg)) (VP (VBD was) (VP (VBN taken) (PP (NP (CD 24) (NNS hours)) (IN before) (NP (DT the) (NN NTG))))))))) (. .))))

Sentence Id: DrugDDI.d253.s24
Potentiation/NN of/IN the/DT hypotensive/JJ effects/NNS of/IN nitrates/NNS for/IN patients/NNS with/IN ischemic/JJ heart/NN disease/NN has/VBZ not/RB been/VBN evaluated/VBN ,/, and/CC concomitant/JJ use/NN of/IN Vardenafil/NN and/CC nitrates/NNS is/VBZ contraindicated/VBN ./.

(ROOT (S1 (S (S (S (NP (NP (NN Potentiation)) (PP (IN of) (NP (NP (DT the) (JJ hypotensive) (NNS effects)) (PP (IN of) (NP (NNS nitrates))) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ ischemic) (NN heart) (NN disease)))))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN evaluated))))) (, ,) (CC and) (S (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN Vardenafil)) (CC and) (NP (NNS nitrates))))) (VP (VBZ is) (VP (VBN contraindicated))))) (. .))))

Sentence Id: DrugDDI.d253.s25
Nifedipine/NN :/: Vardenafil/NN 20/CD mg/NN ,/, when/WRB co-administered/VBN with/IN slow-release/JJ nifedipine/NN 30/CD mg/NN or/CC 60/CD mg/NN once/RB daily/RB ,/, did/VBD not/RB affect/VB the/DT relative/JJ bioavailability/NN (/-LRB- AUC/NN )/-RRB- or/CC maximum/JJ concentration/NN (/-LRB- Cmax/NN )/-RRB- of/IN nifedipine/NN ,/, a/DT drug/NN that/WDT is/VBZ metabolized/VBN via/IN CYP3A4/NN ./.

(ROOT (S1 (S (S (NP (NP (NN Nifedipine)) (: :) (NP (NP (NN Vardenafil)) (ADJP (CD 20) (NN mg))) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN co-administered) (PP (IN with) (NP (NP (JJ slow-release) (NN nifedipine) (CD 30) (NN mg)) (CC or) (NP (NP (CD 60) (NN mg)) (ADVP (RB once) (RB daily)))))))) (, ,)) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (NP (DT the) (JJ relative) (NN bioavailability)) (PRN (-LRB- -LRB-) (NP (NN AUC)) (-RRB- -RRB-))) (CC or) (NP (NP (NP (JJ maximum) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NN Cmax)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NN nifedipine)) (, ,) (NP (NP (DT a) (NN drug)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (VP (VBN metabolized) (PP (IN via) (NP (NN CYP3A4))))))))))))))) (. .))))

Sentence Id: DrugDDI.d253.s26
Nifedipine/NN did/VBD not/RB alter/VB the/DT plasma/NN levels/NNS of/IN Vardenafil/NN when/WRB taken/VBN in/IN combination/NN ./.

(ROOT (S1 (S (S (NP (NN Nifedipine)) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NN Vardenafil))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN in) (NP (NN combination)))))))) (. .))))

Sentence Id: DrugDDI.d253.s27
In/IN these/DT patients/NNS whose/WP$ hypertension/NN was/VBD controlled/VBN with/IN nifedipine/NN ,/, Vardenafil/NN 20/CD mg/NN produced/VBD mean/JJ additional/JJ supine/NN systolic/diastolic/JJ blood/NN pressure/NN reductions/NNS of/IN 6/5/CD mm/NN Hg/NN compared/VBN to/TO placebo/NN ./.

(ROOT (S1 (S (S (PP (IN In) (NP (NP (DT these) (NNS patients)) (SBAR (WHNP (WP$ whose) (NN hypertension)) (S (VP (VBD was) (VP (VBN controlled) (PP (IN with) (NP (NN nifedipine))))))))) (, ,) (NP (NP (NN Vardenafil)) (ADJP (CD 20) (NN mg))) (VP (VBD produced) (NP (NP (NP (JJ mean) (JJ additional) (NN supine) (JJ systolic/diastolic) (NN blood) (NN pressure)) (NNS reductions)) (PP (IN of) (NP (ADJP (CD 6/5) (NN mm)) (NN Hg)))) (PP (VBN compared) (PP (TO to) (NP (NN placebo)))))) (. .))))

Sentence Id: DrugDDI.d253.s28
Alpha-blockers/NNS :/: When/WRB Vardenafil/NN 10/CD or/CC 20/CD mg/NN was/VBD given/VBN to/TO healthy/JJ volunteers/NNS either/CC simultaneously/RB or/CC 6/CD hours/NNS after/IN a/DT 10/CD mg/NN dose/NN of/IN terazosin/NN ,/, significant/JJ hypotension/NN developed/VBD in/IN a/DT substantial/JJ number/NN of/IN subjects/NNS ./.

(ROOT (S1 (S (NP (NP (NNS Alpha-blockers)) (: :) (S (SBAR (WHADVP (WRB When)) (S (NP (NN Vardenafil) (CD 10) (CC or) (CD 20) (NN mg)) (VP (VBD was) (UCP (VP (VBN given) (PP (TO to) (NP (JJ healthy) (NNS volunteers)))) (CC either) (ADVP (RB simultaneously)) (CC or) (PP (NP (CD 6) (NNS hours)) (IN after) (NP (NP (DT a) (ADJP (CD 10) (NN mg)) (NN dose)) (PP (IN of) (NP (NN terazosin))))))))) (, ,) (NP (JJ significant) (NN hypotension)) (VP (VBD developed) (PP (IN in) (NP (NP (DT a) (JJ substantial) (NN number)) (PP (IN of) (NP (NNS subjects))))))) (. .)))))

Sentence Id: DrugDDI.d253.s29
With/IN simultaneous/JJ dosing/NN of/IN Vardenafil/NN 10/CD mg/NN and/CC terazosin/NN 10/CD mg/NN ,/, 6/CD of/IN 8/CD subjects/NNS experienced/VBN a/DT standing/JJ systolic/JJ blood/NN pressure/NN of/IN less/JJR than/IN 85/CD mm/NN Hg/NN ./.

(ROOT (S1 (S (S (PP (IN With) (NP (NP (JJ simultaneous) (NN dosing)) (PP (IN of) (NP (NP (NN Vardenafil) (CD 10) (NN mg)) (CC and) (NP (NN terazosin) (CD 10) (NN mg)))))) (, ,) (NP (QP (CD 6) (IN of) (CD 8)) (NNS subjects)) (VP (VBN experienced) (NP (NP (DT a) (JJ standing) (JJ systolic) (NN blood) (NN pressure)) (PP (IN of) (NP (QP (JJR less) (IN than) (CD 85)) (NN mm) (NN Hg)))))) (. .))))

Sentence Id: DrugDDI.d253.s30
With/IN simultaneous/JJ dosing/NN of/IN Vardenafil/NN 20/CD mg/NN and/CC terazosin/NN 10/CD mg/NN ,/, 2/CD of/IN 9/CD subjects/NNS experienced/VBN a/DT standing/JJ systolic/JJ blood/NN pressure/NN of/IN less/JJR than/IN 85/CD mm/NN Hg/NN ./.

(ROOT (S1 (S (S (PP (IN With) (NP (NP (JJ simultaneous) (NN dosing)) (PP (IN of) (NP (NP (NN Vardenafil) (CD 20) (NN mg)) (CC and) (NP (NN terazosin) (CD 10) (NN mg)))))) (, ,) (NP (QP (CD 2) (IN of) (CD 9)) (NNS subjects)) (VP (VBN experienced) (NP (NP (DT a) (JJ standing) (JJ systolic) (NN blood) (NN pressure)) (PP (IN of) (NP (QP (JJR less) (IN than) (CD 85)) (NN mm) (NN Hg)))))) (. .))))

Sentence Id: DrugDDI.d253.s31
When/WRB Vardenafil/NN dosing/NN was/VBD separated/VBN from/IN terazosin/NN 10/CD mg/NN by/IN 6/CD hours/NNS ,/, 7/CD of/IN 28/CD subjects/NNS who/WP received/VBD 20/CD mg/NN of/IN Vardenafil/NN experienced/VBN a/DT decrease/NN in/IN standing/JJ systolic/JJ blood/NN pressure/NN below/IN 85/CD mm/NN Hg/NN ./.

(ROOT (S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN Vardenafil) (NN dosing)) (VP (VBD was) (VP (VBN separated) (PP (IN from) (NP (NN terazosin) (CD 10) (NN mg))) (PP (IN by) (NP (CD 6) (NNS hours))))))) (, ,) (NP (NP (QP (CD 7) (IN of) (CD 28)) (NNS subjects)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (CD 20) (NN mg)) (PP (IN of) (NP (NN Vardenafil)))))))) (VP (VBN experienced) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (JJ standing) (JJ systolic) (NN blood) (NN pressure)) (PP (IN below) (NP (ADJP (CD 85) (NN mm)) (NN Hg)))))))) (. .))))

Sentence Id: DrugDDI.d253.s32
In/IN a/DT similar/JJ study/NN with/IN tamsulosin/NN in/IN healthy/JJ volunteers/NNS ,/, 1/CD of/IN 24/CD subjects/NNS dosed/VBN with/IN Vardenafil/NN 20/CD mg/NN and/CC tamsulosin/NN 0.4/CD mg/NN separated/VBN by/IN 6/CD hours/NNS experienced/VBN a/DT standing/JJ systolic/JJ blood/NN pressure/NN below/IN 85/CD mm/NN Hg/NN ./.

(ROOT (S1 (S (PP (IN In) (NP (NP (DT a) (JJ similar) (NN study)) (PP (IN with) (NP (NN tamsulosin))) (PP (IN in) (NP (JJ healthy) (NNS volunteers))))) (, ,) (NP (NP (QP (CD 1) (IN of) (CD 24)) (NNS subjects)) (VP (VBN dosed) (PP (IN with) (NP (NP (NP (NN Vardenafil) (CD 20) (NN mg)) (CC and) (NP (NN tamsulosin) (CD 0.4) (NN mg))) (VP (VBN separated) (PP (IN by) (NP (CD 6) (NNS hours)))))))) (VP (VBN experienced) (NP (NP (DT a) (JJ standing) (JJ systolic) (NN blood) (NN pressure)) (PP (IN below) (NP (ADJP (CD 85) (NN mm)) (NN Hg))))) (. .))))

Sentence Id: DrugDDI.d253.s33
Two/CD of/IN 16/CD subjects/NNS dosed/VBN simultaneously/RB with/IN Vardenafil/NN 10/CD mg/NN and/CC tamsulosin/NN 0.4/CD mg/NN experienced/VBN a/DT standing/JJ systolic/JJ blood/NN pressure/NN below/IN 85/CD mm/NN Hg/NN ./.

(ROOT (S1 (S (S (NP (NP (CD Two)) (PP (IN of) (NP (NP (CD 16) (NNS subjects)) (VP (VBN dosed) (ADVP (RB simultaneously)) (PP (IN with) (NP (NP (NN Vardenafil) (CD 10) (NN mg)) (CC and) (NP (NN tamsulosin) (CD 0.4) (NN mg)))))))) (VP (VBN experienced) (NP (NP (DT a) (JJ standing) (JJ systolic) (NN blood) (NN pressure)) (PP (IN below) (NP (ADJP (CD 85) (NN mm)) (NN Hg)))))) (. .))))

Sentence Id: DrugDDI.d253.s34
The/DT administration/NN of/IN lower/JJR doses/NNS of/IN Vardenafil/NN with/IN alpha-blockers/NNS has/VBZ not/RB been/VBN completely/RB evaluated/VBN to/TO determine/VB if/IN they/PRP can/MD be/VB safely/RB administered/VBN together/RB ./.

(ROOT (S1 (S (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NP (JJR lower) (NNS doses)) (PP (IN of) (NP (NP (NN Vardenafil)) (PP (IN with) (NP (NNS alpha-blockers)))))))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB completely)) (VP (VBN evaluated) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (PRP they)) (VP (MD can) (VP (VB be) (ADVP (RB safely)) (VP (VBN administered) (ADVP (RB together)))))))))))))) (. .))))

Sentence Id: DrugDDI.d253.s35
Based/VBN on/IN these/DT data/NNS ,/, Vardenafil/NN should/MD not/RB be/VB used/VBN in/IN patients/NNS on/IN alpha-blocker/NN therapy/NN ./.

(ROOT (S1 (S (S (PP (VBN Based) (PP (IN on) (NP (DT these) (NNS data)))) (, ,) (NP (NN Vardenafil)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (NN alpha-blocker) (NN therapy))))))))) (. .))))

Sentence Id: DrugDDI.d253.s36
Ritonavir/NN and/CC indinavir/NN :/: Upon/IN concomitant/JJ administration/NN of/IN 5/CD mg/NN of/IN Vardenafil/NN with/IN 600/CD mg/NN BID/NN ritonavir/NN ,/, the/DT Cmax/NN and/CC AUC/NN of/IN ritonavir/NN were/VBD reduced/VBN by/IN approximately/RB 20/CD %./NN

(ROOT (S1 (S (NP (NP (NP (NN Ritonavir)) (CC and) (NP (NN indinavir))) (: :) (S (PP (IN Upon) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (CD 5) (NN mg)) (PP (IN of) (NP (NN Vardenafil))) (PP (IN with) (NP (ADJP (CD 600) (NN mg)) (NN BID) (NN ritonavir))))))) (, ,) (NP (NP (DT the) (NP (NN Cmax)) (CC and) (NP (NN AUC))) (PP (IN of) (NP (NN ritonavir)))) (VP (VBD were) (VP (VBN reduced) (PP (IN by) (NP (QP (RB approximately) (CD 20)) (NN %.))))))))))

Sentence Id: DrugDDI.d253.s37
Upon/IN administration/NN of/IN 10/CD mg/NN of/IN Vardenafil/NN with/IN 800/CD mg/NN TID/NN indinavir/NN ,/, the/DT Cmax/NN and/CC AUC/NN of/IN indinavir/NN were/VBD reduced/VBN by/IN 40/CD %/NN and/CC 30/CD %/NN ,/, respectively/RB ./.

(ROOT (S1 (S (S (PP (IN Upon) (NP (NP (NN administration)) (PP (IN of) (NP (NP (CD 10) (NN mg)) (PP (IN of) (NP (NN Vardenafil))) (PP (IN with) (NP (ADJP (CD 800) (NN mg)) (NN TID) (NN indinavir))))))) (, ,) (NP (NP (DT the) (NP (NN Cmax)) (CC and) (NP (NN AUC))) (PP (IN of) (NP (NN indinavir)))) (VP (VBD were) (VP (VBN reduced) (PP (IN by) (NP (NP (CD 40) (NN %)) (CC and) (NP (CD 30) (NN %)) (, ,) (ADVP (RB respectively))))))) (. .))))

Sentence Id: DrugDDI.d253.s38
Alcohol/NN :/: Alcohol/NN (/-LRB- 0.5/CD g/kg/NN body/NN weight/NN :/: approximately/RB 40/CD mL/NN of/IN absolute/JJ alcohol/NN in/IN a/DT 70/CD kg/NN person/NN )/-RRB- and/CC vardenafil/NN plasma/NN levels/NNS were/VBD not/RB altered/VBN when/WRB dosed/VBN simultaneously/RB ./.

(ROOT (S1 (S (S (NP (NP (NN Alcohol)) (: :) (NP (NP (NN Alcohol)) (PRN (-LRB- -LRB-) (NP (CD 0.5) (NN g/kg) (NN body) (NN weight)) (: :) (NP (NP (QP (RB approximately) (CD 40)) (NN mL)) (PP (IN of) (NP (NP (JJ absolute) (NN alcohol)) (PP (IN in) (NP (DT a) (CD 70) (NN kg) (NN person)))))) (-RRB- -RRB-))) (CC and) (NP (NN vardenafil) (NN plasma) (NNS levels))) (VP (VBD were) (RB not) (VP (VBN altered)) (SBAR (WHADVP (WRB when)) (S (VP (VBN dosed) (ADVP (RB simultaneously))))))) (. .))))

Sentence Id: DrugDDI.d253.s39
Vardenafil/NN (/-LRB- 20/CD mg/NN )/-RRB- did/VBD not/RB potentiate/VB the/DT hypotensive/JJ effects/NNS of/IN alcohol/NN during/IN the/DT 4-hour/JJ observation/NN period/NN in/IN healthy/JJ volunteers/NNS when/WRB administered/VBN with/IN alcohol/NN (/-LRB- 0.5/CD g/kg/NN body/NN weight/NN )./CD

(ROOT (S1 (S (NP (NP (NP (NN Vardenafil)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN mg)) (-RRB- -RRB-))) (VP (VBD did) (RB not) (VP (VB potentiate) (NP (NP (DT the) (JJ hypotensive) (NNS effects)) (PP (IN of) (NP (NN alcohol))) (PP (IN during) (NP (NP (DT the) (JJ 4-hour) (NN observation) (NN period)) (PP (IN in) (NP (JJ healthy) (NNS volunteers))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN with) (NP (NN alcohol))) (PRN (-LRB- -LRB-) (NP (CD 0.5) (NN g/kg) (NN body) (NN weight) (CD -RRB-.)))))))))))

Sentence Id: DrugDDI.d253.s40
Aspirin/NN :/: Vardenafil/NN (/-LRB- 10/CD mg/NN and/CC 20/CD mg/NN )/-RRB- did/VBD not/RB potentiate/VB the/DT increase/NN in/IN bleeding/JJ time/NN caused/VBN by/IN aspirin/NN (/-LRB- two/CD 81/CD mg/NN tablets/NNS )./CD

(ROOT (S1 (S (NP (NP (NN Aspirin)) (: :) (S (NP (NP (NN Vardenafil)) (PRN (-LRB- -LRB-) (NP (NP (CD 10) (NN mg)) (CC and) (NP (CD 20) (NN mg))) (-RRB- -RRB-))) (VP (VBD did) (RB not) (VP (VB potentiate) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NP (JJ bleeding) (NN time)) (VP (VBN caused) (PP (IN by) (NP (NN aspirin) (-LRB- -LRB-) (CD two) (CD 81) (NN mg) (NNS tablets) (CD -RRB-.))))))))))))))

Sentence Id: DrugDDI.d253.s41
Other/JJ interactions/NNS :/: Vardenafil/NN had/VBD no/DT effect/NN on/IN the/DT pharmacodynamics/NNS of/IN glyburide/NN (/-LRB- glucose/NN and/CC insulin/NN concentrations/NNS )/-RRB- and/CC warfarin/NN (/-LRB- prothrombin/NN time/NN or/CC other/JJ pharmacodynamic/JJ parameters/NNS )./NN

(ROOT (S1 (S (NP (NP (JJ Other) (NNS interactions)) (: :) (S (NP (NN Vardenafil)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacodynamics)) (PP (IN of) (NP (NP (NP (NN glyburide)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN glucose)) (CC and) (NP (NN insulin))) (NNS concentrations)) (-RRB- -RRB-))) (CC and) (NP (NN warfarin)) (-LRB- -LRB-) (NP (NN prothrombin) (NN time)) (CC or) (NP (JJ other) (JJ pharmacodynamic) (NNS parameters)) (NP (NN -RRB-.))))))))))))

Sentence Id: DrugDDI.d528.s0
Zidovudine/NN :/: There/EX is/VBZ no/DT significant/JJ pharmacokinetic/JJ interaction/NN between/IN ZDV/NN and/CC zalcitabine/NN which/WDT has/VBZ been/VBN confirmed/VBN clinically/RB ./.

(ROOT (S1 (S (S (NP (NN Zidovudine)) (: :) (S (NP (EX There)) (VP (VBZ is) (NP (NP (DT no) (JJ significant) (JJ pharmacokinetic) (NN interaction)) (PP (IN between) (NP (NP (NN ZDV)) (CC and) (NP (NN zalcitabine)))) (SBAR (WHNP (WDT which)) (S (VP (VBZ has) (VP (VBN been) (VP (VBN confirmed) (ADVP (RB clinically))))))))))) (. .))))

Sentence Id: DrugDDI.d528.s1
Zalcitabine/NN also/RB has/VBZ no/DT significant/JJ effect/NN on/IN the/DT intracellular/JJ phosphorylation/NN of/IN ZDV/NN ,/, as/IN shown/VBN in/FW vitro/FW in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS or/CC in/IN two/CD other/JJ cell/NN lines/NNS (/-LRB- U937/NN and/CC Molt-4/NN )./NN

(ROOT (S1 (S (NP (NN Zalcitabine)) (ADVP (RB also)) (VP (VBZ has) (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ intracellular) (NN phosphorylation)) (PP (IN of) (NP (NN ZDV))))) (, ,) (SBAR (IN as) (S (VP (VBN shown) (ADVP (FW in) (FW vitro)) (PP (PP (IN in) (NP (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells))) (CC or) (PP (IN in) (NP (NP (CD two) (JJ other) (NN cell) (NNS lines)) (PRN (-LRB- -LRB-) (NP (NP (NN U937)) (CC and) (NP (NN Molt-4)) (NP (NN -RRB-.))))))))))))))

Sentence Id: DrugDDI.d528.s2
In/IN the/DT same/JJ study/NN it/PRP was/VBD shown/VBN that/IN didanosine/NN and/CC stavudine/NN had/VBD no/DT significant/JJ effect/NN on/IN the/DT intracellular/JJ phosphorylation/NN of/IN zalcitabine/NN in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS ./.

(ROOT (S1 (S (S (PP (IN In) (NP (DT the) (JJ same) (NN study))) (NP (PRP it)) (VP (VBD was) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (NN didanosine)) (CC and) (NP (NN stavudine))) (VP (VBD had) (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ intracellular) (NN phosphorylation)) (PP (IN of) (NP (NN zalcitabine))) (PP (IN in) (NP (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells))))))))))) (. .))))

Sentence Id: DrugDDI.d528.s3
Lamivudine/NN :/: In/FW vitro/FW studies/NNS in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS ,/, U937/NN and/CC Molt-4/NN cells/NNS revealed/VBD that/IN lamivudine/NN significantly/RB inhibited/VBD zalcitabine/NN phosphorylation/NN in/IN a/DT dose/NN dependent/JJ manner/NN ./.

(ROOT (S1 (S (NP (NP (NN Lamivudine)) (: :) (S (NP (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (PP (IN in) (NP (NP (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells)) (, ,) (NP (NN U937)) (CC and) (NP (NN Molt-4) (NNS cells))))) (VP (VBD revealed) (SBAR (IN that) (S (NP (NN lamivudine)) (ADVP (RB significantly)) (VP (VBD inhibited) (NP (NN zalcitabine) (NN phosphorylation)) (PP (IN in) (NP (DT a) (ADJP (NN dose) (JJ dependent)) (NN manner)))))))) (. .)))))

Sentence Id: DrugDDI.d528.s4
Effects/NNS were/VBD already/RB seen/VBN with/IN doses/NNS corresponding/VBG to/TO relevant/JJ plasma/NN levels/NNS in/IN humans/NNS ,/, and/CC the/DT intracellular/JJ phosphorylation/NN of/IN zalcitabine/NN to/TO its/PRP$ three/CD metabolites/NNS (/-LRB- including/VBG the/DT active/JJ zalcitabine/NN triphosphate/NN metabolite/NN )/-RRB- was/VBD significantly/RB inhibited/VBN ./.

(ROOT (S1 (S (S (S (NP (NNS Effects)) (VP (VBD were) (ADVP (RB already)) (VP (VBN seen) (PP (IN with) (NP (NP (NNS doses)) (VP (VBG corresponding) (PP (TO to) (NP (NP (JJ relevant) (NN plasma) (NNS levels)) (PP (IN in) (NP (NNS humans))))))))))) (, ,) (CC and) (S (NP (NP (DT the) (JJ intracellular) (NN phosphorylation)) (PP (IN of) (NP (NN zalcitabine))) (PP (TO to) (NP (NP (PRP$ its) (CD three) (NNS metabolites)) (PRN (-LRB- -LRB-) (VP (VBG including) (NP (DT the) (JJ active) (NN zalcitabine) (NN triphosphate) (NN metabolite))) (-RRB- -RRB-))))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN inhibited))))) (. .))))

Sentence Id: DrugDDI.d528.s5
Zalcitabine/NN inhibited/VBD lamivudine/NN phosphorylation/NN at/IN high/JJ concentration/NN ratios/NNS (/-LRB- 10/CD and/CC 100/CD )/-RRB- ;/: ./.

(ROOT (S1 (S (S (NP (NN Zalcitabine)) (VP (VBD inhibited) (NP (NN lamivudine) (NN phosphorylation)) (PP (IN at) (NP (JJ high) (NN concentration) (NNS ratios))) (PRN (-LRB- -LRB-) (QP (CD 10) (CC and) (CD 100)) (-RRB- -RRB-))) (: ;)) (. .))))

Sentence Id: DrugDDI.d528.s6
however/RB ,/, it/PRP is/VBZ considered/VBN to/TO be/VB unlikely/JJ that/IN this/DT decrease/NN of/IN phosphorylated/VBN lamivudine/NN concentration/NN is/VBZ of/IN clinical/JJ significance/NN ,/, as/IN lamivudine/NN is/VBZ a/DT more/RBR efficient/JJ substrate/NN for/IN deoxycytidine/NN kinase/NN than/IN zalcitabine/NN ./.

(ROOT (S1 (S (S (ADVP (RB however)) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN considered) (S (VP (TO to) (VP (VB be) (ADJP (JJ unlikely) (SBAR (IN that) (S (NP (NP (DT this) (NN decrease)) (PP (IN of) (NP (VBN phosphorylated) (NN lamivudine) (NN concentration)))) (VP (VBZ is) (PP (IN of) (NP (JJ clinical) (NN significance))) (, ,) (SBAR (IN as) (S (NP (NN lamivudine)) (VP (VBZ is) (NP (NP (DT a) (ADJP (RBR more) (JJ efficient)) (NN substrate)) (PP (IN for) (NP (NN deoxycytidine) (NN kinase))) (PP (IN than) (NP (NN zalcitabine))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d528.s7
These/DT in/FW vitro/FW studies/NNS suggest/VBP that/IN concomitant/JJ administration/NN of/IN zalcitabine/NN and/CC lamivudine/NN in/IN humans/NNS may/MD result/VB in/IN sub-therapeutic/JJ concentrations/NNS of/IN active/JJ phosphorylated/JJ zalcitabine/NN ,/, which/WDT may/MD lead/VB to/TO a/DT decreased/VBN antiretroviral/JJ effect/NN of/IN zalcitabine/NN ./.

(ROOT (S1 (S (S (NP (DT These) (ADJP (FW in) (FW vitro)) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN zalcitabine)) (CC and) (NP (NN lamivudine)))) (PP (IN in) (NP (NNS humans)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (JJ sub-therapeutic) (NNS concentrations)) (PP (IN of) (NP (NP (JJ active) (JJ phosphorylated) (NN zalcitabine)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (DT a) (VBN decreased) (JJ antiretroviral) (NN effect)) (PP (IN of) (NP (NN zalcitabine))))))))))))))))))) (. .))))

Sentence Id: DrugDDI.d528.s9
Concomitant/JJ use/NN of/IN zalcitabine/NN and/CC lamivudine/NN is/VBZ not/RB recommended/VBN ./.

(ROOT (S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NP (NN zalcitabine)) (CC and) (NP (NN lamivudine))))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .))))

Sentence Id: DrugDDI.d528.s10
Saquinavir/NN :/: The/DT combination/NN of/IN HIVID/NN ,/, saquinavir/NN ,/, and/CC ZDV/NN has/VBZ been/VBN studied/VBN (/-LRB- as/IN triple/JJ combination/NN )/-RRB- in/IN adults/NNS ./.

(ROOT (S1 (S (NP (NP (NN Saquinavir)) (: :) (S (NP (NP (DT The) (NN combination)) (PP (IN of) (NP (NP (NN HIVID)) (, ,) (NP (NN saquinavir)) (, ,) (CC and) (NP (NN ZDV))))) (VP (VBZ has) (VP (VBN been) (VP (VBN studied) (PRN (-LRB- -LRB-) (PP (IN as) (NP (JJ triple) (NN combination))) (-RRB- -RRB-)) (PP (IN in) (NP (NNS adults))))))) (. .)))))

Sentence Id: DrugDDI.d528.s11
Pharmacokinetic/JJ data/NNS suggest/VBP that/IN absorption/NN ,/, metabolism/NN ,/, and/CC elimination/NN of/IN each/DT of/IN these/DT drugs/NNS are/VBP unchanged/JJ when/WRB they/PRP are/VBP used/VBN together/RB ./.

(ROOT (S1 (S (S (NP (JJ Pharmacokinetic) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NP (NN absorption)) (, ,) (NP (NN metabolism)) (, ,) (CC and) (NP (NN elimination))) (PP (IN of) (NP (NP (DT each)) (PP (IN of) (NP (DT these) (NNS drugs)))))) (VP (VBP are) (ADJP (JJ unchanged)) (SBAR (WHADVP (WRB when)) (S (NP (PRP they)) (VP (VBP are) (VP (VBN used) (ADVP (RB together))))))))))) (. .))))

Sentence Id: DrugDDI.d528.s12
Drugs/NNS Associated/VBN With/IN Peripheral/JJ Neuropathy/NN :/: The/DT concomitant/JJ use/NN of/IN HIVID/NN with/IN drugs/NNS that/WDT have/VBP the/DT potential/NN to/TO cause/VB peripheral/JJ neuropathy/NN should/MD be/VB avoided/VBN where/WRB possible/JJ ./.

(ROOT (S1 (S (NP (NP (NP (NNS Drugs)) (VP (VBN Associated) (PP (IN With) (NP (JJ Peripheral) (NN Neuropathy))))) (: :) (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NN HIVID))) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VB cause) (NP (JJ peripheral) (NN neuropathy)))))))))))) (VP (MD should) (VP (VB be) (VP (VBN avoided) (SBAR (WHADVP (WRB where)) (FRAG (JJ possible))))))) (. .)))))

Sentence Id: DrugDDI.d528.s13
Drugs/NNS that/WDT have/VBP been/VBN associated/VBN with/IN peripheral/JJ neuropathy/NN include/VBP antiretroviral/JJ nucleoside/NN analogues/NNS ,/, chloramphenicol/NN ,/, cisplatin/NN ,/, dapsone/NN ,/, disulfiram/NN ,/, ethionamide/NN ,/, glutethimide/NN ,/, gold/NN ,/, hydralazine/NN ,/, iodoquinol/NN ,/, isoniazid/NN ,/, metronidazole/NN ,/, nitrofurantoin/NN ,/, phenytoin/NN ,/, ribavirin/NN ,/, and/CC vincristine/NN ./.

(ROOT (S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (JJ peripheral) (NN neuropathy))) (S (VP (VBP include) (NP (NP (NP (JJ antiretroviral) (NN nucleoside) (NNS analogues)) (, ,) (NP (NN chloramphenicol)) (, ,) (NP (NN cisplatin))) (, ,) (NP (NP (NN dapsone)) (, ,) (NP (NN disulfiram)) (, ,) (NP (NN ethionamide)) (, ,) (NP (NN glutethimide)) (, ,) (NP (NN gold)) (, ,) (NP (NN hydralazine)) (, ,) (NP (NN iodoquinol)) (, ,) (NP (NN isoniazid)) (, ,) (NP (NN metronidazole)) (, ,) (NP (NN nitrofurantoin)) (, ,) (NP (NN phenytoin)) (, ,) (NP (NN ribavirin)) (, ,) (CC and) (NP (NN vincristine))))))))))))) (. .))))

Sentence Id: DrugDDI.d528.s14
Concomitant/JJ use/NN of/IN HIVID/NN with/IN didanosine/NN is/VBZ not/RB recommended/VBN ./.

(ROOT (S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN HIVID))) (PP (IN with) (NP (NN didanosine)))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .))))

Sentence Id: DrugDDI.d528.s15
Intravenous/JJ Pentamidin/NN e/NN :/: Treatment/NN with/IN HIVID/NN should/MD be/VB interrupted/VBN when/WRB the/DT use/NN of/IN a/DT drug/NN that/WDT has/VBZ the/DT potential/NN to/TO cause/VB pancreatitis/NN is/VBZ required/VBN ./.

(ROOT (S1 (S (NP (NP (JJ Intravenous) (NN Pentamidin) (NN e)) (: :) (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NN HIVID)))) (VP (MD should) (VP (VB be) (VP (VBN interrupted))) (SBAR (WHADVP (WRB when)) (S (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (DT a) (NN drug)) (SBAR (WHNP (WDT that)) (S (VP (VBZ has) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VB cause) (NP (NN pancreatitis)))))))))))) (VP (VBZ is) (VP (VBN required))))))) (. .)))))

Sentence Id: DrugDDI.d528.s16
Death/NN due/IN to/TO fulminant/JJ pancreatitis/NN possibly/RB related/JJ to/TO intravenous/JJ pentamidin/NN e/NN and/CC HIVID/NN has/VBZ been/VBN reported/VBN ./.

(ROOT (S1 (S (S (NP (NP (NN Death)) (PP (IN due) (TO to) (NP (JJ fulminant) (NN pancreatitis))) (ADJP (ADVP (RB possibly)) (JJ related) (PP (TO to) (NP (NP (JJ intravenous) (NN pentamidin) (NN e)) (CC and) (NP (NN HIVID)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported))))) (. .))))

Sentence Id: DrugDDI.d528.s17
If/IN intravenous/JJ pentamidin/NN e/NN is/VBZ required/VBN to/TO treat/VB Pneumocystis/NN carinii/NN pneumonia/NNS ,/, treatment/NN with/IN HIVID/NN should/MD be/VB interrupted/VBN ./.

(ROOT (S1 (S (S (SBAR (IN If) (S (NP (JJ intravenous) (NN pentamidin) (NN e)) (VP (VBZ is) (VP (VBN required) (S (VP (TO to) (VP (VB treat) (NP (NN Pneumocystis) (NN carinii) (NNS pneumonia))))))))) (, ,) (NP (NP (NN treatment)) (PP (IN with) (NP (NN HIVID)))) (VP (MD should) (VP (VB be) (VP (VBN interrupted))))) (. .))))

Sentence Id: DrugDDI.d528.s18
Amphotericin/NN ,/, Foscarnet/NN ,/, and/CC Aminoglycosides/NN :/: Drugs/NNS such/JJ as/IN amphotericin/NN ,/, foscarnet/NN ,/, and/CC aminoglycosides/NNS may/MD increase/VB the/DT risk/NN of/IN developing/VBG peripheral/JJ neuropathy/NN or/CC other/JJ HIVID/NN -associated/JJ adverse/JJ events/NNS by/IN interfering/VBG with/IN the/DT renal/JJ clearance/NN of/IN zalcitabine/NN (/-LRB- thereby/RB raising/VBG systemic/JJ exposure/NN )./NN

(ROOT (S1 (S (NP (NP (NP (NN Amphotericin)) (, ,) (NP (NN Foscarnet)) (, ,) (CC and) (NP (NN Aminoglycosides))) (: :) (S (NP (NP (NNS Drugs)) (PP (JJ such) (IN as) (NP (NP (NN amphotericin)) (, ,) (NP (NN foscarnet)) (, ,) (CC and) (NP (NNS aminoglycosides))))) (VP (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (VBG developing) (ADJP (NP (NP (JJ peripheral) (NN neuropathy)) (CC or) (NP (JJ other) (NN HIVID))) (JJ -associated)) (JJ adverse) (NNS events)))) (PP (IN by) (S (VP (VBG interfering) (PP (IN with) (NP (NP (DT the) (JJ renal) (NN clearance)) (PP (IN of) (NP (NN zalcitabine)))))))))) (-LRB- -LRB-) (S (ADVP (RB thereby)) (VP (VBG raising) (NP (JJ systemic) (NN exposure) (NN -RRB-.))))))))))

Sentence Id: DrugDDI.d528.s19
Patients/NNS who/WP require/VBP the/DT use/NN of/IN one/CD of/IN these/DT drugs/NNS with/IN HIVID/NN should/MD have/VBP frequent/JJ clinical/JJ and/CC laboratory/JJ monitoring/NN with/IN dosage/JJ adjustment/NN for/IN any/DT significant/JJ change/NN in/IN renal/JJ function/NN ./.

(ROOT (S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBP require) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (CD one)) (PP (IN of) (NP (DT these) (NNS drugs))))) (PP (IN with) (NP (NN HIVID)))))))) (VP (MD should) (VP (VBP have) (NP (JJ frequent) (ADJP (ADJP (JJ clinical)) (CC and) (ADJP (JJ laboratory))) (NN monitoring)) (PP (IN with) (NP (NP (JJ dosage) (NN adjustment)) (PP (IN for) (NP (NP (DT any) (JJ significant) (NN change)) (PP (IN in) (NP (JJ renal) (NN function))))))))) (. .))))

Sentence Id: DrugDDI.d528.s20
Probenecid/NN or/CC Cimetidine/NN :/: Concomitant/JJ administration/NN of/IN probenecid/NN or/CC cimetidine/NN decreases/VBZ the/DT elimination/NN of/IN zalcitabine/NN ,/, most/RBS likely/RB by/IN inhibition/NN of/IN renal/JJ tubular/JJ secretion/NN of/IN zalcitabine/NN ./.

(ROOT (S1 (S (NP (NP (NP (NN Probenecid)) (CC or) (NP (NN Cimetidine))) (: :) (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN probenecid)) (CC or) (NP (NN cimetidine))))) (VP (VBZ decreases) (NP (NP (DT the) (NN elimination)) (PP (IN of) (NP (NN zalcitabine)))) (, ,) (PP (ADVP (RBS most) (RB likely)) (IN by) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (JJ renal) (JJ tubular) (NN secretion)) (PP (IN of) (NP (NN zalcitabine))))))))) (. .)))))

Sentence Id: DrugDDI.d528.s21
Patients/NNS receiving/VBG these/DT drugs/NNS in/IN combination/NN with/IN zalcitabine/NN should/MD be/VB monitored/VBN for/IN signs/NNS of/IN toxicity/NN and/CC the/DT dose/NN of/IN zalcitabine/NN reduced/VBD if/IN warranted/VBN ./.

(ROOT (S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (DT these) (NNS drugs)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN zalcitabine))))))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (PP (IN for) (NP (NP (NNS signs)) (PP (IN of) (NP (NN toxicity))))))))) (CC and) (S (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN zalcitabine)))) (VP (VBD reduced) (SBAR (IN if) (S (VP (VBN warranted)))))) (. .))))

Sentence Id: DrugDDI.d528.s22
Magnesium/NN /Aluminum-containing/JJ Antacid/JJ Products/NNS :/: Absorption/NN of/IN zalcitabine/NN is/VBZ moderately/RB reduced/VBN (/-LRB- approximately/RB 25/CD %/NN )/-RRB- when/WRB coadministered/VBN with/IN magnesium/NN /aluminum-containing/NN antacid/JJ products/NNS ./.

(ROOT (S1 (S (NP (NP (NN Magnesium) (JJ /Aluminum-containing) (JJ Antacid) (NNS Products)) (: :) (S (NP (NP (NN Absorption)) (PP (IN of) (NP (NN zalcitabine)))) (VP (VBZ is) (ADVP (RB moderately)) (VP (VBN reduced) (PRN (-LRB- -LRB-) (NP (QP (RB approximately) (CD 25)) (NN %)) (-RRB- -RRB-)) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NN magnesium) (NN /aluminum-containing) (JJ antacid) (NNS products))))))))) (. .)))))

Sentence Id: DrugDDI.d528.s23
The/DT clinical/JJ significance/NN of/IN this/DT reduction/NN is/VBZ not/RB known/VBN ,/, hence/RB zalcitabine/NN is/VBZ not/RB recommended/VBN to/TO be/VB ingested/VBN simultaneously/RB with/IN magnesium/NN //: aluminum-containing/JJ antacids/NNS ./.

(ROOT (S1 (S (S (S (NP (NP (DT The) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT this) (NN reduction)))) (VP (VBZ is) (RB not) (VP (VBN known)))) (, ,) (ADVP (RB hence)) (S (NP (NN zalcitabine)) (VP (VBZ is) (RB not) (VP (VBN recommended) (S (VP (TO to) (VP (VB be) (VP (VBN ingested) (ADVP (RB simultaneously)) (PP (IN with) (NP (NP (NN magnesium)) (: /) (NP (JJ aluminum-containing) (NNS antacids)))))))))))) (. .))))

Sentence Id: DrugDDI.d528.s24
Metoclopramide/NN :/: Bioavailability/NN is/VBZ mildly/RB reduced/VBN (/-LRB- approximately/RB 10/CD %/NN )/-RRB- when/WRB zalcitabine/NN and/CC metoclopramide/NN are/VBP coadministered/VBN ./.

(ROOT (S1 (S (S (NP (NN Metoclopramide) (: :) (NN Bioavailability)) (VP (VBZ is) (ADVP (RB mildly)) (VP (VBN reduced) (PRN (-LRB- -LRB-) (NP (QP (RB approximately) (CD 10)) (NN %)) (-RRB- -RRB-)) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN zalcitabine)) (CC and) (NP (NN metoclopramide))) (VP (VBP are) (VP (VBN coadministered)))))))) (. .))))

Sentence Id: DrugDDI.d528.s25
Doxorubicin/NN :/: Doxorubicin/NN caused/VBD a/DT decrease/NN in/IN zalcitabine/NN phosphorylation/NN (/-LRB- 50/CD %/NN inhibition/NN of/IN total/JJ phosphate/NN formation/NN )/-RRB- in/IN U937/Molt/NN 4/CD cells/NNS ./.

(ROOT (S1 (S (NP (NP (NN Doxorubicin)) (: :) (S (NP (NN Doxorubicin)) (VP (VBD caused) (NP (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NN zalcitabine) (NN phosphorylation)))) (-LRB- -LRB-) (NP (NP (ADJP (CD 50) (NN %)) (NN inhibition)) (PP (IN of) (NP (JJ total) (NN phosphate) (NN formation)))) (-RRB- -RRB-)) (PP (IN in) (NP (NN U937/Molt) (CD 4) (NNS cells))))) (. .)))))

Sentence Id: DrugDDI.d528.s26
Although/IN there/EX may/MD be/VB decreased/VBN zalcitabine/NN activity/NN because/IN of/IN lessened/JJ active/JJ metabolite/NN formation/NN ,/, the/DT clinical/JJ relevance/NN of/IN these/DT in/FW vitro/FW results/NNS are/VBP not/RB known/VBN ./.

(ROOT (S1 (S (S (SBAR (IN Although) (S (NP (EX there)) (VP (MD may) (VP (VB be) (NP (VBN decreased) (NN zalcitabine) (NN activity)) (PP (IN because) (IN of) (NP (JJ lessened) (JJ active) (NN metabolite) (NN formation))))))) (, ,) (NP (NP (DT the) (JJ clinical) (NN relevance)) (PP (IN of) (NP (DT these) (ADJP (FW in) (FW vitro)) (NNS results)))) (VP (VBP are) (RB not) (VP (VBN known)))) (. .))))

